

# **Interventions To Prevent Age-Related Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer's-Type Dementia**



## **Interventions To Prevent Age-Related Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer's-Type Dementia**

**Prepared for:**

Agency for Healthcare Research and Quality  
U.S. Department of Health and Human Services  
5600 Fishers Lane  
Rockville, MD 20857  
www.ahrq.gov

**Contract No. 290-2015-00008-I**

**Prepared by:**

Minnesota Evidence-based Practice Center  
Minneapolis, MN

**Investigators:**

Robert L. Kane, M.D.  
Mary Butler, Ph.D., M.B.A.  
Howard A. Fink, M.D., M.P.H.  
Michelle Brasure, Ph.D., M.L.I.S.  
Heather Davila, M.P.A.  
Priyanka Desai, M.H.P.  
Eric Jutkowitz, B.A.  
Ellen McCreedy, Ph.D.  
Victoria A. Nelson, M.Sc.  
J. Riley McCarten, M.D.  
Collin Calvert, B.A.  
Edward Ratner, M.D.  
Laura S. Hemmy, Ph.D.  
Terry Barclay, Ph.D., L.P.

This report is based on research conducted by the Minnesota Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-2015-00008-I). The findings and conclusions in this document are those of the authors, who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.

**None of the investigators have any affiliations or financial involvement that conflicts with the material presented in this report.**

The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information, i.e., in the context of available resources and circumstances presented by individual patients.

This report is made available to the public under the terms of a licensing agreement between the author and the Agency for Healthcare Research and Quality. This report may be used and reprinted without permission except those copyrighted materials that are clearly noted in the report. Further reproduction of those copyrighted materials is prohibited without the express permission of copyright holders.

AHRQ or U.S. Department of Health and Human Services endorsement of any derivative products that may be developed from this report, such as clinical practice guidelines, other quality enhancement tools, or reimbursement or coverage policies, may not be stated or implied.

This report may periodically be assessed for the currency of conclusions. If an assessment is done, the resulting surveillance report describing the methodology and findings will be found on the Effective Health Care Program Web site at [www.effectivehealthcare.ahrq.gov](http://www.effectivehealthcare.ahrq.gov). Search on the title of the report.

Persons using assistive technology may not be able to fully access information in this report. For assistance contact [EffectiveHealthCare@ahrq.hhs.gov](mailto:EffectiveHealthCare@ahrq.hhs.gov).

**Suggested citation:** Kane RL, Butler M, Fink HA, Brasure M, Davila H, Desai P, Jutkowitz E, McCreedy E, Nelson VA, McCarten JR, Calvert C, Ratner E, Hemmy LS, Barclay T. Interventions To Prevent Age-Related Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer’s-Type Dementia. Comparative Effectiveness Review No. 188. (Prepared by the Minnesota Evidence-based Practice Center under Contract No. 290-2015-00008-I.) AHRQ Publication No. 17-EHC008-EF. Rockville, MD: Agency for Healthcare Research and Quality; March 2017. [www.effectivehealthcare.ahrq.gov/reports/final.cfm](http://www.effectivehealthcare.ahrq.gov/reports/final.cfm). doi: <https://doi.org/10.23970/AHRQEPCER188>.

## Preface

The Agency for Healthcare Research and Quality (AHRQ), through its Evidence-based Practice Centers (EPCs), sponsors the development of systematic reviews to assist public- and private-sector organizations in their efforts to improve the quality of health care in the United States. These reviews provide comprehensive, science-based information on common, costly medical conditions, and new health care technologies and strategies. The National Institute on Aging of the National Institutes of Health requested this report from the AHRQ Evidence-based Practice Center (EPC) Program. The report was presented October 25, 2016, at the National Academies of Sciences, Engineering, and Medicine public meeting Preventing Dementia and Cognitive Impairment: A Workshop.

The reports and assessments provide organizations with comprehensive, evidence-based information on common medical conditions and new health care technologies and strategies. They also identify research gaps in the selected scientific area, identify methodological and scientific weaknesses, suggest research needs, and move the field forward through an unbiased, evidence-based assessment of the available literature. The EPCs systematically review the relevant scientific literature on topics assigned to them by AHRQ and conduct additional analyses when appropriate prior to developing their reports and assessments.

To bring the broadest range of experts into the development of evidence reports and health technology assessments, AHRQ encourages the EPCs to form partnerships and enter into collaborations with other medical and research organizations. The EPCs work with these partner organizations to ensure that the evidence reports and technology assessments they produce will become building blocks for health care quality improvement projects throughout the Nation. The reports undergo peer review and public comment prior to their release as a final report.

AHRQ expects that these systematic reviews will be helpful to health plans, providers, purchasers, government programs, and the health care system as a whole. Transparency and stakeholder input are essential to the Effective Health Care Program.

If you have comments on this systematic review, they may be sent by mail to the Task Order Officers named below at: Agency for Healthcare Research and Quality, 5600 Fishers Lane, Rockville, MD 20857, or by email to [epc@ahrq.hhs.gov](mailto:epc@ahrq.hhs.gov).

Sharon B. Arnold, Ph.D.  
Acting Director  
Agency for Healthcare Research and Quality

Stephanie Chang, M.D., M.P.H.  
Director  
Evidence-based Practice Center Program  
Center for Evidence and Practice Improvement  
Agency for Healthcare Research and Quality

Arlene S. Bierman, M.D., M.S.  
Director  
Center for Evidence and Practice Improvement  
Agency for Healthcare Research and Quality

Kim Wittenberg, M.A., and David W.  
Niebuhr, M.D., M.P.H., M.S.  
Task Order Officers  
Center for Evidence and Practice Improvement  
Agency for Healthcare Research and Quality

## Acknowledgments

We wish to thank Stephanie Trudeau and McKay Winzenried, who helped as research assistants; Cheryl Cole-Hill, Marianna Valadez, and Nancy Russell for their assistance in producing this report; and Melissa McPheeters, Melinda Kelley, Kim Wittenberg, and David Niebuhr for their helpful comments and edits during the writing process.

## Key Informants and Technical Expert Panel

The role of the Key Informants was filled by the National Academies of Sciences, Engineering, and Medicine Committee on Preventing Dementia and Cognitive Impairment, which will use the report to help develop its own recommendations report on the state of knowledge on the efficacy, comparative effectiveness, and harms of interventions to prevent or delay the onset of age-related cognitive decline, mild cognitive impairment, or clinical Alzheimer's-type dementia for the National Academies and the National Institute on Aging. (An overview of the National Academies' conflict-of-interest policies can be found at <http://nationalacademies.org/studyprocess/index.html>; detailed information is available at [http://www8.nationalacademies.org/cp/information.aspx?key=Conflict\\_of\\_Interest](http://www8.nationalacademies.org/cp/information.aspx?key=Conflict_of_Interest).) Because the National Academies Committee would not see the draft Key Questions, PICOTS (populations, interventions, comparators, outcomes, timing, and settings), and analytic framework until the Key Questions were posted for public comment, a panel of content experts from Federal agencies acted as proxy Key Informants prior to posting. The proxy Key Informants disclosed any financial conflicts of interest greater than \$10,000 and any other relevant business or professional conflicts of interest. The role of the Technical Expert Panel (TEP) was filled by the National Academies Committee.

The list of proxy Key Informants who provided input to this report follows:

Susan Cooley, Ph.D.  
Chief, Geriatric Research & Evaluation  
U.S. Department of Veterans Affairs  
Washington, DC

Rod Corriveau, Ph.D.  
Program Director, Extramural Research Program  
National Institute of Neurological Disorders and Stroke  
Washington, DC

Jonathan King, Ph.D.  
Program Director, Division of Behavioral and Social Research  
National Institute on Aging  
Washington, DC

Lisa McGuire, Ph.D.  
Lead, Alzheimer's Disease and Healthy Aging Program  
Centers for Disease Control & Prevention  
Atlanta, GA

Claudia Moy, Ph.D.  
Program Director, Office of Clinical Research  
National Institute of Neurological Disorders and Stroke  
Washington, DC

Laurie Ryan, Ph.D.  
Chief, Dementias of Aging  
National Institute on Aging  
Washington, DC

Jane Tilly, Dr.P.H., M.P.A.  
Brain Health and Dementia Programs Team Lead  
Administration for Community Living  
Washington, DC

Molly Wagster, Ph.D.  
Chief, Behavioral and Systems Neuroscience Branch  
National Institute on Aging  
Washington, DC

## **Peer Reviewers**

Prior to publication of the final evidence report, the EPC sought input from independent Peer Reviewers without financial conflicts of interest. However, the conclusions and synthesis of the scientific literature presented in this report do not necessarily represent the views of individual reviewers.

Peer Reviewers must disclose any financial conflicts of interest greater than \$10,000 and any other relevant business or professional conflicts of interest. Because of their unique clinical or content expertise, individuals with potential nonfinancial conflicts may be retained. The TOO and the EPC work to balance, manage, or mitigate any potential nonfinancial conflicts of interest identified.

The list of Peer Reviewers follows:

Nikolaos Scarmeas, M.D., M.S., Ph.D.  
National and Kapodistrian University of Athens  
Columbia University  
New York, NY

Robert Wallace, M.D., M.Sc.  
College of Public Health  
University of Iowa  
Iowa City, IA

John Williams, M.D.  
School of Medicine  
Duke University  
Durham, NC

# Interventions To Prevent Age-Related Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer's-Type Dementia

## Structured Abstract

**Objective.** This review assessed evidence for interventions aimed at preventing or delaying the onset of age-related cognitive decline, mild cognitive impairment (MCI), or clinical Alzheimer's-type dementia (CATD).

**Data sources.** Ovid Medline<sup>®</sup>, Ovid PsycINFO<sup>®</sup>, Ovid Embase<sup>®</sup>, and Cochrane Central Register of Controlled Trials (CENTRAL) bibliographic databases; hand searches of references of prior reviews, eligible studies, gray literature; expert recommendations.

**Review methods.** Two investigators screened abstracts and full-text articles of identified references. Eligible studies included randomized and nonrandomized controlled trials and quasi-experimental observational studies published to September 2016 that enrolled people with normal cognition and/or MCI. We extracted data, assessed risk of bias, summarized results for studies without high risk of bias, and evaluated strength of evidence for studies with sufficient sample size. Cognitive outcomes were grouped into domains to facilitate analysis; strength of evidence was assessed by MCI or CATD incidence and cognitive outcome domain.

**Results.** We identified 263 eligible studies addressing 13 classes of interventions: cognitive training, physical activity, nutraceuticals, diet, multimodal interventions, hormone therapy, vitamins, antihypertensive treatment, lipid lowering treatment, nonsteroidal anti-inflammatory drugs (NSAIDs), antidementia drugs, diabetes treatment, and "other interventions." We found no high-strength evidence for the effectiveness of any intervention to delay or prevent age-related cognitive decline, MCI, and/or CATD. Moderate-strength evidence shows cognitive training in adults with presumed normal cognition improves performance in the cognitive domain trained (memory, reasoning, or processing speed), but not transfer of benefits to other cognitive areas and little evidence for benefit beyond 2 years; evidence for effect on CATD is weak. Interventions with moderate-strength evidence for having *no* benefit in cognitive performance included: vitamin E in women; B<sub>12</sub> plus folic acid for executive/attention/processing speed; and angiotensin-converting enzyme plus thiazide versus placebo and angiotensin receptor blockers versus placebo on brief cognitive screening tests. We found low-strength evidence that the selective estrogen receptor modulator raloxifene reduced risk of probable MCI, but also that estrogen replacement with or without progesterone therapy increased risk of MCI and CATD. Physical activity interventions show no consistent benefit in preventing cognitive decline, but the percent of results showing benefit was unlikely to be explained solely by chance, providing a signal of a possible relationship. A few other interventions (vitamin B<sub>12</sub> plus folic acid; nutraceuticals; one multimodal intervention using diet, physical activity, and cognitive training; antihypertensives; and NSAIDs) showed at least one positive finding for a specific outcome, some reaching low strength of evidence, but these were more than offset by findings of no effect for other outcomes. Many interventions (e.g., nutraceuticals; one multimodal intervention using lifestyle advice and drug treatment; hormone therapy; antihypertensives; NSAIDs; acetylcholinesterase inhibitors; diabetes management) showed low-strength evidence for no



benefit for some cognitive performance tests. We found no eligible studies for the following interventions: depression treatment, smoking cessation, and community-level interventions.

**Conclusions.** We found mostly low-strength evidence that a wide variety of interventions had little to no benefit for preventing or delaying age-related cognitive decline, MCI, or CATD. There was moderate-strength evidence that cognitive training improved performance in the trained cognitive domains, but not in domains not trained. Evidence of an effect on CATD incidence was weak. There was a mix of positive and negative findings for different outcomes, all of low strength, for physical activity, antihypertensives, NSAIDs, B vitamins, nutraceuticals, and multimodal interventions. Signals seem more promising for physical activity and vitamin B<sub>12</sub> plus folic acid. Testing interventions that address modifiable risk factors can help to establish their causative role in MCI and CATD. Methodological problems in the available literature were widespread and should be addressed in future studies, including use of consistent cognitive outcome measures, longer followups, and recognizing that attrition is a major problem in longer studies. More work is needed to understand the relationship between intermediate outcomes such as cognitive test results and the onset of mild cognitive impairment and dementia.

# Contents

<b>Executive Summary</b> .....	ES-1
<b>Chapter 1. Introduction</b> .....	1
Background .....	1
Cognitive Impairment .....	1
Dementia—Definitions and Diagnostics .....	1
Age-Related Cognitive Decline and Mild Cognitive Impairment—Definitions and Diagnostics .....	
Distinguishing Between Mild Cognitive Impairment and Dementia .....	2
Causes of Cognitive Impairment .....	3
Interventions To Prevent or Slow Cognitive Decline .....	4
Interventions and Underlying Theories .....	4
Methods To Measure Intervention Impact— Measuring Cognitive Function and Biomarkers .....	
Scope and Key Questions .....	6
Key Questions .....	6
Analytic Framework .....	9
Report Organization .....	9
<b>Chapter 2. Methods</b> .....	11
Protocol Development .....	11
Criteria for Inclusion/Exclusion of Studies in the Review .....	11
Literature Search Strategies .....	12
Data Abstraction and Data Management .....	13
Assessing Methodological Risk of Bias of Individual Studies .....	13
Data Synthesis .....	13
Assessing the Strength of Evidence for Major Comparisons and Outcomes .....	14
Assessing Applicability .....	15
Peer Review and Public Commentary .....	15
<b>Chapter 3. Search Results</b> .....	16
<b>Chapter 4A. Results: Cognitive Training</b> .....	18
Key Messages .....	18
Eligible Studies .....	18
Advanced Cognitive Training for Independent and Vital Elderly (ACTIVE) Trial .....	18
Other Studies .....	24
Effect of Training on Adults With Normal Cognition .....	25
Effect of Training on People With Mild Cognitive Impairment .....	30
Interpreting the Findings .....	34
<b>Chapter 4B. Results: Physical Activity Interventions</b> .....	39
Key Messages .....	39
Eligible Studies .....	39
Logic of Physical Activity Interventions .....	39
Adults With Normal Cognition .....	40
Efficacy: Physical Activity Versus Inactive Control .....	40
Comparative Effectiveness: Physical Activity Versus Active Comparison .....	52
Adults With MCI .....	56
Efficacy: Physical Activity Versus Inactive Control .....	56

Interpreting the Findings.....	57
<b>Chapter 4C. Results: Nutraceutical Interventions .....</b>	<b>60</b>
Key Messages .....	60
Eligible Studies .....	60
Logic of Nutraceutical Interventions .....	60
Adults With Normal Cognition.....	60
Omega-3 Versus Placebo .....	61
Ginkgo Biloba Extract .....	62
Other Nutraceuticals .....	63
Adults With MCI .....	75
Nutraceuticals Versus Inactive Control .....	75
Interpreting the Findings.....	75
<b>Chapter 4D. Results: Diet Interventions.....</b>	<b>78</b>
Key Messages .....	78
Eligible Studies .....	78
Logic of Diet Interventions.....	78
Adults With Normal Cognition.....	78
Protein Supplement Versus Placebo .....	78
Energy-Deficit Diet Versus Inactive Control .....	78
Adults With MCI .....	79
Interpreting the Findings.....	79
<b>Chapter 4E. Results: Multimodal Interventions.....</b>	<b>82</b>
Key Messages .....	82
Eligible Studies .....	82
Logic of Multimodal Interventions.....	82
Adults With Normal Cognition.....	83
Efficacy: Multimodal Interventions Versus Inactive Control.....	83
Comparative Effectiveness: Multimodal Interventions Versus Active Comparison.....	93
Adults With MCI .....	97
Interpreting the Findings.....	97
<b>Chapter 4F. Results: Hormone Therapy Interventions .....</b>	<b>98</b>
Key Messages .....	98
Eligible Studies .....	98
Logic of Hormone Therapy Interventions .....	98
Adults With Normal Cognition.....	99
Efficacy: Hormone Therapy Versus Inactive Control .....	100
Comparative Effectiveness: Hormone Therapies Versus Active Comparison .....	119
Adults With MCI .....	122
Efficacy: Hormone Therapies Versus Inactive Control .....	122
Interpreting the Findings.....	125
<b>Chapter 4G. Results: Vitamin Interventions.....</b>	<b>126</b>
Key Messages .....	126
Eligible Studies .....	126
Logic of Vitamin Interventions.....	126
Adults With Normal Cognition.....	126
Efficacy: Vitamins Versus Inactive Control (Placebo).....	126

Comparative Effectiveness: Vitamins Versus Active Comparison .....	138
Adults With MCI .....	140
Efficacy: Vitamins Versus Inactive Control .....	140
Interpreting the Findings.....	141
<b>Chapter 4H. Results: Antihypertensive Treatment.....</b>	<b>144</b>
Key Messages .....	144
Eligible Studies .....	144
Logic of Antihypertensive Treatments .....	144
Adults With Normal Cognition.....	145
Antihypertensive Medication(s) Versus Placebo.....	147
Intensive Versus Standard Antihypertensive Medication.....	148
Antihypertensive Medication Treatments Versus Each Other.....	148
Adults With MCI .....	158
Interpreting the Findings.....	158
<b>Chapter 4I. Results: Lipid Lowering Treatment.....</b>	<b>159</b>
Key Messages .....	159
Eligible Studies .....	159
Logic of Lipid Lowering Treatments.....	159
Adults With Normal Cognition.....	159
Statin Versus Placebo .....	160
Statin Plus Ezetimibe Versus Placebo .....	161
Statin Plus Fenofibrate Versus Statin Plus Placebo.....	162
Statin Versus Alpha Tocopherol.....	162
Adults With MCI .....	167
Interpreting the Findings.....	167
<b>Chapter 4J. Results: Nonsteroidal Anti-Inflammatory Drugs.....</b>	<b>168</b>
Key Messages .....	168
Eligible Studies .....	168
Logic of NSAIDs .....	168
Adults With Normal Cognition.....	168
NSAIDs Versus Placebo.....	168
Adults With MCI .....	170
Interpreting the Findings.....	170
<b>Chapter 4K. Results: Antidementia Drugs.....</b>	<b>172</b>
Key Messages .....	172
Eligible Studies .....	172
Logic of Antidementia Drugs .....	172
Adults With Normal Cognition.....	172
Adults With MCI .....	174
Interpreting the Findings.....	174
<b>Chapter 4L. Results: Diabetes Medication Treatment.....</b>	<b>177</b>
Key Messages .....	177
Eligible Studies .....	177
Logic of Diabetes Medication Treatment .....	177
Adults With Normal Cognition.....	177
Adults With MCI .....	180

Interpreting the Findings.....	180
<b>Chapter 4M. Results: Other Interventions.....</b>	<b>183</b>
Key Messages .....	183
Eligible Studies .....	183
Adults With Normal Cognition.....	183
Adults With MCI .....	183
<b>Chapter 4N. Results: Agreement of Biomarkers and Measures of Cognitive Performance .....</b>	<b>187</b>
Key Messages .....	187
Association Between Biomarkers and Cognitive Tests .....	187
<b>Chapter 5. Discussion .....</b>	<b>192</b>
Dementia Incidence .....	192
Cognitive Performance .....	195
Methods Issues.....	201
Types of Studies.....	203
Value of Biomarkers .....	203
Limitations of the Review Process .....	203
<b>Chapter 6. Conclusion .....</b>	<b>205</b>
<b>Chapter 7. Suggestions for Future Research.....</b>	<b>209</b>
Prioritizing Future Research .....	209
Study Design/Methodology .....	209
Measurement.....	210
<b>References.....</b>	<b>212</b>
<b>Abbreviations .....</b>	<b>231</b>

## Tables

Table A. Summary of key messages by intervention class.....	ES-7
Table 1.1. DSM-5 underlying causes of major neurocognitive disorders .....	3
Table 1.2. Interventions aimed at preventing age-related cognitive decline, MCI, and/or CATD..	4
Table 1.3. Populations, interventions, comparators, outcomes, timing, and settings (PICOTS)....	8
Table 2.1 Study inclusion criteria .....	11
Table 3.1. Eligible publications by intervention type .....	17
Table 4A.1. Conclusions: Cognitive training in adults with normal cognition .....	19
Table 4A.2. Key ACTIVE studies .....	22
Table 4A.3. Effect of domain specific training on 2-, 5-, and 10-year cognitive testing outcomes (reported as effect sizes).....	23
Table 4A.4. Effect of domain specific training on 5- and 10- year cognitive testing outcomes (mean changes in test score from baseline) .....	23
Table 4A.5. Effect sizes for various activity outcomes .....	24
Table 4A.6. Training interventions for older adults with normal cognition.....	26
Table 4A.7. Cognitive testing interventions for adults with mild cognitive impairment .....	31
Table 4A.8. Summary of overall results of cognitive training for older adults with normal cognition .....	36
Table 4A.9. Summary of overall results of cognitive training for cognitively impaired older adults.....	37

Table 4B.1. Conclusions: Physical activity versus inactive comparisons in adults with normal cognition .....	40
Table 4B.2. Results overview: Physical activity versus inactive comparisons in adults with normal cognition .....	44
Table 4B.3. Results overview: Physical activity versus active comparisons in adults with normal cognition .....	53
Table 4B.4. Conclusions: Physical activity versus inactive comparisons in adults with MCI.....	56
Table 4B.5. Results overview: Physical activity interventions versus inactive comparisons for adults with MCI .....	58
Table 4C.1. Conclusions: Nutraceuticals in adults with normal cognition.....	60
Table 4C.2. Results overview: Nutraceuticals in adults with normal cognition.....	65
Table 4C.3. Results overview: Nutraceutical interventions in adults with MCI .....	76
Table 4D.1. Results overview: Diet interventions in adults with normal cognition.....	80
Table 4E.1. Components of multimodal interventions for low/medium risk of bias trials .....	83
Table 4E.2. Conclusions: Multimodal interventions versus inactive comparisons in adults with normal cognition .....	83
Table 4E.3. Results overview: Multimodal interventions versus inactive comparisons in adults with normal cognition .....	88
Table 4E.4. Results overview: Multimodal interventions versus active comparisons in adults with normal cognition .....	94
Table 4F.1. Conclusions: Hormone therapies versus inactive comparisons in adults with normal cognition .....	99
Table 4F.2. Results overview: Hormone therapies versus inactive controls in adults with normal cognition .....	106
Table 4F.3. Results overview: Hormone therapy versus active controls in adults with normal cognition .....	120
Table 4F.4. Results overview: Hormone therapy versus inactive controls in adults with MCI ..	123
Table 4G.1. Conclusions: Vitamins versus placebo in adults with normal cognition .....	127
Table 4G.2. Results overview: Vitamins versus inactive comparisons (placebo) in adults with normal cognition .....	133
Table 4G.3. Results overview: Vitamins versus active comparisons in adults with normal cognition .....	139
Table 4G.4. Conclusions: Vitamins versus inactive comparisons in adults with MCI.....	140
Table 4G.5. Results overview: Vitamins versus inactive comparisons in adults with MCI.....	142
Table 4H.1. Conclusions: Antihypertensives in adults with normal cognition .....	145
Table 4H.2. Results overview: Antihypertensive treatments in adults with normal cognition ...	150
Table 4I.1. Conclusions: Lipid lowering interventions in adults with normal cognition .....	160
Table 4I.2. Results overview: Lipid lowering interventions in adults with normal cognition ....	163
Table 4J.1. Conclusions: NSAIDs in adults with normal cognition .....	168
Table 4J.2. Results overview: NSAIDs versus inactive comparisons in adults with normal cognition .....	171
Table 4K.1. Results overview: Antidementia medication in adults with normal cognition .....	173
Table 4K.2. Conclusions: Antidementia medications in adults with MCI .....	174
Table 4K.3. Results overview: Antidementia medications in adults with MCI .....	176
Table 4L.1. Conclusions: Antidiabetic interventions in adults with normal cognition .....	178
Table 4L.2. Results overview: Antidiabetic interventions in adults with normal cognition .....	179

Table 4L.3. Results overview: Antidiabetic interventions in adults with MCI .....	181
Table 4M.1. Results overview: Other intervention in adults with normal cognition .....	185
Table 4M.2. Results overview: Other intervention in adults with MCI .....	186
Table 4N.1. Summary of agreement between biomarkers and cognitive tests .....	189
Table 5.1. Symbol sizes and related sample size information. ....	192
Table 5.2. Findings from smaller single studies for which strength of evidence was not assessed, by intervention type .....	202
Table 6.1. Summary of results chapters key messages .....	205

## Figures

Figure 1.1. Analytic framework for interventions to prevent cognitive decline, mild cognitive impairment, and clinical Alzheimer’s-type dementia .....	9
Figure 3.1. Literature flow diagram .....	16
Figure 5.1. Summary: Dementia or MCI incidence by intervention type .....	194
Figure 5.2. Summary of the tests of cognitive performance: results of ACTIVE trial .....	196
Figure 5.3. Summary of the tests of cognitive performance from additional cognitive training trials other than ACTIVE for adults with normal cognition .....	197
Figure 5.4. Summary of the tests of cognitive performance from additional cognitive training trials other than ACTIVE for adults with MCI .....	198
Figure 5.5. Summary of the tests of cognitive performance for physical activity versus inactive comparisons for adults with normal cognition .....	200

## Appendixes

Appendix A. Search Strategies
Appendix B. Risk of Bias Assessment Tool
Appendix C. Cognitive Performance Outcomes
Appendix D. Excluded References
Appendix E. Prospective Cohort Studies
Appendix F. Cognitive Training Interventions
Appendix G. Physical Activity Interventions
Appendix H. Nutraceutical Interventions
Appendix I. Diet Interventions
Appendix J. Multimodal Interventions
Appendix K. Hormone Interventions
Appendix L. Vitamin Interventions
Appendix M. Antihypertension Treatment
Appendix N. Lipid Lowering Treatment
Appendix O. Nonsteroidal Anti-Inflammatory Drugs
Appendix P. Antidementia Drugs
Appendix Q. Diabetic Medication Treatment
Appendix R. Other Interventions
Appendix S. Biomarkers

# Executive Summary

## Background

Dementia severely erodes individuals' functioning and quality of life, creates burden and stress on the entire family, and is a major predictor of institutionalization. Although the age and sex standardized prevalence of dementia and the rates of incident dementia have fallen over the last several decades,<sup>1, 2</sup> the number of U.S. adults over 70 with dementia and mild cognitive impairment is rising.<sup>3, 4</sup> Additionally, dementia-related costs are high, exceeding even those of heart disease and cancer, and are often paid directly by families.<sup>5</sup> Given such enormous family and societal burdens, identifying interventions with potential to prevent or delay the onset of dementia is an urgent public health priority. Although many putative risk factors have been identified, the challenge is to identify any interventions that can lead to reductions in dementia incidence and make them more widespread.

The terminology used to describe dementia and cognitive impairment is inconsistent and changing, although the National Institute on Aging (NIA) and the Alzheimer's Association have jointly issued criteria and guidelines.<sup>6</sup> Diagnosis of a neurocognitive disorder due to Alzheimer's disease requires steadily progressive cognitive decline from a previous level, generally with predominant early impairment in learning and memory that occurs outside the context of delirium and is not better explained by other mental disorders. If the decline interferes with independence in everyday activities, it is classified as major; if not, as mild. For this report, the term clinical Alzheimer's-type dementia (CATD) is used to recognize the clinical reality that a certain diagnosis of Alzheimer's disease is rarely possible in clinical settings and patients often have dementia from some unknown mix of etiologies. This term (CATD) is designed to be inclusive but does exclude several other forms of dementia (such as Lewy body disease, infectious disease, frontotemporal, traumatic brain injury, or isolated post-stroke dementia), including some that can otherwise be well-identified. Because the literature currently does not use the term CATD, we specified whenever the diagnosis of dementia was defined.

Some decline in cognition with aging is considered normal or inevitable, particularly for people past the age of 60 years. For example, reaction time and speed of processing are known to decline slowly throughout adulthood. Therefore, greater difficulty learning new information by 70 or 80 years old may not necessarily be a warning sign of neurocognitive disease in the absence of other signs or symptoms of cognitive difficulty. This type of normal cognitive aging is called age-related cognitive decline and is highly variable between individuals.<sup>7</sup> The relationship between age-related cognitive decline and dementia is unclear.

If the magnitude of cognitive decline exceeds a threshold (variously defined), the individual is said to have an intermediate form of cognitive impairment. This threshold may be defined symptomatically when the cognitive decline is recognized by the affected individual, caregiver, or health professional, and requires the individual to compensate using tools, such as lists, maps, or pill boxes, to continue to perform daily activities. This threshold also may be defined based upon formal cognitive testing scores below norms for younger populations, even if there are no changes in function. In 1995, Petersen et al. formally defined mild cognitive impairment (MCI) as the presence of subjective memory complaints and performance on memory testing 1.5 standard deviations below age-appropriate norms, in the setting of preserved activities of daily living.<sup>8</sup> Subsequently, the definition of MCI was broadened to include amnesic, multiple (cognitive) domain, and single non-memory domain subtypes.<sup>9</sup> MCI corresponds to mild neurocognitive disorder in the Diagnostic and Statistical Manual of Mental Disorders Fifth



Edition (DSM-5).<sup>10</sup> Roughly half of people with MCI will progress to a more severe form of cognitive decline over about 3 years.<sup>11</sup>

A separate Institute of Medicine committee (not connected with this study) recently recognized that using a history of functional decline to distinguish between MCI and dementia is a problem,<sup>7</sup> because the presence of functional impairment depends on social factors independent of the underlying disease causing cognitive impairment. Recognizing and measuring cognitive and functional decline depends upon the life-circumstances of the individual and the source of information about cognitive and functional performance (e.g., self, caregiver, and employer). For example, minor forgetfulness for a retiree may have less impact on function and be reported differently than it would for the same person still in a cognitively challenging workplace. Likewise, modest loss of numeric skills may be unreported and insignificant for many older adults, but catastrophic for a scientist or an accountant.

Alzheimer's disease is the most commonly diagnosed dementia, but people may be affected by several types of dementia simultaneously. Individuals who meet the clinical criteria for Alzheimer's disease are more likely than others to have certain genetic markers, patterns on brain imaging (e.g., hippocampal atrophy), specific types of protein accumulation in the brain, or abnormal appearance of brain cells examined at autopsy. Yet, the relationship between these laboratory or imaging findings and measures of cognition are inconsistent and it is not clear whether some of these laboratory or imaging findings are causes of or caused by Alzheimer's disease. This type of uncertainty greatly complicates efforts to prevent or slow impairments in cognition that are a prelude to Alzheimer's disease.

A number of reviews have assessed the evidence of relationships between risk and protective factors and/or cognitive decline, MCI, and CATD, including the 2015 Institute of Medicine report on cognitive aging cited above<sup>7</sup> and a 2010 Agency for Healthcare Research and Quality (AHRQ) systematic review.<sup>12</sup> Nonmodifiable risk factors for CATD include age, sex, race/ethnicity, and family history. Certain medical conditions are associated with an increased risk of developing MCI and CATD, including depression, cancer, cardiovascular disease, diabetes, delirium, thyroid disorders, chronic kidney disease, and loss of hearing and/or vision. Modifiable risk or protective factors may include diet, physical activity, education and intellectual engagement, social engagement, alcohol, smoking, and substance abuse, medications, and vitamins. Interventions represent one way to establish the veracity of risk factors. If changing a putative risk factor changes the cognitive course, it will be seen as more salient. Interventions have been developed to prevent or treat chronic diseases and to modify risk factors and protective factors. Multidomain interventions address multiple risk factors simultaneously, including nutrition, physical activity, cognitive training, social activity, and/or vascular risk factor management.<sup>13</sup>

Theories justifying various interventions to slow or prevent cognitive decline are diverse. If cognitive decline is due to natural age-related degeneration of the brain, the theory of neuroplasticity suggests that cognitive training could be useful to stimulate the brain to build additional neural pathways and to retain existing ones to build brain reserve against future decline. If brain degeneration and cognitive decline are due to toxins or lack of specific nutrients, changes in diet or nutritional supplements could be effective. If adequate blood flow to the brain is important in preventing cognitive decline, then medications and exercise that stimulate and maintain the health of the vascular system may be helpful. If inflammation is part of the disease process, anti-inflammatory drugs may be effective. These theories support prevention trials testing cognitive training, physical exercise, cardiovascular and other medications, diets, and

nutraceuticals (products derived from food sources that are purported to provide extra health benefits). Preventive efforts can target people with any level of cognitive function, from normal, to age-related cognitive decline, to MCI, and finally, to dementia.

Research participants seeking to slow or prevent age-related cognitive decline, MCI, and CATD may have more than one risk factor. CATD may result from cumulative and possibly synergistic effects. Interventions may address one or multiple possible mechanisms with complex or multiple prevention strategies. Differential effects of interventions on subgroups defined on the basis of cumulative risk factors (both modifiable and nonmodifiable) may be of concern. Many studies testing the association of preventive factors or effectiveness of interventions for preventing dementia have looked at only the one-to-one relationship with a single risk factor or intervention. Few studies used multidomain interventions, and potentially none have explored the possibility of cumulative or synergistic effects.

Timing and measurement choices affect cognitive decline prevention studies. Researchers can recruit participants at any point along the cognitive continuum. Various proposed strategies target young and middle-aged adults with no evidence of cognitive decline, older adults worried about age-related changes, people with documented MCI, and those with major neurocognitive disorders. Common diseases that cause cognitive decline, especially CATD, progress slowly. Lengthy time periods are required between an intervention and the expectation of measurable cognitive decline or function in those not receiving an effective preventive intervention; the younger the participant, the longer the latency period. Short-term benefits on cognitive tests or biomarkers are uncertain predictors of long-term effects on cognition.

Proof that an intervention prevents or delays MCI or dementia ideally includes evidence that the intervention led to fewer individuals with a subsequent diagnosis of MCI or CATD. Such measures are rarely possible, due to the extended study length required (i.e., >10 years) or the extremely large number of participants (i.e., thousands) required, plus the complexity of measuring both cognition and functional abilities. Over shorter terms and in smaller studies, changes in cognitive function are assessed using validated neurocognitive tests addressing various domains of cognition. To assess changes in brain functional abnormalities earlier or with greater sensitivity than is possible with behavior-based testing or interviews, a variety of laboratory and brain imaging tests are used as biomarker measures to look for changes in specific biologic substances, structures, or processes. Improvement or slower deterioration from baseline biomarker measures could indicate a slowing of age- or disease-related decline as a result of an intervention, to the extent that the biomarker is an accurate reflection of brain capacity and activity. As noted before, there is a good deal of inconsistency regarding the relationship between biomarkers and cognitive function.

## **Scope and Key Questions**

This systematic review is focused on intervention studies that target populations who are cognitively normal or may have age-related changes or MCI but do not yet have dementia. Specifically, this review examines the effectiveness of interventions to delay or slow cognitive decline or dementia, and did not examine the epidemiological literature on risk factors for cognitive decline or dementia. With the focus on CATD, the review does not include dementia due to specific, identifiable conditions such as Lewy body, infectious diseases, frontotemporal, and traumatic brain injury. The review does include studies addressing vascular components of mixed dementia, but clear post-stroke dementia is out of scope. Intermediate outcomes, such as measures of biomarkers and cognitive test performance, are included. However, since the review

is focused on prevention, studies must be at least 6 months in duration to demonstrate some sustainability of the intervention effects. It is important to note that this duration requirement by necessity eliminates many short-term studies in this field.

The review addresses two Key Questions (KQs) and the PICOTS (populations, interventions, comparisons, outcomes, timing, and setting) framework that address the effects of interventions for delaying or slowing age-related cognitive decline and preventing, delaying or slowing MCI and clinical Alzheimer's-type dementia. The third KQ addresses the strength of association between various intermediate outcomes (e.g., biomarkers) with MCI and CATD.

KQ 1: In adults with normal cognition, what are the effectiveness, comparative effectiveness, and harms of interventions for:

- i. Delaying or slowing age-related cognitive decline?
  - ii. Preventing, slowing, or delaying the onset of MCI?
  - iii. Preventing, slowing, or delaying the onset of clinical Alzheimer's-type dementia?
- a. Do effectiveness, comparative effectiveness, and harms of interventions differ as a function of patient characteristics (i.e., age, sex, race/ethnicity, family history, education, socioeconomic status, risk factor status)?

KQ 2: In adults with MCI, what are the effectiveness, comparative effectiveness, and harms of interventions for preventing, slowing, or delaying the onset of clinical Alzheimer's-type dementia?

- a. Do effectiveness, comparative effectiveness, and harms of interventions differ as a function of patient characteristics (i.e., age, sex, race/ethnicity, family history, education, socioeconomic status, risk factor status)?

KQ 3: What is the strength of association between outcome measures examined in KQs 1 or 2 including (but not limited to) cognitive test results, biomarkers, and brain imaging results and the incidence of MCI or clinical Alzheimer's-type dementia?

## Methods

Because of the overall plan for the use of this review given by our NIA sponsor, this project follows a unique model. The role of the Key Informants was filled by the National Academies of Sciences, Engineering, and Medicine (the National Academies) Committee on Preventing Dementia and Cognitive Impairment. The National Academies Committee will use the report to help develop its own report to the NIA on the state of knowledge on the efficacy, comparative effectiveness, and harms of interventions to prevent or delay the onset of age-related cognitive decline, MCI, or CATD. Because the National Academies Committee did not see the draft KQs, PICOTS, and analytic framework until the KQs were posted for public comment, a panel of content experts from Federal agencies acted as proxy Key Informants prior to posting. The content experts were drawn from the NIA, the National Institute of Neurological Disorders and Stroke, the Department of Veterans Affairs, the Administration for Community Living, and the Centers for Disease Control & Prevention. There was not a separate, independent Key Informant panel. The role of the Technical Expert Panel was then filled by the National Academies Committee.

A complete description of the methods can be found in the full report.

## **Literature Search Strategy**

We searched Ovid Medline<sup>®</sup>, Ovid PsycINFO<sup>®</sup>, Ovid Embase<sup>®</sup>, and the Cochrane Central Register of Controlled Trials (CENTRAL) to identify randomized controlled trials (RCTs), nonrandomized controlled trials, and prospective cohort studies published and indexed in bibliographic databases between January 2009 and September 2016. We supplemented bibliographic database searches with backward citation searches of highly relevant systematic reviews and included studies.

## **Eligibility**

We included randomized and nonrandomized controlled trials and observational studies published in English that examined one or more interventions to prevent, delay, or slow age-related cognitive decline, MCI, and CATD in adults with normal cognition and/or MCI, used a comparator group, and reported outcomes of interest in participants at least 6 months or more after the initiation of the intervention. Observational studies were included if they were prospective quasi-experimental cohort studies that had at least 250 participants per arm.

Two independent investigators independently determined study eligibility and resolved disagreements through discussions; when needed, a third investigator was consulted until consensus was achieved.

## **Data Extraction**

We extracted data from included studies into evidence tables including author, year of publication, population, intervention, comparison, outcomes, timing, and setting. Results were extracted only from studies assessed as having low to moderate risk of bias. Initial data abstraction was quality checked by a second investigator.

## **Quality (Risk of Bias) Assessment of Individual Studies**

The risk of bias of eligible studies was assessed by two independent investigators using an instrument based on AHRQ guidance.<sup>14</sup> Two investigators consulted to reconcile any discrepancies in overall risk of bias assessments and, when needed, a third investigator was consulted to reconcile the summary judgment. Overall summary risk of bias assessments for each study were classified as low, medium, or high based on the collective risk of bias inherent in each quality domain and confidence that the results are believable given the study's limitations.

## **Data Synthesis**

We summarized results in summary tables and synthesized evidence for each unique population, intervention, comparison, and outcome and harm. We organized evidence tables and results by intervention type and population addressed. Subgroups, where possible, were examined and reported separately.

We reported summary results for primary and intermediate outcomes and harms. Intermediate cognitive outcomes were assessed using neuropsychological tests or biomarkers. Because studies used a highly varied set of tests, we opted to group them into categories to facilitate analysis. We categorized neuropsychological tests for extraction and analysis by their purpose and/or what they attempt to measure, such as specific cognitive domains (e.g., executive function, memory) (Appendix C of the full report). Since cognitive interventions often targeted

individual cognitive functions, we reported on these domains in greater detail than was necessary for other sections of the report. The wide variety and inconsistency of tests used made it difficult to summarize the findings and prevented meta-analysis. For the cognitive training interventions we did use Cohen's D to estimate effect size where possible.

## Strength of the Body of Evidence

We evaluated the overall strength of evidence for MCI or CATD incidence, or cognitive performance domains based on four strength of evidence domains: (1) study limitations (internal validity including risk of bias, either low or medium); (2) directness (single, direct link between the intervention and outcome); (3) consistency (similarity of effect direction and size); and (4) precision (degree of certainty around an estimate) with the study limitations domain having considerable importance.<sup>15</sup> Study limitations were rated as low, moderate, or high according to study design and conduct. The possible strength of evidence grades were:

- **High:** High confidence that the evidence reflects the true effect. Further research is unlikely to change the estimates.
- **Moderate:** Moderate confidence that the estimate reflects the true effect. Further research may change estimates and our confidence in the estimates.
- **Low:** Limited confidence that the estimate of effect lies close to true effect. Further research is likely to change confidence in the estimate of effect, and may change the estimate.
- **Insufficient:** Evidence is either unavailable or does not permit a conclusion.

## Applicability

Applicability of studies was determined according to the PICOTS framework. Study characteristics that were evaluated to assess applicability included, but were not limited to, the population from which the study participants were enrolled, narrow eligibility criteria, baseline cognitive function, and patient and intervention characteristics different than those described by population studies.<sup>16</sup>

## Results

We identified 9,448 unique references, 263 of which were eligible for our review. Table A provides a summary of the key messages from the results chapters detailing intervention results. Of the 13 classes of interventions examined, we found no high-strength evidence for any intervention to delay or prevent age-related cognitive decline, MCI, and/or CATD. A few specific interventions reached moderate strength evidence for *no* benefit in cognitive performance: vitamin E in women; and angiotensin converting enzyme and thiazide versus placebo and angiotensin receptor blockers versus placebo on specifically brief cognitive screening tests. We found low-strength evidence that the selective estrogen receptor modulator (SERM) raloxifene reduced risk of probable MCI. However, there was also low-strength evidence that estrogen replacement with or without progesterone therapy increased the risk of MCI and CATD.

A few intervention types show more potential than others at benefiting cognitive performance. We found moderate-strength evidence that cognitive training can improve cognitive function in the domain trained up to 2 years (low strength of evidence at 5 and 10 years), but generalization/transfer to other domains was rare. Although there was some evidence

for improvement in instrumental activities of daily living (IADLs), these studies had design problems and short-term studies may not predict long-term outcomes. Moreover, IADLs may be a benefit *per se*, but are not directly linked to dementia.

Although the evidence is less compelling, physical activity and perhaps vitamin B<sub>12</sub> plus folic acid may also show potential benefit. While the majority of the results for physical activity showed little to no effect, the percent of results showing benefit in cognitive performance, particularly in resistance training and aerobic exercise, were unlikely to be explained solely by chance. Results for B<sub>12</sub> plus folic acid are more spotty and so less persuasive; vitamin B<sub>12</sub> and folic acid showed benefit in brief cognitive test performance and memory, but not for executive/attention/processing speed. There were also conflicting findings for B<sub>12</sub> when used in combination with other B vitamins.

Notably, not all interventions for risk factors of interest were addressed by the eligible literature sufficiently for an assessment of these strategies to be made. For example, obesity is a risk factor of concern but it can be studied only in the context of prevention/intervention by assessing the impact of weight loss interventions. In the current systematic review, only one medium risk of bias trial specifically targeted weight loss. Some classes of interventions of interest were absent from the literature altogether, including interventions aimed at depression, smoking cessation, or community-level interventions. Other intervention types were represented by a literature set that was relatively sparse and likely did not represent a full range of possible interventions designs, such as sleep interventions. Lastly, with respect to the stroke prevention literature, although this study included the literature relevant to the vascular components of mixed dementias, it deliberately excluded dementia caused specifically by stroke. Thus, the findings may underestimate the effects of controlling blood pressure on dementias as a whole.

**Table A. Summary of key messages by intervention class**

Intervention	Key Message
Cognitive Training	<ul style="list-style-type: none"> <li>• Most studies addressed intermediate outcomes of cognitive training in terms of cognitive performance and a few measures of brain activity.</li> <li>• The Advanced Cognitive Training for Independent and Vital Elderly (ACTIVE) trial provided the strongest and most comprehensive design to assess the effect of cognitive training on cognitive performance for older adults with normal cognition. Its results provide moderate-strength evidence at 2 years (but low-strength at 5 and 10 years) that cognitive training can improve cognitive function in the domain trained, but transfer to other domains was rare. There is some suggestion that processing speed training is associated with improved IADL performance, but longer term studies were rated as low strength of evidence.</li> <li>• Other than the ACTIVE trial, the few studies that examined CATD incidence or cognitive performance showed mixed results.</li> </ul>
Physical Activity Interventions	<ul style="list-style-type: none"> <li>• Studies of physical activity interventions examined a wide variety of activities potentially targeting different pathways to affect cognition.</li> <li>• Evidence is insufficient to conclude whether physical activity interventions prevent MCI or CATD incidence.</li> <li>• Low-strength evidence shows that multicomponent physical activity interventions offer no clear benefit in cognitive performance over attention control in adults with normal cognition.</li> <li>• Evidence was insufficient to conclude whether other types of physical activity interventions had benefits for cognitive outcomes in adults with normal cognition.</li> <li>• While the majority of results showed no significant difference, the pattern of results across very different types of physical activity interventions provides an <i>indication</i> of effectiveness of physical activity.</li> </ul>

Nutraceutical Interventions	<ul style="list-style-type: none"> <li>• Low-strength evidence suggests omega-3 fatty acids and ginkgo biloba did not reduce CATD incidence or improve cognitive performance in adults with normal cognition.</li> <li>• Evidence is insufficient to conclude whether resveratrol or plant sterol/stanol esters reduced CATD incidence or improved cognitive performance in adults with normal cognition.</li> <li>• Few studies examined the effects of nutraceuticals on adults with MCI.</li> </ul>
Diet Interventions	<ul style="list-style-type: none"> <li>• Evidence is insufficient to conclude whether protein supplementation or energy-deficit diets have an effect on cognitive performance or incidence of MCI or CATD.</li> </ul>
Multimodal Interventions	<ul style="list-style-type: none"> <li>• Evidence is insufficient to conclude whether most multimodal interventions offer benefits for cognitive performance or incidence of MCI or CATD, largely because few studies have examined interventions with similar components.</li> <li>• Low-strength evidence shows that a multimodal intervention composed of diet, physical activity, and cognitive training provides benefits in executive function/attention/processing speed.</li> <li>• Low-strength evidence shows that a multimodal intervention composed of lifestyle advice and drug treatment is not effective in reducing incidence of CATD or benefiting brief cognitive test performance or memory.</li> </ul>
Hormone Therapy Interventions	<ul style="list-style-type: none"> <li>• Hormone therapy shows mixed results of harm and benefit.</li> <li>• Low-strength evidence suggests that estrogen therapy may slightly increase the risk of probable MCI and CATD when the two diagnostic categories are examined together.</li> <li>• Low-strength evidence suggests that estrogen plus progestin therapy may slightly increase the risk of probable CATD.</li> <li>• Low-strength evidence suggests that raloxifene may decrease the risk of MCI but not the risk of CATD or of a combined outcome of MCI or CATD compared to placebo.</li> <li>• In addition to these outcomes, hormone therapy has been associated with serious adverse events, including increased risk of certain cancers and cardiovascular disease</li> </ul>
Vitamin Interventions	<ul style="list-style-type: none"> <li>• Moderate-strength evidence shows no benefit in cognitive performance for vitamin E in women.</li> <li>• There was some signal that B<sub>12</sub> plus folic acid may benefit brief cognitive test performance and memory but not executive function/attention/processing speed.</li> <li>• Low-strength evidence for folic acid (0.4 mg) plus vitamin B<sub>12</sub> (0.1-0.5 mg) shows benefit in brief cognitive test performance and memory.</li> <li>• Moderate-strength evidence shows no benefit for folic acid (0.4 mg) plus B<sub>12</sub> (0.1-0.5 mg) versus placebo for executive/attention/processing speed.</li> <li>• Low-strength evidence for vitamin B<sub>12</sub> (0.02-0.5 mg), B<sub>6</sub> (3-10 mg), and folate (0.56-1 mg) shows no benefit for executive/attention/processing speed.</li> <li>• Low-strength evidence shows no benefit in cognitive performance for multivitamins, vitamin C (in women), vitamin D with calcium (in women), or beta carotene (in women).</li> <li>• Low-strength evidence shows no benefit in incident MCI or CATD for multivitamins or vitamin D with calcium.</li> <li>• In adults with MCI, low-strength evidence shows no benefit for vitamin E in incident CATD.</li> </ul>
Antihypertensive Treatment	<ul style="list-style-type: none"> <li>• Generally, low-strength evidence shows that 3 to 4.7 years of antihypertensive treatment regimens versus placebo appear to have no benefit on cognitive test performance in adults with normal cognition.</li> <li>• Moderate-strength evidence shows that angiotensin converting enzyme (ACE) plus thiazide versus placebo and angiotensin receptor blockers (ARBs) versus placebo have no benefit on brief cognitive screening tests.</li> <li>• Low-strength evidence shows that intensive versus standard antihypertensive control shows no benefit on cognitive test performance.</li> <li>• Low-strength evidence shows no benefit on cognitive test performance of</li> </ul>

	<p>any fixed antihypertensive treatment regimen versus another among those directly compared.</p> <ul style="list-style-type: none"> <li>• Effects of stepped multiple agent antihypertensive medication regimens to reduce risk of dementia are inconsistent; one trial showed a positive effect but three other trials found no effect of antihypertensive treatment on CATD incidence.</li> <li>• The only two trials that reported subgroup data found no differential effect of treatment group on cognition by participant age or other baseline characteristics.</li> </ul>
Lipid Lowering Treatment	<ul style="list-style-type: none"> <li>• Evidence was insufficient to assess the effect of 5 years of statin treatment on the risk of incident CATD or for preventing MCI.</li> <li>• Low-strength evidence shows a small, 6-month improvement in executive/attention/ processing speed with placebo treatment that was not found with statin treatment, presumed to be due to practice effects and of uncertain clinical significance.</li> <li>• Low-strength evidence shows no benefit on brief cognitive test performance, executive/attention/processing speed, or memory for statin plus fenofibrate versus statin plus placebo in adults with normal cognition.</li> <li>• Evidence was insufficient to assess whether effects of statins on any cognitive outcomes differ by patient age, baseline lipid level, or other characteristics.</li> </ul>
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)	<ul style="list-style-type: none"> <li>• No evidence was available for the effect of low-dose aspirin on MCI or CATD incidence.</li> <li>• Low-strength evidence shows no benefit for low-dose aspirin on brief cognitive screening tests, multidomain neuropsychological performance, or memory, even with 10 years of use.</li> <li>• Low-strength evidence shows no benefit for NSAIDs, including both selective and nonselective cyclooxygenase-2 (COX-2) inhibitors, to reduce CATD incidence, or to benefit multidomain neuropsychological performance or memory, with 8 years of followup after 1 to 3 years of use.</li> </ul>
Antidementia Treatments	<ul style="list-style-type: none"> <li>• Low-strength evidence shows AChEI antidementia drugs did not reduce the incidence of CATD in persons with MCI over 3 years; evidence is insufficient for persons with normal cognition.</li> <li>• Low-strength evidence shows AChEIs for 3 years provide no significant effect on cognitive performance in adults with MCI.</li> </ul>
Diabetes Medication Treatment	<ul style="list-style-type: none"> <li>• No studies reported on the effect of diabetes treatment on the risk of incident clinical diagnoses of MCI or CATD.</li> <li>• In middle-aged older adults with diabetes and presumed normal cognition, low-strength evidence shows intensive versus standard glycemic control had no significant effect on cognitive performance.</li> </ul>
Other Interventions	<ul style="list-style-type: none"> <li>• Evidence was insufficient for lithium, a nicotine patch, individual piano instruction, multitask rhythmic exercise to music, sleep interventions, and social engagement.</li> <li>• We found no relevant studies for depression treatments, smoking cessation, or community-level interventions.</li> </ul>
Agreement of Biomarkers and Measures of Cognitive Performance	<ul style="list-style-type: none"> <li>• Only a few (9) low or medium risk of bias studies for cognitive performance also used biomarkers; most of those used some form of brain scan.</li> <li>• The overall rate of agreement between biomarkers and cognitive testing was 57%, but 90% of that agreement resulted from both approaches showing no effect. When the biomarker showed a significant result, there was agreement in 25% of cognitive tests conducted.</li> </ul>

AChEI= acetylcholinesterase inhibitor; CATD= clinical Alzheimer’s-type dementia; IADL=instrumental activities of daily living; MCI=mild cognitive impairment; NSAIDs=nonsteroidal anti-inflammatory drugs

## Discussion

Research on interventions to prevent or slow age-related cognitive decline, MCI, or CATD has focused largely on their effect on decline in measures of cognition. The reasons for this are many, including: 1) Meaningful investigation of dementia-onset requires either a long followup



period or a large cohort of older individuals. 2) Long followups in the target population face serious attrition problems due to death or comorbidities. 3) The risk of selective attrition whereby the intervention might also affect mortality risk and hence create attrition bias if survivors have more health problems.

Interventions to slow or prevent age-related cognitive decline, MCI, or CATD are often chosen because of evidence from epidemiological studies that examine actions of individuals at higher or lower than expected risk for these conditions. In other cases, theories of brain function (e.g., neuroplasticity) justify the development and testing of experimental interventions. Not all such interventions would be expected to be found to be effective in controlled experiments. This systematic review cast a wide net and only a few interventions showed any evidence of an effect, all of which raise many questions. Most of the studies showed no benefit to those receiving interventions compared to control groups. Four intervention classes show some positive results and seem the most promising for further study: cognitive training, physical activity, raloxifene, and vitamin B<sub>12</sub> although the evidence for vitamin B<sub>12</sub> and raloxifene is lower than the others. Problems with study designs make strong conclusions difficult. Assessing the strength of evidence for negative findings is a special challenge. There is a persistent concern about Type II errors.

## **Dementia Incidence**

The preponderance of studies showed no effect. Raloxifene may reduce risk of MCI. However, in the case of estrogen therapy (with or without progesterone), the control groups did better than the experimental groups, suggesting a de facto harm.

Cognitive decline is almost always a precursor of dementia. Impairment below a designated threshold helps to define CATD and/or MCI. But not all individuals with cognitive decline develop CATD, and we do not know whether interventions that show effects on selected areas of cognitive performance can also stave off dementing conditions. Presumably, the broader the effect an intervention has on multiple cognitive domains, the more likely it will also have preventive effects. But improving (or slowing the decline of) performance in one given cognitive domain does not automatically imply protection against dementia. For example, some cognitive training does seem to improve performance in the specific area of the training, but the results do not generalize to improved performance in other cognitive domains. The strongest effect of cognitive training found in this analysis was in enhancing processing speed, but extrapolating that benefit to a reduced risk of CATD is not yet established. For example, improving a person's useful field of vision can help with driving a car, and it might facilitate some IADLs, but neither of those benefits necessarily slows the onset of CATD.

## **Cognitive Performance**

The studies used a wide variety of instruments to assess cognitive performance. To facilitate analysis and interpretation, we categorized tests and measures into four groups (brief cognitive test performance, multidomain neuropsychological performance, executive function/attention/processing speed, and memory); some tests fit into more than one of these four groups.

Cognitive training studies were dominated by the ACTIVE trial, which investigated the effects of different types of group-based cognitive training on various cognitive performance outcomes for presumably cognitively healthy participants. For the most part, the training had sustained effects (up to 2 years) on cognitive performance in the domain trained but there was little evidence of generalization to other cognitive domains. There was an effort to assess the

effects of booster training, but assignment to receive a booster was not random; participants with high initial compliance received most of the boosters. More work on cognitive training with longer followup is needed.

While the majority of results for physical activity showed no significant difference, resistance training and aerobic exercise produced some positive results in cognitive performance, although neither intervention shows an overwhelming or consistent effect.

While the overall findings for the remaining interventions showed little benefit, several studies of the treatment of hypertension showed improved cognitive functioning. Given that hypertension control is already a goal for the treatment of cardiovascular disease, these positive outcomes can be viewed as a potential additional benefit from efforts to control blood pressure. Ironically, if the hypertensive treatment lowered mortality, its benefits for dementia might be underestimated because of selective attrition.

Vitamin B<sub>12</sub> and folic acid also showed benefit in brief cognitive test performance and memory, but not for executive/attention/processing speed. There were also conflicting findings for B<sub>12</sub> when in combinations with other B vitamins. The other vitamins had no substantial benefit on cognition. Little or no benefit for cognitive performance was shown for multivitamins, vitamin C, vitamin D with calcium, or beta carotene (all low strength of evidence). Vitamins may work differently if given to a person to address an insufficiency compared to a megadose for a person with otherwise adequate basic vitamin intake. The participants varied widely in this and other respects.

The role of biomarkers as intermediate outcomes is unclear. Our results show a low level of agreement between the biomarker measures (which were primarily some form of brain scan) and various cognitive tests. More needs to be known about their ability to predict the clinical course of persons with various levels of cognitive function.

## **Limitations of the Review Process**

This review encountered several limitations, including but limited to those stemming from the topic and our approach to address it. For example, (as requested) we deliberately excluded dementias with specific and clear etiologies, including stroke. By doing so, we may underestimate the importance of hypertension treatment. The outcomes of interest were inconsistently defined in the literature, and there were numerous and widely varied interventions to address those outcomes. Other limitations arose from conceptual and methodologic issues with eligible studies. These included sample size, length of followup, measurement issues, and attrition. Our search strategy was challenging to design given the wide range of interventions and types of studies measuring cognitive outcomes as secondary outcomes. We designed a strategy to capture a wide variety of intervention types and outcomes with a degree of precision making the review process feasible and efficient. The scale and scope of the topic made identifying all relevant studies extremely difficult. We addressed this by supplementing our bibliographic database searches with citation searches.

To address the multiplicity of cognitive performance tests used, we arbitrarily clustered tests into domains. Because these domains were composites of various tests with different scoring systems, meta-analysis proved unwieldy to conduct. Instead we opted to simply show the proportion of tests.

Assessing and interpreting the strength of evidence for many studies that showed no difference was difficult, especially when we were unable to use meta-analysis to address small sample size issues. Several reviewers urged a clear distinction between the absence of strong

evidence of an effect and strong evidence of no effect. We have tried to make that distinction whenever feasible.

Searches were difficult because key words could only identify studies that assessed cognitive performance outcomes as secondary outcomes if the study abstract listed the cognitive performance outcomes. Finding a balanced set of articles in cohort and add-on studies was difficult because the results were more likely to be noted in abstracts if they were positive.

## **Prioritizing Future Research**

Effective use of scarce research dollars will require substantial investments in a limited number of well-designed trials of sufficient power and duration. Interventions selected to receive funding will need to be chosen carefully. The full effects of hypertension control should include attention to stroke. Priority should be given to interventions that already show some promise, most notably cognitive training and physical activity. However, the decision to exclude specific stroke-related dementia may underestimate the effect of antihypertension treatment. Although it cannot be said with complete certainty that other types of interventions have no effect, work examining NSAIDS, statins, nutraceuticals, and others has shown little promise. Moderate-strength evidence showing no benefit for some antihypertensive treatments and vitamin E for cognitive performance support assigning low priority to these areas.

## **Recommendations for Design and Methodology of Future Studies**

Future trials such as RCTs or pragmatic trials using electronic health records from health systems should be designed *intentionally* to study methods of slowing and preventing age-related cognitive decline, MCI, and CATD incidence. Many studies originally designed for other purposes have added cognitive measures post-hoc. These “add-on” trials have frequently used less sophisticated measures, have not adequately evaluated baseline characteristics, and have not randomly assigned participants, all of which confound data and limit conclusions.

Another common limitation is that most trials have been too short to observe clinically meaningful change in cognitive function. Many were designed with an intervention period of one year or less with limited or no follow-up, making it impossible to draw conclusions about longer-term outcomes in most cases. Trials that address dementia incidence must be even longer. Designing trials of appropriate duration requires careful consideration of several key factors, including cohort characteristics (e.g., subject age, presence or absence of known risk factors of cognitive decline, cognitively normal versus MCI) and whether outcomes are intended to detect a delay in cognitive decline or a reduction in dementia incidence. Focusing on longitudinal investigations with followup periods of 10 years or more would greatly benefit the field and provide more insight about prevention. This will also require designing studies to actively minimize, or at least appropriately deal with, attrition. One way to accomplish this is by prioritizing enrollment of older cohorts although it is important to note that the most ideal age for intervention remains unknown and may vary by type of intervention. The danger of this strategy, however, lies in the possibility that treatment effects are stronger for persons in midlife than in late life. Epidemiological studies in hypertension point in this direction.

In addition to dedicated trials and longer intervention and followup periods, studies that assess dose-response relationships and underlying mechanisms of action are needed. Establishing the dose-response relationship can be done in two ways. Multiple arms of varying dosage could be used initially; alternatively, once an effect has been demonstrated, studies that assess dose-response relationships and underlying mechanisms of action could be implemented. Finally, the

vast majority of studies testing the effectiveness of interventions to delay or slow age-related cognitive decline or prevent onset of MCI or CATD have focused narrowly on a single intervention. Given that the causes of dementia are complex and multifactorial, studies should address interventions that modify multiple risk factors. Several such trials, focusing on multiple risk factors simultaneously (multi-domain interventions) have been initiated.<sup>12</sup> Three of these trials (FINGER, MAPT, PreDIVA) enrolled older adults and implemented multi-domain interventions with components addressing nutrition, physical activity, cognitive training, social activity, and/or vascular risk factor management. Of the two studies that have published results, while the more clinical multidomain PreDIVA trial did not find benefit,<sup>17</sup> results from the FINGER trial, which used a more lifestyle-based approach, were promising.<sup>18</sup> More studies assessing a combination of interventions would benefit the field. The key issue in designing such studies is choosing the best “package” of interventions. Current wisdom suggests that RCTs should use the most powerful combinations and leave the decisions about less potent versions to subsequent studies. The first critical question is whether a combination of strong interventions can achieve the goal.

## Measurement

Consistent shortcomings across existing studies reveal many opportunities to improve the measurement techniques of future trials. Future research should employ a more consistent set of validated tests to assess cognitive performance. To date, cognitive outcomes have been measured using a wide array of neuropsychological tests. The sheer volume of cognitive measures used in the literature complicates comparisons across trials, particularly when an attempt is made to cluster or group tests into domains as most do not fit neatly into one category. Research in the field could be enhanced greatly through development of consensus guidelines that encourage investigators to use a common core standardized battery or batteries of tests in these trials. Although no one measure is adequate for all applications, movement towards the use of batteries with good psychometric qualities and already in common use in aging populations (such as those included in the National Alzheimer’s Coordinating Center data set ([https://www.alz.washington.edu/WEB/forms\\_uds.html](https://www.alz.washington.edu/WEB/forms_uds.html)) or drawn from the National Institutes of Health Toolbox (<http://www.healthmeasures.net/explore-measurement-systems/nih-toolbox>)) could potentially help to narrow the field.

The baseline status of participants needs to be better measured and documented. Baseline cognitive status is variously described and often not tested. While some researchers measured baseline cognitive function as part of the trial design, the degree of measurement varied widely (e.g., brief cognitive screening versus more elaborate neuropsychological test performance). Finally, future research trials that include incident CATD as a study outcome should evaluate participants using formal diagnostic guidelines for Alzheimer’s disease such as those from the NIA and the Alzheimer’s Association.<sup>6</sup> Including both measures of cognitive performance and CATD incidence as study outcomes would allow researchers to better understand how these two constructs are related. For trials that cannot include incident CATD as an outcome for whatever reason, more work is needed to define what degree of change in neuropsychological test performance is considered clinically meaningful. Consistently including objective and performance-based measures of everyday function (IADLs) in future trials may help address these questions.

## Conclusion

At present, there is not sufficient strength of evidence to justify large-scale investing in public health activities aimed at preventing dementia; some results may be viewed as potential added benefits to already identified public health interventions. There was moderate-strength evidence that cognitive training improved performance in the trained cognitive domains, but not in domains not trained, and the evidence of an effect of cognitive training on reducing CATD incidence was weak. There was a mix of positive and negative findings, all of low strength, for physical activity, antihypertensives, NSAIDs, vitamin B<sub>12</sub>, nutraceuticals, and multimodal interventions. Signals seem more promising for resistance training and aerobic exercise, and vitamin B<sub>12</sub>.

The substantial work on modifiable risk factors would be better informed by testing interventions that address them to establish their putative causal role. A number of intervention areas, some of which have been identified as presumptive risk factors, do not seem fruitful avenues for further study; resources should be directed toward more promising interventions. Longer, larger, and better studies are needed. Future research on interventions should address methodological problems uncovered in this review, including using a variety of different outcome measures (cognitive tests) and short followups. For longer studies, attrition is a major problem. More work is needed to understand the relationship between intermediate outcomes like cognitive testing and the onset of dementia.

## References

1. Langa KM, Larson EB, Crimmins EM, et al. A Comparison of the Prevalence of Dementia in the United States in 2000 and 2012. *JAMA Internal Medicine* 2016 Nov 21, 2016doi: 10.1001/jamainternmed.2016.6807. PMID: 27893041.
2. Satizabal CL, Beiser AS, Chouraki V, et al. Incidence of Dementia over Three Decades in the Framingham Heart Study. *N Engl J Med*. 2016 Feb 11;374(6):523-32. doi: 10.1056/NEJMoa1504327. PMID: 26863354.
3. Plassman BL, Langa KM, Fisher GG, et al. Prevalence of cognitive impairment without dementia in the United States. *Ann Intern Med*. 2008 Mar 18;148(6):427-34. PMID: 18347351.
4. Williams JW, Plassman BL, Burke J, et al. Preventing Alzheimer's Disease and Cognitive Decline (Prepared by the Duke Evidence-based Practice Center Under Contract No. HHS 290-2007-10066-I). Rockville, MD: 2010. Available at <http://effectivehealthcare.ahrq.gov/>.
5. Kelley A, McGarry K, Gorges R, et al. The Burden of Health Care Costs for Patients With Dementia in the Last 5 Years of Life. *Burden of Health Care Costs for Patients With Dementia*. *Ann Intern Med*. 2015; Published online 27 October 2015 doi:10.7326/M15-0381. PMID: 26502320
6. Jack CR, Jr., Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's & Dementia*. 2011 May;7(3):257-62. doi: 10.1016/j.jalz.2011.03.004. PMID: 21514247.
7. IOM (Institute of Medicine). *Cognitive aging: progress in understanding and opportunities for action*. Washington, DC: The National Academies Press; 2015.
8. Petersen RC, Smith GE, Ivnik RJ. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. [Erratum appears in *JAMA* 1995 Aug 16;274(7):538] *1995 JAMA* 273(16):1274-1278. PMID: 7646655
9. Petersen RC, Doody R, Kurz A. Current concepts in mild cognitive impairment." *Archives of Neurology* 2001 58(12):1985-1992. PMID: 11735772.
10. Petersen RC. Mild cognitive impairment as a diagnostic entity. *Journal of Internal Medicine*. 2004 Sep;256(3):183-94. PMID: 15324362.
11. Cooper C, Sommerlad A, Lyketsos CG, et al. Modifiable predictors of dementia in mild cognitive impairment: a systematic review and meta-analysis. *American Journal of Psychiatry*. 2015 Apr;172(4):323-34. doi: <http://dx.doi.org/10.1176/appi.ajp.2014.14070878>. PMID: 25698435.
12. Williams JW, Plassman BL, Burke J, et al. Preventing Alzheimer's disease and cognitive decline. Evidence Report/Technology Assessment. 2010 Apr(193):1-727. PMID: 21500874.
13. Solomon A, Mangialasche F, Richard E, et al. Advances in the prevention of Alzheimer's disease and dementia. *Journal of Internal Medicine*. 2014;275(3):229-50. PMID: 24605807.
14. Viswanathan M, Ansari M, Berkman N, et al. Assessing the Risk of Bias of Individual Studies in Systematic Reviews of Health Care Interventions AHRQ. Agency for Healthcare Research and Quality; March 2012. *Methods Guide for Comparative Effectiveness Reviews*. AHRQ Publication No. 12-EHC047-EF. Available at <http://effectivehealthcare.ahrq.gov/>.
15. Berkman ND, Lohr KN, Ansari M, et al. Grading the strength of a body of evidence when assessing health care interventions: an EPC update. *J Clin Epidemiol*. 2015 Nov;68(11):1312-24. doi: 10.1016/j.jclinepi.2014.11.023. Epub 2014 Dec 20. PMID: 25721570
16. Atkins D, Chang S, Gartlehner G, et al. Assessing the applicability of studies when comparing medical interventions. Agency for Healthcare Research and Quality; January 2011. *Methods Guide for Comparative Effectiveness Reviews*. AHRQ Publication No. 11-EHC019-EF. Available at <http://effectivehealthcare.ahrq.gov/>.

17. Moll van Charante EP, Richard E, Eurelings LS, et al. Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA): A cluster-randomised controlled trial. *The Lancet*. 2016 Aug;388(10046):797-805. doi: <http://dx.doi.org/10.1016/S0140-6736%2816%2930950-3>. PMID: 27474376
18. Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. *Lancet*. 2015 Jun 6;385(9984):2255-63. doi: 10.1016/S0140-6736(15)60461-5. PMID: 25771249.

# Chapter 1. Introduction

## Background

Dementia severely erodes individuals' functioning and quality of life, creates burden and stress on the entire family, and is a major predictor of institutionalization. Although the age and sex standardized prevalence of dementia and the rates of incident dementia have fallen over the last several decades,<sup>1, 2</sup> the number of U.S. adults over 70 with dementia and mild cognitive impairment is rising.<sup>3, 4</sup>

Additionally, dementia-related costs are high, exceeding even those of heart disease and cancer, and are often paid directly by families.<sup>5</sup> Given such enormous family and societal burdens, identifying interventions with potential to prevent or delay the onset of dementia is an urgent public health priority. Although many putative risk factors have been identified, the challenge is to identify any interventions that can lead to reductions in dementia incidence and make them more widespread.

## Cognitive Impairment

### Dementia—Definitions and Diagnostics

Research on dementia has been affected by changes in nomenclature and classification. Most published work was done under the Fourth Edition of the Diagnostic Statistical Manual of Mental Disorders (DSM-4), but the Fifth Edition (DSM-5) published in 2013 made substantive changes to the language describing cognitive impairment. It laid out a set of six distinct neurocognitive domains, some of which are associated with specific parts of the brain. These changes can affect the way various elements of dementia are diagnosed and viewed. Other tests, such as blood tests or radiologic images, are often performed to rule out different diagnoses. The term dementia is slowly being replaced by the DSM-5 defined phrase “major neurocognitive disorder,” which is more inclusive than dementia. For example, the earlier definition of dementia excluded those with only loss of ability to express or understand speech due to a stroke, while DSM-5 would include such individuals in its more broadly defined syndrome.

Even beyond the shift from DSM-4 to DSM-5, the terminology used to discuss dementia and cognitive impairment is inconsistent and changing. Several criteria have been used to diagnose dementia (typically dementia-causing diseases), including criteria described by the National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and the Alzheimer's Disease and Related Disorders Association (ADRDA) in 1983.<sup>6</sup> More recently, the National Institute on Aging (NIA) and the Alzheimer's Association jointly issued criteria and guidelines.<sup>7</sup> Specific etiologies of neurocognitive disorders include Alzheimer's disease and other less common conditions (e.g., frontotemporal lobar degeneration, Lewy body disease, traumatic brain injury, etc.).<sup>8</sup> Diagnosis of a neurocognitive disorder due to Alzheimer's disease requires steadily progressive cognitive decline, generally with early predominant impact on the cognitive domain of learning and memory, from a previous level occurring outside the context of delirium not better explained by other mental disorders. If the decline interferes with independence in everyday activities, it is classified as major; if not, mild. Other tests, such as blood tests or radiologic images, are often performed to rule out



different diagnoses. For this report, the term clinical Alzheimer's-type dementia (CATD) is used to recognize the clinical reality that a precise diagnosis of Alzheimer's disease is rarely available and clinicians are often working with patients with dementia from some unknown mix of etiologies. This term (CATD) is designed to be inclusive but does exclude several other forms of dementia (such as Lewy body disease or infectious disease; see Table 1.1), including some that can otherwise be well-identified). Note that the literature currently does not use the term CATD; we specified whenever the diagnosis of dementia was defined.

## **Age-Related Cognitive Decline and Mild Cognitive Impairment—Definitions and Diagnostics**

Some subtle decline in cognition associated with aging is considered normal or inevitable, particularly for people past the age of 60 years. For example, reaction time and speed of processing are known to decline slowly throughout adulthood. Therefore, greater difficulty learning new information by 70 or 80 years old may not necessarily be a warning sign of neurocognitive disease in the absence of other signs or symptoms of cognitive difficulty.

If the extent of decline crosses a threshold (variously defined), the individual is said to have some intermediate form of cognitive impairment. One way of defining this threshold is when the decline in cognition is recognized by an individual, caregiver, or health professional and requires the individual to compensate using tools such as lists, maps, or pill boxes to continue to perform daily activities. Another way cognitive decline has been defined is based upon formal cognitive testing scores below norms for younger populations, even if there are no changes in function. After a variety of terms were proposed for such early or minimal changes in cognition, in 1988 the term mild cognitive impairment (MCI) was coined which compares an individual's cognitive performance against same-aged normative samples.<sup>9</sup> Roughly half of people with MCI will progress to a more severe form of cognitive decline over about 3 years.<sup>10</sup> The relationship between progression from overall cognitive decline to dementia is less clear.

Petersen's criteria are typically used to diagnose MCI as characterized by a subjective decline in cognition and objective neurological testing threshold without a loss of function. MCI corresponds to mild neurocognitive disorder in the DSM-5.<sup>11</sup> In contrast, cognitive aging that is the process of normal changes that occur as individuals age is called age-related cognitive decline and is highly variable.<sup>12</sup>

## **Distinguishing Between Mild Cognitive Impairment and Dementia**

A separate Institute of Medicine (IOM) committee (not connected with this study) has recently recognized potential problems with using cognitive and functional decline elements of the definition for dementia and MCI.<sup>12</sup> They note, "The natural history that leads to Alzheimer's-type dementia could be summarized as follows: persons with normal cognition start developing deterioration in their cognitive performance of slow onset and progression. When this deterioration achieves a 'clinically significant' level of cognitive deterioration that is documented objectively, this level of deterioration may be called cognitive impairment. This cognitive impairment may or may not be accompanied

by subjective cognitive complaints. If the cognitive impairment is not accompanied by significant functional impairment (i.e., persons can live independently despite cognitive impairment), the cognitive impairment can be termed *mild cognitive impairment* or *cognitive impairment without dementia*. If deterioration in cognitive performance continues to the point where a person cannot maintain independent function, the cognitive impairment is called *dementia*. Given this natural history, cognitive performance is recognized as a patient-centered outcome.” The problem with using such criteria to define dementia and MCI is that functional impairment depends on social factors independent of the underlying disease causing cognitive impairment. Recognizing and measuring cognitive and functional decline depend upon the life-circumstances of the individual and the source of information about cognitive and functional performance (e.g., self, caregiver, and employer). For example, minor forgetfulness for a retiree may have less impact on function and be reported differently than it would for the same person still in a cognitively challenging workplace. Likewise, modest loss of numeric skills may be unreported and insignificant for many older adults, but catastrophic for a scientist or an accountant.

## Causes of Cognitive Impairment

Dozens of specific diseases can cause major neurocognitive disorder (Table 1.1). Alzheimer’s disease is the most common diagnosis in this set, but persons with dementia may experience several types simultaneously. Individuals who meet the clinical criteria for Alzheimer’s disease are more likely than others to have certain genetic markers, patterns on brain imaging (e.g. atrophy), specific types of protein accumulation in the brain, or abnormal appearance of brain cells examined at autopsy. Yet, the relationship between these findings and measures of cognition are inconsistent and not constant. We do not know whether some of the biological changes underlying laboratory or imaging findings are causes of or caused by Alzheimer’s disease. This type of uncertainty greatly complicates efforts to prevent or slow impairments in cognition that are a prelude to Alzheimer’s disease. In this report, we use the term CATD to exclude most of the conditions italicized in Table 1.1.

**Table 1.1. DSM-5 underlying causes of major neurocognitive disorders**

<b>Cause</b>
<i>Frontotemporal lobar degeneration</i>
<i>Lewy body disease</i>
<i>Traumatic brain injury</i>
<i>Substance/medication use</i>
<i>HIV infection</i>
<i>Prion disease</i>
<i>Parkinson’s disease</i>
<i>Huntington’s disease</i>
<i>Another medical condition</i>
Alzheimer’s disease
Vascular disease
Multiple etiologies
Unspecified

Source: American Psychiatric Association (2013). Neurocognitive Disorders. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington, VA, American Psychiatric Association.  
 Italicized causes are outside the scope of this review.

# Interventions To Prevent or Slow Cognitive Decline

## Interventions and Underlying Theories

A number of reviews have assessed the evidence of the relationships between risk and protective factors and/or cognitive decline, MCI, and CATD, including the 2015 Institute of Medicine report on cognitive aging cited above<sup>12</sup> and a 2010 Agency for Healthcare Research and Quality (AHRQ) systematic review.<sup>13</sup> Several risk factors are correlated with incident CATD, some modifiable and others not. Nonmodifiable risk factors include age, sex, race/ethnicity, and family history. Certain medical conditions are associated with an increased risk of developing MCI and CATD, including depression, cancer, cardiovascular disease, diabetes, delirium, thyroid disorders, chronic kidney disease, and loss of hearing and/or vision. Modifiable risk or protective factors may include diet, physical activity, education and intellectual engagement, social engagement, alcohol, smoking, and substance abuse, medications, and vitamins. Interventions represent one way to establish the veracity of risk factors. If changing a putative risk factor changes the cognitive course, it will be seen as more salient. Interventions have been developed to address chronic disease status and modifiable risk factors as well as protective factors. Table 1.2 lists a number of interventions that have either been explored or suggested. More comprehensive intervention programs address multiple risk factors simultaneously with multi-domain interventions with components addressing nutrition, physical activity, cognitive training, social activity, and/or vascular risk factor management.<sup>14</sup>

**Table 1.2. Interventions aimed at preventing age-related cognitive decline, MCI, and/or CATD**

Interventions (Examples)
Aspirin/nonsteroidal anti-inflammatory drugs (NSAIDS)
Cardiovascular and cerebrovascular disease treatments (medications and nonpharmacologic interventions)
Cognitive stimulation and training
Community-level interventions (built environment)
Depression treatments (medications and nonpharmacologic interventions)
Diabetes treatments (medications and nonpharmacologic interventions)
Diet Types (Mediterranean, low fat, vegetarian, etc.)
Hormone therapies (estrogen, selective estrogen receptor modulators, testosterone)
Music-based interventions (dancing, playing music)
Nutraceuticals (gingko biloba, fish oil)
Obesity treatments (medications and nonpharmacologic interventions)
Pharmacologic (statins, cholinesterase inhibitors, nicotine)
Physical activity (aerobic, resistance training, balance, dancing)
Sleep disorder treatments (medications and nonpharmacologic interventions)
Smoking cessation
Social engagement (network, social activities)
Vitamin supplements (multivitamins, vitamin B, vitamin D)

MCI=Mild Cognitive Impairment; CATD=Clinical Alzheimer's-Type Dementia

Interventions cannot change nonmodifiable risk factors. However, age, sex, race/ethnicity, and family history are relevant to intervention effectiveness because they can modify the effect of interventions. Further, provider perceptions of and attitudes toward nonmodifiable risk factors may themselves be modifiable. Genetic factors (i.e., ApoE status) have been shown to modify the degree to which risk factors and interventions correlate with cognitive decline.<sup>12</sup>

Theories justifying various interventions to slow or prevent cognitive decline are diverse. If cognitive decline is due to natural age-related degeneration of the brain, the theory of neuroplasticity suggests that cognitive training could be useful to stimulate the brain to build additional pathways and retain existing ones to build brain reserve against future decline. If brain degeneration and cognitive decline are due to toxins or lack of specific nutrients, changes in diet or nutritional supplements could be effective. If adequate blood flow to the brain is important in preventing cognitive decline, then medications and exercise that stimulate and maintain the health of the vascular system are reasonable. If inflammation is part of the process, antiinflammatory drugs may be effective. These theories support prevention trials testing cognitive training, physical exercise, cardiovascular and other medications, diets, and nutraceuticals (products derived from food sources that are purported to provide extra health benefits).

Preventive efforts can target any time point on the cognitive spectrum, which spans from healthy cognition to the normal age-related cognitive decline that everyone experiences to abnormal and subclinical cognitive decline to MCI, and finally, to dementia.

Research participants seeking to slow or prevent age-related cognitive decline, MCI, and CATD may have more than one risk factor. CATD may result from cumulative and possibly synergistic effects. Interventions may address one or multiple possible mechanisms with complex or multiple prevention strategies. Differential effects of interventions on subgroups defined on the basis of cumulative risk factors (both modifiable and nonmodifiable) may be of concern. Many studies testing the association of preventive factors or effectiveness of interventions for preventing dementia have looked at only the one-to-one relationship with a single risk factor or intervention. Rarely have studies used multidomain interventions, and potentially none have explored the possibility of cumulative or synergistic effects.

## **Methods To Measure Intervention Impact—Measuring Cognitive Function and Biomarkers**

Timing and measurement choices affect cognitive decline prevention studies. Researchers can recruit participants at any point along the cognitive continuum. Various proposed strategies target young and middle-aged adults with no evidence of cognitive decline, older adults worried about age-related changes, people with documented MCI, and those with major neurocognitive disorders. Common diseases that cause cognitive decline, especially CATD, progress slowly. Lengthy time periods are required between an intervention and the expectation of measurable cognitive decline or function in those not receiving an effective preventive intervention; the younger the participant, the longer the latency period. Short-term benefits on cognitive tests or biomarker measures are uncertain predictors of long-term effects on cognition.

Proof that an intervention prevents or delays MCI or dementia ideally includes evidence that the intervention led to fewer individuals with a subsequent diagnosis of MCI or CATD. Such measures are rarely possible, due to the extended study length required (i.e., >10 years) or the extremely large number of participants (i.e., thousands) required plus the complexity of measuring both cognition and functional abilities. Over shorter terms and in smaller studies, changes in cognitive function are assessed using validated neurocognitive tests addressing various domains of cognition. The range of

testing includes both simple tests performed in a primary care clinic (such as drawing a clock face and remembering three words) and hours-long, comprehensive cognitive testing performed by a neuropsychologist measuring multiple domains of cognition.<sup>15</sup>

To assess changes in brain functional abnormalities earlier or with greater sensitivity than is possible with behavior-based testing or interviews, a variety of laboratory and brain imaging tests are used to look for changes in specific biologic substances, structures, or processes; collectively these are called biomarkers. Examples include total brain and hippocampal volumes; white matter hyperintensity volume;<sup>16</sup> uptake with fluorodeoxyglucose positron emission tomography (PET) in key areas of the brain (e.g., temporomedial lobes); accumulation of brain amyloid ascertained with brain PET; and cerebrospinal fluid levels of tau, phosphorylated-tau, and amyloid beta.

Improvement or a slower deterioration from baseline of specific biomarker measures could indicate a slowing of age- or disease-related decline as a result of an intervention, to the extent that the biomarker is an accurate reflection of brain capacity and activity. As noted before, there is a good deal of inconsistency regarding the relationships between biomarkers. However, many studies have included or focused on measures of biomarkers and cognitive function.

## Scope and Key Questions

This systematic review is focused on intervention studies that target populations who are cognitively normal or may have age-related changes or MCI but do not yet have dementia. With the focus on CATD, the review does not include forms of dementia with multiple other causes, e.g., Lewy body, infectious diseases, frontotemporal, and traumatic brain injury (see the italicized conditions in Table 1.1). The review does include studies addressing vascular components of mixed dementia, but clear post-stroke dementia is out of scope. Intermediate outcomes such as measures of biomarkers and cognitive performance are included. However, since the review is focused on prevention, studies must be of at least 6 months duration to demonstrate some level of sustainability of the intervention effects. It is important to note that this duration requirement by necessity leaves out many short-term studies in this field.

## Key Questions

The review addresses two Key Questions (KQs) and the PICOTS (populations, interventions, comparisons, outcomes, timing, and setting) framework that address the effects of interventions for delaying or slowing age-related cognitive decline and preventing, delaying, or slowing MCI and clinical Alzheimer's-type dementia (Table 1.3). The third KQ addresses the strength of association between various intermediate outcomes (e.g. biomarkers) with MCI and CATD.

KQ 1: In adults with normal cognition, what are the effectiveness, comparative effectiveness, and harms of interventions for:

- i. Delaying or slowing age-related cognitive decline?
- ii. Preventing, delaying, or slowing the onset of MCI?
- iii. Preventing, delaying, or slowing the onset of clinical Alzheimer's-type dementia?

- a. Do effectiveness, comparative effectiveness, and harms of interventions differ as a function of patient characteristics (i.e., age, sex, race/ethnicity, family history, education, socioeconomic status, risk factor status)?

KQ 2: In adults with MCI, what are the effectiveness, comparative effectiveness, and harms of interventions for preventing, slowing, or delaying the onset of clinical Alzheimer's-type dementia?

- a. Do effectiveness, comparative effectiveness, and harms of interventions differ as a function of patient characteristics (i.e., age, sex, race/ethnicity, family history, education, socioeconomic status, risk factor status)?

KQ 3: What is the strength of association between outcome measures examined in KQs 1 or 2 including (but not limited to) cognitive test results, biomarkers, and brain imaging results and the incidence of MCI or clinical Alzheimer's-type dementia?

**Table 1.3. Populations, interventions, comparators, outcomes, timing, and settings (PICOTS)**


PICOTS	KQ 1	KQ 2	KQ 3
Population	Adults with normal cognition	Adults with MCI	Adults with normal cognition or MCI
Intervention	Interventions aimed at preventing, delaying, or slowing the development of age-related cognitive decline, incident MCI or CATD	Interventions aimed at preventing, delaying, or slowing the development of CATD	The analysis will be limited to intermediate outcomes uncovered in KQs 1-2
Comparators	Placebo Usual care Waitlist Information or attention control Active control	Placebo Usual care Waitlist Information or attention control Active control	NA
Outcomes	<p>Final health or patient-centered outcomes: normal cognition, age-related cognitive decline, incident MCI or CATD (includes vascular or mixed dementia incidence but not post-stroke dementia incidence)</p> <p>Intermediate outcomes: Biomarker protein level(s) Cognitive test results Brain matter volume Brain cell activity level</p> <p><u>As determined by:</u> Blood/CSF tests, Validated cognitive test results, and Brain scans Structural imaging - CT, MRI, PET Functional Imaging – PET, fMRI Molecular imaging – PET, fMRI, SPECT</p> <p>Adverse effects of intervention(s): Pharmacologic side effects, Psychological, Financial, Physical</p>	<p>Final health or patient-centered outcomes: Incident CATD (includes vascular or mixed dementia incidence but not post-stroke dementia incidence)</p> <p>Intermediate outcomes: Biomarker protein level(s) Cognitive test results Brain matter volume Brain cell activity level</p> <p><u>As determined by:</u> Blood/CSF tests, Validated cognitive test results, and Brain scans Structural imaging - CT, MRI, PET Functional Imaging – PET, fMRI Molecular imaging – PET, fMRI, SPECT</p> <p>Adverse effects of intervention(s): Pharmacologic side effects, Psychological, Financial, Physical</p>	<p>Final health or patient-centered outcomes: Incident MCI or CATD (includes vascular or mixed dementia incidence but not post-stroke dementia incidence)</p>
Timing	Minimum followup of 6 months for intermediate outcomes	Minimum followup of 6 months for intermediate outcomes	None
Settings	Community-dwelling adults, including assisted living	Community-dwelling adults, including assisted living	Community-dwelling adults, including assisted living

CATD=clinical Alzheimer’s-type dementia; CSF=cerebrospinal fluid; CT=computerized tomography; fMRI=functional magnetic resonance imaging; KQ=Key Question; MCI=mild cognitive impairment; MRI=magnetic resonance imaging; NA=not applicable; PET=positron emission tomography; SPECT=single photon emission computed tomography

## Analytic Framework

Figure 1.1 is a traditional analytic framework, illustrating the relationship of intermediate and final outcomes. It should be noted, however, that the outcomes listed as intermediate may be measured at several times over an extended period and several themselves contribute to the diagnosis of MCI or CATD.

**Figure 1.1. Analytic framework for interventions to prevent cognitive decline, mild cognitive impairment, and clinical Alzheimer’s-type dementia**



CSF=cerebrospinal fluid; KQ=Key Question

## Report Organization

This report is organized in several chapters. Following the Methods chapter, we present the overall search results in Chapter 3 and syntheses conducted for each class of prevention interventions in Chapters 4A through 4M. Chapter 4A presents the systematic review of literature for cognitive training, Chapter 4B for physical activity interventions, and so on through Chapter 4M for other interventions. Since the introduction and the methods used applied to all the



interventions, we present that material in separate chapters rather than duplicating them in each results chapter. Each of Chapters 4A through 4M presenting results is otherwise intended to stand on its own; therefore, each includes discussions specific to the intervention of interest. Next, Chapter 4N provides information on the linkages between biomarkers, cognitive performance, and incident MCI or dementia. The report finishes with a discussion of overarching themes (Chapter 5), overall conclusions with a summary of key findings (Chapter 6), and suggested future research (Chapter 7).

# Chapter 2. Methods

## Protocol Development

Because of the overall plan for the use of this review given by the National Institute on Aging (NIA) sponsor, this project follows a unique model. The role of the Key Informants was filled by the Committee on Preventing Dementia and Cognitive Impairment of the National Academies of Sciences, Engineering, and Medicine (The National Academies), which will use the report to help develop its own report to the NIA on the state of knowledge on the efficacy, comparative effectiveness, and harms of interventions to prevent or delay the onset of age-related cognitive decline, MCI, or CATD. (An overview of the National Academies' conflict of interest policies can be found at <http://nationalacademies.org/studyprocess/index.html>; detailed information is available at [http://www8.nationalacademies.org/cp/information.aspx?key=Conflict\\_of\\_Interest](http://www8.nationalacademies.org/cp/information.aspx?key=Conflict_of_Interest).) Because the National Academies Committee did not see the draft Key Questions, PICOTS, and analytic framework until the KQs were posted for public comment, a panel of content experts from federal agencies acted as proxy Key Informants prior to posting. The content experts were drawn from the NIA, the National Institute of Neurological Disorders and Stroke, the Department of Veterans Affairs, the Administration for Community Living, and the Centers for Disease Control and Prevention. There was not a separate, independent Key Informant panel. The role of the Technical Expert Panel was then filled by the National Academies Committee.

## Criteria for Inclusion/Exclusion of Studies in the Review

We included studies that met our inclusion criteria based upon the PICOTS framework outlined above and the study-specific inclusion criteria described in Table 2.1.

**Table 2.1. Study inclusion criteria**

Category	Criteria for Inclusion
Study Enrollment	For KQ1: Adults with normal cognition. For KQ2: Adults with MCI. For KQ3: Adults with normal or abnormal cognition who have had testing such as cognitive tests, blood/CSF testing, or brain imaging used in intervention studies in KQ1 or KQ2.
Study Objective	For KQ1: To test the efficacy, comparative effectiveness, and harms of interventions to prevent, delay, or slow cognitive decline, onset of MCI, or clinical Alzheimer's-type dementia. For KQ2: To test the efficacy, comparative effectiveness, and harms of interventions to prevent, delay or slow clinical Alzheimer's-type dementia. For KQ3: To examine the association between biomarker outcomes and incidence of MCI of clinical Alzheimer's-type dementia.
Study Design	For KQ1-2: RCTs of any size and large prospective quasi-experimental cohort studies with comparator arms ( $n \geq 250$ per arm). For KQ3: Studies identified in KQs 1 and 2
Outcomes	Cognitive performance measured with validated instruments, biomarker measures associated with clinical Alzheimer's-type dementia, and incident MCI or clinical Alzheimer's-type dementia (pure vascular dementia including strokes is excluded)
Timing	For KQ1-2: Minimum followup of 6 months for intermediate outcomes. For KQ3: No minimum followup.
Publication Type	Published in peer-reviewed journals and grey literature with full text available (if sufficient information to assess eligibility and risk of bias are provided).
Language of Publication	English

## Literature Search Strategies

We searched Ovid Medline, Ovid PsycINFO, Ovid Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) to identify randomized controlled trials (RCT), nonrandomized controlled trials, and prospective cohort studies published and indexed in bibliographic databases between January 2009 and September 2016. We identified eligible studies published prior to 2009 using the previous AHRQ review, including the excluded study bibliography.<sup>13</sup> Our search strategy (Appendix A) included relevant medical subject headings and natural language terms for two concepts: 1) the conditions of dementia, MCI, cognitive decline, and 2) interventions—a wide variety of intervention types. These concepts were combined with filters for relevant intervention study designs. We supplemented bibliographic database searching with citation searches of recent relevant systematic reviews. To confirm that we identified all high-quality, quasi-experimental studies, we supplemented our bibliographic database search for potentially relevant publications using a list of longitudinal studies provided by the National Academies Committee. We will update searches while the draft report is under public/peer review.

A significant challenge to developing our bibliographic database search strategy was the wide variety of interventions that have been suggested to influence cognitive decline and the fact that many of these interventions have a primary purpose other than preventing this decline. Our search strategy to identify intervention studies with cognitive outcomes measured as secondary to the purpose of a given study must acknowledge the risk of identifying a biased set of studies because dementia results will be more likely noted in abstracts if they are positive. For example, intervention studies with the primary goal of reducing blood pressure or managing diabetes are more likely to mention cognitive outcomes in titles or abstracts when those results are significant. Therefore, our search strategy was more likely to identify studies with significant results and unlikely to identify all studies measuring cognitive outcomes. This issue is especially challenging when secondary outcomes may only be identified during a full text review. It was not feasible to screen the full text of all publications of studies evaluating any intervention suggested to benefit cognitive outcomes. To address this challenge, we revisited the larger evidence base for specific interventions where cognitive outcomes were likely secondary to the primary purpose of the intervention when synthesized results clearly suggested a benefit from that intervention to preventing cognitive decline.

Bibliographic database search results were downloaded to EndNote. Two independent investigators reviewed titles and abstracts to identify publications of studies potentially relevant to our inclusion criteria. Two investigators independently screened the full-text of those studies identified to determine if inclusion criteria were met. Differences in screening decisions were resolved by consultation between investigators, and, if necessary, consultation with a third investigator. Exclusion reasons for citations that underwent full-text screening were documented.

We searched grey literature sources to identify relevant completed and ongoing studies using ClinicalTrials.gov. These results were used to identify studies, outcomes, and analyses not reported in the published literature to assess publication and reporting bias and inform future research needs.

## Data Abstraction and Data Management

Studies meeting inclusion criteria were distributed among investigators for data extraction. We extracted author, year of publication, population, intervention, comparison, outcomes, timing, and setting. Results were extracted from studies assessed as having low to moderate risk of bias. Summary tables were created and reviewed by a second investigator, checking for accuracy.

## Assessing Methodological Risk of Bias of Individual Studies

We created an instrument to assess risk of bias components specific to study design to assess risk of bias of eligible studies based upon AHRQ guidance (Appendix B).<sup>17</sup> Relevant components included participant selection, method of randomization or selection, blinding, allocation concealment, and attrition. Two investigators independently assessed risk of bias for all eligible studies and consulted with each other to reconcile discrepancies in overall risk of bias. Overall risk of bias assessments for each study were classified low, moderate, or high based on the collective risk of bias inherent in each domain and confidence that the results were believable given study limitations.

## Data Synthesis

We summarized results in summary tables, excluding studies with high risk of bias and synthesized the evidence for each unique population, intervention, comparison, and outcome and harm. We organized evidence tables and results by intervention type and the population addressed. Subgroups, where possible, were examined and reported separately.

We reported summary results for primary and intermediate outcomes and harms. Intermediate cognitive outcomes were assessed using neuropsychological tests or biomarker measurements in the literature. Because studies used a highly varied set of tests, we grouped them into categories to facilitate analysis. We categorized neuropsychological tests by their purpose and/or what they attempt to measure, such as specific cognitive domains (e.g., executive function, memory) (Appendix C) for extraction and analysis. Since cognitive interventions were specifically targeting cognitive functions, we reported on a more complete set of cognitive domains for cognitive interventions. The wide variety on inconsistency of tests used made it difficult to summarize the findings and prevented meta-analysis. For the cognitive training component we did use Cohen's D where possible.

Changes in neuropsychological test scores can vary in clinical significance. While cognitive function declines as we age, it can be challenging to identify a level of change that is concerning. Reliable change indices have been suggested for many commonly used instruments assessing cognitive function. These serve to provide a benchmark of meaningful change in the test scores for individuals.<sup>18</sup> Methods for calculating reliable change indices ensure that the degree of change is not due to chance or measurement error; later refined to also account for practice effects, and regression to the mean.<sup>18</sup> However, such scores were not developed to assess meaningful differences between groups of individuals, the comparisons of interest to systematic reviewers. We identified published reliable change indices for many commonly used instruments (Appendix C) and used these to facilitate interpretation of statistically significant results. For outcomes measured with instruments lacking established thresholds to measure improvement, we calculated standard effect sizes and required a small effect size ( $d \geq 0.2$ ) to conclude efficacy or comparative effectiveness. Effect sizes were calculated using STATA 14/SE (Stata).<sup>19</sup> We

assessed clinical and methodological heterogeneity and variation in effect size to determine appropriateness of pooling data.<sup>20</sup> Clinical and methodological heterogeneity precluded quantitative pooling of results.

## **Assessing the Strength of Evidence for Major Comparisons and Outcomes**

When sufficient data were available (more than one study or one large study [ $n \geq 500$ ]), the overall strength of evidence for select outcomes within each comparison were evaluated based on five required domains: 1) study limitations (risk of bias); 2) directness (single, direct link between intervention and outcome); 3) consistency (similarity of effect direction and size); 4) precision (degree of certainty around an estimate); and 5) reporting bias.<sup>21</sup> Study limitations were rated as low, medium, or high based on study design and the risk of bias of eligible studies in a particular evidence base (comparison). Consistency was rated as consistent, inconsistent, or unknown/not applicable (e.g., single study) based on whether intervention effects were similar in direction and magnitude, and statistical significance of all studies. Directness was rated as direct or indirect based on whether inference required observations across studies. That is, more than one step between the intervention and the outcome of interest was needed to reach the conclusion. For instance, a medication that lowers blood pressure might affect dementia risk by first lowering blood pressure. The reduced blood pressure may then lower the risk of dementia. This relationship is indirect. However, if a medication directly lowers dementia risk without acting through altering a risk factor such as blood pressure, the relationship would be direct. Indirectness can also occur when the study uses a shorter followup time to test a relationship. Such evidence may help formulate a potential linkage, but it does not test it directly. Precision was rated as precise or imprecise based on the degree of certainty surrounding each effect estimate or qualitative finding. An imprecise estimate is one for which the confidence interval is wide enough to include clinically distinct conclusions. For outcomes found to have at least moderate or high strength of evidence, we assessed reporting bias by evaluating the potential for publication bias, selective outcome reporting bias, and selective analysis reporting bias by comparing reported results with those mentioned in the methods section and assessment of the grey literature to assess potentially unpublished studies. Publication bias is more easily addressed for RCTs than observational studies by searching for registered trials using sources like ClinicalTrials.gov. (However, we did not identify any observational studies to include.) Other factors we considered in assessing strength of evidence include the presence of a dose-response relationship, the presence of confounders, and the strength of the association.

Assessing strength of evidence for studies with null findings is especially challenging because several strength of evidence are designed to address differences. Although it is important to assess the strength of evidence for negative (no effect) findings, it is hard to assess effect size when there is no effect. We tried to separate statements about the scientific quality of the evidence from those addressing the nature of the findings themselves. Due to the large number of comparisons with null findings (i.e. intervention and comparison yielded results that were not statistically different from each other), we assessed strength of evidence and formulated results cautiously. When assessing precision, it was important to identify the level of precision that provided confidence of no effect.

Based on these factors, the overall strength of evidence for each outcome from a given intervention was rated as:

- **High:** Very confident that estimate of effect lies close to true effect. Few or no deficiencies in body of evidence, findings believed to be stable.
- **Moderate:** Moderately confident that estimate of effect lies close to true effect. Some deficiencies in body of evidence; findings likely to be stable, but some doubt.
- **Low:** Limited confidence that estimate of effect lies close to true effect; major or numerous deficiencies in body of evidence. Additional evidence necessary before concluding that findings are stable or that estimate of effect is close to true effect.
- **Insufficient:** No evidence, unable to estimate an effect, or no confidence in estimate of effect. No evidence is available or the body of evidence precludes judgment.

An overall rating of high strength of evidence would imply that the included studies were RCTs with a low risk of bias, with consistent, direct, and precise domains. We assessed strength of evidence for key final health outcomes measured with validated scales.

Tables presenting summary strength of evidence for conclusions drawn from the data synthesis are provided in each Results chapter that had at least one intervention type with sufficient evidence to arrive at a strength-of-evidence rating. Tables were not created for intervention types for which all outcomes for the intervention type for a given population (adults with normal cognition or adults with MCI) was either too limited (only one study with fewer than 500 participants) or nonexistent.

## Assessing Applicability

Applicability of studies was determined according to the PICOTS framework. Study characteristics that were evaluated to assess applicability included, but were not limited to, the population from which the study participants were enrolled, narrow eligibility criteria, baseline cognitive function, and patient and intervention characteristics different than those described by population studies.<sup>22</sup> Here again data were frequently missing or implied. For example, baseline cognitive status was not consistently or precisely assessed in many instances. Applicability issues are addressed in Chapter 5.


## Peer Review and Public Commentary

Experts in dementia and systematic reviews were invited to provide external peer review of this systematic review; AHRQ and an associate editor also provided comments. The draft report was posted on the AHRQ Web site for 4 weeks to elicit public comment. We addressed all reviewer comments, revising the text as appropriate, and documented everything in a disposition of comments report that will be made available after AHRQ posts the final systematic review on the Effective Health Care Web site.

## Chapter 3. Search Results

Bibliographic database searches identified 9,448 unique references (Figure 3.1). Title and abstract screening of these yielded 1,116 references for full text review. Hand searching identified an additional 185 references yielding a total of 1,301 references for full text review. Full text review yielded 263 references eligible for our review. Common exclusion reasons included ineligible populations (n=320; e.g., individuals with dementia), ineligible study designs (n=188; i.e., nonexperimental designs), ineligible interventions (n=186; interventions not intended to prevent dementia), and inadequate followup time (n=224; followup less than 6 months). Appendix D provides a list of excluded studies and reasons for exclusions. Appendix E provides a list of prospective cohort studies related to health and aging topics that prompted special searches in an attempt to find relevant articles.

**Figure 3.1. Literature flow diagram**



Studies were categorized and results analyzed by the intervention types addressed (Table 3.1). Several studies are grouped in multiple intervention types because they addressed more than one intervention type in multiple arms. As Table 3.1 shows, not all interventions expected per the protocol were informed by published studies.

**Table 3.1. Eligible publications by intervention type**

<b>Report Intervention Type</b>	<b>Protocol Type</b>	<b>Eligible Articles</b>
Cognitive interventions	Cognitive stimulation and training	46
Physical activity/exercise	Physical activity	48
Nutraceuticals	Nutraceuticals	25
Diet types	Diet types	9
Multimodal interventions	(No direct match to groups listed in original protocol)	21
Hormone therapy	Hormone therapies	44
Vitamins	Vitamin supplements	29
Antihypertensive treatment	Cardiovascular and cerebrovascular disease treatments	24
Lipid lowering treatment	Cardiovascular and cerebrovascular disease treatments	10
Nonsteroidal anti-inflammatory drugs	Aspirin/NSAIDS	8
Acetylcholinesterase inhibitors	Pharmacologic	13
Diabetes medication treatment	Diabetes treatments	8
<i>Other interventions</i>		
Other drugs	Pharmacologic	2
Social engagement	Social engagement	2
Sleep disorder treatments	Sleep disorder treatments	2
Music-based interventions	Music-based interventions	2
Depression treatments	Depression treatments	0
Obesity treatments	Obesity treatments	0
Smoking cessation	Smoking cessation	0
Community-level interventions	Community-level interventions	0
	Brain stimulation	1
<b>TOTAL INTERVENTIONS</b>		<b>294</b>
	Minus duplicates (publications in more than 1 intervention type)	-31
<b>TOTAL PUBLICATIONS</b>		<b>263</b>

NSAIDS=Nonsteroidal anti-inflammatory drugs



# Chapter 4A. Results: Cognitive Training

## Key Messages

- Most studies addressed intermediate outcomes of cognitive training in terms of cognitive performance and a few measures of brain activity.
- The Advanced Cognitive Training for Independent and Vital Elderly (ACTIVE) trial provided the strongest and most comprehensive design to assess the effect of cognitive training on cognitive performance for older adults with normal cognition. Its results provide moderate-strength evidence at 2 years (but low-strength at 5 and 10 years) that cognitive training can improve cognitive function in the domain trained, but transfer to other domains was rare. There is some suggestion that processing speed training is associated with improved instrumental activities of daily living (IADL) performance, but longer term studies were rated as low strength of evidence.
- Other than the ACTIVE trial, the few studies that examined clinical Alzheimer's-type dementia (CATD)\* incidence or cognitive performance showed mixed results.

\*Note that the literature currently does not use the term CATD; we specified whenever the diagnosis of dementia was defined.

## Eligible Studies

Out of the 38 studies of cognitive training interventions that met inclusion criteria after review of full text, only 11 studies (12 articles) had medium or low risk of bias. Appendix F provides evidence tables, summary risk of bias assessments, and assessments of strength of evidence for key comparisons and outcomes.

We assessed strength of evidence based on a best-evidence approach, using the trial best designed to test the question of interest. Other relevant trials are then presented in followup sections as context for and consistency with best evidence.

## Advanced Cognitive Training for Independent and Vital Elderly (ACTIVE) Trial

The ACTIVE trial is the most ambitious study to date to test alternative forms of cognitive training. It has received wide attention and serves as a model for subsequent work. The overarching goal of the study was to test whether different types of cognitive training could improve daily life (as captured in IADLs, problem solving, and speed of performance); but also improved cognitive performance, which as an intermediate outcome is a focus of interest for this review. Its findings have been interpreted differently by various groups of investigators.<sup>16, 23, 24</sup>

Among the large number of publications from the ACTIVE trial, we actively discuss four, three of which reported the results for proximal and primary outcomes, as described in the ACTIVE protocol, at 2 years,<sup>25</sup> 5 years,<sup>26</sup> and 10 years.<sup>27</sup> We include the latter two publications although they have high risk of bias because of the salience of the topic. The fourth study looked at incident dementia at 5 years.<sup>28</sup> Although assessing dementia was not part of the original ACTIVE protocol and was rated as having high risk of bias, we include the latter study because this outcome is of particular interest for our review. Conclusions based on the ACTIVE trial are provided in Table 4A.1.

**Table 4A.1. Conclusions: Cognitive training in adults with normal cognition**

Comparison	Outcome	Conclusion and Effect Size (ES)	Strength of Evidence (justification)
Cognitive training k=1	Dementia	Unable to draw conclusion.	Insufficient (high study limitations, imprecise)
	MCI	Unable to draw conclusion.	Insufficient (high study limitations, imprecise)
	Reasoning	Improvement with reasoning training (ES=0.26). No significant differences with memory or speed of processing training. (n=2,832; 2 years).	Moderate (medium study limitations, indirect)
		Improvement remained at 5 (ES=0.26) and 10 years (ES=0.23)	Low (high study limitation, indirect, precise)
	Processing speed	Improvement with speed of processing training (ES=0.87). No significant differences with reasoning or memory training. (n=2,832; 2 years).	Moderate (medium study limitations, indirect)
Improvement remained at 5 (ES=0.76) and 10 years (ES=0.66).		Low (high study limitation, indirect, precise)	
Memory	Improvement with memory training intervention (ES=0.17). No significant differences with reasoning speed of processing training. (n=2,832; 2 years).	Moderate (medium study limitations, indirect)	
	Improvement remained at 5 (ES=0.23) but not 10 years.	Low (high study limitation, indirect)	

ES=effect size; k=number of studies included; MCI=mild cognitive impairment; n=sample size

Between March 1998 and October 1999, 2,832 adults aged 65 years or older whose Mini-Mental State Examination (MMSE) scores were  $\geq 23$ , and who were living independent of formal care were enrolled in the trial at one of the five ACTIVE field centers. Participants were randomized to one of three training arms or a no-contact control arm. Each of the training arms targeted a different domain: memory, reasoning, or processing speed. Proximal outcomes (changes on cognitive testing), primary outcomes (changes in functioning, everyday problem solving, driving), and secondary outcomes (health service utilization, mobility, quality of life) were evaluated. Because each arm focused on a different domain, we can contrast the specific effects of training on the extent of spillover, or transfer, into other domains as well as to explore the impact of each arm on more generalizable effects like IADLs. (The ACTIVE trial included other outcomes, such as depression and specific performance of tasks like driving, which were not judged salient to the Key Questions in this review.)

The three intervention arms: 1) provided strategies for solving problems, remembering, or responding quickly to information; 2) used trainers to demonstrate the strategy; 3) incorporated individual and group exercises; 4) provided feedback on performance; 5) fostered self-efficacy with regard to performance; and 6) applied strategies to real-world tasks. In all three conditions, the first five sessions focused on strategy instruction and exercises to practice the strategy, while the last five sessions provided additional practice exercises but introduced no new strategies. Content for each of the 10 sessions was scripted in a trainer's manual. The first set of sessions emphasized cognitive performance, whereas the last five sessions emphasized adaptation to daily life. Initial training was conducted between May 1998 and December 1999. The reasoning and speed of processing arms, but not the memory arm, were tailored to participant baseline performance.<sup>29</sup> Booster training at 1 and 3 years (1 month before testing) was given to a random sample of participants in each arm who completed the initial ten sessions.

Memory was evaluated using the Hopkins Verbal Learning Test, Rey Auditory-Verbal Learning Test, and the Rivermead Behavioral Memory Test. Reasoning was evaluated using the word series, letter series, and letter sets tests. Speed was evaluated using Digit Symbols Substitution, Digit Symbols Copy, and the Useful Field of View (UFOV) test. All measures were traditional examiner-administered tests with the exception of the computer-based UFOV. Timed IADL was assessed for five tasks: using a phone book, reading food and medication labels, finding an item on a crowded pantry shelf, and counting change.

Findings from the four studies are summarized in Table 4A.2. Only the 2-year outcome study had a medium risk of bias.<sup>25</sup> As noted above, the 5-year and 10-year outcome studies had a high risk of bias due to attrition but are retained here because of the scarcity of long-term followup studies. Attrition at 5 years was 33 percent based on enrollment numbers (attrition rates were essentially the same for all arms including controls); attrition at 10 years was 57 percent (55 percent attrition for reasoning and speed arms, 58 percent for memory arm, and 60 percent for control arm), but only about 18 percent of the sample loss at 5 years was attributable to death. Thus, much of the sample loss was unexplained. By 10 years, death accounted for about 25 percent of the attrition. Participant factors that predicted 10-year attrition included: being older, male, or unmarried; having physical or mental health concerns; consuming more alcohol; and exhibiting worse performance on cognitive outcomes. Predictors of attrition were reported as similar across arms. Efforts were made to assess the impact of attrition, including using linear mixed methods, multiple imputation, survival analysis, and sensitivity analysis, but none of these efforts completely excluded attrition effects. Further, the studies did not indicate whether those who withdrew by virtue of self-reported or proxy-reported dementia were assigned to the worse cognitive category. Finally, the booster effect was also biased, because those receiving boosters had a compliance rate on the initial training of 80 percent or better. We rated the strength of evidence for the 2-year outcomes as moderate, but for the reasons discussed above, the 5- and 10-year outcomes were rated low.

The ACTIVE trial was not designed to study the incidence of dementia, and no psychometrically or clinically valid measures of dementia were included. Regular contact with the cohorts was not maintained, and reasons for sample loss were not well established. In the Unverzagt study the determination of dementia relied on three different sources (MMSE, a decrease in the cognitive composite measure of 1.5 standard deviations (SD), or a report from a proxy or the subject that the subject had dementia).<sup>28</sup> For the purpose of this analysis, dementia was defined as the first occasion of measurement (immediate post-test, 1-year, 2-year, 3-year, and 5-year followup) in which a participant had any of these outcomes: 1) Memory composite 1.5 SD below the ACTIVE sample baseline mean; and Reasoning composite, Speed composite, or Vocabulary 1.5 SD below the mean; and functional impairment defined as MDS IADL Total Performance at or below the 10th percentile of the ACTIVE sample baseline; 2) first visit in which MMSE<22 and all subsequent visits are MMSE<22 or are missing; 3) interval self- or proxy-report of diagnosis of dementia or Alzheimer disease during the followup; 4) interval self- or proxy-report of institutionalization during the followup; or 5) deactivation from the study due to the family refusing access to the subject. Because some participants who were lost to followup were inferred to have dementia, the purported dementia rates are confounded by the attrition rates. A sensitivity analysis that assigned all those assumed to have dementia and who were not retested to a low performance level on cognitive tests could provide one estimate of long-term effects, although the dementia may not have affected all areas of performance equally. Baseline impairment was associated with a higher rate of dementia as classified by the study. So, too, was

the drop-out rate. We rated the strength of evidence for this aspect of the ACTIVE portfolio as insufficient.

**Table 4A.2. Key ACTIVE studies**

Characteristics	Ball, 2002 <sup>25</sup>	Willis, 2006 <sup>26</sup>	Unverzagt, 2012 <sup>28</sup>	Rebok, 2014 <sup>27</sup>
<b>Risk of Bias</b>	Medium	High	High	High
<b>N completed / randomized</b>	2,244/2,832	1,879/2,832	1,879/2,832	1,220/2,832
<b>Attrition (%)</b>	21%	33%	33%	57%
<b>Followup Duration</b>	2 years	5 years	5 years	10 years
<b>Design</b>	For all three arms, the intervention was administered in a small-group setting (3-4 preferred, 5 maximum) by a certified trainer. Participants received 10, 60- to 70-minute trainings over 6 weeks. Sixty percent of the compliant initial sample (those attending at least 8 of the 10 sessions) were randomly chosen to receive two booster training interventions at about 1 year and 3 years. Each booster included four sessions that were similar in content and structure to the initial training.			
<b>Testing Outcomes</b>	Cognitive Testing in Domains Related to Training (Memory, Reasoning, Speed)	None	Cognitive Testing in Domains Related to Training (Memory, Reasoning, Speed)	Cognitive Testing in Domains Related to Training (Memory, Reasoning, Speed)
<b>Primary Outcomes</b>	Everyday Problem Solving, Everyday Speed, IADL/ADL, Driving Habits	Dementia Diagnosis (estimated)	Everyday Problem Solving, Everyday Speed, IADL/ADL,	Everyday Problem Solving, Everyday Speed, IADL/ADL,
<b>Key Findings</b>	<ul style="list-style-type: none"> <li>• Participants improved on tests related to the domain in which they were trained and not the other domains</li> <li>• Broader outcomes (e.g. everyday problem-solving, functioning, and driving) were not affected by trainings</li> </ul>	<ul style="list-style-type: none"> <li>• Participants improved on tests related to the domain in which they were trained and not the other domains</li> <li>• Reasoning training (not memory or speed) improved IADLs at 5 years</li> </ul>	<ul style="list-style-type: none"> <li>• Hazard model (based on original sample of 2,832) to assess risk of incident dementia over five year period</li> <li>• Cases of incident dementia did not differ between intervention (combined) and control arms</li> <li>• Incidence of dementia was higher for people with diabetes, heart failure and stroke/TIA</li> </ul>	<ul style="list-style-type: none"> <li>• Participants in speed and reasoning arms sustained improvement on tests related to the domain in which they were tested but not the other domains</li> <li>• Memory improvement was no longer sustained for participants in memory arm</li> <li>• Participants in each intervention group reported less difficulty with self-reported instrumental activities of daily living</li> </ul>

ADL=activities of daily living; IADL=instrumental activities of daily living; TIA=transient ischemic attack

Overall, as shown in Table 4A.3, at 2 and 5 years participants did better in the domain for which they received training and not the other domains (except speed positively affects reasoning at 5 years). These advantages are sustained for up to 10 years for two of the three domains (reasoning and speed of processing training). The effect sizes for memory and reasoning are modest. The effect size for speed of processing training is medium to large. (Bear in mind that high attrition in all arms could create bias.)

**Table 4A.3. Effect of domain specific training on 2-, 5-, and 10-year cognitive testing outcomes (reported as effect sizes)**

Timing	Outcomes	Memory	Reasoning	Speed of Processing
2-year Outcomes	Memory	<b>0.17*</b>	0.03	0.05
	Reasoning	0.05	<b>0.26*</b>	0.02
	Speed of Processing	-0.03	-0.04	<b>0.87*</b>
5-year Outcomes	Memory	<b>0.23*</b>	0.05	0.05
	Reasoning	0.01	<b>0.26*</b>	0.02
	Speed of Processing	0.01	<b>0.15*</b>	<b>0.76*</b>
10-year Outcomes	Memory	0.06	0.11	0.05
	Reasoning	0.02	<b>0.23*</b>	0.06
	Speed of Processing	0.07	0.01	<b>0.66*</b>

\*p<.01 (also noted by bold font)

Effect size = (group mean-control mean at time point) – (group mean at baseline) divided by intrasubject standard deviation

Table 4A.4 shows the mean change in test score by treatment arm. These should be interpreted in the context of the score range of the domain scores. Statistically significant improvements in the memory and reasoning arms are not associated with large changes in actual mean scores. For example, at 5 years the memory-training group showed a mean change of one point on a 132-point scale. By contrast, speed of processing showed a gain of 240 points out of a possible 1500. By 10 years, that gain, while still significant, had fallen to 24 points. The other arms, by contrast, showed actual losses in performance. All of these findings must be viewed while recognizing the attrition rates.

**Table 4A.4. Effect of domain specific training on 5- and 10- year cognitive testing outcomes (mean changes in test score from baseline)**

Timing	Outcome	Memory	Reasoning	Speed of Processing	Control
5-year Outcomes	Memory (possible range 0-132)	<b>-1.0*</b>	-4.8	-5.3	-4.0
	Reasoning (possible range 0-75)	4.3	<b>8.1*</b>	4.2	5.2
	Speed of Processing (possible range 0-1500)	79.1	<b>119.6*</b>	<b>241.8*</b>	-96.1
10-year Outcomes	Memory (possible range 0-132)	-10.6	-11.2	-12.7	-9.4
	Reasoning (possible range (0-75)	-3.5	<b>-0.1*</b>	-3.9	-3.0
	Speed of Processing (possible range 0-1500)	-144.4	-126.2	<b>24.3*</b>	-123.3

\*p<.01 (also noted by bold font)

Effect size = (group mean-control mean at time point) – (group mean at baseline) divided by intrasubject standard deviation

As shown in Tables 4A.5, compared to participants who did not receive reasoning training, participants who received reasoning training and were assessed at five years showed significant benefits in IADLs, but no changes in incident dementia were observed at 5 years. By the 10-year assessment all participants showed significant benefits in IADLs. Reasoning and speed training

were associated with fewer motor vehicle collisions.<sup>30, 31</sup> Depression was assessed but was deemed outside of this review’s scope.<sup>32, 33</sup> Again, the high attrition rates need to be considered.

In an effort to establish generalizability, Prindle and McArdle<sup>34</sup> compared the demographic characteristics of the ACTIVE sample to the sample in the Health and Retirement Study,<sup>35</sup> a representative sample of about 20,000 Americans. They found similar patterns of measurable demographic variables, but cannot correct for unmeasured differences in cognition or other factors associated with volunteering for the study. Likewise, additional analyses focused on participants with algorithmic classification of cognitive impairment and found no difference between participants with low cognition versus those who were not low.<sup>36, 37</sup>

**Table 4A.5. Effect sizes for various activity outcomes**

Timing	IADL Outcome	Memory	Reasoning	Speed of Processing
2-year Outcomes	Every day problem solving	0.07	9.03	0.03
	ADL/IADL	0.02	0.06	0.07
	Everyday speed	0.01	0.03	0.01
	Driving Habits	0.09	0.03	0.08
5-year Outcomes	Every day problem solving	0.15	0.08	0.05
	ADL/IADL	0.20	<b>0.29*</b>	0.26
	Everyday speed	0.04	0.09	0.08
	Driving Habits	NR	NR	NR
10-year Outcomes	Every day problem solving	0.00	0.02	0.01
	ADL/IADL	<b>0.48*</b>	<b>0.38*</b>	<b>0.36*</b>
	Everyday speed	0.02	0.00	0.05
	Driving Habits	NR	NR	NR

\*p<.01 (also noted by bold font) Effect sizes = (group mean-control-mean at time point) – (group mean – control mean at baseline) divided by intrasubject standard deviation. ADL=activities of daily living; IADL=instrumental activities of daily living; NR=not reported

In a study with only a 6-week followup Edwards and her colleagues showed an improvement in timed IADLs after speed of processing training.<sup>38</sup> A second 6-week study, where outcomes were assessed upon completion of training, addressing only those with initial deficits also showed short-term improvement in timed IADL performance.<sup>39</sup>

## Other Studies

We were unable to standardize scores for the cognitive tests. Reliable change indices (RCIs) for most of the tests were not available. We were uncertain about the applicability of the RCIs, as they may not account for differences across populations.<sup>40</sup> It was unclear whether a RCI calculated from a population with normal cognition accurately would capture clinically meaningful change in a population with mild cognitive impairment. In addition, several of the

included studies were conducted in international settings. Previous research shows that a RCI may differ across racial and ethnic groups.<sup>41</sup>

We were able to calculate effect size (Cohen's D) for five studies. Three studies had participants with normal cognition (Miller 2013,<sup>42</sup> Klusmann 2010,<sup>43</sup> and Carretti 2012<sup>44</sup>) and two studies had participants with mild cognitive impairment (MCI) (Rapp 2002,<sup>45</sup> Herrera 2012<sup>46</sup>). We were also able to extract effect sizes and 95% confidence intervals reported in Wolinsky, et al. 2013, which had participants with normal cognition.<sup>47</sup> Four studies reported insufficient data to calculate effect size (Buschert 2012<sup>48</sup> & Forster 2011,<sup>49</sup> Kwok 2012,<sup>50</sup> Vidovich 2015,<sup>51</sup> Stine-Morrow 2014<sup>52</sup>).

## **Effect of Training on Adults With Normal Cognition**

Five of the included trials tested the effect of cognitive training interventions on older adults with normal cognition.<sup>42-44, 47, 52</sup> Three of the five trials for older adults with presumed normal cognition used computer-based interventions;<sup>42, 43, 47</sup> two of which used computer programs directly targeting specific cognitive domains and administered the training individually;<sup>42, 47</sup> one trial used a more general- or activity- based approach to cognitive training by teaching participants how to perform basic tasks on a personal computer in groups of 12 participants.<sup>43</sup> Two trials used a noncomputer-based intervention.<sup>44, 52</sup>

Table 4A.6 describes the included trials that tested the effects of cognitive interventions for older adults with normal cognition.



**Table 4A.6. Training interventions for older adults with normal cognition**

Author, Year Risk of Bias	N Completed/ Randomized Attrition (%) Followup	Domains Trained	Mode	Intensity	Testing Outcomes	Patient-Centered Outcomes; Other Outcomes	Key Findings
<b>Wolinsky, 2013</b> <sup>47</sup> Low	620/681 9% 1 year	Speed of processing	Individual, computer-based training	10 hours over 5 weeks, booster at 11 months	Primary outcome = Useful Field of View (UFOV) test	None	<ul style="list-style-type: none"> <li>Used one of the ACTIVE tools, speed of processing arm</li> <li>Found significant changes on domain trained using UFOV test</li> <li>Mixed results on 9 other secondary testing outcomes</li> </ul>
<b>Miller, 2013</b> <sup>42</sup> Medium	69/84 18% 6 months	Short- & long-term memory, language, visual/spatial processing, reasoning, calculation	Individual, computer-based training	13 hours over 8 weeks	Delayed memory, immediate memory, & language	None	<ul style="list-style-type: none"> <li>Computer program trained 5 domains</li> <li>Only 2 of the 5 domains (or 3 of 6 depending on how you count long vs. short term memory) were formally tested</li> <li>Only delayed memory showed improvement (immediate memory and language not significant)</li> <li>Individual tests combined in results to present a "domain score"</li> </ul>
<b>Klusmann, 2010</b> <sup>43</sup> Medium	230/259 11% 6 months	None specifically trained	Group, computer-based training	112.5 hours over 6 months of in-class instruction (90 minutes per session)	Delayed memory, immediate memory, & executive attention	None	<ul style="list-style-type: none"> <li>Computer training resulted in statistically significant improvements in story recall (immediate and delayed), free recall (long delay), and one of the two tests of executive functioning/ attention (TMT B/A).</li> <li>Computer training did not improve free recall (short delay), verbal fluency, or executive functioning (as measured with the Stroop test)</li> <li>Effect sizes for statistically significant improvements were small</li> </ul>
<b>Carretti, 2013</b> <sup>44</sup> Medium	36/40 4% 6 months	Working memory	Individual, computer-based training	2.5-3.5 hours over 2 weeks (50-70 minutes per session, 3 sessions total)	Working memory, listening comprehension, reading comprehension, and fluid intelligence.	None	<ul style="list-style-type: none"> <li>Participants who received working memory training showed improvements in working memory, and listening comprehension compared with controls.</li> <li>Working memory training did not improve reading comprehension or fluid</li> </ul>

							intelligence compared with control.
<b>Stine-Morrow, 2014</b> <sup>52</sup> Medium	395/461 14% 8 months	Reasoning (cognitive training arm), divergent thinking (engagement arm)	Group, non-computer based or individual, non-computer based	24 hours over 16 weeks of formal engagement, with 15 hours per week of work related to team-based project in engagement arm	Processing speed, verbal episodic memory, visual/spatial processing, reasoning and divergent thinking	None	<ul style="list-style-type: none"> <li>• Participants did better in domain for which they were trained (reasoning for training arm, divergent thinking for engagement arm)</li> <li>• Spillover effects were not observed, engagement or training did not improve processing speed, visual-spatial, or verbal episodic memory compared with waitlist controls.</li> </ul>

ACTIVE=Advanced Cognitive Training for Independent and Vital Elderly; TMT B/A=Trail Making Test B and A; UFOV=Useful Field of View

The Iowa Health and Active Minds Study (IHAMS) used a version of the speed of processing tool from the ACTIVE trial.<sup>47</sup> Six hundred eighty-one adults with normal cognition were randomized separately based on their age at baseline (50-64 year-olds vs. 65 or older). Similar to the ACTIVE design, a booster was provided, but here to a pre-randomized group at 11 months. (Unlike ACTIVE, the booster assignment was made at the outset.) The authors used a university-based attention control activity (computerized crosswords) compared with one of three active intervention arms (visual speed of processing training at the university, visual speed of processing training at the university with a booster, or the same visual speed of processing training at home on the participant's personal computer). Ten hours of training were provided over 5 weeks (similar to ACTIVE). Outcomes were assessed at baseline and at 6 months and 1 year post-training. The primary outcome was determined using the UFOV test. Similar to the ACTIVE trial, the IHAMS found the visual speed of processing intervention positively affected tests of performance in that domain up to 1 year post-intervention (effect size 0.32 onsite, 0.37 at home, and 0.58 with booster, favoring the intervention). Nine additional cognitive tests were administered: Trail Making Tests (TMT) A and B, Symbol Digit Modalities Test (SDMT), Stroop Color and Word Tests (3 tests), Controlled Oral Word Association Test (COWAT), and the Digit Vigilance Test (DVT). Many of these additional tests can evaluate higher-order cognitive domains (e.g., executive functioning) than the training specifically targeted. For the onsite training interventions, significant effects of training on these secondary outcomes were found on TMT A, SDMT, and Stroop-Word, but not TMT B, Stroop-Color, Stroop Color-Word, COWAT, or DVT. For the onsite training intervention with boosters, significant effects of training on these secondary outcomes were found on TMT B, SDMT, and Stroop-Word, but not TMT A, Stroop-Color, Stroop Color-Word, COWAT, or DVT. For the at home training, significant effects of training on these secondary outcomes were found on TMT A and B, SDMT, and Stroop-Word, but not Stroop-Color, Stroop Color-Word, COWAT, or DVT. Across all of the secondary outcomes, effects sizes were smaller than in the trained domain and few exceed 0.5. This may suggest more potential for cognitive transfer than that seen in the ACTIVE study, although one cannot rule out that the timed nature of the tests may be driving improvement. Also, the large number of analyses needs to be kept in mind. Of the 30 analyses that were done, six had a positive Cohen's D. Effect sizes were generally small; few exceeded 0.5. The UFOV results were meant to reflect skills useful in daily life (e.g., driving) but were not necessarily evidence of overall cognitive performance.

The study by Miller was much smaller, enrolling just 84 participants.<sup>42</sup> The intervention was an individual-level, computerized, brain-training program focusing on six domains (short- and long-term memory, language, visual spatial processing, reasoning, and calculation). Presumably cognitively normal participants were asked to use the program 20-25 minutes a day, 5 days a week, for 8 weeks. Outcomes were evaluated by domain-specific tests of immediate memory, delayed memory, and language (visual spatial processing, reasoning, and calculation not evaluated). Outcomes were evaluated at baseline and at 2 months and 6 months. Individual tests were combined and only overall domain scores were reported. Only one of the three domains showed significant improvement (delayed memory). Measures of overall cognition were not reported. None of the six memory tests reported in the study had a positive Cohen's D in our analysis.

The Klusmann trial was conducted in Berlin, Germany, and enrolled 259 nondepressed women with over the age of 70.<sup>43</sup> Participants were randomized to a computer-based cognitive intervention, a physical activity intervention, or a nonintervention control arm. The cognitive

intervention was a group computer courses taught approximately three times per week, 90 minutes per class, for 6 months. Course activities included: learning to email and use the internet, taking and editing pictures or videos, playing games, word processing, or drawing. Neuropsychological testing was conducted using traditional examiner administered tests at baseline and at 6 months post-intervention. Tests measured: immediate and delayed story recall (RBMT), short and long delay free word recall (FCSRT), semantic verbal fluency, and executive functioning tasks (Stroop, TMT B/A). Six months of computer classes significantly improved immediate and delayed story recall, free recall (long delay), and one of the two tests of executive functioning (TMT B/A), compared with a no intervention control. Computer training did not improve free recall (short delay), verbal fluency, or the other executive measure (Stroop). This Cognitive Training Chapter of our report is restricted to comparisons between the cognitive intervention arm and the no-contact control. However, it is notable that the exercise and cognitive interventions resulted in significant changes on the same tests at followup, compared with no-contact controls. Of the four memory tests included in the study, two (RBMT immediate and delayed recall) showed positive Cohen's D. The effect sizes for both were 0.33. Neither of the two tests of executive/ attention/processing speed domains showed positive Cohen's D. Klusmann et al. argue that this outcome may be due to improved "management of new complex situations," and not training mental "muscles," as may be supposed for domain-specific training.

The study by Carretti et al. was a small trial, enrolling just 40 participants.<sup>44</sup> The intervention was individual-level working memory training using audio recordings for word recall and computers for text recall. Participants in the intervention group were asked to complete three training sessions, 50-70 minutes each, over a 2-week period with 2 days between sessions. The control group also attended three sessions with experimenters where they filled out paper-pencil questionnaires. Outcomes were evaluated at baseline, after completing training, and at 6 months. Outcomes measures included tests of working memory, listening comprehension, reading comprehension, and fluid intelligence. Participants receiving working memory training showed significant improvements in working memory and listening comprehension outcomes compared with those in the control group. No significant differences were observed between groups for reading comprehension or fluid intelligence outcomes. The Cohen's D values for the memory tests were quite high, ranging between 1.4 to 1.9.

Another pathway through which group activities may affect cognitive outcomes is through social engagement. The Stine-Morrow et al. study aimed to test the differential effects of domain-specific cognitive training and engagement activities that may broadly stimulate the mind.<sup>52</sup> This study enrolled 461 adults with normal cognition over the age of 60 who were doing less than 15 hours of scheduled activity (work or volunteering) per week. Subjects were randomized to a group intervention aimed at engagement and problem-solving, an individual intervention with cognitive training in inductive reasoning, or a waitlist control. In the engagement arm, participants were put in teams, practiced weekly, and competed in the Odyssey of the Mind—a tournament-style competition in which teams are judged on their ability to develop a solution to a novel problem without preparation and on their ability to present a solution to a problem that they have prepared in advance. The training arm consisted of paper-pencil weekly lessons and activities focused on inductive reasoning. Both active intervention arms were 16 weeks (including breaks for winter holidays and weather-related cancellations). Posttests were conducted between 30 and 32 weeks. Five cognitive domains were assessed before and after the intervention: processing speed (Letter and Pattern Comparison, Finding As), reasoning (Letter Sets, Number Series, Letter Series, Word Series, everyday problem-solving),

visual-spatial processing (card rotation, hidden patterns), divergent thinking (alternate uses task, opposites task), verbal episodic memory (Hopkins Verbal Learning Test, delayed recall score, and immediate sentence free-recall). Participants in the training arm showed greater improvement in reasoning (the skill to which they were trained) than the engagement or control arms. Improvements in reasoning between the engagement and control arms did not differ. Participants in the engagement arm showed greater improvements in the divergent thinking outcome (also the skill they practiced) than the training and waitlist arms. However, generalizations of training to other cognitive abilities from either intervention arm were not observed. No significant differences were seen in processing speed, visual-spatial, or verbal episodic memory between study arms.

## **Effect of Training on People With Mild Cognitive Impairment**

Five included studies (six articles) enrolled participants with MCI or memory complaints (Table 4A.7). The studies used group interventions that were not computer-based.

**Table 4A.7. Cognitive testing interventions for adults with mild cognitive impairment**

Author, Year Risk of Bias	N Completed/ Randomized Attrition (%) Followup	Domains Trained	Mode	Intensity	Testing Outcomes	Patient-Centered Outcomes; Other outcomes	Key Findings
<b>Buschert, 2012</b> <sup>53</sup> <b>Forster, 2011</b> <sup>49</sup> Medium	18/24 21%  28 months	Mnemonic memory training	Small group (12 participants)	12 hours over 6 weeks	Brief cognitive test performance/Multidomain neuropsychological test performance (ADAS-Cog, MMSE), Immediate & delayed memory (RBANS), TMT A & B	Conversion to CATD; Glucose uptake (PET scans)	<ul style="list-style-type: none"> <li>• Intervention improved 1 of 2 global cognitive measures (ADAS-cog)</li> <li>• 1 of 4 domain-specific tests was significantly improved (RBANS immediate memory);</li> <li>• Forster study reports FDG-PET results: intervention group showed no decline in uptake during the 6-months, while control showed widespread decline in uptake.</li> <li>• Half of the control/ delayed intervention group converted to CATD during the 28 month followup, but none of the early intervention group converted to CATD</li> </ul>
<b>Rapp, 2002</b> <sup>45</sup> Medium	16/19 16%  6 months	Memory	Small group (Size not reported)	12 hours over 6 weeks	Word list (immediate and delayed). shopping list (immediate and delayed), names and faces (immediate and delayed), paragraph (immediate and delayed)	Self-rated memory (Memory Functioning Questionnaire)	<ul style="list-style-type: none"> <li>• No significant effects of training at 6 months on the eight objective measures of memory</li> <li>• Present memory self-rated higher in intervention group at 6 months</li> </ul>
<b>Vidovich, 2015</b> <sup>51</sup> Low (1 year outcome only)	154/160 38%  24 months (reported 12 months)	Attention, memory, executive processes	Small group (6-9 participants)	15 hours over 5 weeks	Brief cognitive test performance/Multidomain neuropsychological test performance (CERAD, MMSE, CAMCOG-R), Memory (CVLT-II), Attention or Processing (DS Forward, Symbol Search, TMT A), executive (COWAT, TMT B)	Perception of memory (Memory Functioning Questionnaire)	<ul style="list-style-type: none"> <li>• 1 of 9 cognitive assessments (DS Forward) showed slightly significant effects of intervention at 1 and 2 years</li> <li>• No differences in brief cognitive test performance/ multidomain neuropsychological test performance measures or perceptions of memory were found</li> </ul>

<b>Kwok, 2012</b> <sup>50</sup> Medium	197/223 12%  12 months	Attention/ processing speed, memory, reasoning	Small- group (3- 5 participan ts)	18 hours over 12 weeks	Brief cognitive test performance/Multidomain neuropsychological test performance (Chinese MMSE, Chinese Mattis Dementia Rating Scale)	Subjective memory complaints	<ul style="list-style-type: none"> <li>• Intentionally uses same domains as ACTIVE, but different tools used to assess</li> <li>• Although they were using global measures of cognition, only domain scores reported in results section (unclear from which tools domains originated)</li> <li>• Training did not affect domain scores overall, but did improve scores for those subgroup with less education</li> </ul>
<b>Herrera, 2012</b> <sup>46</sup> Medium	22/22 No attrition reported  6 months	Recognition , working memory, recall	Individual, computer- based	24 hours over 12 weeks	Recognition (Doors Recognition Sets A and B, DMS48), Working memory (DS Forward and Backward), Recall (BEM- 144 12-word-list, 16-Item free and cued, MMSE 3 words, Rey Complex Figure)	None	<ul style="list-style-type: none"> <li>• Results were mixed</li> <li>• 1 of 3 recognition tests improved at 6 months</li> <li>• 1 of 2 working memory tests improved at 6 months</li> <li>• 2 of 4 recall tests improved at 6 months</li> </ul>

ACTIVE= Advanced Cognitive Training for Independent and Vital Elderly; ADAS-Cog=Alzheimer's Disease Assessment Scale-Cognitive Subscale; BEM-144= Batterie d'Efficiency Mnesique 144; CATD=clinical Alzheimer's-type dementia; CERAD= Consortium to Establish a Registry for Alzheimer's Disease; CAMCOG-R=Cambridge Cognitive Examination-Revised; COWAT=Controlled Oral Word Association Test; CVLT-II=California Verbal Learning Test-Second Edition; DS=Digit Span (Forward & Backward); DMS48=delayed matching-to-sample task; FDG-PET=fluorodeoxyglucose positron emission tomography; MMSE=Mini Mental State Examination; PET=positron emission tomography; RBANS=Repeatable Battery for Neuropsychological Status; TMT A/B=Trail Making Test A & B

In one trial, 24 participants were randomized to receive either 12 hours of cognitive training, including formal mnemonic memory training and informal activities to foster cognitive and social engagement, or a control condition that involved monthly paper-pencil activities.<sup>48, 49</sup> A crossover design was used. The intensity and duration of the intervention was similar to the ACTIVE and IHAMS trials: 2 hours a week for 6 weeks. The target in this study was brief cognitive test performance/multidomain neuropsychological test performance as measured by the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) and MMSE. However, three other domain-specific tests were also used to evaluate the effectiveness of the intervention: Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) memory subscores and TMT. Conversion to CATD was also evaluated. The intervention improved one of the two global measures of cognition (ADAS-Cog), but not the other (MMSE), and these results were sustained for 22 months post-intervention. One of the four domain-specific tests was significantly improved (RBANS immediate memory); RBANS delayed memory and TMT A and B were not significantly improved by the intervention. The author argues these null findings on the domain-specific tests over time support the case for their intervention to have a "true" impact and not merely a byproduct of attention or practice effects. In this small sample, half of the control or delayed intervention group converted to CATD during the 28-month followup, but none of the early intervention group converted to CATD. Even the trial authors are cautious to avoid overstating this finding, given the size of the study. FDG-PET was used to measure declines in brain glucose uptake as a marker of disease progression. People with MCI who received the intervention showed no decline in glucose uptake during the 6-month study period, while people with MCI who did not receive the intervention showed widespread declines in uptakes.

Another small trial randomized 19 participants to either a cognitive training intervention (n=9) or a no-intervention control group (n=10).<sup>45</sup> The group intervention, which ran 2 hours per week for 6 weeks, involved a combination of coping skills education (moderating mood, sleep, relaxation) and training of specific memory techniques (chunking, categorization, cueing). Results from eight objective measures of memory and nine subjective measures of memory were reported. The objective memory measures included immediate and delayed word list, shopping list, names and faces, and paragraph. The nine subjective measures of memory originated from one tool, the Memory Functioning Questionnaire, and included self-reported present memory ability, frequency of forgetting, retrospective functioning, general functioning, perceived impact of memory functioning, seriousness, memory skill use, inevitable decline, and effort utility. No significant effects of training were seen at 6 months on the eight objective measures of memory. Participants in the intervention group self-rated their memory more positively than those in the control group at 6 months (1/9 subjective measures). For all eight reported test results, none of the analyses showed a positive Cohen's D.

The Promoting Healthy Ageing with Cognitive Exercise (PACE) trial randomized 160 adults with MCI to a cognitive activity intervention or an educational control.<sup>51</sup> Participants in the intervention and control arms met in small groups for 90 minutes, twice a week, for five weeks. The intervention arm received strategies specific to improving attention, processing speed, executive functioning, memory, and language. The educational (control) arm received information and participated in small group discussions about physical activity, stress, depression, sleep, and expectations for retirement. Participants in both arms received a telephone call at 6 months. Participants in the intervention arm completed 30 minutes of cognitive exercises prior to this booster call. Three measures of brief cognitive test performance/



multidomain neuropsychological test performance (Consortium to Establish a Registry for Alzheimer's Disease [CERAD] cognitive battery; MMSE; Cambridge Cognitive Examination-Revised), three measures of attention or processing speed (Digit Span, Symbol Search, TMT A), two measures of executive functioning (TMT B, Controlled Oral Word Association Test), and one measure of memory (California Verbal Learning Test- Second Edition) were used at baseline, after 1 year, and 2 years post-intervention. Only one of these nine assessments showed a slightly significant effect of the intervention (Digit Span Forward), which the authors state is of questionable clinical significance.

Kwok enrolled 223 adults over the age of 65 with “subjective memory complaints” but no identified dementia (>19 on the Chinese MMSE).<sup>50</sup> The intervention used in the Kwok trial is based on the ACTIVE trial intervention and focused on the same three domains: attention/processing speed, memory, and reasoning. Training was conducted 1.5 hours per week for 12 weeks (twice as long as ACTIVE). The control condition was a health lecture each week for the same 12-week period. Assessments were conducted at baseline, and 12 weeks and 9 months post-intervention. Outcomes included: subjective memory complaints (Chinese Memory Symptom Scale) and brief cognitive test performance/multidomain neuropsychological test performance (Chinese versions of the MMSE and the Mattis Dementia Rating Scale battery). Overall, no significant improvements in cognition were found post-intervention or at 1 year, although some subgroup analyses by education level showed significance (training was more effective for those with less education).

The Herrera et al. trial is different from the other cognitive training trials targeting people with existing MCI because it is an individual, computer-based intervention.<sup>46</sup> Twenty-two people with MCI were randomized to cognitive training or cognitive activity (control) 60 minutes, twice a week, for 12 weeks. The cognitive training involved a number of memory and attention training tasks on the computer, such as memorizing a group of pictures or a group of words spoken by the computer for later identification, or testing the time it took for participants to identify a target image. Participants in the control arm completed various computer-based cognitive activities including matching countries and capitals, organizing items into groups, finding similarities and differences, and reading comprehension. Verbal memory outcomes were assessed using the Digit Span, 12-word list recall (BEM-144), 16-item free and cued reminding test, and the memory subscore of the MMSE. Visual memory was assessed using Doors and People, DMS48 test, and the Rey-Osterrieth Complex Figure recall. The authors conceptualize these outcomes as recognition (Doors Recognition Sets A and B, DMS48), working memory (Digit Span Forward and Backward), and recall (BEM-144 12-word list, 16 item free and cued, MMSE-3 words, Rey Complex Figure). Results were mixed. One of three recognition tests improved at 6 months compared to control condition (Doors, Set A); one of two working memory tests improved (Digit Span Forward); and two of four recall tests improved (BEM-144 and MMSE). This small study showed remarkable results when analyzed with Cohen's D. For six of the seven reported memory tests showed a positive Cohen's D result. Effect sizes ranged between 1.9 and 3.1. Both of the tests in the executive, attention, processing speed category showed positive Cohen's D results, with effect sizes up to 4.5.

## Interpreting the Findings

The overall results are summarized in Tables 4A.8 and 4A.9. The ACTIVE trial showed most clearly that cognitive training could improve performance on the domain being trained but there was little generalization to other cognitive domains. There was also no difference in dementia

diagnosis at 5 years. There may be an IADL effect at 10 years but there was high attrition. CATD results are hard to interpret because the design was *post hoc*. Processing speed training was associated with IADL improvement (or less decline) but that benefit is not linked to dementia *per se*.

When reviewing the larger literature set, in contrast to the ACTIVE trial, most of the other studies showed mixed results; at times one test for a domain is significant and the other is not. A few studies show sustained improvement in the domain that was trained, similar to ACTIVE. The intensity of domain-specific training was relatively consistent (10-18 hours over 5-12 weeks). This extent of treatment seems to continue to show an effect 5-10 years later. The booster effect in ACTIVE is hard to assess because the sampling was not random. Effect sizes are mostly small; however, speed of processing effect sizes are larger.

Overall, the results are consistent with a theoretical base that assumes various areas of the brain can be trained to perform better (or lose ability less quickly) but this training has little effect on other areas.

**Table 4A.8. Summary of overall results of cognitive training for older adults with normal cognition**

Author, Year	Domains Trained	Group/ Individual	Computer/ No Computer	Intensity	Testing Outcomes	Other Outcomes	Tools Used to Assess
Ball, 2002 <sup>25</sup>	Memory, reasoning, speed of processing	Group	Computer	10-12 hours over 6 weeks, booster at 11 months	<ul style="list-style-type: none"> <li>• Speed (only for Attn/ Speed Arm, ES=.87)</li> <li>• Memory (only for Attn/ Speed arm, ES=.17)</li> <li>• Reasoning (only for Reasoning Arm, ES=.26)</li> </ul>	<ul style="list-style-type: none"> <li>• NS Everyday problem solving</li> <li>• NS IADL</li> <li>• NS Everyday Speed Habits</li> </ul>	<ul style="list-style-type: none"> <li>• Memory (HVLTL, RAVLT, and RBMT)</li> <li>• Reasoning (word series, letter series, letter sets)</li> <li>• Speed (DSST, Digit Symbol Copy, UFOV)</li> </ul>
Wolinsky, 2013 <sup>47</sup>	Speed of processing	Individual	Computer	10 hours over 5 weeks, booster at 11 months	<ul style="list-style-type: none"> <li>• Speed (ES=.32-.58 depending on booster)</li> <li>• NS Executive (+ TMT A and B, SDMT, and Stroop-Word,</li> <li>• NS Stroop-Color, COWAT or DVT)</li> </ul>	None	<ul style="list-style-type: none"> <li>• Speed (UVOF)</li> <li>• Executive (TMT A and B, SDMT, SCWT, COWAT, and the DVT)</li> </ul>
Miller, 2013 <sup>42</sup>	Short- and long-term memory, language, visual spatial processing, reasoning, and calculation	Individual	Computer	13 hours over 8 weeks	<ul style="list-style-type: none"> <li>• Delayed memory</li> <li>• NS Immediate memory</li> <li>• NS language</li> <li>• (Other domains not reported)</li> </ul>	None	<ul style="list-style-type: none"> <li>• Delayed (Delayed Buschke-Fuld, Delayed Rey-Osterrieth, VP)</li> <li>• Immediate (Buschke-Fuld Total, Rey-Osterrieth Copy, VP Total)</li> <li>• Language (FAS, Animal Naming, BNT)</li> </ul>
Carretti, 2013 <sup>44</sup>	Working memory	Individual	Computer	2.5-3.5 hours over 2 weeks (50-70 minutes per session, 3 sessions total)	<ul style="list-style-type: none"> <li>• Delayed memory</li> <li>• NS Immediate memory</li> <li>• NS language</li> <li>• (Other domains not reported)</li> </ul>	<ul style="list-style-type: none"> <li>• Listening comprehension (True/False, Map Drawing)</li> <li>• NS Reading Comprehension</li> <li>• NS Fluid Intelligence</li> </ul>	<ul style="list-style-type: none"> <li>• Working Memory (Categorization Working Memory Span Test, Working Memory Updating Word Span Test)</li> <li>• Listening Comprehension (True/False Questions, Map Drawing)</li> <li>• Reading Comprehension (Adapted from Nelson-Denny Reading Test)</li> <li>• Fluid Intelligence (Cattell Culture Fair Test, Scale 3)</li> </ul>

<b>Klusmann, 2010</b> <sup>43</sup>	None, general computer instruction	Group	Computer	112.5 hours over 6 months of in-class instruction	<ul style="list-style-type: none"> <li>• Delayed Memory</li> <li>• NS Immediate Memory</li> <li>• NS Executive Attention</li> <li>• NS Verbal Fluency</li> </ul>	None	<ul style="list-style-type: none"> <li>• Immediate and delayed story recall (RBMT)</li> <li>• Short and long delay free word recall (FCSRT)</li> <li>• Semantic verbal fluency</li> <li>• Executive functioning (SCWT, TMT B/A)</li> </ul>
-------------------------------------	------------------------------------	-------	----------	---	--	------	--

Attn=attention; BNT=Boston Naming Test; COWAT=Controlled Oral Word Association Test; DSST=Digit Symbol Substitution Test; DVT=Digit Vigilance Test; ES=effect size; FAS=verbal fluency test using words starting with F, A, and S; FCSRT=Free and Cues Selective Reminding Test; HVL=Hopkins Verbal Learning Test; IADL=instrumental activities of daily living; NS=no statistically significant difference; RAVLT= Rey Auditory Verbal Learning Test; RBMT=Rivermead Behavioral Memory Test; SCWT=Stroop Color Word Test; SDMT=Symbol Digit Modalities Test; TMT=Trail Making Test (Parts A & B); UFOV=Useful Field of View; VP=verbal proficiency

**Table 4A.9. Summary of overall results of cognitive training for cognitively impaired older adults**

Author, Year	Domains Trained	Group/ Individual	Computer/ No Computer	Intensity	Testing Outcomes	Other Outcomes	Tools Used to Assess
<b>Buschert, 2012</b> <sup>48</sup> <b>Forster, 2011</b> <sup>49</sup>	Mnemonic memory training	Group	No Computer	12 hours over 6 weeks	<ul style="list-style-type: none"> <li>• NS Global Cognition (+ ADAS-Cog, NS MMSE, ES=.26)</li> <li>• NS Immediate &amp; Delayed Memory (+ immediate, NS delayed)</li> <li>• NS Executive/Attention</li> </ul>	<ul style="list-style-type: none"> <li>• Conversion to CATD</li> <li>• Glucose uptake</li> </ul>	<ul style="list-style-type: none"> <li>• Brief cognitive test performance/ Multidomain neuropsychological test performance (ADAS-Cog &amp; MMSE)</li> <li>• Immediate &amp; Delayed Memory (RBANS)</li> <li>• Executive/Attention (TMT A &amp; B)</li> </ul>
<b>Kwok, 2012</b> <sup>50</sup>	Memory, reasoning, speed of processing	Group	No Computer	18 hours over 12 weeks	<ul style="list-style-type: none"> <li>• NS Attention</li> <li>• NS Initiation/ preservation</li> <li>• NS Construction</li> <li>• NS Conceptualization</li> <li>• NS Memory</li> </ul>	Subjective Memory Complaints (results not reported)	<ul style="list-style-type: none"> <li>• Attention, initiation/ preservation, construction, conceptualization, and memory (Domains from Chinese Mattis Dementia Rating Scale)</li> <li>• Subjective memory complaints (Chinese Memory Symptom Scale)</li> </ul>
<b>Rapp, 2002</b> <sup>45</sup>	Memory	Group	No Computer	12 hours over 6 weeks	<ul style="list-style-type: none"> <li>• NS Memory</li> </ul>	Present self-rated memory improved	Word list (immediate and delayed), shopping list (immediate and delayed), names and faces (immediate and delayed), paragraph (immediate and delayed)

<b>Vidovich, 2015</b> <sup>51</sup>	Attention, memory, executive processes	Group	No Computer	15 hours over 5 weeks	<ul style="list-style-type: none"> <li>• NS Global Cognition</li> <li>• NS Memory</li> <li>• NS Executive</li> <li>• Attention or Processing (+ DS Forward, NS DS Backward, symbol search, and TMT B)</li> </ul>	No differences in perception of memory	Brief cognitive test performance/ Multidomain neuropsychological test performance (CERAD, MMSE, CAMCOG-R), Memory (CVLT-II), Attention or Processing (DS, Symbol Search, TMT B), executive (COWAT, TMT A)
<b>Herrera, 2012</b> <sup>46</sup>	Memory, executive, attention, processing speed  Note: authors classify as recognition, working memory and recall	Individual	Computer	24 hours over 12 weeks	<ul style="list-style-type: none"> <li>• Recognition (+ Doors Set A, NS Doors B and DSM48)</li> <li>• Working memory (+ DS Forward, NS DS Backward)</li> <li>• Working memory (+BEM-144 12-word list and MMSE 3 words, NS 16-Item free and cued and Rey Complex Figure)</li> </ul>	NR	Recognition (Doors Recognition Sets A and B, DMS48), Working memory (DS Forward and Backward), Recall (BEM-144 12-word-list, 16-Item free and cued, MMSE-3 words, Rey Complex Figure)

ADAS-Cog=Alzheimer's Disease Assessment Scale-Cognitive Subscale; BEM-44= Batterie d'Efficiency Mnesique 144; CAMCOG-R=Cambridge Cognition Examination-Revised; CATD=clinical Alzheimer's-type dementia; CERAD=Consortium to Establish a Registry for Alzheimer's Disease; COWAT=Controlled Oral Word Association Test; CVLT-II=California Verbal Learning Test, Second Edition; DMS48=Delayed Matching-to-Sample Task; DS=Digit Span; ES=effect size; MMSE=Mini-Mental State Examination; NR=not reported; NS=no statistically significant difference; RBANS=Repeat Battery for the Assessment of Neuropsychological Status; TMT=Trail Making Test (A & B)

# Chapter 4B. Results: Physical Activity Interventions

## Key Messages

- Studies of physical activity interventions examined a wide variety of activities potentially targeting different pathways to affect cognition.
- Evidence is insufficient to conclude whether physical activity interventions prevent mild cognitive impairment (MCI) or clinical Alzheimer’s-type dementia (CATD)\* incidence.
- Low-strength evidence shows that multicomponent physical activity interventions offer no clear benefit in cognitive performance over attention control in adults with normal cognition.
- Evidence was insufficient to conclude whether other types of physical activity interventions had benefits for cognitive outcomes in adults with normal cognition.
- While the majority of results showed no significant difference, the pattern of results across very different types of physical activity interventions provides an *indication* of effectiveness of physical activity.

\* Note that the literature currently does not use the term CATD; we specified whenever the diagnosis of dementia was defined.

## Eligible Studies

We identified 48 eligible publications reporting 43 unique studies of physical activity interventions to prevent age-related cognitive decline, MCI, or CATD.<sup>43, 54-100</sup> Twenty-four were assessed as high risk of bias and not used in our analysis, leaving 19 publications for analysis. We analyzed the efficacy and comparative effectiveness of physical activity interventions separately for adults with normal cognition and those with MCI. Appendix G provides evidence tables, summary risk of bias assessments, and assessments of strength of evidence for key comparisons and outcomes.

## Logic of Physical Activity Interventions

Many observational studies and systematic reviews have identified a correlation between physically active lifestyles and decreased rates of CATD. Generally, the selection bias inherent in observational studies precludes adequate testing of correlations for causal relationships; however, experimental studies designed to test the nature of the correlation between physical activity and reduced dementia risk suggest potential mechanisms of action justifying a potential causal relationship. Many justify the relationship by citing previous research. Authors only sometimes proposed mechanisms of action, which included enhanced blood flow and neuronal connectivity,<sup>80, 91</sup> increased brain volume,<sup>80, 91, 100</sup> potential reductions in  $\beta$ -amyloid deposition,<sup>91</sup> reductions in chronic disease risk,<sup>54, 95</sup> anxiety and depression (which are associated with cognitive function), and lowered blood viscosity (which improves aerobic capacity and cognition).<sup>54</sup>

## Adults With Normal Cognition

### Efficacy: Physical Activity Versus Inactive Control

Twelve randomized controlled trials (RCTs) reported in eight publications with low to medium risk of bias compared physical activity interventions to inactive controls in adults with normal cognition.<sup>54, 60, 71, 80, 83, 85, 86, 89, 91, 95, 97, 100</sup> Total sample sizes ranged from 42 to 1,635. Four studies examined multicomponent physical activity interventions.<sup>83, 91, 95, 100</sup> Single component physical activity interventions consisted of resistance training,<sup>60, 71, 97</sup> aerobic exercise/endurance,<sup>54, 74, 80, 85, 86, 89</sup> and Tai Chi.<sup>95</sup> Inactive comparisons included usual care, information, and/or attention controls (i.e., health education). Results are presented by type of physical activity intervention. Conclusions are summarized in Table 4B.1 and individual study results in Table 4B.2.

**Table 4B.1. Conclusions: Physical activity versus inactive comparisons in adults with normal cognition**

Comparison	Outcome	Conclusion	Strength of Evidence (justification)
Multicomponent physical activity vs. attention control k=4	Dementia	Unable to draw conclusion.	Insufficient (medium study limitations, imprecise, unknown consistency)
	MCI	Unable to draw conclusion.	Insufficient (medium study limitations, imprecise, unknown consistency)
	Brief cognitive test performance	No benefit in brief cognitive test performance with multicomponent physical activity versus attention control (n=155; 6 months to 1 year).	Insufficient (medium study limitations, indirect, imprecise, inconsistent)
	Multidomain neuropsychological performance	No benefit in multidomain neuropsychological performance with multicomponent physical activity versus attention control (n=1,635; 2 years).	Low (medium study limitations, indirect, unknown consistency)
	Executive/Attention/Processing speed	No benefit in executive/attention/processing speed with multicomponent physical activity versus attention control (n=1,885; 6 months to 1 year).	Low (medium study limitations, indirect, imprecise)
	Memory	No benefit in memory with multicomponent physical activity versus attention control (n=1,836; 6 months to 1 year).	Low (medium study limitations, indirect, imprecise)
Resistance training vs. attention control k=3	Dementia	No data available.	Insufficient (no data)
	MCI	No data available.	Insufficient (no data)
	Brief cognitive test performance	No data available.	Insufficient (no data)
	Multidomain neuropsychological performance	No data available.	Insufficient (no data)
	Executive/Attention/Processing speed	No benefit in executive/attention/processing speed with resistance training versus attention control (n=120; 6 months).	Insufficient (medium study limitations, indirect, imprecise, inconsistent)
	Memory	No benefit in brief cognitive test performance with resistance training versus attention control (n=172; 6 months).	Insufficient (medium study limitations, indirect, imprecise, inconsistent)
Aerobic training vs. attention control	Dementia	Limited data.	Insufficient (limited data)
	MCI	No data available.	Insufficient (no data)

Comparison	Outcome	Conclusion	Strength of Evidence (justification)
k=6	Brief cognitive test performance	No benefit in brief cognitive test performance with aerobic training interventions (n=162; 6 months to 1 year).	Insufficient (medium study limitations, indirect, imprecise)
	Multidomain neuropsychological performance	Limited data.	Insufficient (limited data)
	Executive/Attention/Processing speed	Unable to draw conclusion.	Insufficient (medium study limitations, indirect, imprecise, inconsistent)
	Memory	Unable to draw conclusion	Insufficient (medium study limitations, indirect, imprecise, inconsistent)
Tai Chi vs. attention control k=1	Dementia	No data available.	Insufficient (no data)
	MCI	No data available.	Insufficient (no data)
	Brief cognitive test performance	No data available.	Insufficient (no data)
	Multidomain neuropsychological performance	No data available.	Insufficient (no data)
	Executive/Attention/Processing speed	Limited data.	Insufficient (limited data)
	Memory	No data available.	Insufficient (no data)

k=number of studies included; MCI=mild cognitive impairment; n=sample size; vs.=versus

## Multicomponent Physical Activity

Multicomponent physical activity interventions included flexibility, strength, balance, endurance, and/or aerobic components.<sup>83, 91, 95, 100</sup> Enrollment criteria varied by trial. One trial enrolled sedentary adults over 70;<sup>91, 100</sup> another enrolled adults over 60,<sup>95</sup> and the last enrolled frail obese older adults.<sup>83</sup>

Only the large 2-year trial (n=1,635) reported diagnostic outcomes, finding no difference between multicomponent physical activity and attention control in diagnosis of MCI or CATD.<sup>91</sup> Evidence was insufficient to conclude whether a multicomponent physical activity intervention prevents MCI or CATD over a 2-year time period when compared with attention control in adults with normal cognition.

Two trials (n=155) assessed cognition with brief cognitive tests.<sup>83, 100</sup> After the intervention, one trial found no statistical difference between multicomponent physical activity and attention control in changes from baseline (n=102),<sup>74</sup> and one (n=53) showed a statistically significant improvement in Modified Mini-Mental State Examination (3MS) scores.<sup>64</sup> However, the difference in mean change from baseline between intervention and control was three points (95% CI: 1.5 to 4.5). The mean 3MS score in the control group remained nearly the same from baseline (96.3 of 100 possible) to 12 months and the mean score in the moderate physical activity group improved by nearly three points from baseline (94.9 of 100 possible). This three-point change is not likely clinically meaningful given that identified reliable change indices for this instrument range from 5 to 10 points. Evidence was insufficient to conclude whether multicomponent physical activity interventions with durations of 6 months to 1 year have an effect on brief cognitive test performance when compared to attention control in older sedentary adults.



The large 2-year trial (n=1,635) showed no statistical difference with multicomponent physical activity versus attention control in multidomain neuropsychological performance assessed using an investigator-created composite score.<sup>91</sup> Low-strength evidence shows that a multicomponent physical activity intervention with duration of 2 years has no significant effect on multidomain neuropsychological performance when compared with attention control in older sedentary adults.

Four trials (n=1,885) used 13 tests to measure the effects of multicomponent physical activity on executive function/attention/processing speed.<sup>83, 91, 95, 100</sup> Only one of the 13 tests showed a statistically significant improvement with multicomponent physical activity compared with attention control. Low-strength evidence shows that multicomponent physical activity interventions lasting 6 months to 2 years have no significant effect on executive function, attention, or processing speed when compared with attention control in older sedentary adults.

Three trials (n=1,890) reported results of six memory tests; only one test result showed a statistical difference favoring the intervention.<sup>83, 91, 100</sup> Napoli et al. showed greater improvements from baseline with multicomponent physical activity than attention control.<sup>83</sup> Participants improved their verbal fluency (naming animals) by a mean of over 4.1 with multicomponent physical activity, but decreased by 0.8 with attention control, for a mean difference of 4.9. This improvement is not likely clinically meaningful given an identified reliable change index of over 10. Low-strength evidence shows that multicomponent physical activity interventions lasting 6 months to 2 years have no significant effect on memory when compared to attention control in older sedentary adults.

No study of multicomponent physical activity interventions in adults with normal cognition reported other cognitive outcomes, biomarker measures, or adverse effects.

Sink et al. report subgroup effects by sex, age, baseline MMSE and baseline Short Physical Performance Battery scores.<sup>91</sup> Subgroup effects were tested on four outcomes. Two instruments assessed three cognitive domains (executive function, processing speed, and verbal memory) and two composite scores assessed executive function and global cognitive function (according to authors). Physical activity led to better effects on the composite executive function score than health education (attention control) in participants aged 80 to 89. There were no other subgroup differences in executive function.

## **Resistance Training**

Three studies compared resistance training to attention control or placebo.<sup>60, 71, 97</sup> Van de Rest, et al. enrolled adults over 65;<sup>97</sup> Cassilhas et al. enrolled sedentary men between 65 and 75;<sup>60</sup> and Lachman et al. enrolled sedentary older adults with at least one disability.<sup>71</sup> Cassilhas et al. randomized participants to one of three groups (attention control, high-resistance training, and low-resistance training). Lachman et al. randomized participants to the Strong for Life program or waitlist control.

Neither trial reported diagnoses or overall cognitive performance outcomes. Van de Rest reported 11 tests of executive function, attention, and processing speed and Cassilhas et al. reported seven (making comparison for each of the intervention groups to attention control).<sup>60</sup> Evidence was insufficient to draw conclusions about the effects of resistance training on executive function/attention/processing speed or memory. Results were inconsistent. Eight of the 25 comparisons showed a statistically significant improvement in executive function/attention/processing speed with resistance training versus attention control or placebo. Only one of the eight comparisons tested in van de Rest et al. showed a statistically significant

improvement with resistance training compared to placebo control.<sup>97</sup> Cassilhas et al. showed improvements in four of seven tests of executive function, attention, and/or processing speed with high resistance training and three of seven tests of executive function, attention, and/or processing speed with moderate resistance training compared with attention control, scores on digit span, forward; Corsi's block-tapping, backward; and similarities improved with high resistance training compared with attention control.<sup>60</sup> Scores on digit span, forward; Corsi's block-tapping, backward; and similarities improved with moderate resistance training compared with attention control.<sup>60</sup>

Van de Rest reported six measures of memory;<sup>97</sup> Cassilhas et al. reported two;<sup>60</sup> and Lachman et al. reported one.<sup>71</sup> Van de Rest et al. showed no statistical differences between resistance training and attention control in any memory score.<sup>97</sup> Cassilhas et al. showed improvements in one of two memory scores with resistance training; both high and moderate intensity resistance training improved compared with attention control.<sup>60</sup> Lachman et al. showed no statistical difference on memory with resistance training versus waitlist control.<sup>71</sup> Evidence was insufficient to draw conclusions about the effects of resistance training on memory.

None of the resistance training intervention studies reported adverse effects.

Van de Rest et al. examined the effect of frailty on the effect of resistance training on reaction time.<sup>97</sup> Treatment-time interaction was not significant for any of the five reaction time measures compared.

## **Aerobic Activity**

Six trials with low to medium risk of bias compared aerobic or endurance programs to an attention control.<sup>54, 74, 80, 85, 86, 89</sup> Antunes et al. enrolled sedentary older men;<sup>54</sup> Ruscheweyh et al. enrolled healthy older adults;<sup>89</sup> Muscari et al. enrolled healthy older adults;<sup>80</sup> Lautenschlager et al. enrolled adults having difficulty with memory and MMSE scores of 24 or greater;<sup>74</sup> Oken et al. enrolled healthy older adults;<sup>85</sup> Okumiya enrolled healthy older adults.<sup>86</sup>

Only Lautenschlager et al. reported dementia diagnosis outcomes and found that aerobic training was less likely to lead to a diagnosis than attention control.<sup>74</sup> Evidence was insufficient to conclude whether aerobic training offers benefits related to preventing dementia.

Three trials reported either brief cognitive or multidomain neuropsychological test performance. Muscari et al. showed that brief cognitive test performance was better with aerobic training.<sup>80</sup> Oken et al. showed no statistical difference with aerobic exercise with two tests of brief cognitive test performance.<sup>85</sup> Antunes et al. found that multidomain neuropsychological test performance was better with aerobic training.<sup>54</sup> Evidence was insufficient to conclude whether aerobic training offers benefits related to brief cognitive or multidomain neuropsychological test performance.

Other domains of cognitive performance were also reported. Executive function/attention/processing speed were better with aerobic training in two of four tests and memory was better in six of 15 tests. Evidence was insufficient to conclude whether aerobic training offers benefits related to executive function, attention, and/or processing speed, or memory.

## **Tai Chi**

One trial compared Tai Chi to an attention control.<sup>95</sup> Executive function, attention, and/or processing speed were better with Tai Chi than with the attention control. Evidence was insufficient to conclude whether Tai Chi offers benefits related to executive function, attention, and/or processing speed.

**Table 4B.2. Results overview: Physical activity versus inactive comparisons in adults with normal cognition**

Author Year Comparison N= Followup	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
<b>Multicomponent Physical Activity Results Summary k=4; n=1,885</b>	<b>0 of 3 (no difference) k=1</b>	<b>NR</b>	<b>BCT 1 of 2 favors I k=2  MNP 0 of 1 (no difference) k=1</b>	<b>1 of 13 favor I k=4</b>	<b>1 of 6 favor I k=3</b>	<b>3 of 25 favor I</b>	<b>NR</b>
<b>Sink, 2015<sup>91</sup></b> Multicomponent physical activity vs. attention control n=1,635 2 years	NS [Dementia]			NS [DSST]	NS [HVLTL, Immediate Recall]	1 of 15 favor I	NR
	NS [MCI]		<b>MNP</b> NS [Global Composite <sup>a</sup> ]	NS [N-Back, 1 back]	NS [HVLTL, Delayed Recall]		
	NS [Dementia or MCI]			NS [N-Back, 2 back]	NS [HVLTL, Composite <sup>b</sup> ]		
				NS [RT on Task Switching, No]			
				NS [RT on task switching, Yes]			
				I>C [RT on Flanker Test, Congruent]			
				NS [RT on Flanker Test, Incongruent]			
				NS [Composite of Flanker test scores <sup>c</sup> ]			

Author Year Comparison N= Followup	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
<b>Napoli, 2014</b> <sup>83</sup> Multicomponent physical activity vs. attention control n=53 1 year			<b>BCT</b> I>C [3MS]	NS [TMT A]	I>C [Word List Fluency]	2 of 4 favor I	NR
				NS [TMT B]			
<b>Taylor-Piliae, 2010</b> <sup>95</sup> I <sub>1</sub> Multicomponent physical activity vs. attention control n=95 6 months				NS [DS Forward]		0 of 2 (no difference)	NR
				NS [DS Backward]			
<b>Williamson, 2009</b> <sup>100</sup> Multicomponent physical activity vs. attention control n=102 1 year			<b>BCT</b> NS [3MS]	NS [SCWT]	NS [RAVLT]	0 of 4 (no difference)	NR
					NS [DSST]		
<b>Resistance Training Results Summary k=3; n=170</b>	<b>NR</b>	<b>NR</b>	<b>NR</b>	<b>8 of 25 favor I k=3</b>	<b>3 of 11 favor I k=1</b>	<b>11 of 36 favor I</b>	<b>NR</b>
<b>van de Rest, 2014</b> <sup>97</sup> Resistance-type exercise program vs. usual care n=55 6 months				I>C [DS Forward]	NS [Word Learning Test, Immediate Recall-75 Words]	2 of 17 favor I	NR
				NS [DS Backward]	NS [Word Learning Test, Delayed Recall-15 Words]		
				NS [TMT A]	NS Word Learning Test, Decay]		
				NS	NS		

Author Year Comparison N= Followup	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
				[Stroop 1]	[Word Learning Test, Recognition, 30 Words]		
				NS [Stroop 2]	I>C <sup>z</sup> [Attention and Working Memory Composite]		
				NS [Stroop Inference]	NS <sup>z</sup> [Episodic Memory Composite]		
				NS [RT Uncued]			
				NS [RT Cued]			
				NS [Word Fluency-Letter]			
				NS <sup>z</sup> [Processing Speed Composite]			
				NS <sup>z</sup> [Executive Functioning Composite]			
<b>Cassilhas, 2007</b> <sup>60</sup> High resistance training (I <sub>1</sub> ) vs. attention control n=43 males 6 months				I <sub>1</sub> >C [DS Forward]	NS [RCFT, Copy]	5 of 9 favor I	NR
				NS [DS Backward]	I <sub>1</sub> >C [RCFT, Immediate Recall]		
				NS [Corsi Block, Forward]			
				I <sub>1</sub> >C [Corsi Block, Backward]			
				I <sub>1</sub> >C [Corsi Block, Similarities]			
				NS			

Author Year Comparison N= Followup	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
				[Toulouse-Pieron, Cancellations Numbers]			
				I <sub>1</sub> >C [Toulouse-Pieron, Errors]			
<b>Cassilhas, 2007</b> <sup>60</sup> Moderate resistance training (I <sub>2</sub> ) vs. attention control n=42 males 6 months				I <sub>2</sub> >C [DS Forward]	NS [RCFT, Copy]	4 of 9 favor I	NR
				NS [DS Backward]	I <sub>2</sub> >C [RCFT, Immediate Recall]		
				NS [Corsi Block, Forward]			
				I <sub>2</sub> >C [Corsi Block, Backward]			
				I <sub>2</sub> >C [Corsi Block, Similarites]			
				NS [Toulouse-Pieron, Cancellations Numbers]			
				NS [Toulouse-Pieron, Errors]			
<b>Lachman, 2006</b> <sup>71</sup> Resistance training vs. waitlist n=52					NS [DS Backward]		
<b>Aerobic Training Results Summary k=6; n=531</b>	<b>1 of 1 favors I k=1</b>	<b>NR</b>	<b>BCT 1 of 3 favor I k=2  MNP</b>	<b>3 of 14 favor I k=3</b>	<b>6 of 18 favor I k=5</b>	<b>10 of 21 favor I</b>	<b>0 of 3 (no difference) (k=1)</b>

Author Year Comparison N= Followup	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
			1 of 1 favor I k=1				
Antunes, 2015 <sup>54</sup> Multicomponent physical activity vs. usual care n=46 older males 6 months				I>C [Picture Arrangement, WAIS-III]	NS [Verbal Paired Associates, Trial 1, Easy Pair]	7 of 16 favor I	
				I>C [Corsi Block-tapping, Forward]	I>C [Verbal Paired Associates, Trial 1, Hard Pair]		
				NS [Corsi Block-tapping, Backward]	NS [Verbal Paired Associates, Trial 2, Easy Pair]		
					I>C [Verbal Paired Associates, Trial 2, Hard Pair]		
					NS [Verbal Paired Associates, Trial 3, Easy Pair]		
					I>C Memory [Verbal Paired, Trial 3, Hard Pair]		
					NS [Verbal Paired Associates, Recall Test, Easy Pair]		
					NS [Verbal Paired Associates, Recall Test, Hard Pair]		
					I>C [Free Word Recall. Total Words Recalled (Non-		

Author Year Comparison N= Followup	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
					Semantic] I>C [Free Word Recall, Total Words Recalled (Semantic)]		
					NS [Free Word Recall, Intrusions]		
					Unclear [Free Word Recall, Repetitions]		
					Unclear [Free Word Recall, Preservations]		
<b>Ruscheweyh 2011<sup>89</sup></b> Gymnastics vs.no intervention n=42 6 months					NS [RAVLT-German]	0 of 1 (no difference)	
<b>Ruscheweyh 2011<sup>89</sup></b> Nordic walking vs. no intervention n=41 6 months					NS [RAVLT-German]	0 of 1 (no difference)	
<b>Muscari, 2010<sup>80</sup></b> Endurance training vs. information control n=120 1 year			<b>BCT</b> I>C [MMSE]			1 of 1 favor I	NR
<b>Lautenschlager, 2008<sup>74</sup></b> Home-based physical activity vs.	I>C		<b>MNP</b> I>C [ADAS-Cog]	NS [DSST]	NS [Word List, Immediate Recall]	3 of 5 favor I	NS [Cardiovascular problem]
					I>C		



Author Year Comparison N= Followup	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
information control n=170 6 months	[Clinical Dementia Rating, Sum of Boxes (diagnosis estimate)]				[Word List, Delayed Recall]		NS [Stroke]  NS [Shoulder operation]
<b>Oken 2006</b> <sup>85</sup> Aerobic exercise vs. waitlist control n=91 6 months				NS [SCWT Inference]	NS [Word List, Delayed Recall]	0 of 9 (no difference)	
				NS [Covert Orienting (Invalid-Valid)]	NS [Letter-Number Sequencing]		
				NS [Divided Attention]			
				NS [% Errors Above Threshold]			
				NS [Set Shifting: Highest Shift]			
				NS [Simple RT]			
				NS [Choice RT]			
Okumiya 1996 <sup>86</sup> Aerobic exercise program vs. no program n=42 6 months			<b>BCT</b> NS [MMSE]			0 of 2 (no difference)	
			<b>BCT</b> NS [Hasegawa Dementia Scale]				
<b>Tai Chi Results Summary k=1; n=93</b>	<b>NR</b>	<b>NR</b>	<b>NR</b>	<b>1 of 2 favor I (k=1)</b>	<b>NR</b>	<b>NR</b>	<b>NR</b>
<b>Taylor-Piliae,</b>				$I_2 > C$		1 of 2 favor $I_2$	NR

Author Year Comparison N= Followup	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
2010 <sup>95</sup> I <sub>2</sub> Tai Chi vs. attention control n=93 6 months				[DS Backward]			
				NS [DS Forward]			

<sup>a</sup> mean global composite z score composed of Digit Symbol Coding, HVLТ immediate and delayed recall, n-back task, and reaction time on task switching and Flanker tasks; <sup>b</sup> composite z score of HVLТ-R immediate and delayed word recall; <sup>c</sup> composite z score of Flanker congruent and incongruent reaction times. Shading indicates summary rows and columns.

3MS=Modified Mini-Mental State Examination; ADAS-Cog=Alzheimer's Disease Assessment Scale-Cognitive Subscale; BCT=brief cognitive test performance; C=inactive control; DS=Digit Span (Forward or Backward); DSST=Digit Symbol Substitution Test; HVLТ-R=Hopkins Verbal Learning Test-Revised; I=intervention; I<sub>1</sub>=first intervention; I<sub>2</sub>=second intervention; k=number of studies; MCI=mild cognitive impairment; MMSE=Mini-Mental State Examination; MNP=multidomain neuropsychological performance; n=sample size; NR=not reported; NS=no statistically significant difference; RAVLT=Rey Auditory Verbal Learning Test; RCFT=Rey-Osterrieth Complex Figure Test; RT=reaction time; SCWT=Stroop Color Word Test; TMT=Trail-Making Test (Parts A and/or B); vs.=versus; WAIS=Wechsler Adult Intelligence Scale

## Comparative Effectiveness: Physical Activity Versus Active Comparison

Seven studies compared physical activity interventions to active interventions.<sup>56, 60, 62, 83, 85, 89, 95</sup> Individual study results are provided in Table 4B.3. Eggenberger et al. (n=89) compared 6-months of virtual reality dance video game with treadmill walking combined with verbal memory training in adults over 70.<sup>62</sup> Napoli et al. (n=54) compared exercise with an exercise and diet program.<sup>83</sup> Baker et al. (n=34) compared 6-months of an aerobic exercise program with stretching.<sup>56</sup> Taylor-Piliae et al. (n=132) compared multicomponent physical activity with Tai Chi.<sup>95</sup> Cassilhas et al. (n=39) compared a high intensity resistance training with a lower intensity resistance training.<sup>60</sup> Oken et al. (n=91) compared yoga to aerobic exercise.<sup>85</sup> Ruscheweyh et al. (n=41) compared two types of aerobic activity, an aerobic exercise class with Nordic walking.<sup>89</sup>

None of the eligible studies reported diagnostic outcomes. Five comparative effectiveness trials showed no statistical differences in any cognitive category, despite examining many comparisons.<sup>60, 62, 83, 85, 89</sup> These trials are likely underpowered for comparative effectiveness.

Baker et al. showed that executive function/attention/processing speed (measured with four different instruments) improved with aerobic exercise compared with stretching in 3 of the 4 tests.<sup>56</sup> They found no statistically significant difference in memory with aerobic exercise versus stretching.

Taylor-Piliae et al. showed that executive function/attention/processing speed (measured with two different instruments) improved more with Tai Chi than multicomponent physical activity in one of two tests.<sup>95</sup>

Evidence on comparative effectiveness was insufficient due to the heterogeneity in interventions, comparisons, and outcomes examined, resulting in either limited data (n<500 for single studies), or no data.

**Table 4B.3. Results overview: Physical activity versus active comparisons in adults with normal cognition**

Author Year Comparison N= Followup	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
<b>Aerobic vs. Stretching/Toning/ Yoga Results Summary</b> k=2; n=125	NR	NR	NR	3 of 12 favor I <sub>1</sub> k=2	0 of 3 favor I <sub>1</sub> k=2	3 of 15 favor I <sub>1</sub>	NR
<b>Baker, 2010</b> <sup>56</sup> Aerobic exercise (I <sub>1</sub> ) vs. stretching (I <sub>2</sub> ) n=34 6 months				I <sub>1</sub> >I <sub>2</sub> [TMT B]	NR [Story Recall]	3 of 7 favor I <sub>1</sub>	NR
				I <sub>1</sub> >I <sub>2</sub> [Task Switching]			
				I <sub>1</sub> >I <sub>2</sub> [SCWT Inference]			
				NS [Self-Ordered Point Test]			
				NS [Verbal Fluency]			
<b>Oken 2006</b> <sup>85</sup> Yoga vs. aerobic exercise n=91 6 months				NS [SCWT Inference]	NS [Word List, Delayed Recall]	0 of 9 (no difference)	
				NS [Covert Orienting (Invalid-Valid)]	NS [Letter-number sequencing, WAIS-III]		
				NS [Divided Attention Threshold]			
				NS [% Errors Above Threshold]			
				NS [Set Shifting: Highest Shift]			
				NS [Simple RT]			
				NS			

Author Year Comparison N= Followup	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
				[Choice RT]			
<b>Unique Comparisons</b>	NA	NA	NA	NA	NA	NA	NA
<b>Eggenberger, 2015</b> <sup>62</sup> Dance/treadmill memory training vs. treadmill n=89 6 months				NS [TMT A]	NS [Story Recall]	0 of 9 (no difference)	NR
				NS [TMT B]	NS [Paired Associates Learning]		
				NS [Executive Control Task]			
				NS [DS Forward]			
				NS [Age Concentration Test A]			
				NS [Age Concentration Test B]			
				NS [DSST]			
<b>Napoli, 2014</b> <sup>83</sup> I <sub>1</sub> Exercise vs. I <sub>2</sub> diet + exercise n=54 1 year			<b>BCT</b> NS [3MS]	NS [TMT A]	NS [Word List Fluency]	0 of 4 favor (no difference)	NR
				NS [TMT B]			
<b>Ruscheweyh 2011</b> <sup>89</sup> Nordic walking vs. gymnastics n=41 6 months					NS [AVLT]	0 of 1 (no difference)	
<b>Taylor-Piliae, 2010</b> <sup>95</sup> I <sub>1</sub> Multicomponent physical activity vs.				I <sub>2</sub> >I <sub>1</sub> [DS Backward]		1 of 2 favor I <sub>2</sub>	
				NS [DS Forward]			

Author Year Comparison N= Followup	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
I <sub>2</sub> Tai Chi n=70							
<b>Cassilhas, 2007</b> <sup>60</sup> High resistance training (I <sub>1</sub> ) vs. Moderate resistance training (I <sub>2</sub> ) n=39 6 months				NS [DS Forward]	NS [RCFT, Copy]	0 of 9 (no difference)	NR
				NS [DS Backward]	NS [RCFT, Immediate Recall]		
				NS [Corsi Block, Forward]			
				NS [Corsi Block, Backward]			
				NS [Corsi Block, Similarites]			
				NS [Toulouse-Pieron, Cancellations Numbers]			
				NS [Toulouse-Pieron, Errors]			

AVLT=Auditory Verbal Learning Test; C=inactive control; DS=Digit Span (Forward and/or Backward); DSST=Digit Symbol Substitution Test; I=intervention; I<sub>1</sub>=first intervention; I<sub>2</sub>=second intervention; k=number of studies; n=sample size; NR=not reported; NS=no statistically significant difference; RCFT=Rey-Osterrieth Complex Figure Test; RT=reaction time; SCWT=Stroop Color Word Test; TMT=Trail Making Test (A and/or B) vs.=versus; WAIS=Wechsler Adult Intelligence Scale  
Shading indicates summary rows and columns.

## Adults With MCI

Conclusions are provided in Table 4B.4 and individual study results in Table 4B.5.

**Table 4B.4. Conclusions: Physical activity versus inactive comparisons in adults with MCI**

Comparison	Outcome	Conclusion	Strength of Evidence (justification)
Multicomponent physical activity vs. attention control k=1	Dementia	No data available.	Insufficient (no data)
	MCI	No data available.	Insufficient (no data)
	Brief cognitive test performance	Unable to draw conclusion.	Insufficient (medium study limitations, indirect, imprecise)
	Multidomain neuropsychological performance	Limited data.	Insufficient (limited data)
Aerobic training vs. attention control k=2	Memory	Unable to draw conclusion.	Insufficient (medium study limitations, indirect, imprecise)
	Dementia	Limited data.	Insufficient (limited data)
	MCI	No data available.	Insufficient (no data)
	Brief Cognitive Test Performance	No data available.	Insufficient (no data)
	Multidomain Neuropsychological Performance	Unable to draw conclusion.	Insufficient (medium study limitations, indirect, imprecise, inconsistent)
	Executive Function	Unable to draw conclusion.	Insufficient (medium study limitations, indirect, imprecise)
Memory	Unable to draw conclusion.	Insufficient (medium study limitations, indirect, imprecise)	

k=number of studies included; MCI=mild cognitive impairment; vs.=versus

### Efficacy: Physical Activity Versus Inactive Control

We identified four reports of three unique studies comparing physical activity interventions to inactive controls in older adults with MCI.<sup>67, 74, 93, 94</sup> Lautenschlager et al. (n=170) compared a 24-week home-based exercise program with usual care.<sup>74</sup> Hildreth et al. (n=78) compared a 6-month endurance exercise program with placebo in obese older adults with MCI.<sup>67</sup> Suzuki et al. compared a 6-month multicomponent physical activity program to attention control in older adults with MCI or amnesic MCI.<sup>93</sup>

All three trials reported multidomain neuropsychological test performance measured with the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog). Lautenschlager et al. showed improvements with the home-based physical activity program versus usual care.<sup>74</sup> Hildreth et al. showed no statistical difference with endurance exercise versus placebo (for control for a pioglitazone arm) and no exercise.<sup>67</sup> Suzuki et al. showed no statistical difference with a 6-month multicomponent physical activity program versus attention control.<sup>93</sup> Lautenschlager et al. showed no difference in executive function/ attention/processing speed with home exercise versus usual care compared using two different measures.<sup>74</sup> Hildreth et al. used four tests to measure executive function/attention/processing speed and found no differences in any measure.<sup>56</sup> Suzuki et al. showed no difference in memory with multicomponent exercise versus attention control measured with two different measures.<sup>93</sup>

We identified six reports of five unique studies comparing physical activity interventions to active interventions in older adults with MCI.<sup>56, 72, 73, 75, 81</sup> All were assessed high risk of bias.

## **Interpreting the Findings**

These results show no clear and consistent benefit of physical activity interventions in preventing cognitive decline. However, the number of positive results exceeds what would be expected by chance alone; providing a signal of a possible relationship. Given that many of these physical activity intervention studies enrolled older sedentary adults and had followup times as short as 6 months, substantial benefits to cognition might be unlikely. If physical activity lowers risk for cognitive decline and CATD and interventions can be effectively implemented to change behaviors, these interventions likely involve long-term investment and may need to begin earlier in the aging process. Long-term studies enrolling younger adults would greatly benefit the field and provide important insight on prevention.



**Table 4B.5. Results overview: Physical activity interventions versus inactive comparisons for adults with MCI**

Author Year Comparison N= Followup	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
<b>Multicomponent Physical Activity Results Summary k=1; n=100</b>	NR	0 of 2 (no difference) k=1	<b>BCT</b> 1 of 3 favor I k=1  <b>MNP</b> 0 of 1 (no difference) k=1	0 of 4 (no difference) k=1	1 of 5 favors I k=1	2 of 15 favor I	0 of 1 (no difference) k=1
<b>Suzuki, 2013<sup>93</sup></b> Multicomponent physical activity vs. attention control n=100 6 months		NS [MTA-ERC]	<b>BCT</b> NS [MMSE]		NS [WMS-LM I]	0 of 6 (no difference)	NS [Falls and hospitalizati on for illness]
		NS [WBC]	<b>MNP</b> NS [ADAS-Cog]		NS [WMS-LM II]		
<b>Suzuki, 2012<sup>94</sup></b> Multicomponent physical activity vs. attention control (aMCI subgroup of Suzuki 2013) n=50 6 months 12 months			<b>BCT</b> I>C [MMSE, 6 months]	NS [SCWT-I]	I>C [WMS-LM I, 6 months]	2 of 9 favor I	
			<b>BCT</b> NS [MMSE, 12 months]	NS [SCWT-II]	NS [WMS-LM I, 12 months]		
				NS [DSST]	NS [WMS-LM II]		
				NS [LVFT]			
<b>Aerobic Training Results Summary k=2; n=153</b>	0 of 1 (no difference) k=1	NR	<b>MNP</b> 1 of 2 favors I k=2	0 of 8 (no difference) k=2	0 of 5 (no difference) k=2	1 of 16 favor I	0 of 4 (no difference) k=2
<b>Hildreth, 2015<sup>67</sup></b> Endurance training vs. usual care +			<b>MNP</b> NS [ADAS-Cog]	NS [WMS-R VR II]	NS <sup>a</sup> [Memory Composite]	0 of 11 (no difference)	Unclear [Musculo- skeletal Complaints]

Author Year Comparison N= Followup	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
placebo (for control for pioglitazone arm) n=53 6 months				NS [Picture Completion, WAIS-R]	NS [WMS-R, LM II]		
				NS <sup>b</sup> [Executive Function Composite]	NS [RAVLT]		
				NS [TMT B]			
				NS [DSST]			
				NS [SCWT]			
				NS [DSST]			
<b>Lautenschlager, 2008<sup>74</sup></b> Home-based physical activity vs. information control n=100 6 months	NS [CDR, Sum of Boxes (diagnosis estimate)]		<b>MNP</b> I>C [ADAS-Cog]	NS [DSST]	NS [Word List, Immediate Recall]	1 of 5 favor I	NS [Cardiovasc ular Problem]
					NS [Word List, Delayed Recall]		NS [Stroke]  NS [Shoulder Operation]

<sup>a</sup>=Scaled score for domain: visual reproduction II, logical memory II, RAVLT; <sup>b</sup>= Domain scaled score: TMT B, DSST  
Shading indicates summary rows and columns.

ADAS-Cog=Alzheimer's Disease Assessment Scale-Cognitive Subscale; BCT=brief cognitive test performance; C=inactive control; CDR=Clinical Dementia Rating; DSST=Digit Symbol Substitution Test; I=intervention; k=number of studies included; LM=logical memory; LVFT= letter verbal fluency test; MCI=mild cognitive impairment; MMSE=Mini-Mental State Examination; MNP=multidomain neuropsychological test performance; MTA-ERC=medial temporal areas including the entorhinal cortex; n=sample size; NS=no statistically significant difference; RAVLT=Rey Auditory Verbal Learning Test; SCWT=Stroop Color and Word Test; TMT=Trail-Making Test (A and/or B); VR=Visual Reproduction; vs.=versus; WAIS-R=Wechsler Adult Intelligence Scale-Revised; WMS=Wechsler Memory Scale; WBC= whole brain cortices

# Chapter 4C. Results: Nutraceutical Interventions

## Key Messages

- Low-strength evidence suggests omega-3 fatty acids and ginkgo biloba did not improve clinical Alzheimer’s-type dementia (CATD)\* incidence or cognitive performance in adults with normal cognition.
- Evidence is insufficient to conclude whether resveratrol or plant sterol/stanol esters reduced CATD incidence or improved cognitive performance in adults with normal cognition.
- Few studies examined the effects of nutraceuticals on adults with mild cognitive impairment (MCI).

\*Note that the literature currently does not use the term CATD; we specified whenever the diagnosis of dementia was defined.

## Eligible Studies

We identified 25 eligible publications reporting 23 unique studies of nutraceutical interventions to prevent age-related cognitive decline, MCI, or CATD.<sup>59, 101-124</sup> Eight were assessed as high risk of bias and not used in our analysis, leaving 15 studies to use in our analysis. We analyzed the efficacy and comparative effectiveness of nutraceutical interventions separately for adults with normal cognition and those with MCI. Appendix H provides evidence tables, summary risk of bias assessments, and assessments of strength of evidence for key comparisons and outcomes.

## Logic of Nutraceutical Interventions

The logic underlying nutraceuticals varies with the nutraceutical. Targeted pathways include reducing oxidative stress and chronic inflammation, improving vascular function, and supplementing macronutrients found in brain tissue and used in brain function.

## Adults With Normal Cognition

Conclusions are summarized in Table 4C.1 and individual study results in Table 4C.2.

**Table 4C.1. Conclusions: Nutraceuticals in adults with normal cognition**

Comparison	Outcome	Conclusion	Strength of Evidence (justification)
Omega-3 fatty acids vs. inactive control k=7	Dementia	No statistically significant difference in dementia diagnosis with omega-3 fatty acids versus placebo in long term (n=12,536; 6 years; adults with diabetes or glucose intolerance).	Low (high study limitations of composite outcome with component of unequal importance, one of which is not clinical diagnosis and may be achieved due to chance, unknown consistency)
	MCI	No data available.	Insufficient (no data)
	Brief cognitive test performance	No benefit in brief cognitive test performance with omega-3 fatty acids versus placebo in long term (n=16,431; up to 6 years).	Low (medium study limitations, indirect, imprecise)
	Multidomain neuropsychological	No benefit in multidomain neuropsychological performance with omega-3 fatty acids versus	Low (medium study limitations, indirect, imprecise, unknown)

Comparison	Outcome	Conclusion	Strength of Evidence (justification)
	performance	placebo in long term (n=744; 2 years).	consistency)
	Executive/Attention/Processing speed	No benefit in executive/attention/processing speed with omega-3 fatty acids versus placebo in long term (n=5,079; up to 6 years).	Low (medium study limitations, indirect, imprecise)
	Memory	No benefit in memory with omega-3 fatty acids versus placebo in long term (n=3,428; up to 4 years).	Low (medium study limitations, indirect, imprecise)
Omega -3 fatty acids vs. B vitamins (folate, B <sub>6</sub> , B <sub>12</sub> ) k=1	Dementia	No data available.	Insufficient (no data)
	MCI	No data available.	Insufficient (no data)
	Brief cognitive test performance	No benefit in brief cognitive test performance with omega-3 fatty acids versus vitamin B in long term (n=885; 4 years).	Low (medium study limitations, indirect, imprecise, unknown consistency)
	Multidomain neuropsychological performance	No data available.	Insufficient (no data)
	Executive/Attention/Processing speed	No data available.	Insufficient (no data)
	Memory	No benefit in memory with omega-3 fatty acids versus vitamin B in long term (n=885; 4 years).	Low (medium study limitations, indirect, imprecise, unknown consistency)
Omega-3 + B vitamins (folate, B <sub>6</sub> , B <sub>12</sub> ) vs. B vitamins (folate, B <sub>6</sub> , B <sub>12</sub> ) k=1	Dementia	No data available.	Insufficient (no data)
	MCI	No data available.	Insufficient (no data)
	Brief cognitive test performance	No benefit in brief cognitive test performance with B vitamins and omega-3 versus B vitamins alone in long term (n=884; 4 years).	Low (low study limitations, indirect, imprecise, consistency unknown)
	Multidomain neuropsychological performances	No data available.	Insufficient (no data)
	Executive/Attention/Processing speed	No data available.	Insufficient (no data)
	Memory	No benefit in memory with B vitamins with omega-3 versus B vitamins alone in long term (n=884; 4 years).	Low (low study limitations, indirect, imprecise, consistent)
Ginkgo biloba vs. inactive control k=3	Dementia	No statistically significant difference in dementia diagnosis with ginkgo biloba versus placebo in long term (n=5,407; 6 years; adults over 70).	Low (medium study limitations, direct, imprecise, consistent)
	MCI	Limited data.	Insufficient (limited data)
	Brief cognitive test performance	No data available.	Insufficient (no data)
	Multidomain neuropsychological performance	No benefit in multidomain neuropsychological performance with ginkgo biloba versus placebo in long term (n=3,069; 6 years, adults over 70).	Low (medium study limitation, indirect, imprecise, unknown consistency)
	Executive/Attention/Processing speed	No benefit in executive/attention/processing speed with ginkgo biloba versus placebo in long term (n=5,079; 6 years, adults over 70).	Low (medium study limitation, indirect, imprecise)
	Memory	No benefit in memory with ginkgo biloba versus placebo in long term (n=3,187; up to 6 years, adults over 70).	Low (medium study limitation, indirect, imprecise)

k=number of studies included; MCI=mild cognitive impairment; n=sample size; vs.=versus

## Omega-3 Versus Placebo

Seven RCTs with low to medium risk of bias enrolling a total of 21,027 adults compared some form of omega-3 fatty acids versus placebo in adults.<sup>101, 103, 107, 115, 117, 119, 120</sup> Total sample sizes ranged from 65 to 11,685. Yurko-Mauro et al. used only docosahexaenoic acid (DHA),<sup>119</sup>

all others used some combination of eicosapentaenoic acid (EPA) plus DHA. Geleijnse et al. also used alpha-linolenic acid (ALA) as another omega-3 study arm.<sup>107</sup> Only the ORIGIN study (n=15,077) allowed adults already using omega-3 supplementation to participate in the study.<sup>120</sup> All studies assessed baseline cognition; six reported baseline Mini-Mental State Examination (MMSE) score of at least 28<sup>103, 107, 115, 117, 119, 120</sup> while one study used the Isaacs Set Test (35.8).<sup>101</sup> However, only three studies specified a baseline cognition inclusion criterion.<sup>103, 115, 119</sup> Populations studied included adults with diabetes or impaired glucose tolerance,<sup>120</sup> a history or ischemic heart disease,<sup>101</sup> coronary patients,<sup>107</sup> or healthy adults.<sup>103, 115, 117, 119</sup>

No study reported incident diagnosis of dementia or MCI as determined solely by clinical diagnosis. The ORIGIN study, a large multinational study of adults with diabetes or impaired glucose tolerance, used a combination of clinical diagnosis or an MMSE score less than 24 and found no difference in probable dementia incidence between EPA+DHA or placebo groups for the median duration of 6.2 years (HR 0.93 [0.86 to 1.0]).<sup>120</sup>

Overall, the studies provide low-strength evidence suggesting that omega-3 fatty acids do not improve cognitive performance between adults with normal cognition as compared to placebo. None of four studies (n=16,431) found a statistical improvement in brief cognitive test performance, such as the MMSE;<sup>101, 107, 119, 120</sup> likewise, one study that assessed multidomain neuropsychological performance using a global composite also found no statistical difference between groups.<sup>103</sup> Of 32 tests to assess executive function in five studies (n=5,079), 29 tests did not find a significant difference between groups, with a maximum followup of 6 years.<sup>103, 115, 117, 119, 120</sup> The two tests with significant differences that favored the omega-3 fatty acid group were based on 548 participants and for only a 6 month followup.<sup>117, 119</sup> Similarly, of 25 tests to assess memory in five studies (n=3,428),<sup>101, 103, 115, 117, 119</sup> 22 did not find a significant difference between groups, with a maximum followup of 4 years. The three tests with the omega-3 fatty acid group performing better than the placebo group were from a single 6-month study that used six memory tests (n=483).<sup>119</sup>

No studies found significant differences in adverse events for omega-3 supplementation.

Four studies examined the effects of the omega-3 fatty acid interventions versus placebo on several subgroups. No significant differences in effect were found for age,<sup>101, 107, 115, 120</sup> sex,<sup>107, 115, 120</sup> or inclusion criteria disease condition.<sup>107, 120</sup>

Andreeva et al. used a 2X2 factorial design, assigning adults with a history of ischemic heart disease to four groups: placebo, omega-3, B vitamins (folate, B<sub>6</sub>, B<sub>12</sub>), or omega-3 plus B vitamins.<sup>101</sup> Results noted above collapsed the four arms into one group with any omega-3 assignment versus one group without omega-3 assignment. Results when comparing the omega-3 alone group with the B vitamins alone group also found no significant differences between groups for any outcome. Likewise, the omega-3 plus B vitamins versus B vitamins alone did not result in significant differences between groups.

## **Ginkgo Biloba Extract**

Three randomized controlled trials (RCTs) (four publications) with low to medium risk of bias enrolling a total of 5,559 older adults with presumed normal cognition compared 240 mg/day of ginkgo biloba versus placebo in adults.<sup>104, 105, 113, 116</sup> Total sample sizes ranged from 118 to 3,069. All studies assessed baseline cognition, two reporting baseline MMSE scores of at least 27.6<sup>105, 116</sup> while one reported baseline Modified Mini-Mental State Examination (3MS) of 93 and Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) of 6.5.<sup>104, 113</sup>

All studies specified a baseline cognition inclusion criterion.<sup>103, 115, 119</sup> Age inclusion criterion were  $\geq 70$ ,<sup>116</sup>  $\geq 75$ ,<sup>104, 113</sup> and  $\geq 85$ .<sup>105</sup>

Two studies provide low-strength evidence suggesting that ginkgo biloba does not affect incidence of probable CATD compared to placebo.<sup>104, 113, 116</sup> Both studies assessed probable CATD according to Diagnostic Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria by adjudication panels of clinical experts.

Overall the studies also provide low-strength evidence that ginkgo biloba does not improve cognitive performance as compared to placebo. One study that assessed multidomain neuropsychological performance using the 3MS and the ADAS-Cog found no statistical difference between groups.<sup>113</sup> Likewise, no differences between groups were found in either executive function<sup>113</sup> or memory.<sup>105, 113</sup>

All studies reported adverse events. No studies found significant differences in adverse events for omega-3 supplementation. The two larger studies found no differences in adverse events between groups (n=5,437).<sup>104, 113, 116</sup> Dodge et al., who recruited 122 adults 85 years and older with normal cognition, reported a larger number of strokes and transient ischemic attacks (TIA) in the ginkgo biloba group over 3.5 years (7 vs. 0, p=.01).<sup>105</sup> However, the larger study by Vellas et al. (n=2,820) found no significant differences between groups in stroke, hemorrhagic events, and cardiac disorders over 5 years.

Two studies explored the effects of the ginkgo biloba interventions versus placebo on several subgroups. Vellas et al. found differences in effect in men, people who consumed alcohol at baseline, and adults who continued the intervention for at least four years.<sup>116</sup> The authors also advised caution in interpreting the results since they assessed 13 planned subgroups (including age, APOE-4, MMSE  $\leq 27$  at baseline, hypertension, diabetes, hypercholesterolemia, body mass index (BMI)  $\geq 27$ , and failing leg balance test) and did not adjust for multiple testing (all 3 groups showing differences would have been nonsignificant with a Bonferroni correction).<sup>116</sup> In contrast, the GEM study did not find significant effect modification for sex. They also did not find differences for age, sex, race, APOE-E4 status, education, or MCI at baseline. However, CVD at baseline did show a significant treatment by group interaction (p=.02).

## Other Nutraceuticals

Three additional RCTs examined the effects of nutraceuticals on cognition. Resveratrol, a member of a group of plant compounds called polyphenols with possible antioxidant properties, was examined in one study. In this 6-month study on the use of resveratrol in 46 healthy overweight people aged 50-80 years, people assigned to resveratrol performed better on 2 of 6 memory tests and showed significant increases in functional connectivity of the hippocampus to frontal, parietal, and occipital areas of the brain when compared to placebo.<sup>118</sup> No significant changes between groups in total gray matter volume or in the volume or microstructure of the hippocampus were noted.

Schiepers et al. (n=57) compared cognition in 57 adults assigned to consume margarines enriched with plant sterol or stanol esters with those using a control margarine and found after 85 weeks no differences between groups.<sup>111</sup>

Strike et al. (n=27) examined a commercial supplement containing 1 g DHA, 160 mg EPA, 240 mg ginkgo biloba, 60 mg phosphatidylserine, 20 mg vitamin E, 1 mg folic acid, and 20 mcg vitamin B<sub>12</sub> per day versus placebo.<sup>121</sup> The authors hypothesized the combination would provide a synergistic effect. After 6 months, the intervention group improved compared to the control

group in one out of three executive function/attention/processing speed outcomes and one out of three memory tests.

No adverse effects were reported in any study. Due to the evidence base of single studies with small sample sizes ( $n < 500$ ), strength of evidence was not assessed for these three interventions.

**Table 4C.2. Results Overview: Nutraceuticals in adults with normal cognition**

Author Year Comparison N= Follow-up	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsychologi cal Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
<b>Omega-3 Results Summary k=7; n=21,027</b>	0 of 1 (no difference) k=1	1 of 2 favor I k=2	<b>BCT</b> 0 of 9 (no difference) k=4  <b>MNP</b> 0 of 1 (no difference) k=1	2 of 31 favor I k=5	3 of 25 favor I k=1	6 of 68 favor I	0 of 4 (no differenc e) k=2
<b>Cukierman-Yaffe, 2014<sup>120</sup></b> Omega-3 (EPA 465 mg + DHA 375 mg daily) n=15,077 Median 6.2 years	NS [Incident probable cognitive impairment = reported dementia or an MMSE score of < 24] (n=12,536)		<b>BCT</b> NS [MMSE] (n=11,685)	NS [DSST] (n=3,392)		0 of 2 favor I	NR
<b>Witte, 2014<sup>117</sup></b> Omega-3 (fish oil LC-n3-FA) 2.2 grams daily vs. placebo n=65 6 months		I>C [MRI - Gray Matter Volume]		I>C [Executive Composite: Phonemic & Semantic Fluency, TMT A & B, SCWT Parts 1-3]	Ns [Memory Composite: AVLT Learning, Delayed Recall, Recognition, DS Backward]	2 of 6 favor I	NR
		NS [MRI - White Matter Integrity]		NS [Sensorimotor Speed Composite: TMT A, SCWT A & B]			
				NS [DS Forward]			



Author Year Comparison N= Follow-up	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsychologi- cal Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
<b>Geleijnse, Geleijnse 2012</b> <sup>107</sup> Omega-3 (EPA- DHA 400mg/d) vs. placebo n=2,522 40 months			<b>BCT</b> NS [MMSE]			0 of 3 (no difference)	
			<b>BCT</b> NS [Risk of Moderate/Severe Cog Decline, MMSE] <sup>a</sup>				
			<b>BCT</b> NS [Risk of Severe Cog Decline, MMSE] <sup>b</sup>				
<b>Geleijnse, 2012</b> <sup>107</sup> Omega-3 (ALA 200mg/d) vs. placebo n=2,522 40 months			<b>BCT</b> NS [MMSE]			0 of 3 (no difference)	NR
			<b>BCT</b> NS [Risk of Moderate/Severe Cog Decline, MMSE] <sup>a</sup>				
			<b>BCT</b> NS [Risk of Severe Cog Decline, MMSE] <sup>b</sup>				
<b>Andreeva, 2011</b> <sup>101</sup> Omega-3 (EPA- DHA 600 mg/d in a 2:1 ratio) vs. placebo n=1,741 4 years			<b>BCT</b> NS [F-TICS Overall Score]		NS [F-TICS Attention & Semantic Memory Subscore]	0 of 3 (no difference)	NR
					NS [F-TICS Recall/Repetition Subscore]		

Author Year Comparison N= Follow-up	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsychologi cal Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
Dangour, 2010 <sup>103</sup> Omega-3 (EPA 200 mg/d + DHA 500 mg/d) vs. placebo n=744 2 years			MNP NS [Global Composite] <sup>c</sup>	NS [Executive Composite: CVLT Delayed Recall, Location Memory Delayed Recall, Story Recall Delayed]	NS [CVLT – Words Correct]	0 of 17 (no difference)	NS [hospitaliz ation for stroke or MI]
				NS [Processing Speed Composite: Letter Cancellation, Simple RT, Choice RT, DSST]	NS [CVLT - Delayed Recall]		
				NS [Letter Search/ Cancellation]	NS [Memory Composite: CVLT Sum of Words, CVLT Delayed Recall, Location Memory & Delayed, Story Recall & Delayed]		
				NS [SDMT]	NS [Global Delay Composite: CVLT Delayed Recall, Location Memory Delayed Recall, Story Recall delayed]		
				NS [RT, Simple]	NS [Story Recall - Immediate]		
				NS [RT, Choice]	NS [Story Recall - Delayed]		
				NS [DS Forward]	NS [Spatial Memory - Immediate]		
				NS [DS Backward]	NS [Spatial Memory -		

Author Year Comparison N= Follow-up	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsychologi cal Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
					Delayed]		
<b>Yurko-Mauro, 2010</b> <sup>119</sup> Omega-3 (DHA 900 mg/d) n=483 6 months			<b>BCT</b> NS [MMSE]	I>C [CANTAB Stockings of Cambridge]	I>C [CANTAB PAL Battery]	4 of 8 favor I	NS [Infection]
					NS [CANTAB VRM – Free Recall]		NS [Musculos keletal]
					I>C [CANTAB VRM - Immediate Recall]		NS [Gastroint estinal]
					I>C [CANTAB VRM - Delayed Recall]		NS [Nervous System]
					NS [CANTAB SWM]		
					NS [CANTAB PRM - Delayed]		
<b>Van de Rest, 2008</b> <sup>115</sup> Omega-3 (EPA- DHA 400 mg/d) vs. placebo n=196 6 months				NS [Executive Composite: TMT A & B, SCWT Part 3: (part 1 + part 2/2), Word Fluency Animals & Letter]	NS [Memory Composite: Word Learning Immediate, Delayed, & Recognition, DS Backward]	0 of 13 (no difference)	
				NS [Attention Composite]	NS [Word Learning - Immediate Recall]		
				NS [DS Forward]	NS [Word Learning - Delayed Recall]		
				NS [DS Backward]	NS [Word Learning - Recognition]		
				NS [TMT A]			

Author Year Comparison N= Follow-up	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsychologi cal Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
				NS [TMT B]			
				NS [SCWT Part 1]			
				NS [SCWT Part 2]			
				NS [SCWT Part 3: (part 1 + part 2/2)]			
<b>Van de Rest, 2008<sup>115</sup></b> Omega-3 (EPA- DHA 1800 mg/d) vs. placebo n=199 6 months				NS [Executive Composite (Same As Immediately Above)]	NS [Memory Composite (Same As Immediately Above)]	0 of 13 (no difference)	
				NS [Attention Composite]	NS [Word Learning, Immediate Recall]		
				NS [DS Forward]	NS [Word Learning, Delayed Recall]		
				NS [DS Backward]	NS [Word Learning, Recognition]		
				NS [TMT A]			
				NS [TMT B]			
				NS [SCWT Part 1]			
				NS [SCWT Part 2]			
				NS [SCWT Part 3: (part 1 + part 2/2)]			
<b>B vitamins (folate/B<sub>6</sub>/B<sub>12</sub>) vs. omega-3</b>	<b>NR</b>	<b>NR</b>	<b>0 of 1 (no difference) k=1</b>	<b>NR</b>	<b>0 of 2 (no difference) k=1</b>	<b>0 of 3 (no difference)</b>	<b>NR</b>

Author Year Comparison N= Follow-up	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsychologi cal Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
<b>Results Summary k=1; n=885</b>							
<b>Andreeva, 2011<sup>101</sup></b> B vitamins (folate, B <sub>6</sub> , B <sub>12</sub> ) vs. Omega- 3 n=885 4 years			<b>BCT</b> NS [TICS]		NS [TICS Memory]	0 of 3 (no difference)	NR
					NS [TICS Recall]		
<b>B vitamins (folate/B<sub>6</sub>/B<sub>12</sub>) + omega-3 vs. B vitamins Results Summary k=1; n=884</b>	<b>NR</b>	<b>NR</b>	<b>0 of 1 (no difference) k=1</b>	<b>NR</b>	<b>0 of 2 (no difference) k=1</b>	<b>0 of 3 (no difference)</b>	<b>NR</b>
<b>Andreeva, 2011<sup>101</sup></b> B vitamins (folate, B <sub>6</sub> , B <sub>12</sub> ) + omega-3 vs. B vitamins (folate, B <sub>6</sub> , B <sub>12</sub> ) n=884 4 years			<b>BCT</b> NS [TICS]		NS [TICS Memory]	0 of 3 (no difference)	NR
					NS [TICS Recall]		
<b>Ginkgo biloba Results Summary k=3; n=6,041</b>	<b>0 of 11 (no difference) k=3</b>	<b>NR</b>	<b>MNP</b> <b>0 of 1 (no difference) k=1</b>	<b>0 of 5 (no difference) k=1</b>	<b>0 of 4 (no difference) k=2</b>	<b>0 of 10 (no difference)</b>	<b>All serious AEs NS except C&gt;1 [Stroke/ TIA]</b>
<b>Vellas, 2012<sup>116</sup></b> Ginkgo biloba extract (EGb761) 120 mg twice daily vs. placebo n=2,820 5 years	NS [Incidence of Probable CATD, Each Year For 5 Years]					No intermediate outcomes reported	NS [stroke, haemorrh agic events, cardiac disorders]

Author Year Comparison N= Follow-up	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsychologi cal Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
<b>Snitz, 2009</b> <sup>113</sup> <b>DeKosky 2008</b> <sup>104</sup> Ginkgo biloba extract 120 mg twice daily n=3,069 (normal cog & MCI, cognitive test results) n=2,587 (incident AD/dementia) Median 6.1 years	NS [All Dementia]		<b>MNP</b> NS [Composite: 3MS & ADAS-Cog]	NS [Executive Composite: TMT B & SCWT]	NS [Memory Composite: CVLT & Recall Conditions - Modified RCFT]	0 of 9 (no difference)	NS [mortality, CHD, stroke, major bleeding]
	NS [CATD Without Vascular Dementia]			NS [Attention & Psychomotor Speed Composite: WAIS-R DS & TMT A]	NS [CVLT]		
	NS [CATD With Vascular Dementia]			NS [TMT B]	NS [Recall Conditions - Modified RCFT]		
	NS [total CATD]			NS [TMT A]			
				NS [WAIS-R DS]			
<b>Dodge, 2008</b> <sup>105</sup> Ginkgo biloba extract 80 mg three times daily n=118 3 years 6 months	NS [MCI Diagnosi s Estimate: Progress from CDR 0 to CDR 0.5]				NS [CERAD Word List Delayed Recall]	0 of 1 (no difference)	C>I [Stroke/ TIA] [AEs in treatment group]
							NS [Cardiac, renal, falls, other]
<b>Resveratrol</b>	<b>NR</b>	<b>3 of 5 favor I</b>	<b>NR</b>	<b>NR</b>	<b>2 of 6 favor I</b>	<b>5 of 11 favor</b>	<b>NR</b>

Author Year Comparison N= Follow-up	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsychologi cal Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
<b>Results Summary k=1; n=46</b>		<b>k=1</b>			<b>k=1</b>	<b>I</b>	
<b>Witte, 2014<sup>118</sup></b> Resveratrol 200 mg daily n=46 6 months (Resveratrol is a member of a group of plant compounds called polyphenols with possible antioxidant properties)		NS [Total Gray Matter Volume]			I>C [Memory Composite: AVLT Retention, Delayed Recall, Recognition, Learning Ability, 5th Learning Trial]	5 of 11 favor I	
		NS [HC Microstructure]			I>C [AVLT Retention]		
		I>C [Functional Capacity, HC Frontal]			NS [AVLT Delayed Recall]		
		I>C [Functional Capacity, HC Parietal]			NS [AVLT Recognition]		
		I>C [Functional Capacity, HC Occipital]			NS [AVLT Learning Ability]		
					NS [AVLT Fifth Learning Trial]		
<b>Plant Sterols/Stanoles Results Summary</b>	<b>NR</b>	<b>NR</b>	<b>NR</b>	<b>0 of 3 (no difference) k=1</b>	<b>0 of 1 (no difference) k=1</b>	<b>0 of 4 (no difference)</b>	<b>NR</b>
<b>Schiepers, 2009<sup>111</sup></b> Margarines enriched with plant sterol esters (2.5 g/d) or plant stanol				NS [Simple Information Processing Speed Composite: SCWT 1 & 2, Concept Shifting Tests A & B]	NS [Composite: Visual Verbal Word Learning Task Total Free Recall, Delayed Recall, Recognition]	0 of 4 (no difference)	No adverse effects reported

Author Year Comparison N= Follow-up	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsychologi cal Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
esters (2.5 g/d) n=57 1.6 years (85 weeks)				NS [Complex Speed Composite: SCWT 3, Complex Shifting Test]			
				NS [DSST]			
<b>Omega 3 Multinutrient Results Summary k=1; n=27</b>	NR	NR	NR	1 of 3 favor I k=1	1 of 3 favor I k=1	2 of 6 favor I	NR
<b>Strike, 2016</b> <sup>121</sup> Efarex Active 50+ per day vs. placebo n=27 6 months				I>C [CANTAB Motor Screening Task]	I>C [CANTAB VRM Immediate]	2 of 6 favor I	
				NS [CANTAB Motor Screening Touch Accuracy]	NS [CANTAB VRM Delayed]		
				NS [Stockings of Cambridge]	NS [CANTAB PAL]		
<b>Omega-3 versus B Vitamins Results Summary k=1; n=884</b>	NR	NR	BCT 0 of 1 (no difference) k=1  MNP NR k=1	NR	0 of 2 (no difference) k=1	0 of 3 (no difference)	NR



Author Year Comparison N= Follow-up	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsychologi cal Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
Andreeva, 2011 <sup>101</sup> Omega-3 + B vitamins (folate, B <sub>6</sub> , B <sub>12</sub> ) vs. B vitamins (folate, B <sub>6</sub> , B <sub>12</sub> ) n=884 4 years			BCT NS [TICS-m]		NS [TICS-m Memory]	0 of 3 (no difference)	NR
					NS [TICS-m Recall]		

<sup>a</sup>Decrease of 3 or more MMSE points or, if missing, incidence of cognitive decline or dementia.

<sup>b</sup>Decrease of 5 or more MMSE points or, if missing, incidence of cognitive decline or dementia.

<sup>c</sup>Composite: CVLT sum of words recalled, CVLT delayed recall, prospective memory test 1, prospective memory test 2, story recall, story recall delayed, verbal fluency, letter cancellation, location memory, location memory delayed, symbol-letter substitution, digit span forward & backward, simple reaction time, choice reaction time]

Shading indicates summary rows and columns.

3MS=Modified Mini Mental Status Examination; AD=Alzheimer's disease; ADAS-Cog=Alzheimer's Disease Assessment Scale-Cognitive Subscale; Ads=adverse effects; AVLT=Auditory Verbal Learning Test; B<sub>6</sub>=vitamin B<sub>6</sub>; B<sub>12</sub>=vitamin B<sub>12</sub>; BCT=brief cognitive test performance; C=control; CANTAB=Cambridge Neuropsychological Test Automated Battery; CANTAB PAL=Cambridge Neuropsychological Test Automated Battery Paired Associated Learning Test; CATD=clinical Alzheimer's-type dementia; CDR=Clinical Dementia Rating; CERAD= Consortium to Establish a Registry for Alzheimer's Disease; CHD=coronary heart disease; CVLT=California Verbal Learning Test; DHA=docosahexaenoic acid; DS=Digit Span (Forward and/or Backward); DSST=Digit Symbol Substitution; EPA=eicosapentaenoic acid; F-TICS=French version, Telephone Interview Cognitive Status; g/d=grams per day; HC=hippocampus; I=intervention; k=number of studies included; MCI=mild cognitive impairment; mg/d=milligrams per day; MMSE=Mini-Mental State Examination; MNP=multidomain neuropsychological test performance; MRI=magnetic resonance imaging; n=sample size; NR=not reported; NS=no statistically significant difference; PRM=Pattern Recognition Memory; RCFT=Rey-Osterrieth Complex Figure Test; RT=reaction time; SCWT=Stroop Color Word Test; SDMT=symbol digit modalities test; SWM=Spatial Working Memory; TIA=transient ischemic attack; TICS=Telephone Interview Cognitive Status; VRM=Verbal Recognition Memory; WAIS=Wechsler Adult Intelligence Scale;

## Adults With MCI

### Nutraceuticals Versus Inactive Control

Three RCTs compared nutraceuticals to inactive controls in older adults with MCI.<sup>104, 106, 108</sup> Summaries of study results are detailed in Table 4C.3.

Lee et al. (n=36) examined the effects of daily omega-3 fatty acids (fish oil supplementation, DHA 430 mg and EPA 150 mg) on cognitive function in people aged 60 and older with MCI.<sup>108</sup> After 1 year, no significant change in MMSE scores was observed. However, people taking omega-3 performed better than those on placebo on one of three tests of executive function/attention/processing speed, and better on three of five memory tests. No serious adverse effects were reported. Evidence to draw conclusions was insufficient due to limited data (single study with n<500) or no data.

Two (2) studies compared the effects of ginkgo biloba to placebo in people with MCI.<sup>104, 106</sup> Follow-up periods in the studies varied, with Gavrilova's study lasting 6 months<sup>81</sup> and median follow-up in DeKosky et al. lasting 6.1 years.<sup>79</sup>

DeKosky et al. examined diagnostic outcomes.<sup>104</sup> Of five categories of dementia, no significant differences were found between ginkgo and placebo groups. Gavrilova et al. included two objective measures of cognition, both related to the executive function/attention/processing speed domain. In both tests, participants taking ginkgo performed significantly better than those taking placebo.<sup>106</sup>

Gavrilova et al. reported no serious adverse effects.<sup>106</sup> DeKosky et al. found no significant differences between ginkgo and placebo groups in rates of serious adverse effects, including death, bleeding, coronary heart disease (CHD), and stroke.<sup>104</sup> Evidence to draw conclusions was insufficient due to limited data (single study with n<500) or no data.

### Interpreting the Findings

The results show no benefit for the nutraceuticals that have been examined. Some nutraceuticals, such as resveratrol, have not been studied enough to provide sufficient evidence from which to draw conclusions. Most nutraceuticals are based on doses an individual could derive from diet, and are hypothesized to be much less likely to have adverse effects than "therapeutic" doses. However, this also means the interactions with metabolic, environmental, and other nutrition intake may overwhelm possible small effects related to nutritional doses. Designing studies to take such complexity into account is challenging.

**Table 4C.3. Results overview: Nutraceutical interventions in adults with MCI**

Author Year Comparison N= Follow-up	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
<b>Omega-3 Results Summary k=1; n=36</b>	NR	NR	0 of 1 (no difference) k=1	1 of 3 favor I k=1	3 of 5 favor I k=1		No serious AEs reporte d
Lee, 2013 <sup>108</sup> Omega-3 fatty acids (DHA 430 mg and EPA 150 mg) daily n=36 1 year			<b>BCT</b> NS [MMSE]	NS [Composite: CLOX-1, DS Forward]	I>C [Composite: VR I, VR II, RAVLT – Immediate & Delayed Recall, DS Backward]	4 of 9 favor I	No serious AEs reported
				NS [DSST]	I>C [VR I]		
				I>C [DS Forward & Backward]	NS [VR II]		
					NS [RAVLT, Immediate Recall]		
					I>C [RAVLT, Delayed Recall]		
<b>Ginkgo Biloba Results Summary k=2; n=642</b>	0 of 5 (no difference) k=1	NR	NR	2 of 2 favor I	NR k=1	2 of 2 favor I	NS k=1
Gavrilova, 2014 <sup>106</sup> Ginkgo biloba (240 mg) daily n=160 6 months				I>C [TMT A]		2 of 2 favor I	No serious AEs reported
				I>C [TMT B]			
DeKosky, 2008 <sup>104</sup> Ginkgo biloba extract 120 mg twice daily n=482 (MCI sub-	NS [All Dementia]						Serious AEs reported (NS):
	NS						death,

Author Year Comparison N= Follow-up	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
sample) Median 6.1 years	[CATD Without Vascular Dementia]						bleeding, CHD, stroke.
	NS [CATD With Vascular Dementia]						
	NS [Total AD]						
	NS [Vascular Dementia Without CATD]						

AD=Alzheimer's disease; AE=adverse event; BCT=brief cognitive test performance; C=control; CATD: clinical Alzheimer's-type dementia; CHD=coronary heart disease; CLOX-1=Clock Drawing Test; DHA=docosahexaenoic acid; DS=Digit Span (Forward and/or Backward); DSST=Digit Symbol Substitution Test; EPA=eicosapentaenoic acid; I=intervention; k=number of studies included; MMSE=Mini-Mental State Examination; n=sample size; MCI=mild cognitive impairment; mg=milligrams; MMSE=Mini-Mental State Examination; NR=not reported; NS=no statistically significant difference; RAVLT=Rey Auditory Verbal Learning Test; RCT: randomized controlled trial; TMT=Trails Making Test (A & B); VR=visual reproduction  
Shading indicates summary rows and columns.

# Chapter 4D. Results: Diet Interventions

## Key Messages

- Evidence is insufficient to conclude whether protein supplementation or energy-deficit diets have an effect on cognitive performance or incidence of mild cognitive impairment (MCI) or clinical Alzheimer's-type dementia (CATD)\*.

\*Note that the literature currently does not use the term CATD; we specified whenever the diagnosis of dementia was defined.

## Eligible Studies

We identified nine eligible publications reporting six unique studies evaluating the effect of diet interventions to prevent age-related cognitive decline, MCI, or CATD.<sup>69, 83, 125-131</sup> Six studies were high risk of bias (including studies of the Mediterranean diet) and not used in our analysis. All eligible studies enrolled participants with normal cognition. Appendix I provides evidence tables and summary risk of bias assessments.

## Logic of Diet Interventions

Several mechanisms are suggested to link diet to cognitive function and then to age-related cognitive decline, MCI, and CATD. Among these include the link between obesity and CATD with a dietary intervention leading to weight loss and decreased risk.<sup>83, 125</sup> Another proposed mechanism involves the effect of antioxidants (diets rich in these foods) on oxidative stress and vascular impairment, decreasing risk.<sup>129</sup>

## Adults With Normal Cognition

No conclusion table is provided since evidence to draw conclusions was insufficient due to limited data (single study with n<500) or no data.

## Protein Supplement Versus Placebo

Van der Zwaluw et al. compared a protein supplement drink versus a placebo.<sup>130</sup> Sixty-five older adults were randomized to receive either 15mg of protein twice daily or a placebo drink for 24 weeks. No diagnostic outcomes were reported. Despite administering numerous cognitive tests, no statistically significant differences were found in change in executive function/attention/processing speed or memory function. Individual study results are summarized in Table 4D.1. Evidence was insufficient (limited data) to conclude whether protein supplementation has an effect on cognitive outcomes when compared to placebo.

## Energy-Deficit Diet Versus Inactive Control

Napoli et al. reported a single randomized controlled trial (RCT) with medium risk of bias enrolling a total of 107 adults that compared a diet intervention with inactive controls in adults with normal cognition.<sup>83</sup> The intervention consisted of an energy-deficit diet (500-750 kcal per day) while setting weekly behavioral goals and attending weekly weigh-in sessions. A weight-loss goal of approximately 10 percent was to be achieved at 6 months, followed by weight

maintenance for the remaining 6 months. (Weight loss of  $-9.7 \pm 5.4$  kg was reported for the diet group while the control group weight was reported as stable.) The control comparisons consisted of diet education with a prohibition on participating in any weight-loss or exercise program. Individual study results are summarized in Table 4D.1. Evidence was insufficient (limited data) to conclude whether energy-deficit diets have an effect on cognitive outcomes when compared to attention control.

## **Adults With MCI**

No studies address adults with MCI.

## **Interpreting the Findings**

Diet interventions are challenging to study as demonstrated by the proportion of eligible studies that were high risk of bias.

**Table 4D.1. Results overview: Diet interventions in adults with normal cognition**

Author Year Comparison N= Followup	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsychologic al Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
<b>Protein Supplement vs. Placebo Results Summary k=1; n=65</b>	NR	NR	NR	<b>0 of 13 (no difference) k=1</b>	<b>0 of 3 (no difference) k=1</b>	<b>0 of 16 (no difference)</b>	NR
<b>van der Zwaluw, 2014<sup>130</sup></b> Protein drink (15 mg of protein) twice daily vs. placebo n=65 24 weeks				NS [DS Forward]	NS [WLT, Immediate]	0 of 16 (no difference)	NR
				NS [DS Backward]	NS [WLT, Delayed]		
				NS [TMT A]	NS [WLT, Recognition]		
				NS [SCWT 1]			
				NS [SCWT 2]			
				NS [SCWT 3]			
				NS [RT Test]			
				NS [TMT B/A]			
				NS [Word Fluency, Animals]			
				NS [Word Fluency, Letter P]			
				NS [Composite]			
				NS [Composite]			
				NS [Composite]			

Author Year Comparison N= Followup	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsychologic al Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
<b>Energy Restriction Results Summary k=1; n=53</b>	NR	NR	1 of 1 favors I	0 of 2 (no difference)	NR	1 of 3 favors I	NR
<b>Napoli, 2014<sup>83</sup></b> Energy deficit of 500–750 kcal/d from daily requirements vs. control n=53 1 year			<b>BCT</b> I>C [3MS]			1 of 3 favors I	NR
				NS [TMT A]			
				NS [TMT B]			

3MS=Modified Mini-Mental State Examination; BCT=brief cognitive test performance; C=control; DS=Digit Span (Forward and/or Backward); k=number of studies included; kcal/d=calories per day; I=intervention; n=sample size; MNP=multidomain neuropsychological test performance; NR=not reported; NS=no statistically significant difference; RT=reaction time; SCWT=Stroop Color/Word Test; TMT=Trail Making Test (Part A and/or B); vs.=versus; WLT=Word Learning Test. Shading indicates summary rows and columns.



# Chapter 4E. Results: Multimodal Interventions

## Key Messages

- Evidence is insufficient to conclude whether most multimodal interventions offer benefits for cognitive performance or incidence of mild cognitive impairment (MCI) or clinical Alzheimer's-type dementia (CATD),\* largely because few studies have examined interventions with similar components.
- Low-strength evidence shows that a multimodal intervention composed of diet, physical activity, and cognitive training provides benefits in executive function/attention/processing speed.
- Low-strength evidence shows that a multimodal intervention composed of lifestyle advice and drug treatment is not effective in reducing incidence of CATD or benefiting brief cognitive test performance or memory.

\*Note that the literature currently does not use the term CATD; we specified whenever the diagnosis of dementia was defined.

## Eligible Studies

We identified 21 eligible publications that reported unique studies of multimodal interventions to prevent age-related cognitive decline, MCI, or CATD.<sup>62, 66, 69, 72, 83, 87, 97, 126, 132-144</sup> Thirteen were assessed as high risk of bias and not used in our analysis.<sup>66, 69, 72, 87, 132, 134, 136-140, 143, 144</sup> We analyzed the efficacy and comparative effectiveness of multimodal interventions separately for adults with normal cognition and those with MCI. Appendix J provides evidence tables, summary risk of bias assessments, and assessments of strength of evidence for key comparisons and outcomes.

## Logic of Multimodal Interventions

Studies that examine multimodal interventions theorize that an integrated approach to addressing multiple risk factors for CATD may be more successful than single component interventions in producing benefits.<sup>62, 133, 142</sup> Multimodal interventions often include components like physical activity, changes to diet, and cognitive training. Several of the studies included in this review have suggested mechanisms for the relationship between individual components like physical activity<sup>54, 80, 91</sup> or cognitive training<sup>25</sup> and reduced dementia risk. Because an almost infinite number of interventions can be combined, creating categories for review and analysis is a daunting task.

Table 4E.1 lists the components included in the seven studies that had low to medium risk of bias. Six of the eight studies included physical activity as part of the multimodal intervention. The two most frequent combinations across the eight studies were physical activity with changes to diet and physical activity with cognitive training. Other components include protein supplementation and goal setting.

**Table 4E.1. Components of multimodal interventions for low/medium risk of bias trials**

Study	Physical Activity	Diet	Cognitive Training	Protein Supplements	Goal Setting	Lifestyle Advice	Drug Treatment
Clare, 2015 <sup>133</sup>					•		
Eggenberger, 2015 <sup>62</sup>	•		•				
Ngandu, 2015 <sup>142</sup>	•	•	•				
Hars, 2014 <sup>135</sup>	•		•				
Napoli, 2014 <sup>83</sup>	•	•					
van de Rest, 2014 <sup>97</sup>	•			•			
Martin, 2007 <sup>126</sup>	•	•					
Moll van Charante, 2016						•	•

## Adults With Normal Cognition

### Efficacy: Multimodal Interventions Versus Inactive Control

Seven studies with low to medium risk of bias enrolling a total of 5,132 adults compared multimodal interventions with inactive controls in adults with normal cognition.<sup>83, 97, 126, 133, 135, 141, 142</sup> All were randomized controlled trials (RCTs). Total sample sizes ranged from 24 to 3,526. Most interventions included physical activity as a component. Inactive comparisons included health information and maintaining lifestyle habits. Conclusions are summarized in Table 4E.2 and individual study results in Table 4E.3.

**Table 4E.2. Conclusions: Multimodal interventions versus inactive comparisons in adults with normal cognition**

Intervention Components	Outcome	Conclusion	Strength of Evidence (justification)
Physical Activity and Diet k=2	Dementia	No data available.	Insufficient (no data)
	MCI	No data available.	Insufficient (no data)
	Brief cognitive test performance	Limited data.	Insufficient (limited data)
	Multidomain neuropsychological performance	No data available.	Insufficient (no data)
	Executive/Attention/Processing speed	Unable to draw conclusion.	Insufficient (medium study limitations, indirect, imprecise, inconsistent)
	Memory	Limited data.	Insufficient (limited data)
Physical Activity and Cognitive Training k=1	Dementia	No data available.	Insufficient (no data)
	MCI	No data available.	Insufficient (no data)
	Brief cognitive test performance	Limited data.	Insufficient (limited data)
	Multidomain neuropsychological performance	Limited data.	Insufficient (limited data)
	Executive/Attention/Processing speed	No data available.	Insufficient (no data)
	Executive/Attention/Processing speed	No data available.	Insufficient (no data)
Physical Activity, Diet, and Cognitive Training k=1	Dementia	No data available.	Insufficient (no data)
	MCI	No data available.	Insufficient (no data)
	Brief cognitive test	No data available.	Insufficient (no data)

<b>Intervention Components</b>	<b>Outcome</b>	<b>Conclusion</b>	<b>Strength of Evidence (justification)</b>
	performance		
	Multidomain neuropsychological performance	Intervention composed of diet, physical activity, and cognitive training improves multidomain neuropsychological test performance; unclear if improvement is clinically meaningful (n=1,260; 2 years).	Low (indirect, unknown consistency)
	Executive/Attention/Processing speed	Intervention composed of diet, physical activity, and cognitive training improves executive/attention/processing speed; unclear if improvement is clinically meaningful (n=1,260; 2 years).	Low (indirect, unknown consistency)
	Memory	Unable to draw conclusion (n=1,260; 2 years).	Insufficient (indirect, imprecise, inconsistent)
Physical Activity and Protein Supplementation k=1	Dementia	No data available.	Insufficient (no data)
	MCI	No data available.	Insufficient (no data)
	Brief cognitive test performance	No data available.	Insufficient (no data)
	Multidomain neuropsychological performance	No data available.	Insufficient (no data)
	Executive/Attention/Processing speed	Limited data.	Insufficient (limited data)
	Memory	Limited data.	Insufficient (limited data)
Goal Setting and Mentoring k=1	Dementia	No data available.	Insufficient (no data)
	MCI	No data available.	Insufficient (no data)
	Brief cognitive test performance	Limited data.	Insufficient (limited data)
	Multidomain neuropsychological performance	No data available.	Insufficient (no data)
	Executive/Attention/Processing speed	Limited data.	Insufficient (limited data)
	Memory	Limited data.	Insufficient (limited data)
Individualized Lifestyle Advice and Medical Management k=1	Dementia	No benefit to dementia risk from individualized intervention composed of lifestyle advice and medical management (n=526; 6 years).	Low (medium study limitations, direct, imprecise, unknown consistency)
	MCI	No data available.	Insufficient (no data)
	Brief cognitive test performance	No benefit in brief cognitive test performance from individualized intervention composed of lifestyle advice and medical management (n=526; 6 years).	Low (medium study limitations, indirect, unknown consistency)
	Multidomain neuropsychological performance	No data available.	Insufficient (no data)
	Executive/Attention/Processing speed	No data available.	Insufficient (no data)
	Memory	No benefit to memory from individualized intervention composed of lifestyle advice and medical management (n=526; 6 years).	Low (medium study limitations, indirect, unknown consistency)

Intervention Components	Outcome	Conclusion	Strength of Evidence (justification)
		years).	

K=number of studies included; MCI=mild cognitive impairment; n=sample size

## Physical Activity and Diet

Two trials (n=79) compared physical activity and diet with inactive controls.<sup>83, 126</sup> Both enrolled overweight or obese adults. Napoli et al. randomized individuals to an intervention consisting of calorie-restriction diet and multicomponent exercise for 90 minutes, three times per week for 1 year.<sup>83</sup> Martin et al. randomized overweight young to middle aged adults to a calorie restriction diet and structured exercise for 6 months.<sup>126</sup>

Neither trial reported diagnostic outcomes or multidomain neuropsychological test performance. Napoli et al. reported brief cognitive test performance for one measure (Modified Mini-Mental State Examination, 3MS) and found a statistically significant improvement with the physical activity and diet intervention compared with attention control.<sup>83</sup> Martin et al. reports 11 measures of memory, none of which differed between physical activity with diet and attention control.<sup>126</sup> Limited data prevented assessment of strength of evidence for brief cognitive test performance or memory.

Napoli et al. reported two measures of executive function/attention/processing speed,<sup>83</sup> and Martin et al. reported eight.<sup>126</sup> Napoli et al. showed statistically significant improvement in Trail Making Test A from baseline to 1 year in the multimodal intervention group compared with the health information group.<sup>83</sup> The remaining nine measures from Napoli et al. and Martin et al. showed no statistically significant difference with multimodal intervention compared with attention control.<sup>83, 126</sup> Evidence was insufficient to determine whether a multimodal intervention consisting of physical activity and diet improves executive function/attention/processing speed.

## Physical Activity and Cognitive Training

Hars et al. (n=134) compared physical activity and cognitive training with an inactive control.<sup>135</sup> Adults who were frail or had an increased risk of falling were randomized to a structured, music-based exercise or their usual lifestyle habits.<sup>135</sup> The intervention involved weekly 60-minute structured music-based multitasking exercise classes for 6 months.

One measure of brief cognitive test performance (Mini-Mental State Examination, MMSE) showed no statistically significant improvements with the intervention compared with the control. Hars et al. also reported two measures of executive function.<sup>135</sup> Overall, the Frontal Assessment Battery showed no statistically significant improvements with the intervention compared with the control; however, the Sensitivity to Inference subtest of the battery showed statistically significant improvements with the intervention. Limited data prevented assessment of strength of evidence for brief cognitive test performance or executive function. The trial reported on no other diagnoses, cognitive outcomes, biomarker measures, or harms.

## Physical Activity, Diet, and Cognitive Training

Ngandu et al. (n=1,260) compared physical activity, diet, and cognitive training with an inactive control.<sup>142</sup> Adults at risk for cardiovascular disease were randomized to a multimodal intervention (nutritional counseling, multicomponent exercise, cognitive training, and management of metabolic and vascular risk factors) or an attention control. The intervention involved one to three aerobic exercise sessions per week; two to five resistance training

sessions per week; both group and individual cognitive training; and management of vascular risk factors with lifestyle changes for 2 years.

One measure of multidomain neuropsychological test performance was reported. The Neuropsychological Test Battery was significantly higher with multimodal intervention compared with control at 6 months. Low-strength evidence shows that a multimodal intervention consisting of physical activity, diet, and cognitive training improves multidomain neuropsychological performance when compared to attention control.

Three of four subtests (two executive function, two memory) of the Neuropsychological Test Battery showed statistical improvement with intervention compared with control at 6 months. Both executive function measures showed improvement; only one of the memory measures showed improvement. Low-strength evidence shows that a multimodal intervention consisting of physical activity, diet, and cognitive training improves executive function when compared to attention control.

Ngandu et al. reported no other diagnoses, cognitive outcomes, biomarker measures, or harms.<sup>142</sup>

## **Physical Activity and Protein Supplementation**

Van de Rest et al. (n=58) compared physical activity and protein supplementation with usual care.<sup>97</sup> Pre-frail and frail adults were randomized to resistance type exercise with protein supplementation or usual care (no exercise) and placebo for 6 months. The trial reported 11 measures of executive function. Only a composite score of processing speed showed a statistically significant difference between intervention and control groups at 6 months. The same trial also reported six measures of memory, none of which showed a statistically significant difference between groups at 6 months. This trial was likely underpowered. Evidence was insufficient to conclude whether physical activity and protein supplementation improves executive function or memory due to limited data.

Van de Rest et al. reported on no other diagnoses, cognitive outcomes, biomarker measures, or harms.<sup>97</sup>

## **Multimodal Goal Setting**

Clare et al. (n=75) compared goal setting (with and without mentoring) with attention control.<sup>133</sup> Functionally independent community-dwelling older adults participated in setting and discussing goals related to a variety of risk factors, then randomized to goal-setting alone or goal-setting with mentorship. Goal-setting involved an interview and identification of five goals; mentorship involved bi-monthly phone calls to discuss progress towards goals. Duration was 6 months.

Brief cognitive test performance (Montreal Cognitive Assessment), was better with the interventions compared to control. The trial also reported statistically significant improvements for the Trail-Making Test (executive function) and the Immediate Recall sub-test of the California Verbal Learning Test (CVLT) (memory) with intervention compared with control. However, the Delayed Recall subtest of the CVLT showed statistically significant improvements with attention control. Evidence was insufficient to conclude whether goal setting with mentoring improves cognitive outcomes due to limited data. The trial reported on no other diagnoses, cognitive outcomes, biomarker measures, or harms.

## **Lifestyle Advice and Drug Treatment**

Moll van Charante et al. (n=3,526) reports on the Prevention of Dementia by Intensive

Vascular care (PreDIVA) trial which compared a multimodal intervention that aimed to identify risks and provide individualized lifestyle advice and medical management with inactive control.<sup>141</sup> Community-dwelling adults without dementia were randomized to a multimodal intervention (individualized lifestyle advice and, if indicated, medical management of chronic disease) or usual care (based on standards for cardiovascular risk management). The intervention consisted of visits for a general practice nurse every 4 months over 6 years. Nurses assessed cardiovascular risk factors (smoking habits, diet, physical activity, weight, and blood pressure), blood sugar, and cholesterol and provided individualized lifestyle advice based on these assessments. Subjects were prescribed drugs to manage identified cardiovascular risk factors, blood sugar, and cholesterol as needed. Antithrombotic drugs were also prescribed if needed.

At 6 years, there was no statistically significant difference between the intervention and control group in cases of all-cause dementia, Alzheimer's disease, or unspecified types of dementia.<sup>141</sup> Low strength evidence shows individualized multimodal intervention does not decrease dementia incidence.

There were statistically significant differences in cases of dementia in two subgroups: participants with untreated hypertension that were adherent to the intervention and participants without a history of cardiovascular disease who were adherent to the intervention. For both of these subgroups, there were fewer cases of dementia with the intervention.

One measure of brief cognitive test performance was reported. There was no statistically significant difference between intervention and control groups in MMSE scores at 6 years.<sup>141</sup> In addition, one measure of memory was reported. There was no statistically significant difference between intervention and control groups in Visual Association Test A scores at 6 years. Low strength evidence shows individualized multimodal intervention does not benefit brief cognitive test performance or memory.

Moll van Charante et al. reported no difference in serious adverse effects between the intervention and control groups.<sup>141</sup> The study reported no other diagnoses, cognitive outcomes, or biomarker measures.

**Table 4E.3. Results overview: Multimodal interventions versus inactive comparisons in adults with normal cognition**

Author Year Comparison N= Followup	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsychol ogical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
<b>Physical Activity and Diet Results Summary k=2; n=79</b>	NR	NR	<b>BCT 1 of 1 favors I k=1</b>	<b>1 of 10 favors I k=2</b>	<b>0 of 11 (no difference) k=1</b>	<b>2 of 22 favor I</b>	<b>NR</b>
<b>Napoli, 2014</b> <sup>83</sup> Physical activity and diet vs. health information n=55 1 year			<b>BCT I&gt;C [3MS]</b>	I>C [TMT A]		2 of 3 favor I	NR
				NS [TMT B]			
<b>Martin, 2007</b> <sup>126</sup> Physical activity and diet vs. weight maintenance n=24 6 months				NS [CPT-II, Beta (Response Style)]	NS [RAVLT, Trial I-V]	0 of 19 (no difference)	NR
				NS [CPT-II, Omissions]	NS RAVLT, Trial B]		
				NS [CPT-II, Detectability]	NS [RAVLT, Trial VI]		
				NS [CPT-II, RT]	NS [RAVLT, Delayed Recall]		
				NS [CPT-II, RT SE]	NS [RAVLT, Recognition]		
				NS [CPT-II, Commissions]	NS [ACT, 9 sec]		
				NS [CPT-II, Perseverations]	NS [ACT, 18 sec]		
				NS [CPT-II, RT Block Changes]	NS [ACT, 36 sec]		
					NS [BVRT, Correct Deviation]		
					NS [BVRT, Error Deviation]		

Author Year Comparison N= Followup	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsychol ogical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
					NS [BVRT, Correct Deviation]		
<b>Physical Activity and Cognitive Training Results Summary k=1; n=134</b>	NR	NR	BCT 0 fo1 (no difference) k=1	1 of 2 favors I k=1	NR	1 of 3 favors I	NR
<b>Hars, 2014</b> <sup>135</sup> Physical activity and cognitive training vs. usual lifestyle n=134 6 months			BCT NS [MMSE]	NS [FAB]		1 of 2 favors I	NR
				I>C [Sensitivity to Inference Sub-test, FAB]			
<b>Physical Activity, Diet, and Cognitive Training Results Summary k=1; n=1,260</b>	NR	NR	MNP 1 of 1 favors I	2 of 2 favors I k=1	1 of 2 favors I k=1	4 of 5 favors I	
<b>Ngandu, 2015</b> <sup>142</sup> Physical activity, diet, and cognitive training vs. health information n=1,260 2 years			MNP I>C [NTB, Total Score]	I>C NTB, Executive Functioning]	NS [NTB, Memory]	4 of 5 favor I	Unclear [Musculosk eletal pain]
				I>C NTB, Processing Speed]	I>C [NTB, Abbreviated Memory]		
<b>Physical Activity and Protein Supplementation Results Summary k=1; n=58</b>	NR	NR	NR	1 of 11 favors I k=1	0 of 6 (no difference) k=1	1 of 17 favor I	NR
<b>van de Rest, 2014</b> <sup>97</sup>				NS [DS Forward]	NS [Word Learning Test, Immediate Recall-75]	1 of 17 favor I	NR



Author Year Comparison N= Followup	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsychol ogical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
Resistance-type exercise program vs. usual care n=58 6 months					Words]		
				NS [DS Backward]	NS [Word Learning Test, Delayed Recall-15 Words]		
				NS [TMT A]	NS Word Learning Test, Decay]		
				NS [SCWT 1]	NS [Word Learning Test, Recognition, 30 Words]		
				NS [SCWT 2]	NS [Attention and Working Memory Composite]		
				NS [SCWT Inference]	NS <sup>2</sup> [Episodic Memory Composite]		
				NS [RT Uncued]			
				NS [RT Cued]			
				NS [Word Fluency-Letter]			
				I>C <sup>2</sup> [Processing Speed Composite]			
				NS <sup>2</sup> [Executive Functioning Composite]			
<b>Goal Setting and Mentoring Results Summary k=1; n=75</b>	<b>NR</b>	<b>NR</b>	<b>BCT 1 of 1 favors I k=1</b>	<b>1 of 1 favors I k=1</b>	<b>1 of 2 favors I 1 of 2 favors C k=1</b>	<b>3 of 4 favors I 1 of 4 favors C</b>	

Author Year Comparison N= Followup	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsychol ogical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
<b>Clare, 2015</b> <sup>133</sup> Goal setting and goal setting with mentoring vs. health information n=75 6 months			<b>BCT</b> I>C [MoCA]	I>C [TMT]	I>C [CVLT, Immediate Recall]	3 of 4 favors I 1 of 4 favors C	NR
					C>I [CVLT, Delayed Recall]		
<b>Lifestyle Advice and Drug Treatment Summary k=1; n=3,526</b>	<b>1 of 4 favors I k=1</b>	<b>NR</b>	<b>0 of 1 (no difference) k=1</b>	<b>NR</b>	<b>0 of 1 (no difference) k=1</b>	<b>1 of 6 favors I</b>	
<b>Moll van Charante, 2016</b> <sup>141</sup> Lifestyle advice and drug treatment vs. usual care n=3,526 6 years	NS [All-Cause Dementia]	NR	<b>BCT</b> NS [MMSE]		NS [Visual Association Test A]	1 of 6 favors I	NS [Severe Adverse Events]
	NS [AD]						
	NS [Unspecifie d Dementia]						
	I>C [Non- Alzheimer's Dementia]						

<sup>a</sup> mean global composite z score composed of xxx; <sup>b</sup> composite z score of HVLT-R immediate and delayed word recall

3MS=Modified Mini-Mental State Examination; ACT=Auditory Consonant Trigram; AD=Alzheimer's disease; BCT=Brief cognitive test performance; BVRT=Benton Visual Retention Test; C=inactive control; CPT=Continuous Performance Test; CVLT=California Verbal Learning Test; DS=Digit Span (Forward and/or Backward); FAB=Frontal Assessment Battery; I=Intervention; k=number of studies included; MMSE=Mini-Mental State Examination; MoCA=Montreal Cognitive Assessment; MNP=multidomain

neuropsychological test performance; n=sample size; NR=not reported; NS=not significant; NTB=Neuropsychological Test Battery; RAVLT=Rey Auditory Verbal Learning Test; RT=reaction time; SE=standard error; SCWT=Stroop Color Word Test; TMT=Trail Making Test (Part A and/or B); vs.=versus.

Shading indicates summary rows and columns.

## **Comparative Effectiveness: Multimodal Interventions Versus Active Comparison**

Multimodal interventions address several risk factors for CATD at once, potentially creating a synergistic protective effect. Studies compare multimodal interventions with single component interventions to test this hypothesis. Different approaches to multimodal interventions may also affect their potential effectiveness. This is tested in studies comparing different multimodal interventions.

Three studies with low to medium risk of bias compared multimodal interventions with active controls in adults with normal cognition.<sup>62, 83, 126</sup> All were RCTs. Total sample sizes ranged from 24 to 134. All of the interventions included physical activity as a component. Active comparisons were a single component intervention (diet or physical activity alone). Individual study results are summarized in Table 4E.4. No conclusion table is provided since evidence to draw conclusions was insufficient due to limited data (single study with n<500) or no data.

### **Physical Activity and Diet Versus Single-Component**

Two trials (n=90) compared physical activity and diet changes with a single component (diet or physical activity).<sup>83, 126</sup> Napoli et al. reported brief cognitive test performance (3MS) and several measures of executive function/attention/ processing speed outcomes using several instruments, and found no statistically significant improvement with physical activity and diet compared to either single component intervention.<sup>83</sup>

Martin et al. compared physical activity and diet intervention with two diet interventions alone (calorie restriction alone and liquid calorie diet alone).<sup>126</sup> Across both comparisons, the trial reports 22 measures of memory and several measures of executive function/attention/processing speed outcomes using several instruments, none of which showed statistical differences between the physical activity and diet intervention compared with either diet alone. Evidence was inadequate to assess the strength of evidence for brief cognitive test performance or memory.

The trials reported no additional outcomes.

### **Multimodal Versus Multimodal**

Eggenberger et al. (n=46) compared two interventions that each had a physical activity and cognitive training component.<sup>62</sup> Older adults were randomized to either virtual reality game dancing with cognitive training or to treadmill walking with verbal memory exercise. The trial reported seven measures of executive function that showed no statistically significant differences between the intervention groups. The trial also reported two measures of memory that showed no statistically significant differences between the intervention groups. Evidence was insufficient to determine whether different multimodal interventions consisting of physical activity and cognitive training improves executive function/attention/processing speed due to limited data. The trial reported no additional outcomes.

**Table 4E.4. Results overview: Multimodal interventions versus active comparisons in adults with normal cognition**

Author Year Comparison N= Followup	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
<b>Physical Activity and Diet vs. Diet Results Summary k=2; n=102</b>	NR	NR	<b>BCT 1 of 1 favors I k=1</b>	<b>0 of 18 (no difference) k=2</b>	<b>0 of 22 (no difference) k=1</b>	<b>1 of 41 favors I</b>	<b>NR</b>
<b>Napoli, 2014</b> <sup>83</sup> Physical activity and diet vs. diet n=54 1 year			<b>BCT I&gt;C [3MS]</b>	NS [TMT A]		1 of 3 favors I	NR
				NS [TMT B]			
<b>Martin, 2007</b> <sup>126</sup> Physical activity and diet vs. diet n=24 6 months				NS [CPT-II, Beta (response style)]	NS [RAVLT, Trial I-V]	0 of 19 (no difference)	
				NS [CPT-II, Omissions]	NS RAVLT, Trial B]		
				NS [CPT-II, Detectability]	NS [RAVLT, Trial VI]		
				NS [CPT-II, RT]	NS [RAVLT, Delayed Recall]		
				NS [CPT-II, RT SE]	NS [RAVLT, Recognition]		
				NS [CPT-II, Commissions]	NS [ACT, 9 sec]		
				NS [CPT-II, Perseverations]	NS [ACT, 18 sec]		
				NS [CPT-II, RT Block Changes]	NS [ACT, 36 sec]		
					NS [BVRT, Correct Deviation]		
					NS		

Author Year Comparison N= Followup	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
					[BVRT, Error Deviation]		
					NS [BVRT, Correct Deviation]		
<b>Martin, 2007</b> <sup>126</sup> Physical activity and diet vs. diet n=24 6 months				NS [CPT-II, Beta (response style)]	NS [RAVLT, Trial I-V]	0 of 19 (no difference)	
				NS [CPT-II, Omissions]	NS RAVLT, Trial B]		
				NS [CPT-II, Detectability]	NS [RAVLT, Trial VI]		
				NS [CPT-II, Reaction time]	NS [RAVLT, Delayed Recall]		
				NS [CPT-II, RT Std. Error]	NS [RAVLT, Recognition]		
				NS [CPT-II, Commissions]	NS [ACT, 18 sec]		
				NS [CPT-II, Perseverations]	NS [ACT, 36 sec]		
				NS [CPT-II, RT Block Changes]	NS [BVRT, Correct Deviation]		
					NS [BVRT, Error Deviation]		
					NS [BVRT, Correct Deviation]		
					NS [ACT, 18 sec]		
<b>Physical Activity and Diet vs. Physical Activity</b>	<b>NR</b>	<b>NR</b>	<b>BCT 0 of 1 (no difference)</b>	<b>0 of 2 (no difference) k=1</b>	<b>NR</b>	<b>0 of 3 (no difference)</b>	<b>NR</b>

Author Year Comparison N= Followup	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
<b>Results Summary</b> k=1; n=54			k=1				
<b>Napoli, 2014</b> <sup>83</sup> Physical activity and diet vs. physical activity n=54 1 year			<b>BCT</b> NS [3MS]	NS [TMT A]		0 of 3 (no difference)	
				NS [TMT B]			
<b>Physical Activity and Cognitive Training vs. Cognitive Training Results Summary</b> k=1; n=46	NR	NR	NR	0 of 7 (no difference) k=1	0 of 9 (no difference) k=1	0 of 9 (no difference)	NR
<b>Eggenberger, 2015</b> <sup>62</sup> Physical activity and cognitive training vs. cognitive training n=46 6 months				NS [TMT A]	NS [Story Recall]	0 of 9 (no difference)	NR
				NS [TMT B]	NS [PAL]		
				NS [Executive Control]			
				NS [DS Forward]			
				NS [Age Concentration Test A]			
				NS [Age Concentration Test B]			
				NS [DSST]			

3MS=Modified Mini-Mental State Examination; ACT=Auditory Consonant Trigram; BCT=Brief cognitive test performance; BVRT=Benton Visual Retention Test; C=inactive control; CPT=Continuous Performance Test; DS=Digit Span (Forward and/or Backward); I=intervention; k=number of studies included; MNP=Multidomain neuropsychological test performance; n=sample size; NR=not reported; NS=not significant; NTB=Neuropsychological Test Battery; PAL=Paired Associations Learning Test; RAVLT=Rey Auditory Verbal Learning Test; RT=reaction time; SE=standard error; TMT=Trail Making Test (Part A and/or B); vs.=versus.

Shading indicates summary rows and columns.

## Adults With MCI

Only two unique studies compared multimodal interventions to inactive controls in older adults with MCI<sup>66, 136</sup> and two unique studies comparing multimodal interventions with active interventions in older adults with MCI.<sup>66, 72</sup> All were RCTs assessed as high risk of bias.

## Interpreting the Findings

The available evidence is largely insufficient to draw conclusions about the effectiveness of an array of multimodal interventions for cognitive performance or progression to MCI or CATD, largely because the evidence base is weak with small trials of heterogeneous interventions. One important trial does provide sufficient evidence regarding multimodal interventions – the FINGER trial provided low-strength evidence that a combination of physical activity, diet changes, and cognitive training improved multidomain neuropsychological performance and executive function in adults at risk for MCI or CATD, although whether the improvement is clinically meaningful is unclear.<sup>142</sup>

The results of PreDiva study showed no difference between the multimodal and usual care for most outcomes; however, the intervention had no specific cognitive training, physical activity, or diet component.<sup>141</sup> Subjects were counseled to make lifestyle changes, but no specific regimen was implemented. In addition, a large number of participants discontinued the intervention over the 6-year period (final outcomes were obtained through medical records). Results of the ongoing MAPT trial, another large well-designed trial, may provide additional clarity regarding the efficacy and effectiveness of multimodal interventions.<sup>14</sup>

The risk of bias and small sample sizes of identified studies were substantial barriers to our analysis. Of the 20 eligible studies, only eight were of low to medium risk of bias. None of the trials examining multimodal interventions for individuals with MCI were analyzed due to high risk of bias. For adults with normal cognition, nearly all trials had sample sizes less than 100. Multimodal studies make sense to test two concepts: 1) additive effects of strong interventions and 2) overall effects of combinations. The first strategy uses a control of one of the components. The second compares the combination to a control group. The second strategy may facilitate the search for interventions. If a combination does not work, then either component alone likely will not. If it does work, one can compare the marginal benefit of adding the second component.



# Chapter 4F. Results: Hormone Therapy Interventions

## Key Messages

- Hormone therapy shows mixed results of harms and benefits.
- Low-strength evidence suggests that estrogen therapy may slightly increase the risk of probable mild cognitive impairment (MCI) and clinical Alzheimer's-type dementia (CATD)\* when the two diagnostic categories are examined together.
- Low-strength evidence suggests that estrogen plus progestin therapy may slightly increase the risk of probable CATD.
- Low-strength evidence suggests that raloxifene may decrease the risk of MCI but not the risk of CATD or of a combined outcome of MCI or CATD compared to placebo.
- In addition to these outcomes, hormone therapy has been associated with serious adverse events, including increased risk of certain cancers and cardiovascular disease.

\* Note that the literature currently does not use the term CATD; we specified whenever the diagnosis of dementia was defined.

## Eligible Studies

We identified 44 eligible publications reporting 31 unique studies of hormone therapy interventions to prevent age-related cognitive decline, MCI, or CATD.<sup>110, 145-186</sup> Eight studies were assessed as high risk of bias, resulting in 23 low or medium risk of bias studies used in our analysis.<sup>110, 145-147, 152, 165, 169, 182</sup>

Soy and red clover interventions are included in this section due to their phytoestrogenic properties. Not only do the soy and red clover interventions vary considerably from the hormone therapies included in this section, but also the hormone therapies differ from each other.

The majority of studies were designed to examine cognition as a primary outcome. Exceptions included ancillary studies of the longitudinal Women's Health Initiative (WHI),<sup>149, 152, 177-180</sup> two studies investigating the use of selective estrogen receptor modulators (SERMs) in preventing vertebral fractures,<sup>169, 184</sup> two studies (three articles) on the use of hormones to prevent cardiovascular disease,<sup>156, 158, 163</sup> and one study on the effects of testosterone on bone and muscle.<sup>165</sup>

We analyzed the efficacy and comparative effectiveness of hormone therapies separately for adults with normal cognition and those with MCI. Appendix K provides evidence tables, summary risk of bias assessments, and assessments of strength of evidence for key comparisons and outcomes.

## Logic of Hormone Therapy Interventions

Speculation is longstanding about the relationship between the pituitary endocrine axis and aging.<sup>187</sup> While epidemiological studies have suggested that hormone replacement therapy may have a beneficial effect on cognition,<sup>188</sup> randomized trials have produced inconsistent results, even suggesting in some cases that some hormone therapies may have a detrimental effect on cognition.<sup>179, 180</sup> Although it is not precisely a hormone, we included soy in this section because it is often used by people in lieu of hormone replacement therapy.

## Adults With Normal Cognition

Conclusions are summarized in Table 4F.1 and individual study results in Table 4F.2.

**Table 4F.1. Conclusions: Hormone therapies versus inactive comparisons in adults with normal cognition**

Comparison	Outcome	Conclusion	Strength of Evidence (justification)
HRT-estrogen vs. inactive control k=6	Dementia	Increased risk of probable dementia/MCI associated with estrogen therapy (n=2,947; 5-7 years) but no statistically significant difference in risk of probable dementia or MCI when diagnostic categories reported separately.	Low (medium study limitations, unknown consistency)
	MCI	No statistically significant difference between estrogen therapy and placebo groups in risk of MCI (n=2,947; 5-7 years).	Low (medium study limitations, unknown consistency)
	Brief cognitive test performance	Decreased performance in brief cognitive test performance with higher dose estrogen compared to placebo (n=3,364; 5-7 years).	Low (medium study limitations, indirect, imprecise)
	Multidomain neuropsychological performance	Unable to draw conclusion.	Insufficient (medium study limitations, indirect, unknown consistency, imprecise)
	Executive/Attention/Processing speed	No benefit with estrogen compared to placebo (n=2,056; 5-7 years)	Low (medium study limitations, indirect, imprecise)
	Memory	No benefit with estrogen compared to placebo (n=2,056; 5-7 years)	Low (medium study limitations, indirect, imprecise)
HRT-estrogen + progestin vs. inactive control k=5	Dementia	Increased risk of probable dementia associated with estrogen/progestin therapy (n=4,532; 5-7 years) but no statistically significant difference in risk of probable dementia or MCI when the diagnostic categories were combined.	Low (medium study limitations, unknown consistency)
	MCI	No statistically significant difference between estrogen-progestin therapy and placebo in rates of MCI (n=4,532; 5-7 years)	Low (medium study limitations, unknown consistency)
	Brief cognitive test performance	No benefit in brief cognitive test performance with estrogen/progestin versus placebo (n=6,100; up to 7 years).	Low (medium study limitations, indirect)
	Multidomain neuropsychological performance	No data available.	Insufficient (no data)
	Executive/Attention/Processing speed	No benefit in executive/attention/processing speed with estrogen/progestin versus placebo (n=3,007; up to 7 years)	Low (medium study limitations, indirect, imprecise)
	Memory	Decreased memory performance with estrogen/progestin versus placebo (n=3,149; up to 7 years)	Low (medium study limitations, indirect, imprecise)
DHEA vs. inactive control k=1	Dementia	No data available.	Insufficient (no data)
	MCI	No data available.	Insufficient (no data)
	Brief cognitive test performance	Limited data.	Insufficient (limited data)
	Multidomain neuropsychological performance	No data available.	Insufficient (no data)
	Executive/Attention/Processing speed	Limited data.	Insufficient (limited data)
	Memory	Limited data.	Insufficient (limited data)

Comparison	Outcome	Conclusion	Strength of Evidence (justification)
SERM vs. inactive control k=2	Dementia	No statistically significant differences in risk of Alzheimer's disease, any type of dementia, or "dementia or MCI" between 2 doses of raloxifene (60 mg and 120 mg) and placebo (n=5,386; 3 years)	Low (medium study limitations, unknown consistency)
	MCI	Slightly decreased risk of MCI in raloxifene compared to placebo (120mg but not 60 mg of raloxifene) (n=5,386; 3 years).	Low (medium study limitations, unknown consistency)
	Brief cognitive test performance	No data available.	Insufficient (no data)
	Multidomain neuropsychological performance	No data available.	Insufficient (no data)
	Executive/Attention/Processing speed	No benefit in executive/attention/processing speed with SERM versus placebo (n=5,877; 3 years)	Low (medium study limitations, indirect)
	Memory	No benefit in memory with SERM versus placebo (n=5,739; 3 years)	Low (medium study limitations, indirect)
Soy vs. inactive control k=5	Dementia	No data available.	Insufficient (no data)
	MCI	No data available.	Insufficient (no data)
	Brief cognitive test performance	No benefit in brief cognitive test performance with soy versus placebo (n=393; 1 year).	Insufficient (medium study limitations, indirect, imprecise)
	Multidomain neuropsychological performance	No benefit in multidomain neuropsychological performance with soy versus placebo (n=393; 2.5 years)	Insufficient (medium study limitations, indirect, imprecise)
	Executive/Attention/Processing speed	No benefit with soy versus placebo (n=829; up to 2.5 years)	Low (medium study limitations, imprecise)
	Memory	No benefit with soy versus placebo (n=829; up to 2.5 years).	Low (medium study limitations imprecise)
Red clover vs. inactive control k=1	Dementia	No data available.	Insufficient (no data)
	MCI	No data available.	Insufficient (no data)
	Brief cognitive test performance	No data available.	Insufficient (no data)
	Multidomain neuropsychological performance	No data available.	Insufficient (no data)
	Executive/Attention/Processing speed	Limited data.	Insufficient (limited data)
	Memory	Limited data.	Insufficient (limited data)

DHEA=dehydroepiandrosterone; k=number of studies included; MCI=mild cognitive impairment; n=sample size; SERM=selective estrogen receptor modulator; vs.=versus

## Efficacy: Hormone Therapy Versus Inactive Control

Nineteen randomized controlled trials (RCTs) with low to medium risk of bias enrolling a total of 19,154 adults compared hormone therapy interventions to inactive controls in adults with normal cognition.<sup>150, 151, 153-163, 166-168, 172, 174, 175, 177-181, 183-186, 189</sup> Interventions included hormone replacement therapies: estrogen only, combined estrogen and progestin, dehydroepiandrosterone (DHEA), and testosterone; SERM; soy; and red clover. Samples ranged from 23 to 7,478 participants, with followup duration of 6 months to over 5 years.

## Hormone Replacement Therapies

Hormone replacement therapies included estrogen-only therapy, estrogen plus progestin, DHEA, and testosterone. The two testosterone studies were assessed as high risk of bias due to attrition. Enrollment criteria differed among trials, with most studies focusing on older women. The estrogen-only and combined estrogen-progestin trials enrolled premenopausal and postmenopausal women aged 40 to 91 years with normal to “mildly impaired memory functioning”<sup>181</sup> at baseline. The study on DHEA included healthy men and women aged 55 to 85 years, and the studies of testosterone included men aged 65 to 87 years.

### Estrogen Only

Six RCTs (n=4,117) with low to medium risk of bias compared estrogen replacement therapy to placebo in healthy postmenopausal women.<sup>149, 151-153, 157, 160, 174, 175, 177, 178, 180, 183, 186</sup> Studies included several small to moderately-sized RCTs (n=57-567 participants) and two ancillary studies of the large longitudinal WHI (n=2,947, estrogen-only arm), the Women’s Health Initiative Memory Study (WHIMS) and Women’s Health Initiative Study of Cognitive Aging (WHISCA). Study durations ranged from 6 months to over 5 years.

The WHIMS reported diagnostic outcomes (n=2,947).<sup>180</sup> After a mean followup of 7 years, women taking estrogen were significantly more likely to experience probable dementia or MCI when the two diagnostic categories were combined. Although an increase in probable dementia or MCI diagnosis was also observed for women taking estrogen when the diagnostic categories were examined separately, the results did not reach statistical significance. Evidence is low strength that estrogen-only therapy increases the combined risk of probable dementia/MCI given medium study limitations and unknown consistency.

WHIMS participants (520 women aged 71-89 years) were tested for total ischemic lesion volume<sup>149</sup> and changes in brain volume.<sup>178</sup> No differences were found between estrogen and placebo groups in brain lesions. Of four measures of brain volume, women receiving estrogen therapy experienced statistically greater brain atrophy in frontal lobe volume.

Two studies (n=3,364), the WHIMS and Yaffe et al., used the 3MS as a brief test of cognitive performance.<sup>151, 186</sup> The dose of estrogen used in Yaffe et al.’s study was very low, only 0.014 mg daily (compared to 0.625 mg daily in WHIMS). Yaffe et al. found no statistically significant differences between estrogen and placebo groups after two years. After a mean followup of 5.4 years in the WHIMS, however, women taking estrogen performed slightly worse on the Modified Mini-Mental State Examination (3MS) than women taking placebo (difference in mean change from baseline: -0.26, 95% CI: -0.52, 0). Evidence was rated low that higher dose estrogen is associated with decreased performance on the 3MS compared to placebo.

Henderson et al.<sup>160</sup> (n=567) assessed cognition using a multi-domain composite. No difference was found between estrogen and placebo groups. Evidence was rated insufficient.

All six studies (n=2,056) examined changes in cognitive performance related to executive function/attention/processing speed and memory. (A sub-set of 886 WHISCA participants contributed to these outcomes.)<sup>177</sup> Two of 19 tests of executive function, attention, and processing speed favored estrogen, with none of the tests favoring placebo. Similarly, of 35 tests of memory across the studies, two favored estrogen and none favored placebo. Evidence was rated low that estrogen provides no benefit to executive function/ attention/processing speed or memory over placebo.

Henderson et al. found no difference in outcomes between women nearer to and further from menopause.<sup>160</sup> WHIMS investigators conducted subgroup analyses to examine the effects of

baseline risk factors on 3MS scores.<sup>151</sup> Analyses examining the effects of age, education, race/ethnicity, annual household income, Body Mass Index (BMI), smoking status, alcohol consumption, prior cardiovascular disease, treatment for hypertension, diabetes mellitus, presence of moderate or severe vasomotor symptoms, prior hormone therapy use, age at hysterectomy, prior bilateral oophorectomy, prior use of HMG-CoA reductase inhibitors, baseline aspirin use, and baseline 3MS scores on changes in 3MS scores found statistically significant effects based on age, moderate or severe vasomotor symptoms, and baseline 3MS scores.<sup>151</sup>

Henderson et al.<sup>160</sup> (n=567) reported similar rates of serious adverse effects across estrogen and placebo groups. Gorenstein et al. reported no serious adverse effects associated with estrogen therapy and noted that study withdrawals due to adverse effects were similar across estrogen and placebo groups.<sup>157</sup> In the WHIMS, women taking estrogen experienced a higher risk of stroke in addition to a higher risk of probable CATD/MCI than women taking placebo.<sup>180</sup>

### **Estrogen Plus Progestin**

Five RCTs with low to medium risk of bias ranging in size from 23 to 4,532 participants (total n=6,332) compared combination estrogen/progestin therapy with placebo in postmenopausal women. Studies included three small RCTs<sup>150, 158, 181</sup>, the Kronos Early Estrogen Prevention Study-Cognitive and Affective Study (KEEPS-Cog) (n=505)<sup>156</sup> and the WHIMS and WHISCA substudies of the WHI.<sup>149, 175, 178, 179, 189</sup> Specific estrogen/progestin combination therapies varied across studies.

The WHIMS was the only study to report diagnostic outcomes (n=4,532).<sup>179</sup> Of three diagnostic categories, including probable dementia, MCI, or probable dementia/MCI combined, only the probable dementia category showed statistically significant differences between estrogen/progestin and placebo groups, with women receiving estrogen/progestin experiencing higher rates of probable CATD. Evidence was rated low that estrogen-progestin increases the risk of probable CATD.

WHIMS participants (a subset of 883 women aged 71-89 years at the time of MRI scans) were tested for total ischemic lesion volume<sup>149</sup> and changes in brain volume.<sup>178</sup> No differences in brain lesions or brain volume were found between estrogen/progestin and placebo groups.

Three studies (n=6,100) used the 3MS as a brief cognitive test.<sup>156, 158, 175</sup> Only the WHIMS found a statistically significant difference between estrogen/progestin and placebo groups, favoring the controls. Although performance on the 3MS improved over time for both WHIMS groups, the improvement was more marked for women taking placebo.<sup>175</sup> Evidence was rated low.

Four studies (n=3,007) examined the effect of estrogen/progestin therapy versus placebo on cognition in the executive function/attention/processing speed domain.<sup>150, 177</sup> One of nine tests of executive/attention/processing speed favored placebo. Evidence was low-strength that combined estrogen/progestin therapy has no effect on this domain.

All five studies (n=3,149) tested the effects of estrogen/progestin on memory.<sup>156, 158, 175, 181</sup> Four of 16 memory tests favored placebo and no tests favored estrogen/progestin. Evidence was rated low that combined estrogen/progestin therapy negatively affects memory compared to placebo.

Several subgroup analyses were conducted. Tierney found that women in the estrogen/progestin group who scored at or above average at baseline on short-delay recall showed significantly less decline than the placebo group after 1 year, although this same result

was not observed at year 2.<sup>181</sup> No treatment effects were found for women who scored below average on short-delay recall, nor for women in the estrogen-progestin group compared to placebo overall.

In the WHIMS, subgroup analyses examined the relationship between baseline risk factors and 3MS scores by treatment group.<sup>151</sup> Of covariates including age, education, race/ethnicity, annual household income, BMI, smoking status, alcohol consumption, prior cardiovascular disease, treatment for hypertension, diabetes mellitus, presence of moderate or severe vasomotor symptoms, prior hormone therapy use, age at hysterectomy, prior bilateral oophorectomy, prior use of HMG-CoA reductase inhibitors, baseline aspirin use, and baseline 3MS scores statistically significant effects were found only for baseline 3MS scores.<sup>151</sup> Also in the WHIMS,<sup>179</sup> no interaction was found between treatment assignment (estrogen/progestin or placebo) on rates of probable dementia diagnoses for 10 subgroups of women based on age, education, history of stroke, history of diabetes, prior hormone therapy, prior use of estrogen therapy, prior use of estrogen/progestin therapy, prior use of statins, prior use of aspirin, and baseline 3MS score.

Women taking estrogen/progestin in WHIMS experienced increased risk of probable CATD, as well as an increased risk of stroke.<sup>149, 179</sup> Tierney et al. reported death (two in hormone group and two in placebo group), deep vein thrombosis (DVT) (one participant in hormone group with a history of DVT), symptoms of heart failure (three women in hormone group, one of whom withdrew from study), colorectal cancer (one participant) and silent stroke (five participants in hormone group and four in placebo).<sup>181</sup> The reported deaths, silent strokes, and cancer were deemed by study physicians to be unrelated to hormone therapy. Other less serious adverse effects, which were experienced significantly more frequently by women taking hormones, included breast tenderness, vaginal bleeding and discharge, and gastrointestinal problems. In Davison et al., three women discontinued from the study due to vaginal bleeding, including one woman in the hormone group and two taking placebo.<sup>150</sup>

## **DHEA**

One RCT (n=225) compared daily oral DHEA (50mg) to placebo in women and men aged 55 to 85 years with a mean baseline 3MS score of 96.<sup>168</sup> Cognitive outcomes included three measures: a brief cognitive test (the 3MS), a test of executive function, and a test of verbal memory. After 1 year of treatment, no differences were found between DHEA and placebo groups in cognitive function. A total of 33 participants withdrew from the trial due to serious side effects, including 23 people receiving DHEA (67% of withdrawals) and 10 receiving placebo. Serious side effects included chest pain, heart palpitations, and an increase in prostate-specific antigen (PSA) in men. No sub-analyses were reported. Strength of evidence was insufficient due to limited data (single study with n<500).

## **Testosterone**

Two high risk of bias RCTs (n=136) with primary outcomes related to the effects of testosterone on bone density<sup>165, 182</sup> and muscle<sup>165</sup> in older men with low bioavailable testosterone levels examined the effect of testosterone on cognitive performance.

## **Selective Estrogen Receptor Modulators (SERM)**

Two trials (n=7,621) compared the SERM raloxifene (60 mg or 120 mg daily in both trials) with placebo.<sup>172, 184</sup> Both studies enrolled women with osteoporosis aged 66 to 68 years.

Yaffe et al.'s 3-year study (n=7,478) reported diagnostic outcomes.<sup>184</sup> At year 3, women who scored in the bottom 10 percent of cognitive scores or who had symptoms of cognitive impairment were referred for further evaluation. Evaluation for MCI or CATD involved interview, physical, and neurological examination by a clinician who was blinded to treatment, as well as administration of several cognitive tests. Participants suspected of having CATD based on clinical assessment and a Mini-Mental State Examination (MMSE) score of < 24 underwent magnetic resonance imaging (MRI) scans, which were subsequently assessed by a blinded reader to determine whether scans were clinically relevant. Women assigned to 120 mg of raloxifene daily had a 33 percent lower risk of MCI than those taking placebo, although the 95 percent confidence interval was 0.46 to 0.98. The same effect was not observed in women taking the lower dose (60 mg) of raloxifene. No statistically significant differences were found between treatment and placebo groups in three other diagnostic categories, including "Alzheimer's disease," "any type of dementia," and "dementia or MCI." As expected, women found to have MCI or CATD were likely to be older, less educated, more depressed, and further past menopause than women with normal cognition. Evidence was low that raloxifene lowers the risk of MCI.

Both Nickelsen et al. and Yaffe et al. (n=5,877) compared the effects of raloxifene and placebo on executive/attention/processing speed and memory.<sup>172, 184, 185</sup> A total of six cognitive tests related to executive, attention, and processing speed were conducted between the two studies, and a total of nine memory tests. No significant differences were found between raloxifene and placebo groups after 3 years. Strength of evidence was rated low.

No serious adverse effects related to raloxifene were described. In Nickelsen et al.'s study, the percentage of women withdrawing from the study due to adverse effects was similar across treatment and placebo groups.<sup>172</sup>

## Soy

Five low to medium risk of bias RCTs ranging in size from 34 to 350 participants (total n=829) compared soy supplementation to placebo. Populations included men and women without dementia aged 62 to 89 years<sup>155</sup> and generally healthy postmenopausal women.<sup>159, 161, 167</sup> Mean baseline MMSE scores were not reported in Henderson et al.<sup>159</sup> and Kreijkamp-Kaspers et al.,<sup>166</sup> but ranged from 28 to 29 in the other studies.<sup>155, 161, 167</sup> Three of the studies took place over 6 months (n=281),<sup>155, 161, 167</sup> one lasted 1 year (n=202), and one lasted 2.5 years (n=350).<sup>159</sup>

None of the trials reported diagnostic outcomes. Ho<sup>161</sup> (n=191) and Kreijkamp-Kaspers et al.,<sup>166</sup> (n=202) used the MMSE as a brief cognitive test and found no pre/post differences between soy and placebo groups.<sup>161</sup> Strength of evidence was insufficient. Two studies (n=541) tested multi-domain neuropsychological performance and found no statistically significant differences between groups.<sup>159, 161</sup> Evidence was rated as insufficient.

All five studies measured cognitive performance in the executive function/attention/processing speed and memory categories (n=829). Placebo performed better than soy in two of 21 tests of executive function/attention/processing speed. Over the five studies, the soy group performed better on five of 31 memory tests, with the placebo group performing better on one memory test. Evidence is low-strength that soy has no effect on these cognitive domains.

Subanalyses conducted by Kritz-Silverstein et al. found that younger women taking placebo (those aged 50 to 59) improved in verbal memory scores whereas those aged 60 to 74 worsened in verbal memory over time.<sup>167</sup> Neither Henderson nor Ho found differences in cognitive performance based on age.<sup>159, 161</sup>

Ho et al. and Kreijkamp-Kaspers et al. reported no serious adverse effects and no significant differences in adverse effects experienced between treatment and placebo groups.<sup>161, 166</sup> In Henderson et al.'s study, one person in the soy group experienced a stroke and five people in the placebo group reported cancer.<sup>159</sup> No other serious adverse effects were reported.

## **Red Clover**

A single study (n=30)<sup>162</sup> with medium risk of bias compared isoflavone supplementation with red clover to placebo. Red clover performed better than placebo on one of five tests of executive function/attention/processing speed and placebo performed better on two of seven memory tests. However, the study authors note that none of the results remained significant after correcting for multiple comparisons. Strength of evidence was insufficient due to a single study of less than 500 participants.



**Table 4F.2. Results overview: Hormone therapies versus inactive controls in adults with normal cognition**

Author Year Comparison N= Followup	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
<b>HRT-Estrogen Results Summary k=6; n=4,117</b>	1 of 3 favors C k=1	1 of 7 favors C k=1	<b>BCT</b> 1 of 2 favors C k=2  <b>MNP</b> 0 of 1 (no difference) k=1	2 of 19 favors I k=6	2 of 35 favors I k=6	4 of 64 favors I  2 of 64 favors C	
<b>Henderson, 2016<sup>160</sup></b> Oral estrogen therapy (17-beta estradiol 1 mg) daily n=567 2.5 years (5 year outcomes = High ROB)			<b>MNP</b> NS [Global Cognition Composite]	NS [Executive Function Composite]	NS [Verbal Episodic Memory Composite]	0 of 3 (no difference)	1 death in estradiol group; other serious AEs equal between groups but not included in article
<b>Wroolie, 2015<sup>183</sup></b> Continued estrogen-based hormone therapy n=64 2 years				I>C [Attention/Working Memory/Processing Speed Composite]	I>C [Verbal Memory Composite]	2 of 5 favor I	NR
				NS [Executive Function Composite]	NS [Visual Memory Composite]		
					NS [Subjective Memory Composite]		
<b>Women's Health Initiative (WHI) substudies Coker, 2009 Resnick, 2009a Resnick, 2009b Espeland, 2004</b>	NS [Probable Dementia] n=2,947	NS [MRI: Total Brain Volume] n=520	<b>BCT</b> C>I [3MS] N=2,947	NS [Letter Fluency] n=886	NS [BVRT Errors] n=886	2 of 16 favors C	Increased risk of probable dementia in women taking estrogen.
	NS [MCI] n=2,947	NS [MRI: Ventricle Volume]		NS [DS Forward] n=886	NS [CLVT Total List A Trials] n=886		Increased risk of global cognitive

Author Year Comparison N= Followup	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
<b>Shumaker, 2004</b> <b>Rapp, 2003</b> 149, 151, 175, 177, 178, 180 Estrogen (conjugated equine estrogen 0.625 mg) daily n=2,947 Mean followup varies by outcome up to 8 years		n=520					
	C>I [Probable Dementia or MCI] n=2,947	NS [MRI: Hippocampal Volume] n=520		NS [DS Backward] n=886	NS [CVLT Total List B] n=886		decline in women taking estrogen.
		C>I [MRI: Frontal Lobe Volume] n=520			NS [CVLT Short Delay Free] n=886		
		NS [White & Gray Matter] n=520			NS [CVLT Long Delay Free] n=886		
		NS [Basal Ganglia] n=520					
		NS [Total Brain Lesion Volume] n=520					
<b>Gorenstein, 2011</b> <sup>157</sup> Estrogen (conjugated equine estrogen 0.625 mg) daily n=65 6 months				I>C [DS Forward]	I>C [PAL, Easy]	2 of 10 favor I	No serious AEs reported
				NS [DS Backward]	NS [PAL, Difficult]		
				NS [3-min Reasoning Test, Correct]	NS [Immediate Verbal Recall]		
				NS [3-min Reasoning Test, Time]	NS [Delayed Verbal Recall]		
				NS [DSST]	NS [Free Recall of Words]		
<b>Pefanco 2007</b> <sup>174</sup> Estrogen (micronized 17-beta				NS [COWAT]	NS [Immediate Recall]	0 of 22 (no difference)	NR
				NS	NS		

Author Year Comparison N= Followup	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
estradiol 0.25 mg daily n=57 3 years				[Animal Naming]	[Delayed Recall]		
				NS [TMT A]	NS [Fuld Object Memory Evaluation]		
				NS [TMT B]	NS [Total Recall Trial 5]		
				NS [Wisconsin Test]	NS [Total Recall, 5-Minute Delay]		
				NS [Total Perservative Error]	NS [Total Recognized 5- Delay]		
				NS [Digital Written Score]	NS [Wechsler Logical Memory 1]		
					NS [Verbal Paired Association 1]		
					NS [Visual Representation 1]		
					NS [Logical Memory 2]		
					NS [Verbal Paired Association 2]		
					NS [Visual Representation]		
					NS [Recognition Total Score 1]		
					NS [Recognition Total Score 2]		
					NS [Recognition Total Score 3]		

Author Year Comparison N= Followup	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
<b>Yaffe, 2006</b> <sup>186</sup> Estrogen (transdermal patch delivering 0.014 mg estradiol) daily n=417 2 years			<b>BCT</b> NS [3MS]	NS [TMT B]	NS [Logical Memory, Immediate]	0 of 8 (no difference)	NR
					NS [Logical Memory, Delayed]		
					NS [BVMT, Immediate]		
					NS [BVMTt, Delayed]		
					NS [Word List, Memory]		
					NS [Word List, Recall]		
<b>HRT-Estrogen + Progestin Results Summary k=5, n=6,332</b>	<b>1 of 3 favors C k=1</b>	<b>0 of 7 (no differences) k=1</b>	<b>BCT</b> <b>1 of 4 favors C k=3</b>	<b>1 of 9 favors C k=4</b>	<b>4 of 16 favor C k=5</b>	<b>6 of 36 favors C</b>	
<b>Gleason, 2015</b> <sup>156</sup> Estrogen + (conjugated equine estrogen 0.45 mg) + progestin (cyclical micronized progesterone 200mg) daily n=482 (o-CEE + placebo) Mean 3.2 years			<b>BCT</b> NS [3MS]	NS [Visual Attention & Executive Function Composite]	NS [Verbal Learning & Memory Composite]	0 of 4 (no difference)	4 cases of breast cancer 3 in CEE group, 1 in placebo; 2 cardiac or cerebrovascul ar events – 1 placebo, 1 CEE, 2 cases
					NS [Auditory Attention & Working memory Composite]		of major depression, CEE group
<b>Gleason, 2015</b> <sup>156</sup> Estrogen (transdermal estradiol 200 mg)			<b>BCT</b> NS [3MS]	NS [Visual Attention & Executive Function Composite]	NS [Verbal Learning & Memory Composite]	0 of 4 (no difference)	3 cases of breast cancer (2 estradiol, 1 placebo), 1 stroke, 2

Author Year Comparison N= Followup	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
daily + progestin (cyclical micronized progesterone 200 mg) daily n=431 (t-E2 + placebo) Mean 3.2 years					NS [Auditory Attention & Working Memory Composite]		cases of venous thrombotic disease (1 estradiol, 1 placebo)
<b>Women's Health Initiative (WHI) Coker, 2009 Resnick, 2009a Resnick, 2009b Espeland, 2004 Shumaker, 2004 Rapp, 2003</b> <sup>180,149, 151, 175, 177, 178, 189</sup> Estrogen + progestin daily n=4,532 Mean followup varies by outcome up to 8 years	C>I [Probable Dementia] n=4,532	NS [MRI: Total Brain Volume] n=883	<b>BCT</b> C>I [3MS] n=4,532	NS [Letter Fluency] n=1,416	C>I [BVRT Errors] n=1,416	5 of 16 favor C	In addition to increased risk of probable dementia and
	NS [MCI] n=4,532	NS [MRI: Ventricle Volume] n=883		NS [DS Forward] n=1,416	C>I [CLVT Total List A Trials] n=1,416		memory decline, women taking
	NS [Probable Dementia or MCI] n=4,532	NS [MRI: Hippocampal Volume] n=883		NS [DS Backward] n=1,416	NS [CVLT Total List B] n=1,416		estrogen + progestin experienced more strokes
		NS [MRI: Frontal Lobe Volume] n=883			C>I [CVLT Short Delay Free] n=1,416		than women taking placebo
		NS [White and Gray Matter] n=883			C>I [CVLT Long Delay Free] n=1,416		
		NS [Basal Ganglia] n=883					
		NS [Total Brain Lesion Volume] n=883					

Author Year Comparison N= Followup	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
<b>Davison, 2013</b> <sup>150</sup> Estrogen (oral estradiol + progestin (drospirenone) n=23 (n=13 fMRI) 6 months				NS [CogState Identification]	NS [CogState International Shopping List, Learn]	1 of 8 favors C	3 women withdrew from study due to vaginal bleeding: 2 in
				C>I [CogState, Detection Speed]	NS [CogState International Shopping List, Recall]		estrogen + progestin group and 1 in placebo.
				NS [Mental Rotation with functional MRI]	NS [Gorton Maze Learning Task]		No serious AEs were reported.
					NS [Gorton Maze Learning Task, Recall]		
					NS [CogState Continuous Paired Assoc Learning]		
<b>Tierney, 2009</b> <sup>181</sup> Estrogen (1 mg 17- B estradiol) daily + progestin (0.35 mg norethindrone) 3 times weekly n=142 2 years					NS CVLT, Short Delay Recall]	0 of 1 (no difference)	Several serious AEs were reported, including deep vein thrombosis, episodes of heart failure, and stroke. Statistically significant differences between hormone and placebo group were less serious.
<b>Grady, 2002</b> <sup>158</sup> Conjugated			<b>BCT</b> NS [MMSE]	NS [TMT B]	NS [Word List Recall]	0 of 3 (no difference)	

Author Year Comparison N= Followup	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
estrogen 0.625 mg) plus medroxyprogesteron e acetate (2.5 mg) daily n=1,063 Mean 4.2 years							
<b>DHEA Results Summary k=1, n=225</b>	<b>NR</b>	<b>NR</b>	<b>BCT 0 of 1 (no difference) k=1</b>	<b>0 of 1 (no difference) k=1</b>	<b>0 of 2 (no difference) k=1</b>	<b>0 of 4 (no difference)</b>	
<b>Kritz-Silverstein, 2008</b> <sup>168</sup> Oral DHEA 50 mg daily n=225 1 year			<b>BCT NS [MMSE]</b>	<b>NS [TMT B]</b>	<b>NS [Word List Memory]</b>	<b>0 of 4 (no difference)</b>	<b>23 participants experienced AEs,</b>
					<b>NS [Word List Recall]</b>		<b>but no tests of significance are reported</b>
<b>SERM Results Summary k=2, n=7,621</b>	<b>1 of 8 favors I k=1</b>	<b>NR</b>	<b>NR</b>	<b>0 of 6 (no difference) k=2</b>	<b>0 of 9 (no difference) k=2</b>	<b>0 of 15 (no difference)</b>	<b>NR</b>
<b>Yaffe, 2005</b> <sup>184</sup> <b>Yaffe, 2001</b> <sup>185</sup> Raloxifene 60 mg or 120 mg daily vs. placebo n=7,478 years	<b>NS (60 mg group) [MCI]</b>			<b>NS [Short Blessed] n=5,734</b>	<b>NS [Word List Recall] n=5,596</b>	<b>0 of 5 (no difference)</b>	<b>NR</b>
	<b>I&gt;C (120 mg group) [MCI]</b>						
	<b>NS (60 mg group)</b>			<b>NS [TMT A] n=5,685</b>	<b>NS [Word List Memory] n=3,607</b>		
	<b>NS (120 mg group) [CATD]</b>						

Author Year Comparison N= Followup	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
	NS (60 mg group)  NS (120 mg group) [Any Type of Dementia]			NS [TMT B] n=5,538			
	NS (60 mg group)  NS (120 mg group) [Dementia or MCI]						
<b>Nickelsen, 1999</b> <sup>172</sup> Raloxifene 60 mg or 120 mg daily vs. placebo n=143 1 year				NS [WRPAB 2-Letter Search]	NS [MAC Battery: Name-Face Association, Total Acquisition]	0 of 10 (no difference)	No serious AEs reported and % of women with-
				NS [WRPAB 6-Letter Search]	NS [MAC Battery: Name-Face Association, Delayed Recall]		drawing from the study due to AEs was
				NS [WRPAB 4-Choice Serial RT]	NS [MAC Battery: First-Last Name Association, Delayed Recall]		similar across groups
					NS [MAC Battery: First-Last Name Association, Total Acquisition]		
					NS [MAC Battery: Facial Recognition, Number Before 1st Error]		
					NS		



Author Year Comparison N= Followup	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
					[MAC Battery: Telephone Number Recall, Before Interference]		
					NS [MAC Battery: Telephone Number Recall, After Interference]		
<b>Soy Results Summary k=5; n=829</b>	<b>NR</b>	<b>NR</b>	<b>BCT 0 of 2 (no difference) k=2</b>  <b>MNP 0 of 3 (no difference) k=2</b>	<b>2 of 21 favor C k=5</b>	<b>5 of 31 favor I 1 of 31 favors C k=5</b>	<b>5 of 57 favor I</b>  <b>3 of 57 favor C</b>	
<b>Henderson, 2012<sup>159</sup></b> Soy isoflavone rich soy protein 25 g daily vs. matched placebo n=350 2.5 years			<b>MNP NS</b> [Composite, components not described]	NS [SDMT]	NS [Verbal Episodic Memory, List Learning Factor: CVLT Immediate & Delayed Recall]	1 of 15 favors I	1 person (soy group) had a stroke and 5 people (placebo) reported cancer.
			<b>MNP NS</b> [Executive/Expre ssive/Visuospatia l Factor Composite: SDMT, TMT B, Shipley Abstraction, Letter-Number Sequencing, Block Design, Judgment of Line Orientation, BNT]	NS [TMT B]	NS [CVLT, Immediate Recall]		No other serious adverse effects were reported.
				NS	NS		

Author Year Comparison N= Followup	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
				[Shipley Abstraction]	[CVLT, Delayed Recall]		
				NS [Letter-Number Sequencing]	NS [Verbal Episodic Memory, Logical Memory Factor: EBMT, Immediate & Delayed Recall]		
					NS [EBMT, Immediate Recall]		
					NS [EBMT, Delayed Recall]		
					I>C [Visual Episodic Memory Factor: Faces I, Faces II]		
					NS [Faces I]		
					NS [Faces II]		
<b>Gleason, 2009</b> <sup>155</sup> Soy isoflavonea 100 mg daily vs. placebo n=30 6 months				C>I [SCWT]	NS [Buschke Selective Reminding Test, Total of Learning Trials – Words]	4 of 14 favor I	NR
				C>I [TMT B]	NS [Buschke Selective Reminding Test, Learning Slope, Trial 5 vs. Trial 1]	3 of 14 favor C	
				NS [Mazes]	NS [Delayed Recall, Words]		
				NS [Language Fluency, Letter]	NS [Paragraph Recall Test, Total Immediate Recall]		
					NS [Paragraph Recall Test,		

Author Year Comparison N= Followup	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
					Total Delayed Recall]		
					I>C [RCFT, Immediate Recall]		
					I>C [RCFT, Delayed Recall]		
					C>I [Visual Spatial Learning Test, Total Correct Position + Designs]		
					I>C [Visual Spatial Learning Test, Learning Slope Position + Design, Trial 5 vs. Trial 1]		
					I>C [Visual Spatial Learning Test, Learning Slope Incorrect Designs]		
<b>Ho, 2007</b> <sup>161</sup> Soy-derived isoflavones 80 mg vs. placebo n=191 6 months			<b>BCT</b> NS [MMSE]	NS [Color Trail I]	NS [HKLLT, Trials 1-5]	0 of 11 (no difference)	No significant differences in AEs experienced
			<b>MNP</b> NS [Cognitive Score=z scores of all cognitive tests]	NS [Color Trail II]	NS [HKLLT, Short Delay Recall]		or their severity were found between groups.
				NS [DSST – WAIS]	NS [HKLLT, Long Delay Recall]		No serious AEs were reported.
					NS [VR I]		
					NS [VR II]		

Author Year Comparison N= Followup	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
					NS [VR, Copy]		
<b>Kreijkamp-Kaspers, 2004</b> <sup>167</sup> {Kreijkamp-Kaspers, 2004) Soy-derived isoflavones 99 mg vs. placebo n=202 1 year			<b>BCT</b> NS [MMSE]	NS [DS Forward]	NS [RAVLT, Immediate Recall]	0 of 13 (no difference)	No serious AEs reported and no significant
				NS [DS Backward]	NS [RAVLT, Delayed Recall]		differences between groups were found.
				NS [TMT A1]	NS [RAVLT, Recognition]		
				NS [TMT A2]	NS [Doors Test]		
				NS [TMT B]			
				NS [DSST]			
				NS [Verbal Fluency, N]			
				NS [Verbal Fluency, A]			
<b>Kritz-Silverstein, 2003</b> <sup>167</sup> Soy-extracted isoflavones 110 mg daily vs. placebo n=56 6 months				NS [TMT A]	NS [Logical Memory I, Immediate]	0 of 4 (no difference)	NR
				NS [TMT B]	NS [Logical Memory II, Delayed]		
<b>Red Clover Results Summary</b> k=1; n=30	NR	NR	NR	1 of 5 favors I k=1	2 of 7 favor C k=1	1 of 12 favors I  2 of 12 favor C	
<b>Howes, 2004</b> <sup>162</sup> Isoflavones from red clover				NS [Arithmetic Test]	C>I [Digit Recall Test]	1 of 12 favors I 2 of 12 favor C	1 person receiving placebo died. No other

Author Year Comparison N= Followup	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
n=30 6 months							serious
				NS [TMT A]	NS [Memory 1 Test]		AEs were reported.
				NS [TMT B]	NS [Memory 2 Test]		
				I>C [Block Design Test]	NS [Verbal Memory 1 Test]		
				NS [DSST]	C>I [Verbal Memory 2 Test]		
					NS [Visual Memory 1 Test]		
					NS [Visual Memory 2 Test]		

3MS=Modified Mini-Mental State Examination; AE=adverse effect; BCT=brief cognitive test performance; BNT=Boston Naming Test; BVMT=Brief Visuospatial Memory Test; BVRT=Benton Visual Retention Test; C=control; CATD=clinical Alzheimer's-type dementia; COWAT=Controlled Oral Word Association Test; CVLT=California Verbal Learning Test; DHEA=dehydroepiandrosterone; DS=Digit Span (Forward and/or Backward); DSST=Digit Symbol Substitution Test; EBMT=East Boston Memory Test; fMRI=functional magnetic resonance imaging; HKLLT=Hong Kong List Learning Test; HRT=hormone replacement therapy; I=intervention; k=number of studies included; mg=milligrams; MMSE=Mini-Mental State Examination; MNP=multidomain neuropsychological test performance; MRI=magnetic resonance imaging; n=sample size; NS=no statistically significant difference; NR=not reported; PAL=Paired Associated Learning Test; RAVLT=Rey Auditory Verbal Learning Test; RCFT=Rey-Osterrieth Complex Figure Test; SCWT=Stroop Color Word Test; SERM=selective estrogen receptor modulator; TMT=Trail Making Test (Part A and/or B)

Shading indicates summary rows and columns.

## **Comparative Effectiveness: Hormone Therapies Versus Active Comparison**

Two studies (three publications) with low to medium risk of bias compared hormone therapies with active interventions.<sup>170, 171, 173</sup> Results are summarized in Table 4F.3. Both studies enrolled younger postmenopausal women (mean ages: 43 and 52 years) and assessed changes in cognition after a 6-month treatment period. Neither study reported diagnostic outcomes. Limited data prevented assessment of strength of evidence for other cognitive outcomes.

**Table 4F.3. Results overview: Hormone therapy versus active controls in adults with normal cognition**

Author Year Comparison N= Followup	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]	
<b>HRT-Estrogen plus Progestin vs. Tibolone Results Summary k=1; n=50</b>	NR	NR	BCT 0 of 2 (no difference) k=1	NR	NR	0 of 2 (no difference)		
<b>Pan, 2003</b> <sup>173</sup> Estrogen + progestin (CEE 0.625 mg/day + methylprogesterone acetate 5 mg/day) vs. tibolone 2.5 mg/day n=50 6 months			BCT NS [MMSE]			0 of 2 (no difference)	AEs reported but differences	
			BCT NS [CASI]				Not reported in terms of statistical significance.	
<b>HRT-Estrogen plus Testosterone vs. Estrogen Results Summary k=1; n=50</b>	NR	NR	NR	0 of 4 (no difference) k=1	0 of 2 favor I1 (estrogen + testosterone k=1)  1 of 2 favors I-2 (estrogen only) k=1	0 of 6 favor I <sub>1</sub> (estrogen + testosterone)  1 of 6 favors I <sub>2</sub> (estrogen + placebo)		
<b>Moller, 2013</b> <sup>171</sup> <b>Moller, 2010</b> <sup>170</sup> Estrogen + testosterone (I <sub>1</sub> ) versus estrogen + placebo (I <sub>2</sub> ) (estradiol valerate 2 mg/day + testosterone undecanoate 40 mg/day versus estradiol valerate 2 mg/day + placebo) n=50				NS [DSST – WAIS, used to assess cognitive fatigue]* <sup>1</sup>	I <sub>1</sub> < I <sub>2</sub> [Logical Story, Immediate Recall] <sup>2</sup>	0 of 6 favors I <sub>1</sub>	NR (other than 1 withdrawal due to migraine.	
				NS [DSST, Free Recall of Symbols] <sup>1</sup>	NS [Logical Story, Delayed Recall] <sup>2</sup>	1 of 6 favors I <sub>2</sub>		
				NS [DSST, Paired Recall of Symbols] <sup>1</sup>				
				NS [DSST, % Spatial Errors] <sup>2</sup>				

<b>Author Year Comparison N= Followup</b>	<b>Diagnosis</b>	<b>Biomarkers [specific biomarker]</b>	<b>Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]</b>	<b>Executive/Attention/ Processing Speed [instrument]</b>	<b>Memory [instrument]</b>	<b>Intermediate Outcomes Summary</b>	<b>Adverse Effects [specific adverse effect]</b>
6 months (crossover design; total trial period = 12 months)							

\*The difference between the # of digits produced during the first 30 seconds and last 30 seconds of a 90 second session]

AE=adverse effect; BCT=brief cognitive test performance; C=control; CASI=Cognitive Abilities Screening Instrument; DSST=Digit Symbol Substitution Test; HRT=hormone replacement therapy; I=intervention; I<sub>1</sub>=first intervention; I<sub>2</sub>=second intervention; k=number of studies included; mg=milligrams; MMSE=Mini-Mental State Examination; n=sample size; NS=no statistically significant difference; NR=not reported

Shading indicates summary rows and columns.



## Adults With MCI

### **Efficacy: Hormone Therapies Versus Inactive Control**

We identified two RCTs that compared hormone therapies with inactive controls in older adults with MCI.<sup>148, 164</sup> Results are summarized in Table 4F.4. Cherrier et al. compared the effects of testosterone gel (50-100 mg/day) versus placebo on cognitive performance in men diagnosed with MCI (according to Petersen's criteria) and low serum testosterone levels.<sup>148</sup> The study was small (22 men) and conducted over a 6-month period. Of 14 cognitive tests involving memory and executive/attention/processing speed, only one showed a statically significant difference (in a test of verbal memory) between testosterone and placebo groups. Three serious adverse events were reported: one participant visited the emergency department (ED) for chest pains, upper arm pain, and dizziness; a second participant visited the ED for confusion and disorientation; a third participant had a rise in PSA levels and discontinued study medication per study protocol. Evidence was insufficient due to limited data (single study with n<500).

In another study, Kato-Kataoka et al. examined the use of soybean derived phosphatidylserine (soy-PS) at two doses, 100 mg and 300 mg daily, in 78 men and women with MCI and a mean age of 60 (SD: 1 year).<sup>164</sup> Treatment took place over a 6-month period, with an additional 3 months of followup. Two brief tests of cognitive performance (the MMSE and Hasegawa Dementia Scale) and a memory test were used to assess cognition. Although cognitive scores increased from baseline in all three treatment groups (soy-PS at two doses and placebo), no significant differences were observed between soy and placebo groups at any time point. No adverse effects were reported. Evidence was insufficient due to limited data (single study with n<500).

**Table 4F.4. Results overview: Hormone therapy versus inactive controls in adults with MCI**

Author Year Comparison N= Followup	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
<b>HRT-Testosterone Results Summary k=1; n=22</b>	NR	NR	NR	<b>0 of 7 (no difference) k=1</b>	<b>1 of 7 favors I k=1</b>	<b>1 of 14 favors I</b>	
<b>Cherrier, 2015<sup>148</sup></b> Testosterone gel 50-100 mg/d with a target total T level of 500 to 900 ng/dL n=22 6 months				NS [Letter-Number Sequencing, Total Score]	NS [RAVLT, Immediate, Total Score, 4 Trials]	1 of 14 favors I	3 serious AEs reported (2 in treatment and 1 in placebo
				NS [Letter-Number Sequencing, Span]	NS [RAVLT, Short Delay]		group), although no significance tests reported
				NS [Computerized Simple RT, 2-Second Interval]	I>C [RAVLT, Long Delay]		
				NS [Computerized Simple RT, 5-Second Interval]	NS [Story Recall, Immediate]		
				NS [Computerized Choice RT, 2-Second Interval]	NS [Story Recall, Delay]		
				NS [Computerized Choice R, 5-Second Interval]	NS [Visual Spatial Learning Test, Immediate]		
				NS [Mental Rotation]	NS [Visual Spatial Learning Test, Delay]		
<b>Soy Results Summary k=1; n=78</b>	NR	NR	<b>BCT 1 of 2 favors C (100 mg group) k=1  0 of 2 (no difference) (300</b>	NR	<b>0 of 1 (no difference) (100 &amp; 300 mg groups) k=1</b>	<b>1 of 6 favors I (3 tests, 2 doses)</b>	NR

Author Year Comparison N= Followup	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
			mg group) k=1				
Kato-Kataoka, 2010 <sup>164</sup> Soybean derived phosphatidylserine (Soy-PS) 100 mg or 300 mg vs. placebo n=78 9 months			BCT I>C (100 mg group) [MMSE]  BCT NS (300 mg group) [MMSE]		NS (100 mg group) [RBMT]  NS (300 mg group) [RBMT]	1 of 6 favors I	NR
			BCT NS (100 mg group) [Hawegawa Dementia Scale]  BCT NS (300 mg group) [Hawegawa Dementia Scale]				

AE=adverse effect; BCT=brief cognitive test performance; C=control; HRT=hormone replacement therapy; I=intervention; k=number of studies included; mg=milligrams; mg/d=milligrams per day; MMSE=Mini-Mental Status Examination; n=sample size; ng/dL=nanograms per deciliter; NR=not reported; NS=no statistically significant difference; RAVLT=Rey Auditory Verbal Learning Test; RBMT= Rivermead Behavioral Memory Test; RT=reaction time;

Shading indicates summary rows and columns.

## Interpreting the Findings

Overall, evidence demonstrating the effect of hormone therapies on cognitive outcomes was deemed to be low or insufficient. While there was more evidence supporting the conclusion that the harms associated with hormone replacement therapies (estrogen and combined estrogen/progestin therapy in particular) may outweigh their benefits, less is known about the effects of other hormone therapies, such as SERM and plant-based estrogens, on cognition. In most cases, differences in cognitive performance between hormone therapy and control groups tended to be relatively small and lacking in clinical significance.

Some of the most compelling evidence *against* the use of hormone replacement therapy to prevent cognitive decline or dementia arose from the longitudinal WHI, a study well known for the early termination of its estrogen/progestin arm due to associated adverse events—cancer and cardiovascular disease in particular.<sup>190</sup> Particularly when data for women taking either hormone replacement therapy (estrogen-only or estrogen/progestin) were combined,<sup>180</sup> the detrimental effects of hormone therapy on cognition (both in terms of dementia-related diagnoses and cognitive performance) became more pronounced. Importantly, the trial found a 76 percent increased hazard for dementia associated with hormone therapy.<sup>180</sup>

Many studies of the effects of hormone therapies on cognition were relatively short, making it difficult to draw conclusions about the long-term effects of hormone therapies on cognition. Further, the considerable variation in cognitive measures across studies further complicates our ability to draw clear conclusions. Of 31 RCTs included in the review, only two included diagnostic outcomes. Both of the studies were ancillary/substudies of larger longitudinal clinical trials and cognitive outcomes were not the studies' primary outcomes. One of these studies, the WHI, found that hormone replacement therapy (estrogen-only or combined estrogen/progestin therapy) may *increase* the risk of probable dementia and/or MCI. The other study found that the selective estrogen receptor modulator raloxifene may *lower* the risk of MCI when compared to placebo. Both of these studies included older, postmenopausal women and less is known about the effects of hormone therapies on cognition in younger women, or on women who begin using hormone therapies at younger ages. Similarly, little is known about the effects of hormone therapies on cognition in men.

Finally, although a number of studies examined the effects of phytoestrogens (soy in particular) on cognition, none of these studies looked at diagnostic outcomes. Low-strength evidence suggests that soy offers no benefit to cognition related to executive/attention/processing speed or memory, yet evidence was deemed insufficient for other cognitive outcomes.

# Chapter 4G. Results: Vitamin Interventions

## Key Messages

- Moderate-strength evidence shows no benefit in cognitive performance for vitamin E in women.
- There was some signal that B<sub>12</sub> plus folic acid may benefit brief cognitive test performance and memory but not executive function/attention/ processing speed.
- Low-strength evidence for folic acid (0.4 mg) plus vitamin B<sub>12</sub> (0.1-0.5 mg) shows benefit in brief cognitive test performance and memory.
- Moderate-strength evidence shows no benefit for folic acid (0.4 mg) and B<sub>12</sub> (0.1-0.5 mg) versus placebo for executive/attention/processing speed.
- Low-strength evidence for vitamin B<sub>12</sub> (0.02-0.5 mg), B<sub>6</sub> (3-10 mg), and folate (0.56-1 mg) shows no benefit for executive/attention/processing speed.
- Low-strength evidence shows no benefit in cognitive performance for multivitamins, vitamin B with omega-3, vitamin C (in women), vitamin D with calcium (in women), or beta carotene (in women).
- Low-strength evidence shows no benefit in incident MCI or clinical Alzheimer's-type dementia (CATD)\* for multivitamins or vitamin D with calcium.
- In adults with mild cognitive impairment (MCI), low-strength evidence shows no benefit for vitamin E in incident CATD.

\*Note that the literature currently does not use the term CATD; we specified whenever the diagnosis of dementia was defined.

## Eligible Studies

We identified 29 eligible publications reporting 24 unique studies of vitamin interventions to prevent age-related cognitive decline, MCI, or CATD.<sup>98, 101, 102, 191-217</sup> Ten were assessed as high risk of bias and not used in our analysis. Of the remaining 19 publications of 16 unique studies, we analyzed the efficacy and comparative effectiveness of vitamin interventions separately for adults with normal cognition and those with MCI. Appendix L provides evidence tables, summary risk of bias assessments, and assessments of strength of evidence for key comparisons and outcomes.

## Logic of Vitamin Interventions

The logic underlying vitamin use varies with the vitamin. In the case of B vitamins the targeted pathway may involve lowering of homocysteine levels.

## Adults With Normal Cognition

### Efficacy: Vitamins Versus Inactive Control (Placebo)

Twelve randomized controlled trials (RCTs) with low or moderate risk of bias compared vitamins to inactive control (placebo) in adults with normal cognition.<sup>101, 196-199, 201, 202, 205, 208-210, 212</sup> Total sample sizes ranged from 220 to 20,536. Conclusions are summarized in Table 4G.1 and individual study results are shown in Table 4G.2.

**Table 4G.1. Conclusions: Vitamins versus placebo in adults with normal cognition**

Comparison	Outcome	Conclusion	Strength of Evidence (justification)
Multivitamin vs. placebo k=4	Dementia	No statistically significant difference in dementia diagnosis with multivitamins versus placebo long-term (n=20,469; 5 years).	Low (medium study limitations, imprecise, unknown consistency)
	MCI	No statistically significant difference in MCI diagnosis with multivitamins versus placebo long-term (n=20,469; 5 years).	Low (medium study limitations, imprecise, unknown consistency)
	Brief cognitive test performance	Unable to draw conclusion.	Insufficient (medium study limitations, indirect, imprecise, unknown consistency)
	Multidomain neuropsychological performance	No benefit in multidomain neuropsychological performance with multivitamins versus placebo (n=5,296; followup time unclear).	Low (medium study limitations, indirect, precise, unknown consistency)
	Executive/Attention/Processing speed	No benefit in executive/attention/processing speed with multivitamins versus placebo (n=992; up to 1 year).	Low (low-medium study limitations, indirect, precision unclear)
	Memory	No benefit in memory with multivitamins versus placebo (n=5,516; followup time unclear).	Low (low-medium study limitations, indirect, imprecise)
Folic acid vs. placebo k=1	Dementia	No data available.	Insufficient (no data)
	MCI	No data available.	Insufficient (no data)
	Brief cognitive test performance	No data available.	Insufficient (no data)
	Multidomain neuropsychological performance	Unable to draw conclusion.	Insufficient (low study limitations, indirect, precise, unknown consistency)
	Executive/Attention/Processing speed	Unable to draw conclusion.	Insufficient (low study limitations, indirect, imprecise, inconsistent)
	Memory	Unable to draw conclusion.	Insufficient (low study limitations, indirect, unknown consistency)
Folic acid + B <sub>12</sub> vs. placebo k=2	Dementia	No data available.	Insufficient (no data)
	MCI	No data available.	Insufficient (no data)
	Brief cognitive test performance	Unable to draw conclusion.	Insufficient (low study limitations, indirect, inconsistent)
	Multidomain neuropsychological performance	No data available.	Insufficient (no data)
	Executive/Attention/Processing speed	No benefit for executive/attention/processing speed test performance with folic acid (0.4 mg) and B <sub>12</sub> (0.1-0.5 mg) compared to placebo (n=3,456; up to 2 years).	Medium (low study limitations, indirect, precision unclear)
	Memory	Folic acid (0.4 mg) and B <sub>12</sub> (0.1-0.5 mg) improved memory versus placebo (n=3,456; up to 2 years).	Low (low study limitations, indirect, imprecise)
Folate + B <sub>6</sub> +	Dementia	No data available.	Insufficient (no data)

Comparison	Outcome	Conclusion	Strength of Evidence (justification)
B <sub>12</sub> vs. placebo k=2	MCI	No data available.	Insufficient (no data)
	Brief cognitive test performance	No benefit for brief cognitive test performance with folate (0.56-1.0mg), B <sub>6</sub> (3-10mg) and B <sub>12</sub> (0.2-0.5mg) compared to placebo (n=1,124; up to 4 years).	Low (low study limitations, indirect)
	Multidomain neuropsychological performance	No data available.	Insufficient (no data)
	Executive/Attention/Processing speed	Unable to draw conclusion.	Insufficient (low study limitations, indirect, imprecise, inconsistent)
	Memory	No benefit for memory with folate (0.56-1.0mg), B <sub>6</sub> (3-10mg) and B <sub>12</sub> (0.2-0.5mg) compared to placebo (n=1,124; up to 4 years).	Low (low study limitations, indirect, imprecise)
Vitamin E vs. placebo k=2	Dementia	No data available.	Insufficient (no data)
	MCI	No data available.	Insufficient (no data)
	Brief cognitive test performance	No benefit for women in brief cognitive test performance with vitamin E (400-600mg) versus placebo long term (n=7,497; 4 years).	Moderate (low-medium study limitations, indirect)
	Multidomain neuropsychological performance	No benefit for women in multidomain neuropsychological performance with vitamin E versus placebo long term (n=7,497; 4 years).	Moderate (low-medium study limitations, indirect)
	Executive/Attention/Processing speed	No data available.	Insufficient (no data)
	Memory	No benefit for women in memory with vitamin E versus placebo long term (n=7,497; 4 years).	Moderate (low-medium study limitations, indirect t)
Vitamin C vs. placebo k=1	Dementia	No data available.	Insufficient (no data)
	MCI	No data available.	Insufficient (no data)
	Brief cognitive test performance	No benefit for women in brief cognitive test performance with vitamin C versus placebo in long term (n=2,271; 4 years).	Low (low-medium study limitations, indirect, imprecise, unknown consistency)
	Multidomain neuropsychological performance	No benefit for women in multidomain neuropsychological performance with vitamin C versus placebo long term (n=2,271; 4 years).	Low (low-medium study limitations, indirect, imprecise, unknown consistency)
	Executive/Attention/Processing speed	No data available.	Insufficient (no data)
	Memory	No benefit for women in memory with vitamin C versus placebo long term (n=2,471; 4 years).	Low (low-medium study limitations, indirect, imprecise, unknown consistency)
Vitamin D + calcium vs. placebo k=1	Dementia	No statistically significant difference in pooled dementia and MCI diagnosis with vitamin D and calcium versus placebo long term (n=4,122; 7 years).	Low (low-medium study limitations, unknown consistency)
	MCI	See above.	
	Brief cognitive test performance	Unable to draw conclusion.	Insufficient (low-medium study limitations, indirect, imprecise, unknown)

Comparison	Outcome	Conclusion	Strength of Evidence (justification)
			consistency)
	Multidomain neuropsychological performance	No data available.	Insufficient (no data)
	Executive/Attention/Processing speed	No benefit for women in executive/attention/processing speed with vitamin D and calcium versus placebo long term (n=4,122; 7 years).	Low (low-medium study limitations, indirect, unknown consistency)
	Memory	No benefit for women in memory with vitamin D and calcium versus placebo long-term (n=4,122; 7 years).	Low (low-medium study limitations, indirect, imprecise)
Beta carotene vs. placebo k=1	Dementia	No data available.	Insufficient (no data)
	MCI	No data available.	Insufficient (no data)
	Brief cognitive test performance	No benefit for women in brief cognitive test performance with beta carotene versus placebo long term (n=2,271; 4 years).	Low (low-medium study limitations, indirect, imprecise, unknown consistency)
	Multidomain neuropsychological performance	No benefit for women in multidomain neuropsychological performance with beta carotene versus placebo long term (n=2,271; 4 years).	Low (low-medium study limitations, indirect, , unknown consistency)
	Executive/Attention/Processing speed	No data available.	Insufficient (no data)
	Memory	No benefit for women in memory with beta carotene versus placebo long term (n=2,271; 4 years).	Low (low-medium study limitations, indirect, unknown consistency)

B<sub>6</sub>=vitamin B<sub>6</sub>; B<sub>12</sub>=vitamin B<sub>12</sub>; k=number of studies included; MCI=mild cognitive impairment; mg=milligrams; n=sample size; vs.=versus

## Multivitamins

Four RCTs (n=27,613) with low or moderate risk of bias compared multivitamins with placebo. Multivitamin interventions included varying doses and combinations of vitamin A, B vitamins, vitamin C, vitamin D, vitamin E, beta carotene, biotin, cobalamin, copper, folic acid, iodine, iron, magnesium, manganese, niacin, panthothenic acid, pyridoxine, riboflavin, selenium, thiamine, and zinc.<sup>196, 197, 202, 210</sup> Participants varied; studies included physicians over 65,<sup>196</sup> women over 60,<sup>210</sup> adults at serious risk of death from heart disease aged 40 to 80,<sup>197</sup> and adults over 65.<sup>202</sup> Study samples were large, ranging from 1,130 to 20,536, and duration ranged from 6 months to 8.5 years.

Low-strength evidence from one trial (n=20,536) shows no difference for diagnosis of either MCI or CATD over a 5-year period.<sup>197</sup>

In general, low-strength evidence showed no statistical differences on cognitive performance tests, including multidomain neuropsychological performance,<sup>196</sup> executive/attention/processing speed,<sup>202, 210</sup> or memory.<sup>196, 210</sup> Evidence was insufficient for brief cognitive test performance.

None of the trials comparing multivitamins to placebo reported serious adverse effects.

Overall, no differences were found in subgroup analyses. Three trials assessed the effects of lifestyle factors on the effect of multivitamins.<sup>196, 202, 210</sup> Cognitive results did not differ by the lifestyle factors of history of smoking, alcohol use, fruit and vegetable intake or nutritional deficiency.



Two trials assessed the effect of baseline cognition and education, prior supplement use, and comorbidities.<sup>196, 210</sup> Final cognitive or diagnostic results did not differ by cognitive performance at baseline, school graduation and job training. Final cognitive results also did not differ by status of BMI, diabetes, hypertension, hyperlipidemia or depression, or prior use of folates, hormone replacement therapy, or vitamin status.

### **B Vitamins: Folic Acid**

One study (n=818) compared folic acid to placebo.<sup>212</sup> Participants took folic acid (0.8mg) or matching placebo for 3 years. People aged 50-70 with high homocysteine levels likely caused by suboptimal folate concentrations were recruited.

Durga et al. did not report diagnostic outcomes, brief cognitive test performance, or adverse effects. Evidence was insufficient to determine improvement with folic acid for multidomain neuropsychological performance, executive/attention/processing speed, or memory.

### **B Vitamins: Folic Acid and B<sub>12</sub>**

Two studies (n=3,819) compared folic acid and B<sub>12</sub> to placebo.<sup>208, 209</sup> Participants took folic acid (0.4mg) and B<sub>12</sub> (0.1-0.5mg) or a matching placebo for 2 years. One study specifically addressed persons with elevated homocysteine levels of at least 12 micromoles/liter (presumed vitamin deficiency status).<sup>208</sup> Studies recruited adults aged 65+<sup>208</sup> and sedentary adults aged 60-74 with elevated psychological distress.<sup>209</sup>

Neither trial reported diagnostic outcomes, multidomain neuropsychological performance, or adverse effects. Both trials reported brief cognitive test performance (n=3,819). Evidence was insufficient to conclude possible effects.

Both studies reported 11 tests assessing the effect of folic acid/B<sub>12</sub> on executive/attention/processing speed.<sup>208, 209</sup> None showed statistically significant improvement with folic acid/B<sub>12</sub> over placebo (medium-strength of evidence).

Both studies reported seven tests assessing the effect of folic acid/B<sub>12</sub> on memory.<sup>208, 209</sup> Only two of seven tests showed statistically significant improvement with folic acid/B<sub>12</sub>, and the effect sizes were small. Walker et al. reported a Telephone Interview for Cognitive Status (TICS) time by intervention effect size of 0.15 for immediate recall and 0.18 for delayed recall, again (low-strength evidence).<sup>209</sup>

Regarding subgroup analyses, benefit on memory for folic acid/B<sub>12</sub> compared to placebo was reported for participants with low holotranscobalamin levels.<sup>208</sup>

### **B Vitamins: Folate, B<sub>6</sub>, and B<sub>12</sub>**

Two studies (n=1,524) compared folate, B<sub>6</sub> and B<sub>12</sub> to placebo.<sup>101, 201</sup> Participants took folate (0.56-1.0 mg), B<sub>6</sub> (3-10 mg) and B<sub>12</sub> (0.2-0.5 mg) or matching placebo for 2 to 4 years. One trial also randomized participants to folate/B<sub>6</sub>/B<sub>12</sub> with omega-3 versus placebo and folate/B<sub>6</sub>/B<sub>12</sub> versus omega-3; these results are discussed below in comparative efficacy.<sup>101</sup> Studies recruited adults aged 45-70 with heart disease,<sup>101</sup> and adults aged 65+ with healthy cognition and homocysteine levels at least 13 micromoles/liter.<sup>201</sup>

Neither trial reported diagnostic outcomes, multidomain neuropsychological performance, or adverse effects. The studies reported two tests assessing the effect of folate/B<sub>6</sub>/B<sub>12</sub> on brief cognitive test performance; neither were statistically significant with intervention (low-strength evidence).

One study reported two tests assessing the effect of folate/B<sub>6</sub>/B<sub>12</sub> on executive/attention/processing speed, but evidence was insufficient to conclude possible effects.<sup>201</sup>

Both studies reported four tests assessing the effect of folate/B<sub>6</sub>/B<sub>12</sub> on memory.<sup>101, 201</sup> None showed statistically significant improvement with folate/B<sub>6</sub>/B<sub>12</sub> (low-strength evidence).

Subgroup analysis findings were mixed, finding no differences, or possible differences favoring either the placebo or folate/B<sub>6</sub>/B<sub>12</sub>. In particular, Andreeva et al. reported participants with a history of myocardial infarction/unstable angina receiving folate/B<sub>6</sub>/B<sub>12</sub> had lower semantic memory scores (TICS-m subscore) compared to participants of the same age taking placebo (odds ratio: 1.70; 90% CI 1.16 to 2.51). Also, participants aged 65+ and receiving folate/B<sub>6</sub>/B<sub>12</sub> had lower brief cognitive test performance scores (TICS-m) and recall memory scores (TICS-m subscore) compared to participants of the same age taking placebo (p<0.05).<sup>101</sup>

## Vitamin E

Two trials (n=9,201) compared vitamin E with a placebo.<sup>198, 199</sup> Both studies randomized women aged 65+ to vitamin E or placebo every other day. However, one randomized women to 600 IU (equivalent of about 400 mg) vitamin E for 10 years,<sup>198</sup> while the other randomized women with cardiovascular disease or three or more coronary risk factors to 402 mg vitamin E for 9 years.<sup>199</sup> Due to high attrition at longer-term followup time points, results were extracted for both studies at 4-year followup. Kang et al. also included an additional two arms, vitamin C and beta carotene, reported separately below.

Neither trial reported diagnostic outcomes or executive/attention/processing speed. Both trials provide moderate-strength evidence showing no differences between vitamin E compared with placebo at 4-year followup were found in brief cognitive test performance (two tests), multidomain neuropsychological performances (two tests), or memory (two tests).

Kang et al. did not observe adverse effects in either vitamin E or placebo group.<sup>199</sup>

Two trials assessed the effect of several participant characteristics on the effect of vitamin E.<sup>198, 199</sup> Cognitive results did not differ by age, baseline cognition (baseline performance, highest attained education or perceived memory change), supplement use (antioxidants, multivitamins or hormone replacement therapy), comorbidities (body mass index (BMI), cardiovascular disease, diabetes, hypertension, hyperlipidemia or depression), or lifestyle factors (smoking, alcohol use, or exercise).

## Vitamin C

Kang et al. (n=2,824) compared vitamin C with placebo.<sup>199</sup> The trial randomized women aged 65+ with or at risk for cardiovascular disease to 500 mg of vitamin C or placebo daily for 9 years. The longest followup with low or moderate risk of bias was approximately 4 years after baseline cognitive assessments.

The trial did not report diagnostic outcomes or executive/attention/processing speed and provided low-strength evidence showing no statistically significant improvements with vitamin C for brief cognitive test performance or multidomain neuropsychological performances.<sup>199</sup> One test assessing memory reported statistically significant improvement with vitamin C (author-created composite z-score between groups change from baseline: 0.07; 95% CI 0.0 to 0.13, p=0.05).<sup>199</sup> However, the study did not correct for multiple comparisons, and given the small effect size these results were not likely to be clinically meaningful. No serious adverse effects were observed in either vitamin C or placebo arm.

Kang et al. assessed the effect of several participant characteristics on the effect of vitamin C.<sup>199</sup> Only cognitive results differed by incident cardiovascular disease ( $p < 0.01$ ). Cognitive results did not differ by age, baseline cognition (baseline performance or highest attained education), supplement use (antioxidants or multivitamins), comorbidities (prior cardiovascular disease or associated risk factors), or lifestyle factors (smoking or alcohol use).

## **Vitamin D Plus Calcium**

One trial ( $n=4,143$ ) compared vitamin D with calcium to placebo.<sup>205</sup> Participants in the Women's Health Initiative Memory Study were previously randomized to 400 IU vitamin D<sub>3</sub> with 1000 mg calcium or a matching placebo for a mean of 7.8 years. People in the intervention group were also allowed to take an additional supplement containing 1000 mg calcium with 600 mg vitamin D. Followup assessment took place at approximately 7.8 years.

Rossom et al. did not report multidomain neuropsychological performances or adverse effects.<sup>205</sup> Low-strength evidence shows diagnosis of probable dementia or MCI, reported as one pooled outcome, did not differ statistically between vitamin and placebo groups. Evidence was insufficient to conclude differences between vitamin D and calcium versus placebo for brief cognitive test or multidomain neuropsychological performance. One test assessed executive/attention/processing speed and two tests assessed memory; all showed no statistically significant difference with vitamin D and calcium.

## **Beta Carotene**

Kang et al. ( $n=2,824$ ) compared beta carotene with placebo.<sup>199</sup> Women aged 65+ with or at risk for cardiovascular disease were randomized to 50 mg beta carotene or placebo every other day for 9 years. The longest followup with low or moderate risk of bias was approximately 4 years after baseline cognitive assessments.

Kang et al. did not report diagnostic outcomes or executive/attention/processing speed.<sup>199</sup> Low-strength evidence shows no statistically significant improvements with beta carotene for brief cognitive test performance (one test), multidomain neuropsychological performances (one test), or memory (one test). No serious adverse effects were observed in either beta carotene or placebo arm.

One trial assessed the effect of several participant characteristics on the effect of beta carotene.<sup>199</sup> Only one variable was significant; cognitive results differed by dietary antioxidant intake ( $p=0.02$ ). Cognitive results did not differ by age, baseline cognition (baseline performance or highest attained education), multivitamin use, comorbidities (cardiovascular disease or associated risk factors), or lifestyle factors (smoking or alcohol use).

**Table 4G.2. Results overview: Vitamins versus inactive comparisons (placebo) in adults with normal cognition**

Author Year Comparison N= Followup	Diagnosis	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
<b>Multivitamin Results Summary k=4; n=20,536</b>	<b>0 of 2 (no difference) k=1</b>	<b>0 of 3 (no difference) k=2</b>	<b>0 of 3 (no difference) k=2</b>	<b>0 of 2 (no difference) k=2</b>	<b>0 of 8 (no difference)</b>	
<b>Grodstein, 2013</b> <sup>196</sup> Multivitamin vs. placebo n=5,947 (men)		<b>BCT</b> NS [TICS]		NS [Composite <sup>b</sup> ]	0 of 3 (no difference)	NR
		<b>MNP</b> NS [Composite <sup>a</sup> ]				
<b>McNeill, 2007</b> <sup>202</sup> Micronutrient supplement vs. placebo n=910 1 year			NS [DS Forward]		0 of 1 (no difference)	NR
<b>Wolters, 2005</b> <sup>210</sup> Multivitamin vs. placebo n=220 (women) 6 months			NS [Kurztest fuer Allgemeine Intelligenz]	NS [Berliner Amnesit Test]	0 of 3 (no difference)	NR
			NS [WAIS-III Symbol Search]			
<b>Heart Protection Study, 2002</b> <sup>197</sup> Vitamin C + B vitamins + beta carotene vs. placebo n=20,536 5 years	NS [Dementia]	<b>BCT</b> NS [TICS]			0 of 3 (no difference)	NR
	NS [MCI]					
<b>B Vitamins: Folic Acid</b>		<b>MNP</b> 1 of 1 favor I	<b>1 of 3 favor I k=1</b>	<b>1 of 1 favor I k=1</b>	<b>2 of 4 favor I</b>	

Author Year Comparison N= Followup	Diagnosis	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
<b>Results Summary k=1; n=818</b>		<b>k=1</b>				
<b>Durga, 2007</b> <sup>212</sup> B vitamins: folic acid vs. placebo n=818 3 years		<b>MNP</b> I>C [Composite]	I>C [DSST]	I>C [RAVLT]	3 of 5 favor I	NR
			NS [SCWT]			
			NS [Concept Shifting Test]			
<b>B Vitamins: Folic Acid + B<sub>12</sub> Results Summary k=2; n=3,819</b>		<b>BCT</b> 2 of 2 favor I k=2	<b>0 of 11 (no difference) k=2</b>	<b>2 of 7 favor I k=2</b>	<b>2 of 18 favor I</b>	
<b>van der Zwaluw, 2014</b> <sup>208</sup> B vitamins: folic acid + B <sub>12</sub> vs. placebo n=2,919 2 years		<b>BCT</b> I>C [MMSE]	NS [Composite <sup>c</sup> ]	NS [Composite <sup>f</sup> ]	1 of 14 favor I	NR
			NS [Composite <sup>d</sup> ]	NS [RAVLT Immediate Recall]		
			NS [Composite <sup>e</sup> ]	NS [RAVLT Delayed Recall]		
			NS [DS Forward]	NS [RAVLT Recognition]		
			NS [TMT A]			
			NS [TMT B]			
			NS [SCWT 1 & 2]			
			NS [SCWT Interference]			

Author Year Comparison N= Followup	Diagnosis	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
			NS [SDMT]			
<b>Walker, 2012</b> <sup>209</sup> B vitamins: folic acid + B <sub>12</sub> vs. placebo n=900 2 years		<b>BCT</b> I>C [TICS Total]	NS [TICS Orientation/ Calculation]	I>C [TICS Immediate Recall]	3 of 6 favor I	NR
			NS [TICS Attention]	I>C [TICS Delayed Recall]		
				NS [TICS Semantic Memory]		
<b>B Vitamins: Folate + B<sub>6</sub> + B<sub>12</sub> Results Summary k=2; n=1,524</b>		<b>BCT</b> 0 of 2 (no difference) k=2	<b>1 of 2 favor C</b> k=2	<b>0 of 4 (no difference)</b> k=2	<b>1 of 8 favor C</b>	
<b>Andreeva, 2011</b> <sup>101</sup> B vitamins: folate + B <sub>6</sub> + B <sub>12</sub> vs. placebo n=1,248 4 years		<b>BCT</b> NS [TICS]		NS [TICS Memory]	0 of 3 (no difference)	NR
				NS [TICS Recall]		
<b>McMahon, 2006</b> <sup>201</sup> B vitamins: folate + B <sub>6</sub> + B <sub>12</sub> vs. placebo n=276 2 years		<b>BCT</b> NS [MMSE]	NS [RCPM]	NS [RAVLT]	1 of 5 favor C	NR
			C>I [TMT B]	NS [Paragraph Recall]		
<b>Vitamin E Results Summary k=2; n=9,201</b>		<b>BCT</b> 0 of 2 (no difference) k=2  <b>MNP</b> 0 of 2 (no difference) k=2		<b>0 of 2 (no difference)</b> k=2	<b>0 of 6 (no difference)</b>	<b>None</b> k=1
<b>Kang, 2009</b> <sup>199</sup>		<b>BCT</b>		NS	0 of 3 (no	None

Author Year Comparison N= Followup	Diagnosis	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
Vitamin E vs. placebo n=2,824 9 years treatment 5 years followup		NS [TICS]		[Composite]	difference)	
		<b>MNP</b> NS [Composite]				
<b>Kang, 2006<sup>198</sup></b> Vitamin E vs. placebo n=6,377 10 years treatment 4 years followup		<b>BCT</b> NS [TICS]		NS [Composite]	0 of 3 (no difference)	NR
		<b>MNP</b> NS [Composite]				
<b>Vitamin C Results Summary k=1; n=2,824</b>		<b>BCT</b> 0 of 1 (no difference) k=1  <b>MNP</b> 0 of 1 (no difference) k=1		1 of 1 favor I k=1	1 of 3 favor I	None k=1
<b>Kang, 2009<sup>199</sup></b> Vitamin C vs. placebo n=2,824 9 years treatment 5 years followup		<b>BCT</b> NS [TICS]		I>C [Composite]	1 of 3 favor I	None
		<b>MNP</b> NS [Composite]				
<b>Vitamin D + Calcium Results Summary k=1; n=4,143</b>	0 of 1 (no difference) k=1	<b>BCT</b> k=1  0 of 1 (no difference)	0 of 1 (no difference) k=1	0 of 2 (no difference) k=1	0 of 4 (no difference)	
<b>Rossom, 2012<sup>205</sup></b>	NS [Probable]	<b>BCT</b> NS	NS [DS Forward &	NS [CVLT]	0 of 5 (no difference)	NR

Author Year Comparison N= Followup	Diagnosis	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
Vitamin D + calcium vs. placebo n=4,143 8 years	Dementia or MCI]	[MMSE]	Backward (pooled)]			
				NS [BVRT]		
<b>Beta carotene Results Summary k=1; n=2,824</b>		<b>BCT 0 of 1 (no difference) k=1</b>  <b>MNP 0 of 1 (no difference) k=1</b>		<b>0 of 1 (no difference) k=1</b>	<b>0 of 3 (no difference)</b>	<b>None k=1</b>
<b>Kang, 2009<sup>199</sup></b> Vitamin C vs. placebo n=2,824 9 years treatment 5 years followup		<b>BCT NS [TICS]</b>		NS [Composite]	0 of 3 (no difference)	None
		<b>MNP NS [Composite]</b>				

<sup>a</sup> mean multidomain battery composite z score composed of TICS, EBMT, TICS 10-word list delayed recall, and category fluency; <sup>b</sup> composite z score of TICS and EBMT immediate and delayed word recall; <sup>c</sup> composite z score of Attention and working memory (Digit Span Forward & Backward); <sup>d</sup> composite z score of Information Processing Speed (Trails A, Stroop I & II); <sup>e</sup> composite z score of Executive functioning (Trails B, Stroop Interference, Verbal fluency); <sup>f</sup> composite z score of Episodic memory (RAVLT immediate recall, decay, recognition)

B<sub>6</sub>=vitamin B<sub>6</sub>; B<sub>12</sub>=vitamin B<sub>12</sub>; BCT=brief cognitive screening test; BVRT=Benton Visual Retention Test; C=inactive control; CVLT=California Verbal Learning Test; DS=Digit Span (Forward and/or Backward); DSST=Digit Symbol Substitution Test; I=intervention; k=number of studies included; MCI=mild cognitive impairment; MMSE=Mini-Mental State Examination; MNP=multidomain neuropsychological test performance; n=sample size; NR=not reported; NS=no statistically significant difference; RAVLT=Rey Auditory Verbal Learning Test; RCPM=Raven's Colored Progressive Matrices; SCWT=Stroop Color Word Test; SDMT=Symbol Digit Modalities Test; TICS=Telephone Interview for Cognitive Status; TMT=Trail Making Test (Part A and/or B); vs.=versus; WAIS=Wechsler Adult Intelligence Scale

Shading indicates summary rows and columns.



## **Comparative Effectiveness: Vitamins Versus Active Comparison**

One RCT (n=167) compared vitamins with an active control group.<sup>216</sup> Stott et al. analyzed the comparative effectiveness of varying combinations of B vitamins (folic acid/B<sub>12</sub> vs. B<sub>2</sub> vs. B<sub>6</sub> vs. folic acid/B<sub>12</sub>/B<sub>2</sub> vs. folic acid/B<sub>12</sub>/B<sub>6</sub> vs. B<sub>2</sub>/B<sub>6</sub> vs. folic acid/B<sub>12</sub>/B<sub>2</sub>/B<sub>6</sub>). They randomized people aged 65+ with a history of ischemic vascular disease to the above combinations of 2.5 mg folic acid, 25 mg B<sub>2</sub>, 25 mg B<sub>6</sub>, and/or 0.4 mg B<sub>12</sub> daily for 3 months. Cognitive outcomes were assessed at 6 and 12 months. The sample size for this unique comparison was too small to assess strength of evidence. See Table 4G.3 for summary of results.

Other studies that used B vitamins as components of active controls can be found in Chapter 4C.

**Table 4G.3. Results overview: Vitamins versus active comparisons in adults with normal cognition**

Author Year Comparison N= Followup	Diagnosis	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
<b>B vitamins Combinations* Results Summary k=1; n=167</b>		<b>BCT 0 of 1 (no difference) k=1</b>	<b>0 of 1 (no difference) k=1</b>		<b>0 of 2 (no difference)</b>	
<b>Stott, 2005<sup>216</sup></b> B vitamins combinations (folic acid, B <sub>2</sub> , B <sub>6</sub> , B <sub>12</sub> ) n=167 <b>1 year</b>		BCT NS [TICS-M]	NS [SDMT]		0 of 2 (no difference)	NR

\*Participants randomized to one of 7 combinations: 1) folic acid/B<sub>12</sub> 2) B<sub>2</sub> 3) B<sub>6</sub> 4) folic acid/B<sub>12</sub>/B<sub>2</sub> 5) folic acid/B<sub>12</sub>/B<sub>6</sub> 6) B<sub>2</sub>/B<sub>6</sub> 7) folic acid/B<sub>12</sub>/B<sub>2</sub>/B<sub>6</sub>. None were significantly different for any outcome.

B<sub>2</sub>=vitamin B<sub>2</sub>; B<sub>6</sub>=vitamin B<sub>6</sub>; B<sub>12</sub>=vitamin B<sub>12</sub>; BCT=brief cognitive test performance; k=number of studies included; n=sample size; NR=not reported; NS=no statistically significant difference; SDMT=Symbol Digit Modalities Test; TICS-M=Telephone Interview for Cognitive Status-Modified

Shading indicates summary rows and columns.

## Adults With MCI

### Efficacy: Vitamins Versus Inactive Control

Three trials reported in six publications (n=1,038) with low or moderate risk of bias compared vitamins with inactive control (placebo) in adults with MCI.<sup>191, 194, 195, 203, 213, 215</sup> Total sample sizes ranged from 256 to 516. Strength of evidence was only assessed for one study with a sufficiently large sample size.<sup>203</sup> Conclusions are summarized in Table 4G.4 and individual study results for all three trials are in Table 4G.5

One trial (n=516) compared vitamin E to placebo for preventing cognitive decline.<sup>203</sup> They randomized adults aged 55-90 with degenerative amnesic MCI to 2000 IU vitamin E or placebo daily for 3 years. They study also included a donepezil arm, the results of which are discussed in the Chapter 4K.

Evidence was insufficient to determine improvement with vitamin E for brief cognitive test performance, multidomain neuropsychological performance, executive/attention/processing speed, or memory. Two tests assessed differences in diagnosis of CATD at 3 years and found low-strength evidence for no difference between groups. Serious adverse effects did not differ between groups.

**Table 4G.4. Conclusions: Vitamins versus inactive comparisons in adults with MCI**

Comparison	Outcome	Conclusion	Strength of Evidence (justification)
Multivitamin vs. placebo k=1	Dementia	No data available.	Insufficient (no data)
	Brief cognitive test performance	Limited data.	Insufficient (limited data)
	Multidomain neuropsychological performances	No data available.	Insufficient (no data)
	Executive/Attention/Processing speed	No data available.	Insufficient (no data)
	Memory	No data available.	Insufficient (no data)
B Vitamins (folic acid/ B <sub>6</sub> /B <sub>12</sub> ) vs. placebo k=1	Dementia	No data available.	Insufficient (no data)
	Brief cognitive test performance	Limited data.	Insufficient (limited data)
	Multidomain neuropsychological performances	No data available.	Insufficient (no data)
	Executive/Attention/Processing speed	No data available.	Insufficient (no data)
	Memory	Limited data.	Insufficient (limited data)
Vitamin E vs. placebo k=1	Dementia	No statistically significant difference in CATD diagnosis with vitamin E versus placebo long term (n=516; 3 years).	Low (medium study limitations, imprecise)
	Brief cognitive test performance	Unable to draw conclusion.	Insufficient (medium study limitations, indirect, imprecise, unknown consistency)
	Multidomain neuropsychological performances	Unable to draw conclusion.	Insufficient (medium study limitations, indirect, precision unclear, unknown consistency)
	Executive/Attention/Processing speed	Unable to draw conclusion.	Insufficient (medium study limitations, indirect, imprecise, unknown consistency)

Comparison	Outcome	Conclusion	Strength of Evidence (justification)
	Memory	Unable to draw conclusion.	Insufficient (medium study limitations, indirect, imprecise, unknown consistency)

B<sub>6</sub>=vitamin B<sub>6</sub>; B<sub>12</sub>=vitamin B<sub>12</sub>; k=number of studies included; MCI=mild cognitive impairment; n=sample size;

## Interpreting the Findings

Overall, little to no benefit was shown with vitamin use in preventing cognitive decline. The only benefits noted were for folic acid plus B<sub>12</sub> for memory versus placebo in adults with normal cognition; one of these studies administered high doses of folic acid and B<sub>12</sub> in adults with elevated homocysteine levels. However, no benefit was found for folate, B<sub>6</sub>, B<sub>12</sub> versus placebo for brief cognitive test performance or memory. The differences between studies could not be explained by dosage or deficiency state. Further, the positive results were in a small proportion of cognitive performance tests and of small effect size. Additionally, many of the vitamins were examined in a few studies that enrolled only women.

**Table 4G.5. Results overview: Vitamins versus inactive comparisons in adults with MCI**

Author Year Comparison N= Followup	Diagnosis	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
<b>Multivitamin Results Summary k=1; n=256</b>		<b>BCT 0 of 1 (no difference) k=1</b>			<b>0 of 1 (no difference)</b>	
<b>Naeni, 2014<sup>191</sup></b> Vitamin E + vitamin C vs. placebo n=256 1 year		<b>BCT NS [MMSE]</b>				NR
<b>B vitamins: Folic acid + B<sub>6</sub> + B<sub>12</sub> Results Summary k=1; n=217</b>		<b>BCT 0 of 1 (no difference) k=1</b>		<b>0 of 1 (no difference) k=1</b>	<b>0 of 2 (no difference)</b>	
<b>Smith, 2010<sup>207</sup> deJager, 2012(de Jager, 2012 #372} Douaud, 2013<sup>195</sup> Oulhaj 2016<sup>215</sup></b> B vitamins (folic acid + B <sub>12</sub> + B <sub>6</sub> ) vs. placebo n=217 2 years		<b>BCT NS [MMSE]</b>		<b>NS [HVLt]</b>		NR
<b>Vitamin E Results Summary k=1; n=516</b>	<b>0 of 2 (no difference) k=1</b>	<b>BCT 0 of 1 (no difference) k=1  MNP 0 of 1 (no difference) k=1</b>	<b>0 of 1 (no difference) k=1</b>	<b>0 of 1 (no difference) k=1</b>	<b>0 of 4 (no difference)</b>	28% vs. 25%*; reasons NR
<b>Petersen, 2005<sup>203</sup></b> Vitamin E vs. placebo	<b>NS [CATD]</b>	<b>BCT NS [MMSE]</b>	<b>NS [Composite]</b>	<b>NS [Composite]</b>		

<b>Author Year Comparison N= Followup</b>	<b>Diagnosis</b>	<b>Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]</b>	<b>Executive/Attention/ Processing Speed [instrument]</b>	<b>Memory [instrument]</b>	<b>Intermediate Outcomes Summary</b>	<b>Adverse Effects [specific adverse effect]</b>
n=516 3 years	NS [CDR Sum of Boxes]	<b>MNP</b> NS [ADAS-Cog]				

ADAS-Cog=Alzheimer's Disease Assessment Scale-Cognitive Subscale; B<sub>6</sub>=vitamin B<sub>6</sub>; B<sub>12</sub>=vitamin B<sub>12</sub>; BCT=brief cognitive test performance; C=inactive control; CATD=clinical Alzheimer's-type Dementia; CDR=Clinical Dementia Rating; HVLT=Hopkins Verbal Learning Test; k=number of studies included; I=intervention; MCI=mild cognitive impairment; MMSE=Mini-Mental State Examination; MNP=multidomain neuropsychological test performance; n=sample size; NR=not reported; NS=no statistically significant difference; vs.=versus

Shading indicates summary rows and columns.

# Chapter 4H. Results: Antihypertensive Treatment

## Key Messages

- Generally, low-strength evidence shows that 3 to 4.7 years of antihypertensive treatment regimens versus placebo appear to have no benefit on cognitive test performance in adults with normal cognition.
- Moderate-strength evidence shows that angiotensin converting enzyme (ACE) plus thiazide versus placebo and angiotensin receptor blockers (ARBs) versus placebo have no benefit on brief cognitive screening tests.
- Low-strength evidence shows that intensive versus standard antihypertensive control shows no benefit on cognitive test performance.
- Low-strength evidence shows no benefit on cognitive test performance of any fixed antihypertensive treatment regimen versus another among those directly compared.
- Effects of stepped multiple agent antihypertensive medication regimens to reduce risk of dementia are inconsistent; one trial showed a positive effect but three other trials found no effect of antihypertensive treatment on clinical Alzheimer's-type dementia (CATD)\* incidence.
- The only two trials that reported subgroup data found no differential effect of treatment group on cognition by participant age or other baseline characteristics.

\*Note that the literature currently does not use the term CATD; we specified whenever the diagnosis of dementia was defined.

## Eligible Studies

We identified 20 eligible publications reporting 16 unique trials comparing antihypertensive medication treatment to placebo or active control to prevent age-related cognitive decline, mild cognitive decline (MCI), or CATD.<sup>218-241</sup> Three trials were assessed as high risk of bias and not used in our analysis.<sup>219, 225, 229</sup> We did not include studies specifically designed to address clear post-stroke dementia, however, studies addressing mixed dementias including a vascular component *were* included. For our analyses, we evaluated the efficacy and comparative effectiveness of antihypertensive treatment regimens and the strength of evidence for these effects by drug class, but in the text below we present the results within the broader groups of antihypertensive medication treatment (single or multiple agents) versus placebo, intensive versus standard antihypertensive treatment (with respect to blood pressure treatment targets), and antihypertensive medication treatments versus each other (either or both treatment groups may be single or multiple agents). We also evaluated and report results separately for adults with normal cognition and those with MCI. Appendix M provides evidence tables, summary risk of bias assessments, and assessments of strength of evidence for key comparisons and outcomes.

## Logic of Antihypertensive Treatments

A meta-analysis of prospective cohort studies estimated that the presence of hypertension between the ages of 35 and 64 years but not in late life increased the risk of incident Alzheimer's disease by more than 50 percent.<sup>242</sup> Hypertension is thought to contribute to risk of both vascular and Alzheimer's dementia through unclear vascular mechanisms. Presumably hypertension is the

cause or result of vascular changes in the blood supply to the brain that can adversely affect its function. It remains unclear whether this is a direct effect or the result of other factors that affect both the vasculature and the brain.

## Adults With Normal Cognition

Conclusions are summarized in Table 4H.1 and individual study results in Table 4H.2.

**Table 4H.1. Conclusions: Antihypertensives in adults with normal cognition**

Comparison	Outcome	Conclusion	Strength of Evidence (justification)
Antihypertensive(s) vs. placebo			
ARBs vs. placebo k=3	Dementia	No statistically significant difference in dementia diagnoses with ARBs versus placebo (n=4,937; 44 months).	Low (medium study limitations, unknown consistency, suspected reporting bias)
	MCI	No data available.	Insufficient (no data)
	Brief cognitive test performance	No statistically significant difference in brief cognitive test performance with ARBs versus placebo (n=10,863; up to 56 months).	Moderate (medium study limitations, suspected reporting bias)
	Multidomain neuropsychological performance	No data available.	Insufficient (no data)
	Executive/Attention/Processing speed	Unable to draw conclusion.	Insufficient (medium study limitations, unknown consistency, suspected reporting bias)
	Memory	Unable to draw conclusion.	Insufficient (medium study limitations, inconsistent, suspect reporting bias)
Beta blocker vs. placebo k=1	Dementia	No data available.	Insufficient (no data)
	MCI	No data available.	Insufficient (no data)
	Brief cognitive test performance	No data available.	Insufficient (no data)
	Multidomain neuropsychological performance	No data available.	Insufficient (no data)
	Executive/Attention/Processing speed	Unable to draw conclusion.	Insufficient (medium study limitations, unknown precision, unknown consistency, suspected reporting bias)
	Memory	Unable to draw conclusion.	Insufficient (medium study limitations, unknown precision, unknown consistency, suspected reporting bias)
ACE and Thiazide vs. placebo k=2	Dementia	No statistically significant difference in dementia diagnoses with ACE and thiazide versus placebo (n=14,985; up to 4.3 years)	Low (medium study limitations, imprecise suspected reporting bias)
	MCI	No data available.	Insufficient (no data)
	Brief cognitive test performance	No statistically significant difference in brief cognitive test performance with ACE and thiazide versus placebo (n=14,985; up to 4.3 years)	Moderate (medium study limitations, suspected reporting bias)
	Multidomain	No data available.	Insufficient (no data)



Comparison	Outcome	Conclusion	Strength of Evidence (justification)
	neuropsychological performance		
	Executive/Attention/Processing speed	No data available.	Insufficient (no data)
	Memory	No data available.	Insufficient (no data)
Combination therapy vs. placebo k=3	Dementia	Statistically significant difference in dementia diagnoses favoring combination therapy versus placebo (n=3,228; up to 3.9 years).	Low (medium study limitations, imprecise, unknown consistency, suspected reporting bias)
	MCI	No data available	Insufficient (no data)
	Brief cognitive test performance	No statistically significant difference in brief cognitive test performance with beta blocker versus placebo (n=3,228; up to 3.9 years).	Low (medium study limitations, suspected reporting bias)
	Multidomain neuropsychological performance	No data available.	Insufficient (no data)
	Executive/Attention/Processing speed	Unable to draw conclusion.	Insufficient (medium study limitations, unknown precision, unknown consistency, suspected reporting bias)
	Memory	No data available.	Insufficient (no data)
Intensive vs. Standard			
Intensive blood pressure control (systolic blood pressure <120 mmHg) vs. standard blood pressure control (standard therapy (systolic blood pressure <140 mmHg) k=1	Dementia	No data available.	Insufficient (no data)
	Brief cognitive test performance	Unable to draw conclusion.	Insufficient (medium study limitations, unknown consistency, suspected reporting bias)
	Multidomain neuropsychological performance	No data available.	Insufficient (no data)
	Executive/Attention/Processing speed	No statistically significant difference in executive/attention/processing speed with intensive blood pressure control versus standard blood pressure control (n=1,439; 40 months).	Low (medium study limitations, imprecise, suspected reporting bias)
	Memory	No statistically significant difference in memory with intensive blood pressure control versus standard blood pressure control (n=1,439; 40 months).	Low (medium study limitations, unknown consistency, suspected reporting bias).
Antihypertensive vs. Antihypertensive			
Ramipril (I1) up to 10 mg daily vs. (I2) combined ramipril up to 10 mg daily plus telmisartan 80mg daily k=1	Dementia	No data available.	Insufficient (no data)
	MCI	No data available.	Insufficient (no data)
	Brief cognitive test performance	No statistically significant difference in brief cognitive test performance with ramipril versus ramipril combined with telmisartan (n=17,078; 56 months).	Low (medium study limitations, unknown consistency, suspected reporting bias)
	Multidomain neuropsychological performance	No data available.	Insufficient (no data)
	Executive/Attention/Processing speed	No data available.	Insufficient (no data)
	Memory	No data available.	Insufficient (no data)
ARB vs. ACE k=3	Dementia	No data available.	Insufficient (no data)
	MCI	No data available.	Insufficient (no data)

Comparison	Outcome	Conclusion	Strength of Evidence (justification)
	Brief cognitive test performance	No statistically significant difference in brief cognitive test performance with ARB versus ACE (n=17,118; 56 months).	Low (medium study limitations, unknown consistency, suspected reporting bias)
	Multidomain neuropsychological performance	No data available.	Insufficient (no data)
	Executive/Attention/Processing speed	Unable to draw conclusion.	Insufficient (low study limitations, imprecise, unknown consistency, suspected reporting bias)
	Memory	Unable to draw conclusion.	Insufficient (low study limitations, imprecise, inconsistent, suspected reporting bias)

ACE=angiotensin converting enzyme inhibitors; ARB=angiotensin receptor blocker; I1=intervention 1; I2=intervention 2; k=number of studies included; MCI=mild cognitive impairment; mg=milligram; mmHg=millimeter of mercury;

## Antihypertensive Medication(s) Versus Placebo

Eight unique RCTs met eligibility criteria with low to medium risk of bias and randomized participants to an antihypertensive medication treatment (single or multiple agent) versus placebo,<sup>218, 220, 223, 224, 226, 228, 231, 232, 237, 239-241</sup> Five of the eight studies had eligibility criteria related to cognition, including exclusion of participants with dementia,<sup>223, 224, 226, 240</sup> any mental disorder or clinically relevant chronic disease;<sup>237</sup> and either Mini-Mental State Examination (MMSE) <24, severe brain disorders that may interfere with cognitive function, or treatment with antidementia drugs.<sup>228</sup> Four studies reported baseline MMSE, ranging from a median of 26 to 29.<sup>218, 223, 224, 228, 240</sup>

Among the four unique trials that reported incident dementia outcomes,<sup>223, 224, 228, 239, 240</sup> only the Syst-Eur trial reported a significantly reduced risk of dementia in the antihypertensive treatment group versus the placebo group,<sup>223, 224</sup> while the other three trials reported no difference in risk.<sup>228, 239, 240</sup> During the double-blinded portion of the Syst-Eur trial, which was stopped early after planned interim analyses showed a significant reduction in stroke, 11 cases of incident dementia occurred in the antihypertensive treatment group (none with vascular dementia) and 21 in placebo group (two with vascular dementia). Intervention reduced the rate of incident dementia from 7.7 to 3.8 cases per 1000 patient-years (relative risk (RR) 0.50 [0.24-1.00]).

The Syst-Eur trial compared a stepped multiple agent antihypertensive regimen versus placebo, and defined incident dementia diagnosis based on Diagnostic Statistical Manual of Mental Disorders Third Edition (DSM-3) criteria and was validated by a masked review board.<sup>170,171</sup> By comparison, among the three studies that showed no benefit on risk of CATD, one compared a stepped multiple agent antihypertensive regimen versus placebo,<sup>240</sup> one compared a fixed antihypertensive agent combination versus placebo,<sup>239</sup> and one compared monotherapy versus placebo.<sup>228</sup> Among these three studies, a committee defined participants with incident dementia by consensus using DSM-4 criteria in one study,<sup>240</sup> incident dementia was defined using modified ICD-10 research criteria in another,<sup>228</sup> and no definitions were reported in the third study.<sup>239</sup> Followup duration ranged between 2.2 and 4.3 years.

No study reported data on risk of incident MCI.

All eight trials reported at least one cognitive performance outcome.<sup>218, 220, 223, 224, 226, 228, 231, 232, 237, 239, 240</sup> Four trials reported no difference in brief cognitive test performance between the antihypertensive medication treatment and placebo groups.

Three studies reported mixed results for a change in an executive/attention/processing speed test.<sup>220, 226, 228, 231, 232</sup> All three trials reported results for attention; two trials found that individuals randomized to antihypertensive medication had significantly better attention than those assigned placebo,<sup>228,226</sup> while the third study found no difference between treatment groups.<sup>220</sup>

Two studies reported results for a change in memory tests with mixed findings.<sup>220, 231</sup> One study found no between-group difference in scores on the Paired Association Learning Test (PALS) after 9 months follow-up.<sup>220</sup> In another, the antihypertensive treatment group had a statistically significantly smaller decline between baseline and 3.7 years follow-up in the episodic memory domain that was small in magnitude (Cohen D 0.28), but no difference in the change in working memory.<sup>231</sup>

None of these studies reported data on biomarkers.

Three of these eight studies reported information on adverse effects.<sup>228, 237, 240</sup> Participants assigned to methyldopa, but not those assigned to calcium channel blocker, appeared significantly more likely than those assigned to a placebo to experience any adverse event, a sleep disorder, or a sexual disorder, while incidence of life-threatening events, and of headache, fatigue, and cardiovascular or gastrointestinal side effects were similar between each of these antihypertensive treatment groups and placebo.<sup>237</sup> In one trial, significantly fewer serious adverse events occurred in the treatment group ( $p < 0.01$ ).<sup>240</sup>

The TRANSCEND study (ARB vs. placebo) was the only one of the eight eligible RCTs comparing antihypertensive medication treatment versus placebo that reported subgroup analyses.<sup>218</sup> Authors reported no significant differential effects of treatment on cognitive outcomes in patient subgroups defined by age, history of hypertension, or previous stroke or transient ischemic attack (TIA), though they presented no data for these analyses.

## **Intensive Versus Standard Antihypertensive Medication**

Only one study with low to moderate risk of bias randomized 2,977 participants to intensive versus standard blood pressure control (goal systolic blood pressure  $< 120$  vs.  $< 140$  mm Hg).<sup>236</sup> This study reported no data on MCI or CATD outcomes. Despite achieving substantial separation between the groups in systolic blood pressure at 40 months (119.0 vs. 133.2 mm Hg), there was no significant difference between treatment groups at 40 months in brief cognitive screening tests, executive/attention/processing speed, or memory. The study reported results for the measure of change in MRI total brain volume between baseline and 40 months, but these results were not analyzed for this review because attrition exceeded 20 percent in one of the treatment groups. This study reported no data on adverse events. There were no consistent between treatment group differences in change in cognitive performance from baseline as a function of baseline age, gender, executive/attention/processing speed, history of cardiovascular disease, or diabetes duration.

## **Antihypertensive Medication Treatments Versus Each Other**

Eight RCTs met eligibility criteria, had low to medium risk of bias, compared different antihypertensive medication treatment regimens versus each other, and reported cognitive outcomes.<sup>218, 220-222, 227, 230, 235, 237</sup> Only four of the eight trials reported any entry criteria that could relate to cognition. Of these, one study required that participants have some executive dysfunction (CLOX1 clock draw  $< 10$ ) but excluded those with dementia or an MMSE of  $< 20$ ,<sup>227</sup> another excluded participants with either a mental disorder or any “clinically relevant chronic disease,”<sup>237</sup> another excluded participants receiving any psychotropic drug that might interfere with

cognition,<sup>221</sup> and a fourth study excluded individuals with a stroke in the last 6 months.<sup>222</sup> Baseline MMSE scores ranged from a mean of 23<sup>235</sup> to a median of 29.<sup>218</sup>

None of these studies reported data on MCI or CATD outcomes.

One trial reported incident cognitive impairment, which it defined as a composite of incident dementia, incident cognitive impairment, or MMSE <24 in patients without baseline cognitive impairment.<sup>218</sup> During a mean follow-up of 4.7 years, incident cognitive impairment occurred in 8 percent, 7 percent, and 8 percent of participants allocated to ACE inhibitor, ARB, and their combination, respectively. This corresponded to an odds ratio (OR) of 0.95 (95% CI, 0.85-1.07) for combination group versus the ACE inhibitor group and an OR of 0.90 (95% CI, 0.80-1.01) for the ARB group versus the ACE inhibitor group. Authors did not directly compare results between the ARB and combination groups.

All eight trials reported at least one cognitive performance outcome.<sup>218, 220-222, 227, 230, 235, 237</sup> Three reported results for a change in a brief cognitive screening test (MMSE).<sup>62, 218, 230, 235</sup> Two studies found no difference between their different antihypertensive medication treatment arms, in mean MMSE score at follow-up,<sup>230</sup> or incidence of >3 point decline in MMSE.<sup>218</sup> In one study, while individuals randomized to thiazide had no significant improvement in MMSE between baseline and 26 months, those assigned to ARB had a significant improvement in this outcome during that time period.<sup>235</sup> No direct between-group comparison was reported.

Two studies found no difference in executive/attention/processing speed tests between their different antihypertensive medication treatment arms.<sup>220, 222</sup> Three studies reported results for memory tests and found mixed results.<sup>220-222</sup> One study found no difference on the Paired Association Learning Test (PALS) after 9 months follow-up between a group assigned a beta blocker and a group assigned a thiazide-potassium sparing diuretic combination.<sup>220</sup> In another trial, participants randomized to ARB performed significantly better at 6 months than those assigned to beta blocker on both immediate and delayed recall of a word list.<sup>221</sup> In a third trial, participants randomized to ARB plus thiazide performed no differently at 6 months than those assigned to ACE inhibitor plus thiazide group on immediate recall of a word list, but performed significantly better on delayed recall of the word list.<sup>222</sup>

None of these studies reported data on biomarkers.

Four of these studies reported adverse events outcomes.<sup>221, 222, 227, 237</sup> In one study, participants assigned to methyldopa were significantly more likely than those assigned to a calcium channel blocker to experience any adverse event, a sleep disorder, or a sexual disorder, while incidence of life-threatening events, and of headache, fatigue, and cardiovascular or gastrointestinal side effects were similar between these two antihypertensive treatment groups.<sup>237</sup> In another, participants randomized to ARB were significantly less likely to have an adverse event than those assigned to beta blocker.<sup>221</sup> In another trial, there was no significant difference in risk of any adverse event (2.6 percent vs. 5.5 percent) between individuals randomized to ARB plus thiazide and those assigned to ACE inhibitor plus thiazide.<sup>222</sup> In the fourth trial, there was no significant difference in risk of nonelective hospitalizations or other selected adverse events (dizziness, weakness or fatigue, noninjurious fall, cough) between individuals randomized to ACE inhibitor, ARB, or thiazide treatment groups.<sup>227</sup>

The ONTARGET study (ACE inhibitor vs. ARB vs. combination) was the only one of the eight eligible RCTs comparing one antihypertensive medication treatment versus another that reported subgroup analyses.<sup>218</sup> Authors stated that they found no significant differential effects of treatment on cognitive outcomes in patient subgroups defined by age, history of hypertension, or previous stroke or TIA, although they presented no data for these analyses.

**Table 4H.2. Results overview: Antihypertensive treatments in adults with normal cognition**

Author Year Comparison N= Follow-up	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
<b>ARB vs. placebo Results Summary k=3; n=11,120</b>	<b>0 of 1 (no difference) k=1</b>		<b>BCT 0 of 4 (no difference) k=3</b>	<b>1 of 3 favored I k=1</b>	<b>1 of 2 favored I k=1</b>	<b>1 of 9 favored I</b>	<b>0 of 1 (no difference) k=1</b>
<b>Anderson, 2011<sup>218</sup></b> (TRANSCEND trial) telmisartan 80 mg daily vs. placebo n=5,926 56 months median followup			<b>BCT NS [Drop of 3 or more MMSE points]</b>			0 of 1 (no difference)	NR
<b>Saxby, 2008<sup>231</sup></b> (single center in SCOPE trial) candesartan (8 mg – 16mg) daily vs. placebo n=257 44 months mean followup			<b>BCT NS [MMSE]</b>	NS [Executive Function Composite] <sup>a</sup>	I>C [Episodic Memory Composite] <sup>a</sup>	2 of 6 favored I	NR
				I>C [Attention Composite] <sup>a</sup>	NS [Working Memory Composite] <sup>a</sup>		
				NS [Speed of Cognition Composite] <sup>a</sup>			
<b>Lithell, 2003<sup>228</sup></b> <b>Skoog 2005<sup>232</sup></b> (SCOPE trial) Candesartan (8 mg – 16 mg) daily with hydrochlorothiazide 12.5 mg added as needed. When target blood pressure not achieved (<160/90 mmHg) other drugs	NS [Dementia]		<b>BCT NS [MMSE]</b>			0 of 2 (no difference)	
			NS [Significant Cognitive Decline]				NS [serious adverse events]

Author Year Comparison N= Follow-up	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
added as needed vs. placebo daily and hydrochlorothiazide 12.5 mg added as needed. When target blood pressure not achieved (<160/90 mmHg) other drugs added as needed n=4,937 44 months mean followup							
<b>Beta Blocker Results Summary k=1; n=2,401</b>				<b>0 of 1 (no difference)</b>	<b>0 of 1 (no difference)</b>	<b>0 of 2 (no difference)</b>	
<b>Bird, 1990</b> <sup>220</sup> atenolol 50 mg daily vs. placebo n=2,401 9 months				NS [TMT A]	NS [PAL]	0 of 2 (no difference)	NR
<b>Combination Therapy Results Summary k=3; n=6,941</b>	<b>2 of 2 favors I k=2</b>		<b>BCT 0 of 2 (no difference) k=2</b>	<b>1 of 3 favors I k=1</b>		<b>1 of 5 favors I</b>	
<b>Forette, 2002</b> <sup>223</sup> (Syst-Eur trial) Antihypertensive stepwise therapy with titration with goal of lowering systolic blood pressure below 150 mmHg (step 1: nitrendipine 10-40 mg daily; step 2:	I>C [Dementia]		<b>BCT NS [MMSE]</b>			0 of 1 (no difference)	NR

Author Year Comparison N= Follow-up	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
enalapril 5 – 20 mg daily; step 3: hydrochlorothiazide 12.5 – 25 mg daily) vs. placebo n=3,228 3.9 years median follow up							
<b>Forette, 1998</b> <sup>224</sup> (Syst-Eur trial) Antihypertensive stepwise therapy with titration with goal of lowering systolic blood pressure below 150 mm Hg (step 1: nitrendipine 10 -40 mg daily; step 2: enalapril 5 – 20 mg daily; step 3: hydrochlorothiazide 12.5 – 25 mg daily) vs. placebo n=3,162 2-year median follow up	I>C [Dementia]		<b>BCT</b> NS [MMSE]			0 of 1 (no difference)	NR
<b>Gurland, 1988</b> <sup>226</sup> (SHEP trial) Step therapy: step 1: chlorthalidone; step 2: reserpine, metoprolol, or hydralazine) vs. placebo n=551 1 year				NS [DSST]		1 of 3 favors I	NR
				I>C [TMT A]			
				NS [Composite] <sup>b</sup>			

Author Year Comparison N= Follow-up	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
<b>ACE and Thiazide vs. placebo Results Summary k=2; n=14,985</b>	<b>0 of 2 (no difference) k=2</b>		<b>BCT 0 of 3 (no difference) k=2</b>			<b>0 of 3 (no difference)</b>	<b>1 of 2 favored I k=2</b>
<b>ACE and Thiazide vs. placebo</b>							
<b>Peters, 2008<sup>240</sup></b> (HYVET-COG) Indapamide 1.5 mg with optional perindopril (2 mg up to 4mg) vs. matching placebo n=3,845 26.4 months mean followup	NS		<b>BCT NS [MMSE]</b>			0 of 2 (no difference)	
			NS [MMSE <24 or a decline of >3 MMSE points in a year]				I>C [number of adverse events]
<b>ADVANCE Collaborative Group, 2007<sup>239</sup></b> Combined perindopril (2 mg up to 4 mg) and indapamide (0.625 mg up to 1.25 mg) and open label perindopril up to 4 mg vs. matching- placebo and open label perindopril up to 4 mg n=11,140 51 months mean followup	NS		<b>BCT NS [MMSE]</b>			0 of 1 (no difference)	NS [number with serious drug reactions]
<b>Comparative Effectiveness: ARB versus ACE Results Summary</b>			<b>BCT 0 of 1 (no difference) k=1</b>	<b>0 of 1 (no difference) k=1</b>	<b>0 of 3 favored ARB 1 of 3 favored ACE</b>	<b>0 of 5 favored ARB  1 of 5 favored</b>	<b>0 of 2 (no difference)</b>



Author Year Comparison N= Follow-up	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
<b>k=3; n=17,331</b>						ACE	
<b>Hajjar, 2013</b> <sup>227</sup> Lisinopril (10 mg - 40 mg) vs. candesartan (8 mg – 32 mg) vs. hydrochlorothiazid e (12.5 mg – 25 mg) n=53 6 months							NS
<b>Anderson, 2011</b> <sup>218</sup> (ONTARGET trial) ramipril (I <sub>1</sub> ) 5 mg (increased to 10 mg after 2 weeks) daily vs. telmisartan (I <sub>2</sub> ) 80mg daily n = 17,118 56 months median follow up			<b>BCT</b> NS [Drop of 3 or more MMSE points]			0 of 1 (no difference)	NR
<b>Forgari, 2006</b> <sup>222</sup> telmisartan 80mg and hydrochlorothiazide 12.5 mg daily (I <sub>1</sub> ) vs. lisinopril 20 mg and hydrochlorothiazide 12.5 mg daily (I <sub>2</sub> ) n=160 6 months				NS [TMT B]	NS [Word List Memory]	1 of 4 favored ACE	NS
					I <sub>1</sub> >I <sub>2</sub> [Word List Recall]		
					NS [Word List Recognition]		
<b>ARB vs. Thiazide Results Summary k=2; n=122</b>							<b>0 of 2 (no difference) k=2</b>
<b>Hajjar, 2013</b> <sup>227</sup> Lisinopril (10 mg -							NS

Author Year Comparison N= Follow-up	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
40 mg) vs. candesartan (8 mg – 32 mg) vs. hydrochlorothiazid e (12.5 mg – 25 mg) n=53 6 months							
<b>Tedesco, 1999</b> <sup>235</sup> Losartan (I <sub>1</sub> ) 50 mg daily vs. hydrochlorothiazide (I <sub>2</sub> ) 25 mg daily n=69 26 months							NS
<b>Comparative Effectiveness: Intensive vs. Standard Results Summary k=1; n=1,439</b>	NR	NR	BCT 0 of 1 (no difference) k=1	0 of 2 (no difference) k=1	0 of 1 (no difference) k=1	0 of 4 (no difference)	NR
<b>Willamson, 2014</b> <sup>236</sup> (ACCORD BP trial) intensive intervention (systolic blood pressure <120 mmHg) vs. standard therapy (systolic blood pressure <140 mmHg) n=1,439 40 months			BCT NS [MMSE]	NS [SCWT]	NS [RAVLT]	0 of 4 (no difference)	NR
				NS [DSST]			
<b>Comparative Effectives: Intensive vs. standard</b>							
<b>Antihypertensives</b>							

Author Year Comparison N= Follow-up	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
<b>versus Active Comparison Results Summary k=6; n=20,162</b>							
<b>Hajjar, 2013</b> <sup>227</sup> Lisinopril (10 mg - 40 mg) vs. candesartan (8 mg – 32 mg) vs. hydrochlorothiazid e (12.5 mg – 25 mg) n=53 6 months							NS
<b>Sato, 2013</b> <sup>230</sup> (CAMUI trial) combined losartan 50 mg and hydrochlorothiazide 12.5 mg daily vs. combined amlodipine 5 mg and typical dosage of a angiotensin receptor blocker daily n=142 1 year			<b>BCT</b> NS [MMSE]			0 of 1 (no difference)	NS
<b>Anderson, 2011</b> <sup>218</sup> (ONTARGET trial) (1) ramipril up to 10 mg daily vs. (2) combined ramipril up to 10 mg daily plus telmisartan 80 mg daily n=17,078 56 months median			<b>BCT</b> NS [Drop of 3 or more MMSE points]			0 of 1 (no difference)	NR

Author Year Comparison N= Follow-up	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
follow up							
<b>Fogari, 2003</b> <sup>221</sup> Atenolol (I <sub>1</sub> 50 mg with titration to 100 mg) vs. losartan (I <sub>2</sub> 50 mg with titration to 100 mg) n=120 6 months					I <sub>2</sub> > I <sub>1</sub> [Word List Memory]	2 of 2 favors I <sub>2</sub>	NS
					I <sub>2</sub> > I <sub>1</sub> [Word List Recall]		
<b>Yodfat, 1996</b> <sup>237</sup> (LOMIR-MCT-IL trial) Isradipine (I <sub>1</sub> ) 1.25 mg twice a day vs. methyldopa (I <sub>2</sub> ) 250 mg twice a day vs. placebo (I <sub>3</sub> ) n=368 12 months							NS [Life threatening events] I <sub>2</sub> < I <sub>1</sub> , I <sub>3</sub> [adverse reaction]
<b>Bird, 1990</b> <sup>220</sup> atenolol 50 mg daily vs. moduretic (hydrochlorothiaz ide 25 mg and amiloride 2.5 mg) daily n=2,401 9 months				NS [TMT A]	NS [PAL]	0 of 2 (no difference)	NR

<sup>a</sup> Saxby 2008<sup>231</sup> evaluated composite measures of episodic memory (composed of immediate word recall, immediate word recognition, delayed word recall, delayed word recognition, picture recognition), attention (composed simple reaction time, number vigilance, choice reaction time), working memory (composed of spatial memory, numeric working memory), speed of cognition (composed of reaction time scores from episodic memory recognition tasks, attention, and working memory tasks), and executive function (composed of TMT A & B, verbal fluency for letters F, A, and S, verbal fluency for category animals).

<sup>b</sup> Gurland 1988<sup>226</sup> evaluated a composite executive/attention/processing speed measure composed of SHORT-CARE dementia, TMT, and DSST.

ACE=angiotensin converting enzyme inhibitors; ARB=angiotensin receptor blocker; BCT=brief cognitive test performance; C=control; DSST=Digit Symbol Substitution Test; I<sub>1</sub>=intervention 1; I<sub>2</sub>=intervention 2; k=number of studies included; MCI=mild cognitive impairment; mg=milligram; mmHg=millimeter of mercury; MMSE=Mini-Mental Status Examination; NS=no statistically significant difference; NR=not reported; PAL=Paired Association Learning Test; RAVLT=Rey Auditory Verbal Learning Test; SCWT=Stroop Color Word Test; TMT=Trail Making Test (Parts A & B) Shading indicates summary rows and columns.

## Adults With MCI

Just one antihypertensive treatment trial, the HOPE study, met eligibility criteria, had low to medium risk of bias, and evaluated cognitive outcomes in participants categorized at baseline as having mild cognitive impairment.<sup>233, 234</sup> This study randomized 81 older hypertensive adults to ACE inhibitor versus thiazide treatment and followed them for 6 months. Participants were hypertensive, yet had never received prior antihypertensive treatment. They were defined as having a “mild degree of cognitive impairment” based on a baseline MMSE of 20-28 (mean baseline MMSE was 26.1). No information was provided about participant education. Mean age was 76 years. This study reported no data on CATD outcomes. The treatment showed no effect in a model of all cognitive tests at all time-points, including two measures of executive/attention/processing speed and four measures of memory. This study reported no data on biomarker outcomes or adverse events. The study did not report any subgroup analyses. Evidence was insufficient to draw conclusions due to limited data (single study, n<500).

## Interpreting the Findings

Though one trial of stepped multiple agent antihypertensive regimen found a statistically significant reduction in incident CATD, the Syst-Eur trial,<sup>223, 224</sup> it was a large study in which incident dementia was a relatively rare secondary outcome, and the three other trials that compared antihypertensive treatment versus placebo and reported an incident dementia outcome found no difference between treatment groups. We also found low-strength evidence of no difference between different antihypertensive treatment regimens on cognitive performance. However, these results should be interpreted in light of the fact that many trials were probably too short in duration to observe a clinically meaningful change in cognitive function in the middle-aged and older, and largely cognitively normal participants. Though extensive observational data suggest that midlife but not late-life hypertension is associated with a significant increase in risk of dementia,<sup>242</sup> the minimal subgroup data reported from RCTs suggested that there was no difference in the effect of antihypertensive medication treatment on cognition based on participant age.

# Chapter 4I. Results: Lipid Lowering Treatment

## Key Messages

- Evidence was insufficient to assess the effect of 5 years of statin treatment on the risk of incident clinical Alzheimer's-type dementia (CATD)\* or for preventing mild cognitive impairment (MCI).
- Low-strength evidence shows a small, 6-month improvement in executive/attention/processing speed with placebo treatment that was not found with statin treatment, presumed to be due to practice effects and of uncertain clinical significance.
- Low-strength evidence shows no benefit on brief cognitive test performance, executive/attention/processing speed, or memory for statin plus fenofibrate versus statin plus placebo in adults with normal cognition.
- Evidence was insufficient to assess whether effects of statins on any cognitive outcomes differ by patient age, baseline lipid level, or other characteristics.

\*Note that the literature currently does not use the term CATD; we specified whenever the diagnosis of dementia was defined.

## Eligible Studies

We identified 10 eligible publications reporting nine unique studies that compared treatment with lipid lowering medications versus control treatment to prevent age-related cognitive decline, MCI, or CATD.<sup>193, 236, 243-250</sup> Three publications from two studies were rated high risk of bias and excluded from our analyses.<sup>246, 249, 250</sup> The remaining seven studies with low to medium risk of bias were randomized controlled trials (RCTs) that enrolled a total of 23,286 adults.<sup>193, 236, 243-245, 247, 248</sup> Appendix N provides evidence tables, summary risk of bias assessments, and assessments of strength of evidence for key comparisons and outcomes.

## Logic of Lipid Lowering Treatments

A systematic review of prospective cohort studies found mixed results regarding whether saturated fat intake was positively associated with CATD, MCI, or cognitive decline.<sup>251</sup> Authors cited studies suggesting that intracellular cholesterol may impact brain beta amyloid production and deposition. In 2012, based largely on post-marketing adverse event reporting, the Federal Drug Administration revised labeling for statins to warn of a possible associated increase in risk of memory loss, forgetfulness and confusion. These effects were characterized as mild and reversed by stopping use of the statin.<sup>252</sup> However, subsequent systematic reviews of RCTs in both individuals who were cognitively normal and those with CATD showed no difference between statins and placebo in cognitive test performance,<sup>253</sup> including no protective effect with late-life statin use.<sup>254</sup>

## Adults With Normal Cognition

Only two studies excluded participants based on any cognitive criteria; one excluded individuals with a diagnosis of clinical dementia<sup>236</sup> and another excluded individuals with a score on the Mini-Mental State Examination (MMSE) of <24.<sup>247</sup> No studies reported information on the proportion of participants with any cognitive impairment or diagnosis at baseline. Given that, and the largely normal baseline cognitive test performance in the studies that reported results of

baseline cognitive testing, participants in all eligible lipid lowering medication versus control trials were presumed to have normal cognition. A summary of conclusions is provided in Table 4I.1 and individual study results are in Table 4I.2.

**Table 4I.1. Conclusions: Lipid lowering interventions in adults with normal cognition**

Comparison	Outcome	Conclusion	Strength of Evidence (justification)
Statins vs. placebo k=4	Dementia	Unable to draw conclusion.	Insufficient (medium study limitations, unknown precision, unknown consistency, suspected reporting bias)
	MCI	No data available.	Insufficient (no data)
	Brief cognitive test performance	Unable to draw conclusion.	Insufficient (medium study limitations, unknown precision, unknown consistency, suspected reporting bias)
	Multidomain neuropsychological performance	No data available.	Insufficient (no data)
	Executive/Attention/Processing speed	Statistically significant improvement in 2 of 3 executive/attention/process speed outcomes for placebo versus statins (n=948; 6 months).	Low (medium study limitations, imprecise, inconsistent)
	Memory	Unable to draw conclusion.	Insufficient (medium study limitations, imprecise, inconsistent, suspected reporting bias)
Statin plus fenofibrate vs. statin plus placebo k=1	Dementia	No data available.	Insufficient (no data)
	MCI	No data available.	Insufficient (no data)
	Brief cognitive test performance	No statistically significant difference in brief cognitive test performance with statins plus fenofibrate versus statins plus placebo (n=1,538; 40 months)	Low (low study limitations, unknown consistency, suspected reporting bias)
	Multidomain neuropsychological performance	No data available.	Insufficient (no data)
	Executive/Attention/Processing speed	No statistically significant difference in executive/attention/processing speed with statins plus fenofibrate versus statins plus placebo (n=1,538; 40 months).	Low (low study limitations, suspected reporting bias)
	Memory	No statistically significant difference in memory with statins plus fenofibrate versus statins plus placebo (n=1,538; 40 months).	Low (low study limitations, unknown consistency, suspected reporting bias)

k=number of studies included; MCI=mild cognitive impairment; n=sample size; vs.=versus

## Statin Versus Placebo

Four low to medium risk of bias RCTs randomized participants to statin versus placebo and reported cognitive outcomes (n=21,484).<sup>243-245, 247</sup> One large study randomized 20,536 participants to simvastatin (40 mg/day) versus placebo and followed them for 5 years. One trial randomized 209 participants to lovastatin (20 mg/day) versus placebo,<sup>244</sup> and another randomized 308

participants to simvastatin (10 or 40 mg/day) versus placebo and followed them for 6 months. A fourth study randomized 431 participants to lovastatin (20 or 40 mg/day) versus placebo, respectively, and followed them for 6 months.<sup>247</sup> Three studies assessed baseline cognition and found at least normal functioning.<sup>244, 245, 247</sup> One study reported no information about baseline cognitive function.<sup>243</sup> Mean baseline age ranged between 46 and 71 years in three studies reporting, while age range was 40-80 years in a fourth study.

Only one study, which was not originally designed to evaluate cognitive outcomes, reported data on incident MCI or CATD. It reported no difference in the risk of incident dementia during 5 years of followup between participants assigned to statin versus placebo.<sup>243</sup> The same study found no difference between treatment groups in brief cognitive screening test performance at 5 years. However, the strength of evidence was insufficient.

One trial, which compared 40 mg/day lovastatin, 20 mg/day lovastatin, and placebo groups, found no between-treatment difference in change from baseline in one test of executive/attention/processing speed.<sup>247</sup> Two other trials by the same investigators reported between-group differences favoring the placebo group for executive/attention/processing speed, but not for memory. Participants assigned to the placebo group experienced small improvements in performance across all tested cognitive domains at 6 months versus baseline that was thought to be attributable to practice effects, while participants in the statin group had similar improvements from baseline only in memory, but no change from baseline in other cognitive domains. Low-strength evidence from these three studies suggested that statins are associated with less improvement at 6 months than placebo in the domains of executive/attention/processing speed (effect sizes for between-treatment differences <0.2).<sup>244, 245</sup> Evidence was insufficient for no difference between treatment groups in memory at 6 months.

None of these studies reported biomarker results.

One trial reported that between treatment effects on cognitive outcomes did not differ by age category (data not shown),<sup>247</sup> and another reported that within the statin group a decline in cognition was only observed in those whose final low density lipoprotein (LDL) was below the study median,<sup>244</sup> while the other two trials reported no subgroup results.

One study reported no difference between treatment groups in either the number of participants hospitalized (no data provided) or in the percentage of participants who discontinued treatment due to adverse events.<sup>243</sup> Another reported more abdominal complaints in the two lovastatin groups compared to placebo, but no between-group differences in the proportion of participants with other adverse events.<sup>247</sup> None of the other eligible studies reported adverse events data.

## **Statin Plus Ezetimibe Versus Placebo**

One RCT randomized 34 participants to atorvastatin 40 mg/day plus ezetimibe 10mg/day versus placebo and followed them for one year.<sup>248</sup> Participants were excluded for a history of stroke or other severe neurologic condition. Mean baseline MMSE was 27.4 and mean NART IQ was 101.

No data on MCI or CATD outcomes were reported. All between-group differences in executive/attention/processing speed and memory were small and unlikely to be clinically meaningful. Compared with the placebo group, participants randomized to atorvastatin plus ezetimibe had statistically significantly less decline in left amygdala volume, but not in decline in right amygdala volume, in decline in right or left hippocampal volume, or in change in white matter lesion volume.<sup>248</sup> The study did not report any subgroup analyses for cognitive outcomes. This study reported no data on adverse events outcomes.



## **Statin Plus Fenofibrate Versus Statin Plus Placebo**

One study met eligibility criteria with low risk of bias and randomized a subset of participants in the ACCORD trial (n = 10,251 with diabetes and high risk for cardiovascular events).<sup>236</sup> Individuals were excluded from participation if they had preexisting clinical evidence of dementia. Other than reporting a median baseline MMSE of 28, baseline cognitive status was not further defined.

This study reported no data on MCI or CATD outcomes. The study provided low-strength evidence that treatment with statin plus fenofibrate is similar to treatment with statin plus placebo for brief cognitive test performance (MMSE), two measures of executive/attention/processing speed, and memory at 40-month followup. There were no consistent between-treatment differences in change in cognitive performance from baseline as a function of baseline age, gender, executive/attention/processing speed, history of cardiovascular disease, or diabetes duration. The study reported no data on adverse events.

## **Statin Versus Alpha Tocopherol**

One trial met eligibility criteria with medium risk of bias and randomized 41 older adults with high LDL levels to pravastatin 20 mg/day versus tocopherol 400 IU/day for 6 months.<sup>193</sup> The study used no cognitive-related eligibility criteria.

The study reported no data on MCI or CATD outcomes. Although no significant change was observed in executive function within either treatment group between baseline and 6 months, results of direct between-group comparisons were not reported. The study reported no data on biomarkers relevant to cognitive function, and no subgroup analyses for cognitive outcomes. The study reported that there was no between-treatment group difference in any of an extensive list of physical adverse events (e.g., rash, diarrhea, dizziness).

**Table 4I.2. Results overview: Lipid lowering interventions in adults with normal cognition**

Author Year Comparison N= Followup	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
<b>Statin vs. Placebo Results Summary k=4; n=21,484</b>	<b>0 of 1 (no difference) k=1</b>	<b>NR</b>	<b>BCT 0 of 2 (no difference) k=1</b>	<b>0 of 4 favored I 3 of 4 favored C k=2</b>	<b>0 of 4 favored I 1 of 4 favored C k=2</b>	<b>0 of 10 favored I 4 of 10 favored C</b>	<b>0 of 3 (no difference) k=3</b>
<b>Muldoon, 2004<sup>245</sup></b> Simvastatin 10 mg daily or Simvastatin 40 mg daily vs. placebo n=308 6 months				C>I [Composite Executive/Attention/ Processing Speed 1] <sup>a</sup>	C>I [Memory Composite 1]	0 of 3 favored I 2 of 3 favored C	1 person with drew in active therapy due to stroke
					NS [Memory Composite 2]		
<b>Heart Protection Study, 2002<sup>243</sup></b> Simvastatin 40 mg daily vs. matching placebo n=20,536 5 years	NS [Reported number who developed dementia]		<b>BCT NS [TICS]</b>			0 of 2 (no difference)	NS [Hospitalizations]
			<b>BCT NS [TICS &lt;22]</b>				
<b>Muldoon, 2000<sup>244</sup></b> Lovastatin 20 mg daily vs. matching- placebo n=209 6 months				C>I [Composite Measure of Attention] <sup>b</sup>	NS [Working Memory Composite]	0 of 4 favored I 2 of 4 favored C	NR
				C>I [Composite Measure Psychomotor Speed]	NS [Memory Recall Composite]		

Author Year Comparison N= Followup	Diagnosis	Biomarkers [specific biomarker]	Brief cognitive test performance/ Multidomain neuropsycholog ical test performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
<b>Santanello, 1997</b> <sup>247</sup> lovastatin 20mg daily vs. lovastatin 40mg daily vs. placebo n=431 6 months				NS [DSST]		0 of 1 (no difference)	NS [number of events reported]
<b>Statin Plus Ezetimibe Versus Placebo Results Summary k=1; n=34</b>		1 of 5 favor I k=1	BCT 0 of 1 (no difference) k=1	1 of 1 favor I k=1	1 of 2 favor I k=1	3 of 9 favor I	
<b>Tendolkar, 2012</b> <sup>248</sup> Atorvastatin 20mg for 2 weeks then increased to 40mg, after 4 weeks ezetimibe 10mg was added. Standard anticoagulant therapy vs. matching-placebo and standard anticoagulant therapy n=34 1 year		I>C [Left Amygdala Volume]	BCT [MMSE] <sup>c</sup>	I>C [DSST]	NS [Dutch Version RAVLT Immediate Word Recall]	3 of 9 favor I	NR
		NS [Right Amygdala Volume]			I>C [Dutch version RAVLT Delayed Word Recall]		
		NS [Left Hippocampal Volume]					
		NS [Right Hippocampal Volume]					
		NS [White Matter Lesion Volume]					

Author Year Comparison N=	Diagnosis	Biomarkers [specific biomarker]	Brief cognitive test performance/ Multidomain neuropsycholog ical test performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
<b>Statin plus Fenofibrate versus Statin plus Placebo Results Summary k=1; n=1,538</b>			<b>BCT 0 of 1 (no difference) k=1</b>	<b>0 of 2 (no difference) k=1</b>	<b>0 of 1 (no difference) k=1</b>	<b>0 of 4 (no difference)</b>	
<b>Willamson, 2014</b> <sup>236</sup> (ACCORD-MIND Lipid trial) Statin plus Fenofibrate vs. statin n=1538 40 months			<b>BCT NS [MMSE]</b>	NS [SCWT]	NS [RAVLT]	0 of 4 favored I	NR
				NS [DSST]			
<b>Comparative Effectiveness k=2; n=230</b>							
<b>Muldoon, 2004</b> <sup>245d</sup> Simvastatin 10mg daily vs. Simvastatin 40mg daily n=189 6 months							1 person with drew in active therapy due to stroke
<b>Carlsson, 2002</b> <sup>193</sup> Pravastatin 20mg daily vs. tocopherol 440 IU daily n=41 6 month followup				NS [DSST]		0 of 1 (no difference)	NS [Physical adverse events and hospitalizations]

<sup>a</sup>Muldoon 2004<sup>245</sup> evaluated composite measures. If the composite measure was significant then individual measures within the composite were tested. The test of the composite measures within the composite executive/attention/processing speed 1: NS [Digit Vigilance], C>I [Recurrent Words], C>I [Elithorn Mazes]. The test of the composite measures within memory composite: NS [Mirror Tracking], C>I [4-Word Memory]

<sup>b</sup>Muldoon 2000<sup>244</sup> evaluated composite measures. If the composite measure was significant then individual measures within the composite were tested. The test of the composite measures within the attention composite: C>I [Digit Vigilance], C>I [Recurrent Words], C>I [Elithorn Maze]

<sup>c</sup>Tendolkar 2012<sup>248</sup> did not report between-group difference at followup.

<sup>d</sup>Muldoon 2004<sup>245</sup> compared simvastatin 10 mg versus simvastatin 40 mg. Not enough information was reported in the text to extract data. The authors comment on the comparison: “when the two active treatment groups (10 mg and 40 mg) were compared to test for the presence of a dose response relation, we found that the 40 mg dose of simvastatin did not have greater effects on cognitive performance than the 10 mg dose (P >0.15)”

BCT=brief cognitive test performance; C=control; DSST=Digit Symbol Substitution Test; I=intervention; k=number of studies included; mg=milligrams; MMSE=Mini-Mental State Examination; n=sample size; NR=not reported; NS=no statistically significant difference; RAVLT=Rey Auditory Verbal Learning Test; SCWT=Stroop Color Word Test; TICS=Telephone Interview for Cognitive Status; vs.=versus

Shading indicates summary rows and columns.

## **Adults With MCI**

None of the studies were restricted to participants with MCI and none reported results for individuals with MCI.

## **Interpreting the Findings**

Among included studies, statins did not show evidence of improving or maintaining cognitive function versus placebo. Further, though of uncertain clinical significance, in two 6-month studies small improvements versus baseline in nonmemory domains from presumed practice effects were only observed in the placebo and not the statin group. The only study that reported any outcomes favoring intervention compared statin plus ezetimibe versus placebo in only 34 participants, and reported additional results showing no treatment group difference in cognitive performance. Studies were limited by followup that likely was too short to observe clinically meaningful changes in cognition in the middle-aged and older and largely cognitively normal participants.

# Chapter 4J. Results: Nonsteroidal Anti-Inflammatory Drugs

## Key Messages

- No evidence was available for the effect of low-dose aspirin on mild cognitive impairment (MCI) or clinical Alzheimer’s-type dementia (CATD)\* incidence.
- Low-strength evidence shows no benefit for low-dose aspirin on brief cognitive screening tests, multidomain neuropsychological performance, or memory, even with 10 years of use.
- Low-strength evidence shows no benefit for nonsteroidal anti-inflammatory drugs (NSAIDs), including both selective and nonselective cyclooxygenase-2 (COX-2) inhibitors, to reduce CATD incidence, or to benefit multidomain neuropsychological performance or memory, with 8 years of followup after 1 to 3 years of use.

\*Note that the literature currently does not use the term CATD; we specified whenever the diagnosis of dementia was defined.

## Eligible Studies

We identified eight eligible publications reporting four unique studies of NSAIDs to prevent age-related cognitive decline, MCI, or CATD.<sup>255-261</sup> Two were assessed as high risk of bias and were not used in our analysis.<sup>260, 261</sup> We separately analyzed the efficacy of NSAID interventions for adults with normal cognition and those with MCI. Appendix O provides evidence tables, summary risk of bias assessments, and assessments of strength of evidence for key comparisons and outcomes.

## Logic of NSAIDs

Numerous epidemiological studies have shown an association between NSAID use and a reduced prevalence of dementia, specifically Alzheimer’s disease.<sup>262</sup> The brains of those with Alzheimer’s disease have abundant amyloid plaque, which is associated with an inflammatory reaction and related neurodegeneration. In vitro and animal models of Alzheimer’s disease pathology show that NSAIDs reduce plaque-related inflammation and improve function, both at a cellular and behavioral level.

## Adults With Normal Cognition

### NSAIDs Versus Placebo

Two randomized controlled trials (RCTs) in five publications with low to medium risk of bias enrolling a total of 8,905 adults compared NSAIDs to placebo in adults with normal cognition.<sup>255-259</sup> Sample sizes were 2,528 and 6,377. The results of these studies are summarized in Tables 4J.1 and 4J.2.

**Table 4J.1. Conclusions: NSAIDs in adults with normal cognition**

Comparison	Outcome	Conclusion	Strength of Evidence (justification)
Aspirin vs. placebo	Dementia	No data available.	Insufficient (no data)
	MCI	No data available.	Insufficient (no data)

Comparison	Outcome	Conclusion	Strength of Evidence (justification)
k=1	Brief cognitive test performance	No benefit in brief cognitive test performance with aspirin versus placebo long term (n=6,377; 10 years).	Low (medium study limitations, indirect, unknown consistency)
	Multidomain neuropsychological performance	No benefit in multidomain neuropsychological performance with aspirin versus placebo long term (n=6,377; 10 years).	Low (medium study limitations, indirect, unknown consistency)
	Executive/Attention/Processing speed	No data available.	Insufficient (no data)
	Memory	No benefit in memory with aspirin versus placebo long term (n=6,377; 10 years).	Low (medium study limitations, indirect, unknown consistency)
Non-aspirin NSAIDs vs. placebo k=1	Dementia	No significant difference in dementia diagnosis with celecoxib/naproxen versus placebo (n=2,117; 8 years).	Low (medium study limitations, direct, unknown consistency)
	MCI	No data available.	Insufficient (no data)
	Brief cognitive test performance	No benefit in brief cognitive test performance with celecoxib/naproxen versus placebo long term (n=2,117; 8 years).	Low (medium study limitations, indirect, unknown consistency)
	Multidomain neuropsychological performance	No benefit with celecoxib/naproxen versus placebo in multidomain neuropsychological performance long term (n=2,117; 8 years).	Low (medium study limitations, indirect, unknown consistency)
	Executive/Attention/Processing speed	No benefit in executive/attention/processing speed with celecoxib/naproxen versus placebo in long term (n=2,117; 8 years).	Low (medium study limitations, indirect, imprecise)
	Memory	No benefit in memory with celecoxib/naproxen versus placebo in long term (n=2,117; 8 years).	Low (medium study limitations, indirect, imprecise)

k=number of studies included; MCI=mild cognitive impairment; n=sample size; vs.=versus

One trial (n=6,377) compared aspirin (100 mg every other day) to placebo.<sup>259</sup> Subjects were drawn from a pool of 39,876 participants in the Women's Health Study, which enrolled healthy women age 45 and over from 1992 to 1995. No cognitive assessment was performed at baseline. Participants were eligible for the cognitive substudy if they were aged 65 or more and completed an initial cognitive assessment by telephone an average of 5.6 years after randomization. The primary outcome was a global score averaging performance across a battery of cognitive tests in two followup assessment up to a mean of 4 years after the initial cognitive assessment (9.6 years after randomization). The key secondary outcome was a score averaging four measures of verbal memory. The sample provided at least 80 percent power to detect a modest relative risk of 0.76 in aspirin compared with placebo. The trial compared treatment groups in both mean cognitive scores at followup and in change from baseline for brief cognitive test performance, multidomain neuropsychological performance, and memory. The aspirin group performed significantly better in only one of four cognitive tests at only one of two followups, and no better than placebo in change from baseline for any cognitive performance test at the final followup.

The ADAPT trial (n=2,528) was specifically designed to test the hypothesis that NSAIDs, either selective (celecoxib) or nonselective (naproxen) cyclooxygenase-2 inhibitors, would work for the primary prevention of CATD.<sup>255-258</sup> The trial had three arms comparing celecoxib (200 mg twice daily) or naproxen (220mg twice daily) with placebo. Subjects were men and women aged 70 or older with a family history (at least one first-degree relative) of CATD.

The ADAPT trial reported CATD diagnosis at 8-year followup, and brief cognitive test performance, multidomain neuropsychological performance, executive/attention/ processing speed, and memory at 4-year followup. No benefit with either type of NSAID was found for any outcome.



## **Adults With MCI**

The only eligible study had a high risk of bias.<sup>260</sup>

## **Interpreting the Findings**

Despite the compelling epidemiological data and strong pathophysiological rationale, there is no evidence for whether NSAIDs prevent MCI or CATD, and limited available evidence shows no benefit of NSAIDs versus placebo for improving or slowing decline of cognitive performance in adults with normal cognition.

**Table 4J.2. Results overview: NSAIDs versus inactive comparisons in adults with normal cognition**

Author Year Comparison N= Followup	Diagnosis	Brief Cognitive Test Performance/ Multidomain Neuropsychological Test Performance [instrument]	Executive/ Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
<b>Aspirin Results Summary k=1; n=6,377</b>		<b>BCT 0 of 1 (no difference)</b>  <b>MNP 0 of 1 (no difference)</b>		<b>0 of 1 (no difference)</b>	<b>0 of 3 (no difference)</b>	
<b>Kang, 2007<sup>259</sup></b> Aspirin vs. placebo n=6,377 10 years		<b>BCT</b> NS [TICS]  <b>MNP</b> NS [Composite <sup>1</sup> ]		NS [Composite <sup>2</sup> ]	0 of 3 (no difference)	NR
<b>NSAIDs Results Summary k=1; n=2,117</b>	<b>0 of 2 (no difference)</b>	<b>BCT 0 of 2 (no difference)</b>  <b>MNP 0 of 2 (no difference)</b>	<b>0 of 4 (no difference)</b>	<b>0 of 6 (no difference)</b>	<b>0 of 14 (no difference)</b>	
<b>ADAPT<sup>255-258</sup></b> Celecoxib or naproxen vs. placebo n=2,117 8 years (diagnosis) 4 years (brief cognitive test performance, multidomain neuropsychological performance, executive/ attention/processing speed, memory)	Celecoxib: NS Naproxen: NS [CATD]	<b>BCT</b> Celecoxib: NS Naproxen: NS [3MS]  <b>MNP</b> Celecoxib: NS Naproxen: NS [Composite <sup>3</sup> ]	Celecoxib: NS Naproxen: NS [DS Forward]  Celecoxib: NS Naproxen: NS [DS Backward]	Celecoxib: NS Naproxen: NS [HVL]  Celecoxib: NS Naproxen: NS [RBMT]  Celecoxib: NS Naproxen: NS [BVMT]	0 of 14 (no difference)	Study discontinued due to increased cardiovascular risk from celecoxib

<sup>a</sup>TICS, category fluency, 10 words list (immediate and delayed recall), <sup>b</sup>EBMT; 10 words list (immediate and delayed recall), EBMT; <sup>c</sup>HVL, informant-rated Dementia Severity Rating Scale, DS, Naming supermarkets, RBMT  
3MS=Modified Mini-Mental State Examination; BCT=brief cognitive test performance; BVMT=Brief Visuospatial Memory Test; C=inactive control; CATD=Clinical Alzheimer's Type Disease; DS=Digit Span (Forward and/or Backward); EBMT=East Boston Memory Test; HVL=Hopkins Verbal Learning Test; k=number of studies included; I=intervention; MNP=multidomain neuropsychological test performance; n=sample size; NS=no statistically significant difference; NSAIDs=Nonsteroidal anti-inflammatory drugs; NR=not reported; RBMT=Rivermead Behavioral Memory Test; TICS=Telephone Interview for Cognitive Status; vs.=versus  
Shading indicates summary rows and columns.

# Chapter 4K. Results: Antidementia Drugs

## Key Messages

- Low-strength evidence shows acetylcholinesterase inhibitor (AChEI) antidementia drugs did not reduce the incidence of clinical Alzheimer's-type dementia (CATD)\* in persons with mild cognitive impairment (MCI); evidence is insufficient for persons with normal cognition.
- Low-strength evidence shows AChEIs provide no significant effect on cognitive performance in adults with MCI.

\*Note that the literature currently does not use the term CATD; we specified whenever the diagnosis of dementia was defined.

## Eligible Studies

We identified 13 eligible publications involving 10 unique studies of antidementia drugs to prevent age-related cognitive decline, MCI, or CATD.<sup>203, 213, 263-272</sup> All but two studies (and an additional outcome from a third study) were assessed as high risk of bias and not used in our analysis.<sup>264-268, 270, 272, 273</sup> All interventions used in the studies included in the analysis were AChEIs. We analyzed the efficacy of these drugs for adults with normal cognition and those with MCI separately. Appendix P provides evidence tables, summary risk of bias assessments, and assessments of strength of evidence for key comparisons and outcomes.

## Logic of Antidementia Drugs

The AChEIs (donepezil, galantamine, and rivastigmine) have consistently demonstrated a modest but positive benefit to cognition in persons with CATD from mild through severe stages. They may likewise provide benefit to persons with age-related cognitive decline or MCI through the same mechanisms of action by increasing the duration of action of acetylcholine in the synapse through inhibition of its breakdown by acetylcholinesterase. The drugs have been approved by the Federal Drug Administration for people with mild to moderate Alzheimer's disease but not for people with age-related cognitive decline or MCI.

## Adults With Normal Cognition

We identified one study evaluating the use of antidementia medications versus placebo. The individual study results are presented in Table 4K.1. In this small (n=28) RCT of middle-aged menopausal women with subjective complaints of cognitive loss, donepezil had no effect on a variety of objective cognitive outcomes at 26 weeks.<sup>263</sup> The study showed no cognitive benefits in people with normal cognition compared with placebo. No conclusion table is provided given evidence was insufficient due to limited data (single study with n<500).

**Table 4K.1. Results overview: Antidementia medication in adults with normal cognition**

Author Year Comparison N= Followup	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
<b>Donepezil Results Summary k=1; n=28</b>	NR	NR	NR	0 of 2 (no difference) k=1	0 of 2 (no difference) k=1	0 of 4 (no difference)	NR
Devi, 2007 <sup>26,3</sup> Donepezil 5mg/d (6 weeks), then 10mg/d vs. placebo n=28 26 weeks				NS [COWAT]	NS [WMS-III, Logical Memory]	0 of 4 (no difference)	NR
				NS [WMS-III, Working Memory]	NS [Buschke, List Learning]		

COWAT: Controlled Word Association Test; k=number of studies included; mg/d=milligrams per day; n=sample size; NR=not reported; NS=no statistically significant difference; vs.=versus; WMS=Wechsler Memory Scale.

Shading indicates summary rows and columns.

## Adults With MCI

We identified 11 eligible publications reporting eight unique studies of antedementia drug interventions versus placebo to prevent cognitive decline in adults with MCI.<sup>203, 213, 264, 265, 267-273</sup> All but one study were assessed as high risk of bias and not used in our analysis.<sup>264, 265, 267-270, 272, 273</sup> Appendix P provides evidence tables, summary risk of bias assessments, and assessments of strength of evidence for key comparisons and outcomes. Conclusions are summarized in Table 4K.2 and individual study results in Table 4K.3.

**Table 4K.2. Conclusions: Antedementia medications in adults with MCI**

Comparison	Outcome	Conclusion	Strength of Evidence (justification)
AChEI (donepezil) vs. placebo k=1	Dementia	No statistically significant difference in dementia diagnoses with donepezil versus placebo (n=769; 3 years), although improvement was noted at 18 and 24 months.	Low (medium study limitation, imprecise, unknown consistency)
	MCI	No data available.	Insufficient (no data)
	Brief cognitive test performance	No statistically significant difference in brief cognitive test performance with donepezil versus placebo (n=769; 3 years).	Low (medium study limitation, imprecise, unknown consistency)
	Multidomain neuropsychological performance	No statistically significant difference in multidomain neuropsychological performance with donepezil versus placebo (n=769; 3 years).	Low (medium study limitation, imprecise, unknown consistency)
	Executive/Attention/Processing speed	No statistically significant difference in executive function/ attention/processing speed with donepezil versus placebo (n=769; 3 years).	Low (medium study limitation, imprecise, unknown consistency)
	Memory	No statistically significant difference in memory with donepezil versus placebo (n=769; 3 years).	Low (medium study limitation, imprecise, unknown consistency)

AChEI=acetylcholinesterase inhibitor; k=number of studies included; MCI=mild cognitive impairment; n=sample size

One randomized controlled trial (RCT) (n=769) with medium risk of bias compared donepezil to placebo in adults with MCI.<sup>203</sup> Petersen et al. found low-strength evidence that donepezil reduced the likelihood of progression to dementia at 1 year but not at 3 years.<sup>203</sup>

Petersen et al. also assessed cognition with a brief test of cognitive performance (Mini-Mental State Examination, MMSE), two tests of multidomain neuropsychological performance, one test of executive function/attention/ processing speed, and a memory composite.<sup>203</sup> Donepezil performed better than placebo on the MMSE for the first 2 years and on two cognitive test composites (one related to executive/attention/processing speed and the other related to memory) until 18 months, after which there were no differences between groups. No other differences between groups were observed. ApoE4 carriers on donepezil had a reduced likelihood of progression to dementia throughout the 3-year study.

## Interpreting the Findings

The single study with low to medium risk of bias that examined diagnostic outcomes suggests at most a modest benefit of an AChEI (donepezil) in delaying progression from MCI to CATD over 18 months to 2 years, but no benefit of AChEI versus placebo is seen at 3 years, which was the primary outcome. There are even fewer data available to assess the effects of AChEIs in persons with normal cognition; the strength of evidence was insufficient to conclude whether these drugs offer any benefits in this population.

Several large RCTs with high risk of bias were not used in this analysis, but came to the same conclusion: there was no significant benefit of anticholinesterase drugs on the progression of MCI to CATD, biomarkers, or on overall cognitive function. After the earlier, 3-year trial of donepezil (which showed no effects after 3 years) had shown a positive effect at 1 year,<sup>203</sup> donepezil was studied again in a 1-year RCT.<sup>264</sup> Instead of conversion to CATD, the primary outcomes were the modified ADAS-Cog and CDR-sum of the boxes (CDR-SB). This dual primary efficacy endpoint was not reached, though a small but significant decrease (improvement) in the modified Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) was seen. A 2-year RCT employing galantamine to prevent dementia<sup>272, 273</sup> concluded that galantamine failed to significantly influence conversion to dementia. Similarly, a 2-year RCT examining the use of rivastigmine in people with MCI found no significant benefit on rate of progression to Alzheimer's disease or on cognitive function over 4 years.<sup>265</sup>

Several high risk of bias studies examined biomarkers in people with MCI. A 2-year study of galantamine (n=364) found lower rates of brain atrophy in those taking galantamine, but no difference between galantamine and placebo groups in rate of hippocampal atrophy.<sup>273,272</sup> Similarly, data collected as part of the 1-year trial of donepezil in MCI revealed no significant difference in the primary outcome of annualized percentage change (APC) in hippocampal volumes<sup>264</sup> but a significant differences favoring drug (less volume loss) in the secondary outcome of APC in whole brain volumes.<sup>271</sup> While hippocampal volume loss/atrophy is associated with MCI and progression to CATD, and whole brain atrophy is seen in Alzheimer's disease, particularly in the later stages, the significance of these whole brain changes is not obvious, particularly given the negative clinical results of both trials. A number of reviews have looked at the effects of AChEIs on the progression from MCI to CADT. They used more studies than qualified for this review. Some have suggested modest initial benefit that was not sustained<sup>274-276</sup>. They also noted higher rates of adverse events.<sup>275, 276</sup>

**Table 4K.3. Results Overview: Antidementia medications in adults with MCI**

Author Year Comparison N= Follow-up	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsychological Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
<b>Donepezil Results Summary k=1; n=769</b>	<b>0 of 1 (no difference) k=1</b>	<b>0 of 4 (no difference) k=1</b>	<b>BCT 0 of 1 (no difference at 3 years) k=1  MNP 0 of 2 (no difference at 3 years) k=1</b>	<b>0 of 1 (no difference) k=1</b>	<b>0 of 1 (no difference) k=1</b>	<b>0 of 9 (no difference at 3 years)</b>	
<b>Petersen, 2005<sup>203</sup> Jack, 2008<sup>213</sup></b> Donepezil 5mg/d (6 weeks), then 10mg/d vs. placebo n=769 3 years (MRI outcomes = High ROB) <sup>213</sup>	I>C at 6 & 12 mo, then NS [Clinical Criteria]		<b>BCT</b> I>C until 2 years, then NS [MMSE]	NS [Composite]	I>C at 6 and 18 mo, then NS [Composite]	0 of 5 (no difference at 3 years)	NS [Mortality]
			<b>MNP</b> NS [ADAS-Cog-Original]				
			<b>MNP</b> I>C until 18 mo, then NS [ADAS-Cog Modified]				

ADAS-Cog=Alzheimer’s Disease Assessment Scale-Cognitive Subscale; BCT=brief cognitive test performance; C=control; I=intervention; k=number of studies included; mg/d=milligrams per day; MMSE=Mini-Mental State Examination; MNP=multidomain neuropsychological test performance; mo=month; MRI=magnetic resonance imaging; n=sample size; NS=no statistically significant difference; vs.=versus.

Shading indicates summary rows and columns.

# Chapter 4L. Results: Diabetes Medication Treatment

## Key Messages

- No studies reported on the effect of diabetes treatment on the risk of incident clinical diagnoses of mild cognitive impairment (MCI) or clinical Alzheimer's-type dementia (CATD)\*
- In middle-aged older adults with diabetes and presumed normal cognition, low-strength evidence shows intensive versus standard glycemic control had no significant effect on cognitive performance.

\*Note that the literature currently does not use the term CATD; we specified whenever the diagnosis of dementia was defined.

## Eligible Studies

We identified eight eligible studies that compared diabetes medication treatment versus control treatment to prevent age-related cognitive decline, MCI, or CATD.<sup>67, 120, 277-282</sup> We rated three of these studies as having high risk of bias and excluded them from our analyses.<sup>278, 279, 281</sup> The remaining five studies (four unique trials) enrolled a total of 15,672 adults.<sup>67, 120, 280, 282</sup> Appendix Q provides evidence tables, summary risk of bias assessments, and assessments of strength of evidence for key comparisons and outcomes.

## Logic of Diabetes Medication Treatment

A recent meta-analysis of prospective cohort studies estimated that the presence of a diabetes diagnosis between the ages of 20 to 79 years increased the risk of incident CATD by nearly 50 percent.<sup>283</sup> Diabetes may increase risk of Alzheimer's disease through vascular mechanisms, direct effects of elevated blood glucose, insulin resistance associated inflammation, and/or a pathway in which peripheral hyperinsulinemia inhibits brain insulin production, which then results in impaired brain amyloid clearance.<sup>242</sup>

## Adults With Normal Cognition

Two trials, the ACCORD-MIND and the ORIGIN studies, addressed persons with presumed normal cognition but only the ACCORD-MIND study specifically reported excluding participants with preexisting clinical evidence of dementia.<sup>284</sup> Both trials addressed persons at high risk for cardiovascular events; both compared intensive and standard glucose control for diabetics, and both were large substudies. The ACCORD-MIND trial enrolled 2,977 older adults.<sup>280, 282</sup> The ORIGIN study randomized 12,537 older adults.<sup>285</sup> The publication provided no information about how normal cognition was defined and did not report any cognition-related exclusion criteria. Conclusions are reported in Table 4L.1 and individual study results in Table 4L.2.



**Table 4L.1. Conclusions: Antidiabetic interventions in adults with normal cognition**

Comparison	Outcome	Conclusion	Strength of Evidence (justification)
Glycemic control vs. placebo k=2	Dementia	No statistically significant difference in dementia diagnoses with glycemic control versus placebo (n=12,537; 6 years).	Low (due to study limitation of composite outcome with component of unequal importance, one of which is not clinical diagnosis and may be achieved due to chance)
	MCI	No data available.	Insufficient (no data)
	Brief cognitive test performance	A 40-month trial and a 6-year trial found no statistically significant differences in brief cognitive test performance in glycemic control versus placebo (n=15,514; up to 6 years).	Low (medium study limitations, indirect, imprecise)
	Multidomain neuropsychological performance	No data available.	Insufficient (no data)
	Executive/Attention/Processing speed	A 40 -month trial and a six year trial found no statistically significant difference in executive function, attention, and processing speed with glycemic control versus placebo (n=15,514; up to 6 years).	Low (medium study limitations, indirect, imprecise)
Memory	A 40-month trial found no statistically significant difference in memory with glycemic control versus placebo (n=2,977; 3.3 years).	Low (medium study limitations, indirect, imprecise)	

k=number of studies included; MCI=mild cognitive impairment; n=sample size; vs.=versus

No study reported the outcomes of incident clinically diagnosed MCI or dementia. The ORIGIN trial found no difference after a mean followup of 6.2 years in the risk of probable incident cognitive impairment as defined by either a diagnosis of dementia on the study case report forms or a decline in followup Mini-Mental State Examination (MMSE).<sup>120</sup> However, the overall ORIGIN trial reported little difference in mean HbA1C at 6 years between the intensive and standard control groups.<sup>285</sup>

Low-strength evidence from both trials shows no difference in change in cognitive performance between those assigned to intensive versus standard glycemic control. In the ACCORD-MIND trial, over a 40-month followup there was no difference between the groups in the mean decline in MMSE, a global measure of cognition.<sup>280, 282</sup> Similarly, in the ORIGIN trial, over a mean followup of 6.2 years, there was no between-group difference in the mean annualized MMSE decline.<sup>120</sup> Within specific cognitive domains, these trials reported no statistically significant difference between treatment groups for change in verbal memory,<sup>280</sup> executive function,<sup>120, 282</sup> attention,<sup>280</sup> or processing speed.<sup>120, 280, 282</sup>

The ACCORD-MIND trial enrolled participants with normal cognition and measured brain MRI in a subset of participants.<sup>280</sup> Among the 503 participants with followup MRIs at 40 months, those randomized to intensive glycemic control had significantly smaller declines in total brain volume, but significantly more abnormal white matter tissue volume.

The ACCORD-MIND trial reported no difference between the intensive and standard glycemic control groups in risk of mortality.<sup>280</sup>

**Table 4L.2. Results Overview: Antidiabetic interventions in adults with normal cognition**

Author Year Comparison N= Followup	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsychological Test Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
<b>Glycemic Control Results Summary</b> k=2; n=15,514	<b>0 of 1 (no difference) k=1</b>	<b>1 of 2 favor I 1 of 2 favor C k=1</b>	<b>BCT 0 of 2 (no difference) k=2</b>	<b>0 of 3 (no difference) k=2</b>	<b>0 of 1 (no difference) k=1</b>	<b>1 of 8 favors I 1 of 8 favors C</b>	
<b>ACCORD-MIND Trial</b> <b>Sequist, 2013</b> <sup>282</sup> <b>Launer, 2011</b> <sup>280</sup> Intensive glycemic control targeting HbA1c to less than 6.0% vs. standard glycemic control targeting HbA1c to 7-7.9% n=2,977 40 months		I>C [Total Brain Volume]	<b>BCT</b> NS [MMSE]	NS [DSST]	NS [RAVLT]	1 of 6 favors I 1 of 6 favors C	NS [Mortality] <sup>a</sup>
		C>I [Abnormal White Matter]		NS [SCWT]			
<b>Cukierman-Yaffe, 2014</b> <sup>120</sup> Titrated basal insulin glargine targeting a fasting plasma glucose concentration vs. standard of care n=12,537 72 months	NS [MMSE <24, or diagnosed on report forms]		<b>BCT</b> NS [MMSE]	NS [DSST]		0 of 2 (no difference)	NR

<sup>a</sup>In February, 2008, increased mortality risk in the main ACCORD study led to the end of the intensive treatment and a transition of those participants to standard treatment.

BCT=brief cognitive test performance; C=control; DSST=Digit Symbol Substitution Test; HbA1c=hemoglobin A1c; I=intervention; MMSE=Mini-Mental Status Exam; NR=not reported; NS=no statistically significant difference; RAVLT=Rey Auditory Verbal Learning Test; SCWT=Stroop Color Word Test; vs.=versus.

Shading indicates summary rows and columns.

## Adults With MCI

Two trials evaluated the effect of glycemic control on cognition in older adults with MCI. Hildreth et al. randomized 78 older adults with MCI, central obesity (presumed to confer insulin resistance), and no diabetes to pioglitazone versus endurance exercise training or control (placebo, no exercise) for 6 months,<sup>67</sup> while Luchsinger et al. randomized 80 overweight older nondiabetic and diet controlled diabetic adults with amnesic MCI to metformin up to 1000mg twice a day versus placebo for 12 months.<sup>277</sup>

The Hildreth trial reported no information on the risk of CATD, but found no difference in intervention and control groups in change between baseline and 6 months in a single global measure of cognition, the cognitive domains of memory, language, visuospatial or executive function, or in any individual cognitive test.<sup>67</sup> The trial did not report information on biomarker outcomes or adverse events. The trial was likely too small to detect the small changes in cognitive outcomes that might realistically be expected in its MCI population over its 6-month duration, let alone differences in these outcomes between pioglitazone and control groups.

The Luchsinger trial reported that one person in the placebo group and none in the metformin group converted to dementia.<sup>277</sup> In adjusted analyses, there was no difference between groups in change from baseline in two global measures of cognition or in one measure of executive/attention/processing speed, but the metformin group had statistically significantly more improvement from baseline than the placebo group in one of two memory tests. In stratified analyses reported only for the single memory test, between group differences in the memory test were statistically significant in participants  $\leq 63.7$  but not  $> 63.7$  years old, those who were negative but not positive for APOE-4, those with hemoglobin A1c  $\leq 6.0\%$  but not those with  $> 6.0\%$ , and those with an insulin level  $> 9$  IU/dl but not those with insulin  $< 9.0$  IU/dl. There were no significant differences between treatment groups in strata defined by BMI  $<$  or  $\geq 30$  kg/m<sup>2</sup>. There were no significant differences between treatment groups for change from baseline in any of the brain MRI or PET measures reported, or in change in plasma A $\beta$ 42 levels.

Individual study results are provided in Table 4L.3. No conclusion table is provided given evidence was insufficient due to limited data (single study with  $n < 500$ ).

## Interpreting the Findings

Among included studies, there was minimal to no difference between glycemic intervention and control groups in incident cognitive impairment or change in cognitive performance in adults with normal cognition (intensive versus standard control), and minimal difference in any cognitive outcomes in adults with MCI (pharmacologic monotherapy versus placebo). Because there was no substantial change in cognitive performance tests from baseline among control group participants in the included studies, it was not possible for these studies to demonstrate whether intensive glycemic control prevents cognitive decline. However, results do not show that glycemic interventions lead to clinically meaningful improvements in cognition from baseline. Although the small difference in achieved glycemic control between treatment groups in the ORIGIN trial may have limited the ability of that study to observe a difference in cognitive outcomes, cognitive results also were not meaningfully different between treatment groups in the ACCORD-MIND trial despite the markedly improved glycemic control between their intervention and placebo groups.

**Table 4L.3. Results overview: Antidiabetic interventions in adults with MCI**

Author Year Comparison N= Followup	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsychologica I Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
<b>Pioglitazone Results Summary k=1; n=78</b>			<b>MNP 0 of 1 (no difference) k=1</b>	<b>0 of 5 (no difference) k=1</b>	<b>1 of 4 favors I k=1</b>	<b>1 of 10 favors I</b>	
<b>Hildreth, 2015<sup>67</sup></b> Pioglitazone 30mg daily for 1 month, then 45mg daily as tolerated for 5 months vs. placebo n=78 6 months			<b>MNP NS [ADAS-Cog]</b>	<b>NS [SCWT]</b>	<b>NS [RAVLT]</b>	<b>1 of 10 favors I</b>	<b>NR (there were no cases of new</b>
				<b>NS [TMT B]</b>	<b>NS [WMS, Logical Memory II]</b>		<b>or worsening heart failure in the treatment group)</b>
				<b>NS [DS Backward]</b>	<b>NS [Composite]</b>		
				<b>NS [DSST]</b>	<b>I&gt;C [Visual Reproduction]</b>		
				<b>NS [Composite]</b>			
<b>Metformin Results Summary k=1; n=80</b>		<b>0 of 4 (no difference) k=1</b>	<b>BCT 0 of 1 (no difference) k=1</b>  <b>MNP 0 of 1 (no difference) k=1</b>	<b>0 of 1 (no difference) k=1</b>	<b>1 of 3 favors I k=1</b>	<b>1 of 10 favors I</b>	
<b>Luchsinger, 2016<sup>277</sup></b> Metformin 1000mg twice daily for 12 months vs. placebo n=80 1 year		<b>NS [Posterior Cingulate- Precuneus Glucose Update]</b>	<b>BCT NS [MMSE]</b>  <b>MNP NS [ADAS-Cog]</b>	<b>NS [DS]</b>	<b>I&gt;C [Buschke Selective Reminding Test]</b>	<b>1 of 10 favors I</b>	
		<b>NS [Hippocampus Glucose Update]</b>			<b>NS [WMS-Revised, Logical Memory II]</b>		

Author Year Comparison N= Followup	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsychologica l Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
		NS [Para- Hippocampus Glucose Uptake]			NS [Paragraph Recall]		
		NS [Entorhinal Cortex Glucose Uptake]					

ADAS-Cog=Alzheimer's Disease Assessment Scale-Cognitive Subscale; BCT=brief cognitive test; C=control; DS=Digit Span (Forward and/or Backward); DSST=Digit Symbol Substitution Test; I=intervention; k=number of studies; MMSE=Mini-Mental Status Exam; MNP=multidomain neuropsychological test performance; n=sample size; NR=not reported; NS=no statistically significant difference; RAVLT=Rey Auditory Verbal Learning Test; SCWT=Stroop Color Word Test; TMT=Trail Making Test (Part A and/or B); vs.=versus; WMS=Wechsler Memory Scale.

Shading indicates summary rows and columns.

# Chapter 4M. Results: Other Interventions

## Key Messages

- Evidence was insufficient for lithium, a nicotine patch, individual piano instruction, multitask rhythmic exercise to music, sleep interventions, and social engagement.
- We found no relevant studies for depression treatments, smoking cessation, or community-level interventions.

## Eligible Studies

We identified nine eligible studies of other varied interventions to prevent age-related cognitive decline, mild cognitive impairment (MCI), or CATD.<sup>72, 79, 135, 286-291</sup> Five studies for adults with normal cognition<sup>79, 286-288, 291</sup> and one for adults with MCI<sup>72</sup> were assessed as high risk of bias and thus are discussed only briefly. Appendix R provides evidence tables and summary risk of bias assessments.

## Adults With Normal Cognition

Hars et al. (n=134) examined the effects of a weekly 1 hour supervised group class in which participants performed multitask exercises to rhythmic music versus inactive control in adults  $\geq 65$  years who were at increased risk of falling. After 6 months, no significant differences in Mini-Mental State Examination (MMSE) scores or executive function were observed.<sup>135</sup> Adverse events were not reported. Table 4M.1 summarizes results. A conclusion table is not provided since evidence was insufficient due to limited data (single study n<500).

The remaining five studies with adults with normal cognition were high risk of bias. Interventions examined in these studies included: individualized piano instruction for musically naïve older adults (n=31, 9 month followup);<sup>288</sup> personalized sleep plans to extend sleep for obese adults who sleep for shorter periods (n=121, 14 month followup);<sup>286</sup> transcranial random noise stimulation (n=25, 6 month followup);<sup>291</sup> guided progressive muscle relaxation tapes to improve sleep in older adults with reduced sleep quality (n=80, 12 months);<sup>287</sup> and group social interaction for 1 hour three times per week at a neighborhood community center for older adults (n=276, 40 weeks).<sup>79</sup>

## Adults With MCI

Table 4M.2 summarizes results for two medium risk of bias studies of adults with MCI. A conclusion table is not provided since evidence was insufficient due to limited data (single study n<500).

Forlenza et al. (n=45) examined the effects of lithium versus placebo in adults at least 60 years old with amnesic MCI as assessed by the Mayo criteria.<sup>289</sup> Dosage was titrated to a level below that used for affective disorders to avoid problems of tolerability. No difference in conversion to Alzheimer's dementia was found after 12 months. The lithium group showed improvement in amyloid-beta and phosphorylated tau but not total tau when compared to placebo. The study found no severe adverse events deemed related to the treatment.

Newhouse et al. (n=74) examined the effects of transdermal nicotine patches in non-smoking adults at least 55 years old with probable MCI.<sup>290</sup> Numerous cognitive performance tests were assessed as secondary outcomes at 6 months, however not all outcomes were reported as tests of

differences between groups, so the possibility of selective outcome reporting was high.<sup>290</sup> The study found no severe adverse events deemed related to the treatment.

One other study with high risk of bias examined cognitive group social interaction (board games, reading/discussing newspapers) at least three times per week for 1 hour in adults with MCI (n=276, 12 months).<sup>72</sup>

**Table 4M.1. Results overview: Other intervention in adults with normal cognition**

Author Year Comparison N= Followup	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsychological Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
<b>Music Intervention Results Summary k=1; n=134</b>			<b>BCT 0 of 1 (no difference) k=1</b>	<b>0 of 2 (no difference) k=1</b>		<b>0 of 3 (no difference)</b>	
<b>Hars, 2014<sup>135</sup></b> Weekly 1 hour supervised group class; multitask exercises to rhythm n=134 6 months			<b>BCT NS [MMSE]</b>	NS [CLOX-1]		0 of 3 (no difference)	NR
				NS [FAB]			

BCT=brief cognitive test; CLOX-1=Clock Drawing Test; FAB=Frontal Assessment Battery; k=number of studies included; MMSE=Mini-Mental Status Examination; n=sample size; NR=not reported; NS=no statistically significant difference.

Shading indicates summary rows and columns.



**Table 4M.2. Results overview: Other intervention in adults with MCI**

Author Year Comparison N= Followup	Diagnosis	Biomarkers [specific biomarker]	Brief Cognitive Test Performance/ Multidomain Neuropsycholo gical Performance [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
<b>Other Medications Results Summary k=2; n=108</b>	<b>0 of 1 (no difference) k=1</b>	<b>2 of 3 favor I k=1</b>	<b>NR</b>	<b>Unclear</b>	<b>NR</b>	<b>2 of 3 favor I</b>	
<b>Newhouse, 2012<sup>290</sup></b> Nicotine patch 15 mg/day vs. placebo n=67 6 months				Selective outcome reporting			NS [No severe AEs classified as related to drug treatment]
<b>Forlenza, 2011<sup>289</sup></b> Lithium titrated to serum levels 0.25- 0.5 mmol/l vs. placebo n=41 1 year	NS [Conversion to Probable AD]	I>C [Amyloid-Beta]					NS [Ischemic stroke, death due
		NS [Total Tau]					to sepsis; neither
		I>C [Phosphorylated Tau]					deemed due to treatment]

AD=Alzheimer's Disease; AEs=adverse effects; C=control; k=number of studies included; I=intervention; mg/day=milligrams per day; mmol=millimole; n=sample size; NR=not reported; NS=no statistically significant difference; vs.=versus.

Shading indicates summary rows and columns.

# Chapter 4N. Results: Agreement of Biomarkers and Measures of Cognitive Performance

## Key Messages

- Only a few (9) low or medium risk of bias studies used biomarker measures; most of those used some form of brain scan.
- The overall rate of agreement between biomarker measures and cognitive testing was 57 percent, but 90 percent of that agreement resulted from both approaches showing no effect. When the biomarker measure showed a significant result, there was agreement in 25 percent of cognitive tests conducted.

## Association Between Biomarkers and Cognitive Tests

Substantial work has gone into searching for biomarkers in living persons that indicate the level of dementia activity.<sup>292</sup> In most cases, the biomarkers are validated by comparing the measure with a systematic clinical evaluation, but in some cases the biomarker measures may predict subsequent development of cognitive decline. The distinction between biomarkers that are used as early harbingers of incipient disease vs. those that track with disease progression is important. Imaging indices are most often used as an example of the later category but not always. cerebrospinal fluid (CSF) and blood indices are commonly used as either. Biomarkers for early identification might be of interest for those interventions with people with normal cognition and less so with MCI/dementia (and NOT expected to correlate with cognition), whereas those biomarkers that are intended to track with disease progression would be the opposite – of more interest in impaired groups and more expected to agree with observable symptoms.

KQ3 compares the biomarker measure results with cognitive testing results in the studies used for KQs 1 and 2. Only a small number of studies used both biomarker measures and cognitive testing. There were 35 biomarker measures used in 9 studies. One of the studies included two treatment arms. A few studies used only biomarker measures (and were omitted from this comparison). Several other studies included biomarker measures that were assessed as high risk of bias and not included in this analysis. Few studies used the same biomarker measure. The biomarker measures used here were all based on brain scans (MRI or PET).

Table 4N.1 shows the rate of agreement between a given biomarker measure and the cognitive domains that were simultaneously tested. The overall rate of agreement was 57 percent (144/254) but the underlying result of the biomarker played a major role in agreement. Of the 23 cases where the biomarker measure was not significant, there were 197 cognitive tests of which 130 were also not significant (66 percent). Of the 12 cases where the biomarker measure was significant, there were 57 cognitive tests of which 14 agreed with the biomarker (25 percent). There was only one study in which none of the biomarker measures nor cognitive tests were significant.<sup>93, 94</sup> The ability to detect a difference somewhere in the study suggests that lack of statistically significant findings was not solely attributable to small sample sizes. Nonetheless, interpreting the implications of agreement when both approaches failed to detect a difference is challenging.

We used a simple calculation of agreement rates between each biomarker measure and the cognitive tests used in a study to distinguish differences between experimental and control participants. For example, in a study of omega-3 fatty acids,<sup>117</sup> grey matter volume was found to be decreased in those receiving the intervention compared to the controls. In one instance (a test of

executive function/attention/processing speed) the cognitive test showed a similar pattern. In two other measures of executive/attention/processing speed and a memory test, it did not. Hence the rate of agreement for a finding of biomarker difference in this case was 1/4. Similarly, when the grey matter volume showed no significant difference in one study of in adults receiving resveratrol,<sup>118</sup> cognitive performance showed a difference in 2 out of 6 tests of cognition. Hence the agreement rate was 4/6.

**Table 4N.1. Summary of agreement between biomarkers and cognitive tests**

Biomarker	Biomarkers	Diagnosis	Dementia Screens*	Executive/Attention/ Processing Speed	Memory	Agreement Rate	Intervention
MRI-grey matter volume	I>C			I>C, NS, NS	NS	1/4	Omega 3 <sup>117</sup>
	NS				I>C, I>C, NS, NS, NS, NS	4/6	Resveratrol <sup>118</sup>
MRI-white matter integrity	NS			I>C, NS, NS	NS	3/4	Omega 3 <sup>117</sup>
MRI-HC microstructure	NS				I>C, I>C, NS, NS, NS, NS	4/6	Resveratrol <sup>118</sup>
MRI-HC frontal	I>C				I>C, I>C, NS, NS, NS, NS	2/6	
MRI-HC parietal	I>C				I>C, I>C, NS, NS, NS, NS	2/6	
MRI-HC occipital	I>C				I>C, I>C, NS, NS, NS, NS	2/6	
MRI-total brain volume	NS	C>I, NS, NS	C>I	NS, NS, NS	NS, NS, NS, NS, NS	10/12	Estrogen <sup>149, 175, 177, 178, 180, 293</sup>
	NS	C>I, NS, NS	C>I	NS, NS, NS	C>I, C>I, C>I, C>I, NS	6/12	Estrogen+ progestin <sup>149, 151, 175, 177-179</sup>
	I>C		NS	NS, NS	NS	0/4	Glycemic control <sup>280, 282</sup>
MRI-ventricular volume	NS	C>I, NS, NS	C>I	NS, NS, NS	NS, NS, NS, NS, NS	10/12	Estrogen <sup>149, 175, 177, 178, 180, 293</sup>
	NS	C>I, NS, NS	C>I	NS, NS, NS	C>I, C>I, C>I, C>I, NS	6/12	Estrogen+ progestin <sup>149, 151, 175, 177-179</sup>
MRI-HC volume	NS	C>I, NS, NS	C>I	NS, NS, NS	NS, NS, NS, NS, NS	10/12	Estrogen <sup>149, 175, 177, 178, 180, 293</sup>
	NS	C>I, NS, NS	C>I	NS, NS, NS	C>I, C>I, C>I, C>I, NS	6/12	Estrogen+ progestin <sup>149, 151, 175, 177-179</sup>
MRI-whole brain cortices	NS		NS, NS		NS, NS	4/4	Multicomponent physical activity <sup>93, 94</sup>
	NS		NS, NS		NS, NS	4/4	
Left HC volume	NS		NS	I>C	I>C, NS	2/4	Statins <sup>248</sup>
Right HC	NS		NS	I>C	I>C, NS	2/4	

Biomarker	Biomarkers	Diagnosis	Dementia Screens*	Executive/Attention/ Processing Speed	Memory	Agreement Rate	Intervention
<b>volume</b>							
<b>MRI-frontal lobe volume</b>	C>I	C>I, NS, NS	C>I	NS, NS, NS	NS, NS, NS, NS, NS	2/12	Estrogen <sup>149, 175, 177, 178, 180, 293</sup>
	NS	C>I, NS, NS	C>I	NS, NS, NS	C>I, C>I, C>I, C>I, NS	6/12	Estrogen+ progestin <sup>149, 151, 175, 177-179</sup>
<b>Abnormal white matter</b>	C>I		NS	NS, NS	NS	0/4	Glycemic control <sup>280, 282</sup>
<b>White and grey matter</b>	NS	C>I, NS, NS	C>I	NS, NS, NS	NS, NS, NS, NS, NS	10/12	Estrogen <sup>149, 175, 177, 178, 180, 293</sup>
	NS	C>I, NS, NS	C>I	NS, NS, NS	C>I, C>I, C>I, C>I, NS	6/12	Estrogen+ progestin <sup>149, 151, 175, 177-179</sup>
<b>Basal ganglia</b>	NS	C>I, NS, NS	C>I	NS, NS, NS	NS, NS, NS, NS, NS	10/12	Estrogen <sup>149, 175, 177, 178, 180, 293</sup>
	NS	C>I, NS, NS	C>I	NS, NS, NS	C>I, C>I, C>I, C>I, NS	6/12	Estrogen+ progestin <sup>149, 151, 175, 177-179</sup>
<b>Total brain lesion volume</b>	NS	C>I, NS, NS	C>I	NS, NS, NS	NS, NS, NS, NS, NS	10/12	Estrogen <sup>149, 175, 177, 178, 180, 293</sup>
	NS	C>I, NS, NS	C>I	NS, NS, NS	C>I, C>I, C>I, C>I, NS	6/12	Estrogen+ progestin <sup>149, 151, 175, 177-179</sup>
<b>Posterior atrophy</b>	I>C		NS		NS	0/2	Vitamin B <sup>195, 194, 207</sup>
<b>Left amygdala volume</b>	I>C		NS	I>C	I>C, NS	2/4	Statins <sup>248</sup>
<b>Right amygdala volume</b>	NS		NS	I>C	I>C, NS	2/4	
<b>White matter lesion volume</b>	NS		NS	I>C	I>C, NS	2/4	
<b>Glucose uptake (PET scan)</b>	I>C	I>C	I>C, NS	NS, NS	I>C, NS	3/7	Cognitive training <sup>48, 49</sup>
<b>Amyloid-beta</b>	I>C	NS				0/1	Lithium <sup>289</sup>
<b>Phosphorylated tau at threonine</b>	I>C	NS				0/1	
<b>Total tau</b>	NS	NS				1/1	
<b>Overall agreement rate</b>						<b>144/254 (57%)</b>	
<b>Agreement based on</b>						<b>130/197 (66%)</b>	

<b>Biomarker</b>	<b>Biomarkers</b>	<b>Diagnosis</b>	<b>Dementia Screens*</b>	<b>Executive/Attention/ Processing Speed</b>	<b>Memory</b>	<b>Agreement Rate</b>	<b>Intervention</b>
<b>both showing no significant pattern of effect (NS)</b>							
<b>Agreement rate when the biomarker showed a significant difference</b>						<b>14/57 (25%)</b>	

\*Includes both brief tests of cognitive performance and multidomain neuropsychological performance tests  
C=control; HC=hippocampus; I=intervention; NS=no statistically significant difference

## Chapter 5. Discussion

Research on interventions to prevent or slow age-related cognitive decline, mild cognitive impairment (MCI), or clinical Alzheimer's-type dementia (CATD) has focused largely on their effect on decline in measures of cognition. The reasons for this are many, including 1) meaningful investigation of dementia-onset requires either a long followup period or a large cohort of older individuals, 2) long followups in the target population face serious attrition problems due to death or comorbidities, and 3) the risk of selective attrition whereby the intervention might also affect mortality risk and hence create attrition bias if survivors have more health problems.

Interventions to slow or prevent age-related cognitive decline, MCI, or CATD are often chosen because of evidence from epidemiological studies that examine actions of individuals at higher or lower than expected risk for these conditions. In other cases, theories of brain function (e.g., neuroplasticity) justify the development and testing of experimental interventions. Not all such interventions would be expected to be found to be effective in controlled experiments. This systematic review cast a wide net and only a few interventions showed any evidence of an effect, all of which raise many questions. Most of the studies showed no benefit to those receiving interventions compared to control groups. Four intervention classes show some positive results and seem the most promising for further study: cognitive training, physical activity, the selective estrogen receptor modulator (SERM) raloxifene, and B<sub>12</sub> plus folic acid, although the evidence for raloxifene and B<sub>12</sub> plus folic acid is lower than the others. The problems with study designs make strong conclusions difficult. Assessing the strength of evidence for negative findings is a special challenge. There is a persistent concern about Type II errors.

The studies used a wide variety of instruments to assess cognitive performance. To facilitate analysis and interpretation, we categorized tests and measures into four groups (brief cognitive test performance, multidomain neuropsychological performance, executive function/attention/processing speed, and memory); some tests fit into more than one of these four groups.

### Dementia Incidence








Cognitive decline is almost always a precursor of dementia. Impairment below a designated threshold helps to define CATD and/or MCI. But not all individuals with cognitive decline develop CATD, and we do not know whether interventions that show effects on selected areas of cognitive performance can also stave off dementing conditions. Presumably, the broader the effect an intervention has on multiple cognitive domains, the more likely it will also have preventive effects. But improving (or slowing the decline of) performance in one given cognitive domain does not automatically imply protection against dementia. For example, some cognitive training does seem to improve performance in the specific area of the training, but the results do not generalize to improved performance in other cognitive domains. The strongest effect of cognitive training found in this analysis was in enhancing processing speed, but extrapolating that benefit to a reduced risk of CATD is not yet established. For example, improving a person's useful field of vision can help with driving a car, and it might facilitate some instrumental activities of daily living (IADLs), but neither of those benefits necessarily slows the onset of CATD.

Unfortunately for our review, the largest and longest study of prevention of cognitive decline, the ACTIVE trial, was designed to enhance and monitor changes in specific areas of cognitive performance, but not the incidence of CATD. Efforts to adapt the ACTIVE trial to this important outcome were challenging; there was substantial attrition and the CATD diagnosis measures were weak. The measures related to diagnosis of CATD were developed late in the study and relied on

either simple clinical measures or reports from family about cognitive problems or institutionalization. The analyses used did not overcome these problems.

Other interventions do show some benefit in slowing dementia, although the results are mixed at best. What explains the variation in results? To help explore possible answers to this question, and later issues regarding the results for cognitive performance, we provide some summary figures that are intended to provide a bird's-eye view of the results detailed in the previous chapters. The figures do *not* provide detailed information on the specifics of the findings or the assessed strength of evidence. Instead, they show patterns of nonsignificant findings and significant findings that benefit either the intervention or the control groups. Table 5.1 provides a key to interpret the sample size from the symbol size. Different symbols are used to represent different outcomes in the figures. Circles show significant effects favoring interventions. Diamonds and X's show non-significant results for dementia only or composite of dementia or MCI respectively. Squares show incidences when the intervention favors the controls. One symbol is assigned for every reported outcome; if a single study reported multiple outcome measures or tests for a give outcome, multiple symbols will be assigned. For example, if three different tests for memory were used by a single study, three symbols will be assigned to the memory category.

**Table 5.1. Symbol sizes and related sample size information**

Symbol Sizes Used	Sample Sizes Represented
	N<100
	N=100-500
	N=501-1,000
	N=1,001-5,000
	N=5,001-10,000
	N=10,001-15,000
	N=15,000+


N=sample size

Figure 5.1 summarizes the findings on the range of interventions aimed at reducing the incidence of dementia or MCI. The preponderance of studies showed no effect. In the case of estrogen therapy, the control groups did better than the experimental groups for dementia or



composite dementia or MCI, suggesting a de facto harm. This is in contrast to the improvement in MCI alone for SERM (not shown in Figure 5.1).

**Figure 5.1. Summary: Dementia or MCI incidence by intervention type**



\*Categorized by whether results showed statistically significant differences between groups. Each symbol represents a different test measured for each outcome domain. As described in Table 5.1, size of symbol indicates the relative sample size for test. More than one test per domain was frequently used in any given trial. Results for CATD or MCI (per title) are shown; results for less clear categories of dementia are not shown.

\*\* Results for the 3 year outcome.

I=intervention; C=control; k=number of studies; n=sample size; NSAIDs=nonsteroidal anti-inflammatory drugs

Maintaining a long followup cohort is difficult, but important in any future research examining potential interventions that could slow or prevent dementia. In addition to long followup periods, studying the incidence of dementia requires that attrition be minimized. Attrition bias presents challenges similar to those associated with selection bias. However, with attrition, investigators have more information about the dropouts, and those data could permit better modeling to assess its potential impact. Subjects who drop out because of functional reasons should be evaluated for cognitive status. Death will play a censoring role, but analyses can explore its role in attrition bias because a larger pool of variables is available for modeling. The rate of dementia incidence will increase with age. Starting with an older cohort will facilitate accumulating cases with less

attrition, but it will make it more difficult to ascertain the relationship between the intervention and subject age.

## **Cognitive Performance**

Cognitive training studies were dominated by the ACTIVE trial, which investigated the effects of different types of group-based cognitive training on various cognitive performance outcomes for presumably cognitively healthy participants. For the most part, the training had sustained effects (up to 2 years) on cognitive performance in the domain trained but there was little evidence of generalization to other cognitive domains. There was an effort to assess the effects of booster training, but assignment to receive a booster was not random; participants with high initial compliance received most of the boosters.

As shown in Figure 5.2, the ACTIVE study showed mixed effects. For example, across different outcomes in the memory training, one test result found significant benefit with the intervention and two did not. The positive results were in the training domain and one instance of spillover/transfer to an alternate domain. Memory did not show a statistical effect at 10 years. Otherwise the nonsignificant results were for domains not trained, showing generally a lack of generalization/transfer across domains.

**Figure 5.2. Summary of the tests of cognitive performance: results of ACTIVE trial**


	<b>SIGNIFICANT*</b> •=Result favors I	<b>NONSIGNIFICANT*</b> ♦=Results were not statistically significant
<b>2-year Outcomes</b>		
Ball 2002, n=2,832		
Memory Training	•	♦ ♦
Reasoning Training	•	♦ ♦
Speed of Processing Training	•	♦ ♦
<b>5-year Outcomes</b>		
Willis 2006, n=2,832		
Memory Training	•	♦ ♦
Reasoning Training	• •	♦
Speed of Processing Training	•	♦ ♦
<b>10-year Outcomes</b>		
Rebok 2014, n=2,832		
Memory Training		♦ ♦ ♦ ♦
Reasoning Training	•	♦ ♦
Speed of Processing Training	•	♦ ♦
<b>Dementia Diagnosis (5-year)</b>		
Unverzagt 2012, n=2,832		
		♦

\*Categorized by whether results showed statistically significant differences between groups. Each symbol represents a different test measured for each outcome domain. As described in Table 5.1, size of symbol indicates the relative sample size for test. More than one test per domain was frequently used in any given trial. At 2-years, the positive results were for the outcome that matched the domain trained; the nonsignificant results were for the outcomes that did not match the domain trained, showing generally a lack of diffusion across domains. This trend was consistent for memory and speed of processing training at 5-years and reasoning and speed of processing training at 10-years.

I=intervention; C=control; n=sample size

The other cognitive training trials showed basically the same pattern (See Figure 5.3).

**Figure 5.3. Summary of the tests of cognitive performance from additional cognitive training trials other than ACTIVE for adults with normal cognition**




\*Categorized by whether results showed statistically significant differences between groups. Each symbol represents a different test measured for each outcome domain. As described in Table 5.1, size of symbol indicates the relative sample size for test. More than one test per domain was frequently used in any given trial.

I=intervention; C=control; n=sample size

The predominant pattern of the intervention studies is one of no benefit at either the cognitive domain or the dementia level. Some of this absence of effect might be attributed to inadequate statistical power, but many studies were adequately powered. Ideally, the smaller studies might be entered in a meta-analysis, but the wide variety of tests employed forced us to work at the domain level, which, as mentioned, precluded a meta-analyses. We were able to calculate Cohen D's for some of the studies but were still unable to meaningfully pool the data.

Among participants with MCI, the findings are less impressive and rely on small studies. (See Figure 5.4.) Note that two reports (of the same small number of participants), Buschert 2012 & Forster 2011, addressed multiple outcomes.

**Figure 5.4. Summary of the tests of cognitive performance from additional cognitive training trials other than ACTIVE for adults with MCI**




\*Categorized by whether results showed statistically significant differences between groups. Each symbol represents a different test measured for each outcome domain. As described in Table 5.1, size of symbol indicates the relative sample size for test. More than one test per domain was frequently used in any given trial.

I=intervention; n=sample size

Aerobic and resistance training provided the highest proportion of significant positive results among physical activity interventions. Figure 5.5 summarizes the results of these studies. It is organized by type of exercise and cognitive domain assessed. As a result, the same studies appear multiple times. As seen in the figure, while the majority of results showed no significant difference, the pattern of results across very different types of physical activity interventions provides an *indication* of effectiveness of physical activity and raises questions about whether the effect is due to physical activity *per se*. Resistance training appears to have little in common with aerobic exercise, but studies of both have produced some positive results. The underlying logic linking exercise to cognitive function presumed some sort of physiological effect on blood supply or stimulation of naturally occurring chemicals. Given that many of these physical activity intervention studies enrolled older sedentary adults and had followup times as short as 6 months, substantial benefits to cognition might be unlikely. However, if physical activity lowers risk for cognitive decline and CATD and interventions can be effectively implemented to change behaviors, these interventions likely involve long-term investment and may need to begin earlier in the aging process. Also, the different types of exercise showing some effect causes us to reconsider the underlying mechanisms. For example, could the effect lie in some form of socialization

associated with the exercise, which could also explain positive effects of group-based cognitive training, but not similar training done alone? None of the interventions show an overwhelming or consistent effect, but one cannot ignore the positive results. Aerobic and resistance training appears to offer the greatest promise for further research of the effects of physical activity.

**Figure 5.5. Summary of the tests of cognitive performance for physical activity versus inactive comparisons for adults with normal cognition**



Ruscheweyh 2011, n=42

Ruscheweyh 2011 k=1, n=41

Lautenschlager 2008, n=170

Oken 2006, n=91

#### Adverse Events

Lautenschlager 2008, n=170

#### TAI CHI

#### Executive, Attention, Processing Speed

Taylor-Piliae, 2010, n=93



\*Categorized by whether results showed statistically significant differences between groups. Each symbol represents a different test measured for each outcome domain. As described in Table 5.1, size of symbol indicates the relative sample size for test. More than one test per domain was frequently used in any given trial.

I=intervention; n=sample size

While the overall findings for the remaining interventions described in Chapters 4C through 4M showed little benefit, several studies of the treatment of hypertension showed improved cognitive functioning. Given that hypertension control is already a goal for the treatment of cardiovascular disease, these positive outcomes can be viewed as a potential additional benefit from efforts to control blood pressure. Ironically, if the hypertensive treatment lowered mortality, its benefits for dementia might be underestimated because of selective attrition.

Vitamin B<sub>12</sub> and folic acid also showed benefit in brief cognitive test performance and memory, but not for executive/attention/ processing speed. There were also conflicting findings for B<sub>12</sub> when in combinations with other B vitamins. The other vitamins had no substantial benefit on cognition. Little or no benefit for cognitive performance was shown for multivitamins, vitamin C, vitamin D with calcium, or beta carotene (all low strength of evidence). Vitamins work differently if given to a person to address an insufficiency compared to a megadose for a person with otherwise adequate basic vitamin intake. The participants varied widely in this and other respects. In the case of B<sub>12</sub>, large doses would be needed to overcome malabsorption of this vitamin for people with high homocysteine levels.

## Methods Issues

For the vast majority of studies showing no significant effect, we need to separate the potential of small sample sizes from a true lack of effect. Ideally, meta-analysis would make use of many small studies to show an overall pattern, but the populations, interventions, and outcomes assessed were heterogeneous. At best, the categories of cognitive performance were composed of different types of tests and aggregating across domains is not appropriate methodologically.

Although we cannot say with certainty that many interventions *definitely* have no effect, it seems unwise to prioritize future research in areas that show little promise, such as vitamin E, nonsteroidal anti-inflammatory drugs (NSAIDs), statins, and antidiabetic treatment. The argument around antihypertensive treatment is different. Some studies showed benefit and some benefit may be underestimated because of excluding post-stroke dementia studies, but given the extant commitment to blood pressure reduction further studies of its role in preventing dementia should have lower priority than areas less endorsed currently.

Applying strength of evidence criteria to largely negative studies poses challenges. The goal of rating strength of evidence is to assess the level of confidence in the findings. How comfortable can we be that the negative results would not be overturned with further research? Some of the



core elements of strength of evidence are not as helpful for studies that show no effect. Effect size is obviously zero. We can look at risk of bias and consistency. Precision can be examined to some degree, but the crux of the problem is estimating the uncertainty of the Type II error. Studies that show no effect differ from non-inferiority studies, which compare effects of two interventions. Both require looking for Type II errors, which necessitates larger sample sizes than Type I errors.

A separate issue concerns the interpretation of small effect sizes. All but a few of the results showed small changes in scores expressed as a proportion of the score range. In some cases clinicians have determined what constitutes a clinically important difference, but these are typically cast in terms of a given patient’s progress as opposed to the differences in means of study groups.

In deciding what studies warranted strength of evidence rating, we determined not to rate single studies that tested a specific intervention/outcome pair if the total sample was less than 500. As shown in Table 5.2, these eliminations would have little potential effect on the pattern of findings.

**Table 5.2. Findings from smaller single studies for which strength of evidence was not assessed, by intervention type**

Interventions	Number of Findings without Strength of Evidence Rating; Finding Not Reported
Antidementia	0
Antidiabetic	0
Antihypertensive	0
Statins	0
NSAIDs	0
Hormone Therapies	3: 1 for healthy participants NS; 2 for MCI—testosterone 1 of 14 tests favor I; soy 1 of 6 tests favors I
Vitamins	2 (both MCI)—vitamins E+C NS; B vitamins 2 of 6 tests favor I
Nutraceuticals	6: for healthy participants Omega 3 (biomarkers) 1 of 2 favors I; resveratrol 5 of 15 tests favor I; plant sterols/stanols NS. For MCI Omega 3 4 of 9 favor I; ginkgo biloba diagnosis NS, executive function 2 of 2 favor I
Diet	3: for global cognition 1/1 favors I; for memory 2 studies NS
Physical Activity	Multicomponent Physical Activity multidomain composite 2 of 2 favor I; executive function 1 of 2 favor I; memory 1 of 2 favor I

MCI=mild cognitive impairment; I=intervention; NS=no statistically significant difference

In the text, we comment on the studies with risk of bias that were not analyzed. Again, including them would not change the pattern of our findings.

Many limitations arose from the available literature on this topic. A large number of the eligible studies evaluating the effectiveness of interventions in preventing incidence of MCI or Alzheimer’s disease had relatively short durations and followups, although the expected latency period to reach clinical MCI and Alzheimer’s disease and even intermediate cognitive outcomes may be quite long in younger adult populations. Consequently, short-term studies are inadequate to test effectiveness of interventions to prevent these outcomes. At best, they offer some indirect evidence. Studies with longer durations and followup may experience different rates of mortality and loss to followup between intervention and comparison participants that result in biases in missing data and confound interpretation about the effectiveness of the interventions.

Cognitive outcomes were assessed with a wide array of neuropsychologic tests. Some studies tested effects using several different tests over several time periods without any correction for multiple comparisons. Additionally, many studies tested participants at intervals not considered adequate for repeated applications of those tests. Although the specific length of the re-test gap may vary with the test, many opportunities for practice effects occurred.

## Types of Studies

This review was open to three types of studies:

1) Purposefully developed trials: intervention trials designed to address slowing or preventing age-related cognitive decline, MCI, or CATD

2) Add-on trials: trials of an intervention originally targeted at another outcome (e.g., hypertension) to which a cognitive outcome was appended, and

3) Prospective cohort studies: studies that categorized but do not assign an intervention; these frequently rely on self-reported outcomes. (Unfortunately, no studies of this type that used analytic tools to simulate quasi-experimental design and address selection bias in order to test causality were identified in the searches.)

In general, one might expect that the more stringent the design, the less often positive results were seen. The add-on studies (Type 2 above) frequently used less sophisticated measures and had no baseline values. The cohort studies typically had vague measures of exposure to the intervention which was not randomly assigned and hence subject to confounding. The quality of the outcome measures varied.

Baseline cognitive status was not carefully ascertained. While some studies collected baseline cognitive function as part of their design, others paid much less attention. They typically described participants in vague terms such as “normal” or “presumed healthy.” In some cases, participants were described as having cognitive complaints but no diagnosis.

## Value of Biomarkers

The evidence synthesis of measures of biomarkers and cognitive function introduces two important, related challenges. One is understanding the relationship between these outcomes and MCI or dementia incidence. Without a clear understanding of this relationship, it is difficult to interpret findings from short-term studies reporting only biomarkers or cognitive performance.

Biomarkers may have two levels of correlation with more clinical outcomes.

1) They may simultaneously reflect the outcome of interest.

2) They may predict a subsequent change in the outcome interest.

The biomarker measures we encountered were either used alone or in parallel with other outcomes. We limited our analysis of the agreement of biomarkers (primarily magnetic resonance imaging (MRI) and positron emission tomography (PET) scans) to their ability to distinguish outcomes in experimental and control groups.

The role of biomarkers as intermediate outcomes is unclear. Our results show a low level of agreement between the biomarker measures (which were primarily some form of brain scan) and various cognitive tests. The field of biomarkers is expanding rapidly. There has been growing concern about the analytic methodology in one of the more common types of biomarker measures, functional MRI, related to frequent lack of adjustment for large numbers of comparisons.<sup>294</sup> More needs to be known about their ability to predict the clinical course of persons with various levels of cognitive function.

## Limitations of the Review Process

This review encountered several limitations, including but limited to those stemming from the topic and our approach to address it. For example, (as requested by the National Institute on Aging, NIA) we deliberately excluded dementias with specific and clear etiologies, including stroke. By doing so, we may underestimate the importance of hypertension treatment. In addition, many

outcomes of interest were inconsistently defined in the literature and there were numerous and widely varied interventions to address those outcomes. Other limitations arose from conceptual and methodologic issues with eligible studies. These included sample size, length of followup, measurement issues, and attrition. Our search strategy was challenging to design given the wide range of interventions and types of studies measuring cognitive outcomes as secondary outcomes. We designed a strategy to capture a wide variety of intervention types and outcomes with a degree of precision making the review process feasible and efficient. The scale and scope of the topic made identifying all relevant studies extremely difficult. We addressed this by supplementing our bibliographic database searches with citation searches.

To address the multiplicity of cognitive performance tests used, we clustered tests into domains. Because these domains were composites of various tests with different scoring systems, meta-analysis proved unwieldy to conduct. Instead we opted to simply show the proportion of tests. We did use forest plots in some instances and calculated Cohen's D when appropriate. While it would be possible to create a standardized score for each cognitive performance test and ultimately for each domain, we would be concatenating summary measures; such a level of abstraction would likely diminish the value potentially gained from artificially increasing the sample sizes.

As noted earlier, assessing and interpreting the strength of evidence for many studies that showed no difference was difficult, especially when we were unable to use meta-analysis to address small sample size issues. Several reviewers urged a clear distinction between the absence of strong evidence of an effect and strong evidence of no effect. We have tried to make that distinction whenever feasible.

Searches were difficult because key words could only identify studies that assessed cognitive performance outcomes as secondary outcomes if the study abstract listed the cognitive performance outcomes. Finding a balanced set of articles in cohort and add-on studies was difficult because the results were more likely to be noted in abstracts if they were positive.

## Chapter 6. Conclusion

Table 6.1 provides a summary of the key messages from the results chapters detailing intervention results. Of the 13 classes of interventions examined, we found no high-strength evidence for any intervention to delay or prevent age-related cognitive decline, mild cognitive impairment (MCI), and/or clinical Alzheimer’s-type dementia (CATD). A few specific interventions reached moderate-strength evidence for *no* benefit in cognitive performance: vitamin E in women; and angiotensin converting enzyme inhibitors (ACE) and thiazide versus placebo and antiotensin receptor blockers (ARBs) versus placebo on specifically brief cognitive screening tests. We found low-strength evidence that the selective estrogen receptor modulator (SERM) raloxifene reduced risk of probable MCI, however, there was also low-strength evidence that estrogen replacement with or without progestin therapy increased the risk of MCI and CATD.

A few intervention types show more potential than others at benefiting cognitive performance. We found moderate-strength evidence that cognitive training can improve cognitive function in the domain trained up to 2 years (low strength of evidence at 5 and 10 years), but generalization/transfer to other domains was rare. Although there was some evidence for improvement in instrumental activities of daily living (IADLs), these studies had design problems and short-term studies may not predict long-term outcomes. Moreover, IADLs may be a benefit *per se*, but are not directly linked to dementia.

Although the evidence is less compelling, physical activity and perhaps vitamin B<sub>12</sub> plus folic acid may also show potential benefit. While the majority of the results for physical activity showed little to no effect, the percent of results showing benefit in cognitive performance, particularly in resistance training and aerobic exercise, were unlikely to be explained solely by chance. Results for B<sub>12</sub> and folic acid are more spotty and so less persuasive; vitamin B<sub>12</sub> and folic acid showed benefit in brief cognitive test performance and memory, but not for executive/attention/processing speed. There were also conflicting findings for B<sub>12</sub> when used in combination with other B vitamins.

Notably, not all risk factors of interest were addressed by the eligible literature sufficiently for an assessment of these strategies to be made. For example, obesity is a risk factor of concern but it can be studied only in the context of prevention/intervention by assessing the impact of weight loss interventions. In the current systematic review, only one medium risk of bias trial specifically targeted weight loss. Some classes of interventions of interest were absent from the literature altogether, including interventions aimed at depression, smoking cessation, or community-level interventions. Other intervention types were represented by a literature set that was relatively sparse and likely did not represent a full range of possible interventions designs, such as sleep interventions. Lastly, with respect to the stroke prevention literature, although this study included the literature relevant to the vascular components of mixed dementias, it deliberately excluded clear post-stroke dementia. Thus, the findings may underestimate the effects of controlling blood pressure on dementias as a whole.

**Table 6.1. Summary of results chapters key messages**

Intervention	Key Message
Cognitive Training	<ul style="list-style-type: none"> <li>• Most studies addressed intermediate outcomes of cognitive training in terms of cognitive performance and a few measures of brain activity.</li> <li>• The Advanced Cognitive Training for Independent and Vital Elderly (ACTIVE) trial provided the strongest and most comprehensive design to</li> </ul>

	<p>assess the effect of cognitive training on cognitive performance for older adults with normal cognition. Its results provide moderate-strength evidence at 2 years (but low-strength at 5 and 10 years) that cognitive training can improve cognitive function in the domain trained, but transfer to other domains was rare. There is some suggestion that processing speed training is associated with improved IADL performance, but longer term studies were rated as low strength of evidence.</p> <ul style="list-style-type: none"> <li>• Other than the ACTIVE trial, the few studies that examined CATD incidence or cognitive performance showed mixed results.</li> </ul>
Physical Activity Interventions	<ul style="list-style-type: none"> <li>• Studies of physical activity interventions examined a wide variety of activities potentially targeting different pathways to affect cognition.</li> <li>• Evidence is insufficient to conclude whether physical activity interventions prevent MCI or CATD incidence.</li> <li>• Low-strength evidence shows that multicomponent physical activity interventions offer no clear benefit in cognitive performance over attention control in adults with normal cognition.</li> <li>• Evidence was insufficient to conclude whether other types of physical activity interventions had benefits for cognitive outcomes in adults with normal cognition.</li> <li>• While the majority of results showed no significant difference, the pattern of results across very different types of physical activity interventions provides an <i>indication</i> of effectiveness of physical activity.</li> </ul>
Nutraceutical Interventions	<ul style="list-style-type: none"> <li>• Low-strength evidence suggests omega-3 fatty acids and ginkgo biloba did not reduce CATD incidence or improve cognitive performance in adults with normal cognition.</li> <li>• Evidence is insufficient to conclude whether resveratrol or plant sterol/stanol esters reduced CATD incidence or improved cognitive performance in adults with normal cognition.</li> <li>• Few studies examined the effects of nutraceuticals on adults with MCI.</li> </ul>
Diet Interventions	<ul style="list-style-type: none"> <li>• Evidence is insufficient to conclude whether protein supplementation or energy-deficit diets have an effect on cognitive performance or incidence of MCI or CATD.</li> </ul>
Multimodal Interventions	<ul style="list-style-type: none"> <li>• Evidence is insufficient to conclude whether most multimodal interventions offer benefits for cognitive performance or incidence of MCI or CATD, largely because few studies have examined interventions with similar components.</li> <li>• Low-strength evidence shows that a multimodal intervention composed of diet, physical activity, and cognitive training provides benefits in executive function/attention/processing speed.</li> <li>• Low-strength evidence shows that a multimodal intervention composed of lifestyle advice and drug treatment is not effective in reducing incidence of CATD or benefiting brief cognitive test performance or memory.</li> </ul>
Hormone Therapy Interventions	<ul style="list-style-type: none"> <li>• Hormone therapy shows mixed results of harms and benefits.</li> <li>• Low-strength evidence suggests that estrogen therapy may slightly increase the risk of probable MCI and CATD when the two diagnostic categories are examined together.</li> <li>• Low-strength evidence suggests that estrogen plus progestin therapy may slightly increase the risk of probable CATD.</li> <li>• Low-strength evidence suggests that raloxifene may decrease the risk of MCI but not the risk of CATD or of a combined outcome of MCI or CATD compared to placebo.</li> <li>• In addition to these outcomes, hormone therapy has been associated with serious adverse events, including increased risk of certain cancers and cardiovascular disease</li> </ul>
Vitamin Interventions	<ul style="list-style-type: none"> <li>• Moderate-strength evidence shows no benefit in cognitive performance for vitamin E in women.</li> <li>• B vitamins show mixed findings.</li> <li>• Low-strength evidence for folic acid (0.4 mg) plus vitamin B<sub>12</sub> (0.1-0.5 mg) shows benefit in brief cognitive test performance and memory.</li> <li>• Moderate-strength evidence shows no benefit for folic acid (0.4 mg) plus</li> </ul>

	<ul style="list-style-type: none"> <li>B<sub>12</sub> (0.1-0.5 mg) versus placebo for executive/attention/processing speed.</li> <li>Low-strength evidence for vitamin B<sub>12</sub> (0.02=0.5 mg), B<sub>6</sub> (3-10 mg), and folate (0.56-1 mg) shows no benefit for executive/attention/processing speed.</li> <li>Low-strength evidence shows no benefit in cognitive performance for multivitamins, vitamin C (in women), vitamin D with calcium (in women), or beta carotene (in women).</li> <li>Low-strength evidence shows no benefit in incident MCI or CATD for multivitamins or vitamin D with calcium.</li> <li>In adults with MCI, low-strength evidence shows no benefit for vitamin E in incident CATD.</li> </ul>
Antihypertensive Treatment	<ul style="list-style-type: none"> <li>Generally, low-strength evidence shows that 3 to 4.7 years of antihypertensive treatment regimens versus placebo appear to have no benefit on cognitive test performance in adults with normal cognition.</li> <li>Moderate-strength evidence shows that angiotensin converting enzyme (ACE) plus thiazide versus placebo and angiotensin receptor blockers (ARBs) versus placebo have no benefit on brief cognitive screening tests.</li> <li>Low-strength evidence shows that intensive versus standard antihypertensive control shows no benefit on cognitive test performance.</li> <li>Low-strength evidence shows no benefit on cognitive test performance of any fixed antihypertensive treatment regimen versus another among those directly compared.</li> <li>Effects of stepped multiple agent antihypertensive medication regimens to reduce risk of dementia are inconsistent; one trial showed a positive effect but three other trials found no effect of antihypertensive treatment on CATD incidence.</li> <li>The only two trials that reported subgroup data found no differential effect of treatment group on cognition by participant age or other baseline characteristics.</li> </ul>
Lipid Lowering Treatment	<ul style="list-style-type: none"> <li>Evidence was insufficient to assess the effect of 5 years of statin treatment on the risk of incident CATD or for preventing MCI.</li> <li>Low-strength evidence shows a small, 6-month improvement in executive/attention/ processing speed with placebo treatment that was not found with statin treatment, presumed to be due to practice effects and of uncertain clinical significance.</li> <li>Low-strength evidence shows no benefit on brief cognitive test performance, executive/attention/processing speed, or memory for statin plus fenofibrate versus statin plus placebo in adults with normal cognition.</li> <li>Evidence was insufficient to assess whether effects of statins on any cognitive outcomes differ by patient age, baseline lipid level, or other characteristics.</li> </ul>
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)	<ul style="list-style-type: none"> <li>No evidence was available for the effect of low-dose aspirin on MCI or CATD incidence.</li> <li>Low-strength evidence shows no benefit for low-dose aspirin on brief cognitive screening tests, multidomain neuropsychological performance, or memory, even with 10 years of use.</li> <li>Low-strength evidence shows no benefit for nonsteroidal anti-inflammatory drugs (NSAIDs), including both selective and nonselective cyclooxygenase-2 (COX-2) inhibitors, to reduce CATD incidence, or to benefit multidomain neuropsychological performance or memory, with 8 years of followup after 1 to 3 years of use.</li> </ul>
Antidementia Treatments	<ul style="list-style-type: none"> <li>Low-strength evidence shows acetylcholinesterase inhibitor (AChEI) antidementia drugs did not reduce the incidence of CATD in persons with MCI over 3 years; evidence is insufficient for persons with normal cognition.</li> <li>Low-strength evidence shows AChEIs for 3 years provide no significant effect on cognitive performance in adults with MCI.</li> </ul>
Diabetes Medication Treatment	<ul style="list-style-type: none"> <li>No studies reported on the effect of diabetes treatment on the risk of incident clinical diagnoses of MCI or CATD.</li> <li>In middle-aged older adults with diabetes and presumed normal cognition, low-strength evidence shows intensive versus standard glycemic control</li> </ul>

	had no significant effect on cognitive performance.
Other Interventions	<ul style="list-style-type: none"> <li>• Evidence was insufficient for lithium, a nicotine patch, individual piano instruction, multitask rhythmic exercise to music, sleep interventions, and social engagement.</li> <li>• We found no relevant studies for depression treatments, smoking cessation, or community-level interventions.</li> </ul>
Agreement of Biomarkers and Measures of Cognitive Performance	<ul style="list-style-type: none"> <li>• Only a few (9) low or medium risk of bias studies for cognitive performance also used biomarker measures; most of those used some form of brain scan.</li> <li>• The overall rate of agreement between biomarker measures and cognitive testing was 57 percent, but 90 percent of that agreement resulted from both approaches showing no effect. When the biomarker measure showed a significant result, there was agreement in 25 percent of cognitive tests conducted.</li> </ul>

CATD=clinical Alzheimer's-type dementia; MCI=mild cognitive impairment

## Chapter 7. Suggestions for Future Research

The ability to draw meaningful conclusions regarding interventions that can delay or slow age-related cognitive decline and prevent onset of mild cognitive impairment (MCI) or clinical Alzheimer's-type dementia (CATD) is hampered by limitations in existing research. The bulk of the studies examined raise more questions than answers. Low-strength evidence in some areas may provide guidance for prioritizing the types of interventions that deserve further study. However, common problems with study design/methodology and measurement need to be rectified in future research if effective methods of preventing cognitive deterioration in older age are to be identified.

### Prioritizing Future Research

Effective use of scarce research dollars will require substantial investments in a limited number of well-designed trials of sufficient power and duration. Interventions selected to receive funding will need to be chosen carefully. The full effects of hypertension control should include attention to stroke. Priority should be given to interventions that already show some promise, most notably cognitive training and physical activity. However, the decision to exclude specific stroke-related dementia may underestimate the effect of antihypertension treatment. Although it cannot be said with complete certainty that other types of interventions have no effect, work examining hormone replacement therapy, nonsteroidal anti-inflammatory drugs (NSAIDs), statins, nutraceuticals, and others has shown little promise. Moderate-strength evidence showing no benefit for vitamin E for cognitive performance support assigning low priority to this area.

### Study Design/Methodology

Future trials should be designed *intentionally* to study methods of slowing and preventing age-related cognitive decline, MCI, and CATD incidence. Many studies originally designed for other purposes have added cognitive measures post-hoc. These “add-on” trials have frequently used less sophisticated measures, have not adequately evaluated baseline characteristics, and have not randomly assign participants, all of which confound data and limit conclusions.

Another common limitation is that most trials have been too short to observe clinically meaningful change in cognitive function. Many were designed with an intervention period of one year or less with limited or no follow-up, making it impossible to draw conclusions about longer-term outcomes in most cases. Trials that address dementia incidence must be even larger and longer. Designing trials of appropriate duration requires careful consideration of several key factors, including cohort characteristics (e.g., subject age, presence or absence of known risk factors of cognitive decline, cognitively normal versus MCI) and whether outcomes are intended to detect a delay in cognitive decline or a reduction in dementia incidence. Focusing on longitudinal investigations with followup periods of 10 years or more would greatly benefit the field and provide more insight about prevention. This will also require designing studies to actively minimize, or at least appropriately deal with, attrition. One way to accomplish this is by prioritizing enrollment of older cohorts although it is important to note that the most ideal age for intervention remains unknown and may vary by type of intervention. The danger of this strategy, however, lies in the possibility that treatment effects are stronger for persons in midlife than in late life. Epidemiological studies in hypertension point in this direction.



In addition to dedicated trials, larger sample sizes and longer intervention and followup periods, studies that assess dose-response relationships and underlying mechanisms of action are needed. Establishing the dose-response relationship can be done in two ways. Multiple arms of varying dosage could be used initially; alternatively, once an effect has been demonstrated, studies that assess dose-response relationships and underlying mechanisms of action could be implemented. Knowing that a specific intervention, such as cognitive training or a particular form of physical activity, could meaningfully impact dementia incidence is only helpful to the extent that various intensities of the intervention have been studied and reported. Equally important is more clearly elucidating the specific mechanisms associated with positive effects. For example, the underlying logic linking physical activity to improved cognitive performance has historically been physiological effects on blood or oxygen supply or stimulation of neurochemicals. However, the fact that remarkably different forms of physical activity, such as resistance training and aerobic exercise, show possible effects on cognition suggests that the mechanism of action may need to be reconsidered. Perhaps the effect lies in socialization, which could help explain positive effects associated with group-based cognitive training, but not similar training done alone.

Finally, the vast majority of studies testing the effectiveness of interventions to delay or slow age-related cognitive decline or prevent onset of MCI or CATD have focused narrowly on a single intervention. Given that the causes of dementia are complex and multifactorial, studies should address interventions that modify multiple risk factors. Several such trials, focusing on multiple risk factors simultaneously (multidomain interventions) have been initiated.<sup>14</sup> Three of these trials (FINGER, MAPT, PreDIVA) enrolled older adults and implemented multidomain interventions with components addressing nutrition, physical activity, cognitive training, social activity, and/or vascular risk factor management. Of the two studies with published results, while the more clinical multidomain PreDIVA trial did not find benefit,<sup>141</sup> results from the FINGER trial, which used a more lifestyle-based approach, were promising.<sup>142</sup> More studies assessing a combination of interventions would benefit the field. The key issue in designing such studies is choosing the best “package” of interventions. Current wisdom suggests that randomized controlled trials (RCTs) should use the most powerful combinations and leave the decisions about less potent versions to subsequent studies. The first critical question is whether a combination of strong interventions can achieve the goal.

## Measurement

Consistent shortcomings across existing studies reveal many opportunities to improve the measurement techniques of future trials. Future research should employ a more consistent set of validated tests to assess cognitive performance. To date, cognitive outcomes have been measured using a wide array of neuropsychological tests. This practice is problematic because the ability to detect change in cognitive performance over time is greatly influenced by the sensitivity, specificity, and reliability of the test. Although there are no perfect tests, the psychometric properties of neuropsychological measures vary considerably. For this reason, some are probably preferred over others. In addition, the sheer volume of cognitive measures used in the literature complicates comparisons across trials, particularly when an attempt is made to cluster or group tests into domains as most do not fit neatly into one category. Moreover, it is not uncommon for studies to use many tests over several time periods without any correction for multiple comparisons. Practice effects are also a concern when participants are evaluated at timeframes designed to complement the duration of the study but not at intervals acceptable for repeated

applications of the tests. Research in the field could be enhanced greatly through development of consensus guidelines that encourage investigators to use a common core standardized battery or batteries of tests in these trials. Such a model has precedence in the pharmaceutical industry, and in Alzheimer's disease clinical trial research specifically, which unified methodology many years ago using the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) and by defining appropriate test/re-test timeframes. Although no one measure is adequate for all applications, movement towards the use of batteries with good psychometric qualities and already in common use in aging populations (such as those included in the National Alzheimer's Coordinating Center data set [https://www.alz.washington.edu/WEB/forms\\_uds.html](https://www.alz.washington.edu/WEB/forms_uds.html) or drawn from the National Institutes of Health Toolbox <http://www.healthmeasures.net/explore-measurement-systems/nih-toolbox>) could potentially help to narrow the field.

The baseline status of participants needs to be better measured and documented. Baseline cognitive status is variously described and often not tested. While some researchers measured baseline cognitive function as part of the trial design, the degree of measurement varied widely (e.g., brief cognitive screening versus more elaborate neuropsychological test performance). Complicating matters, some trials describe participants with terms like "normal" or "presumed healthy" while in other cases participants are described as having cognitive complaints but no diagnosis. Self-reported cognitive status is not an acceptable proxy for objective measurement. Studies examining the impact of physical activity on cognitive performance report enrolling "sedentary" adults yet fail to define exactly what this means or how this classification was determined. Standardization or common understanding of such terms is lacking. The use of appropriate attention controls can help identify the effects specific to the intervention versus those that arise from other specific factors (e.g., socialization or general therapeutic relationships).

Finally, future research trials that include incident CATD as a study outcome should evaluate participants using formal diagnostic guidelines for Alzheimer's disease such as those from the National Institute on Aging (NIA) and the Alzheimer's Association.<sup>6</sup> Including both measures of cognitive performance and CATD incidence as study outcomes would allow researchers to better understand how these two constructs are related. Important questions include: 1) what patterns of cognitive change predict dementia? 2) do some domains predict better than others and therefore become more important targets of intervention? 3) does the difference lie in the number of cognitive domains affected? 4) is the rate of change important? and 5) in what specific populations are particular interventions most effective—in healthy adults or those with mild cognitive impairment or other risk factors? These questions, in turn, reflect the diagnostic criteria used to identify dementia. For trials that cannot include incident CATD as an outcome for whatever reason, more work is needed to define what degree of change in neuropsychological test performance is considered clinically meaningful. This question still lacks consensus, and a range of values may be needed to establish what is considered clinically meaningful and to whom. Moreover, meaningful change may vary depending upon differing baseline level of function. Consistently including objective and performance-based measures of everyday function (IADLs) in future trials may help address these questions.

## References

1. Langa KM, Larson EB, Crimmins EM, et al. A Comparison of the Prevalence of Dementia in the United States in 2000 and 2012. *JAMA Internal Medicine* 2016 Nov 21, 2016doi: 10.1001/jamainternmed.2016.6807. PMID: 27893041.
2. Satizabal CL, Beiser AS, Chouraki V, et al. Incidence of Dementia over Three Decades in the Framingham Heart Study. *N Engl J Med*. 2016 Feb 11;374(6):523-32. doi: 10.1056/NEJMoa1504327. PMID: 26863354.
3. Plassman BL, Langa KM, Fisher GG, et al. Prevalence of cognitive impairment without dementia in the United States. *Ann Intern Med*. 2008 Mar 18;148(6):427-34. PMID: 18347351.
4. Williams JW, Plassman BL, Burke J, et al. Preventing Alzheimer's Disease and Cognitive Decline (Prepared by the Duke Evidence-based Practice Center Under Contract No. HHS 290-2007-10066-I). Rockville, MD: 2010.
5. Kelley A, McGarry K, Gorges R, et al. The Burden of Health Care Costs for Patients With Dementia in the Last 5 Years of Life. *Burden of Health Care Costs for Patients With Dementia*. *Ann Intern Med*. 2015; Published online 27 October 2015 doi:10.7326/M15-0381.
6. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's & Dementia*. 2011 May;7(3):263-9. doi: <http://dx.doi.org/10.1016/j.jalz.2011.03.005>. PMID: 21514250.
7. Jack CR, Jr., Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's & Dementia*. 2011 May 2011;7(3):257-62. doi: 10.1016/j.jalz.2011.03.004. PMID: 21514247.
8. American Psychiatric Association. *Neurocognitive Disorders*. *Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition*. Arlington, VA: American Psychiatric Association; 2013.
9. Golomb J, Kluger A, Ferris SH. Mild cognitive impairment: historical development and summary of research. *Dialogues Clin Neurosci*. 2004 Dec;6(4):351-67. PMID: 22034453.
10. Cooper C, Sommerlad A, Lyketsos CG, et al. Modifiable predictors of dementia in mild cognitive impairment: a systematic review and meta-analysis. *American Journal of Psychiatry*. 2015 Apr;172(4):323-34. doi: <http://dx.doi.org/10.1176/appi.ajp.2014.14070878>. PMID: 25698435.
11. Petersen RC. Mild cognitive impairment as a diagnostic entity. *Journal of Internal Medicine*. 2004 Sep;256(3):183-94. PMID: 15324362.
12. IOM (Institute of Medicine). *Cognitive aging: progress in understanding and opportunities for action*. Washington, DC: The National Academies Press; 2015.
13. Williams JW, Plassman BL, Burke J, et al. Preventing Alzheimer's disease and cognitive decline. *Evidence Report/Technology Assessment*. 2010 Apr(193):1-727. PMID: 21500874.
14. Solomon A, Mangialasche F, Richard E, et al. Advances in the prevention of Alzheimer's disease and dementia. *Journal of Internal Medicine*. 2014;275(3):229-50. PMID: 24605807.
15. National Institutes of Health. *Cognitive and Emotional Health Project: The Healthy Brain*. 2016. <http://trans.nih.gov/CEHP/hbpcog-list.htm>. Accessed on August 26 2016.
16. Lampit A, Valenzuela M, Gates NJ. Computerized Cognitive Training Is Beneficial for Older Adults. *J Am Geriatr Soc*. 2015 Dec 2015;63(12):2610-2. doi: 10.1111/jgs.13825. PMID: 26662712.

17. Viswanathan M, Ansari M, Berkman N, et al. Assessing the Risk of Bias of Individual Studies in Systematic Reviews of Health Care Interventions. Agency for Healthcare Research and Quality; March 2012. Methods Guide for Comparative Effectiveness Reviews. AHRQ Publication No. 12-EHC047-EF. Available at <http://effectivehealthcare.ahrq.gov/>.
18. Stein J, Lippa M, Braehler E, et al. The assessment of changes in cognitive functioning: reliable change indices for neuropsychological instruments in the elderly - a systematic review. *Dementia & Geriatric Cognitive Disorders*. 2010;29(3):275-86. doi: <http://dx.doi.org/10.1159/000289779>. PMID: 20375509.
19. Bagoz PG. Meta-analysis in Stata using gllamm. *Res Synth Methods*. 2015 Dec 2015;6(4):310-32.
20. Fu R, Gartlehner G, Grant M, et al. Conducting quantitative synthesis when comparing medical interventions: AHRQ and the Effective Health Care Program. *Journal of Clinical Epidemiology*. 2011 Nov;64(11):1187-97. PMID: 21477993.
21. Berkman ND, Lohr KN, Ansari M, et al. Grading the strength of a body of evidence when assessing health care interventions: an EPC update. *J Clin Epidemiol*. 2015 Nov;68(11):1312-24. doi: 10.1016/j.jclinepi.2014.11.023. Epub 2014 Dec 20. PMID: 25721570
22. Atkins D, Chang S, Gartlehner G, et al. Assessing the applicability of studies when comparing medical interventions. Agency for Healthcare Research and Quality; January 2011. Methods Guide for Comparative Effectiveness Reviews. AHRQ Publication No. 11-EHC019-EF. Available at <http://effectivehealthcare.ahrq.gov/>.
23. Ratner E, Atkinson D. Why Cognitive Training and Brain Games Will Not Prevent or Forestall Dementia. *J Amer Geriatr Soc*. 2015 Dec 2015;63(12):2612-4. doi: 10.1111/jgs.1\_13825. PMID: 26660360.
24. Simons DJ, Boot WR, Charness N, et al. Do "Brain-Training" Programs Work? *Psychol Sci Public Interest*. 2016 Oct 2017;17(3):103-86. doi: 10.1177/1529100616661983. PMID: 27697851.
25. Ball K, Berch DB, Helmers KF, et al. Effects of cognitive training interventions with older adults: a randomized controlled trial. *JAMA*. 2002 Nov 13;288(18):2271-81. PMID: 12425704.
26. Willis SL, Tennstedt SL, Marsiske M, et al. Long-term effects of cognitive training on everyday functional outcomes in older adults. *JAMA*. 2006 Dec 20;296(23):2805-14. PMID: 17179457.
27. Rebok GW, Ball K, Guey LT, et al. Ten-year effects of the advanced cognitive training for independent and vital elderly cognitive training trial on cognition and everyday functioning in older adults. *Journal of the American Geriatrics Society*. 2014 Jan;62(1):16-24. doi: <http://dx.doi.org/10.1111/jgs.12607>. PMID: 24417410.
28. Unverzagt FW, Guey LT, Jones RN, et al. ACTIVE cognitive training and rates of incident dementia. *J Int Neuropsychol Soc*. 2012 Jul;18(4):669-77. doi: 10.1017/s1355617711001470. PMID: 22400989.
29. Jobe JB, Smith DM, Ball K, et al. ACTIVE: a cognitive intervention trial to promote independence in older adults. *Control Clin Trials*. 2001 Aug;22(4):453-79. PMID: 11514044.
30. Ball K, Edwards JD, Ross LA, et al. Cognitive training decreases motor vehicle collision involvement of older drivers. *J Amer Geriatr Soc*. 2010 Nov 2010;58(11):2107-13. doi: 10.1111/j.1532-5415.2010.03138.x. PMID: 21054291.
31. Edwards JD, delahunt PB, Mahncke HW. Cognitive Speed of Processing Training Delays Driving Cessation. *J Gerontol A Biol Sci Med Sci*. 2009 Dec 2009;64(12):1262-7. doi: 10.1093/gerona/64.12.1262. PMID: 19726665.
32. Gallo JJ, R. BH, Morales KH, et al. Depression, cardiovascular disease, diabetes, and 2-year mortality among older primary care patients. *Am J Geriatr Psychiatry*; 2005. p. 748-55. PMID: 16166403
33. Wolinsky FD, Vander Weg MW, Martin R, et al. The Effect of Speed-of-Processing Training on Depressive Symptoms in ACTIVE. *Journal of Gerontology: Medical Sciences*. 2009 Jan 30, 2009;64A(4):468-72. doi: 10.1093/gerona/gln044. PMID: 19181719

34. Prindle JJ, McArdle JJ. How representative is the ACTIVE sample? A statistical comparison of the ACTIVE sample and the HRS sample. *J of Aging and Health*. 2013 Dec 2013;25(8S):85S-102S. doi: 1177/0898264313497795. PMID: 24385641
35. The University of Michigan Health and Retirement Study. The University of Michigan Health and Retirement Study (HRS). 2016.
36. Cook SE, Marsiske M, Thomas KR, et al. Identification of Mild Cognitive Impairment in ACTIVE: Algorithmic Classification and Stability. *J Int Neuropsychol Soc*. 2013 Jan 2013;9(1):73-87. doi: 10.1017/S1355617712000938. PMID: 23095218
37. Unverzagt FW, Kasten L, Johnson KE, et al. Effect of memory impairment on training outcomes in ACTIVE. *Journal of the International Neuropsychological Society*. 2007 Nov;13(6):953-60. PMID: 17942013.
38. Edwards JD, Wadley VG, Myers R, et al. Transfer of a speed of processing intervention to near and far cognitive functions. *Gerontology*. 2002;48:329-40. doi: 10.1159/000065259. PMID: 12169801
39. Edwards JD, Wadley VG, Vance DE, et al. The impact of speed of processing training on cognitive and everyday performance. *Aging & Mental Health*. 2005;9:262-71. doi: 10.1080/13607860412331336788. PMID: 16019280
40. Duff K. Evidence-Based Indicators of Neuropsychological Change in the Individual Patient: Relevant Concepts and Methods. *Archives of Clinical Neuropsychology*. 2012 May 2012;27(3):248-61. doi: 10.1093/arclin/acr120. PMID: 22382384.
41. Pedraza O, Smith GE, Ivnik RJ, et al. Reliable change on the Dementia Rating Scale. *J Int Neuropsychol Soc*. 2007 Jul 2007;13(4):716-20. PMID: 17521486.
42. Miller KJ, Dye RV, Kim J, et al. Effect of a computerized brain exercise program on cognitive performance in older adults. *American Journal of Geriatric Psychiatry*. 2013 Jul;21(7):655-63. doi: <http://dx.doi.org/10.1016/j.jagp.2013.01.077>. PMID: 23602310.
43. Klusmann V, Evers A, Schwarzer R, et al. Complex mental and physical activity in older women and cognitive performance: a 6-month randomized controlled trial. *J Gerontol A Biol Sci Med Sci*. 2010 Jun;65(6):680-8. doi: 10.1093/gerona/glq053. PMID: 20418350.
44. Carretti B, Borella E, Zavagnin M, et al. Gains in language comprehension relating to working memory training in healthy older adults. *Int J Geriatr Psychiatry*. 2013 May;28(5):539-46. doi: 10.1002/gps.3859. PMID: 22821686.
45. Rapp S, Brenes G, Marsh AP. Memory enhancement training for older adults with mild cognitive impairment: a preliminary study. *Aging & Mental Health*. 2002 Feb;6(1):5-11. PMID: 11827617.
46. Herrera C, Chambon C, Michel BF, et al. Positive effects of computer-based cognitive training in adults with mild cognitive impairment. *Neuropsychologia*. 2012 Jul;50(8):1871-81. doi: <http://dx.doi.org/10.1016/j.neuropsychologia.2012.04.012>. PMID: 22525705.
47. Wolinsky FD, Vander Weg MW, Howren MB, et al. A randomized controlled trial of cognitive training using a visual speed of processing intervention in middle aged and older adults. *PLoS ONE [Electronic Resource]*. 2013;8(5):e61624. doi: <http://dx.doi.org/10.1371/journal.pone.0061624>. PMID: 23650501.
48. Buschert VC, Giegling I, Teipel SJ, et al. Long-term observation of a multicomponent cognitive intervention in mild cognitive impairment. *Journal of Clinical Psychiatry*. 2012 Dec;73(12):e1492-8. doi: <http://dx.doi.org/10.4088/JCP.11m07270>. PMID: 23290333.
49. Forster S, Buschert VC, Teipel SJ, et al. Effects of a 6-month cognitive intervention on brain metabolism in patients with amnesic MCI and mild Alzheimer's disease. *Journal of Alzheimer's Disease*. 2011;26 Suppl 3:337-48. doi: <http://dx.doi.org/10.3233/JAD-2011-0025>. PMID: 21971473.
50. Kwok TC, Bai X, Li JC, et al. Effectiveness of cognitive training in Chinese older people with subjective cognitive complaints: a randomized placebo-controlled trial. *International Journal of Geriatric Psychiatry*. 2013 Feb;28(2):208-15. doi: <http://dx.doi.org/10.1002/gps.3812>. PMID: 22528470.

51. Vidovich MR, Lautenschlager NT, Flicker L, et al. The PACE study: A randomized clinical trial of cognitive activity strategy training for older people with mild cognitive impairment. *American Journal of Geriatric Psychiatry*. 2015 01 Apr;23(4):360-72. doi: <http://dx.doi.org/10.1016/j.jagp.2014.04.002>. PMID: 2014736543.
52. Stine-Morrow EA, Payne BR, Roberts BW, et al. Training versus engagement as paths to cognitive enrichment with aging. *Psychology & Aging*. 2014 Dec;29(4):891-906. doi: <http://dx.doi.org/10.1037/a0038244>. PMID: 25402337.
53. Buchman AS, Boyle PA, Yu L, et al. Total daily physical activity and the risk of AD and cognitive decline in older adults. *Neurology*. 2012 2012/4/24;78(17):1323-9. doi: 10.1212/WNL.0b013e3182535d35. PMID: 22517108
54. Antunes HK, De Mello MT, Santos-Galduroz RF, et al. Effects of a physical fitness program on memory and blood viscosity in sedentary elderly men. *Braz J Med Biol Res*. 2015 Sep;48(9):805-12. doi: 10.1590/1414-431X20154529. PMID: 26222648.
55. Baker LD, Frank LL, Foster-Schubert K, et al. Aerobic exercise improves cognition for older adults with glucose intolerance, a risk factor for Alzheimer's disease. *J Alzheimers Dis*. 2010;22(2):569-79. doi: 10.3233/JAD-2010-100768. PMID: 20847403.
56. Baker LD, Frank LL, Foster-Schubert K, et al. Effects of aerobic exercise on mild cognitive impairment: a controlled trial. *Arch Neurol*. 2010 Jan;67(1):71-9. doi: 10.1001/archneurol.2009.307. PMID: 20065132.
57. Best JR, Chiu BK, Liang Hsu C, et al. Long-term effects of resistance exercise training on cognition and brain volume in older women: Results from a randomized controlled trial. *Journal of the International Neuropsychological Society*. 2015 Nov;21(10):745-56. doi: <http://dx.doi.org/10.1017/S1355617715000673>. PMID: 2015-53115-004.
58. Blumenthal JA, Emery CF, Madden DJ, et al. Long-term effects of exercise on psychological functioning in older men and women. *Journal of Gerontology*. 1991 Nov;46(6):P352-61. PMID: 1940092.
59. Bun S, Ikejima C, Kida J, et al. A combination of supplements may reduce the risk of Alzheimer's disease in elderly Japanese with normal cognition. *J Alzheimers Dis*. 2015;45(1):15-25. doi: 10.3233/JAD-142232. PMID: 25524956.
60. Cassilhas RC, Viana VA, Grassmann V, et al. The impact of resistance exercise on the cognitive function of the elderly. *Med Sci Sports Exerc*. 2007 Aug;39(8):1401-7. doi: 10.1249/mss.0b013e318060111f. PMID: 17762374.
61. Colcombe SJ, Erickson KI, Scalf PE, et al. Aerobic exercise training increases brain volume in aging humans. *Journals of Gerontology Series A-Biological Sciences & Medical Sciences*. 2006 Nov;61(11):1166-70. PMID: 17167157.
62. Eggenberger P, Schumacher V, Angst M, et al. Does multicomponent physical exercise with simultaneous cognitive training boost cognitive performance in older adults? A 6-month randomized controlled trial with a 1-year follow-up. *Clin Interv Aging*. 2015 17 Aug;10:1335-49. doi: 10.2147/CIA.S87732. PMID: 26316729.
63. Erickson KI, Voss MW, Prakash RS, et al. Exercise training increases size of hippocampus and improves memory. *Proceedings of the National Academy of Sciences of the United States of America*. 2011 Feb 15;108(7):3017-22. doi: <http://dx.doi.org/10.1073/pnas.1015950108>. PMID: 21282661.
64. Evers A, Klusmann V, Schwarzer R, et al. Improving cognition by adherence to physical or mental exercise: a moderated mediation analysis. *Aging Ment Health*. 2011 May;15(4):446-55. doi: 10.1080/13607863.2010.543657. PMID: 21500011.
65. Ferreira L, Tanaka K, Santos-Galduroz RF, et al. Respiratory training as strategy to prevent cognitive decline in aging: a randomized controlled trial. *Clin Interv Aging*. 2015 20 Mar;10:593-603. doi: 10.2147/CIA.S79560. PMID: 25848235.
66. Fiatarone Singh MA, Gates N, Saigal N, et al. The Study of Mental and Resistance Training (SMART) study-resistance training and/or cognitive training in mild cognitive impairment: a randomized, double-blind, double-sham controlled trial. *J Am Med Dir Assoc*. 2014 Dec;15(12):873-80. doi: 10.1016/j.jamda.2014.09.010. PMID: 25444575.
67. Hildreth KL, Van Pelt RE, Moreau KL, et al. Effects of pioglitazone or exercise in older adults with mild cognitive impairment and insulin

- resistance: a pilot study. *Dement Geriatr Cogn Dis Extra*. 2015 Jan-Apr;5(1):51-63. doi: 10.1159/000371509. PMID: 25852732.
68. Hotting K, Reich B, Holzschneider K, et al. Differential cognitive effects of cycling versus stretching/coordination training in middle-aged adults. *Health Psychol*. 2012 Mar;31(2):145-55. doi: 10.1037/a0025371. PMID: 21895371.
69. Komulainen P, Kivipelto M, Lakka T, et al. Exercise, fitness and cognition—A randomised controlled trial in older individuals: The DR's EXTRA study. *European Geriatric Medicine*. 2010;1(5):266-72.
70. Kramer AF, Hahn S, Cohen NJ, et al. Ageing, fitness and neurocognitive function. *Nature*. 1999 Jul 29;400(6743):418-9. PMID: 10440369.
71. Lachman ME, Neupert SD, Bertrand R, et al. The effects of strength training on memory in older adults. *Journal of Aging & Physical Activity*. 2006 Jan;14(1):59-73. PMID: 16648652.
72. Lam LC, Chan WC, Leung T, et al. Would older adults with mild cognitive impairment adhere to and benefit from a structured lifestyle activity intervention to enhance cognition?: a cluster randomized controlled trial. *PLoS One*. 2015 31 Mar;10(3):e0118173. doi: 10.1371/journal.pone.0118173. PMID: 25826620.
73. Lam LC, Chau RC, Wong BM, et al. A 1-year randomized controlled trial comparing mind body exercise (Tai Chi) with stretching and toning exercise on cognitive function in older Chinese adults at risk of cognitive decline. *J Am Med Dir Assoc*. 2012 Jul;13(6):568 e15-20. doi: 10.1016/j.jamda.2012.03.008. PMID: 22579072.
74. Lautenschlager NT, Cox KL, Flicker L, et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. *JAMA*. 2008 Sep 3;300(9):1027-37. doi: 10.1001/jama.300.9.1027. PMID: 18768414.
75. Law LL, Barnett F, Yau MK, et al. Effects of functional tasks exercise on older adults with cognitive impairment at risk of Alzheimer's disease: a randomised controlled trial. *Age Ageing*. 2014 Nov;43(6):813-20. doi: 10.1093/ageing/afu055. PMID: 24850540.
76. Liu-Ambrose T, Donaldson MG, Ahamed Y, et al. Otago home-based strength and balance retraining improves executive functioning in older fallers: a randomized controlled trial. *Journal of the American Geriatrics Society*. 2008 Oct;56(10):1821-30. doi: <http://dx.doi.org/10.1111/j.1532-5415.2008.01931.x>. PMID: 18795987.
77. Liu-Ambrose T, Nagamatsu LS, Graf P, et al. Resistance training and executive functions: a 12-month randomized controlled trial. *Archives of Internal Medicine*. 2010 Jan 25;170(2):170-8. doi: <http://dx.doi.org/10.1001/archinternmed.2009.494>. PMID: 20101012.
78. Madden DJ, Blumenthal JA, Allen PA, et al. Improving aerobic capacity in healthy older adults does not necessarily lead to improved cognitive performance. *Psychology & Aging*. 1989 Sep;4(3):307-20. PMID: 2803624.
79. Mortimer JA, Ding D, Borenstein AR, et al. Changes in brain volume and cognition in a randomized trial of exercise and social interaction in a community-based sample of non-demented Chinese elders. *J Alzheimers Dis*. 2012;30(4):757-66. doi: 10.3233/JAD-2012-120079. PMID: 22451320.
80. Muscari A, Giannoni C, Pierpaoli L, et al. Chronic endurance exercise training prevents aging-related cognitive decline in healthy older adults: a randomized controlled trial. *Int J Geriatr Psychiatry*. 2010 Oct;25(10):1055-64. doi: 10.1002/gps.2462. PMID: 20033904.
81. Nagamatsu LS, Chan A, Davis JC, et al. Physical activity improves verbal and spatial memory in older adults with probable mild cognitive impairment: a 6-month randomized controlled trial. *J Aging Res*. 2013;2013(861893):861893. doi: 10.1155/2013/861893. PMID: 23509628.
82. Nagamatsu LS, Handy TC, Hsu CL, et al. Resistance training promotes cognitive and functional brain plasticity in seniors with probable mild cognitive impairment. *Arch Intern Med*. 2012 Apr 23;172(8):666-8. doi: 10.1001/archinternmed.2012.379. PMID: 22529236.
83. Napoli N, Shah K, Waters DL, et al. Effect of weight loss, exercise, or both on cognition and quality of life in obese older adults. *Am J Clin Nutr*. 2014 Jul;100(1):189-98. doi: 10.3945/ajcn.113.082883. PMID: 24787497.

84. Nguyen MH, Kruse A. A randomized controlled trial of Tai chi for balance, sleep quality and cognitive performance in elderly Vietnamese. *Clin Interv Aging*. 2012;7:185-90. doi: 10.2147/CIA.S32600. PMID: 22807627.
85. Oken BS, Zajdel D, Kishiyama S, et al. Randomized, controlled, six-month trial of yoga in healthy seniors: effects on cognition and quality of life. *Alternative Therapies in Health & Medicine*. 2006 Jan-Feb;12(1):40-7. PMID: 16454146.
86. Okumiya K, Matsubayashi K, Wada T, et al. Effects of exercise on neurobehavioral function in community-dwelling older people more than 75 years of age. *Journal of the American Geriatrics Society*. 1996 May;44(5):569-72. PMID: 8617907.
87. Oswald WD, Gunzelmann T, Rupprecht R, et al. Differential effects of single versus combined cognitive and physical training with older adults: the SimA study in a 5-year perspective. *European Journal of Ageing*. 2006;3(4):179-92.
88. Rosano C, Venkatraman VK, Guralnik J, et al. Psychomotor speed and functional brain MRI 2 years after completing a physical activity treatment. *J Gerontol A Biol Sci Med Sci*. 2010 Jun;65(6):639-47. doi: 10.1093/gerona/gdq038. PMID: 20348185.
89. Ruscheweyh R, Willemer C, Kruger K, et al. Physical activity and memory functions: an interventional study. *Neurobiology of Aging*. 2011 Jul;32(7):1304-19. doi: <http://dx.doi.org/10.1016/j.neurobiolaging.2009.08.01>. PMID: 19716631.
90. Satoh M, Ogawa J, Tokita T, et al. The effects of physical exercise with music on cognitive function of elderly people: Mihama-Kiho project. *PLoS One*. 2014;9(4):e95230. doi: 10.1371/journal.pone.0095230. PMID: 24769624.
91. Sink KM, Espeland MA, Castro CM, et al. Effect of a 24-Month Physical Activity Intervention vs. Health Education on Cognitive Outcomes in Sedentary Older Adults: The LIFE Randomized Trial. *JAMA*. 2015 Aug 25;314(8):781-90. doi: 10.1001/jama.2015.9617. PMID: 26305648.
92. Smiley-Oyen AL, Lowry KA, Francois SJ, et al. Exercise, fitness, and neurocognitive function in older adults: the "selective improvement" and "cardiovascular fitness" hypotheses. *Annals of Behavioral Medicine*. 2008 Dec;36(3):280-91. doi: <http://dx.doi.org/10.1007/s12160-008-9064-5>. PMID: 18825471.
93. Suzuki T, Shimada H, Makizako H, et al. A randomized controlled trial of multicomponent exercise in older adults with mild cognitive impairment. *PLoS One*. 2013;8(4):e61483. doi: 10.1371/journal.pone.0061483. PMID: 23585901.
94. Suzuki T, Shimada H, Makizako H, et al. Effects of multicomponent exercise on cognitive function in older adults with amnesic mild cognitive impairment: a randomized controlled trial. *BMC Neurol*. 2012;12:128. doi: 10.1186/1471-2377-12-128. PMID: 23113898.
95. Taylor-Piliae RE, Newell KA, Cherin R, et al. Effects of Tai Chi and Western exercise on physical and cognitive functioning in healthy community-dwelling older adults. *J Aging Phys Act*. 2010 Jul;18(3):261-79. PMID: 20651414.
96. ten Brinke LF, Bolandzadeh N, Nagamatsu LS, et al. Aerobic exercise increases hippocampal volume in older women with probable mild cognitive impairment: a 6-month randomised controlled trial. *Br J Sports Med*. 2015 Feb;49(4):248-54. doi: 10.1136/bjsports-2013-093184. PMID: 24711660.
97. van de Rest O, van der Zwaluw NL, Tieland M, et al. Effect of resistance-type exercise training with or without protein supplementation on cognitive functioning in frail and pre-frail elderly: secondary analysis of a randomized, double-blind, placebo-controlled trial. *Mech Ageing Dev*. 2014 Mar-Apr;136-137:85-93. doi: 10.1016/j.mad.2013.12.005. PMID: 24374288.
98. van Uffelen JG, Chinapaw MJ, van Mechelen W, et al. Walking or vitamin B for cognition in older adults with mild cognitive impairment? A randomised controlled trial. *British Journal of Sports Medicine*. 2008 May;42(5):344-51. doi: <http://dx.doi.org/10.1136/bjism.2007.044735>. PMID: 18308888.
99. Williams P, Lord SR. Effects of group exercise on cognitive functioning and mood in older women. *Australian & New Zealand Journal of Public Health*. 1997 Feb;21(1):45-52. PMID: 9141729.



100. Williamson JD, Espeland M, Kritchevsky SB, et al. Changes in cognitive function in a randomized trial of physical activity: results of the lifestyle interventions and independence for elders pilot study. *J Gerontol A Biol Sci Med Sci*. 2009 Jun;64(6):688-94. doi: 10.1093/gerona/glp014. PMID: 19244157.
101. Andreeva VA, Kesse-Guyot E, Barberger-Gateau P, et al. Cognitive function after supplementation with B vitamins and long-chain omega-3 fatty acids: ancillary findings from the SU.FOL.OM3 randomized trial. *Am J Clin Nutr*. 2011 Jul;94(1):278-86. doi: 10.3945/ajcn.110.006320. PMID: 21593490.
102. Chew EY, Clemons TE, Agron E, et al. Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial. *JAMA*. 2015 Aug 25;314(8):791-801. doi: 10.1001/jama.2015.9677. PMID: 26305649.
103. Dangour AD, Allen E, Elbourne D, et al. Effect of 2-y n-3 long-chain polyunsaturated fatty acid supplementation on cognitive function in older people: a randomized, double-blind, controlled trial. *American Journal of Clinical Nutrition*. 2010 Jun;91(6):1725-32. doi: <http://dx.doi.org/10.3945/ajcn.2009.29121>. PMID: 20410089.
104. DeKosky ST, Williamson JD, Fitzpatrick AL, et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial.[Erratum appears in *JAMA*. 2008 Dec 17;300(23):2730]. *JAMA*. 2008 Nov 19;300(19):2253-62. doi: <http://dx.doi.org/10.1001/jama.2008.683>. PMID: 19017911.
105. Dodge HH, Zitzelberger T, Oken BS, et al. A randomized placebo-controlled trial of Ginkgo biloba for the prevention of cognitive decline. *Neurology*. 2008 May 6;70(19 Pt 2):1809-17. doi: <http://dx.doi.org/10.1212/01.wnl.0000303814.13509.db>. PMID: 18305231.
106. Gavrilova SI, Preuss UW, Wong JW, et al. Efficacy and safety of Ginkgo biloba extract EGb 761 in mild cognitive impairment with neuropsychiatric symptoms: a randomized, placebo-controlled, double-blind, multi-center trial. *International Journal of Geriatric Psychiatry*. 2014 Oct;29(10):1087-95. doi: <http://dx.doi.org/10.1002/gps.4103>. PMID: 24633934.
107. Geleijnse JM, Giltay EJ, Kromhout D. Effects of n-3 fatty acids on cognitive decline: a randomized, double-blind, placebo-controlled trial in stable myocardial infarction patients. *Alzheimer's & Dementia*. 2012 Jul;8(4):278-87. doi: <http://dx.doi.org/10.1016/j.jalz.2011.06.002>. PMID: 21967845.
108. Lee LK, Shahar S, Chin AV, et al. Docosahexaenoic acid-concentrated fish oil supplementation in subjects with mild cognitive impairment (MCI): a 12-month randomised, double-blind, placebo-controlled trial. *Psychopharmacology*. 2013 Feb;225(3):605-12. doi: <http://dx.doi.org/10.1007/s00213-012-2848-0>. PMID: 22932777.
109. Lewis JE, Melillo AB, Tiozzo E, et al. A double-blind, randomized clinical trial of dietary supplementation on cognitive and immune functioning in healthy older adults.[Erratum appears in *BMC Complement Altern Med*. 2014;14:332]. *BMC Complementary & Alternative Medicine*. 2014;14:43. doi: <http://dx.doi.org/10.1186/1472-6882-14-43>. PMID: 24495355.
110. Maki PM, Rubin LH, Fornelli D, et al. Effects of botanicals and combined hormone therapy on cognition in postmenopausal women. *Menopause*. 2009 Nov-Dec;16(6):1167-77. doi: 10.1097/gme.0b013e3181ace484. PMID: 19590458.
111. Schiepers OJ, de Groot RH, van Boxtel MP, et al. Consuming functional foods enriched with plant sterol or stanol esters for 85 weeks does not affect neurocognitive functioning or mood in statin-treated hypercholesterolemic individuals. *Journal of Nutrition*. 2009 Jul;139(7):1368-73. doi: <http://dx.doi.org/10.3945/jn.108.103721>. PMID: 19458031.
112. Sinn N, Milte CM, Street SJ, et al. Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial. *British Journal of Nutrition*. 2012 Jun;107(11):1682-93. doi: <http://dx.doi.org/10.1017/S0007114511004788>. PMID: 21929835.
113. Snitz BE, O'Meara ES, Carlson MC, et al. Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. *JAMA*. 2009 Dec 23;302(24):2663-70. doi: <http://dx.doi.org/10.1001/jama.2009.1913>. PMID: 20040554.

114. Stonehouse W, Conlon CA, Podd J, et al. DHA supplementation improved both memory and reaction time in healthy young adults: a randomized controlled trial. *American Journal of Clinical Nutrition*. 2013 May;97(5):1134-43. doi: <http://dx.doi.org/10.3945/ajcn.112.053371>. PMID: 23515006.
115. van de Rest O, Geleijnse JM, Kok FJ, et al. Effect of fish oil on cognitive performance in older subjects: a randomized, controlled trial. *Neurology*. 2008 Aug 5;71(6):430-8. doi: <http://dx.doi.org/10.1212/01.wnl.0000324268.45138.86>. PMID: 18678826.
116. Vellas B, Coley N, Ousset PJ, et al. Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. *Lancet Neurology*. 2012 Oct;11(10):851-9. doi: [http://dx.doi.org/10.1016/S1474-4422\(12\)70206-5](http://dx.doi.org/10.1016/S1474-4422(12)70206-5). PMID: 22959217.
117. Witte AV, Kerti L, Hermannstadter HM, et al. Long-chain omega-3 fatty acids improve brain function and structure in older adults. *Cerebral Cortex*. 2014 Nov;24(11):3059-68. doi: <http://dx.doi.org/10.1093/cercor/bht163>. PMID: 23796946.
118. Witte AV, Kerti L, Margulies DS, et al. Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults. *Journal of Neuroscience*. 2014 Jun 4;34(23):7862-70. doi: <http://dx.doi.org/10.1523/JNEUROSCI.0385-14.2014>. PMID: 24899709.
119. Yurko-Mauro K, McCarthy D, Rom D, et al. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. *Alzheimer's & Dementia*. 2010 Nov;6(6):456-64. doi: <http://dx.doi.org/10.1016/j.jalz.2010.01.013>. PMID: 20434961.
120. Cukierman-Yaffe T, Bosch J, Diaz R, et al. Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial. *Lancet Diabetes Endocrinol*. 2014 Jul;2(7):562-72. doi: 10.1016/S2213-8587(14)70062-2. PMID: 24898834.
121. Strike SC, Carlisle A, Gibson EL, et al. A High Omega-3 Fatty Acid Multinutrient Supplement Benefits Cognition and Mobility in Older Women: A Randomized, Double-blind, Placebo-controlled Pilot Study. *J Gerontol A Biol Sci Med Sci*. 2016 Feb;71(2):236-42. doi: 10.1093/gerona/glv109. PMID: 26265727.
122. Scherrer B, Andrieu S, Ousset PJ, et al. Analysing Time to Event Data in Dementia Prevention Trials: The Example of the GuidAge Study of EGb761. *Journal of Nutrition, Health & Aging*. 2015 Dec;19(10):1009-11. doi: <http://dx.doi.org/10.1007/s12603-015-0582-0>. PMID: 26624212.
123. Mahmoudi MJ, Hedayat M, Sharifi F, et al. Effect of low dose omega-3 poly unsaturated fatty acids on cognitive status among older people: a double-blind randomized placebo-controlled study. *J Diabetes Metab Disord*. 2014 Feb 07;13(1):34. doi: 10.1186/2251-6581-13-34. PMID: 24507770.
124. Boespflug EL, McNamara RK, Eliassen JC, et al. Fish Oil Supplementation Increases Event-Related Posterior Cingulate Activation in Older Adults with Subjective Memory Impairment. *J Nutr Health Aging*. 2016 Feb;20(2):161-9. doi: 10.1007/s12603-015-0609-6. PMID: 26812512.
125. Brinkworth GD, Buckley JD, Noakes M, et al. Long-term effects of a very low-carbohydrate diet and a low-fat diet on mood and cognitive function. *Arch Intern Med*. 2009 Nov 9;169(20):1873-80. doi: 10.1001/archinternmed.2009.329. PMID: 19901139.
126. Martin CK, Anton SD, Han H, et al. Examination of cognitive function during six months of calorie restriction: results of a randomized controlled trial. *Rejuvenation Res*. 2007 Jun;10(2):179-90. doi: 10.1089/rej.2006.0502. PMID: 17518698.
127. Martinez-Lapiscina EH, Clavero P, Toledo E, et al. Mediterranean diet improves cognition: the PREDIMED-NAVARRA randomised trial. *J Neurol Neurosurg Psychiatry*. 2013 Dec;84(12):1318-25. doi: 10.1136/jnnp-2012-304792. PMID: 23670794.
128. Martinez-Lapiscina EH, Clavero P, Toledo E, et al. Virgin olive oil supplementation and long-term cognition: the PREDIMED-NAVARRA randomized, trial. *J Nutr Health Aging*. 2013;17(6):544-52. doi: 10.1007/s12603-013-0027-6. PMID: 23732551.

129. Valls-Pedret C, Sala-Vila A, Serra-Mir M, et al. Mediterranean Diet and Age-Related Cognitive Decline: A Randomized Clinical Trial. *JAMA Intern Med.* 2015 Jul;175(7):1094-103. doi: 10.1001/jamainternmed.2015.1668. PMID: 25961184.
130. van der Zwaluw NL, van de Rest O, Tieland M, et al. The impact of protein supplementation on cognitive performance in frail elderly. *Eur J Nutr.* 2014 Apr;53(3):803-12. doi: 10.1007/s00394-013-0584-9. PMID: 24045855.
131. Wouters-Wesseling W, Wagenaar LW, Rozendaal M, et al. Effect of an enriched drink on cognitive function in frail elderly persons. *Journals of Gerontology Series A-Biological Sciences & Medical Sciences.* 2005 Feb;60(2):265-70. PMID: 15814873.
132. Carlson MC, Saczynski JS, Rebok GW, et al. Exploring the effects of an "everyday" activity program on executive function and memory in older adults: Experience Corps. *Gerontologist.* 2008 Dec;48(6):793-801. PMID: 19139252.
133. Clare L, Nelis SM, Jones IR, et al. The Agewell trial: a pilot randomised controlled trial of a behaviour change intervention to promote healthy ageing and reduce risk of dementia in later life. *BMC Psychiatry.* 2015;15:25. doi: 10.1186/s12888-015-0402-4. PMID: 25880911.
134. Clark F, Jackson J, Carlson M, et al. Effectiveness of a lifestyle intervention in promoting the well-being of independently living older people: results of the Well Elderly 2 Randomised Controlled Trial. *J Epidemiol Community Health.* 2012 Sep;66(9):782-90. doi: 10.1136/jech.2009.099754. PMID: 21636614.
135. Hars M, Herrmann FR, Gold G, et al. Effect of music-based multitask training on cognition and mood in older adults. *Age Ageing.* 2014 Mar;43(2):196-200. doi: 10.1093/ageing/aft163. PMID: 24212920.
136. Johari SM, Shahar S, Ng TP, et al. A Preliminary Randomized Controlled Trial of Multifaceted Educational Intervention for Mild Cognitive Impairment Among Elderly Malays in Kuala Lumpur. *International Journal of Gerontology.* 2014 Jun;8(2):74-80. doi: 10.1016/j.ijge.2013.07.002. PMID: WOS:000339088200006.
137. Kobe T, Witte A, Schnelle A, et al. Combined omega-3 fatty acids, aerobic exercise and cognitive stimulation prevents decline in gray matter volume of the frontal, Parietal and cingulate cortex in patients with mild cognitive impairment. *NeuroImage.* 2016 01 May;131:226-38. doi: <http://dx.doi.org/10.1016/j.neuroimage.2015.09.050>. PMID: 607245692.
138. Lee KS, Lee Y, Back JH, et al. Effects of a multidomain lifestyle modification on cognitive function in older adults: an eighteen-month community-based cluster randomized controlled trial. *Psychother Psychosom.* 2014;83(5):270-8. doi: 10.1159/000360820. PMID: 25116574.
139. Lehtisalo J, Lindstrom J, Ngandu T, et al. Association of Long-Term Dietary Fat Intake, Exercise, and Weight with Later Cognitive Function in the Finnish Diabetes Prevention Study. *Journal of Nutrition, Health & Aging.* 2016 Feb;20(2):146-54. doi: <http://dx.doi.org/10.1007/s12603-015-0565-1>. PMID: 26812510.
140. McDaniel MA, Binder EF, Bugg JM, et al. Effects of cognitive training with and without aerobic exercise on cognitively demanding everyday activities. *Psychol Aging.* 2014 Sep;29(3):717-30. doi: 10.1037/a0037363. PMID: 25244489.
141. Moll van Charante EP, Richard E, Eurelings LS, et al. Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA): A cluster-randomised controlled trial. *The Lancet.* 2016 Aug;388(10046):797-805. doi: <http://dx.doi.org/10.1016/S0140-6736%2816%2930950-3>. PMID: 2016-41615-029.
142. Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. *Lancet.* 2015 Jun 6;385(9984):2255-63. doi: 10.1016/S0140-6736(15)60461-5. PMID: 25771249.
143. Tesky VA, Thiel C, Banzer W, et al. Effects of a Group Program to Increase Cognitive Performance Through Cognitively Stimulating Leisure Activities in Healthy Older Subjects. *GeroPsych.* 2011 01 Jun;24(2):83-92. doi: 10.1024/1662-9647/a000035. PMID: 2011313185.

144. Yesavage JA, Friedman L, Ashford JW, et al. Acetylcholinesterase inhibitor in combination with cognitive training in older adults. *J Gerontol B Psychol Sci Soc Sci*. 2008 Sep;63(5):P288-94. PMID: 18818443.
145. Alhola P, Tuomisto H, Saarinen R, et al. Estrogen + progestin therapy and cognition: a randomized placebo-controlled double-blind study. *J Obstet Gynaecol Res*. 2010 Aug;36(4):796-802. doi: 10.1111/j.1447-0756.2010.01214.x. PMID: 20666948.
146. Binder EF, Schechtman KB, Birge SJ, et al. Effects of hormone replacement therapy on cognitive performance in elderly women. *Maturitas*. 2001 Apr 20;38(2):137-46. PMID: 11306202.
147. Casini ML, Marelli G, Papaleo E, et al. Psychological assessment of the effects of treatment with phytoestrogens on postmenopausal women: a randomized, double-blind, crossover, placebo-controlled study. *Fertil Steril*. 2006 Apr;85(4):972-8. doi: 10.1016/j.fertnstert.2005.09.048. PMID: 16580383.
148. Cherrier MM, Anderson K, Shofer J, et al. Testosterone treatment of men with mild cognitive impairment and low testosterone levels. *Am J Alzheimers Dis Other Dement*. 2015 Jun;30(4):421-30. doi: 10.1177/1533317514556874. PMID: 25392187.
149. Coker LH, Hogan PE, Bryan NR, et al. Postmenopausal hormone therapy and subclinical cerebrovascular disease: the WHIMS-MRI Study. *Neurology*. 2009 Jan 13;72(2):125-34. doi: 10.1212/01.wnl.0000339036.88842.9e. PMID: 19139363.
150. Davison SL, Bell RJ, Robinson PJ, et al. Continuous-combined oral estradiol/drospirenone has no detrimental effect on cognitive performance and improves estrogen deficiency symptoms in early postmenopausal women: a randomized placebo-controlled trial. *Menopause*. 2013 Oct;20(10):1020-6. doi: 10.1097/GME.0b013e318287474f. PMID: 23591255.
151. Espeland MA, Rapp SR, Shumaker SA, et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. *JAMA*. 2004 Jun 23;291(24):2959-68. doi: 10.1001/jama.291.24.2959. PMID: 15213207.
152. Espeland MA, Brunner RL, Hogan PE, et al. Long-term effects of conjugated equine estrogen therapies on domain-specific cognitive function: results from the Women's Health Initiative study of cognitive aging extension. *J Am Geriatr Soc*. 2010 Jul;58(7):1263-71. doi: 10.1111/j.1532-5415.2010.02953.x. PMID: 20649689.
153. Espeland MA, Shumaker SA, Leng I, et al. Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years. *JAMA Intern Med*. 2013 Aug 12;173(15):1429-36. doi: 10.1001/jamainternmed.2013.7727. PMID: 23797469.
154. Espeland MA, Shumaker SA, Limacher M, et al. Relative effects of tamoxifen, raloxifene, and conjugated equine estrogens on cognition. *J Womens Health (Larchmt)*. 2010 Mar;19(3):371-9. doi: 10.1089/jwh.2009.1605. PMID: 20136553.
155. Gleason CE, Carlsson CM, Barnet JH, et al. A preliminary study of the safety, feasibility and cognitive efficacy of soy isoflavone supplements in older men and women. *Age Ageing*. 2009 Jan;38(1):86-93. doi: 10.1093/ageing/afn227. PMID: 19054783.
156. Gleason CE, Dowling NM, Wharton W, et al. Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS-Cognitive and Affective Study. *PLoS Med*. 2015 Jun;12(6):e1001833; discussion e. doi: 10.1371/journal.pmed.1001833. PMID: 26035291.
157. Gorenstein C, Renno J, Jr., Vieira Filho AH, et al. Estrogen replacement therapy and cognitive functions in healthy postmenopausal women: a randomized trial. *Arch Womens Ment Health*. 2011 Oct;14(5):367-73. doi: 10.1007/s00737-011-0230-6. PMID: 21732218.
158. Grady D, Yaffe K, Kristof M, et al. Effect of postmenopausal hormone therapy on cognitive function: the Heart and Estrogen/progestin Replacement Study. *Am J Med*. 2002 Nov;113(7):543-8. PMID: 12459399.
159. Henderson VW, St John JA, Hodis HN, et al. Long-term soy isoflavone supplementation and cognition in women: a randomized, controlled trial. *Neurology*. 2012 Jun 5;78(23):1841-8. doi: 10.1212/WNL.0b013e318258f822. PMID: 22665144.

160. Henderson VW, St John JA, Hodis HN, et al. Cognitive effects of estradiol after menopause: A randomized trial of the timing hypothesis. *Neurology*. 2016 Aug 16;87(7):699-708. doi: 10.1212/wnl.0000000000002980. PMID: 27421538.
161. Ho SC, Chan AS, Ho YP, et al. Effects of soy isoflavone supplementation on cognitive function in Chinese postmenopausal women: a double-blind, randomized, controlled trial. *Menopause*. 2007 May-Jun;14(3 Pt 1):489-99. doi: 10.1097/GME.0b013e31802c4f4f. PMID: 17308499.
162. Howes JB, Bray K, Lorenz L, et al. The effects of dietary supplementation with isoflavones from red clover on cognitive function in postmenopausal women. *Climacteric*. 2004 Mar;7(1):70-7. PMID: 15259285.
163. Kantarci K, Lowe VJ, Lesnick TG, et al. Early postmenopausal transdermal 17beta-estradiol therapy and amyloid-beta deposition. *Journal of Alzheimer's Disease*. 2016;53(2):547-56. doi: <http://dx.doi.org/10.3233/JAD-160258>. PMID: 2016-36847-015.
164. Kato-Kataoka A, Sakai M, Ebina R, et al. Soybean-derived phosphatidylserine improves memory function of the elderly Japanese subjects with memory complaints. *J Clin Biochem Nutr*. 2010 Nov;47(3):246-55. doi: 10.3164/jcbn.10-62. PMID: 21103034.
165. Kenny AM, Bellantoni S, Gruman CA, et al. Effects of transdermal testosterone on cognitive function and health perception in older men with low bioavailable testosterone levels. *J Gerontol A Biol Sci Med Sci*. 2002 May;57(5):M321-5. PMID: 11983727.
166. Kreijkamp-Kaspers S, Kok L, Grobbee DE, et al. Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women: a randomized controlled trial. *Jama*. 2004 Jul 7;292(1):65-74. doi: 10.1001/jama.292.1.65. PMID: 15238592.
167. Kritz-Silverstein D, Von Muhlen D, Barrett-Connor E, et al. Isoflavones and cognitive function in older women: the SOy and Postmenopausal Health In Aging (SOPHIA) Study. *Menopause*. 2003 May-Jun;10(3):196-202. PMID: 12792289.
168. Kritz-Silverstein D, von Muhlen D, Laughlin GA, et al. Effects of dehydroepiandrosterone supplementation on cognitive function and quality of life: the DHEA and Well-Ness (DAWN) Trial. *J Am Geriatr Soc*. 2008 Jul;56(7):1292-8. doi: 10.1111/j.1532-5415.2008.01768.x. PMID: 18482290.
169. Legault C, Maki PM, Resnick SM, et al. Effects of tamoxifen and raloxifene on memory and other cognitive abilities: cognition in the study of tamoxifen and raloxifene. *J Clin Oncol*. 2009 Nov 1;27(31):5144-52. doi: 10.1200/JCO.2008.21.0716. PMID: 19770382.
170. Moller MC, Bartfai AB, Radestad AF. Effects of testosterone and estrogen replacement on memory function. *Menopause*. 2010 Sep-Oct;17(5):983-9. doi: 10.1097/gme.0b013e3181dc2e40. PMID: 20555288.
171. Moller MC, Radestad AF, von Schoultz B, et al. Effect of estrogen and testosterone replacement therapy on cognitive fatigue. *Gynecol Endocrinol*. 2013 Feb;29(2):173-6. doi: 10.3109/09513590.2012.730568. PMID: 23095007.
172. Nickelsen T, Lufkin EG, Riggs BL, et al. Raloxifene hydrochloride, a selective estrogen receptor modulator: safety assessment of effects on cognitive function and mood in postmenopausal women. *Psychoneuroendocrinology*. 1999 Jan;24(1):115-28. PMID: 10098223.
173. Pan HA, Wang ST, Pai MC, et al. Cognitive function variations in postmenopausal women treated with continuous, combined HRT or tibolone. A comparison. *J Reprod Med*. 2003 May;48(5):375-80. PMID: 12815913.
174. Pefanco MA, Kenny AM, Kaplan RF, et al. The effect of 3-year treatment with 0.25 mg/day of micronized 17beta-estradiol on cognitive function in older postmenopausal women. *J Am Geriatr Soc*. 2007 Mar;55(3):426-31. doi: 10.1111/j.1532-5415.2007.01085.x. PMID: 17341247.
175. Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. *Jama*. 2003 May 28;289(20):2663-72. doi: 10.1001/jama.289.20.2663. PMID: 12771113.

176. Rasgon NL, Geist CL, Kenna HA, et al. Prospective randomized trial to assess effects of continuing hormone therapy on cerebral function in postmenopausal women at risk for dementia. *PLoS One*. 2014;9(3):e89095. doi: 10.1371/journal.pone.0089095. PMID: 24622517.
177. Resnick SM, Espeland MA, An Y, et al. Effects of conjugated equine estrogens on cognition and affect in postmenopausal women with prior hysterectomy. *J Clin Endocrinol Metab*. 2009 Nov;94(11):4152-61. doi: 10.1210/jc.2009-1340. PMID: 19850684.
178. Resnick SM, Espeland MA, Jaramillo SA, et al. Postmenopausal hormone therapy and regional brain volumes: the WHIMS-MRI Study. *Neurology*. 2009 Jan 13;72(2):135-42. doi: 10.1212/01.wnl.0000339037.76336.cf. PMID: 19139364.
179. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. *JAMA*. 2003 May 28;289(20):2651-62. doi: 10.1001/jama.289.20.2651. PMID: 12771112.
180. Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. *JAMA*. 2004 Jun 23;291(24):2947-58. doi: 10.1001/jama.291.24.2947. PMID: 15213206.
181. Tierney MC, Oh P, Moineddin R, et al. A randomized double-blind trial of the effects of hormone therapy on delayed verbal recall in older women. *Psychoneuroendocrinology*. 2009 Aug;34(7):1065-74. doi: 10.1016/j.psyneuen.2009.02.009. PMID: 19297102.
182. Vaughan C, Goldstein FC, Tenover JL. Exogenous testosterone alone or with finasteride does not improve measurements of cognition in healthy older men with low serum testosterone. *J Androl*. 2007 Nov-Dec;28(6):875-82. doi: 10.2164/jandrol.107.002931. PMID: 17609296.
183. Wroolie TE, Kenna HA, Williams KE, et al. Cognitive Effects of Hormone Therapy Continuation or Discontinuation in a Sample of Women at Risk for Alzheimer Disease. *American Journal of Geriatric Psychiatry*. 2015 01 Nov;23(11):1117-26. doi: <http://dx.doi.org/10.1016/j.jagp.2015.05.009>. PMID: 609354671.
184. Yaffe K, Krueger K, Cummings SR, et al. Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. *Am J Psychiatry*. 2005 Apr;162(4):683-90. doi: 10.1176/appi.ajp.162.4.683. PMID: 15800139.
185. Yaffe K, Krueger K, Sarkar S, et al. Cognitive function in postmenopausal women treated with raloxifene. *N Engl J Med*. 2001 Apr 19;344(16):1207-13. doi: 10.1056/nejm200104193441604. PMID: 11309635.
186. Yaffe K, Vittinghoff E, Ensrud KE, et al. Effects of ultra-low-dose transdermal estradiol on cognition and health-related quality of life. *Arch Neurol*. 2006 Jul;63(7):945-50. doi: 10.1001/archneur.63.7.945. PMID: 16831962.
187. Finch C, Landfield P. Neuroendocrine and autonomic functions in aging mammals. *Handbook of the biology of aging/editors, CE Finch, EL Schneider, with the assistance of associate editors, RC Adelman, GM Martin, EJ Masoro*. 1985.
188. Hogervorst E, Williams J, Budge M, et al. The nature of the effect of female gonadal hormone replacement therapy on cognitive function in postmenopausal women: a meta-analysis. *Neuroscience*. 2000;101(3):485-512.
189. Resnick SM, Maki PM, Rapp SR, et al. Effects of combination estrogen plus progestin hormone treatment on cognition and affect. *J Clin Endocrinol Metab*. 2006 May;91(5):1802-10. doi: 10.1210/jc.2005-2097. PMID: 16522699.
190. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. *JAMA*. 2002;288(3):321-33. PMID: 12117397

191. Naeini AM, Elmadfa I, Djazayerly A, et al. The effect of antioxidant vitamins E and C on cognitive performance of the elderly with mild cognitive impairment in Isfahan, Iran: a double-blind, randomized, placebo-controlled trial. *Eur J Nutr*. 2014 Aug;53(5):1255-62. doi: 10.1007/s00394-013-0628-1. PMID: 24326981.
192. Brady CB, Gaziano JM, Cxypoliski RA, et al. Homocysteine lowering and cognition in CKD: the Veterans Affairs homocysteine study. *Am J Kidney Dis*. 2009 Sep;54(3):440-9. doi: 10.1053/j.ajkd.2009.05.013. PMID: 19628319.
193. Carlsson CM, Papcke-Benson K, Carnes M, et al. Health-related quality of life and long-term therapy with pravastatin and tocopherol (vitamin E) in older adults. *Drugs Aging*. 2002;19(10):793-805. PMID: 12390056.
194. de Jager CA, Oulhaj A, Jacoby R, et al. Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial. *Int J Geriatr Psychiatry*. 2012 Jun;27(6):592-600. doi: 10.1002/gps.2758. PMID: 21780182.
195. Douaud G, Refsum H, de Jager CA, et al. Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment. *Proc Natl Acad Sci U S A*. 2013 Jun 4;110(23):9523-8. doi: 10.1073/pnas.1301816110. PMID: 23690582.
196. Grodstein F, O'Brien J, Kang JH, et al. Long-term multivitamin supplementation and cognitive function in men: a randomized trial. *Ann Intern Med*. 2013 Dec 17;159(12):806-14. doi: 10.7326/0003-4819-159-12-201312170-00006. PMID: 24490265.
197. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet*. 2002 Jul 6;360(9326):23-33. doi: 10.1016/S0140-6736(02)09328-5. PMID: 12114037.
198. Kang JH, Cook N, Manson J, et al. A randomized trial of vitamin E supplementation and cognitive function in women. *Arch Intern Med*. 2006 Dec 11-25;166(22):2462-8. doi: 10.1001/archinte.166.22.2462. PMID: 17159011.
199. Kang JH, Cook NR, Manson JE, et al. Vitamin E, vitamin C, beta carotene, and cognitive function among women with or at risk of cardiovascular disease: The Women's Antioxidant and Cardiovascular Study. *Circulation*. 2009 Jun 2;119(21):2772-80. doi: 10.1161/CIRCULATIONAHA.108.816900. PMID: 19451353.
200. Kesse-Guyot E, Fezeu L, Jeandel C, et al. French adults' cognitive performance after daily supplementation with antioxidant vitamins and minerals at nutritional doses: a post hoc analysis of the Supplementation in Vitamins and Mineral Antioxidants (SU.VI.MAX) trial. *Am J Clin Nutr*. 2011 Sep;94(3):892-9. doi: 10.3945/ajcn.110.007815. PMID: 21775560.
201. McMahon JA, Green TJ, Skeaff CM, et al. A controlled trial of homocysteine lowering and cognitive performance. *N Engl J Med*. 2006 Jun 29;354(26):2764-72. doi: 10.1056/NEJMoa054025. PMID: 16807413.
202. McNeill G, Avenell A, Campbell MK, et al. Effect of multivitamin and multiminerall supplementation on cognitive function in men and women aged 65 years and over: a randomised controlled trial. *Nutr J*. 2007;6:10. doi: 10.1186/1475-2891-6-10. PMID: 17474991.
203. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. *N Engl J Med*. 2005 Jun 9;352(23):2379-88. doi: 10.1056/NEJMoa050151. PMID: 15829527.
204. Remington R, Lortie JJ, Hoffmann H, et al. A Nutritional Formulation for Cognitive Performance in Mild Cognitive Impairment: A Placebo-Controlled Trial with an Open-Label Extension. *J Alzheimers Dis*. 2015 01 Oct;48(3):591-5. doi: 10.3233/JAD-150057. PMID: 26402075.
205. Rossom RC, Espeland MA, Manson JE, et al. Calcium and vitamin D supplementation and cognitive impairment in the women's health initiative. *J Am Geriatr Soc*. 2012 Dec;60(12):2197-205. doi: 10.1111/jgs.12032. PMID: 23176129.

206. Smith A, Clark R, Nutt D, et al. Anti-oxidant vitamins and mental performance of the elderly. *Human Psychopharmacology-Clinical and Experimental*. 1999 Oct;14(7):459-71. doi: Doi 10.1002/(Sici)1099-1077(199910)14:7<459::Aid-Hup128>3.0.Co;2-0. WOS:000083485200003.
207. Smith AD, Smith SM, de Jager CA, et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. *PLoS One*. 2010;5(9):e12244. doi: 10.1371/journal.pone.0012244. PMID: 20838622.
208. van der Zwaluw NL, Dhonukshe-Rutten RA, van Wijngaarden JP, et al. Results of 2-year vitamin B treatment on cognitive performance: secondary data from an RCT. *Neurology*. 2014 Dec 2;83(23):2158-66. doi: 10.1212/WNL.0000000000001050. PMID: 25391305.
209. Walker JG, Batterham PJ, Mackinnon AJ, et al. Oral folic acid and vitamin B-12 supplementation to prevent cognitive decline in community-dwelling older adults with depressive symptoms--the Beyond Ageing Project: a randomized controlled trial. *Am J Clin Nutr*. 2012 Jan;95(1):194-203. doi: 10.3945/ajcn.110.007799. PMID: 22170358.
210. Wolters M, Hickstein M, Flintermann A, et al. Cognitive performance in relation to vitamin status in healthy elderly German women--the effect of 6-month multivitamin supplementation. *Prev Med*. 2005 Jul;41(1):253-9. doi: 10.1016/j.ypmed.2004.11.007. PMID: 15917019.
211. Cockle S, Haller J, Kimber S, et al. The influence of multivitamins on cognitive function and mood in the elderly. *Aging & Mental Health*. 2000;4(4):339-53.
212. Durga J, van Boxtel MP, Schouten EG, et al. Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial. *Lancet*. 2007 Jan 20;369(9557):208-16. PMID: 17240287.
213. Jack CR, Jr., Petersen RC, Grundman M, et al. Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. *Neurobiology of Aging*. 2008 Sep;29(9):1285-95. PMID: 17452062.
214. Kang JH, Cook N, Manson J, et al. A trial of B vitamins and cognitive function among women at high risk of cardiovascular disease. *American Journal of Clinical Nutrition*. 2008 Dec;88(6):1602-10. doi: <http://dx.doi.org/10.3945/ajcn.2008.26404>. PMID: 19064521.
215. Oulhaj A, Jerneren F, Refsum H, et al. Omega-3 fatty acid status enhances the prevention of cognitive decline by B Vitamins in mild cognitive impairment. *Journal of Alzheimer's Disease*. 2015 10 Dec;50(2):547-57. doi: <http://dx.doi.org/10.3233/JAD-150777>. PMID: 608047606.
216. Stott DJ, MacIntosh G, Lowe GD, et al. Randomized controlled trial of homocysteine-lowering vitamin treatment in elderly patients with vascular disease. *American Journal of Clinical Nutrition*. 2005 Dec;82(6):1320-6. PMID: 16332666.
217. Yaffe K, Clemons TE, McBee WL, et al. Impact of antioxidants, zinc, and copper on cognition in the elderly: a randomized, controlled trial. *Neurology*. 2004 Nov 9;63(9):1705-7. PMID: 15534261.
218. Anderson C, Teo K, Gao P, et al. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. *Lancet Neurology*. 2011 Jan;10(1):43-53. doi: [http://dx.doi.org/10.1016/S1474-4422\(10\)70250-7](http://dx.doi.org/10.1016/S1474-4422(10)70250-7). PMID: 20980201.
219. Applegate WB, Pressel S, Wittes J, et al. Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program. *Archives of Internal Medicine*. 1994 Oct 10;154(19):2154-60. PMID: 7944835.
220. Bird AS, Blizard RA, Mann AH. Treating hypertension in the older person: an evaluation of the association of blood pressure level and its reduction with cognitive performance. *Journal of Hypertension*. 1990 Feb;8(2):147-52. PMID: 2162877.
221. Fogari R, Mugellini A, Zoppi A, et al. Influence of losartan and atenolol on memory function in very elderly hypertensive patients. *Journal of Human Hypertension*. 2003 Nov;17(11):781-5. PMID: 14578918.



222. Fogari R, Mugellini A, Zoppi A, et al. Effect of telmisartan/hydrochlorothiazide vs. lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. *Journal of Human Hypertension*. 2006 Mar;20(3):177-85. PMID: 16306998.
223. Forette F, Seux ML, Staessen JA, et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study.[Erratum appears in *Arch Intern Med*. 2003 Jan 27;163(2):241.]. *Archives of Internal Medicine*. 2002 Oct 14;162(18):2046-52. PMID: 12374512.
224. Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. *Lancet*. 1998 Oct 24;352(9137):1347-51. PMID: 9802273.
225. Goldstein G, Materson BJ, Cushman WC, et al. Treatment of hypertension in the elderly: II. Cognitive and behavioral function. Results of a Department of Veterans Affairs Cooperative Study. *Hypertension*. 1990 Apr;15(4):361-9. PMID: 2318518.
226. Gurland BJ, Teresi J, Smith WM, et al. Effects of treatment for isolated systolic hypertension on cognitive status and depression in the elderly. *Journal of the American Geriatrics Society*. 1988 Nov;36(11):1015-22. PMID: 3171039.
227. Hajjar I, Hart M, Chen YL, et al. Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial. *Journal of the American Geriatrics Society*. 2013 Feb;61(2):194-201. doi: <http://dx.doi.org/10.1111/jgs.12100>. PMID: 23350899.
228. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. *Journal of Hypertension*. 2003 May;21(5):875-86. PMID: 12714861.
229. Perez-Stable EJ, Halliday R, Gardiner PS, et al. The effects of propranolol on cognitive function and quality of life: a randomized trial among patients with diastolic hypertension. *American Journal of Medicine*. 2000 Apr 1;108(5):359-65. PMID: 10759091.
230. Sato N, Saijo Y, Sasagawa Y, et al. Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial: results after 1 year. *J Hypertens*. 2013 Jun;31(6):1245-55. doi: 10.1097/HJH.0b013e32835fdf60. PMID: 23492647.
231. Saxby BK, Harrington F, Wesnes KA, et al. Candesartan and cognitive decline in older patients with hypertension: a substudy of the SCOPE trial. *Neurology*. 2008 May 6;70(19 Pt 2):1858-66. doi: <http://dx.doi.org/10.1212/01.wnl.0000311447.85948.78>. PMID: 18458219.
232. Skoog I, Lithell H, Hansson L, et al. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). *American Journal of Hypertension*. 2005 Aug;18(8):1052-9. PMID: 16109319.
233. Starr JM, Whalley LJ. Differential cognitive outcomes in the Hypertensive Old People in Edinburgh study. *Journal of the Neurological Sciences*. 2005 Mar 15;229-230:103-7. PMID: 15760627.
234. Starr JM, Whalley LJ, Deary IJ. The effects of antihypertensive treatment on cognitive function: results from the HOPE study. *Journal of the American Geriatrics Society*. 1996 Apr;44(4):411-5. PMID: 8636587.
235. Tedesco MA, Ratti G, Mennella S, et al. Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. *American Journal of Hypertension*. 1999 Nov;12(11 Pt 1):1130-4. PMID: 10604491.
236. Williamson JD, Launer LJ, Bryan RN, et al. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. *JAMA Intern Med*. 2014 Mar;174(3):324-33. doi: 10.1001/jamainternmed.2013.13656. PMID: 24493100.
237. Yodfat Y, Bar-On D, Amir M, et al. Quality of life in normotensives compared to hypertensive men treated with isradipine or methyldopa as monotherapy or in combination with captopril: the LOMIR-MCT-IL study. *Journal of Human Hypertension*. 1996 Feb;10(2):117-22. PMID: 8867566.

238. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. *JAMA*. 1991 Jun 26;265(24):3255-64. PMID: 2046107.
239. Patel A, Group AC, MacMahon S, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. *Lancet*. 2007 Sep 8;370(9590):829-40. PMID: 17765963.
240. Peters R, Beckett N, Forette F, et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. *Lancet Neurology*. 2008 Aug;7(8):683-9. doi: [http://dx.doi.org/10.1016/S1474-4422\(08\)70143-1](http://dx.doi.org/10.1016/S1474-4422(08)70143-1). PMID: 18614402.
241. Prince MJ, Bird AS, Blizard RA, et al. Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. *BMJ*. 1996 Mar 30;312(7034):801-5. PMID: 8608285.
242. Barnes D, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. *Lancet Neurology*. 2011 Sept 2011;10(9):819-28. doi: 10.1016/S1474-4422(11)70072-2. PMID: 21775213.
243. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet*. 2002 Jul 6;360(9326):7-22. doi: 10.1016/S0140-6736(02)09327-3. PMID: 12114036.
244. Muldoon MF, Barger SD, Ryan CM, et al. Effects of lovastatin on cognitive function and psychological well-being. *Am J Med*. 2000 May;108(7):538-46. PMID: 10806282.
245. Muldoon MF, Ryan CM, Sereika SM, et al. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. *Am J Med*. 2004 Dec 1;117(11):823-9. doi: 10.1016/j.amjmed.2004.07.041. PMID: 15589485.
246. Parale GP, Baheti NN, Kulkarni PM, et al. Effects of atorvastatin on higher functions. *Eur J Clin Pharmacol*. 2006 Apr;62(4):259-65. doi: 10.1007/s00228-005-0073-z. PMID: 16489473.
247. Santanello NC, Barber BL, Applegate WB, et al. Effect of pharmacologic lipid lowering on health-related quality of life in older persons: results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study. *J Am Geriatr Soc*. 1997 Jan;45(1):8-14. PMID: 8994481.
248. Tendolkar I, Enajat M, Zwiers MP, et al. One-year cholesterol lowering treatment reduces medial temporal lobe atrophy and memory decline in stroke-free elderly with atrial fibrillation: evidence from a parallel group randomized trial. *Int J Geriatr Psychiatry*. 2012 Jan;27(1):49-58. doi: 10.1002/gps.2688. PMID: 21308791.
249. Trompet S, van Vliet P, de Craen AJ, et al. Pravastatin and cognitive function in the elderly. Results of the PROSPER study. *J Neurol*. 2010 Jan;257(1):85-90. doi: 10.1007/s00415-009-5271-7. PMID: 19653027.
250. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. *Lancet*. 2002 Nov 23;360(9346):1623-30. PMID: 12457784.
251. Barnard N, Bunner A, Agarwal U. Saturated and trans fats and dementia: a systematic review. *Neurobiol. Aging*. 2014;35:Suppl 2:S65-73. doi: 10.1016/j.neurobiolaging.2014.02.030. PMID: 24916582
252. FDA. FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs. 2012. <http://www.fda.gov/drugs/drugsafety/ucm293101.htm>.
253. Ott B, Daiello L, Dahabreh I, et al. Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials. *J Gen Intern Med*. 2015 Mar 2015;30(3):348-58. doi: 10.1007/s11606-014-3115-3. PMID: 25575908.
254. Power M, Weuve J, Sharrett A, et al. Statins, cognition, and dementia—systematic review and methodological commentary. *Nat Rev Neurol*. 2015 Apr 2015;11(4):220-9. doi: 10.1038/nrneurol.2015.35. PMID: 25799928.

255. Adapt Research Group. Results of a follow-up study to the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). *Alzheimer's & Dementia*. 2013 Nov;9(6):714-23. doi: <http://dx.doi.org/10.1016/j.jalz.2012.11.012>. PMID: 23562431.
256. Adapt Research Group, Lyketsos CG, Breitner JC, et al. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. *Neurology*. 2007 May 22;68(21):1800-8. PMID: 17460158.
257. Adapt Research Group, Martin BK, Szekely C, et al. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. *Archives of Neurology*. 2008 Jul;65(7):896-905. doi: <http://dx.doi.org/10.1001/archneur.2008.65.7.nct70006>. PMID: 18474729.
258. Breitner JC, Baker LD, Montine TJ, et al. Extended results of the Alzheimer's disease anti-inflammatory prevention trial. *Alzheimer's & Dementia*. 2011 Jul;7(4):402-11. doi: <http://dx.doi.org/10.1016/j.jalz.2010.12.014>. PMID: 21784351.
259. Kang JH, Cook N, Manson J, et al. Low dose aspirin and cognitive function in the women's health study cognitive cohort. *BMJ*. 2007 May 12;334(7601):987. PMID: 17468120.
260. Small GW, Siddarth P, Silverman DH, et al. Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with age-related memory loss: randomized controlled study. *American Journal of Geriatric Psychiatry*. 2008 Dec;16(12):999-1009. doi: <http://dx.doi.org/10.1097/JGP.0b013e31818cd3a4>. PMID: 19038899.
261. Thal LJ, Ferris SH, Kirby L, et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. *Neuropsychopharmacology*. 2005 Jun;30(6):1204-15. PMID: 15742005.
262. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. *Neurology*. 1996 Aug;47(2):425-32. PMID: 8757015.
263. Devi G, Massimi S, Schultz S, et al. A double-blind, placebo-controlled trial of donepezil for the treatment of menopause-related cognitive loss. *Gend Med*. 2007 Dec;4(4):352-8. PMID: 18215726.
264. Doody RS, Ferris SH, Salloway S, et al. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. *Neurology*. 2009 May 5;72(18):1555-61. doi: 10.1212/01.wnl.0000344650.95823.03. PMID: 19176895.
265. Feldman HH, Ferris S, Winblad B, et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEX study. *Lancet Neurol*. 2007 Jun;6(6):501-12. doi: 10.1016/S1474-4422(07)70109-6. PMID: 17509485.
266. Gavrilova SI, Kolykhalov IV, Fedorova YB, et al. Potential of Preventive Treatment of Alzheimer's Disease: Results of a Three-Year Prospective Open Comparative Trial of the Efficacy and Safety of Courses of Treatment with Cerebrolysin and Cavinton in Elderly Patients with Mild Cognitive Impairment Syndrome. *Neuroscience and Behavioral Physiology*. 2011 May;41(4):391-8. doi: 10.1007/s11055-011-9427-4. PMID: 2011362050.
267. Peters O, Lorenz D, Fesche A, et al. A combination of galantamine and memantine modifies cognitive function in subjects with amnesic MCI. *J Nutr Health Aging*. 2012;16(6):544-8. PMID: 22659994.
268. Petrella JR, Prince SE, Krishnan S, et al. Effects of donepezil on cortical activation in mild cognitive impairment: a pilot double-blind placebo-controlled trial using functional MR imaging. *AJNR Am J Neuroradiol*. 2009 Feb;30(2):411-6. doi: 10.3174/ajnr.A1359. PMID: 19001543.
269. Reynolds CF, 3rd, Butters MA, Lopez O, et al. Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy. *Arch Gen Psychiatry*. 2011 Jan;68(1):51-60. doi: 10.1001/archgenpsychiatry.2010.184. PMID: 21199965.
270. Salloway S, Ferris S, Kluger A, et al. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. *Neurology*. 2004 Aug 24;63(4):651-7. PMID: 15326237.

271. Schuff N, Suhy J, Goldman R, et al. An MRI substudy of a donepezil clinical trial in mild cognitive impairment. *Neurobiol Aging*. 2011 Dec;32(12):2318 e31-41. doi: 10.1016/j.neurobiolaging.2010.04.005. PMID: 20541841.
272. Winblad B, Gauthier S, Scinto L, et al. Safety and efficacy of galantamine in subjects with mild cognitive impairment. *Neurology*. 2008 May 27;70(22):2024-35. doi: 10.1212/01.wnl.0000303815.69777.26. PMID: 18322263.
273. Prins ND, van der Flier WA, Knol DL, et al. The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial. *Alzheimers Res Ther*. 2014 21 Jul;6(4):47. doi: 10.1186/alzrt275. PMID: 25478019.
274. Diniz BS, Pinto JA, Jr., Gonzaga ML, et al. To treat or not to treat? A meta-analysis of the use of cholinesterase inhibitors in mild cognitive impairment for delaying progression to Alzheimer's disease. *Eur Arch Psychiatry Clin Neurosci*. 2009 June 2009;259(4):248-56. doi: 10.1007/s00406-008-0864-1. PMID: 19224111.
275. Birks J, Flicker L. Donepezil for mild cognitive impairment. *Cochrane Database of Systematic Reviews*. 2006 Jul 2006;19(3) PMID: 16856114
276. Russ T, Morling J. Cholinesterase inhibitors for mild cognitive impairment. *Cochrane Database of Systematic Reviews*. 2012 Sept 2012;12(9)doi: 10.1002/14651858.CD009132.pub2. PMID: 22972133
277. Luchsinger JA, Perez T, Chang H, et al. Metformin in Amnestic Mild Cognitive Impairment: Results of a Pilot Randomized Placebo Controlled Clinical Trial. *J Alzheimer's Dis*. 2016;51(2):501-14. doi: 10.3233/JAD-150493. PMID: 26890736
278. Cheatham RA, Roberts SB, Das SK, et al. Long-term effects of provided low and high glycemic load low energy diets on mood and cognition. *Physiol Behav*. 2009 Sep 7;98(3):374-9. doi: 10.1016/j.physbeh.2009.06.015. PMID: 19576915.
279. Koekkoek PS, Ruis C, van den Donk M, et al. Intensive multifactorial treatment and cognitive functioning in screen-detected type 2 diabetes--the ADDITION-Netherlands study: a cluster-randomized trial. *J Neurol Sci*. 2012 Mar 15;314(1-2):71-7. doi: 10.1016/j.jns.2011.10.028. PMID: 22093142.
280. Launer LJ, Miller ME, Williamson JD, et al. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. *Lancet Neurol*. 2011 Nov;10(11):969-77. doi: 10.1016/S1474-4422(11)70188-0. PMID: 21958949.
281. Luchsinger JA, Palmas W, Teresi JA, et al. Improved diabetes control in the elderly delays global cognitive decline. *J Nutr Health Aging*. 2011 Jun;15(6):445-9. PMID: 21623465.
282. Seaquist ER, Miller ME, Fonseca V, et al. Effect of thiazolidinediones and insulin on cognitive outcomes in ACCORD-MIND. *J Diabetes Complications*. 2013 Sep-Oct;27(5):485-91. doi: 10.1016/j.jdiacomp.2013.03.005. PMID: 23680059.
283. Cheng G, Huang C, Deng H, et al. Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. *Intern Med*. 2012 May 2012;42(5):484-91. doi: 10.1111/j.1445-5994.2012.02758.x. PMID: 22372522.
284. Williamson JD, Miller ME, Bryan RN, et al. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. *Am J Cardiol*. 2007 Jun 18;99(12A):112i-22i. doi: 10.1016/j.amjcard.2007.03.029. PMID: 17599421.
285. Origin Trial Investigators, Gerstein HC, Bosch J, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. *N Engl J Med*. 2012 Jul 26;367(4):319-28. doi: 10.1056/NEJMoa1203858. PMID: 22686416.
286. Lucassen EA, Piaggi P, Dsurney J, et al. Sleep extension improves neurocognitive functions in chronically sleep-deprived obese individuals. *PLoS One*. 2014;9(1):e84832. doi: 10.1371/journal.pone.0084832. PMID: 24482677.

287. Sun J, Kang J, Wang P, et al. Self-relaxation training can improve sleep quality and cognitive functions in the older: a one-year randomised controlled trial. *J Clin Nurs*. 2013 May;22(9-10):1270-80. doi: 10.1111/jocn.12096. PMID: 23574290.
288. Bugos JA, Perlstein WM, McCrae CS, et al. Individualized piano instruction enhances executive functioning and working memory in older adults. *Aging Ment Health*. 2007 Jul;11(4):464-71. doi: 10.1080/13607860601086504. PMID: 17612811.
289. Forlenza OV, Diniz BS, Radanovic M, et al. Disease-modifying properties of long-term lithium treatment for amnesic mild cognitive impairment: randomised controlled trial. *Br J Psychiatry*. 2011 May;198(5):351-6. doi: 10.1192/bjp.bp.110.080044. PMID: 21525519.
290. Newhouse P, Kellar K, Aisen P, et al. Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial. *Neurology*. 2012 Jan 10;78(2):91-101. doi: 10.1212/WNL.0b013e31823efcbb. PMID: 22232050.
291. Snowball A, Tachtsidis I, Popescu T, et al. Long-term enhancement of brain function and cognition using cognitive training and brain stimulation. *Curr Biol*. 2013 Jun 3;23(11):987-92. doi: 10.1016/j.cub.2013.04.045. PMID: 23684971.
292. Sonnen J, Montine K, Quinn J, et al. Biomarkers for cognitive impairment and dementia in elderly people. *Lancet Neurology*. 2008 Aug 2008;7(8):704-14. doi: 10.1016/S1474-4422(08)70162-5. PMID: 18635019.
293. Espeland MA, Rapp SR, Bray GA, et al. Long-term impact of behavioral weight loss intervention on cognitive function. *Journals of Gerontology Series A-Biological Sciences & Medical Sciences*. 2014;69(9):1101-8. PMID: 24619151.
294. Eklund A, Nichols TE, Knutsson H. Cluster failure: Why fMRI inferences for spatial extent have inflated false-positive rates. *Proceedings of the National Academy of Sciences of the United States of America*. 2016 2016 July 12;113(28):7900-5. doi: 10.1073/pnas.1602413113. PMID: 27357684.

## Abbreviations

3MS	Modified Mini-Mental State Examination
ACE	Angiotensin converting enzyme inhibitors
ACTIVE	Advanced Cognitive Training for Independent and Vital Elderly
AD	Alzheimer's Disease
ADAS-Cog	Alzheimer's Disease Assessment Scale-Cognitive Subscale
ADL	Activities of daily living
AE	Adverse Events
APC	Annualized percentage change
ARB`	Antiotensin receptor blocker
AVLT	Auditory Verbal Learning Test
BCT	Brief cognitive test
BEM-144	Batterie d'Efficiency Mnesique 144
BID	Twice daily
BMI	Body Mass Index
BNT	Boston Naming Test
BVMT	Brief Visuospatial Memory Test
BVRT	Benton Visual Retention Test
C	Control
CAMCOG	Cambridge Cognition Examination
CANTAB PAL	Cambridge Neuropsychological Test Automated Battery Paired Associated Learning Test
CANTAB	Cambridge Neuropsychological Test Automated Battery Paired Associated Learning Test
CATD	Clinical Alzheimer's-type Dementia
CDR	Clinial Dementia Rating
CEE	Conjugated equine estrogen
CERAD	Consortium to Establish a Registry for Alzheimer's Disease
CI	Confidence interval
CLOX-1	Clock Drawing Test
CSF	Cerebrospinal fluid
CHD	Coronary heart disease
COWAT	Controlled Oral Word Association Test
CPT	Continuous Performance Task
CT	Computerized tomography
CVFT	Category Verbal Fluency Test
CVLT	California Verbal Learning Test
DHA	Docosahexaenoic acid
DHEA	dehydroepiandrosterone
DMS48	Delayed Matching-to-Sample Task
DS	Digit Span (Forward or Backward)
DSM	Diagnostic Statistical Manual of Mental Disorders
DSST	Digit Symbol Substitution Test
DVT	Digit Vigilance Test
EBMT	East Boston Memory Test
EPA	Eicosapentaenoic acid

ES	Effect size
FAB	Frontal Assessment Battery
FCRST	Free and Cued Selective Reminding Test
FDG-PET	Fluorodeoxyglucose positron emission tomography
fMRI	Functional magnetic resonance imaging
F-TICS	French version, Telephone Interview Cognitive Status
HC	Hippocampus
HKLLT	Hong Kong List Learning Test
HRT	Hormone replacement therapy
HVLT	Hopkins Verbal Learning Test
I	Intervention
IADL	Instrumental activities of daily living
IHAMS	Iowa Health and Active Minds Study
IOM	Institute of Medicine
ITT	Intention to treat
IU	International Units
k	Number of studies included
KQ	Key Question
LDL	Low density lipoprotein
MCI	Mild cognitive impairment
MG	Milligrams
MMSE	Mini-Mental State Examination
MNP	Multidomain neuropsychological test performance
MRI	Magnetic resonance imaging
n	Number of participants
NINCDS-ADRDA	National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association
NR	Not reported
NS	Not significant
NSAIDs	Nonsteroidal anti-inflammatory drugs
NTB	Neuropsychological test battery
OR	Odds ratio
PALS	Paired Association Learning Test
PET	Positron emission tomography
PICOTS	Populations, Interventions, Comparisons, Outcomes, Timing, and Setting
PRM	Pattern Recognition Memory
QAD	Every other day
RAVLT	Rey Auditory Verbal Learning Test
RBANS	Repeatable Battery for Neuropsychological Status
RBMT	Rivermead Behavioral Memory Test
RCFT	Rey-Osterrieth Complex Figure Test
RCI	Reliable Change Index
RCPM	Raven's Colored Progressive Matrices
RCT	Randomized controlled trial
ROB	Risk of bias
RT	Reaction time

SCWT	Stroop Test (color, word, interference)
SDMT	Symbol Digit Modalities Test
SERM	Selective estrogen receptor modulator
SoE	Strength of Evidence
SPECT	Single photon emission computed tomography
SWM	Spatial Working Memory
TIA	Transient ischemic attack
TICS	Telephone Interview for Cognitive Status
TICS-M	Telephone Interview for Cognitive Status-Modified
TMT	Trail Making Test (parts A and/or B)
UFOV	Useful Field of View
VP	Verbal proficiency
VR	Visual Reproduction
VRM	Verbal Recognition Memory
WAIS	Wechsler Adult Intelligence Scale
WMS	Wechsler Memory Scale



# Appendix A. Search Strategies

## Database: Ovid MEDLINE(R)

### Search Strategy: RCTs

- 
- 1 exp Tertiary Prevention/ or exp Secondary Prevention/ or exp Primary Prevention/ (141964)
  - 2 prevent\*.ti. (216549)
  - 3 protect\*.ti. (118660)
  - 4 delay\*.ti. (51184)
  - 5 ((reduc\* or decreas\* or effect\* or lower\* or modif\* or change\* or stop\* or improv\* or increas\* or enhanc\* or rais\*) and risk\*).ti. (43135)
  - 6 1 or 2 or 3 or 4 or 5 (545854)
  - 7 lifestyle\*.ti. (8489)
  - 8 life style.ti. (1355)
  - 9 exp Health Behavior/ (133222)
  - 10 exp Motor Activity/ (216634)
  - 11 ((physical or aerobic\* or leisure) and (activit\* or fitness)).ti. (25122)
  - 12 exercis\*.ti. (84377)
  - 13 exp Diet/ (218815)
  - 14 diet\*.ti. (134912)
  - 15 fruit\*.ti. (16048)
  - 16 vegetable\*.ti. (7963)
  - 17 nutrition\*.ti. (74518)
  - 18 fat\*.ti. (181033)
  - 19 caffeine.ti. (9030)
  - 20 sodium.ti. (73002)
  - 21 salt\*.ti. (34028)
  - 22 alcohol\*.ti. (103760)
  - 23 ((smok\* or tobacco) and (quit or cessation or stop\*)).ti. (9709)
  - 24 ((metacognitive or cognitive or mental or brain or memory or social or perceptual or computer) and (activit\* or train\* or stimulat\* or intervention or engag\* or rehab\*)).ti. (36862)
  - 25 exp \*Pharmacology, Clinical/ (1700)
  - 26 exp Pharmaceutical Preparations/ (674904)
  - 27 drug\*.ti. (298706)
  - 28 medication\*.ti. (29416)
  - 29 pharmacopsychiatry.ti. (51)
  - 30 exp Psychopharmacology/ (5429)
  - 31 lovastatin/ or simvastatin/ or pravastatin/ (11705)
  - 32 statin\*.ti. (9993)
  - 33 exp Antihypertensive Agents/ (234730)
  - 34 anti-hypertensive\*.ti. (541)
  - 35 antihypertensive\*.ti. (10665)
  - 36 exp Cholinesterase Inhibitors/ (44525)
  - 37 Acetylcholinesterase inhibitor\*.ti. (815)
  - 38 (Donepezil or Aricept or Memantine or Namenda or Rivastigmine or Exelon or Galantamine or razadyne or Quetiapine or seroquel).ti. (4354)
  - 39 cholinesterase inhibitor\*.ti. (1161)
  - 40 exp Antibodies, Monoclonal/ or exp Antibodies, Monoclonal, Humanized/ (190958)
  - 41 anti amyloid\*.ti. (125)
  - 42 antiamyloid\*.ti. (26)
  - 43 Solanezumab.ti. (15)
  - 44 crenezumab.ti. (0)

45 gantenerumab.ti. (6)  
46 crenezumab.ab. (4)  
47 antiplatlet.ti. (0)  
48 anti-platelet.ti. (782)  
49 (Triflusal or Ticlid or plavix or brilinta or persantine or Ticlopidine or Dipyridomole or Clopidogrel).ti. (4606)  
50 exp Hypoglycemic Agents/ (206876)  
51 (Pioglitazone or actos or Glucophage or metformin).ti. (6739)  
52 ((gonadal or sex) adj steroid\*).ti. (3910)  
53 exp Hormone Replacement Therapy/ (21950)  
54 estrogen\*.ti. (46056)  
55 progest\*.ti. (27523)  
56 medroxyprogesterone\*.ti. (1983)  
57 estradiol.ti. (17656)  
58 raloxifene.ti. (1169)  
59 exp Cyclooxygenase 2 Inhibitors/ (10161)  
60 (Celecoxib or Rofecoxib).ti. (2498)  
61 exp Anti-Inflammatory Agents, Non-Steroidal/ (170835)  
62 (Ibuprofen or Tarenflurbil or flurbiprofen or Flurizan or Naproxen or Aspirin).ti. (19958)  
63 exp Dietary Supplements/ (49171)  
64 supplement\*.ti. (42004)  
65 nutraceutical\*.ti. (625)  
66 exp Nootropic Agents/ (28153)  
67 nootropic\*.ti. (444)  
68 exp Vitamins/ (279374)  
69 exp Minerals/ (129537)  
70 omega.ti. (7082)  
71 ginkgo biloba.ti. (1700)  
72 ginko biloba.ti. (6)  
73 folate.ti. (7866)  
74 fish oil.ti. (2892)  
75 saffron.ti. (288)  
76 crocus sativus.ti. (206)  
77 fuzhisan.ti. (7)  
78 melissa.ti. (155)  
79 beta carotene.ti. (2945)  
80 vitamin\*.ti. (79987)  
81 ((manag\* or control\* or lower\* or reduc\* or decreas\* or loss or lose) and (weight or BMI or body mass index  
or overweight or obes\* or diabetes or depress\* or cardio\* or vascular or blood pressure or hypertension or  
cholesterol or hypercholesterolemia or homocysteine)).ti. (84346)  
82 or/6-81 (3655158)  
83 dementia/ or alzheimer disease/ (104784)  
84 dement\*.ti. (33084)  
85 exp Cognition/ (119536)  
86 exp Mild Cognitive Impairment/ or exp Cognition Disorders/ (68412)  
87 memory disorders/ (16505)  
88 executive funtion/ (0)  
89 exp memory/ (107625)  
90 cognition.ti. (7518)  
91 ((cognit\* or neurocognit\* or memory or neuropsy\* or neuro\*) adj (impair\* or disorder\* or dysfunction\* or  
function\* ag?ing or declin\* or status or perform\* or diabil\* or disable\* or maint\* or enhanc\*)).ti. (31889)  
92 ((maint\* or impair\* or disorder\* or declin\* or enhanc\*) adj (cognit\* or neurocognit\* or memory or neuropsy\*  
or neuro\*)).ti. (1900)  
93 (amyloid or tau or plasticity).ti. (44515)  
94 ((brain or grey matter or gray matter) adj3 (function\* or scan\* or mri or volume or chang\* or imag\*)).ti.  
(15993)

95 exp Biological Markers/ (681977)  
 96 (83 or 86) and 95 (6502)  
 97 83 or 84 or 85 or 86 or 87 or 88 or 89 or 90 or 91 or 92 or 93 or 96 (403150)  
 98 82 and 97 (65610)  
 99 \*Alzheimer Disease/pc [Prevention & Control] (1256)  
 100 \*Mild Cognitive Impairment/pc [Prevention & Control] (48)  
 101 Cognition Disorders/pc [Preventions & Control] (2341)  
 102 or/98-101 (66756)  
 103 98 or 102 (66756)  
 104 randomized controlled trials as topic/ (100210)  
 105 randomized controlled trial/ (404260)  
 106 random allocation/ (85128)  
 107 double blind method/ (132506)  
 108 single blind method/ (21176)  
 109 clinical trial/ (495811)  
 110 clinical trial, phase i.pt. (15460)  
 111 clinical trial, phase ii.pt. (25039)  
 112 clinical trial, phase iii.pt. (10500)  
 113 clinical trial, phase iv.pt. (1099)  
 114 controlled clinical trial.pt. (89967)  
 115 randomized controlled trial.pt. (404260)  
 116 multicenter study.pt. (192213)  
 117 clinical trial.pt. (495811)  
 118 exp Clinical trials as topic/ (286404)  
 119 or/104-118 (1096584)  
 120 (clinical adj trial\$.tw. (219796)  
 121 ((singl\$ or doubl\$ or treb\$ or tripl\$) adj (blind\$3 or mask\$3)).tw. (129617)  
 122 placebos/ (32961)  
 123 placebo\$.tw. (159399)  
 124 randomly allocated.tw. (17236)  
 125 (allocated adj2 random\$.tw. (19800)  
 126 120 or 121 or 122 or 123 or 124 or 125 (425064)  
 127 119 or 126 (1229155)  
 128 103 and 127 (13446)  
 129 limit 128 to humans (12721)  
 130 limit 129 to (addresses or autobiography or bibliography or biography or case reports or classical article or  
 clinical conference or comment or congresses or consensus development conference or consensus development  
 conference, nih or "corrected and republished article" or dataset or dictionary or directory or editorial or  
 evaluation studies or historical article or in vitro or interactive tutorial or interview or lectures or legal cases or  
 legislation or letter or news or newspaper article or observational study or patient education handout or  
 periodical index or portraits or validation studies or video-audio media or webcasts) (838)  
 131 129 not 130 (11883)  
 132 limit 131 to yr="2009 -Current" (4830)

# Database: Ovid MEDLINE(R)

## Search Strategy: Observational Studies

Database: Ovid MEDLINE(R) <1946 to January Week 4 2016>

Search Strategy:

- 
- 1 exp Tertiary Prevention/ or exp Secondary Prevention/ or exp Primary Prevention/ (141964)
  - 2 prevent\*.ti. (216549)
  - 3 protect\*.ti. (118660)
  - 4 delay\*.ti. (51184)
  - 5 ((reduc\* or decreas\* or effect\* or lower\* or modif\* or change\* or stop\* or improv\* or increas\* or enhanc\* or rais\*) and risk\*).ti. (43135)
  - 6 (biomarker\* adj2 enrich\*).ti. (11)
  - 7 intervention\*.ti. (83501)
  - 8 program\*.ti. (139255)
  - 9 multidomain\*.ti. (421)
  - 10 multi-domain\*.ti. (143)
  - 11 multicomponent\*.ti. (1987)
  - 12 multi-component\*.ti. (561)
  - 13 multifactoral\*.ti. (15)
  - 14 multi-factoral\*.ti. (2)
  - 15 approach\*.ti. (175606)
  - 16 lifestyle\*.ti. (8489)
  - 17 life style.ti. (1355)
  - 18 exp Health Behavior/ (133222)
  - 19 exp Motor Activity/ (216634)
  - 20 ((physical or aerobic\* or leisure) and (activit\* or fitness)).ti. (25122)
  - 21 exercis\*.ti. (84377)
  - 22 exp Diet/ (218815)
  - 23 diet\*.ti. (134912)
  - 24 fruit\*.ti. (16048)
  - 25 vegetable\*.ti. (7963)
  - 26 nutrition\*.ti. (74518)
  - 27 fat\*.ti. (181033)
  - 28 caffeine.ti. (9030)
  - 29 sodium.ti. (73002)
  - 30 salt\*.ti. (34028)
  - 31 alcohol\*.ti. (103760)
  - 32 ((smok\* or tobacco) and (quit or cessation or stop\*)).ti. (9709)
  - 33 ((metacognitive or cognitive or mental or brain or memory or social or perceptual or computer) and (activit\* or train\* or stimulat\* or intervention or engag\* or rehab\*)).ti. (36862)
  - 34 exp \*Pharmacology, Clinical/ (1700)
  - 35 exp Pharmaceutical Preparations/ (674904)
  - 36 drug\*.ti. (298706)
  - 37 medication\*.ti. (29416)
  - 38 pharmacopsychiatry.ti. (51)
  - 39 exp Psychopharmacology/ (5429)
  - 40 lovastatin/ or simvastatin/ or pravastatin/ (11705)
  - 41 statin\*.ti. (9993)
  - 42 exp Antihypertensive Agents/ (234730)
  - 43 anti-hypertensive\*.ti. (541)
  - 44 antihypertensive\*.ti. (10665)
  - 45 exp Cholinesterase Inhibitors/ (44525)
  - 46 Acetylcholinesterase inhibitor\*.ti. (815)

47 (Donepezil or Aricept or Memantine or Namenda or Rivastigmine or Exelon or Galantamine or razadyne or  
 Quetiapine or seroquel).ti. (4354)  
 48 cholinesterase inhibitor\*.ti. (1161)  
 49 exp Antibodies, Monoclonal/ or exp Antibodies, Monoclonal, Humanized/ (190958)  
 50 anti amyloid\*.ti. (125)  
 51 antiamyloid\*.ti. (26)  
 52 Solanezumab.ti. (15)  
 53 crenezumab.ti. (0)  
 54 gantenerumab.ti. (6)  
 55 crenezumab.ab. (4)  
 56 antiplatelet.ti. (0)  
 57 anti-platelet.ti. (782)  
 58 (Triflusal or Ticlid or plavix or brilinta or persantine or Ticlopidine or Dipyridomole or Clopidogrel).ti.  
 (4606)  
 59 exp Hypoglycemic Agents/ (206876)  
 60 (Pioglitazone or actos or Glucophage or metformin).ti. (6739)  
 61 ((gonadal or sex) adj steroid\*).ti. (3910)  
 62 exp Hormone Replacement Therapy/ (21950)  
 63 estrogen\*.ti. (46056)  
 64 progest\*.ti. (27523)  
 65 medroxyprogesterone\*.ti. (1983)  
 66 estradiol.ti. (17656)  
 67 raloxifene.ti. (1169)  
 68 exp Cyclooxygenase 2 Inhibitors/ (10161)  
 69 (Celecoxib or Rofecoxib).ti. (2498)  
 70 exp Anti-Inflammatory Agents, Non-Steroidal/ (170835)  
 71 (Ibuprofen or Tarenflurbil or flurbiprofen or Flurizan or Naproxen or Aspirin).ti. (19958)  
 72 exp Dietary Supplements/ (49171)  
 73 supplement\*.ti. (42004)  
 74 nutraceutical\*.ti. (625)  
 75 exp Nootropic Agents/ (28153)  
 76 nootropic\*.ti. (444)  
 77 exp Vitamins/ (279374)  
 78 exp Minerals/ (129537)  
 79 omega.ti. (7082)  
 80 ginkgo biloba.ti. (1700)  
 81 ginko biloba.ti. (6)  
 82 folate.ti. (7866)  
 83 fish oil.ti. (2892)  
 84 saffron.ti. (288)  
 85 crocus sativus.ti. (206)  
 86 fuzhisan.ti. (7)  
 87 melissa.ti. (155)  
 88 beta carotene.ti. (2945)  
 89 vitamin\*.ti. (79987)  
 90 ((manag\* or control\* or lower\* or reduc\* or decreas\* or loss or lose) and (weight or BMI or body mass index  
 or overweight or obes\* or diabetes or depress\* or cardio\* or vascular or blood pressure or hypertension or  
 cholesterol or hypercholesterolemia or homocysteine)).ti. (84346)  
 91 or/1-90 (3967512)  
 92 dementia/ or alzheimer disease/ (104784)  
 93 dement\*.ti. (33084)  
 94 exp Mild Cognitive Impairment/ or exp Cognition Disorders/ (68412)  
 95 ((cognit\* or neurocognit\* or memory or neuropsy\* or neuro\*) adj (impair\* or disorder\* or dysfunction\* or  
 diabil\* or disable\*)).ti. (23706)  
 96 ((impair\* or disorder\*) adj (cognit\* or neurocognit\* or memory)).ti. (576)

97 or/92-96 (175046)  
 98 \*Alzheimer Disease/pc [Prevention & Control] (1256)  
 99 \*Mild Cognitive Impairment/pc [Prevention & Control] (48)  
 100 Cognition Disorders/pc [Preventions & Control] (2341)  
 101 or/98-100 (3558)  
 102 (91 and 97) or 101 (34439)  
 103 exp cohort studies/ (1486668)  
 104 cohort\$.tw. (295133)  
 105 controlled clinical trial.pt. (89967)  
 106 epidemiologic studies/ (6963)  
 107 (follow up adj stud\$.tw. (37939)  
 108 longitudinal.tw. (142385)  
 109 (observational adj stud\$.tw. (48091)  
 110 Comparative Study/ (1720170)  
 111 103 or 104 or 105 or 106 or 107 or 108 or 109 or 110 (3175113)  
 112 102 and 111 (7550)  
 113 limit 112 to humans (7069)  
 114 limit 113 to "all child (0 to 18 years)" (691)  
 115 limit 114 to "all adult (19 plus years)" (372)  
 116 113 not 114 (6378)  
 117 115 or 116 (6750)  
 118 limit 117 to (addresses or autobiography or bibliography or biography or case reports or clinical conference or  
 comment or congresses or consensus development conference or consensus development conference, nih or  
 dataset or dictionary or directory or editorial or in vitro or interactive tutorial or interview or lectures or legal  
 cases or legislation or letter or news or newspaper article or patient education handout or periodical index or  
 portraits or validation studies or video-audio media or webcasts) (360)  
 119 117 not 118 (6390)  
 120 limit 119 to yr="2009 - 2016" (2812)

# Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations

## Search Strategy: RCTs

- 
- 1 exp Tertiary Prevention/ or exp Secondary Prevention/ or exp Primary Prevention/ (0)
  - 2 prevent\*.ti. (16727)
  - 3 protect\*.ti. (9964)
  - 4 delay\*.ti. (5679)
  - 5 ((reduc\* or decreas\* or effect\* or lower\* or modif\* or change\* or stop\* or improv\* or increas\* or enhanc\* or rais\*) and risk\*).ti. (5717)
  - 6 1 or 2 or 3 or 4 or 5 (37733)
  - 7 lifestyle\*.ti. (1346)
  - 8 life style.ti. (73)
  - 9 exp Health Behavior/ (0)
  - 10 exp Motor Activity/ (0)
  - 11 ((physical or aerobic\* or leisure) and (activit\* or fitness)).ti. (3604)
  - 12 exercis\*.ti. (7474)
  - 13 exp Diet/ (0)
  - 14 diet\*.ti. (11652)
  - 15 fruit\*.ti. (2919)
  - 16 vegetable\*.ti. (892)
  - 17 nutrition\*.ti. (6266)
  - 18 fat\*.ti. (15032)
  - 19 caffeine.ti. (503)
  - 20 sodium.ti. (5610)
  - 21 salt\*.ti. (5744)
  - 22 alcohol\*.ti. (9093)
  - 23 ((smok\* or tobacco) and (quit or cessation or stop\*)).ti. (976)
  - 24 ((metacognitive or cognitive or mental or brain or memory or social or perceptual or computer) and (activit\* or train\* or stimulat\* or intervention or engag\* or rehab\*)).ti. (3677)
  - 25 exp \*Pharmacology, Clinical/ (0)
  - 26 exp Pharmaceutical Preparations/ (0)
  - 27 drug\*.ti. (21843)
  - 28 medication\*.ti. (3542)
  - 29 pharmacopsychiatry.ti. (2)
  - 30 exp Psychopharmacology/ (0)
  - 31 lovastatin/ or simvastatin/ or pravastatin/ (0)
  - 32 statin\*.ti. (1193)
  - 33 exp Antihypertensive Agents/ (0)
  - 34 anti-hypertensive\*.ti. (46)
  - 35 antihypertensive\*.ti. (505)
  - 36 exp Cholinesterase Inhibitors/ (0)
  - 37 Acetylcholinesterase inhibitor\*.ti. (84)
  - 38 (Donepezil or Aricept or Memantine or Namenda or Rivastigmine or Exelon or Galantamine or razadyne or Quetiapine or seroquel).ti. (565)
  - 39 cholinesterase inhibitor\*.ti. (89)
  - 40 exp Antibodies, Monoclonal/ or exp Antibodies, Monoclonal, Humanized/ (0)
  - 41 anti amyloid\*.ti. (18)
  - 42 antiamyloid\*.ti. (3)
  - 43 Solanezumab.ti. (3)
  - 44 crenezumab.ti. (1)
  - 45 gantenerumab.ti. (0)
  - 46 crenezumab.ab. (5)

47 antiplatlet.ti. (1)  
48 anti-platelet.ti. (74)  
49 (Triflusal or Ticlid or plavix or brilinta or persantine or Ticlopidine or Dipyridomole or Clopidogrel).ti. (515)  
50 exp Hypoglycemic Agents/ (0)  
51 (Pioglitazone or actos or Glucophage or metformin).ti. (1160)  
52 ((gonadal or sex) adj steroid\*).ti. (134)  
53 exp Hormone Replacement Therapy/ (0)  
54 estrogen\*.ti. (1884)  
55 progest\*.ti. (985)  
56 medroxyprogesterone\*.ti. (51)  
57 estradiol.ti. (676)  
58 raloxifene.ti. (78)  
59 exp Cyclooxygenase 2 Inhibitors/ (0)  
60 (Celecoxib or Rofecoxib).ti. (207)  
61 exp Anti-Inflammatory Agents, Non-Steroidal/ (0)  
62 (Ibuprofen or Tarenflurbil or flurbiprofen or Flurizan or Naproxen or Aspirin).ti. (1397)  
63 exp Dietary Supplements/ (0)  
64 supplement\*.ti. (4634)  
65 nutraceutical\*.ti. (127)  
66 exp Nootropic Agents/ (0)  
67 nootropic\*.ti. (28)  
68 exp Vitamins/ (0)  
69 exp Minerals/ (0)  
70 omega.ti. (1008)  
71 ginkgo biloba.ti. (149)  
72 ginko biloba.ti. (1)  
73 folate.ti. (495)  
74 fish oil.ti. (242)  
75 saffron.ti. (81)  
76 crocus sativus.ti. (55)  
77 fuzhisan.ti. (1)  
78 melissa.ti. (40)  
79 beta carotene.ti. (163)  
80 vitamin\*.ti. (6567)  
81 ((manag\* or control\* or lower\* or reduc\* or decreas\* or loss or lose) and (weight or BMI or body mass index  
or overweight or obes\* or diabetes or depress\* or cardio\* or vascular or blood pressure or hypertension or  
cholesterol or hypercholesterolemia or homocysteine)).ti. (9325)  
82 or/6-81 (152409)  
83 dementia/ or alzheimer disease/ (0)  
84 dement\*.ti. (3196)  
85 exp Cognition/ (0)  
86 exp Mild Cognitive Impairment/ or exp Cognition Disorders/ (0)  
87 memory disorders/ (0)  
88 executive funtion/ (0)  
89 exp memory/ (0)  
90 cognition.ti. (1391)  
91 ((cognit\* or neurocognit\* or memory or neuropsy\* or neuro\*) adj (impair\* or disorder\* or dysfunction\* or  
function\* ag?ing or declin\* or status or perform\* or diabil\* or disable\* or maint\* or enhanc\*).ti. (4103)  
92 ((maint\* or impair\* or disorder\* or declin\* or enhanc\*) adj (cognit\* or neurocognit\* or memory or neuropsy\*  
or neuro\*)).ti. (216)  
93 (amyloid or tau or plasticity).ti. (4251)  
94 ((brain or grey matter or gray matter) adj3 (function\* or scan\* or mri or volume or chang\* or imag\*).ti.  
(1579)  
95 exp Biological Markers/ (0)  
96 (83 or 86) and 95 (0)



97 83 or 84 or 85 or 86 or 87 or 88 or 89 or 90 or 91 or 92 or 93 or 96 (12603)  
 98 82 and 97 (1485)  
 99 \*Alzheimer Disease/pc [Prevention & Control] (0)  
 100 \*Mild Cognitive Impairment/pc [Prevention & Control] (0)  
 101 Cognition Disorders/pc [Preventions & Control] (0)  
 102 or/98-101 (1485)  
 103 98 or 102 (1485)  
 104 randomized controlled trials as topic/ (0)  
 105 randomized controlled trial/ (759)  
 106 random allocation/ (0)  
 107 double blind method/ (0)  
 108 single blind method/ (0)  
 109 clinical trial/ (472)  
 110 clinical trial, phase i.pt. (29)  
 111 clinical trial, phase ii.pt. (42)  
 112 clinical trial, phase iii.pt. (35)  
 113 clinical trial, phase iv.pt. (2)  
 114 controlled clinical trial.pt. (55)  
 115 randomized controlled trial.pt. (759)  
 116 multicenter study.pt. (399)  
 117 clinical trial.pt. (472)  
 118 exp Clinical trials as topic/ (0)  
 119 or/104-118 (1245)  
 120 (clinical adj trial\$.tw. (26676)  
 121 ((singl\$ or doubl\$ or treb\$ or tripl\$) adj (blind\$3 or mask\$3)).tw. (9179)  
 122 placebos/ (0)  
 123 placebo\$.tw. (11961)  
 124 randomly allocated.tw. (2339)  
 125 (allocated adj2 random\$.tw. (2515)  
 126 120 or 121 or 122 or 123 or 124 or 125 (40573)  
 127 119 or 126 (41429)  
 128 103 and 127 (147)

## Database: Embase Classic+Embase

### Search Strategy: RCTs

---

- 1 prevention/ or "prevention and control"/ or primary prevention/ or prophylaxis/ or protection/ (388002)
- 2 prevent\*.ti. (292863)
- 3 protect\*.ti. (166106)
- 4 delay\*.ti. (70519)
- 5 ((reduc\* or decreas\* or effect\* or lower\* or modif\* or change\* or stop\* or improv\* or increas\* or enhanc\* or rais\*) and risk\*).ti. (68778)
- 6 (biomarker\* adj2 enrich\*).ti. (29)
- 7 intervention\*.ti. (128336)
- 8 program\*.ti. (190084)
- 9 multidomain\*.ti. (482)
- 10 multi-domain\*.ti. (196)
- 11 multicomponent\*.ti. (3473)
- 12 multi-component\*.ti. (1062)
- 13 multifactoral\*.ti. (25)
- 14 multi-factoral\*.ti. (2)
- 15 approach\*.ti. (256521)
- 16 lifestyle\*.ti. (13016)
- 17 life style.ti. (1723)
- 18 exp physical activity/ (295154)
- 19 exp exercise/ (263840)
- 20 ((physical or aerobic\* or leisure) and (activit\* or fitness)).ti. (35810)
- 21 exercis\*.ti. (118665)
- 22 exp Diet/ (271531)
- 23 diet\*.ti. (181510)
- 24 fruit\*.ti. (23508)
- 25 vegetable\*.ti. (11437)
- 26 nutrition\*.ti. (103074)
- 27 fat\*.ti. (247795)
- 28 caffeine.ti. (12266)
- 29 sodium.ti. (99989)
- 30 salt\*.ti. (48776)
- 31 alcohol\*.ti. (151585)
- 32 ((smok\* or tobacco) and (quit or cessation or stop\*)).ti. (13072)
- 33 ((metacognitive or cognitive or mental or brain or memory or social or perceptual or computer) and (activit\* or train\* or stimulat\* or intervention or engag\* or rehab\*)).ti. (53741)
- 34 exp \*drug therapy/ (652263)
- 35 drug\*.ti. (450662)
- 36 medication\*.ti. (48020)
- 37 pharmacopsychiatry.ti. (90)
- 38 exp Psychopharmacology/ (27649)
- 39 lovastatin/ or simvastatin/ or pravastatin/ (44198)
- 40 statin\*.ti. (16827)
- 41 exp Antihypertensive Agents/ (628950)
- 42 anti-hypertensive\*.ti. (972)
- 43 antihypertensive\*.ti. (16198)
- 44 exp Cholinesterase Inhibitors/ (83861)
- 45 Acetylcholinesterase inhibitor\*.ti. (1226)
- 46 (Donepezil or Aricept or Memantine or Namenda or Rivastigmine or Exelon or Galantamine or razadyne or Quetiapine or seroquel).ti. (7323)
- 47 cholinesterase inhibitor\*.ti. (1672)

48 exp Antibodies, Monoclonal/ or exp Antibodies, Monoclonal, Humanized/ (394269)  
49 anti amyloid\*.ti. (214)  
50 antiamyloid\*.ti. (40)  
51 Solanezumab.ti. (43)  
52 crenezumab.ti. (2)  
53 gantenerumab.ti. (9)  
54 crenezumab.ab. (14)  
55 antiplatelet.ti. (8)  
56 anti-platelet.ti. (1311)  
57 (Triflusal or Ticlid or plavix or brilinta or persantine or Ticlopidine or Dipyridomole or Clopidogrel).ti.  
(8156)  
58 exp Hypoglycemic Agents/ (408843)  
59 (Pioglitazone or actos or Glucophage or metformin).ti. (12917)  
60 ((gonadal or sex) adj steroid\*).ti. (4750)  
61 exp Hormone Replacement Therapy/ (52856)  
62 estrogen\*.ti. (59100)  
63 progest\*.ti. (35701)  
64 medroxyprogesterone\*.ti. (2555)  
65 estradiol.ti. (22509)  
66 raloxifene.ti. (1622)  
67 exp Cyclooxygenase 2 Inhibitors/ (42579)  
68 (Celecoxib or Rofecoxib).ti. (3619)  
69 exp Anti-Inflammatory Agents, Non-Steroidal/ (490780)  
70 (Ibuprofen or Tarenflurbil or flurbiprofen or Flurizan or Naproxen or Aspirin).ti. (30083)  
71 exp Dietary Supplements/ (72740)  
72 supplement\*.ti. (59036)  
73 nutraceutical\*.ti. (1163)  
74 exp Nootropic Agents/ (98194)  
75 nootropic\*.ti. (693)  
76 exp Vitamins/ (573824)  
77 exp Minerals/ (36345)  
78 omega.ti. (10406)  
79 ginkgo biloba.ti. (2538)  
80 ginko biloba.ti. (20)  
81 folate.ti. (10490)  
82 fish oil.ti. (3894)  
83 saffron.ti. (625)  
84 crocus sativus.ti. (434)  
85 fuzhisan.ti. (12)  
86 melissa.ti. (356)  
87 beta carotene.ti. (3702)  
88 vitamin\*.ti. (113036)  
89 ((manag\* or control\* or lower\* or reduc\* or decreas\* or loss or lose) and (weight or BMI or body mass index  
or overweight or obes\* or diabetes or depress\* or cardio\* or vascular or blood pressure or hypertension or  
cholesterol or hypercholesterolemia or homocysteine)).ti. (127982)  
90 or/1-89 (6007082)  
91 \*dementia/ or \*alzheimer disease/ (122973)  
92 (dementia or cognitive impair\*).ti. (60302)  
93 \*Cognition/ (57927)  
94 \*Mild Cognitive Impairment/ (5955)  
95 \*memory disorders/ (2392)  
96 \*executive funtion/ (0)  
97 exp \*memory/ (86144)  
98 cognition.ti. (12039)

- 99 ((cognit\* or neurocognit\* or memory or neuropsych\* or neuro\*) adj (impair\* or disorder\* or dysfunction\* or function\* ag?ing or declin\* or status or perform\* or diabil\* or disable\* or maint\* or enhanc\*)).ti. (50252)
- 100 ((maint\* or impair\* or disorder\* or declin\* or enhanc\*) adj (cognit\* or neurocognit\* or memory or neuropsych\* or neuro\*)).ti. (2750)
- 101 (amyloid or tau or plasticity).ti. (59657)
- 102 ((brain or grey matter or gray matter) adj3 (function\* or scan\* or mri or volume or chang\* or imag\*)).ti. (23708)
- 103 exp Biological Markers/ (172233)
- 104 (91 or 94) and 103 (4462)
- 105 91 or 92 or 94 or 95 or 96 or 97 or 101 or 104 (274389)
- 106 \*Alzheimer Disease/pc [Prevention & Control] (2840)
- 107 \*Mild Cognitive Impairment/pc [Prevention & Control] (42)
- 108 106 or 107 (2870)
- 109 90 and 105 (57490)
- 110 108 or 109 (58108)
- 111 limit 110 to human (41595)
- 112 limit 111 to (embryo <first trimester> or infant <to one year> or child <unspecified age> or preschool child <1 to 6 years> or school child <7 to 12 years> or adolescent <13 to 17 years>) (1366)
- 113 limit 112 to (adult <18 to 64 years> or aged <65+ years>) (596)
- 114 (111 not 112) or 113 (40825)
- 115 Clinical trial/ (861651)
- 116 Randomized controlled trial/ (394622)
- 117 Randomization/ (69534)
- 118 Single blind procedure/ (21500)
- 119 Double blind procedure/ (130682)
- 120 Crossover procedure/ (46320)
- 121 Placebo/ (286985)
- 122 Randomized controlled trial\$.tw. (129567)
- 123 Rct.tw. (19484)
- 124 Random allocation.tw. (1561)
- 125 Randomly allocated.tw. (24259)
- 126 Allocated randomly.tw. (2119)
- 127 (allocated adj2 random).tw. (905)
- 128 (waitlist or wait list).tw. (4382)
- 129 115 or 116 or 117 or 118 or 119 or 120 or 121 or 122 or 123 or 124 or 125 or 126 or 127 or 128 (1271460)
- 130 Case study/ (45524)
- 131 Case report.tw. (324413)
- 132 Abstract report/ or letter/ (967648)
- 133 130 or 131 or 132 (1330767)
- 134 129 not 133 (1236125)
- 135 114 and 134 (9013)
- 136 limit 135 to (book or book series or conference abstract or conference paper or conference proceeding or "conference review" or editorial or letter or note or short survey or trade journal) (2271)
- 137 135 not 136 (6742)
- 138 limit 137 to yr="2009 -Current" (2443)

## Database: Embase Classic+Embase

### Search Strategy: Observational Studies

---

- 1 prevention/ or "prevention and control"/ or primary prevention/ or prophylaxis/ or protection/ (388002)
- 2 prevent\*.ti. (292863)
- 3 protect\*.ti. (166106)
- 4 delay\*.ti. (70519)
- 5 ((reduc\* or decreas\* or effect\* or lower\* or modif\* or change\* or stop\* or improv\* or increas\* or enhanc\* or rais\*) and risk\*).ti. (68778)
- 6 (biomarker\* adj2 enrich\*).ti. (29)
- 7 intervention\*.ti. (128336)
- 8 program\*.ti. (190084)
- 9 multidomain\*.ti. (482)
- 10 multi-domain\*.ti. (196)
- 11 multicomponent\*.ti. (3473)
- 12 multi-component\*.ti. (1062)
- 13 multifactoral\*.ti. (25)
- 14 multi-factoral\*.ti. (2)
- 15 approach\*.ti. (256521)
- 16 lifestyle\*.ti. (13016)
- 17 life style.ti. (1723)
- 18 exp physical activity/ (295154)
- 19 exp exercise/ (263840)
- 20 ((physical or aerobic\* or leisure) and (activit\* or fitness)).ti. (35810)
- 21 exercis\*.ti. (118665)
- 22 exp Diet/ (271531)
- 23 diet\*.ti. (181510)
- 24 fruit\*.ti. (23508)
- 25 vegetable\*.ti. (11437)
- 26 nutrition\*.ti. (103074)
- 27 fat\*.ti. (247795)
- 28 caffeine.ti. (12266)
- 29 sodium.ti. (99989)
- 30 salt\*.ti. (48776)
- 31 alcohol\*.ti. (151585)
- 32 ((smok\* or tobacco) and (quit or cessation or stop\*)).ti. (13072)
- 33 ((metacognitive or cognitive or mental or brain or memory or social or perceptual or computer) and (activit\* or train\* or stimulat\* or intervention or engag\* or rehab\*)).ti. (53741)
- 34 exp \*drug therapy/ (652263)
- 35 drug\*.ti. (450662)
- 36 medication\*.ti. (48020)
- 37 pharmacopsychiatry.ti. (90)
- 38 exp Psychopharmacology/ (27649)
- 39 lovastatin/ or simvastatin/ or pravastatin/ (44198)
- 40 statin\*.ti. (16827)
- 41 exp Antihypertensive Agents/ (628950)
- 42 anti-hypertensive\*.ti. (972)
- 43 antihypertensive\*.ti. (16198)
- 44 exp Cholinesterase Inhibitors/ (83861)
- 45 Acetylcholinesterase inhibitor\*.ti. (1226)
- 46 (Donepezil or Aricept or Memantine or Namenda or Rivastigmine or Exelon or Galantamine or razadyne or Quetiapine or seroquel).ti. (7323)
- 47 cholinesterase inhibitor\*.ti. (1672)

48 exp Antibodies, Monoclonal/ or exp Antibodies, Monoclonal, Humanized/ (394269)  
49 anti amyloid\*.ti. (214)  
50 antiamyloid\*.ti. (40)  
51 Solanezumab.ti. (43)  
52 crenezumab.ti. (2)  
53 gantenerumab.ti. (9)  
54 crenezumab.ab. (14)  
55 antiplatelet.ti. (8)  
56 anti-platelet.ti. (1311)  
57 (Triflusal or Ticlid or plavix or brilinta or persantine or Ticlopidine or Dipyridomole or Clopidogrel).ti.  
(8156)  
58 exp Hypoglycemic Agents/ (408843)  
59 (Pioglitazone or actos or Glucophage or metformin).ti. (12917)  
60 ((gonadal or sex) adj steroid\*).ti. (4750)  
61 exp Hormone Replacement Therapy/ (52856)  
62 estrogen\*.ti. (59100)  
63 progest\*.ti. (35701)  
64 medroxyprogesterone\*.ti. (2555)  
65 estradiol.ti. (22509)  
66 raloxifene.ti. (1622)  
67 exp Cyclooxygenase 2 Inhibitors/ (42579)  
68 (Celecoxib or Rofecoxib).ti. (3619)  
69 exp Anti-Inflammatory Agents, Non-Steroidal/ (490780)  
70 (Ibuprofen or Tarenflurbil or flurbiprofen or Flurizan or Naproxen or Aspirin).ti. (30083)  
71 exp Dietary Supplements/ (72740)  
72 supplement\*.ti. (59036)  
73 nutraceutical\*.ti. (1163)  
74 exp Nootropic Agents/ (98194)  
75 nootropic\*.ti. (693)  
76 exp Vitamins/ (573824)  
77 exp Minerals/ (36345)  
78 omega.ti. (10406)  
79 ginkgo biloba.ti. (2538)  
80 ginko biloba.ti. (20)  
81 folate.ti. (10490)  
82 fish oil.ti. (3894)  
83 saffron.ti. (625)  
84 crocus sativus.ti. (434)  
85 fuzhisan.ti. (12)  
86 melissa.ti. (356)  
87 beta carotene.ti. (3702)  
88 vitamin\*.ti. (113036)  
89 ((manag\* or control\* or lower\* or reduc\* or decreas\* or loss or lose) and (weight or BMI or body mass index  
or overweight or obes\* or diabetes or depress\* or cardio\* or vascular or blood pressure or hypertension or  
cholesterol or hypercholesterolemia or homocysteine)).ti. (127982)  
90 or/1-89 (6007082)  
91 \*dementia/ or \*alzheimer disease/ (122973)  
92 (dementia or cognitive impair\*).ti. (60302)  
93 \*Cognition/ (57927)  
94 \*Mild Cognitive Impairment/ (5955)  
95 \*memory disorders/ (2392)  
96 \*executive funtion/ (0)  
97 exp \*memory/ (86144)  
98 cognition.ti. (12039)

- 99 ((cognit\* or neurocognit\* or memory or neuropsych\* or neuro\*) adj (impair\* or disorder\* or dysfunction\* or function\* ag?ing or declin\* or status or perform\* or diabil\* or disable\* or maint\* or enhanc\*)).ti. (50252)
- 100 ((maint\* or impair\* or disorder\* or declin\* or enhanc\*) adj (cognit\* or neurocognit\* or memory or neuropsych\* or neuro\*)).ti. (2750)
- 101 (amyloid or tau or plasticity).ti. (59657)
- 102 ((brain or grey matter or gray matter) adj3 (function\* or scan\* or mri or volume or chang\* or imag\*)).ti. (23708)
- 103 exp Biological Markers/ (172233)
- 104 91 or 92 or 94 or 99 or 100 (177159)
- 105 \*Alzheimer Disease/pc [Prevention & Control] (2840)
- 106 \*Mild Cognitive Impairment/pc [Prevention & Control] (42)
- 107 105 or 106 (2870)
- 108 90 and 104 (46186)
- 109 107 or 108 (46804)
- 110 limit 109 to human (37668)
- 111 limit 110 to (embryo <first trimester> or infant <to one year> or child <unspecified age> or preschool child <1 to 6 years> or school child <7 to 12 years> or adolescent <13 to 17 years>) (928)
- 112 limit 111 to (adult <18 to 64 years> or aged <65+ years>) (353)
- 113 (110 not 111) or 112 (37093)
- 114 Clinical study/ (132584)
- 115 longitudinal study/ (85243)
- 116 prospective study/ (322344)
- 117 cohort analysis/ (230562)
- 118 (cohort adj stud\*).mp. (158158)
- 119 (observational adj stud\*).mp. (119842)
- 120 (follow up adj stud\*).mp. (57729)
- 121 (epidemiologic\* adj stud\*).mp. (88591)
- 122 (cross sectional adj stud\*).mp. (205524)
- 123 or/114-122 (1136620)
- 124 113 and 123 (4143)
- 125 limit 124 to (book or book series or chapter or conference abstract or conference paper or conference proceeding or "conference review" or editorial or erratum or letter or note or "review" or short survey or trade journal) (1652)
- 126 124 not 125 (2491)
- 127 limit 126 to yr="2009 -Current" (1644)

# Database: PsycINFO

## Search Strategy: RCTs

---

- 1 prophylaxis/ or prevention/ (14810)
- 2 prevent\*.ti. (21271)
- 3 protect\*.ti. (8537)
- 4 delay\*.ti. (5830)
- 5 ((reduc\* or decreas\* or effect\* or lower\* or modif\* or change\* or stop\* or improv\* or increas\* or enhanc\* or rais\*) and risk\*).ti. (7006)
- 6 intervention\*.ti. (36138)
- 7 program\*.ti. (35798)
- 8 multidomain\*.ti. (22)
- 9 multi-domain\*.ti. (34)
- 10 multicomponent\*.ti. (176)
- 11 multi-component\*.ti. (101)
- 12 lifestyle\*.ti. (2645)
- 13 ((metacognitive or cognitive or mental or brain or memory or social or perceptual or computer) and (activit\* or train\* or stimulat\* or intervention or engag\* or rehab\*).ti. (16817)
- 14 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 (126101)
- 15 \*dementia/ or \*alzheimer disease/ (35185)
- 16 \*mild cognitive impairment/ (0)
- 17 ((cognit\* or neurocognit\* or memory or neuropsych\* or neuro\*) adj (impair\* or disorder\* or dysfunction\* or function\* ag?ing or declin\* or status or perform\* or diabil\* or disable\* or maint\* or enhanc\*).ti. (15609)
- 18 ((maint\* or impair\* or disorder\* or declin\* or enhanc\*) adj (cognit\* or neurocognit\* or memory or neuropsych\* or neuro\*).ti. (990)
- 19 (amyloid or tau or plasticity).ti. (9730)
- 20 ((brain or grey matter or gray matter) adj3 (function\* or scan\* or mri or volume or chang\* or imag\*).ti. (4219)
- 21 biological marker/ (6893)
- 22 dementia/ or alzheimer disease/ (39250)
- 23 21 and 22 (1529)
- 24 15 or 16 or 17 or 18 or 19 or 20 or 23 (58609)
- 25 14 and 24 (4017)
- 26 limit 25 to human (3317)
- 27 limit 26 to (embryo <first trimester> or infant <to one year> or child <unspecified age> or preschool child <1 to 6 years> or school child <7 to 12 years> or adolescent <13 to 17 years>) [Limit not valid in PsycINFO; records were retained] (72)
- 28 limit 27 to (adult <18 to 64 years> or aged <65+ years>) [Limit not valid in PsycINFO; records were retained] (12)
- 29 (26 not 27) or 28 (3257)
- 30 limit 29 to (clinical trial or randomized controlled trial or controlled clinical trial or multicenter study or phase 1 clinical trial or phase 2 clinical trial or phase 3 clinical trial or phase 4 clinical trial) [Limit not valid in PsycINFO; records were retained] (3257)
- 31 limit 30 to (book or book series or conference abstract or conference paper or conference proceeding or "conference review" or editorial or letter or note or "review" or short survey or trade journal) [Limit not valid in PsycINFO; records were retained] (283)
- 32 30 not 31 (2974)
- 33 limit 32 to yr="2009 -Current" (2013)



# Database: PsycINFO

## Search Strategy: Observational Studies

---

- 1 prophylaxis/ or prevention/ (14810)
- 2 prevent\*.ti. (21271)
- 3 protect\*.ti. (8537)
- 4 delay\*.ti. (5830)
- 5 ((reduc\* or decreas\* or effect\* or lower\* or modif\* or change\* or stop\* or improv\* or increas\* or enhanc\* or rais\*) and risk\*).ti. (7006)
- 6 intervention\*.ti. (36138)
- 7 program\*.ti. (35798)
- 8 multidomain\*.ti. (22)
- 9 multi-domain\*.ti. (34)
- 10 multicomponent\*.ti. (176)
- 11 multi-component\*.ti. (101)
- 12 lifestyle\*.ti. (2645)
- 13 ((metacognitive or cognitive or mental or brain or memory or social or perceptual or computer) and (activit\* or train\* or stimulat\* or intervention or engag\* or rehab\*)).ti. (16817)
- 14 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 (126101)
- 15 \*dementia/ or \*alzheimer disease/ (35185)
- 16 \*mild cognitive impairment/ (0)
- 17 ((cognit\* or neurocognit\* or neuropsych\* or neuro\*) adj (impair\* or disorder\* or dysfunction\*)).ti. (9474)
- 18 15 or 16 or 17 (41904)
- 19 14 and 18 (2846)
- 20 limit 19 to human (2537)
- 21 (cohort or longitudinal or prospective).ti,ab. (115078)
- 22 exp Longitudinal Studies/ (1595)
- 23 Prospective Studies/ (216)
- 24 21 or 22 or 23 (115252)
- 25 limit 24 to "reviews (best balance of sensitivity and specificity)" (53066)
- 26 24 not 25 (62186)
- 27 20 and 26 (85)
- 28 limit 27 to yr="2009 -Current" (55)

# **Cochrane Central Register of Controlled Trials**

Precise search on dementia, cognitive impairment terms

## Database: Ovid MEDLINE(R)

### Search Strategy:

- 
- 1 exp Memory Disorders/ or exp Neuropsychological Tests/ or exp Alzheimer Disease/ or exp Cognition/ or exp Cognition Disorders/ (298451)
  - 2 exp Alzheimer Disease/ (73521)
  - 3 ((cognit\* or memory) adj2 (impair\* or declin\*)).ti,ab. (58569)
  - 4 exp Mild Cognitive Impairment/ (3643)
  - 5 cognition.ti,ab. (34845)
  - 6 (cognitive adj (performan\* or test\*)).ti,ab. (15238)
  - 7 1 or 2 or 3 or 4 or 5 or 6 (329242)
  - 8 exp Cardiovascular Diseases/dh, dt, rh, su, th [Diet Therapy, Drug Therapy, Rehabilitation, Surgery, Therapy] (766074)
  - 9 exp Depression/dh, dt, th [Diet Therapy, Drug Therapy, Therapy] (21954)
  - 10 exp Sleep Wake Disorders/dh, dt, th [Diet Therapy, Drug Therapy, Therapy] (19655)
  - 11 (sleep adj (quality or duration or time)).ti. (2355)
  - 12 exp Diabetes Mellitus, Type 2/dh, dt, th [Diet Therapy, Drug Therapy, Therapy] (32195)
  - 13 8 or 9 or 10 or 11 or 12 (837027)
  - 14 7 and 13 (8871)
  - 15 limit 14 to (clinical study or clinical trial, all or clinical trial, phase i or clinical trial, phase ii or clinical trial, phase iii or clinical trial, phase iv or clinical trial or comparative study or controlled clinical trial or meta analysis or multicenter study or observational study or pragmatic clinical trial or randomized controlled trial or systematic reviews) (2669)
  - 16 limit 15 to yr="2009 -Current" (1210)

## Appendix B. Risk of Bias Assessment Tool


Review the methods of each trial and assess each risk of bias component as described in these instructions. You may need to have separate assessments for different outcomes (i.e. different measures; different time points may have different attrition rates). Remember, this tool is not an algorithm. Discretion must be applied.

### 1) Selection Bias

Systematic differences between baseline characteristics of the groups that arise from self-selection of treatments, physician-directed selection of treatments, or association of treatment assignments with demographic, clinical, or social characteristics.

- Did method of randomization create biased allocation to interventions (inadequate randomization)?
- “Good” Randomization: Random numbers table, computer random number generator
- “Poor” Randomization: Randomized based on week of the month of birthday
- No Randomization: Non-randomized clinical trial, observational study

Figure B1. Risk of bias: Selection bias




## 2) Attrition

Systematic differences in the loss of participants from the study and how they were accounted for in the results (e.g., incomplete followup, differential attrition). Those who drop out of the study or who are lost to followup may be systematically different from those who remain in the study. Attrition bias can potentially change the collective (group) characteristics of the relevant groups and their observed outcomes in ways that affect study results by confounding and spurious associations.

- Reasons for incomplete/missing data adequately explained?
- Do the author's attempt to address attrition in the analysis?

**Figure B2. Risk of bias: Attrition**



## Notes

- Report attrition rate in spreadsheet.
- If a study reports outcomes at multiple intervals (e.g., 6 months, 12 months, 18 months) assess attrition at each time-point and record separately.
- Analysis should be done with appropriate method (i.e., sensitivity analysis with various scenarios; last value forward would only be appropriate for interventions that are supposed to improve the outcomes (i.e., memory training that intends to improve memory).

## 3) Selection and Attrition Bias Overall

Assess joint selection and attrition bias. If either selection or attrition bias is high, the risk of bias is HIGH.

**Table B1. Selection and attrition bias overall**

<b>Selection Bias</b>	Low	Low	Medium	Low	Medium	Medium	High
<b>Attrition Bias</b>	Low	Medium	Low	High	Medium	High	X
<b>Action</b>	Assess other biases	Assess other biases	Assess other biases	STOP	Assess other biases	STOP	STOP

## 4) Other Biases

### A. Detection Bias

Systematic differences in outcomes assessment among groups being compared, including systematic misclassification of the exposure or intervention, covariates, or outcomes because of variable definitions and timings, diagnostic thresholds, recall from memory, inadequate assessor blinding, and faulty measurement techniques. Erroneous statistical analysis might also affect the validity of effect estimates.

- Were the outcome assessors blinded to the intervention (“outcome assessor blinded”)?
- Was the timing of the outcome assessment similar in all groups (“comparable timing outcomes assessment”)?
- Was the scale used to measure outcomes validated, reliable?
- Were outcomes measured in clinically meaningful ways?

**Table B2. Detection bias**

<b>Domain</b>	<b>Options</b>		<b>Overall Rating</b>
Outcome assessor blinded	Yes	No	All 4 Yes =Low 2 or 3 Yes = Medium 3+ No=High
Outcome assessor independent	Yes	No	
Comparable timing outcomes assessment	Yes	No	
Outcome assessment instrument/measurement quality	Yes (Adequate )	No (Inadequate )	

## B. Performance Bias

Systematic differences in the care provided to participants and protocol deviation. Examples include contamination of the control group with the exposure or intervention, unbalanced provision of additional interventions or co-interventions, difference in co-interventions, and inadequate blinding of providers and participants.

### Notes

- Intention-to-Treat (ITT): Includes every subject according to randomized treatment assignment. Ignores noncompliance, protocol deviations, withdrawal, and anything that happens after randomization.
- Concurrent Intervention: Study participants are receiving another intervention (i.e., treatment) that is not part of the intervention being tested. Example: Participants are randomized to a physical activity intervention (or no intervention), but are also dieting.

**Table B3. Performance bias**

Domain	Options	Rating	Overall Rating
1a. RCTs-ITT	Yes	Low	<i>Low</i> All Low=Low
	No/Not reported	High	
1b. Obs-Adjustment for known confounders	Adequate	Low	1-Low, 2-Low, 3-N/A=Low  <i>Medium</i> 1-Low, 2-Low, 3-High=Medium 1-Low, 2-Medium, 3-Low=Medium
	Inadequate	High	
2. Concurrent intervention	Yes-Adjusted	Medium	1-Low, 2-Medium, 3-N/A=Medium  1-Medium, 2-Medium, 3-N/A=Medium 1-Medium, 2-High, 3-Low=Medium 1-Medium, 2-Medium, 3-High=Medium
	Yes-Unadjusted	High	
	No	Low	
	Unclear/Not Reported	NR	
3. Participant Blinding	Yes	Low	<i>High</i> 1-High + Anything Else=High 2+ High=High
	No	Medium	
	N/A	N/A	

## C. Reporting Bias

Systematic differences between reported and unreported findings (e.g., differential reporting of outcomes or harms, incomplete reporting of study findings, potential for bias in reporting through source of funding).

- Was a select group of outcomes reported?

### Notes

- Compare results to methods section and/ or protocol.
- Check if some results are reported in a different publication.


**Table B4. Reporting bias**

Domain	Options	Rating
All outcomes reported	Yes	Low
	No	Medium
	Not Reported	Medium

## 5) Overall Rob



**Figure B5. Overall risk of bias**



## Appendix C. Cognitive Performance Outcomes

**Appendix Table C1. Cognitive outcomes categorization**

Test Names	Common Abbreviations	Cognitive Outcome Categorization
Abstraction (Shipley Inst. of Living Scales subtest)		Executive/Attention/Processing Speed
AD Cooperative Studies AD Assessment Scale - Cognitive Subscale	ADAS-Cog, ADCS-Cog	Multidomain Neuropsychological Test Performance
AD Cooperative Studies ADL in MCI Scale	ADCS-MCI-ADL	Multidomain Neuropsychological Test Performance
AD Cooperative Studies Activities of Daily Living Scale	ADCS-ADL	Multidomain Neuropsychological Test Performance
Babcock Story Recall		Memory
Benton Visual Retention Test	BVRT	Memory
Blessed Dementia Rating Scale: Blessed Information Memory Concentration	BIMC	Brief Cognitive Test Performance
Blessed Dementia Rating Scale: Blessed Rating Scale	BRS, DRS, BDS, Dementia score	Brief Cognitive Test Performance
Block Design (WAIS subtest)	BD	Visuospatial
Boston Naming Test - multiple versions: 15, 30, 60-items	BNT	Language
Brief Visuospatial Memory Test	BVMT, BVMT-R	Memory
Brixton Spatial Anticipation Test	Brixton	Executive/Attention/Processing Speed
Buschke Selective Reminding Test	SRT	Memory
California Verbal Learning Test - multiple versions	CVLT, CVLT-II	Memory
Cancellation Tests (several versions: bell, star, letter, ...)		Visuospatial
Cambridge Neuropsychological Test Automated Battery (part of the CAMDEX)	CANTAB	Multidomain Neuropsychological Test Performance
CERAD word list / list learning subtest	CERAD	Memory
Clock Drawing Tests (many versions & featured in screening tools)	CDT, CLOX	Visuospatial
Cognitive Abilities Screening Instrument	CASI	Brief Cognitive Test Performance
Consortium to Establish a Registry for Alzheimer's Disease (cognitive battery)	CERAD	Multidomain Neuropsychological Test Performance
Continuous Performance Test	CPT	Executive/Attention/Processing Speed
Corsi Block Tapping - forwards & backwards (similar		Executive/Attention/Processing Speed

to Spatial Span)		
Delis–Kaplan Executive Function System	D-KEFS	Executive/Attention/Processing Speed
Digit Span - forwards & backwards (WAIS/WMS subtest)	DS, DSp	Executive/Attention/Processing Speed
Digit Symbol Coding (WAIS subtest; inverse of Symbol Digit Modalities)	DSy	Executive/Attention/Processing Speed
East Boston Story or East Boston Memory Test	EBMT	Memory
Faces - parts I & II (WMS subtest)		Memory
Finger Tapping Test	FTT	Motor
Grip Strength / Hand Dynamometer		Motor
Grooved Pegboard		Motor
Hopkins Verbal Learning Test	HVLT, HVLT-R	Memory
Judgement of Line Orientation	JLO	Visuospatial
Letter Digit Substitution (Coding) Test	LDST	Executive/Attention/Processing Speed
Letter-Number Sequencing (most commonly a WAIS subtest)	LNS	Executive/Attention/Processing Speed
Letter Sets		Executive/Attention/Processing Speed
Logical Memory - parts I & II (WMS subtest)	LM, LMI, LMII	Memory
Matrix Reasoning (WAIS subtest)		Executive/Attention/Processing Speed
Mattis Dementia Rating Scale	MDRS, DRS	Multidomain Neuropsychological Test Performance
Maze Tracing (including Porteus Maze Test)		Executive/Attention/Processing Speed
Mini-Mental State Examination	MMSE	Brief Cognitive Test Performance
Modified Mini-Mental State Examination	3MS, 3MSE	Brief Cognitive Test Performance
Montreal Cognitive Assessment	MoCA	Brief Cognitive Test Performance
N-Back		Executive/Attention/Processing Speed
National Adult Reading Test	NART	Language
Neurobehavioral Cognitive Status Examination (original Cognistat paper test)	NCSE	Multidomain Neuropsychological Test Performance
New York University Paragraph Recall		Memory
Number Series		Executive/Attention/Processing Speed
Picture Completion (many versions, most commonly a WAIS subtest)	PC	Executive/Attention/Processing Speed; Visuospatial
Purdue Pegboard	PPT, PPBT	Motor
Raven's Progressive Matrices (several versions including Colored & Advanced)	RPM, RCPM	Executive/Attention/Processing Speed

Reaction Time Tests (many versions: simple, choice, auditory, visual...)	RT, SRT	Executive/Attention/Processing Speed
Repeatable Battery for the Assessment of Neuropsychological Status	RBANS	Multidomain Neuropsychological Test Performance
Rey Auditory Verbal Learning Test	RAVLT (may see AVLT or RVLTL)	Memory
Rey-Osterrieth Complex Figure Test	CFT, RCFT, Rey-O, Rey	Memory; Visuospatial
Rivermead Behavioral Memory Test - multiple versions	RBMT, RBMT-II, RBMT-3	Memory
Self-Ordered Pointing Task(Test)	SOPT	Executive/Attention/Processing Speed
Short Portable Mental Status Questionnaire	SPMSQ	Brief Cognitive Test Performance
Short Test of Mental Status	STMS	Brief Cognitive Test Performance
Syndrom Kurztest - SKT (German)	SKT	Executive/Attention/Processing Speed; Memory
Spatial Span - forwards & backwards (WMS subtest; similar to Corsi Block Tapping)		Executive/Attention/Processing Speed
Stroop - color, word, interference (there are many versions of the Stroop)		Executive/Attention/Processing Speed
Symbol Digit Modalities Test (inverse of Digit Symbol)	SDMT	Executive/Attention/Processing Speed
Taylor Complex Figure		Memory; Visuospatial
Telephone Interview for Cognitive Status	TICS	Brief cognitive test performance
Telephone Interview for Cognitive Status, modified	TICS-M, mTICS	Brief cognitive test performance
Token Test		Language
Trail Making Test - part A	TMT A	Executive/Attention/Processing Speed
Trail Making Test - part B (or B-A, B/A, etc.)	TMT B	Executive/Attention/Processing Speed
Verbal Fluency, Phonemic/Phonological or Letter	VF, PVF, FAS, CFL, COWAT, COWA	Executive/Attention/Processing Speed; Language
Verbal Fluency, Semantic or Category	VF, SVF, animals, names, fruits/vegetables	Language
Visual Reproduction (WMS subtest)	VR, VRI, VR II, Vis Rep	Memory
Useful Field of View	UFOV	Executive/Attention/Processing Speed
Walter Reed performance assessment battery		Multidomain Neuropsychological Test Performance
Wechsler Adult Intelligence Scale - multiple versions	WAIS, WAIS-R, WAIS-III, WAIS-IV	Multidomain Neuropsychological Test Performance
Wechsler Memory Scale - multiple versions	WMS, WMS-R, WMS-III, WMS-IV	Memory
Wisconsin Card Sorting Test	WCST	Executive/Attention/Processing Speed

**Appendix Table C2. Neuropsychological tests and reliable change indices**

<b>Cognitive Domain</b>	<b>Instrument</b>	<b>Measurement Properties</b>	<b>Reliable Change Indices</b>
Global Cognitive Function	Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog)	Used to measure cognitive impairment in the assessment of Alzheimer's disease. Tests several cognitive domains, including memory, language, and praxis.  Range: 0-70; higher scores indicate worse cognition <sup>17</sup>	4 pts (6 months); considered to be clinically important, but not meaningful; no established RCI's <sup>17</sup>
	Mini-Mental State Examination (MMSE)	11 items assessing cognitive function: orientation, registration, attention and calculation, recall, language (range 0-30)  Range: 0-30; higher scores indicate better <sup>18</sup>	2.73 pts (3 months) 3.60 pts (5 years) <sup>19</sup>
	Modified Mini-Mental State Examination (3MS)	15 items: 11 from MMSE plus 4 additional items assessing long-term memory, abstract thinking, category fluency, delayed recall  Range: 0-100; higher scores indicate better cognition <sup>18</sup>	5 pts <sup>20</sup> 7.41 pts (3 months) 9.82 pts (5 years) <sup>19</sup>
	Telephone Interview for Cognitive Status (TICS)	11 items assessing word list memory, orientation, attention, repetition, conceptual knowledge, nonverbal praxis  Range: 0-41; higher scores indicate better cognition <sup>18</sup>	None identified
Executive, Attention, Processing Speed	Tower Test	Varying number of items assessing spatial planning, rule learning, inhibition of impulsive and perseverative responding, and the ability to establish and maintain instructional set. Subjects must construct towers using 5 circular pieces, placed onto one of 3 pegs. Towers constructed must be identical to a picture shown. Subjects are not allowed to place a larger piece on a smaller piece, and must move one piece at a time.  Range: 0-30 <sup>21</sup>	None identified
	Digit Span Forward*†	Varying number of items assessing attention efficiency and capacity: subjects asked to listen to a sequence of numbers read and then recite back in order (reported as either subscore or summary score with Digit Span Backward)	None identified; part of WAIS-III WMI and VIQ
	Digit Span Backward*†	Varying number of items assessing executive function and especially working memory: sequence of numbers read, participants asked to read sequence back in reverse order (reported as either subscore or summary score with Digit Span Forward)	None identified; part of WAIS-III WMI and VIQ
	Digit Symbol Substitution Test*	Varying number of items assessing psychomotor ability, sustained attention, processing speed and working memory: participants asked to use a key to substitute certain items within rows of numbers (Digit Symbol) or symbols (Symbol Digit Modalities) (score comprised of items completed within the specified time).	None identified; part of WAIS-III PSI and PIQ

	Stroop Interference Test	3 to 4 parts (depending on the version). Original version has 4 parts. Part 1: rows of written color names written in black ink, and the subject must say the written word. Part 2: the subject reads color names printed in colored ink, ignoring the printed color. Part 3: Subject names the colors of squares. Part 4: the subject uses the printed words from part 2, but must say the color of the ink each word is printed in instead of saying the word.  Range: Time to completion and number of errors. Higher raw time and raw errors indicate worse cognition. <sup>18</sup>	None identified
	Trail Making Test Part A (Trails A)	Assesses visual attention and processing speed: subject asked to draw lines connecting circled numbers in sequence (score comprised of both time to complete task and number of errors made; higher score indicates lower function, unless age-scaled score is presented)  Range: Time, in seconds, required for completion; higher raw scores indicate worse cognition while higher scaled scores indicate better cognition. Additionally, if error rate is reported, then higher error rates indicate worse cognition. <sup>18</sup>	Scores to calculate RCI: T2-T1 mean, SD: -0.96, 7.54 <sup>22</sup>
	Vigil/Continuous Performance Task (CPT)	Varying number of items assessing sustained and selective attention. Letters flash by one at a time on a computer screen. Subject must press the spacebar after they see an 'A' followed immediately by a 'K'. <sup>18</sup>	None identified
	Wisconsin Card Sorting Test (WCST)	Cards are presented to the subject. Subject is told to match the cards, but not how to match; however, he or she is told whether a particular match is right or wrong. <sup>18</sup>	None identified
Intelligence Quotient (Verbal Comprehension, Perceptual Reasoning, Working Memory, Processing Speed)	Wechsler Adult Intelligence Scale (WAIS)	Published battery of neuropsychological tests with varying numbers of core and optional subtests. WAIS-III assesses Verbal Comprehension (Similarities, Vocabulary, Information); Working Memory (Digit Span, Arithmetic, [Letter-Number Sequencing], [Comprehension]); Perceptual Organization (Picture Completion, Block Design, Matrix Reasoning); and Processing Speed (Digit Symbol, [Symbol Search], [Picture Arrangement], [Object Assembly]). [Bracketed] subtests are optional. <sup>18</sup>	VIQ: 9 pts PIQ: 11 pts FSIQ: 9 pts VCI: 11 pts POI: 13 pts WMI: 12 pts PSI: 14 pts (WAIS-III) <sup>23</sup>
Memory	Wechsler Memory Scale (WMS)	Published battery of neuropsychological tests with varying numbers of core and optional tests. WMS-III assesses auditory presentation (Logical Memory I and II, Verbal Paired Associates I and II, [Letter-Number Sequencing], [Information and Orientation], [Word Lists I and II], [Mental Control], [Digit Span]) and visual presentation (Faces I and II, Family Pictures I and II, [Spatial Span], [Visual Reproduction I and II]). <sup>18</sup>	None identified
	Benton Visual Retention Test (BVRT)	10 items (designs) assessing visual memory and perception: subjects are shown one design at a time and asked to draw it from memory (score based on either correctness of drawing or number of errors made; higher error scores indicate lower function)	None identified

		Range: 0-10; higher scores indicate better cognition <sup>18</sup>	
	Rey-Osterrich Complex Figure	3 part test assessing visuospatial abilities, memory, attention, planning, and working memory (executive functions). Subject asked to reproduce a complicated line drawing 3 times: first by copying it while looking at the figure, second by reproducing it immediately afterwards from memory, and third by reproducing the figure again after a 20 to 30-minute delay <sup>18</sup>	Scores to calculate RCI: Copy T2-T1 mean, SD: -0.03, 1.76 Immediate Recall T2-T1 mean, SD: 2.48, 4.51 Delayed Recall T2-T1 mean, SD: 2.30, 4.32 <sup>24</sup>
	Buschke Selective Reminding Test	12 items in one list assessing verbal recall and recognition, with a possible 12 trials. List is read aloud until subject recalls all 12 words three times in a row, or until items are read 12 total times (whichever occurs first). After a 20 to 30-minute delay, subjects are asked to recall the 12 words again. Then a recognition trial may be given, which consists of a longer list of words that is read one word at a time; subjects respond 'yes' or 'no' if the word was on the original list of 12.  Range: 0-12 for each trial and the recognition score, with higher scores indicating better cognition. Also an intrusion score for the recognition portion, counting each incorrect 'yes' given; higher scores indicate worse cognition <sup>18</sup>	None identified
	California Verbal Learning Test (CVLT)	32 items in two lists (A & B) of 16 words assessing verbal recall and recognition: List A is presented five times for learning and List B is presented once as a distractor  Range: Total Recall Score is 20-80; all other scores are z-scores -5 to +5; higher error and recency-recall index scores indicate worse cognition; all other higher scores indicate better cognition <sup>18</sup>	None identified
	Rey Auditory Verbal Learning Test (RAVLT)	30 items in two lists assessing verbal recall and recognition. First a list of 15 words is read aloud and subjects are asked to recall as many as possible (over 5 trials, with the list repeated each time). Then subjects are read a 15 word distractor list and asked to recall as many of the distractor words as possible (1 trial). Afterwards subjects are asked to recall as many of the original 15 words as possible (without being read the list). After a 20-minute delay period, subjects are asked to recall the original list of 15-words again (1 trial). Then a recognition trial may be given, which consists of a longer list of words that is read one word at a time; subjects respond 'yes' or 'no' if the word was on the original list of 15.  Range: 0-15 for each trial (1-5, the distractor, delayed recall, and recognition) with higher scores indicating better cognition. Also an intrusion score for the recognition portion, counting each incorrect 'yes' given; higher scores indicate worse cognition. <sup>18</sup>	(decline; improvement) Trial 1:-2.77; 2.65 Trial 5: -3.51; 2.63 Sum 1-5: -11.64; 9.36 Interference: -3.03; 3.11 Trial 7: -4.73; 3.57 Delay: -4.96; 3.60 Recognition: -3.47; 3.69 (12 months) <sup>25</sup>
	Wechsler Adult Intelligence Scale (WAIS)	Published battery of neuropsychological tests with varying numbers of core and optional subtests. WAIS-III assesses Verbal Comprehension (Similarities, Vocabulary, Information); Working Memory (Digit Span, Arithmetic, [Letter-Number Sequencing], [Comprehension]); Perceptual Organization (Picture Completion, Block Design, Matrix Reasoning); and Processing Speed (Digit Symbol, [Symbol Search],	VIQ: 9 pts PIQ: 11 pts FSIQ: 9 pts VCI: 11 pts POI: 13 pts

		[Picture Arrangement], [Object Assembly]. [Bracketed] subtests are optional. <sup>18</sup>	WMI: 1 2pts PSI: 14 pts (WAIS-III) <sup>23</sup>
Language	Boston Naming Test (BNT)	60 items assessing word retrieval. Subjects are shown pictures and asked to name what they are pictures of, and receive semantic cues if needed  Range: 0-60; higher scores indicate better cognition <sup>18</sup>	4 pts (9-15 months); 6 pts (16-24 months)Sachs, 2012 #618}
	Verbal Fluency Test	Varying number of items assessing spontaneous verbal production: subjects asked to produce as many words beginning with a specific letter (phonemic/letter fluency) or as many words in a specific category such as “animals” (semantic/category fluency) as is possible in one minute  Range (phonemic fluency): sum of all admissible words for the three letters; higher scores indicate better cognition  Range (semantic fluency): sum of all admissible words for the semantic categories; higher scores indicate better cognition <sup>18</sup>	(Decline; improvement) Letter ‘S’: -5.5; 9.8 Animals: -7.6; 10.5 (1 month) <sup>26</sup>

\*Subtest of WAIS; †Subtest of WMS

Abbreviations: 3MS=Modified Mini-Mental State Examination; BNT=Boston Naming Test; BVRT=Benton Visual Retention Test; CERAD=Consortium to Establish a Registry for Alzheimer’s Disease; CPT=Continuous Performance Task; CVLT=California Verbal Learning Test; DKEFS=Delis-Kaplan Executive Function System; FSIQ=Full Scale IQ; MMSE=Mini-Mental State Examination; PIQ=Performance IQ; POI=Perceptual Organization Index; PSI=Processing Speed Index; RCI=Reliable Change Index; RVL=Rey Verbal Learning Test; SDMT=Symbol Digit Modalities Test; TICS=Telephone Interview for Cognitive Status; Trails A= Trail Making Test Part A; Trails B=Trail Making Test Part B; VCI=Verbal Comprehension Index; VIQ=Verbal IQ; WAIS=Wechsler Adult Intelligence Scale; WMI=Working Memory Index; WMS=Wechsler Memory Scale



## Appendix D. Excluded References

Excluded References<sup>1-243244-316317-523524-771772-920921-1037</sup>

[Public title] Disease-modifying properties of lithium in the neurobiology of Alzheimer's disease; [Scientific title] Disease-modifying properties of lithium in the neurobiology of Alzheimer's disease: a double-blind, placebo-controlled prevention study in elderly patients with mild cognitive impairment. 2010.  
<http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/416/CN-00738416/frame.html>. *Ineligible population*

Nourishing Xin and Shen method improved mild cognitive impairment due to subcortical small vessel disease: a clinical study. [Chinese]. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine / Zhongguo Zhong xi yi jie he xue hui, Zhongguo Zhong yi yan jiu yuan zhu ban. 2015 01 Jan;35(1):41-5. PMID 25790673. *Inadequate follow up time*

Abbatecola AM, Lattanzio F, Molinari AM, et al. Rosiglitazone and cognitive stability in older individuals with type 2 diabetes and mild cognitive impairment. Diabetes Care. 2010 Aug;33(8):1706-11. PMID 20435794. *Not cognitive decline prevention intervention*

Abdullah L, Luis C, Paris D, et al. Serum Abeta levels as predictors of conversion to mild cognitive impairment/Alzheimer disease in an ADAPT subcohort. Molecular Medicine. 2009 November-December;15(11-12):432-7. PMID 2010010064. *Not cognitive decline prevention intervention*

Abelson JL, Khan S, Young EA, et al. Cognitive modulation of endocrine responses to CRH stimulation in healthy subjects. Psychoneuroendocrinology. 2010 Apr;35(3):451-9. PMID 19758763. *Inadequate follow up time*

Abizanda P, Leon M, Dominguez-Martin L, et al. Effects of a short-term occupational therapy intervention in an acute geriatric unit. A randomized clinical trial. Maturitas. 2011 Jul;69(3):273-8. PMID 21600709. *Inadequate follow up time*

Ablin JN, Clauw DJ, Lyden AK, et al. Effects of sleep restriction and exercise deprivation on somatic symptoms and mood in healthy adults. Clinical & Experimental Rheumatology. 2013 Nov-Dec;31(6 Suppl 79):S53-9. PMID 24373363. *Inadequate follow up time*

Abner E, Schmitt F, Caban AH, et al. Dual cognitive screening for dementia: Preliminary case ascertainment in the antioxidant Alzheimer's prevention (Preadvise) trial [Journal: Conference Abstract]. 2012.

<http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/737/CN-01004737/frame.html>

[http://ac.els-cdn.com/S1552526012005171/1-s2.0-S1552526012005171-main.pdf?\\_tid=ae514dc0-c392-11e5-9470-](http://ac.els-cdn.com/S1552526012005171/1-s2.0-S1552526012005171-main.pdf?_tid=ae514dc0-c392-11e5-9470-)

0000aacb35f&acdnat=1453747226\_8f943887053a7c81bbe29ad13ae1155d. Accessed on 4 suppl. 1 8. *Not cognitive decline prevention intervention*

Afzal S, Bojesen SE, Nordestgaard Bo G. Reduced 25-hydroxyvitamin D and risk of Alzheimer's disease and vascular dementia. *Alzheimer's and Dementia*. 2014 May;10(3):296-302. PMID 2014293602. *Not cognitive decline prevention intervention*

Agnew-Blais JC, Wassertheil-Smoller S, Kang JH, et al. Folate, vitamin B-6, and vitamin B-12 intake and mild cognitive impairment and probable dementia in the Women's Health Initiative Memory Study. *Journal of the Academy of Nutrition & Dietetics*. 2015 Feb;115(2):231-41. PMID 25201007. *Not cognitive decline prevention intervention*

Aguiar P, Monteiro L, Feres A, et al. Rivastigmine transdermal patch and physical exercises for Alzheimer's disease: a randomized clinical trial. *Current Alzheimer Research*. 2014;11(6):532-7. PMID 24938502. *Ineligible population*

Aguirre E, Spector A, Hoe J, et al. Maintenance Cognitive Stimulation Therapy (CST) for dementia: a single-blind, multi-centre, randomized controlled trial of Maintenance CST vs. CST for dementia. *Trials [Electronic Resource]*. 2010;11:46. PMID 20426866. *Ineligible population*

Aisen PS, Gauthier S, Ferris SH, et al. Tramiprosate in mild-to-moderate Alzheimer's disease - A randomized, double-blind, placebo-controlled, multi-centre study (the alphase study). *Archives of Medical Science*. 2011 February;7(1):102-11. PMID 2011142367. *Ineligible population*

Akbaraly TN, Portet F, Fustini S, et al. Leisure activities and the risk of dementia in the elderly: results from the Three-City Study. *Neurology*. 2009 Sep 15;73(11):854-61. PMID 19752452. *Not cognitive decline prevention intervention*

Akbaraly TN, Singh-Manoux A, Marmot MG, et al. Education attenuates the association between dietary patterns and cognition. *Dementia & Geriatric Cognitive Disorders*. 2009;27(2):147-54. PMID 19182482. *Not cognitive decline prevention intervention*

Akhondzadeh S, Sabet MS, Harirchian MH, et al. Saffron in the treatment of patients with mild to moderate Alzheimer's disease: a 16-week, randomized and placebo-controlled trial. *Journal of Clinical Pharmacy & Therapeutics*. 2010 Oct;35(5):581-8. PMID 20831681. *Ineligible population*

Almaraz AC, Driver-Dunckley ED, Woodruff BK, et al. Efficacy of rivastigmine for cognitive symptoms in Parkinson disease with dementia. *The neurologist*. 2009 Jul;15(4):234-7. PMID 19590387. *Ineligible study design*

Almeida OP, Yeap BB, Alfonso H, et al. Older men who use computers have lower risk of dementia. PLoS ONE [Electronic Resource]. 2012;7(8):e44239. PMID 22937167. *Not cognitive decline prevention intervention*

Alosco ML, Spitznagel MB, Cohen R, et al. Decreases in body mass index after cardiac rehabilitation predict improved cognitive function in older adults with heart failure. Journal of the American Geriatrics Society. 2014 Nov;62(11):2215-6. PMID 25413196. *Ineligible study design*

Altmann A, Tian L, Henderson VW, et al. Sex modifies the APOE-related risk of developing Alzheimer disease. Annals of Neurology. 2014 Apr;75(4):563-73. PMID 24623176. *Ineligible study design*

Alvarez XA, Cacabelos R, Sampedro C, et al. Combination treatment in Alzheimer's disease: results of a randomized, controlled trial with cerebrolysin and donepezil. Current Alzheimer Research. 2011 Aug;8(5):583-91. PMID 21679156. *Ineligible population*

Alvarez XA, Sampedro C, Cacabelos R, et al. Reduced TNF-alpha and increased IGF-I levels in the serum of Alzheimer's disease patients treated with the neurotrophic agent cerebrolysin. International Journal of Neuropsychopharmacology. 2009 Aug;12(7):867-72. PMID 19531281. *Ineligible population*

Alves J, Alves-Costa F, Magalhaes R, et al. Cognitive stimulation for Portuguese older adults with cognitive impairment: a randomized controlled trial of efficacy, comparative duration, feasibility, and experiential relevance. American Journal of Alzheimer's Disease & Other Dementias. 2014 Sep;29(6):503-12. PMID 24526760. *Inadequate follow up time*

Amagase H, Sun B, Nance DM. Immunomodulatory effects of a standardized Lycium barbarum fruit juice in Chinese older healthy human subjects. Journal of Medicinal Food. 2009 Oct;12(5):1159-65. PMID 19857084. *Inadequate follow up time*

Ambrosius WT, Sink KM, Foy CG, et al. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clinical Trials. 2014 Oct;11(5):532-46. PMID 24902920. *Ineligible study design*

Amenta F, Carotenuto A, Fasanaro AM, et al. The ASCOMALVA trial: association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease with cerebrovascular injury: interim results. Journal of the Neurological Sciences. 2012 Nov 15;322(1-2):96-101. PMID 22959283. *Ineligible population*

Amenta F, Carotenuto A, Fasanaro AM, et al. The ASCOMALVA (Association between the Cholinesterase Inhibitor Donepezil and the Cholinergic Precursor Choline Alphoscerate in Alzheimer's Disease) Trial: interim results after two years of treatment.

Journal of Alzheimer's Disease. 2014;42 Suppl 3:S281-8. PMID 24898643. *Ineligible population*

Amenta F, Carotenuto A, Fasanaro G, et al. Preliminary results of ASCOMALVA trial on the association of donepezil and choline alfoscerate in Alzheimer's disease with associated cerebrovascular injury. [Italian]  
Studio sull'effetto dell'associazione tra l'inibitore delle colinesterasi donepezil e il precursore colinergico colina alfoscerato sui sintomi della malattia di Alzheimer con danno vascolare associato (ASCOMALVA). primi risultati. Giornale di Gerontologia. 2011 April;59(2):89-98. PMID 2011290156. *Ineligible population*

Amieva H, Stoykova R, Matharan F, et al. What aspects of social network are protective for dementia? Not the quantity but the quality of social interactions is protective up to 15 years later. Psychosomatic Medicine. 2010 Nov;72(9):905-11. PMID 20807876. *Not cognitive decline prevention intervention*

Ancelin ML, Carriere I, Barberger-Gateau P, et al. Lipid lowering agents, cognitive decline, and dementia: The three-city study. Journal of Alzheimer's Disease. 2012;30(3):629-37. PMID 2012367868. *Not cognitive decline prevention intervention*

Ancelin ML, Carriere I, Helmer C, et al. Steroid and nonsteroidal anti-inflammatory drugs, cognitive decline, and dementia. Neurobiology of Aging. 2012 Sep;33(9):2082-90. PMID 22071123. *Not cognitive decline prevention intervention*

Andel R, Crowe M, Hahn EA, et al. Work-related stress may increase the risk of vascular dementia. Journal of the American Geriatrics Society. 2012 Jan;60(1):60-7. PMID 22175444. *Ineligible population*

Andersen F, Viitanen M, Halvorsen DS, et al. The effect of stimulation therapy and donepezil on cognitive function in Alzheimer's disease. A community based RCT with a two-by-two factorial design. BMC Neurology. 2012;12:59. PMID 22813231. *Ineligible population*

Anderson S, White-Schwoch T, Choi HJ, et al. Training changes processing of speech cues in older adults with hearing loss. The effect of hearing loss on neural processing. 2015. *Inadequate follow up time*

Anderson S, White-Schwoch T, Parbery-Clark A, et al. Reversal of age-related neural timing delays with training. Proceedings of the National Academy of Sciences of the United States of America. 2013 Mar 12;110(11):4357-62. PMID 23401541. *Inadequate follow up time*

Anderson-Hanley C, Arciero PJ, Brickman AM, et al. Exergaming and older adult cognition: a cluster randomized clinical trial. American Journal of Preventive Medicine. 2012 Feb;42(2):109-19. PMID 22261206. *Inadequate follow up time*

Andreasen N, Simeoni M, Ostlund H, et al. First administration of the Fc-attenuated anti-beta amyloid antibody GSK933776 to patients with mild Alzheimer's disease: A randomized, placebo-controlled study. PLoS ONE. 2015 19 Mar;10(3)PMID 2015879759. *Ineligible population*

Andreeva VA, Whegang-Youdom S, Touvier M, et al. Midlife dietary vitamin D intake and subsequent performance in different cognitive domains. Annals of Nutrition & Metabolism. 2014;65(1):81-9. PMID 25227981. *No relevant outcomes reported*

Annweiler C, Ferland G, Barberger-Gateau P, et al. Vitamin K antagonists and cognitive impairment: results from a cross-sectional pilot study among geriatric patients. Journals of Gerontology Series A-Biological Sciences & Medical Sciences. 2015 Jan;70(1):97-101. PMID 25151653. *Ineligible study design*

Annweiler C, Rolland Y, Schott AM, et al. Higher vitamin D dietary intake is associated with lower risk of Alzheimer's disease: a 7-year follow-up. Journals of Gerontology Series A-Biological Sciences & Medical Sciences. 2012 Nov;67(11):1205-11. PMID 22503994. *Cohort study with inadequate sample size*

Anstey KJ, Bahar-Fuchs A, Herath P, et al. Body brain life: A randomized controlled trial of an online dementia risk reduction intervention in middle-aged adults at risk of Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions. 2015 14 Oct;1(1):72-80. PMID 2015440238. *No relevant outcomes reported*

Anstey KJ, Byles JE, Luszcz MA, et al. Cohort profile: The Dynamic Analyses to Optimize Ageing (DYNOPTA) project. International Journal of Epidemiology. 2010 Feb;39(1):44-51. PMID 19151373. *Not cognitive decline prevention intervention*

Anton Alvarez X, Sampedro C, Cacabelos R, et al. Reduced TNF- and increased IGF-I levels in the serum of Alzheimer's disease patients treated with the neurotrophic agent Cerebrolysin. International Journal of Neuropsychopharmacology. 2009 August;12(7):867-72. PMID 2009469772. *Ineligible population*

Antonenko D, Floel A. Non-invasive brain stimulation in neurology: Transcranial direct current stimulation to enhance cognitive functioning. [German] Nichtinvasive Stimulationsverfahren in der Neurologie: Transkranielle Gleichstromstimulation zur kognitiven Funktionsverbesserung. Nervenarzt. 2016 01 Aug;87(8):838-45. PMID 610354183. *Not available in English*

Apostolo JL, Cardoso DF, Rosa AI, et al. The effect of cognitive stimulation on nursing home elders: a randomized controlled trial. Journal of Nursing Scholarship. 2014 May;46(3):157-66. PMID 24597922. *Ineligible population*

Apostolova LG, Babakchianian S, Hwang KS, et al. Ventricular enlargement and its clinical correlates in the imaging cohort from the ADCS MCI donepezil/vitamin E study. *Alzheimer Disease & Associated Disorders*. 2013 Apr-Jun;27(2):174-81. PMID 23694947. *Cohort study with inadequate sample size*

Arab L, Biggs ML, O'Meara ES, et al. Gender differences in tea, coffee, and cognitive decline in the elderly: the Cardiovascular Health Study. *Journal of Alzheimer's Disease*. 2011;27(3):553-66. PMID 21841254. *Not cognitive decline prevention intervention*

Araki A, Iimuro S, Sakurai T, et al. Long-term multiple risk factor interventions in Japanese elderly diabetic patients: the Japanese Elderly Diabetes Intervention Trial--study design, baseline characteristics and effects of intervention. *Geriatrics & gerontology international*. 2012 Apr;12 Suppl 1:7-17. PMID 22435936. *No relevant outcomes reported*

Araki T, Wake R, Miyaoka T, et al. The effects of combine treatment of memantine and donepezil on Alzheimer's disease patients and its relationship with cerebral blood flow in the prefrontal area. *International Journal of Geriatric Psychiatry*. 2014 Sep;29(9):881-9. PMID 24436135. *Ineligible population*

Arntzen KA, Schirmer H, Wilsgaard T, et al. Moderate wine consumption is associated with better cognitive test results: a 7 year follow up of 5033 subjects in the Tromso Study. *Acta Neurologica Scandinavica*. 2010;Supplementum.(190):23-9. PMID 20586731. *Not cognitive decline prevention intervention*

Articus K, Baier M, Tracik F, et al. A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease. *International Journal of Clinical Practice*. 2011 Jul;65(7):790-6. PMID 21645184. *Ineligible population*

Athilingam P, Edwards JD, Valdes EG, et al. Computerized auditory cognitive training to improve cognition and functional outcomes in patients with heart failure: Results of a pilot study. *Heart & Lung*. 2015 Mar-Apr;44(2):120-8. PMID 25592205. *Inadequate follow up time*

Au R, Seshadri S, Knox K, et al. The Framingham Brain Donation Program: neuropathology along the cognitive continuum. *Current Alzheimer Research*. 2012 Jul;9(6):673-86. PMID 22471865. *Not cognitive decline prevention intervention*

Azhar ZM, Zubaidah JO, Norjan KO, et al. A pilot placebo-controlled, double-blind, and randomized study on the cognition-enhancing benefits of a proprietary chicken meat ingredient in healthy subjects. *Nutrition Journal*. 2013;12:121. PMID 23945213. *Inadequate follow up time*

Bachinskaya N, Hoerr R, Ihl R. Alleviating neuropsychiatric symptoms in dementia: The effects of Ginkgo biloba extract EGb 761. Findings from a randomized controlled trial. *Neuropsychiatric Disease and Treatment*. 2011;7(1):209-15. PMID 2011559394. *Ineligible population*

Baker LD, Asthana S, Cholerton BA, et al. Cognitive response to estradiol in postmenopausal women is modified by high cortisol. *Neurobiology of Aging*. 2012 Apr;33(4):829.e9-20. PMID 21855173. *Inadequate follow up time*

Baker LD, Cross DJ, Minoshima S, et al. Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. *Archives of Neurology*. 2011 Jan;68(1):51-7. PMID 20837822. *Inadequate follow up time*

Bakker A, Albert MS, Krauss G, et al. Response of the medial temporal lobe network in amnesic mild cognitive impairment to therapeutic intervention assessed by fMRI and memory task performance. *NeuroImage: Clinical*. 2015;7:688-98. PMID 2015830727. *Inadequate follow up time*

Ballesteros S, Prieto A, Mayas J, et al. Brain training with non-action video games enhances aspects of cognition in older adults: a randomized controlled trial. *Frontiers in aging neuroscience*. 2014;6:277. *Inadequate follow up time*

Ballesteros S, Prieto A, Mayas J, et al. Corrigendum: Brain training with non-action video games enhances aspects of cognition in older adults: a randomized controlled trial. *Frontiers in aging neuroscience*. 2015. *Inadequate follow up time*

Bamidis PD, Fissler P, Papageorgiou SG, et al. Gains in cognition through combined cognitive and physical training: the role of training dosage and severity of neurocognitive disorder. *Frontiers in aging neuroscience*. 2015;7. *Inadequate follow up time*

Barban F, Annicchiarico R, Pantelopoulos S, et al. Protecting cognition from aging and Alzheimer's disease: A computerized cognitive training combined with reminiscence therapy. *International Journal of Geriatric Psychiatry*. 2016 01 Apr;31(4):340-8. PMID 605331877. *Inadequate follow up time*

Barnes DE, Mehling W, Wu E, et al. Preventing Loss of Independence through Exercise (PLIE): A pilot clinical trial in older adults with dementia. *PLoS ONE*. 2015 11 Feb;10(2)PMID 2015767557. *Ineligible population*

Barnes DE, Santos-Modesitt W, Poelke G, et al. The Mental Activity and eXercise (MAX) trial: a randomized controlled trial to enhance cognitive function in older adults. *JAMA Internal Medicine*. 2013 May 13;173(9):797-804. PMID 23545598. *Inadequate follow up time*

Barnes DE, Yaffe K, Belfor N, et al. Computer-based cognitive training for mild cognitive impairment: results from a pilot randomized, controlled trial. *Alzheimer Disease & Associated Disorders*. 2009 Jul-Sep;23(3):205-10. PMID 19812460. *Inadequate follow up time*

Barnes DE, Yaffe K, Byers AL, et al. Midlife vs late-life depressive symptoms and risk of dementia: differential effects for Alzheimer disease and vascular dementia. *Archives of General Psychiatry*. 2012 May;69(5):493-8. PMID 22566581. *Not cognitive decline prevention intervention*

Barone P, Santangelo G, Morgante L, et al. A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients. *European Journal of Neurology*. 2015 Aug;22(8):1184-91. PMID 25962410. *Inadequate follow up time*

Barrett DW, Gonzalez-Lima F. Transcranial infrared laser stimulation produces beneficial cognitive and emotional effects in humans. *Neuroscience*. 2013 Jan 29;230:13-23. PMID 23200785. *Inadequate follow up time*

Barton DL, Burger K, Novotny PJ, et al. The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9. *Supportive Care in Cancer*. 2013 Apr;21(4):1185-92. PMID 23150188. *Ineligible population*

Batty GD, Li Q, Huxley R, et al. Oral disease in relation to future risk of dementia and cognitive decline: prospective cohort study based on the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) trial. *European Psychiatry: the Journal of the Association of European Psychiatrists*. 2013 Jan;28(1):49-52. PMID 21964484. *Not cognitive decline prevention intervention*

Bauer I, Hughes M, Rowsell R, et al. Omega-3 supplementation improves cognition and modifies brain activation in young adults. *Human Psychopharmacology*. 2014 Mar;29(2):133-44. PMID 24470182. *Inadequate follow up time*

Baurle P, Suter A, Wormstall H. Safety and effectiveness of a traditional ginkgo fresh plant extract - results from a clinical trial. *Forschende Komplementarmedizin (2006)*. 2009 Jun;16(3):156-61. PMID 19657199. *Inadequate follow up time*

Bayer-Carter JL, Green PS, Montine TJ, et al. Diet intervention and cerebrospinal fluid biomarkers in amnesic mild cognitive impairment. *Archives of Neurology*. 2011 Jun;68(6):743-52. PMID 21670398. *Inadequate follow up time*

Beck C, Fausett JK, Krukowski RA, et al. A randomized trial of a community-based cognitive intervention for obese senior adults. *Journal of Aging & Health*. 2013 Feb;25(1):97-118. PMID 23248351. *Inadequate follow up time*



Beck SM, Ruge H, Schindler C, et al. Effects of Ginkgo biloba extract EGb 761 on cognitive control functions, mental activity of the prefrontal cortex and stress reactivity in elderly adults with subjective memory impairment-A randomized double-blind placebo-controlled trial. *Human Psychopharmacology: Clinical and Experimental*. 2016 May;31(3):227-42. PMID 2016-22663-005. *Inadequate follow up time*

Belchior P, Marsiske M, Sisco SM, et al. Video game training to improve selective visual attention in older adults. *Computers in human behavior*. 2013;29(4):1318-24. *Inadequate follow up time*

Bentley P, Driver J, Dolan RJ. Modulation of fusiform cortex activity by cholinesterase inhibition predicts effects on subsequent memory. *Brain*. 2009 Sep;132(Pt 9):2356-71. PMID 19605530. *Not cognitive decline prevention intervention*

Bergamaschi S, Arcara G, Calza A, et al. One-year repeated cycles of cognitive training (CT) for Alzheimer's disease. *Aging-Clinical & Experimental Research*. 2013 Aug;25(4):421-6. PMID 23784727. *Ineligible population*

Bernick C, Cummings J, Raman R, et al. Age and rate of cognitive decline in Alzheimer disease: Implications for clinical trials. *Archives of Neurology*. 2012 July;69(7):901-5. PMID 2012409204. *Ineligible population*

Berr C, Portet F, Carriere I, et al. Olive oil and cognition: results from the three-city study. *Dementia & Geriatric Cognitive Disorders*. 2009;28(4):357-64. PMID 19887798. *Not cognitive decline prevention intervention*

Berry AS, Zanto TP, Clapp WC, et al. The influence of perceptual training on working memory in older adults. *PLoS ONE [Electronic Resource]*. 2010;5(7):e11537. PMID 20644719. *Inadequate follow up time*

Bettermann K, Arnold AM, Williamson J, et al. Statins, risk of dementia, and cognitive function: secondary analysis of the ginkgo evaluation of memory study. *Journal of Stroke & Cerebrovascular Diseases*. 2012 Aug;21(6):436-44. PMID 21236699. *Not cognitive decline prevention intervention*

Beydoun MA, Beason-Held LL, Kitner-Triolo MH, et al. Statins and serum cholesterol's associations with incident dementia and mild cognitive impairment. *Journal of Epidemiology & Community Health*. 2011 Nov;65(11):949-57. PMID 20841372. *Not cognitive decline prevention intervention*

Bickel H, Ander KH, Bronner M, et al. Reduction of long-term care dependence after an 8-year primary care prevention program for stroke and dementia: The INVADE trial. *Journal of the American Heart Association*. 2012 August;1(4) PMID 2013312020. *Ineligible population*

Bielak AA, Anstey KJ, Christensen H, et al. Activity engagement is related to level, but not change in cognitive ability across adulthood. *Psychology & Aging*. 2012 Mar;27(1):219-28. PMID 21806303. *Not cognitive decline prevention intervention*

Biemans E, Hart HE, Rutten GE, et al. Cobalamin status and its relation with depression, cognition and neuropathy in patients with type 2 diabetes mellitus using metformin. *Acta Diabetologica*. 2015 Apr;52(2):383-93. PMID 25315630. *Ineligible study design*

Bisby JA, King JA, Brewin CR, et al. Acute effects of alcohol on intrusive memory development and viewpoint dependence in spatial memory support a dual representation model. *Biological Psychiatry*. 2010 Aug 1;68(3):280-6. PMID 20202625. *Inadequate follow up time*

Bjerke M, Kern S, Blennow K, et al. Cerebrospinal fluid fatty acid-binding protein 3 is related to dementia development in a population-based sample of older adult women followed for 8 years. *Journal of Alzheimer's Disease*. 2016;49(3):733-41. PMID 20151037428. *Ineligible study design*

Blackburn DJ, Krishnan K, Fox L, et al. Prevention of Decline in Cognition after Stroke Trial (PODCAST): a study protocol for a factorial randomised controlled trial of intensive versus guideline lowering of blood pressure and lipids. *Trials [Electronic Resource]*. 2013;14:401. PMID 24266960. *Ineligible population*

Blackwell T, Yaffe K, Laffan A, et al. Associations of objectively and subjectively measured sleep quality with subsequent cognitive decline in older community-dwelling men: the MrOS sleep study. *Sleep*. 2014;37(4):655-63. PMID 24899757. *Ineligible study design*

Blasko I, Hinterberger M, Kemmler G, et al. Conversion from mild cognitive impairment to dementia: influence of folic acid and vitamin B12 use in the VITA cohort. *Journal of Nutrition, Health & Aging*. 2012 Aug;16(8):687-94. PMID 23076510. *Not cognitive decline prevention intervention*

Blennow K, Zetterberg H, Rinne JO, et al. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. *Archives of Neurology*. 2012 Aug;69(8):1002-10. PMID 22473769. *Ineligible population*

Block GA, Mitchel YB, Tobert JA, et al. Comparative effects of pravastatin and lovastatin on nighttime sleep and daytime performance. *Clinical Cardiology*. 1992 Oct;15(10):A24, 790. PMID 1395179. *Inadequate follow up time*

Blumenthal JA, Smith PJ, Welsh-Bohmer K, et al. Can lifestyle modification improve neurocognition? Rationale and design of the ENLIGHTEN clinical trial. *Contemporary Clinical Trials*. 2013 Jan;34(1):60-9. PMID 23000080. *Ineligible study design*

Boche D, Donald J, Love S, et al. Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer's disease. *Acta Neuropathologica*. 2010 Jul;120(1):13-20. PMID 20532897. *Ineligible population*

Bohm M, Schumacher H, Leong D, et al. Systolic blood pressure variation and mean heart rate is associated with cognitive dysfunction in patients with high cardiovascular risk. *Hypertension*. 2015 Mar;65(3):651-61. PMID 25583157. *Not cognitive decline prevention intervention*

Boissoneault J, Sklar A, Prather R, et al. Acute effects of moderate alcohol on psychomotor, set shifting, and working memory function in older and younger social drinkers. *Journal of Studies on Alcohol & Drugs*. 2014 Sep;75(5):870-9. PMID 25208205. *Inadequate follow up time*

Boss HM, Van Schaik SM, Deijle IA, et al. A randomised controlled trial of aerobic exercise after transient ischaemic attack or minor stroke to prevent cognitive decline: the MoveIT study protocol. *BMJ Open*. 2014;4(12):e007065. PMID 25552615. *Ineligible population*

Bossers WJ, Scherder EJ, Boersma F, et al. Feasibility of a combined aerobic and strength training program and its effects on cognitive and physical function in institutionalized dementia patients. A pilot study. *PLoS ONE [Electronic Resource]*. 2014;9(5):e97577. PMID 24844772. *Inadequate follow up time*

Bouchard P. [Cognitive risks and HRT]. *Revue du Praticien*. 2010 Oct 20;60(8):1137-8. PMID 21197753. *Not available in English*

Bowen ME. A prospective examination of the relationship between physical activity and dementia risk in later life. *American Journal of Health Promotion*. 2012 Jul-Aug;26(6):333-40. PMID 22747314. *Not cognitive decline prevention intervention*

Bowen RL, Perry G, Xiong C, et al. A clinical study of lupron depot in the treatment of women with Alzheimer's disease: preservation of cognitive function in patients taking an acetylcholinesterase inhibitor and treated with high dose lupron over 48 weeks. *Journal of Alzheimer's Disease*. 2015;44(2):549-60. PMID 25310993. *Ineligible population*

Boyle PA, Buchman AS, Barnes LL, et al. Effect of a purpose in life on risk of incident Alzheimer disease and mild cognitive impairment in community-dwelling older persons. *Archives of General Psychiatry*. 2010 Mar;67(3):304-10. PMID 20194831. *Not cognitive decline prevention intervention*

Boyle PA, Buchman AS, Wilson RS, et al. Association of muscle strength with the risk of Alzheimer disease and the rate of cognitive decline in community-dwelling older persons. *Archives of Neurology*. 2009 November;66(11):1339-44. PMID 2009598988. *Not cognitive decline prevention intervention*

Bozoki A, Radovanovic M, Winn B, et al. Effects of a computer-based cognitive exercise program on age-related cognitive decline. *Archives of Gerontology & Geriatrics*. 2013 Jul-Aug;57(1):1-7. PMID 23542053. *Inadequate follow up time*

Brainin M, Matz K, Nemec M, et al. Prevention of poststroke cognitive decline: ASPIS - a multicenter, randomized, observer-blind, parallel group clinical trial to evaluate multiple lifestyle interventions - study design and baseline characteristics. *International Journal of Stroke*. 2015 01 Jun;10(4):627-35. PMID 2014768731. *Ineligible population*

Braun AK, Kubiak T, Kuntsche J, et al. SGS: a structured treatment and teaching programme for older patients with diabetes mellitus--a prospective randomised controlled multi-centre trial. *Age & Ageing*. 2009 Jul;38(4):390-6. PMID 19454403. *No relevant outcomes reported*

Breitner JCS, Haneuse SJPA, Walker R, et al. Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. *Neurology*. 2009 02 Jun;72(22):1899-905. PMID 2009338455. *Not cognitive decline prevention intervention*

Brown AK, Liu-Ambrose T, Tate R, et al. The effect of group-based exercise on cognitive performance and mood in seniors residing in intermediate care and self-care retirement facilities: a randomised controlled trial. *British Journal of Sports Medicine*. 2009 Aug;43(8):608-14. PMID 18927162. *Ineligible population*

Brown D, Spanjers K, Atherton N, et al. Development of an exercise intervention to improve cognition in people with mild to moderate dementia: Dementia And Physical Activity (DAPA) Trial, registration ISRCTN32612072. *Physiotherapy (United Kingdom)*. 2015 01 Jun;101(2):126-34. PMID 2015778040. *Ineligible population*

Brown ES, Zaidel L, Allen G, et al. Effects of lamotrigine on hippocampal activation in corticosteroid-treated patients. *Journal of Affective Disorders*. 2010 November;126(3):415-9. PMID 2010547628. *Ineligible population*

Brown PD, Pugh S, Laack NN, et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. *Neuro-Oncology*. 2013 Oct;15(10):1429-37. PMID 23956241. *Ineligible population*

Bruce J, Hancock L, Roberg B, et al. Impact of armodafinil on cognition in multiple sclerosis: a randomized, double-blind crossover pilot study. *Cognitive & Behavioral Neurology*. 2012 Sep;25(3):107-14. PMID 22960434. *Ineligible population*

Brunetti V, Losurdo A, Testani E, et al. Rivastigmine for refractory REM behavior disorder in mild cognitive impairment. *Current Alzheimer Research*. 2014 Mar;11(3):267-73. PMID 24597506. *No relevant outcomes reported*

Buchman AS, Boyle PA, Yu L, et al. Total daily physical activity and the risk of AD and cognitive decline in older adults. *Neurology*. 2012 Apr 24;78(17):1323-9. PMID 22517108. *Not cognitive decline prevention intervention*

Buecking B, Struwer J, Waldermann A, et al. What determines health-related quality of life in hip fracture patients at the end of acute care?--a prospective observational study. *Osteoporosis International*. 2014 Feb;25(2):475-84. PMID 23783644. *Ineligible population*

Burstein AH, Grimes I, Galasko DR, et al. Effect of TTP488 in patients with mild to moderate Alzheimer's disease. *BMC Neurology*. 2014 January 15;14(1)PMID 2015890655. *Ineligible population*

Buschert VC, Friese U, Teipel SJ, et al. Effects of a newly developed cognitive intervention in amnesic mild cognitive impairment and mild Alzheimer's disease: a pilot study. *Journal of Alzheimer's Disease*. 2011;25(4):679-94. PMID 21483095. *Ineligible population*

Byeon H, Lee Y, Lee SY, et al. Association of alcohol drinking with verbal and visuospatial memory impairment in older adults: Clinical Research Center for Dementia of South Korea (CREDOS) study. *International Psychogeriatrics*. 2015 Mar;27(3):455-61. PMID 25119654. *Inadequate follow up time*

Cadar D, Pikhart H, Mishra G, et al. The role of lifestyle behaviors on 20-year cognitive decline. *Journal of Aging Research*. 2012;2012 (no pagination)(304014)PMID 2012621473. *Not cognitive decline prevention intervention*

Cancela JM, Vila Suarez MH, Vasconcelos J, et al. Efficacy of brain gym training on the cognitive performance and fitness level of active older adults: A preliminary study. *Journal of Aging and Physical Activity*. 2015 Oct;23(4):653-8. PMID 2015-49570-012. *Inadequate follow up time*

Cao C, Loewenstein DA, Lin X, et al. High Blood caffeine levels in MCI linked to lack of progression to dementia. *Journal of Alzheimer's Disease*. 2012;30(3):559-72. PMID 22430531. *Not cognitive decline prevention intervention*

Caramelli P, Laks J, Palmini AL, et al. Effects of galantamine and galantamine combined with nimodipine on cognitive speed and quality of life in mixed dementia: a 24-week, randomized, placebo-controlled exploratory trial (the REMIX study). *Arquivos de Neuro-Psiquiatria*. 2014 Jun;72(6):411-7. PMID 24964105. *Ineligible population*

Carlson MC, Erickson KI, Kramer AF, et al. Evidence for neurocognitive plasticity in at-risk older adults: the experience corps program. *The journals of gerontology*. 2009 Dec;Series A, Biological sciences and medical sciences. 64(12):1275-82. PMID 19692672. *No relevant outcomes reported*

Carlsson CM, Nondahl DM, Klein BE, et al. Increased atherogenic lipoproteins are associated with cognitive impairment: effects of statins and subclinical atherosclerosis. *Alzheimer Disease & Associated Disorders*. 2009 Jan-Mar;23(1):11-7. PMID 19266697. *Ineligible study design*

Carretti B, Borella E, Fostinelli S, et al. Benefits of training working memory in amnesic mild cognitive impairment: specific and transfer effects. *International Psychogeriatrics*. 2013 Apr;25(4):617-26. PMID 23253363. *Inadequate follow up time*

Carriere I, Fourrier-Reglat A, Dartigues JF, et al. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study. *Archives of Internal Medicine*. 2009 Jul 27;169(14):1317-24. PMID 19636034. *Not cognitive decline prevention intervention*

Casoli T, Giuli C, Baliotti M, et al. Effect of cognitive training on the expression of brain-derived neurotrophic factor in lymphocytes of mild cognitive impairment patients. *Rejuvenation Research*. 2014 Apr;17(2):235-8. PMID 24127698. *Inadequate follow up time*

Cereda E, Sacchi MC, Malavazos AE. Central obesity and increased risk of dementia more than three decades later. *Neurology*. 2009 Mar 17;72(11):1030-1; author reply 1. PMID 19289749. *Not cognitive decline prevention intervention*

Cervellati C, Trentini A, Romani A, et al. Serum paraoxonase and arylesterase activities of paraoxonase-1 (PON-1), mild cognitive impairment, and 2-year conversion to dementia: A pilot study. *Journal of Neurochemistry*. 2015 Oct;135(2):395-401. PMID 26178739. *Not cognitive decline prevention intervention*

Chan A, Paskavitz J, Remington R, et al. Efficacy of a vitamin/nutriceutical formulation for early-stage Alzheimer's disease: A 1-year, open-label pilot study with an 16-month caregiver extension. *American Journal of Alzheimer's Disease and other Dementias*. 2009 December-January;23(6):571-85. PMID 2009009400. *Ineligible population*

Chang M, Jonsson PV, Snaedal J, et al. The effect of midlife physical activity on cognitive function among older adults: AGES--Reykjavik Study. *Journals of Gerontology Series A-Biological Sciences & Medical Sciences*. 2010 Dec;65(12):1369-74. PMID 20805238. *Ineligible study design*

Chang SL, Tsai AC. Gender differences in the longitudinal associations of depressive symptoms and leisure-time physical activity with cognitive decline in > 57 year-old Taiwanese. *Preventive Medicine*. 2015 August 01;77:68-73. PMID 2015071830. *Not cognitive decline prevention intervention*

Chang YK, Etnier JL. Exploring the dose-response relationship between resistance exercise intensity and cognitive function. *Journal of Sport & Exercise Psychology*. 2009 Oct;31(5):640-56. PMID 20016113. *Inadequate follow up time*

Chao TF, Liu CJ, Chen SJ, et al. Statins and the risk of dementia in patients with atrial fibrillation: A nationwide population-based cohort study. *International Journal of Cardiology*. 2015 23 Jul;196:91-7. PMID 2015217508. *Not cognitive decline prevention intervention*

Chen CL, Ikram K, Anqi Q, et al. The NeuroAiD II (MLC901) in vascular cognitive impairment study (NEURITES). *Cerebrovascular Diseases*. 2013;35 Suppl 1:23-9. PMID 23548916. *Ineligible population*

Chen PY, Liu SK, Chen CL, et al. Long-term statin use and dementia risk in Taiwan. *Journal of Geriatric Psychiatry & Neurology*. 2014 Sep;27(3):165-71. PMID 24578458. *Not cognitive decline prevention intervention*

Chen S, Yao X, Liang Y, et al. Alzheimer's disease treated with combined therapy based on nourishing marrow and reinforcing Qi. *Journal of Traditional Chinese Medicine*. 2015 Jun;35(3):255-9. PMID 26237827. *Ineligible population*

Cheng Y, Wang YJ, Yan JC, et al. Effects of carotid artery stenting on cognitive function in patients with mild cognitive impairment and carotid stenosis. *Experimental and Therapeutic Medicine*. 2013 April;5(4):1019-24. PMID 2013144752. *Cohort study with inadequate sample size*

Cheng Y, Wu W, Feng W, et al. The effects of multi-domain versus single-domain cognitive training in non-demented older people: a randomized controlled trial. *BMC Medicine*. 2012;10:30. PMID 22453114. *Inadequate follow up time*

Cherbuin N, Anstey KJ. The Mediterranean diet is not related to cognitive change in a large prospective investigation: the PATH Through Life study. *American Journal of Geriatric Psychiatry*. 2012 Jul;20(7):635-9. PMID 21937919. *Not cognitive decline prevention intervention*

Cherrier MM, Anderson K, David D, et al. A randomized trial of cognitive rehabilitation in cancer survivors. *Life Sciences*. 2013 Oct 17;93(17):617-22. PMID 24012579. *Ineligible population*

- Chiu WC, Ho WC, Lin MH, et al. Angiotension receptor blockers reduce the risk of dementia. *Journal of Hypertension*. 2014 Apr;32(4):938-47. PMID 24406780. *Not cognitive decline prevention intervention*
- Choi SH, Park KW, Na DL, et al. Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study. *Current Medical Research & Opinion*. 2011 Jul;27(7):1375-83. PMID 21561398. *Ineligible population*
- Chou CY, Chou YC, Chou YJ, et al. Statin use and incident dementia: a nationwide cohort study of Taiwan. *International Journal of Cardiology*. 2014 May 1;173(2):305-10. PMID 24681022. *Ineligible study design*
- Choudhary P, Lonnen K, Emery CJ, et al. Comparing hormonal and symptomatic responses to experimental hypoglycaemia in insulin- and sulphonylurea-treated Type 2 diabetes. *Diabetic Medicine*. 2009 Jul;26(7):665-72. PMID 19573114. *No relevant outcomes reported*
- Christopher MS, Jacob KL, Neuhaus EC, et al. Cognitive and behavioral changes related to symptom improvement among patients with a mood disorder receiving intensive cognitive-behavioral therapy. *Journal of Psychiatric Practice*. 2009 Mar;15(2):95-102. PMID 19339843. *Inadequate follow up time*
- Chu DC, Fox KR, Chen LJ, et al. Components of late-life exercise and cognitive function: an 8-year longitudinal study. *Prevention Science*. 2015 May;16(4):568-77. PMID 25297968. *No relevant outcomes reported*
- Chuang CS, Lin CL, Lin MC, et al. Decreased prevalence of dementia associated with statins: A national population-based study. *European Journal of Neurology*. 2015 01 Jun;22(6):912-8. PMID 2015971469. *Not cognitive decline prevention intervention*
- Chuang YF, Breitner JC, Chiu YL, et al. Use of diuretics is associated with reduced risk of Alzheimer's disease: the Cache County Study. *Neurobiology of Aging*. 2014 Nov;35(11):2429-35. PMID 24910391. *Ineligible study design*
- Ciarmiello A, Gaeta MC, Benso F, et al. FDG-PET in the evaluation of brain metabolic changes induced by cognitive stimulation in aMCI subjects. *Current Radiopharmaceuticals*. 2015 01 Jun;8(1):69-75. PMID 2015110096. *Inadequate follow up time*
- Clare L, Linden DE, Woods RT, et al. Goal-oriented cognitive rehabilitation for people with early-stage Alzheimer disease: a single-blind randomized controlled trial of clinical efficacy. *American Journal of Geriatric Psychiatry*. 2010 Oct;18(10):928-39. PMID 20808145. *Ineligible population*



Claxton A, Baker LD, Hanson A, et al. Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia.[Erratum appears in J Alzheimers Dis. 2015;45(4):1269-70; PMID: 25869922]. Journal of Alzheimer's Disease. 2015;44(3):897-906. PMID 25374101. *Ineligible population*

Claxton A, Baker LD, Hanson A, et al. Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's Disease dementia. Journal of Alzheimer's Disease. 2015;44(3):897-906. PMID 2015740466. *Ineligible population*

Claxton A, Baker LD, Wilkinson CW, et al. Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer's disease. Journal of Alzheimer's Disease. 2013;35(4):789-97. PMID 23507773. *Ineligible population*

Colcombe SJ, Kramer AF, McAuley E, et al. Neurocognitive aging and cardiovascular fitness: recent findings and future directions. Journal of Molecular Neuroscience. 2004;24(1):9-14. PMID 15314244. *Ineligible study design*

Collins N, Sachs-Ericsson N, Preacher KJ, et al. Smoking increases risk for cognitive decline among community-dwelling older Mexican Americans. American Journal of Geriatric Psychiatry. 2009 Nov;17(11):934-42. PMID 20104052. *Not cognitive decline prevention intervention*

Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003 Jun 14;361(9374):2005-16. PMID 12814710. *No relevant outcomes reported*

Concha JB, Kravitz HM, Chin MH, et al. Review of type 2 diabetes management interventions for addressing emotional well-being in Latinos. Diabetes Educator. 2009 Nov-Dec;35(6):941-58. PMID 19773526. *Ineligible study design*

Cooper ZD, Foltin RW, Hart CL, et al. A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers. Addiction Biology. 2013 Nov;18(6):993-1002. PMID 22741619. *Inadequate follow up time*

Cordasco KM, Asch SM, Bell DS, et al. A low-literacy medication education tool for safety-net hospital patients. American Journal of Preventive Medicine. 2009 Dec;37(6 Suppl 1):S209-16. PMID 19896021. *No relevant outcomes reported*

Cornelli U. Treatment of Alzheimer's disease with a cholinesterase inhibitor combined with antioxidants. *Neurodegenerative Diseases*. 2010;7(1-3):193-202. PMID 20224285. *Ineligible population*

Corsentino EA, Collins N, Sachs-Ericsson N, et al. Religious attendance reduces cognitive decline among older women with high levels of depressive symptoms. *Journals of Gerontology Series A-Biological Sciences & Medical Sciences*. 2009 Dec;64(12):1283-9. PMID 19675176. *Not cognitive decline prevention intervention*

Cote S, Carmichael PH, Verreault R, et al. Nonsteroidal anti-inflammatory drug use and the risk of cognitive impairment and Alzheimer's disease. *Alzheimer's & Dementia*. 2012 May;8(3):219-26. PMID 22546354. *Not cognitive decline prevention intervention*

Cotroneo AM, Castagna A, Putignano S, et al. Effectiveness and safety of citicoline in mild vascular cognitive impairment: the IDEALE study. *Clinical Interventions In Aging*. 2013;8:131-7. PMID 23403474. *Ineligible population*

Craft S, Baker LD, Montine TJ, et al. Intranasal insulin therapy for Alzheimer disease and amnesic mild cognitive impairment: a pilot clinical trial. *Archives of Neurology*. 2012 Jan;69(1):29-38. PMID 21911655. *Ineligible population*

Craik FI, Winocur G, Palmer H, et al. Cognitive rehabilitation in the elderly: effects on memory. *Journal of the International Neuropsychological Society*. 2007 Jan;13(1):132-42. PMID 17166312. *Ineligible study design*

Crane PK, Gibbons LE, Arani K, et al. Midlife use of written Japanese and protection from late life dementia. *Epidemiology*. 2009 Sep;20(5):766-74. PMID 19593152. *Not cognitive decline prevention intervention*

Creavin ST, Gallacher J, Pickering J, et al. High caloric intake, poor cognition and dementia: the Caerphilly Prospective Study. *European Journal of Epidemiology*. 2012 Mar;27(3):197-203. PMID 22392589. *Not cognitive decline prevention intervention*

Crichton GE, Elias MF, Dore GA, et al. Measurement-to-measurement blood pressure variability is related to cognitive performance: the Maine Syracuse study. *Hypertension*. 2014 Nov;64(5):1094-101. PMID 25156168. *No relevant outcomes reported*

Cronberg T, Lilja G, Horn J, et al. Neurologic Function and Health-Related Quality of Life in Patients Following Targeted Temperature Management at 33degreeC vs 36degreeC After Out-of-Hospital Cardiac Arrest: A Randomized Clinical Trial. *JAMA Neurology*. 2015 Jun;72(6):634-41. PMID 25844993. *Ineligible population*

Cukierman-Yaffe T, Anderson C, Teo K, et al. Dysglycemia and Cognitive Dysfunction and Ill Health in People With High CV Risk: Results From the

ONTARGET/TRANSCEND Studies. *Journal of Clinical Endocrinology & Metabolism*. 2015 Jul;100(7):2682-9. PMID 26020764. *Not cognitive decline prevention intervention*

Cukierman-Yaffe T, Gerstein HC, Williamson JD, et al. Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND) trial. *Diabetes Care*. 2009 Feb;32(2):221-6. PMID 19171735. *Not cognitive decline prevention intervention*

Cummings J, Froelich L, Black SE, et al. Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm) in Alzheimer's disease. *Dementia and Geriatric Cognitive Disorders*. 2012 July;33(5):341-53. PMID 2012461797. *Ineligible population*

Cummings JL, Lyketsos CG, Peskind ER, et al. Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial. *JAMA*. 2015 Sep 22-29;314(12):1242-54. PMID 26393847. *Ineligible population*

Dahl A, Hassing LB, Fransson E, et al. Being overweight in midlife is associated with lower cognitive ability and steeper cognitive decline in late life. *Journals of Gerontology Series A-Biological Sciences & Medical Sciences*. 2010 Jan;65(1):57-62. PMID 19349594. *Ineligible population*

Damoiseaux JS, Prater KE, Miller BL, et al. Functional connectivity tracks clinical deterioration in Alzheimer's disease. *Neurobiology of Aging*. 2012 April;33(4):828.e19-.e30. PMID 2012085742. *Ineligible population*

Dangour AD, Allen E, Elbourne D, et al. Fish consumption and cognitive function among older people in the UK: baseline data from the OPAL study. *Journal of Nutrition, Health & Aging*. 2009 Mar;13(3):198-202. PMID 19262951. *Not cognitive decline prevention intervention*

Danhauer SC, Legault C, Bandos H, et al. Positive and negative affect, depression, and cognitive processes in the Cognition in the Study of Tamoxifen and Raloxifene (Co-STAR) Trial. *Aging Neuropsychology & Cognition*. 2013;20(5):532-52. PMID 23237718. *No relevant outcomes reported*

Dannhauser TM, Cleverley M, Whitfield TJ, et al. A complex multimodal activity intervention to reduce the risk of dementia in mild cognitive impairment--ThinkingFit: pilot and feasibility study for a randomized controlled trial. *BMC Psychiatry*. 2014;14:129. PMID 24886353. *Inadequate follow up time*

Danthiir V, Burns NR, Nettelbeck T, et al. The older people, omega-3, and cognitive health (EPOCH) trial design and methodology: a randomised, double-blind, controlled trial investigating the effect of long-chain omega-3 fatty acids on cognitive ageing and

wellbeing in cognitively healthy older adults. *Nutrition Journal*. 2011;10:117. PMID 22011460. *Ineligible study design*

Davis JL, Rhudy JL, Pruiksma KE, et al. Physiological predictors of response to exposure, relaxation, and rescripting therapy for chronic nightmares in a randomized clinical trial. *Journal of Clinical Sleep Medicine*. 2011 Dec 15;7(6):622-31. PMID 22171201. *Ineligible population*

de Andrade LP, Gobbi LT, Coelho FG, et al. Benefits of multimodal exercise intervention for postural control and frontal cognitive functions in individuals with Alzheimer's disease: a controlled trial. *Journal of the American Geriatrics Society*. 2013 Nov;61(11):1919-26. PMID 24219193. *Ineligible population*

de Bruijn RF, Bos MJ, Portegies ML, et al. The potential for prevention of dementia across two decades: the prospective, population-based Rotterdam Study. *BMC Medicine*. 2015;13:132. PMID 26195085. *Not cognitive decline prevention intervention*

de Bruijn RF, Schrijvers EM, de Groot KA, et al. The association between physical activity and dementia in an elderly population: the Rotterdam Study.[Erratum appears in *Eur J Epidemiol*. 2013 May;28(5):447-8]. *European Journal of Epidemiology*. 2013 Mar;28(3):277-83. PMID 23385659. *Ineligible study design*

De Bruijn RFAG, Schrijvers EMC, De Groot KA, et al. The association between physical activity and dementia in an elderly population: The Rotterdam Study. *European Journal of Epidemiology*. 2013 March;28(3):277-83. PMID 2013314732. *Not cognitive decline prevention intervention*

de Gobbi Porto FH, Coutinho AMN, de Sa Pinto AL, et al. Effects of aerobic training on cognition and brain glucose metabolism in subjects with mild cognitive impairment. *Journal of Alzheimer's Disease*. 2015;46(3):747-60. PMID 2015-57104-018. *Ineligible study design*

de Jong FJ, Masaki K, Chen H, et al. Thyroid function, the risk of dementia and neuropathologic changes: the Honolulu-Asia aging study. *Neurobiology of Aging*. 2009 Apr;30(4):600-6. PMID 17870208. *Not cognitive decline prevention intervention*

de Koning EJ, van Schoor NM, Penninx BW, et al. Vitamin D supplementation to prevent depression and poor physical function in older adults: Study protocol of the D-Vitaal study, a randomized placebo-controlled clinical trial. *BMC Geriatrics*. 2015;15:151. PMID 26585952. *No relevant outcomes reported*

Dean AJ, Bellgrove MA, Hall T, et al. Effects of vitamin D supplementation on cognitive and emotional functioning in young adults--a randomised controlled trial. *PLoS ONE [Electronic Resource]*. 2011;6(11):e25966. PMID 22073146. *Inadequate follow up time*

Defina LF, Willis BL, Radford NB, et al. The association between midlife cardiorespiratory fitness levels and later-life dementia: a cohort study.[Summary for patients in *Ann Intern Med*. 2013 Feb 5;158(3):I-36; PMID: 23381057]. *Annals of Internal Medicine*. 2013 Feb 5;158(3):162-8. PMID 23381040. *Not cognitive decline prevention intervention*

DeHaven MJ, Ramos-Roman MA, Gimpel N, et al. The GoodNEWS (Genes, Nutrition, Exercise, Wellness, and Spiritual Growth) Trial: a community-based participatory research (CBPR) trial with African-American church congregations for reducing cardiovascular disease risk factors--recruitment, measurement, and randomization.[Erratum appears in *Contemp Clin Trials*. 2012 Nov;33(6):1321 Note: Duval, Julie [corrected to Duvahl, Julie]]. *Contemporary Clinical Trials*. 2011 Sep;32(5):630-40. PMID 21664298. *No relevant outcomes reported*

Dersu, II, Spencer HT, Grigorian PA, et al. The effect of mydriatic solutions on cognitive function. *Seminars in Ophthalmology*. 2015 Jan;30(1):36-9. PMID 23952181. *Inadequate follow up time*

Desideri G, Kwik-Urbe C, Grassi D, et al. Benefits in cognitive function, blood pressure, and insulin resistance through cocoa flavanol consumption in elderly subjects with mild cognitive impairment: the Cocoa, Cognition, and Aging (CoCoA) study. *Hypertension*. 2012 Sep;60(3):794-801. PMID 22892813. *Inadequate follow up time*

Desikan RS, Thompson WK, Holland D, et al. Heart fatty acid binding protein and Abeta-associated Alzheimer's neurodegeneration. *Molecular Neurodegeneration*. 2013;8:39. PMID 24088526. *Cohort study with inadequate sample size*

Devanand DP. Donepezil treatment of older adults with cognitive impairment and depression (DOTCODE study): clinical rationale and design. *Contemporary clinical trials*. 2014 01 Mar;37(2):200-8. PMID 24315979. *Ineligible population*

Devore EE, Grodstein F, van Rooij FJ, et al. Dietary intake of fish and omega-3 fatty acids in relation to long-term dementia risk. *American Journal of Clinical Nutrition*. 2009 Jul;90(1):170-6. PMID 19474131. *Not cognitive decline prevention intervention*

Devore EE, Grodstein F, van Rooij FJ, et al. Dietary antioxidants and long-term risk of dementia. *Archives of Neurology*. 2010 Jul;67(7):819-25. PMID 20625087. *Not cognitive decline prevention intervention*

Devore EE, Kang JH, Breteler MM, et al. Dietary intakes of berries and flavonoids in relation to cognitive decline. *Annals of Neurology*. 2012 Jul;72(1):135-43. PMID 22535616. *Not cognitive decline prevention intervention*

Di Stefano F, Epelbaum S, Coley N, et al. Prediction of Alzheimer's Disease Dementia: Data from the GuidAge Prevention Trial. *Journal of Alzheimer's Disease*. 2015 01 Oct;48(3):793-804. PMID 2015438468. *Ineligible study design*

Diamond K, Mowszowski L, Cockayne N, et al. Randomized controlled trial of a healthy brain ageing cognitive training program: effects on memory, mood, and sleep. *Journal of Alzheimer's Disease*. 2015;44(4):1181-91. PMID 25408218. *Ineligible population*

Diener HC. [No immediate dementia prevention from antihypertensive therapy]. 2009. <http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/346/CN-00757346/frame.html>. Accessed on 1 32. *Not available in English*

Diniz BS, Pinto JA, Jr., Gonzaga ML, et al. To treat or not to treat? A meta-analysis of the use of cholinesterase inhibitors in mild cognitive impairment for delaying progression to Alzheimer's disease. *European Archives of Psychiatry & Clinical Neuroscience*. 2009 Jun;259(4):248-56. PMID 19224111. *Ineligible study design*

Dodel R, Rominger A, Bartenstein P, et al. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. *Lancet Neurology*. 2013 Mar;12(3):233-43. PMID 23375965. *Ineligible population*

Doi T, Makizako H, Shimada H, et al. Effects of multicomponent exercise on spatial-temporal gait parameters among the elderly with amnesic mild cognitive impairment (aMCI): preliminary results from a randomized controlled trial (RCT). *Archives of Gerontology & Geriatrics*. 2013 Jan-Feb;56(1):104-8. PMID 23063111. *No relevant outcomes reported*

Dong ZH, Zhang CY, Pu BH. [Effects of ginkgo biloba tablet in treating mild cognitive impairment]. [Chinese]. *Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine / Zhongguo Zhong xi yi jie he xue hui, Zhongguo Zhong yi yan jiu yuan zhu ban*. 2012 Sep;32(9):1208-11. PMID 23185760. *Not available in English*

D'Onofrio G, Sancarlo D, Addante F, et al. A pilot randomized controlled trial evaluating an integrated treatment of rivastigmine transdermal patch and cognitive stimulation in patients with Alzheimer's disease. *International Journal of Geriatric Psychiatry*. 2015 01 Sep;30(9):965-75. PMID 2015662652. *Ineligible population*

Doody RS, Ferris S, Salloway S, et al. Safety and tolerability of donepezil in mild cognitive impairment: open-label extension study. *American Journal of Alzheimer's Disease & Other Dementias*. 2010 Mar;25(2):155-9. PMID 19949165. *Ineligible population*

Doody RS, Geldmacher DS, Farlow MR, et al. Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine. *Dementia & Geriatric Cognitive Disorders*. 2012;33(2-3):164-73. PMID 22572767. *Ineligible population*

Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. *New England Journal of Medicine*. 2014 Jan 23;370(4):311-21. PMID 24450890. *Ineligible population*

Dotson VM, Beydoun MA, Zonderman AB. Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment. *Neurology*. 2010 Jul 6;75(1):27-34. PMID 20603482. *Not cognitive decline prevention intervention*

Drake C, Gumenyuk V, Roth T, et al. Effects of armodafinil on simulated driving and alertness in shift work disorder. *Sleep*. 2014 Dec;37(12):1987-94. PMID 25325498. *No relevant outcomes reported*

Dretsch MN, Johnston D, Bradley RS, et al. Effects of omega-3 fatty acid supplementation on neurocognitive functioning and mood in deployed U.S. soldiers: a pilot study. *Military Medicine*. 2014 Apr;179(4):396-403. PMID 24690964. *Ineligible population*

Drks. ELITE study - Nutrition, lifestyle and individual information for the prevention of stroke, dementia and heart attack. 2014.  
<http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/895/CN-01066895/frame.html>. *Ineligible study design*

Drumond Marra HL, Myczkowski ML, Maia Memoria C, et al. Transcranial Magnetic Stimulation to Address Mild Cognitive Impairment in the Elderly: A Randomized Controlled Study. *Behavioural Neurology*. 2015;2015(287843) PMID 2015173487. *Inadequate follow up time*

Dunbar GC, Kuchibhatla RV, Lee G. A randomized double-blind study comparing 25 and 50 mg TC-1734 (AZD3480) with placebo, in older subjects with age-associated memory impairment. *Journal of Psychopharmacology*. 2011 August;25(8):1020-9. PMID 2011470672. *Ineligible population*

Duron E, Rigaud AS, Dubail D, et al. Effects of antihypertensive therapy on cognitive decline in Alzheimer's disease. *American Journal of Hypertension*. 2009 Sep;22(9):1020-4. PMID 19590498. *Ineligible population*

Dustman RE, Ruhling RO, Russell EM, et al. Aerobic exercise training and improved neuropsychological function of older individuals. *Neurobiology of Aging*. 1984;5(1):35-42. PMID 6738784. *Inadequate follow up time*

Dysken MW, Sano M, Asthana S, et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: The TEAM-AD VA cooperative randomized trial. JAMA - Journal of the American Medical Association. 2014;311(1):33-44. PMID 2014045856. *Ineligible population*

Dysken MW, Sano M, Asthana S, et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial.[Erratum appears in JAMA. 2014 Mar 19;311(11):1161]. JAMA. 2014 Jan 1;311(1):33-44. PMID 24381967. *Ineligible population*

Eckroth-Bucher M, Siberski J. Preserving cognition through an integrated cognitive stimulation and training program. American Journal of Alzheimer's Disease & Other Dementias. 2009 Jun-Jul;24(3):234-45. PMID 19346501. *Ineligible population*

Edwards J, Wadley V, Myers R, et al. Transfer of a speed of processing intervention to near and far cognitive functions. Gerontology. 2002 Sep-Oct;48(5):329-40. PMID 12169801. *Ineligible population*

Edwards JD, Delahunt PB, Mahncke HW. Cognitive speed of processing training delays driving cessation. Journals of Gerontology Series A-Biological Sciences & Medical Sciences. 2009 Dec;64(12):1262-7. PMID 19726665. *No relevant outcomes reported*

Edwards JD, Myers C, Ross LA, et al. The longitudinal impact of cognitive speed of processing training on driving mobility. Gerontologist. 2009 Aug;49(4):485-94. PMID 19491362. *No relevant outcomes reported*

Edwards JD, Ruva CL, O'Brien JL, et al. An examination of mediators of the transfer of cognitive speed of processing training to everyday functional performance. Psychology & Aging. 2013 Jun;28(2):314-21. PMID 23066808. *Inadequate follow up time*

Edwards JD, Valdes EG, Peronto C, et al. The Efficacy of InSight Cognitive Training to Improve Useful Field of View Performance: A Brief Report. Journals of Gerontology Series B-Psychological Sciences & Social Sciences. 2015 May;70(3):417-22. PMID 24211819. *Inadequate follow up time*

Edwards JD, Wadley VG, Vance DE, et al. The impact of speed of processing training on cognitive and everyday performance. Aging & Mental Health. 2005 May;9(3):262-71. PMID 16019280. *Inadequate follow up time*

Elias MF, Goodell AL. Diet and exercise: blood pressure and cognition: to protect and serve. Hypertension. 2010 Jun;55(6):1296-8. PMID 20385968. *Inadequate follow up time*

Ellis KA, Bush AI, Darby D, et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals



recruited for a longitudinal study of Alzheimer's disease. *International Psychogeriatrics*. 2009 Aug;21(4):672-87. PMID 19470201. *Ineligible study design*

Ellis KA, Rowe CC, Villemagne VL, et al. Addressing population aging and Alzheimer's disease through the Australian imaging biomarkers and lifestyle study: collaboration with the Alzheimer's Disease Neuroimaging Initiative. *Alzheimer's & Dementia*. 2010 May;6(3):291-6. PMID 20451879. *Ineligible study design*

Ellis KA, Szoek C, Bush AI, et al. Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL). *International Psychogeriatrics*. 2014 Apr;26(4):543-54. PMID 24252258. *Ineligible study design*

Elmstahl S, Widerstrom E. Orthostatic intolerance predicts mild cognitive impairment: incidence of mild cognitive impairment and dementia from the Swedish general population cohort Good Aging in Skane. *Clinical Interventions In Aging*. 2014;9:1993-2002. PMID 25429211. *Not cognitive decline prevention intervention*

Engedal K, Davis B, Richarz U, et al. Two galantamine titration regimens in patients switched from donepezil. *Acta Neurologica Scandinavica*. 2012 Jul;126(1):37-44. PMID 21992111. *Ineligible population*

Erickson KI, Colcombe SJ, Wadhwa R, et al. Training-induced plasticity in older adults: effects of training on hemispheric asymmetry. *Neurobiology of Aging*. 2007 Feb;28(2):272-83. PMID 16480789. *Inadequate follow up time*

Erickson KI, Raji CA, Lopez OL, et al. Physical activity predicts gray matter volume in late adulthood: the Cardiovascular Health Study. *Neurology*. 2010 Oct 19;75(16):1415-22. PMID 20944075. *Ineligible study design*

Esin E, Ergen A, Cankurtaran M, et al. Influence of antimuscarinic therapy on cognitive functions and quality of life in geriatric patients treated for overactive bladder. *Aging & Mental Health*. 2015;19(3):217-23. PMID 25555041. *Ineligible population*

Eskelinen MH, Ngandu T, Tuomilehto J, et al. Midlife coffee and tea drinking and the risk of late-life dementia: a population-based CAIDE study. *Journal of Alzheimer's Disease*. 2009;16(1):85-91. PMID 19158424. *Not cognitive decline prevention intervention*

Espeland MA, Rapp SR, Bray GA, et al. Long-term impact of behavioral weight loss intervention on cognitive function. *Journals of Gerontology Series A-Biological Sciences & Medical Sciences*. 2014 Sep;69(9):1101-8. PMID 24619151. *Ineligible population*

Espeland MA, Tindle HA, Bushnell CA, et al. Brain volumes, cognitive impairment, and conjugated equine estrogens. *Journals of Gerontology Series A-Biological Sciences &*

Medical Sciences. 2009 Dec;64(12):1243-50. PMID 19729392. *Not cognitive decline prevention intervention*

Estruch R, Ros E, Salas-Salvado J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet.[Erratum appears in N Engl J Med. 2014 Feb 27;370(9):886]. New England Journal of Medicine. 2013 Apr 4;368(14):1279-90. PMID 23432189. *No relevant outcomes reported*

Etgen T, Sander D, Chonchol M, et al. Chronic kidney disease is associated with incident cognitive impairment in the elderly: The INVADE study. Nephrology Dialysis Transplantation. 2009 October;24(10):3144-50. PMID 2009517458. *Not cognitive decline prevention intervention*

Etgen T, Sander D, Huntgeburth U, et al. Physical activity and incident cognitive impairment in elderly persons: the INVADE study. Archives of Internal Medicine. 2010 Jan 25;170(2):186-93. PMID 20101014. *Not cognitive decline prevention intervention*

Euser SM, Sattar N, Wittman JC, et al. A prospective analysis of elevated fasting glucose levels and cognitive function in older people: results from PROSPER and the Rotterdam Study. Diabetes. 2010 Jul;59(7):1601-7. PMID 20393152. *Ineligible population*

Fairchild JK, Scogin FR. Training to Enhance Adult Memory (TEAM): an investigation of the effectiveness of a memory training program with older adults. Aging & Mental Health. 2010 Apr;14(3):364-73. PMID 20425656. *Inadequate follow up time*

Fallah N, Hsu CL, Bolandzadeh N, et al. A multistate model of cognitive dynamics in relation to resistance training: the contribution of baseline function. Annals of Epidemiology. 2013 Aug;23(8):463-8. PMID 23830936. *No relevant outcomes reported*

Fan HG, Park A, Xu W, et al. The influence of erythropoietin on cognitive function in women following chemotherapy for breast cancer. Psycho-Oncology. 2009 Feb;18(2):156-61. PMID 18561284. *Ineligible population*

Fan YL, Wan JQ, Zhou ZW, et al. Neurocognitive improvement after carotid artery stenting in patients with chronic internal carotid artery occlusion: a prospective, controlled, single-center study. Vascular & Endovascular Surgery. 2014 May;48(4):305-10. PMID 24643000. *Ineligible population*

Farokhnia M, Shafiee Sabet M, Iranpour N, et al. Comparing the efficacy and safety of *Crocus sativus* L. with memantine in patients with moderate to severe Alzheimer's disease: a double-blind randomized clinical trial. Human Psychopharmacology. 2014 Jul;29(4):351-9. PMID 25163440. *Ineligible population*

Feart C, Samieri C, Rondeau V, et al. Adherence to a Mediterranean diet, cognitive decline, and risk of dementia.[Erratum appears in JAMA. 2009 Dec 9;302(22):2436]. JAMA. 2009 Aug 12;302(6):638-48. PMID 19671905. *Ineligible population*

Feldman HH, Doody RS, Kivipelto M, et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology. 2010 March;74(12):956-64. PMID 2010189030. *Ineligible population*

Felix HC, Adams B, Fausett JK, et al. Calculating reach of evidence-based weight loss and memory improvement interventions among older adults attending Arkansas senior centers, 2008-2011. Preventing Chronic Disease. 2012;9:E63. PMID 22360874. *No relevant outcomes reported*

Feliziani FT, Polidori MC, De Rango P, et al. Cognitive performance in elderly patients undergoing carotid endarterectomy or carotid artery stenting: a twelve-month follow-up study. Cerebrovascular Diseases. 2010 Aug;30(3):244-51. PMID 20664257. *Ineligible population*

Feng L, Fam J, Rawtaer I, et al. Mindful awareness practice for the prevention of dementia: A randomised controlled trial [Journal: Conference Abstract]. 2014. <http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/105/CN-01053105/frame.html>. Accessed on 10 suppl. 1 43. *Ineligible study design*

Feng L, Li J, Ng TP, et al. Tea drinking and cognitive function in oldest-old Chinese. Journal of Nutrition, Health & Aging. 2012;16(9):754-8. PMID 23131816. *Ineligible population*

Ferris S, Lane R, Sfikas N, et al. Effects of gender on response to treatment with rivastigmine in mild cognitive impairment: A post hoc statistical modeling approach. Gender Medicine. 2009 Jul;6(2):345-55. PMID 19682661. *Ineligible study design*

Ferris S, Nordberg A, Soinen H, et al. Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment. Pharmacogenetics and Genomics. 2009 Aug;19(8):635-46. PMID 19617863. *Ineligible study design*

Fiala M, Halder RC, Sagong B, et al. omega-3 Supplementation increases amyloid-beta phagocytosis and resolvin D1 in patients with minor cognitive impairment. FASEB Journal. 2015 Jul;29(7):2681-9. PMID 25805829. *Ineligible population*

Fields C, Drye L, Vaidya V, et al. Celecoxib or naproxen treatment does not benefit depressive symptoms in persons age 70 and older: findings from a randomized controlled trial. American Journal of Geriatric Psychiatry. 2012 Jun;20(6):505-13. PMID 21775876. *No relevant outcomes reported*

Finn M, McDonald S. Computerised cognitive training for older persons with mild cognitive impairment: A pilot study using a randomised controlled trial design. *Brain Impairment*. 2011 December;12(3):187-99. PMID 2012003537. *Inadequate follow up time*

Fiocco AJ, Scarcello S, Marzolini S, et al. The effects of an exercise and lifestyle intervention program on cardiovascular, metabolic factors and cognitive performance in middle-aged adults with type II diabetes: a pilot study. *Canadian Journal of Diabetes*. 2013 Aug;37(4):214-9. PMID 24070883. *Ineligible study design*

Ford AH, Flicker L, Alfonso H, et al. Vitamins B(12), B(6), and folic acid for cognition in older men.[Erratum appears in *Neurology*. 2011 Aug 23;77((8):804 Note: Dosage error in published abstract; MEDLINE/PubMed abstract corrected; Dosage error in article text]. *Neurology*. 2010 Oct 26;75(17):1540-7. PMID 20861451. *Ineligible population*

Forster S, Buschert VC, Buchholz HG, et al. Effects of a 6-month cognitive intervention program on brain metabolism in amnesic mild cognitive impairment and mild Alzheimer's disease. *Journal of Alzheimer's Disease*. 2011;25(4):695-706. PMID 21498904. *Ineligible population*

Forti P, Olivelli V, Rietti E, et al. Serum thyroid-stimulating hormone as a predictor of cognitive impairment in an elderly cohort. *Gerontology*. 2012;58(1):41-9. PMID 21430364. *Not cognitive decline prevention intervention*

Foubert-Samier A, Le Goff M, Helmer C, et al. Change in leisure and social activities and risk of dementia in elderly cohort. *Journal of Nutrition, Health & Aging*. 2014 Dec;18(10):876-82. PMID 25470802. *Not cognitive decline prevention intervention*

Fowler SB. Cognition training interventions for healthy older people and older people with mild cognitive impairment. *Clinical Nurse Specialist*. 2011 Jul-Aug;25(4):178-9. PMID 21654372. *Ineligible study design*

Fox C, Richardson K, Maidment ID, et al. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. *Journal of the American Geriatrics Society*. 2011 Aug;59(8):1477-83. PMID 21707557. *Not cognitive decline prevention intervention*

Fox M, Berzuini C, Knapp LA. Cumulative estrogen exposure, number of menstrual cycles, and Alzheimer's risk in a cohort of British women. *Psychoneuroendocrinology*. 2013 Dec;38(12):2973-82. PMID 24064221. *Ineligible population*

Frolich L, Ashwood T, Nilsson J, et al. Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer's disease: a phase IIb dose-finding study. *Journal of Alzheimer's Disease*. 2011;24(2):363-74. PMID 21258153. *Inadequate follow up time*

- Gaitan A, Garolera M, Cerulla N, et al. Efficacy of an adjunctive computer-based cognitive training program in amnesic mild cognitive impairment and Alzheimer's disease: a single-blind, randomized clinical trial. *International Journal of Geriatric Psychiatry*. 2013 Jan;28(1):91-9. PMID 22473855. *Ineligible population*
- Galasko DR, Peskind E, Clark CM, et al. Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. *Archives of Neurology*. 2012 Jul;69(7):836-41. PMID 22431837. *Ineligible population*
- Ganio MS, Armstrong LE, Casa DJ, et al. Mild dehydration impairs cognitive performance and mood of men. *British Journal of Nutrition*. 2011 Nov;106(10):1535-43. PMID 21736786. *No relevant outcomes reported*
- Gao Q, Niti M, Feng L, et al. Omega-3 polyunsaturated fatty acid supplements and cognitive decline: Singapore Longitudinal Aging Studies. *Journal of Nutrition, Health & Aging*. 2011 Jan;15(1):32-5. PMID 21267519. *Not cognitive decline prevention intervention*
- Gao S, Nguyen JT, Hendrie HC, et al. Accelerated weight loss and incident dementia in an elderly African-American cohort. *Journal of the American Geriatrics Society*. 2011 Jan;59(1):18-25. PMID 21054328. *Not cognitive decline prevention intervention*
- Garand L, Rinaldo DE, Alberth MM, et al. Effects of problem solving therapy on mental health outcomes in family caregivers of persons with a new diagnosis of mild cognitive impairment or early dementia: a randomized controlled trial. *American Journal of Geriatric Psychiatry*. 2014 Aug;22(8):771-81. PMID 24119856. *Ineligible population*
- Gates NJ, Valenzuela M, Sachdev PS, et al. Study of Mental Activity and Regular Training (SMART) in at risk individuals: a randomised double blind, sham controlled, longitudinal trial. *BMC Geriatrics*. 2011;11:19. PMID 21510896. *Ineligible study design*
- Gaudig M, Richarz U, Han J, et al. Effects of galantamine in Alzheimer's disease: double-blind withdrawal studies evaluating sustained versus interrupted treatment. *Current Alzheimer Research*. 2011 Nov;8(7):771-80. PMID 21707533. *Ineligible population*
- Gavrilova SI, Fedorova IB, Gantman, et al. [Ceraxon (citicoline) in the treatment of the mild cognitive impairment syndrome]. [Russian]. *Zhurnal nevrologii i psikiatrii imeni S.S. 2011;Korsakova / Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov [i] Vserossiiskoe obshchestvo psikiatrov*. 111(12):16-20. PMID 22433803. *Not available in English*
- Gavrilova SI, Kolykhalov IV, Fedorova Ya B, et al. Possibilities of preventive treatment of Alzheimer's disease: Results of the 3-year open prospective comparative study on efficacy and safety of the course therapy with cerebrolysin and cavinton in elderly

patients with the syndrome of mild cognitive impairment. [Russian]. Zhurnal Nevrologii i Psikiatrii imeni S.S. 2010;Korsakova. 110(1):62-9. PMID 2010707327. *Not available in English*

Geda YE, Roberts RO, Knopman DS, et al. Physical exercise, aging, and mild cognitive impairment: a population-based study. Archives of Neurology. 2010 Jan;67(1):80-6. PMID 20065133. *Not cognitive decline prevention intervention*

Geda YE, Silber TC, Roberts RO, et al. Computer activities, physical exercise, aging, and mild cognitive impairment: a population-based study. Mayo Clinic Proceedings. 2012 May;87(5):437-42. PMID 22560523. *Not cognitive decline prevention intervention*

Gelber RP, Petrovitch H, Masaki KH, et al. Lifestyle and the risk of dementia in Japanese-american men. Journal of the American Geriatrics Society. 2012 Jan;60(1):118-23. PMID 22211390. *Ineligible study design*

Gelber RP, Ross GW, Petrovitch H, et al. Antihypertensive medication use and risk of cognitive impairment: the Honolulu-Asia Aging Study. Neurology. 2013 Sep 3;81(10):888-95. PMID 23911753. *Ineligible population*

Gengo F, Cwudzinski D, Kinkel P, et al. Effects of treatment with lovastatin and pravastatin on daytime cognitive performance. Clinical Cardiology. 1995 Apr;18(4):209-14. PMID 7788948. *Inadequate follow up time*

Genon S, Collette F, Moulin CJ, et al. Verbal learning in Alzheimer's disease and mild cognitive impairment: fine-grained acquisition and short-delay consolidation performance and neural correlates. Neurobiology of Aging. 2013 Feb;34(2):361-73. PMID 22592018. *Ineligible population*

Germano da Paz O, Guillaumon AT, Lopes TM, et al. Carotid stenting versus endarterectomy cognitive outcomes. Annals of Vascular Surgery. 2014 May;28(4):893-900. PMID 24361382. *Ineligible population*

Gharacholou SM, Reid KJ, Arnold SV, et al. Cognitive impairment and outcomes in older adult survivors of acute myocardial infarction: findings from the translational research investigating underlying disparities in acute myocardial infarction patients' health status registry. American Heart Journal. 2011 Nov;162(5):860-9.e1. PMID 22093202. *Ineligible population*

Giannantoni A, Cagini R, Del Zingaro M, et al. Botulinum A toxin intravesical injections for painful bladder syndrome: impact upon pain, psychological functioning and Quality of Life. Current Drug Delivery. 2010 Dec;7(5):442-6. PMID 20950262. *Ineligible study design*

Gilbertson R, Prather R, Nixon SJ. Acute alcohol administration and placebo effectiveness in older moderate drinkers: influences on cognitive performance. *Journal of Studies on Alcohol & Drugs*. 2010 May;71(3):345-50. PMID 20409427. *Inadequate follow up time*

Gildengers AG, Butters MA, Albert SM, et al. Design and Implementation of an Intervention Development Study: Retaining Cognition while Avoiding Late-Life Depression (ReCALL). *American Journal of Geriatric Psychiatry*. 2016 01 Jun;24(6):444-54. PMID 610534434. *No relevant outcomes reported*

Glasser SP, Wadley V, Judd S, et al. The association of statin use and statin type and cognitive performance: analysis of the reasons for geographic and racial differences in stroke (REGARDS) study. *Clinical Cardiology*. 2010 May;33(5):280-8. PMID 20513066. *Ineligible study design*

Godin O, Tzourio C, Maillard P, et al. Antihypertensive treatment and change in blood pressure are associated with the progression of white matter lesion volumes: the Three-City (3C)-Dijon Magnetic Resonance Imaging Study. *Circulation*. 2011 Jan 25;123(3):266-73. PMID 21220733. *Not cognitive decline prevention intervention*

Goh KL, Bhaskaran K, Minassian C, et al. Angiotensin receptor blockers and risk of dementia: Cohort study in UK Clinical Practice Research Datalink. *British Journal of Clinical Pharmacology*. 2015 01 Feb;79(2):337-50. PMID 2015433482. *Not cognitive decline prevention intervention*

Gold M, Alderton C, Zvartau-Hind M, et al. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. *Dementia & Geriatric Cognitive Disorders*. 2010;30(2):131-46. PMID 20733306. *Ineligible population*

Gomm W, Von Holt K, Thome F, et al. Association of proton pump inhibitors with risk of dementia: A pharmacoepidemiological claims data analysis. *JAMA Neurology*. 2016 April;73(4):410-6. PMID 610001802. *Not cognitive decline prevention intervention*

Gonzalez-Palau F, Franco M, Bamidis P, et al. The effects of a computer-based cognitive and physical training program in a healthy and mildly cognitive impaired aging sample. *Aging & Mental Health*. 2014 Sep;18(7):838-46. PMID 24697325. *Inadequate follow up time*

Gooding AL, Choi J, Fiszdon JM, et al. Comparing three methods of computerised cognitive training for older adults with subclinical cognitive decline. *Neuropsychological rehabilitation*. 2015:1-12. *Inadequate follow up time*

Gooding AL, Choi J, Fiszdon JM, et al. Comparing three methods of computerised cognitive training for older adults with subclinical cognitive decline. *Neuropsychological*

Rehabilitation. 2016 Sep;26(5-6):810-21. PMID 2016-34409-008. *Inadequate follow up time*

Gottesman RF, Schneider AL, Albert M, et al. Midlife hypertension and 20-year cognitive change: the atherosclerosis risk in communities neurocognitive study. JAMA Neurology. 2014 Oct;71(10):1218-27. PMID 25090106. *Not cognitive decline prevention intervention*

Goveas JS, Hogan PE, Kotchen JM, et al. Depressive symptoms, antidepressant use, and future cognitive health in postmenopausal women: the Women's Health Initiative Memory Study. International Psychogeriatrics. 2012 Aug;24(8):1252-64. PMID 22301077. *Ineligible population*

Graessel E, Stemmer R, Eichenseer B, et al. Non-pharmacological, multicomponent group therapy in patients with degenerative dementia: a 12-month randomized, controlled trial. BMC Medicine. 2011 01 Dec;9(129)PMID 2012024517. *Ineligible population*

Grande G, Vanacore N, Maggiore L, et al. Physical activity reduces the risk of dementia in mild cognitive impairment subjects: a cohort study. Journal of Alzheimer's Disease. 2014;39(4):833-9. PMID 24296815. *Not cognitive decline prevention intervention*

Green RC, Schneider LS, Amato DA, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA. 2009 Dec 16;302(23):2557-64. PMID 20009055. *Ineligible population*

Greenaway MC, Duncan NL, Smith GE. The memory support system for mild cognitive impairment: randomized trial of a cognitive rehabilitation intervention. International Journal of Geriatric Psychiatry. 2013 Apr;28(4):402-9. PMID 22678947. *Not cognitive decline prevention intervention*

Grossheinrich N, Rau A, Pogarell O, et al. Theta burst stimulation of the prefrontal cortex: safety and impact on cognition, mood, and resting electroencephalogram. Biological Psychiatry. 2009 May 1;65(9):778-84. PMID 19070834. *Inadequate follow up time*

Group AI. Study design of Aspirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial. Contemporary Clinical Trials. 2013 Nov;36(2):555-64. PMID 24113028. *Ineligible study design*

Grove RA, Harrington CM, Mahler A, et al. A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer's disease. Current Alzheimer Research. 2014 Jan;11(1):47-58. PMID 24359500. *Inadequate follow up time*



Gu Y, Luchsinger JA, Stern Y, et al. Mediterranean diet, inflammatory and metabolic biomarkers, and risk of Alzheimer's disease. *Journal of Alzheimer's Disease*. 2010;22(2):483-92. PMID 20847399. *Not cognitive decline prevention intervention*

Gu Y, Nieves JW, Stern Y, et al. Food combination and Alzheimer disease risk: a protective diet. *Archives of Neurology*. 2010 Jun;67(6):699-706. PMID 20385883. *Ineligible population*

Guekht AB, Moessler H, Novak PH, et al. Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial. *Journal of Stroke & Cerebrovascular Diseases*. 2011 Jul-Aug;20(4):310-8. PMID 20656516. *Ineligible population*

Guerriero F, Botarelli E, Mele G, et al. An innovative intervention for the treatment of cognitive impairment-Emisymmetric bilateral stimulation improves cognitive functions in Alzheimer's disease and mild cognitive impairment: An open-label study. *Neuropsychiatric Disease and Treatment*. 2015 Sep;11:2391-404. PMID 2015-45683-001. *Inadequate follow up time*

Guo M, Mi J, Jiang QM, et al. Metformin may produce antidepressant effects through improvement of cognitive function among depressed patients with diabetes mellitus. *Clinical & Experimental Pharmacology & Physiology*. 2014 Sep;41(9):650-6. PMID 24862430. *Ineligible population*

Guo RZ, Zhou WQ, Luo ZG. [Effect of modified huanglian wendan decoction in treating senile patients with mild cognitive impairment of turbid-phlegm blocking orifice syndrome]. [Chinese]. *Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine / Zhongguo Zhong xi yi jie he xue hui, Zhongguo Zhong yi yan jiu yuan zhu ban*. 2010 Jan;30(1):33-6. PMID 20353029. *Ineligible population*

Gupta VB, Wilson AC, Burnham S, et al. Follow-up plasma apolipoprotein e levels in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) cohort. *Alzheimer's Research and Therapy*. 2015 20 Feb;7 (1) (no pagination)(16) PMID 2015908818. *Not cognitive decline prevention intervention*

Gustafson DR, Backman K, Lissner L, et al. Leptin and dementia over 32 years-The Prospective Population Study of Women. *Alzheimer's & Dementia*. 2012 Jul;8(4):272-7. PMID 22748937. *No relevant outcomes reported*

Gustavsson A, Jonsson L, Parmler J, et al. Disease progression and costs of care in Alzheimer's disease patients treated with donepezil: a longitudinal naturalistic cohort. *European Journal of Health Economics*. 2012 Oct;13(5):561-8. PMID 21822729. *Ineligible study design*

Guvenal T, Durna A, Erden O, et al. Effects of different postmenopausal hormone therapy regimens on cerebral blood flow and cognitive functions. *Advances in Therapy*. 2009 Aug;26(8):805-11. PMID 19672567. *No relevant outcomes reported*

Haag MD, Hofman A, Koudstaal PJ, et al. Duration of antihypertensive drug use and risk of dementia: A prospective cohort study. *Neurology*. 2009 May 19;72(20):1727-34. PMID 19228584. *Not cognitive decline prevention intervention*

Haag MDM, Hofman A, Koudstaal PJ, et al. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. *Journal of Neurology, Neurosurgery and Psychiatry*. 2009 January;80(1):13-7. PMID 2009031438. *Not cognitive decline prevention intervention*

Hackney ME, Byers C, Butler G, et al. Adapted Tango Improves Mobility, Motor-Cognitive Function, and Gait but Not Cognition in Older Adults in Independent Living. *Journal of the American Geriatrics Society*. 2015 Oct;63(10):2105-13. PMID 26456371. *Inadequate follow up time*

Haenisch B, von Holt K, Wiese B, et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. *European Archives of Psychiatry and Clinical Neuroscience*. 2015 24 Oct;265(5):419-28. PMID 2014850429. *Not cognitive decline prevention intervention*

Hagger-Johnson G, Sabia S, Brunner EJ, et al. Combined impact of smoking and heavy alcohol use on cognitive decline in early old age: Whitehall II prospective cohort study. *British Journal of Psychiatry*. 2013 Aug;203(2):120-5. PMID 23846998. *Not cognitive decline prevention intervention*

Haig GM, Pritchett Y, Meier A, et al. A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer's dementia. *Journal of Alzheimer's Disease*. 2014;42(3):959-71. PMID 25024314. *Ineligible population*

Haimov I, Shatil E. Cognitive training improves sleep quality and cognitive function among older adults with insomnia. *PLoS ONE [Electronic Resource]*. 2013;8(4):e61390. PMID 23577218. *Inadequate follow up time*

Hajjar I, Hart M, Chen YL, et al. Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: A double-blind randomized clinical trial. *Archives of Internal Medicine*. 2012 12 Mar;172(5):442-4. PMID 2012161874. *Ineligible study design*

Hajjar I, Hart M, Mack W, et al. Aldosterone, cognitive function, and cerebral hemodynamics in hypertension and antihypertensive therapy. *American Journal of Hypertension*. 2015 Mar;28(3):319-25. PMID 25213687. *Not cognitive decline prevention intervention*

Hajjar I, Hart M, Milberg W, et al. The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: role of the renin angiotensin system inhibition. *BMC Geriatrics*. 2009;9:48. PMID 19922631. *Ineligible study design*

Hajjar I, Levey A. Association Between Angiotensin Receptor Blockers and Longitudinal Decline in Tau in Mild Cognitive Impairment. *JAMA neurology*. 2015 01 Sep;72(9):1069-70. PMID 26368351. *Not cognitive decline prevention intervention*

Hall CB, Lipton RB, Sliwinski M, et al. Cognitive activities delay onset of memory decline in persons who develop dementia. *Neurology*. 2009 Aug 4;73(5):356-61. PMID 19652139. *Cohort study with inadequate sample size*

Haller S, Montandon ML, Rodriguez C, et al. Acute caffeine administration effect on brain activation patterns in mild cognitive impairment. *Journal of Alzheimer's Disease*. 2014;41(1):101-12. PMID 24577471. *Inadequate follow up time*

Hampel H, Ewers M, Burger K, et al. Lithium trial in Alzheimer's disease: A randomized, single-blind, placebo-controlled, multicenter 10-week study. *Journal of Clinical Psychiatry*. 2009 June;70(6):922-31. PMID 2009309012. *Inadequate follow up time*

Hampstead BM, Sathian K, Phillips PA, et al. Mnemonic strategy training improves memory for object location associations in both healthy elderly and patients with amnesic mild cognitive impairment: a randomized, single-blind study. *Neuropsychology*. 2012 May;26(3):385-99. PMID 22409311. *Inadequate follow up time*

Hampstead BM, Stringer AY, Stilla RF, et al. Mnemonic strategy training partially restores hippocampal activity in patients with mild cognitive impairment. *Hippocampus*. 2012 Aug;22(8):1652-8. PMID 22368035. *Inadequate follow up time*

Han JW, Oh K, Yoo S, et al. Development of the ubiquitous spaced retrieval-based memory advancement and rehabilitation training program. *Psychiatry Investigation*. 2014 January;11(1):52-8. PMID 2014094656. *Ineligible study design*

Han YR, Song MS, Lim JY. The effects of a cognitive enhancement group training program for community-dwelling elders. *Journal of Korean Academy of Nursing*. 2010 Oct;40(5):724-35. PMID 21157174. *Not available in English*

Hanson AJ, Bayer JL, Baker LD, et al. Differential effects of meal challenges on cognition, metabolism, and biomarkers for apolipoprotein Ebeta 4 carriers and adults with mild cognitive impairment. *Journal of Alzheimer's Disease*. 2015 28 Aug;48(1):205-18. PMID 2015360283. *Inadequate follow up time*

Hanson AJ, Bayer-Carter JL, Green PS, et al. Effect of apolipoprotein E genotype and diet on apolipoprotein E lipidation and amyloid peptides: randomized clinical trial. *JAMA Neurology*. 2013 Aug;70(8):972-80. PMID 23779114. *Inadequate follow up time*

Hardy JL, Nelson RA, Thomason ME, et al. Enhancing cognitive abilities with comprehensive training: A large, online, randomized, active-controlled trial. *PLoS ONE*. 2015 Sep;10(9)PMID 2016-01698-001. *Inadequate follow up time*

Harper PC, Roe CM. Thyroid medication use and subsequent development of dementia of the Alzheimer type. *Journal of Geriatric Psychiatry & Neurology*. 2010 Mar;23(1):63-9. PMID 19666883. *Cohort study with inadequate sample size*

Harrington C, Sawchak S, Chiang C, et al. Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies. *Current Alzheimer Research*. 2011 Aug;8(5):592-606. PMID 21592048. *Ineligible population*

Harris E, Macpherson H, Vitetta L, et al. Effects of a multivitamin, mineral and herbal supplement on cognition and blood biomarkers in older men: a randomised, placebo-controlled trial. *Human Psychopharmacology*. 2012 Jul;27(4):370-7. PMID 22711385. *Inadequate follow up time*

Harrison RW, Ashton CH. Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers. *British Journal of Clinical Pharmacology*. 1994 Mar;37(3):231-6. PMID 8198930. *Inadequate follow up time*

Hasler F, Studerus E, Lindner K, et al. Investigation of serotonin-1A receptor function in the human psychopharmacology of MDMA. *Journal of Psychopharmacology*. 2009 Nov;23(8):923-35. PMID 18635693. *Inadequate follow up time*

Hauer D, Weis F, Campolongo P, et al. Glucocorticoid-endocannabinoid interaction in cardiac surgical patients: relationship to early cognitive dysfunction and late depression. *Reviews in the Neurosciences*. 2012;23(5-6):681-90. PMID 23006898. *Ineligible population*

Helmer C, Stengel B, Metzger M, et al. Chronic kidney disease, cognitive decline, and incident dementia: The 3C Study. *Neurology*. 2011 06 Dec;77(23):2043-51. PMID 2011672094. *Not cognitive decline prevention intervention*

Helmstaedter C, Witt JA. Cognitive outcome of antiepileptic treatment with levetiracetam versus carbamazepine monotherapy: a non-interventional surveillance trial. *Epilepsy & Behavior*. 2010 May;18(1-2):74-80. PMID 20462801. *Ineligible study design*

Henderson ST, Vogel JL, Barr LJ, et al. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: A randomized, double-blind, placebo-controlled, multicenter trial. *Nutrition and Metabolism*. 2009;6(31)PMID 2009460801. *Ineligible population*

Hendrie HC, Baiyewu O, Lane KA, et al. Homocysteine levels and dementia risk in Yoruba and African Americans. *International Psychogeriatrics*. 2013 Nov;25(11):1859-66. PMID 23899991. *Not cognitive decline prevention intervention*

Heneka MT, Fink A, Doblhammer G. Effect of pioglitazone medication on the incidence of dementia. *Annals of Neurology*. 2015 Aug;78(2):284-94. PMID 25974006. *Not cognitive decline prevention intervention*

Herrschaft H, Nacu A, Likhachev S, et al. Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg. *Journal of Psychiatric Research*. 2012 Jun;46(6):716-23. PMID 22459264. *Ineligible population*

Hietanen H, Pietila A, Kahonen M, et al. Ankle blood pressure and dementia: A prospective follow-up study. *Blood Pressure Monitoring*. 2013 February;18(1):16-20. PMID 2013023251. *Not cognitive decline prevention intervention*

Hill NL, Kolanowski AM, Fick D, et al. Personality as a moderator of cognitive stimulation in older adults at high risk for cognitive decline. *Research in Gerontological Nursing*. 2014 Jul-Aug;7(4):159-70. PMID 24635006. *Not cognitive decline prevention intervention*

Hinkelmann K, Wingenfeld K, Kuehl LK, et al. Stimulation of the mineralocorticoid receptor improves memory in young and elderly healthy individuals. *Neurobiology of Aging*. 2015 Feb;36(2):919-24. PMID 25442112. *Inadequate follow up time*

Holinski S, Claus B, Alaaraj N, et al. Cerebroprotective effect of piracetam in patients undergoing open heart surgery. *Annals of Thoracic & Cardiovascular Surgery*. 2011;17(2):137-42. PMID 21597409. *Ineligible population*

Holtzman DM. CSF biomarkers for secondary prevention trials: Why markers of amyloid deposition and neurodegeneration are both important. *Archives of Neurology*. 2012 Jun;69(6):691-2. PMID 2012-16571-001. *Ineligible study design*

Holzgreve H. [Hypertensive and organ damage. Dementia and cognitive impairment]. *MMW Fortschritte der Medizin*. 2011 Sep 22;153(38):99-100. PMID 21977804. *Not available in English*

Homma A, Imai Y, Tago H, et al. Long-term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52-week, open-label, multicenter,

extension study in Japan. *Dementia & Geriatric Cognitive Disorders*. 2009;27(3):232-9. PMID 19246907. *Ineligible population*

Hoogenhout EM, de Groot RH, van der Elst W, et al. Effects of a comprehensive educational group intervention in older women with cognitive complaints: a randomized controlled trial. *Aging & Mental Health*. 2012;16(2):135-44. PMID 21780962. *Inadequate follow up time*

Hooshmand B, Solomon A, Kareholt I, et al. Associations between serum homocysteine, holotranscobalamin, folate and cognition in the elderly: a longitudinal study. *Journal of Internal Medicine*. 2012 Feb;271(2):204-12. PMID 22077644. *Not cognitive decline prevention intervention*

Hornslien AG, Sandset EC, Bath PM, et al. Effects of candesartan in acute stroke on cognitive function and quality of life: results from the Scandinavian Candesartan Acute Stroke Trial. *Stroke*. 2013 Jul;44(7):2022-4. PMID 23660849. *Ineligible population*

Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. *New England Journal of Medicine*. 2012 Mar 8;366(10):893-903. PMID 22397651. *Ineligible population*

Hsu CC, Wahlqvist ML, Lee MS, et al. Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. *Journal of Alzheimer's Disease*. 2011;24(3):485-93. PMID 21297276. *Not cognitive decline prevention intervention*

Hsu CY, Huang CC, Chan WL, et al. Angiotensin-receptor blockers and risk of Alzheimer's disease in hypertension population--a nationwide cohort study. *Circulation Journal*. 2013;77(2):405-10. PMID 23149416. *Not cognitive decline prevention intervention*

Hsu CY, Huang CC, Chan WL, et al. Angiotensin-receptor blockers and risk of alzheimer's disease in hypertension population - A nationwide cohort study. *Circulation Journal*. 2013;77(2):405-10. PMID 2013074487. *Not cognitive decline prevention intervention*

Huang CQ, Dong BR, Zhang YL, et al. Association of cognitive impairment with smoking, alcohol consumption, tea consumption, and exercise among Chinese nonagenarians/centenarians. *Cognitive & Behavioral Neurology*. 2009 Sep;22(3):190-6. PMID 19741330. *Not cognitive decline prevention intervention*

Hughes TF, Becker JT, Lee CW, et al. Independent and combined effects of cognitive and physical activity on incident MCI. *Alzheimer's and Dementia*. 2015 November;11(11):1377-84. PMID 2015949579. *Not cognitive decline prevention intervention*

Hughes TF, Flatt JD, Fu B, et al. Engagement in social activities and progression from mild to severe cognitive impairment: the MYHAT study. *International Psychogeriatrics*. 2013 Apr;25(4):587-95. PMID 23257280. *Not cognitive decline prevention intervention*

Ihl R, Bachinskaya N, Korczyn AD, et al. Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial. *International Journal of Geriatric Psychiatry*. 2011 Nov;26(11):1186-94. PMID 21140383. *Ineligible population*

Ihl R, Tribanek M, Bachinskaya N, et al. Efficacy and tolerability of a once daily formulation of Ginkgo biloba extract EGb 761 in Alzheimer's disease and vascular dementia: results from a randomised controlled trial. *Pharmacopsychiatry*. 2012 Mar;45(2):41-6. PMID 22086747. *Ineligible population*

Ihle-Hansen H, Thommessen B, Fagerland MW, et al. Multifactorial vascular risk factor intervention to prevent cognitive impairment after stroke and TIA: a 12-month randomized controlled trial. *International Journal of Stroke*. 2014 Oct;9(7):932-8. PMID 23205666. *Ineligible population*

Ikeda M, Mori E, Kosaka K, et al. Long-term safety and efficacy of donepezil in patients with dementia with Lewy bodies: results from a 52-week, open-label, multicenter extension study. *Dementia & Geriatric Cognitive Disorders*. 2013;36(3-4):229-41. PMID 23949147. *Ineligible population*

Ikeda M, Mori E, Matsuo K, et al. Donepezil for dementia with Lewy bodies: A randomized, placebo-controlled, confirmatory phase III trial. *Alzheimer's Research and Therapy*. 2015;7(1) PMID 2015872011. *Ineligible population*

Ilieva I, Boland J, Farah MJ. Objective and subjective cognitive enhancing effects of mixed amphetamine salts in healthy people. *Neuropharmacology*. 2013 Jan;64:496-505. PMID 22884611. *Inadequate follow up time*

Inaba M, White L, Bell C, et al. White matter lesions on brain magnetic resonance imaging scan and 5-year cognitive decline: The honolulu-asia aging study. *Journal of the American Geriatrics Society*. 2011 August;59(8):1484-9. PMID 2011457234. *Cohort study with inadequate sample size*

Irizarry MC, Raman R, Schwarzschild MA, et al. Plasma urate and progression of mild cognitive impairment. *Neurodegenerative Diseases*. 2009;6(1-2):23-8. PMID 19066433. *Not cognitive decline prevention intervention*

Irwin C, Leveritt M, Shum D, et al. The effects of dehydration, moderate alcohol consumption, and rehydration on cognitive functions. *Alcohol*. 2013 May;47(3):203-13. PMID 23352231. *Inadequate follow up time*

Ishihara H, Oka F, Shirao S, et al. Cognitive outcome differences on the side of carotid artery stenting. *Journal of Vascular Surgery*. 2013 Jan;57(1):125-30. PMID 23141681. *Ineligible population*

Iso-Markku P, Waller K, Kujala UM, et al. Physical activity and dementia: long-term follow-up study of adult twins. *Annals of Medicine*. 2015 Mar;47(2):81-7. PMID 25613168. *Not cognitive decline prevention intervention*

Iwasa H, Yoshida Y, Kai I, et al. Leisure activities and cognitive function in elderly community-dwelling individuals in Japan: a 5-year prospective cohort study. *Journal of Psychosomatic Research*. 2012 Feb;72(2):159-64. PMID 22281459. *Not cognitive decline prevention intervention*

Jackson PA, Deary ME, Reay JL, et al. No effect of 12 weeks' supplementation with 1 g DHA-rich or EPA-rich fish oil on cognitive function or mood in healthy young adults aged 18-35 years. *British Journal of Nutrition*. 2012 Apr;107(8):1232-43. PMID 21864417. *Inadequate follow up time*

Jacobs HI, Riphagen JM, Razat CM, et al. Transcutaneous vagus nerve stimulation boosts associative memory in older individuals. *Neurobiology of Aging*. 2015 May;36(5):1860-7. PMID 2015-13241-001. *Inadequate follow up time*

Jacobs HIL, Riphagen JM, Razat CM, et al. Transcutaneous vagus nerve stimulation boosts associative memory in older individuals. *Neurobiology of Aging*. 2015;36(5):1860-7. PMID 2015849982. *Inadequate follow up time*

Jacobs V, Woller SC, Stevens SM, et al. Percent time with a supratherapeutic INR in atrial fibrillation patients also using an antiplatelet agent is associated with long-term risk of dementia. *Journal of Cardiovascular Electrophysiology*. 2015 November;26(11):1180-6. PMID 2015478510. *Cohort study with inadequate sample size*

Janicki SC, Park N, Cheng R, et al. Estrogen receptor alpha variants affect age at onset of Alzheimer's disease in a multiethnic female cohort. *Dementia & Geriatric Cognitive Disorders*. 2014;38(3-4):200-13. PMID 24732579. *Not cognitive decline prevention intervention*

Jaremka LM, Derry HM, Bornstein R, et al. Omega-3 supplementation and loneliness-related memory problems: secondary analyses of a randomized controlled trial. *Psychosomatic Medicine*. 2014 Oct;76(8):650-8. PMID 25264972. *Inadequate follow up time*

Jean L, Simard M, Wiederkehr S, et al. Efficacy of a cognitive training programme for mild cognitive impairment: results of a randomised controlled study. *Neuropsychological Rehabilitation*. 2010 Jun;20(3):377-405. PMID 20029715. *Inadequate follow up time*



Jernerer F, Elshorbagy AK, Oulhaj A, et al. Brain atrophy in cognitively impaired elderly: the importance of long-chain omega-3 fatty acids and B vitamin status in a randomized controlled trial. *American Journal of Clinical Nutrition*. 2015 Jul;102(1):215-21. PMID 25877495. *Ineligible study design*

Jiang B, Ding C, Yao G, et al. Intervention effect of folic acid and vitamin B12 on vascular cognitive impairment complicated with hyperhomocysteinemia. *Journal of Medical Biochemistry*. 2014 April-June;33(2):169-74. PMID 2014475097. *Ineligible population*

Jiang D, Chu X, Hu L, et al. Yizhi Xingnao prescription improves the cognitive function of patients after a transient ischemic attack. *Neural Regeneration Research*. 2012 February;7(6):434-9. PMID 2012142010. *Ineligible population*

Jick H, Zornberg GL, Jick SS, et al. Statins and the risk of dementia.[Erratum appears in *Lancet* 2001 Feb 17;357(9255):562]. *Lancet*. 2000 Nov 11;356(9242):1627-31. PMID 11089820. *Ineligible study design*

Joas E, Backman K, Gustafson D, et al. Blood pressure trajectories from midlife to late life in relation to dementia in women followed for 37 years. *Hypertension*. 2012 Apr;59(4):796-801. PMID 22331381. *Not cognitive decline prevention intervention*

Johansson L, Guo X, Hallstrom T, et al. Common psychosocial stressors in middle-aged women related to longstanding distress and increased risk of Alzheimer's disease: A 38-year longitudinal population study. *BMJ Open*. 2013;3 (9) (no pagination)(e003142)PMID 2013640644. *Not cognitive decline prevention intervention*

Johnston H, Boutin H, Allan SM. Assessing the contribution of inflammation in models of Alzheimer's disease. *Biochemical Society Transactions*. 2011 August;39(4):886-90. PMID 2011415298. *Ineligible study design*

Kamegaya T, Araki Y, Kigure H, et al. Twelve-week physical and leisure activity programme improved cognitive function in community-dwelling elderly subjects: a randomized controlled trial. *Psychogeriatrics: The Official Journal of the Japanese Psychogeriatric Society*. 2014 Mar;14(1):47-54. PMID 24528600. *Inadequate follow up time*

Kang JH, Grodstein F. Regular use of nonsteroidal anti-inflammatory drugs and cognitive function in aging women. *Neurology*. 2003 May 27;60(10):1591-7. PMID 12771247. *Not cognitive decline prevention intervention*

Karr JE, Grindstaff TR, Alexander JE. Omega-3 polyunsaturated fatty acids and cognition in a college-aged population. *Experimental & Clinical Psychopharmacology*. 2012 Jun;20(3):236-42. PMID 22250656. *Inadequate follow up time*

Kaschel R. [Ginkgo extract in people with declining mental performance]. Pharmazie in Unserer Zeit. 2009;38(5):432-9. PMID 19711319. *Not available in English*

Kaschel R. Specific memory effects of Ginkgo biloba extract EGb 761 in middle-aged healthy volunteers. Phytomedicine. 2011 Nov 15;18(14):1202-7. PMID 21802920. *Inadequate follow up time*

Katon W, Lyles CR, Parker MM, et al. Association of depression with increased risk of dementia in patients with type 2 diabetes: the Diabetes and Aging Study. Archives of General Psychiatry. 2012 Apr;69(4):410-7. PMID 22147809. *Not cognitive decline prevention intervention*

Kawashima R. [Prevention of dementia by social activity]. Nippon Rinsho - Japanese Journal of Clinical Medicine. 2011 Dec;69 Suppl 10(Pt 2):212-6. PMID 22755186. *Not available in English*

Kawashima R. Mental exercises for cognitive function: clinical evidence. Journal of Preventive Medicine & Public Health / Yebang Uihakhoe Chi. 2013 Jan;46 Suppl 1:S22-7. PMID 23412645. *Ineligible population*

Kay GG, Maruff P, Scholfield D, et al. Evaluation of cognitive function in healthy older subjects treated with fesoterodine. Postgraduate Medicine. 2012 May;124(3):7-15. PMID 22691894. *Inadequate follow up time*

Kay GG, Staskin DR, MacDiarmid S, et al. Cognitive effects of oxybutynin chloride topical gel in older healthy subjects: a 1-week, randomized, double-blind, placebo- and active-controlled study. Clinical Drug Investigation. 2012 Oct 1;32(10):707-14. PMID 22909146. *Inadequate follow up time*

Kean RJ, Lamport DJ, Dodd GF, et al. Chronic consumption of flavanone-rich orange juice is associated with cognitive benefits: an 8-wk, randomized, double-blind, placebo-controlled trial in healthy older adults. American Journal of Clinical Nutrition. 2015 Mar;101(3):506-14. PMID 25733635. *Inadequate follow up time*

Kelly J, Fulford J, Vanhatalo A, et al. Effects of short-term dietary nitrate supplementation on blood pressure, O<sub>2</sub> uptake kinetics, and muscle and cognitive function in older adults. American Journal of Physiology - Regulatory Integrative & Comparative Physiology. 2013 Jan 15;304(2):R73-83. PMID 23174856. *Inadequate follow up time*

Kennedy DO, Dodd FL, Robertson BC, et al. Monoterpenoid extract of sage (Salvia lavandulaefolia) with cholinesterase inhibiting properties improves cognitive performance and mood in healthy adults. Journal of Psychopharmacology. 2011 Aug;25(8):1088-100. PMID 20937617. *Inadequate follow up time*

Kennedy DO, Veasey RC, Watson AW, et al. Vitamins and psychological functioning: a mobile phone assessment of the effects of a B vitamin complex, vitamin C and minerals on cognitive performance and subjective mood and energy. *Human Psychopharmacology*. 2011 Jun-Jul;26(4-5):338-47. PMID 21751253. *Inadequate follow up time*

Kennelly S, Abdullah L, Kenny RA, et al. Apolipoprotein e genotype-specific short-term cognitive benefits of treatment with the antihypertensive nilvadipine in Alzheimer's patients--an open-label trial. *International Journal of Geriatric Psychiatry*. 2012 April;27(4):415-22. PMID 2012157085. *Ineligible population*

Kennelly S, Abdullah L, Kenny RA, et al. Apolipoprotein E genotype-specific short-term cognitive benefits of treatment with the antihypertensive nilvadipine in Alzheimer's patients--an open-label trial. *International Journal of Geriatric Psychiatry*. 2012 Apr;27(4):415-22. PMID 21560164. *Ineligible population*

Kern S, Skoog I, Ostling S, et al. Does low-dose acetylsalicylic acid prevent cognitive decline in women with high cardiovascular risk? A 5-year follow-up of a non-demented population-based cohort of Swedish elderly women. *BMJ Open*. 2012;2 (5) (no pagination)(e001288)PMID 2012683493. *Not cognitive decline prevention intervention*

Kersten H, Molden E, Tolo IK, et al. Cognitive effects of reducing anticholinergic drug burden in a frail elderly population: a randomized controlled trial. *Journals of Gerontology Series A-Biological Sciences & Medical Sciences*. 2013 Mar;68(3):271-8. PMID 22982689. *Ineligible population*

Kesler S, Hadi Hosseini SM, Heckler C, et al. Cognitive training for improving executive function in chemotherapy-treated breast cancer survivors. *Clinical Breast Cancer*. 2013 Aug;13(4):299-306. PMID 23647804. *Ineligible population*

Kesse-Guyot E, Andreeva VA, Lassale C, et al. Mediterranean diet and cognitive function: a French study. *American Journal of Clinical Nutrition*. 2013 Feb;97(2):369-76. PMID 23283500. *Not cognitive decline prevention intervention*

Kesse-Guyot E, Andreeva VA, Touvier M, et al. Overall and abdominal adiposity in midlife and subsequent cognitive function. *Journal of Nutrition, Health & Aging*. 2015 Feb;19(2):183-9. PMID 25651444. *Not cognitive decline prevention intervention*

Kessing LV, Forman JL, Andersen PK. Does lithium protect against dementia? *Bipolar Disorders*. 2010 Feb;12(1):87-94. PMID 20148870. *Ineligible study design*

Khachaturian AS, Chapman J, Farrer L, et al. Healthy aging and preclinical dementia: the United States-Israel Longitudinal Database project. *Alzheimer's & Dementia*. 2010 Nov;6(6):475-81. PMID 21044777. *Ineligible study design*

Kim DH, Grodstein F, Rosner B, et al. Seafood types and age-related cognitive decline in the Women's Health Study. *Journals of Gerontology Series A-Biological Sciences & Medical Sciences*. 2013 Oct;68(10):1255-62. PMID 23554464. *Not cognitive decline prevention intervention*

Kim GH, Jeon S, Im K, et al. Structural brain changes after traditional and robot-assisted multi-domain cognitive training in community-dwelling healthy elderly. *PLoS ONE*. 2015 21 Apr;10(4)PMID 2015967293. *Inadequate follow up time*

Kim JM, Stewart R, Bae KY, et al. Role of BDNF val66met polymorphism on the association between physical activity and incident dementia. *Neurobiology of Aging*. 2011 Mar;32(3):551.e5-12. PMID 20172629. *Not cognitive decline prevention intervention*

Kim SJ, Lee JH, Lee DY, et al. Neurocognitive dysfunction associated with sleep quality and sleep apnea in patients with mild cognitive impairment. *American Journal of Geriatric Psychiatry*. 2011 Apr;19(4):374-81. PMID 20808148. *Ineligible study design*

Kim SY, Choi SH, Rollema H, et al. Phase II crossover trial of varenicline in mild-to-moderate Alzheimer's disease. *Dementia & Geriatric Cognitive Disorders*. 2014;37(3-4):232-45. PMID 24247022. *Ineligible population*

Kim YW, Shin JC, An YS. Changes in cerebral glucose metabolism in patients with posttraumatic cognitive impairment after memantine therapy: a preliminary study. *Annals of Nuclear Medicine*. 2010 Jun;24(5):363-9. PMID 20237871. *Ineligible population*

Kinsella GJ, Mullaly E, Rand E, et al. Early intervention for mild cognitive impairment: a randomised controlled trial. *Journal of Neurology, Neurosurgery & Psychiatry*. 2009 Jul;80(7):730-6. PMID 19332424. *Inadequate follow up time*

Kivipelto M, Solomon A, Ahtiluoto S, et al. The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER): study design and progress. *Alzheimer's & Dementia*. 2013 Nov;9(6):657-65. PMID 23332672. *Ineligible study design*

Klados MA, Styliadis C, Frantzidis CA, et al. Beta-band functional connectivity is reorganized in mild cognitive impairment after combined computerized physical and cognitive training. *Frontiers in neuroscience*. 2016;10. *Inadequate follow up time*

Klepin HD, Geiger AM, Bandos H, et al. Cognitive factors associated with adherence to oral antiestrogen therapy: results from the cognition in the study of tamoxifen and raloxifene (Co-STAR) study. *Cancer Prevention Research*. 2014 Jan;7(1):161-8. PMID 24253314. *No relevant outcomes reported*

Klusmann V, Evers A, Schwarzer R, et al. Activity experiences shape perceived fitness trajectories: results from a 6-month randomized controlled trial in older women. *Aging Neuropsychology & Cognition*. 2011 May;18(3):328-39. PMID 21557117. *No relevant outcomes reported*

Ko HJ, Youn CH. Effects of laughter therapy on depression, cognition and sleep among the community-dwelling elderly. *Geriatrics & gerontology international*. 2011 Jul;11(3):267-74. PMID 21241447. *Inadequate follow up time*

Kocoska-Maras L, Radestad AF, Carlstrom K, et al. Cognitive function in association with sex hormones in postmenopausal women. *Gynecological Endocrinology*. 2013 Jan;29(1):59-62. PMID 22967437. *Inadequate follow up time*

Kocoska-Maras L, Zethraeus N, Radestad AF, et al. A randomized trial of the effect of testosterone and estrogen on verbal fluency, verbal memory, and spatial ability in healthy postmenopausal women. *Fertility & Sterility*. 2011 Jan;95(1):152-7. PMID 20667535. *Inadequate follow up time*

Kohler S, Baars MA, Spauwen P, et al. Temporal evolution of cognitive changes in incident hypertension: prospective cohort study across the adult age span. *Hypertension*. 2014 Feb;63(2):245-51. PMID 24296281. *Not cognitive decline prevention intervention*

Konagai C, Yanagimoto K, Hayamizu K, et al. Effects of krill oil containing n-3 polyunsaturated fatty acids in phospholipid form on human brain function: a randomized controlled trial in healthy elderly volunteers. *Clinical Interventions In Aging*. 2013;8:1247-57. PMID 24098072. *Inadequate follow up time*

Kostis JB, Rosen RC, Wilson AC. Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia. *Journal of Clinical Pharmacology*. 1994 Oct;34(10):989-96. PMID 7836550. *Inadequate follow up time*

Koushyar H, Najafi Z, Azhari A, et al. Comparison of the effect of fun and regular physical activity on the changes in the incidence of depression and cognitive disorders of elderly women living in nursing homes at Mashhad. [Persian]. *Iranian Journal of Obstetrics, Gynecology and Infertility*. 2014;17(132):1-9. PMID 2015761086. *Not available in English*

Krikorian R, Boespflug EL, Fleck DE, et al. Concord grape juice supplementation and neurocognitive function in human aging. *Journal of Agricultural & Food Chemistry*. 2012 Jun 13;60(23):5736-42. PMID 22468945. *Inadequate follow up time*

Krikorian R, Eliassen JC, Boespflug EL, et al. Improved cognitive-cerebral function in older adults with chromium supplementation. *Nutritional Neuroscience*. 2010 Jun;13(3):116-22. PMID 20423560. *Inadequate follow up time*

Krikorian R, Nash TA, Shidler MD, et al. Concord grape juice supplementation improves memory function in older adults with mild cognitive impairment. *British Journal of Nutrition*. 2010 Mar;103(5):730-4. PMID 20028599. *Inadequate follow up time*

Krikorian R, Shidler MD, Nash TA, et al. Blueberry supplementation improves memory in older adults. *Journal of Agricultural & Food Chemistry*. 2010 Apr 14;58(7):3996-4000. PMID 20047325. *Inadequate follow up time*

Kristensen PL, Hoi-Hansen T, Boomsma F, et al. Vascular endothelial growth factor during hypoglycemia in patients with type 1 diabetes mellitus: relation to cognitive function and renin-angiotensin system activity. *Metabolism: Clinical & Experimental*. 2009 Oct;58(10):1430-8. PMID 19573885. *Not cognitive decline prevention intervention*

Krupp LB, Christodoulou C, Melville P, et al. Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis. *Neurology*. 2011 Apr 26;76(17):1500-7. PMID 21519001. *Ineligible population*

Kryscio RJ, Abner EL, Schmitt FA, et al. A randomized controlled Alzheimer's disease prevention trial's evolution into an exposure trial: the PREADViSE Trial. *Journal of Nutrition, Health & Aging*. 2013 Jan;17(1):72-5. PMID 23299383. *Ineligible study design*

Kulmala J, Solomon A, Kareholt I, et al. Association between mid- to late life physical fitness and dementia: evidence from the CAIDE study. *Journal of Internal Medicine*. 2014 Sep;276(3):296-307. PMID 24444031. *Not cognitive decline prevention intervention*

Kurz A, Thone-Otto A, Cramer B, et al. CORDIAL: cognitive rehabilitation and cognitive-behavioral treatment for early dementia in Alzheimer disease: a multicenter, randomized, controlled trial. *Alzheimer Disease & Associated Disorders*. 2012 Jul-Sep;26(3):246-53. PMID 21986341. *Ineligible population*

Kuster OC, Fissler P, Laptinskaya D, et al. Cognitive change is more positively associated with an active lifestyle than with training interventions in older adults at risk of dementia: A controlled interventional clinical trial. *BMC Psychiatry*. 2016 08 Sep;16(1) (no pagination)(315) PMID 612014603. *Inadequate follow up time*

Kwok T, Lee J, Law CB, et al. A randomized placebo controlled trial of homocysteine lowering to reduce cognitive decline in older demented people. *Clinical Nutrition*. 2011 Jun;30(3):297-302. PMID 21216507. *Ineligible population*

Kwok T, Wong A, Chan G, et al. Effectiveness of cognitive training for Chinese elderly in Hong Kong. *Clinical Interventions In Aging*. 2013;8:213-9. PMID 23440076. *Inadequate follow up time*

Kwok TC, Lam LC, Sea MM, et al. A randomized controlled trial of dietetic interventions to prevent cognitive decline in old age hostel residents. *European Journal of Clinical Nutrition*. 2012 Oct;66(10):1135-40. PMID 22948946. *Ineligible population*

Kwon JC, Kim EG, Kim JW, et al. A multicenter, open-label, 24-week follow-up study for efficacy on cognitive function of donepezil in Binswanger-type subcortical vascular dementia. *American Journal of Alzheimer's Disease & Other Dementias*. 2009 Aug-Sep;24(4):293-301. PMID 19383979. *Ineligible population*

Laforce R, Jr., Buteau JP, Paquet N, et al. The value of PET in mild cognitive impairment, typical and atypical/unclear dementias: A retrospective memory clinic study. *American Journal of Alzheimer's Disease & Other Dementias*. 2010 Jun;25(4):324-32. PMID 20539026. *Cohort study with inadequate sample size*

Laitala VS, Hjelmborg J, Koskenvuo M, et al. Shorter adult stature increases the impact of risk factors for cognitive impairment: a comparison of two Nordic twin cohorts. *Twin Research & Human Genetics: the Official Journal of the International Society for Twin Studies*. 2011 Dec;14(6):544-52. PMID 22506310. *Ineligible study design*

Laitala VS, Kaprio J, Koskenvuo M, et al. Coffee drinking in middle age is not associated with cognitive performance in old age. *American Journal of Clinical Nutrition*. 2009 Sep;90(3):640-6. PMID 19587088. *Not cognitive decline prevention intervention*

Lam JH. Can leisure activities slow dementia progression in nursing home residents? A cluster-randomized controlled trial. *International psychogeriatrics / IPA*. 2014 01 Apr;26(4):637-43. PMID 24411480. *Ineligible population*

Lam LC, Chan WM, Kwok TC, et al. Effectiveness of Tai Chi in maintenance of cognitive and functional abilities in mild cognitive impairment: a randomised controlled trial. *Hong Kong Medical Journal*. 2014 Jun;20(3 Suppl 3):20-3. PMID 25001031. *Ineligible population*

Lam LC, Chau RC, Wong BM, et al. Interim follow-up of a randomized controlled trial comparing Chinese style mind body (Tai Chi) and stretching exercises on cognitive function in subjects at risk of progressive cognitive decline. *International Journal of Geriatric Psychiatry*. 2011 Jul;26(7):733-40. PMID 21495078. *Inadequate follow up time*

Lamport DJ, Saunders C, Butler LT, et al. Fruits, vegetables, 100% juices, and cognitive function. *Nutrition Reviews*. 2014 Dec;72(12):774-89. PMID 25399992. *Ineligible study design*

Langballe EM, Ask H, Holmen J, et al. Alcohol consumption and risk of dementia up to 27 years later in a large, population-based sample: the HUNT study, Norway. *European*

Journal of Epidemiology. 2015 Sep;30(9):1049-56. PMID 25968174. *Not cognitive decline prevention intervention*

Langlois F, Vu TT, Chasse K, et al. Benefits of physical exercise training on cognition and quality of life in frail older adults. Journals of Gerontology Series B-Psychological Sciences & Social Sciences. 2013 May;68(3):400-4. PMID 22929394. *Inadequate follow up time*

Lapid MI, Drake MT, Geske JR, et al. Hypovitaminosis D in psychogeriatric inpatients. Journal of Nutrition, Health & Aging. 2013 Mar;17(3):231-4. PMID 23459975. *Cohort study with inadequate sample size*

Laudisio A, Marzetti E, Pagano F, et al. Digoxin and cognitive performance in patients with heart failure: A cohort, pharmacoepidemiological survey. Drugs and Aging. 2009;26(2):103-12. PMID 2009078141. *Ineligible population*

Launer LJ, Hughes T, Yu B, et al. Lowering midlife levels of systolic blood pressure as a public health strategy to reduce late-life dementia: perspective from the Honolulu Heart Program/Honolulu Asia Aging Study. Hypertension. 2010 Jun;55(6):1352-9. PMID 20404223. *Not cognitive decline prevention intervention*

Leduc V, De Beaumont L, Theroux L, et al. HMGCR is a genetic modifier for risk, age of onset and MCI conversion to Alzheimer's disease in a three cohorts study. Molecular Psychiatry. 2015 24 Jul;20(7):867-73. PMID 2014735037. *Not cognitive decline prevention intervention*

Lee ATC, Richards M, Chan WC, et al. Intensity and Types of Physical Exercise in Relation to Dementia Risk Reduction in Community-Living Older Adults. Journal of the American Medical Directors Association. 2015 01 Oct;16(10):899.e1-.e7. PMID 2015442379. *Not cognitive decline prevention intervention*

Lee CE, Kilgour A, Lau YK. Efficacy of walking exercise in promoting cognitive-psycho-social functions in men with prostate cancer receiving androgen deprivation therapy. BMC Cancer. 2012;12:324. PMID 22846379. *Ineligible population*

Lee J, Pase M, Pipingas A, et al. Switching to a 10-day Mediterranean-style diet improves mood and cardiovascular function in a controlled crossover study. Nutrition. 2015 May;31(5):647-52. PMID 25837207. *Inadequate follow up time*

Lee JG, Lee SW, Lee BJ, et al. Adjunctive memantine therapy for cognitive impairment in chronic schizophrenia: A placebo-controlled pilot study. Psychiatry Investigation. 2012;9(2):166-73. PMID 2012388152. *Ineligible population*

Lee TS, Goh SJ, Quek SY, et al. A brain-computer interface based cognitive training system for healthy elderly: a randomized control pilot study for usability and preliminary



efficacy. PLoS ONE [Electronic Resource]. 2013;8(11):e79419. PMID 24260218.  
*Inadequate follow up time*

Lee TS, Quek SY, Goh SJ, et al. A pilot randomized controlled trial using EEG-based brain-computer interface training for a Chinese-speaking group of healthy elderly. *Clinical Interventions In Aging*. 2015;10:217-27. PMID 25624754. *Inadequate follow up time*

Lee Y, Back JH, Kim J, et al. Systematic review of health behavioral risks and cognitive health in older adults. *International Psychogeriatrics*. 2010 Mar;22(2):174-87. PMID 19883522. *Ineligible study design*

Lee Y, Kim J, Han ES, et al. Changes in physical activity and cognitive decline in older adults living in the community. *Age*. 2015;37(2) PMID 2015787853. *Not cognitive decline prevention intervention*

Lee YK, Hou SW, Lee CC, et al. Increased risk of dementia in patients with mild traumatic brain injury: a nationwide cohort study. PLoS ONE [Electronic Resource]. 2013;8(5):e62422. PMID 23658727. *Ineligible population*

Legault C, Jennings JM, Katula JA, et al. Designing clinical trials for assessing the effects of cognitive training and physical activity interventions on cognitive outcomes: the Seniors Health and Activity Research Program Pilot (SHARP-P) study, a randomized controlled trial. *BMC Geriatrics*. 2011;11:27. PMID 21615936. *Inadequate follow up time*

Lenz RA, Pritchett YL, Berry SM, et al. Adaptive, Dose-finding Phase 2 Trial Evaluating the Safety and Efficacy of ABT-089 in Mild to Moderate Alzheimer Disease. *Alzheimer Disease and Associated Disorders*. 2015 07 Sep;29(3):192-9. PMID 2015359676. *Ineligible population*

Leoutsakos JM, Muthen BO, Breitner JC, et al. Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial. *International Journal of Geriatric Psychiatry*. 2012 Apr;27(4):364-74. PMID 21560159. *Ineligible study design*

Leufkens TR, Lund JS, Vermeeren A. Highway driving performance and cognitive functioning the morning after bedtime and middle-of-the-night use of gaboxadol, zopiclone and zolpidem. *Journal of Sleep Research*. 2009 Dec;18(4):387-96. PMID 19552733. *Inadequate follow up time*

Leung GT, Fung AW, Tam CW, et al. Examining the association between participation in late-life leisure activities and cognitive function in community-dwelling elderly Chinese

in Hong Kong. *International Psychogeriatrics*. 2010 Feb;22(1):2-13. PMID 19785918. *Not cognitive decline prevention intervention*

Leung GT, Fung AW, Tam CW, et al. Examining the association between late-life leisure activity participation and global cognitive decline in community-dwelling elderly Chinese in Hong Kong. *International Journal of Geriatric Psychiatry*. 2011 Jan;26(1):39-47. PMID 21157849. *Not cognitive decline prevention intervention*

Levin OS, Yunishchenko NA, Dudarova MA. Efficacy of akatinol memantine in moderate cognitive impairments. *Neuroscience & Behavioral Physiology*. 2010 Oct;40(8):926-33. PMID 20683775. *Ineligible study design*

Lewis JE, McDaniel HR, Agronin ME, et al. The effect of an aloe polymannose multivitamin complex on cognitive and immune functioning in Alzheimer's disease. *Journal of Alzheimer's Disease*. 2013;33(2):393-406. PMID 22976077. *Ineligible population*

Li F, Harmer P, Liu Y, et al. Tai Ji Quan and global cognitive function in older adults with cognitive impairment: a pilot study. *Archives of Gerontology & Geriatrics*. 2014 May-Jun;58(3):434-9. PMID 24398166. *Inadequate follow up time*

Li G, Shofer JB, Rhew IC, et al. Age-varying association between statin use and incident Alzheimer's disease. *Journal of the American Geriatrics Society*. 2010 Jul;58(7):1311-7. PMID 20533968. *Not cognitive decline prevention intervention*

Li NC, Lee A, Whitmer RA, et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: Prospective cohort analysis. *BMJ (Online)*. 2010 16 Jan;340(7738):141. PMID 2010062843. *Not cognitive decline prevention intervention*

Li R, Polat U, Makous W, et al. Enhancing the contrast sensitivity function through action video game training. *Nature Neuroscience*. 2009 May;12(5):549-51. PMID 19330003. *Inadequate follow up time*

Li R, Polat U, Scalzo F, et al. Reducing backward masking through action game training. *Journal of Vision*. 2010;10(14) PMID 21191129. *Ineligible study design*

Liang J, Li F, Wei C, et al. Rationale and design of a multicenter, phase 2 clinical trial to investigate the efficacy of traditional Chinese medicine sailuotong in vascular dementia. *Journal of Stroke and Cerebrovascular Diseases*. 2014;23(10):2626-34. PMID 2014873944. *Ineligible study design*

Liao JN, Chao TF, Liu CJ, et al. Risk and prediction of dementia in patients with atrial fibrillation - A nationwide population-based cohort study. *International Journal of Cardiology*. 2015 15 Sep;199:25-30. PMID 2015376315. *Ineligible population*

Liao KM, Ho CH, Ko SC, et al. Increased Risk of Dementia in Patients With Chronic Obstructive Pulmonary Disease. *Medicine*. 2015 Jun;94(23):e930. PMID 26061317. *Ineligible population*

Liao MT, Lin LY, Yang YH, et al. ACEI and ARB did not reduce the incidence of dementia in patients with atrial fibrillation: A nationwide cohort study. *Acta Cardiologica Sinica*. 2013 July;29(4):323-7. PMID 2013464598. *Ineligible population*

Licastro F, Porcellini E, Chiappelli M, et al. Multivariable network associated with cognitive decline and dementia. *Neurobiology of Aging*. 2010 February;31(2):257-69. PMID 2009623669. *Not cognitive decline prevention intervention*

Lieb W, Beiser AS, Vasan RS, et al. Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging. *JAMA - Journal of the American Medical Association*. 2009 16 Dec;302(23):2565-72. PMID 2009657832. *Ineligible study design*

Lim AS, Yu L, Kowgier M, et al. Modification of the relationship of the apolipoprotein E epsilon4 allele to the risk of Alzheimer disease and neurofibrillary tangle density by sleep. *JAMA Neurology*. 2013 Dec;70(12):1544-51. PMID 24145819. *Not cognitive decline prevention intervention*

Lin CC, Chou CH, Fan YM, et al. Increased risk of dementia among sleep-related movement disorders: A population-based longitudinal study in Taiwan. *Medicine (United States)*. 2015;94 (51) (no pagination)(e2331)PMID 20160007822. *Not cognitive decline prevention intervention*

Lin CH, Chen PK, Chang YC, et al. Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: a randomized, double-blind, placebo-controlled trial. *Biological Psychiatry*. 2014 May 1;75(9):678-85. PMID 24074637. *Ineligible population*

Lin CH, Sheu WHH. Hypoglycaemic episodes and risk of dementia in diabetes mellitus: 7-year follow-up study. *Journal of Internal Medicine*. 2013 January;273(1):102-10. PMID 2013003846. *Not cognitive decline prevention intervention*

Lin F, Heffner KL, Ren P, et al. Cognitive and Neural Effects of Vision-Based Speed-of-Processing Training in Older Adults with Amnesic Mild Cognitive Impairment: A Pilot Study. *Journal of the American Geriatrics Society*. 2016;64(6):1293-8. *Inadequate follow up time*

Lin JN, Lin CL, Lin MC, et al. Increased Risk of Dementia in Patients With Acute Organophosphate and Carbamate Poisoning: A Nationwide Population-Based Cohort

Study. *Medicine*. 2015 Jul;94(29):e1187. PMID 26200627. *Not cognitive decline prevention intervention*

Lindenmayer JP, Khan A. Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. *Schizophrenia Research*. 2011 February;125(2-3):267-77. PMID 2011052376. *Ineligible population*

Lippa CF, Rosso A, Hepler M, et al. Levetiracetam: a practical option for seizure management in elderly patients with cognitive impairment. *American Journal of Alzheimer's Disease & Other Dementias*. 2010 Mar;25(2):149-54. PMID 19001351. *Inadequate follow up time*

Lipton RB, Hirsch J, Katz MJ, et al. Exceptional parental longevity associated with lower risk of Alzheimer's disease and memory decline. *Journal of the American Geriatrics Society*. 2010 Jun;58(6):1043-9. PMID 20487085. *Cohort study with inadequate sample size*

Littlejohns TJ, Henley WE, Lang IA, et al. Vitamin D and the risk of dementia and Alzheimer disease. *Neurology*. 2014 Sep 2;83(10):920-8. PMID 25098535. *Not cognitive decline prevention intervention*

Litvinenko IV, Vorob'ev SV, Lobzin VY, et al. Possibilities of pharmacological modulation of brain glutamatergic system in the treatment of vascular cognitive impairment. [Russian]. *Zhurnal Nevrologii i Psihiatrii imeni S.S. 2013;Korsakova*. 2013(9):29-35. PMID 2014590162. *Not available in English*

Litvinenko IV, Vorob'ev SV, Lobzin VY, et al. Possibilities of pharmacological modulation of brain glutamatergic system in the treatment of vascular cognitive impairment. *Zhurnal Nevrologii i Psihiatrii imeni S.S. 2013;Korsakova*. 2013(9):29-35. PMID 2013654201. *Ineligible population*

Liu C, Zeng CL, Zhen LR. Effects of HMG-CoA reductase inhibitors on primary hypertension patients with vascular cognitive impairment. [Chinese]. *Chinese Pharmaceutical Journal*. 2010 May;45(9):706-9. PMID 2010492740. *Not available in English*

Liu YH, Wang DX, Li LH, et al. The effects of cardiopulmonary bypass on the number of cerebral microemboli and the incidence of cognitive dysfunction after coronary artery bypass graft surgery. *Anesthesia & Analgesia*. 2009 Oct;109(4):1013-22. PMID 19762724. *Cohort study with inadequate sample size*

Liu-Ambrose T, Donaldson MG. Exercise and cognition in older adults: is there a role for resistance training programmes? *British Journal of Sports Medicine*. 2009 Jan;43(1):25-7. PMID 19019904. *Ineligible study design*

Liu-Ambrose T, Eng JJ, Boyd LA, et al. Promotion of the mind through exercise (PROMoTE): a proof-of-concept randomized controlled trial of aerobic exercise training in older adults with vascular cognitive impairment. BMC Neurology. 2010;10:14. PMID 20158920. *Ineligible study design*

Llamas-Velasco S, Contador I, Villarejo-Galende A, et al. Physical activity as protective factor against dementia: A prospective population-based study (NEDICES). Journal of the International Neuropsychological Society. 2015 Nov;21(10):861-7. PMID 2015-53115-014. *Ineligible study design*

Lobo E, Dufouil C, Marcos G, et al. Is there an association between low-to-moderate alcohol consumption and risk of cognitive decline? American Journal of Epidemiology. 2010 Sep 15;172(6):708-16. PMID 20699263. *Not cognitive decline prevention intervention*

Loef M, Walach H. Fruit, vegetables and prevention of cognitive decline or dementia: a systematic review of cohort studies. Journal of Nutrition, Health & Aging. 2012 Jul;16(7):626-30. PMID 22836704. *Ineligible study design*

Loewenstein DA, Acevedo A, Czaja SJ, et al. Cognitive rehabilitation of mildly impaired Alzheimer disease patients on cholinesterase inhibitors. American Journal of Geriatric Psychiatry. 2004 Jul-Aug;12(4):395-402. PMID 15249277. *Ineligible population*

Lohman MC, Rebok GW, Spira AP, et al. Depressive symptoms and memory performance among older adults: results from the ACTIVE memory training intervention. Journal of Aging & Health. 2013 Dec;25(8 Suppl):209S-29S. PMID 23006426. *Not cognitive decline prevention intervention*

Lopez LB, Kritz-Silverstein D, Barrett Connor E. High dietary and plasma levels of the omega-3 fatty acid docosahexaenoic acid are associated with decreased dementia risk: the Rancho Bernardo study. Journal of Nutrition, Health & Aging. 2011 Jan;15(1):25-31. PMID 21267518. *Cohort study with inadequate sample size*

Louis ED, Benito-Leon J, Bermejo-Pareja F, et al. Antihypertensive agents and risk of Parkinson's disease, essential tremor and dementia: a population-based prospective study (NEDICES). Neuroepidemiology. 2009;33(3):286-92. PMID 19696520. *Not cognitive decline prevention intervention*

Lovell MA, Abner E, Kryscio R, et al. Calcium Channel Blockers, Progression to Dementia, and Effects on Amyloid Beta Peptide Production. Oxidative Medicine and Cellular Longevity. 2015;2015 (no pagination)(787805)PMID 2015195362. *Not cognitive decline prevention intervention*

Lovestone S, Boada M, Dubois B, et al. A phase II trial of tideglusib in alzheimer's disease. *Journal of Alzheimer's Disease*. 2015;45(1):75-88. PMID 2015808408. *Ineligible population*

Lovheim H, Gilthorpe J, Adolfsson R, et al. Reactivated herpes simplex infection increases the risk of Alzheimer's disease. *Alzheimer's and Dementia*. 2015 01 Jun;11(6):593-9. PMID 2014736948. *Not cognitive decline prevention intervention*

Low LF, Anstey KJ, Sachdev P. Use of medications with anticholinergic properties and cognitive function in a young-old community sample. *International Journal of Geriatric Psychiatry*. 2009 Jun;24(6):578-84. PMID 19021151. *Not cognitive decline prevention intervention*

Lu PH, Edland SD, Teng E, et al. Donepezil delays progression to AD in MCI subjects with depressive symptoms. *Neurology*. 2009 Jun 16;72(24):2115-21. PMID 19528519. *No relevant outcomes reported*

Lu PH, Masterman DA, Mulnard R, et al. Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men. *Arch Neurol*. 2006 Feb;63(2):177-85. PMID 16344336. *Ineligible population*

Luck T, Lupp M, Angermeyer MC, et al. Impact of impairment in instrumental activities of daily living and mild cognitive impairment on time to incident dementia: results of the Leipzig Longitudinal Study of the Aged. *Psychological Medicine*. 2011 May;41(5):1087-97. PMID 20667169. *Ineligible study design*

Luck T, Lupp M, Wiese B, et al. Prediction of incident dementia: impact of impairment in instrumental activities of daily living and mild cognitive impairment--results from the German study on ageing, cognition, and dementia in primary care patients. *American Journal of Geriatric Psychiatry*. 2012 Nov;20(11):943-54. PMID 22706332. *Not cognitive decline prevention intervention*

Luck T, Riedel-Heller SG, Lupp M, et al. Apolipoprotein E epsilon 4 genotype and a physically active lifestyle in late life: analysis of gene-environment interaction for the risk of dementia and Alzheimer's disease dementia. *Psychological Medicine*. 2014 Apr;44(6):1319-29. PMID 23883793. *Not cognitive decline prevention intervention*

Luck T, Riedel-Heller SG, Lupp M, et al. Risk factors for incident mild cognitive impairment--results from the German Study on Ageing, Cognition and Dementia in Primary Care Patients (AgeCoDe). *Acta Psychiatrica Scandinavica*. 2010 Apr;121(4):260-72. PMID 19824992. *Not cognitive decline prevention intervention*

Luttenberger K, Hofner B, Graessel E. Are the effects of a non-drug multimodal activation therapy of dementia sustainable? Follow-up study 10 months after completion

of a randomised controlled trial. BMC Neurology. 2012;12:151. PMID 23217188.  
*Ineligible population*

Lynga P, Persson H, Hagg-Martinell A, et al. Weight monitoring in patients with severe heart failure (WISH). A randomized controlled trial. European Journal of Heart Failure. 2012 Apr;14(4):438-44. PMID 22371525. *No relevant outcomes reported*

Ma F, Wu T, Miao R, et al. Conversion of mild cognitive impairment to dementia among subjects with diabetes: a population-based study of incidence and risk factors with five years of follow-up. Journal of Alzheimer's Disease. 2015;43(4):1441-9. PMID 25159674.  
*Not cognitive decline prevention intervention*

Mahdavi A, Besharat MA, Taghizadeh ME, et al. Effectiveness of multi-sensory stimulations upon restoration of cognitive performance of patients exposed vascular dementia. Der Pharmacia Lettre. 2015;7(7):19-22. PMID 2015257115. *Ineligible population*

Maher-Edwards G, De'Ath J, Barnett C, et al. A 24-week study to evaluate the effect of rilapladib on cognition and cerebrospinal fluid biomarkers of Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions. 2015 15 Oct;1(2):131-40. PMID 2015445710. *Ineligible population*

Maher-Edwards G, Dixon R, Hunter J, et al. SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study. International Journal of Geriatric Psychiatry. 2011 May;26(5):536-44. PMID 20872778. *Ineligible population*

Maher-Edwards G, Watson C, Ascher J, et al. Two randomized controlled trials of SB742457 in mild-to-moderate Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions. 2015 14 Oct;1(1):23-36. PMID 2015441551. *Ineligible population*

Maher-Edwards G, Zvartau-Hind M, Hunter AJ, et al. Double-blind, controlled phase ii study of a 5-ht6 receptor antagonist, sb-742457, in alzheimer's disease. Current Alzheimer Research. 2010;7(5):374-85. PMID 2010637453. *Ineligible population*

Mahncke HW, Bronstone A, Merzenich MM. Brain plasticity and functional losses in the aged: scientific bases for a novel intervention. Progress in Brain Research. 2006;157:81-109. PMID 17046669. *Ineligible study design*

Mahncke HW, Connor BB, Appelman J, et al. Memory enhancement in healthy older adults using a brain plasticity-based training program: a randomized, controlled study. Proceedings of the National Academy of Sciences of the United States of America. 2006 Aug 15;103(33):12523-8. PMID 16888038. *Inadequate follow up time*

- Maillot P, Perrot A, Hartley A. Effects of interactive physical-activity video-game training on physical and cognitive function in older adults. *Psychology & Aging*. 2012 Sep;27(3):589-600. PMID 22122605. *Inadequate follow up time*
- Maki PM. A systematic review of clinical trials of hormone therapy on cognitive function: effects of age at initiation and progestin use. *Ann N Y Acad Sci*. 2005 Jun;1052:182-97. PMID 16024761. *Ineligible study design*
- Maki PM, Dennerstein L, Clark M, et al. Perimenopausal use of hormone therapy is associated with enhanced memory and hippocampal function later in life. *Brain Research*. 2011 Mar 16;1379:232-43. PMID 21078303. *Cohort study with inadequate sample size*
- Maki PM, Henderson VW. Hormone therapy, dementia, and cognition: the Women's Health Initiative 10 years on. *Climacteric*. 2012 Jun;15(3):256-62. PMID 22612612. *Ineligible study design*
- Makino KM, Porsteinsson AP. Memantine: A treatment for Alzheimers disease with a new formulation. *Aging Health*. 2011 June;7(3):349-62. PMID 2011351492. *Ineligible study design*
- Makizako H, Doi T, Shimada H, et al. Does a multicomponent exercise program improve dual-task performance in amnesic mild cognitive impairment? A randomized controlled trial. *Aging-Clinical & Experimental Research*. 2012 Dec;24(6):640-6. PMID 23211228. *No relevant outcomes reported*
- Malkki H. Dementia: New study puts its FINGER on prevention of cognitive decline. *Nature Reviews Neurology*. 2015 11 May;11(5):248. PMID 2015865264. *Ineligible study design*
- Mamikonyan E, Xie SX, Melvin E, et al. Rivastigmine for mild cognitive impairment in Parkinson disease: A placebo-controlled study. *Movement Disorders*. 2015 01 Jun;30(7):912-8. PMID 2015970313. *Ineligible population*
- Mammarella N, Fairfield B. Where did I put my keys? - a 'we' intervention to promote memory in healthy older adults: a controlled pilot study. *Gerontology*. 2013;59(4):349-54. PMID 23364128. *Inadequate follow up time*
- Man DW, Chung JC, Lee GY. Evaluation of a virtual reality-based memory training programme for Hong Kong Chinese older adults with questionable dementia: a pilot study. *International Journal of Geriatric Psychiatry*. 2012 May;27(5):513-20. PMID 21681818. *Ineligible population*
- Manenti R, Brambilla M, Petesi M, et al. Enhancing verbal episodic memory in older and young subjects after non-invasive brain stimulation. *Frontiers in Aging Neuroscience*. 2013;5(SEP)PMID 2014170746. *Inadequate follow up time*



Mangialasche F, Solomon A, Kareholt I, et al. Serum levels of vitamin E forms and risk of cognitive impairment in a Finnish cohort of older adults. *Experimental Gerontology*. 2013 Dec;48(12):1428-35. PMID 24113154. *Cohort study with inadequate sample size*

Mannikko R, Komulainen P, Schwab U, et al. The Nordic diet and cognition--The DR's EXTRA Study. *British Journal of Nutrition*. 2015 Jul;114(2):231-9. PMID 26104270. *No relevant outcomes reported*

Marek GJ, Katz DA, Meier A, et al. Efficacy and safety evaluation of HSD-1 inhibitor ABT-384 in Alzheimer's disease. *Alzheimer's & Dementia*. 2014 Oct;10(5 Suppl):S364-73. PMID 24418055. *Ineligible population*

Marmeleira JF, Godinho MB, Fernandes OM. The effects of an exercise program on several abilities associated with driving performance in older adults. *Accident Analysis & Prevention*. 2009 Jan;41(1):90-7. PMID 19114142. *Inadequate follow up time*

Marra HLD, Myczkowski ML, Memoria CM, et al. Transcranial magnetic stimulation to address mild cognitive impairment in the elderly: A randomized controlled study. *Behavioural Neurology*. 2015;2015:287843. PMID 2015-27339-001. *Inadequate follow up time*

Marshall GA, Zoller AS, Lorus N, et al. Functional activities questionnaire items that best discriminate and predict progression from clinically normal to mild cognitive impairment. *Current Alzheimer Research*. 2015;12(5):493-502. PMID 2015125099. *Ineligible study design*

Marzona I, O'Donnell M, Teo K, et al. Increased risk of cognitive and functional decline in patients with atrial fibrillation: results of the ONTARGET and TRANSCEND studies. *CMAJ Canadian Medical Association Journal*. 2012 Apr 3;184(6):E329-36. PMID 22371515. *No relevant outcomes reported*

Mastroiacovo D, Kwik-Urbe C, Grassi D, et al. Cocoa flavanol consumption improves cognitive function, blood pressure control, and metabolic profile in elderly subjects: the Cocoa, Cognition, and Aging (CoCoA) Study--a randomized controlled trial. *American Journal of Clinical Nutrition*. 2015 Mar;101(3):538-48. PMID 25733639. *Inadequate follow up time*

Matousek RH, Sherwin BB. A randomized controlled trial of add-back estrogen or placebo on cognition in men with prostate cancer receiving an antiandrogen and a gonadotropin-releasing hormone analog. *Psychoneuroendocrinology*. 2010 Feb;35(2):215-25. PMID 19615826. *Inadequate follow up time*

Mavaddat N, Roalfe A, Fletcher K, et al. Warfarin versus aspirin for prevention of cognitive decline in atrial fibrillation: randomized controlled trial (Birmingham Atrial

Fibrillation Treatment of the Aged Study). *Stroke*. 2014 May;45(5):1381-6. PMID 24692475. *Ineligible population*

Mayas J, Parmentier FB, Andres P, et al. Plasticity of attentional functions in older adults after non-action video game training: a randomized controlled trial. *PLoS ONE* [Electronic Resource]. 2014;9(3):e92269. PMID 24647551. *Inadequate follow up time*

McGuinness B, Fuchs M, Barrett SL, et al. Platelet membrane beta-secretase activity in mild cognitive impairment and conversion to dementia: A longitudinal study. *Journal of Alzheimer's Disease*. 2015 24 Dec;49(4):1095-103. PMID 20160029198. *Cohort study with inadequate sample size*

McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. *International Journal of Neuropsychopharmacology*. 2014 Oct;17(10):1557-67. PMID 24787143. *Inadequate follow up time*

Meador KJ, Gevins A, Leese PT, et al. Neurocognitive effects of brivaracetam, levetiracetam, and lorazepam. *Epilepsia*. 2011 Feb;52(2):264-72. PMID 20887370. *Inadequate follow up time*

Mechaeil R, Gard P, Jackson A, et al. Cognitive enhancement following acute losartan in normotensive young adults. *Psychopharmacology*. 2011 Sep;217(1):51-60. PMID 21484242. *Inadequate follow up time*

Mecocci P, Bladstrom A, Stender K. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies. *International Journal of Geriatric Psychiatry*. 2009 May;24(5):532-8. PMID 19274640. *Ineligible population*

Mehlig K, Skoog I, Waern M, et al. Physical activity, weight status, diabetes and dementia: a 34-year follow-up of the population study of women in Gothenburg. *Neuroepidemiology*. 2014;42(4):252-9. PMID 24923622. *Not cognitive decline prevention intervention*

Meinzer M, Antonenko D, Lindenberg R, et al. Electrical brain stimulation improves cognitive performance by modulating functional connectivity and task-specific activation. *Journal of Neuroscience*. 2012 Feb 1;32(5):1859-66. PMID 22302824. *Not cognitive decline prevention intervention*

Meinzer M, Lindenberg R, Antonenko D, et al. Anodal transcranial direct current stimulation temporarily reverses age-associated cognitive decline and functional brain activity changes. *Journal of Neuroscience*. 2013 Jul 24;33(30):12470-8. PMID 23884951. *Inadequate follow up time*

- Meinzer M, Lindenberg R, Phan MT, et al. Transcranial direct current stimulation in mild cognitive impairment: Behavioral effects and neural mechanisms. *Alzheimer's and Dementia*. 2015 01 Sep;11(9):1032-40. PMID 2015397617. *Inadequate follow up time*
- Meiron O, Lavidor M. Prefrontal oscillatory stimulation modulates access to cognitive control references in retrospective metacognitive commentary. *Clinical Neurophysiology*. 2014 Jan;125(1):77-82. PMID 23831184. *Inadequate follow up time*
- Mejia-Arango S, Zuniga-Gil C. Diabetes mellitus as a risk factor for dementia in the mexican elder population  
Diabetes mellitus como factor de riesgo de demencia en la poblacion adulta mayor mexicana. *Revista de Neurologia*. 2011;53(7):397-405. PMID 2011559427. *Not available in English*
- Melloni M, Sedeno L, Couto B, et al. Preliminary evidence about the effects of meditation on interoceptive sensitivity and social cognition. *Behavioral & Brain Functions [Electronic Resource]: BBF*. 2013;9:47. PMID 24365106. *Inadequate follow up time*
- Merchant RA, Li B, Yap KB, et al. Use of drugs with anticholinergic effects and cognitive impairment in community-living older persons. *Age & Ageing*. 2009 Jan;38(1):105-8. PMID 19008305. *Not cognitive decline prevention intervention*
- Merritt P, Stangl B, Hirshman E, et al. Administration of dehydroepiandrosterone (DHEA) increases serum levels of androgens and estrogens but does not enhance short-term memory in post-menopausal women. *Brain Research*. 2012 Nov 5;1483:54-62. PMID 22985672. *Inadequate follow up time*
- Miao YC, Tian JZ, Shi J, et al. Effects of Chinese medicine for tonifying the kidney and resolving phlegm and blood stasis in treating patients with amnesic mild cognitive impairment: a randomized, double-blind and parallel-controlled trial. *Zhong Xi Yi Jie He Xue Bao/Journal of Chinese Integrative Medicine*. 2012 Apr;10(4):390-7. PMID 22500712. *Inadequate follow up time*
- Middleton LE, Manini TM, Simonsick EM, et al. Activity energy expenditure and incident cognitive impairment in older adults. *Archives of Internal Medicine*. 2011 Jul 25;171(14):1251-7. PMID 21771893. *Cohort study with inadequate sample size*
- Miettinen PS, Jauhiainen AM, Tarkka IM, et al. Long-term response to cholinesterase inhibitor treatment is related to functional MRI response in Alzheimer's disease. *Dementia and Geriatric Cognitive Disorders*. 2015 14 Oct;40(5-6):243-55. PMID 2015348323. *Ineligible population*
- Milte CM, Sinn N, Street SJ, et al. Erythrocyte polyunsaturated fatty acid status, memory, cognition and mood in older adults with mild cognitive impairment and healthy controls.

Prostaglandins Leukotrienes & Essential Fatty Acids. 2011 May-Jun;84(5-6):153-61. PMID 21392955. *Not cognitive decline prevention intervention*

Mintzer MZ, Kleykamp BA, Griffiths RR. Dose Effects of Triazolam and Scopolamine on Metamemory. Experimental and Clinical Psychopharmacology. 2010 February;18(1):17-31. PMID 2010110883. *Inadequate follow up time*

Mishra J, de Villers-Sidani E, Merzenich M, et al. Adaptive training diminishes distractibility in aging across species. Neuron. 2014 Dec 3;84(5):1091-103. PMID 25467987. *Ineligible population*

Mishra J, Gazzaley A. Cross-species approaches to cognitive neuroplasticity research. NeuroImage. 2016;131:4-12. *Ineligible population*

Mishra J, Rolle C, Gazzaley A. Neural plasticity underlying visual perceptual learning in aging. Brain Research. 2015 Jul 1;1612:140-51. PMID 25218557. *Inadequate follow up time*

Miwa K, Tanaka M, Okazaki S, et al. Increased total homocysteine levels predict the risk of incident dementia independent of cerebral small-vessel diseases and vascular risk factors. Journal of Alzheimer's Disease. 2015 09 Oct;49(2):503-13. PMID 2015551994. *Not cognitive decline prevention intervention*

Miyoshi I, Fujimoto Y, Yamada M, et al. Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimer's disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study. International Journal of Clinical Pharmacology & Therapeutics. 2013 Dec;51(12):911-23. PMID 24131736. *Ineligible population*

Modrego PJ, Fayed N, Errea JM, et al. Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy. European Journal of Neurology. 2010 Mar;17(3):405-12. PMID 19874395. *Ineligible population*

Mohagheghi A, Arfaie A, Amiri S, et al. Preventive effect of liothyronine on electroconvulsive therapy-induced memory deficit in patients with major depressive disorder: a double-blind controlled clinical trial. BioMed Research International. 2015;2015:503918. PMID 25945337. *Ineligible population*

Mohs RC, Shiovitz TM, Tariot PN, et al. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study. American Journal of Geriatric Psychiatry. 2009 Sep;17(9):752-9. PMID 19700948. *Ineligible population*

Mokhova OI. [The use of reminyl (galantamine) in the treatment of probable vascular dementia]. Zhurnal Nevrologii i Psikhiiatrii Imeni S.S. Korsakova. 2009;109(9):77-9. PMID 19911468. *Not available in English*

Molinuevo JL, Berthier ML, Rami L. Donepezil provides greater benefits in mild compared to moderate Alzheimer's disease: implications for early diagnosis and treatment. Archives of Gerontology & Geriatrics. 2011 Jan-Feb;52(1):18-22. PMID 19948364. *Ineligible population*

Molinuevo JL, Frolich L, Grossberg GT, et al. Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch. Alzheimer's Research and Therapy. 2015 08 Mar;7(1)PMID 2015957412. *Ineligible population*

Montine TJ, Sonnen JA, Montine KS, et al. Adult changes in thought study: Dementia is an individually varying convergent syndrome with prevalent clinically silent diseases that may be modified by some commonly used therapeutics. Current Alzheimer Research. 2012 July;9(6):718-23. PMID 2012391770. *Ineligible study design*

Moon JH, Lim S, Han JW, et al. Serum 25-hydroxyvitamin D level and the risk of mild cognitive impairment and dementia: The Korean Longitudinal Study on Health and Aging (KLoSHA). Clinical Endocrinology. 2015 01 Jul;83(1):36-42. PMID 2015796039. *Cohort study with inadequate sample size*

Moon SY, Na DL, Seo SW, et al. Impact of white matter changes on activities of daily living in mild to moderate dementia. European Neurology. 2011 April;65(4):223-30. PMID 2011224387. *Ineligible population*

Moore EM, Mander AG, Ames D, et al. Increased risk of cognitive impairment in patients with diabetes is associated with metformin. Diabetes Care. 2013 October;36(10):2981-7. PMID 2014022050. *Ineligible population*

Moore EM, Mander AG, Ames D, et al. Increased risk of cognitive impairment in patients with diabetes is associated with metformin.[Erratum appears in Diabetes Care. 2013 Nov;36(11):3850]. Diabetes Care. 2013 Oct;36(10):2981-7. PMID 24009301. *Ineligible population*

Morgan GS, Gallacher J, Bayer A, et al. Physical activity in middle-age and dementia in later life: findings from a prospective cohort of men in Caerphilly, South Wales and a meta-analysis. Journal of Alzheimer's Disease. 2012;31(3):569-80. PMID 22647258. *Not cognitive decline prevention intervention*

Morillas-Ruiz JM, Rubio-Perez JM, Albaladejo MD, et al. Effect of an antioxidant drink on homocysteine levels in Alzheimer's patients. Journal of the Neurological Sciences. 2010 Dec 15;299(1-2):175-8. PMID 20850133. *Ineligible population*

Morimoto BH, Schmechel D, Hirman J, et al. A double-blind, placebo-controlled, ascending-dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment. *Dementia & Geriatric Cognitive Disorders*. 2013;35(5-6):325-36. PMID 23594991. *Inadequate follow up time*

Moro V, Condoleo MT, Valbusa V, et al. Cognitive stimulation of executive functions in mild cognitive impairment: Specific efficacy and impact in memory. *American Journal of Alzheimer's Disease and other Dementias*. 2015 25 Mar;30(2):153-64. PMID 2015867211. *Ineligible study design*

Morris MC, Tangney CC, Wang Y, et al. MIND diet slows cognitive decline with aging. *Alzheimer's and Dementia*. 2015 01 Sep;11(9):1015-22. PMID 2015186686. *Not cognitive decline prevention intervention*

Morris MC, Tangney CC, Wang Y, et al. MIND diet associated with reduced incidence of Alzheimer's disease. *Alzheimer's and Dementia*. 2015 01 Sep;11(9):1007-14. PMID 2015807456. *Not cognitive decline prevention intervention*

Moss DE, Fariello RG, Sahlmann J, et al. A randomized phase I study of methanesulfonyl fluoride, an irreversible cholinesterase inhibitor, for the treatment of Alzheimer's disease. *British Journal of Clinical Pharmacology*. 2013 May;75(5):1231-9. PMID 2013232518. *Inadequate follow up time*

Mowszowski L, Hermens DF, Diamond K, et al. Cognitive training enhances pre-attentive neurophysiological responses in older adults 'at risk' of dementia. *Journal of Alzheimer's Disease*. 2014;41(4):1095-108. PMID 24787916. *Inadequate follow up time*

Mozolic JL, Long AB, Morgan AR, et al. A cognitive training intervention improves modality-specific attention in a randomized controlled trial of healthy older adults. *Neurobiology of Aging*. 2011 Apr;32(4):655-68. PMID 19428142. *Inadequate follow up time*

Mrazek MD, Franklin MS, Phillips DT, et al. Mindfulness training improves working memory capacity and GRE performance while reducing mind wandering. *Psychological Science*. 2013 May;24(5):776-81. PMID 23538911. *Inadequate follow up time*

Muller U, Rowe JB, Rittman T, et al. Effects of modafinil on non-verbal cognition, task enjoyment and creative thinking in healthy volunteers. *Neuropharmacology*. 2013 Jan;64:490-5. PMID 22820554. *Inadequate follow up time*

Muniz R, Serra CM, Reisberg B, et al. Cognitive-motor intervention in alzheimer's disease: Long-term results from the maria wolff trial. *Journal of Alzheimer's Disease*. 2015;45(1):295-304. PMID 2015808400. *Ineligible population*

Muniza R, Serraa CM, Reisberga B, et al. Cognitive-motor intervention in Alzheimer's disease: Long-term results from the Maria Wolff trial. *Journal of Alzheimer's Disease*. 2015;45(1):295-304. PMID 2015-10451-026. *Ineligible population*

Murphy GM, Jr., Sarginson JE, Ryan HS, et al. BDNF and CREB1 genetic variants interact to affect antidepressant treatment outcomes in geriatric depression. *Pharmacogenetics and Genomics*. 2013 Jun;23(6):301-13. PMID 23619509. *Inadequate follow up time*

Musicco M. Lifestyle and rate of progression of cognitive decline: Results of the SINDEM cohort study. *Journal of Alzheimer's Disease*. 2011;23(SUPPL. 1):S17-S8. PMID 2011121429. *Not cognitive decline prevention intervention*

Musicco M, Adorni F, Di Santo S, et al. Inverse occurrence of cancer and Alzheimer disease: A population-based incidence study. *Neurology*. 2013 23 Jul;81(4):322-8. PMID 2013498921. *Not cognitive decline prevention intervention*

Na HR, Kim S, Choi SH, et al. Donepezil treatment in Alzheimer's disease patients with and without cerebrovascular lesions: a preliminary report. *Geriatrics & gerontology international*. 2011 Jan;11(1):90-7. PMID 20825496. *Ineligible population*

Nagata K, Yokoyama E, Yamazaki T, et al. Effects of yokukansan on behavioral and psychological symptoms of vascular dementia: an open-label trial. *Phytomedicine*. 2012 Apr 15;19(6):524-8. PMID 22421528. *Ineligible population*

Naismith SL, Diamond K, Carter PE, et al. Enhancing memory in late-life depression: the effects of a combined psychoeducation and cognitive training program. *American Journal of Geriatric Psychiatry*. 2011 Mar;19(3):240-8. PMID 20808114. *Inadequate follow up time*

Naismith SL, Glozier N, Burke D, et al. Early intervention for cognitive decline: is there a role for multiple medical or behavioural interventions? *Early intervention in psychiatry*. 2009 Feb;3(1):19-27. PMID 21352171. *Ineligible study design*

Nakamura Y, Kitamura S, Homma A, et al. Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer's disease: results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan. *Expert Opinion on Pharmacotherapy*. 2014 May;15(7):913-25. PMID 24673497. *Ineligible population*

Napryeyenko O, Sonnik G, Tartakovsky I. Efficacy and tolerability of Ginkgo biloba extract EGb 761 by type of dementia: analyses of a randomised controlled trial. *Journal of the Neurological Sciences*. 2009 Aug 15;283(1-2):224-9. PMID 19286192. *Ineligible population*

Naqvi R, Liberman D, Rosenberg J, et al. Preventing cognitive decline in healthy older adults. *CMAJ Canadian Medical Association Journal*. 2013 Jul 9;185(10):881-5. PMID 23589432. *Ineligible study design*

Narasimhalu K, Effendy S, Sim CH, et al. A randomized controlled trial of rivastigmine in patients with cognitive impairment no dementia because of cerebrovascular disease. *Acta Neurologica Scandinavica*. 2010 Apr;121(4):217-24. PMID 19951274. *Ineligible population*

Nardone R, Tezzon F, Holler Y, et al. Transcranial magnetic stimulation (TMS)/repetitive TMS in mild cognitive impairment and Alzheimer's disease. *Acta Neurologica Scandinavica*. 2014 Jun;129(6):351-66. PMID 24506061. *Ineligible study design*

Narendran R, Frankle WG, Mason NS, et al. Improved working memory but no effect on striatal vesicular monoamine transporter type 2 after omega-3 polyunsaturated fatty acid supplementation. *PLoS ONE [Electronic Resource]*. 2012;7(10):e46832. PMID 23056476. *No relevant outcomes reported*

Nasab NM, Bahrammi MA, Nikpour MR, et al. Efficacy of rivastigmine in comparison to ginkgo for treating Alzheimer's dementia. *JPMA - Journal of the Pakistan Medical Association*. 2012 Jul;62(7):677-80. PMID 23866514. *Ineligible population*

Nascimento CM, Teixeira CV, Gobbi LT, et al. A controlled clinical trial on the effects of exercise on neuropsychiatric disorders and instrumental activities in women with Alzheimer's disease. *Revista Brasileira de Fisioterapia*. 2012 Jun;16(3):197-204. PMID 22499405. *Ineligible population*

Nathan PJ, Watson J, Lund J, et al. The potent M1 receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction. *International Journal of Neuropsychopharmacology*. 2013 May;16(4):721-31. PMID 22932339. *Inadequate follow up time*

Nelson C, Wengreen HJ, Munger RG, et al. Dietary folate, vitamin B-12, vitamin B-6 and incident Alzheimer's disease: the cache county memory, health and aging study. *Journal of Nutrition, Health & Aging*. 2009 Dec;13(10):899-905. PMID 19924351. *Not cognitive decline prevention intervention*

Newhouse P, Albert K, Astur R, et al. Tamoxifen improves cholinergically modulated cognitive performance in postmenopausal women. *Neuropsychopharmacology*. 2013 Dec;38(13):2632-43. PMID 23867982. *Inadequate follow up time*

Newhouse PA, Dumas J, Wilkins H, et al. Estrogen treatment impairs cognitive performance after psychosocial stress and monoamine depletion in postmenopausal women. *Menopause*. 2010 Jul;17(4):860-73. PMID 20616673. *Inadequate follow up time*



Neznamov GG, Teleshova ES. Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin. *Neuroscience & Behavioral Physiology*. 2009 Mar;39(3):311-21. PMID 19234797. *Inadequate follow up time*

Ng TP, Feng L, Yap KB, et al. Long-term metformin usage and cognitive function among older adults with diabetes. *Journal of Alzheimer's Disease*. 2014;41(1):61-8. PMID 24577463. *Cohort study with inadequate sample size*

Ngandu T, Lehtisalo J, Levalahti E, et al. Recruitment and baseline characteristics of participants in the finnish geriatric intervention study to prevent cognitive impairment and disability (FINGER)-A randomized controlled lifestyle trial. *International Journal of Environmental Research and Public Health*. 2014 10 Sep;11(9):9345-60. PMID 2014842635. *Ineligible population*

Nho K, Kim S, Risacher SL, et al. Protective variant for hippocampal atrophy identified by whole exome sequencing. *Annals of Neurology*. 2015 Mar;77(3):547-52. PMID 2015-07189-001. *Not cognitive decline prevention intervention*

Nilsson A, Radeborg K, Salo I, et al. Effects of supplementation with n-3 polyunsaturated fatty acids on cognitive performance and cardiometabolic risk markers in healthy 51 to 72 years old subjects: a randomized controlled cross-over study. *Nutrition Journal*. 2012;11:99. PMID 23173831. *Inadequate follow up time*

Nishiguchi S, Yamada M, Tanigawa T, et al. A 12-Week Physical and Cognitive Exercise Program Can Improve Cognitive Function and Neural Efficiency in Community-Dwelling Older Adults: A Randomized Controlled Trial. *Journal of the American Geriatrics Society*. 2015 Jul;63(7):1355-63. PMID 26114906. *Inadequate follow up time*

Noguchi-Shinohara M, Yuki S, Dohmoto C, et al. Consumption of green tea, but not black tea or coffee, is associated with reduced risk of cognitive decline. *PLoS ONE*. 2014 14 May;9(5)PMID 2014356288. *Cohort study with inadequate sample size*

Nolan JM, Loskutova E, Howard A, et al. The impact of supplemental macular carotenoids in Alzheimer's disease: a randomized clinical trial. *Journal of Alzheimer's Disease*. 2015;44(4):1157-69. PMID 25408222. *Ineligible population*

Nordberg A, Kadir A, Andreasen N, et al. Correlations between Alzheimer's Disease Cerebrospinal Fluid Biomarkers and Cerebral Glucose Metabolism after 12 Months of Phenserine Treatment. *Journal of Alzheimer's Disease*. 2015 03 Aug;47(3):691-704. PMID 2015255626. *Ineligible population*

Norton MC, Clark CJ, Tschanz JT, et al. The design and progress of a multidomain lifestyle intervention to improve brain health in middle-aged persons to reduce later Alzheimer's disease risk: The Gray Matters randomized trial. *Alzheimer's and Dementia: Translational Research and Clinical Interventions*. 2015 14 Oct;1(1):53-62. PMID 2015440968. *Ineligible study design*

Norton MC, Dew J, Smith H, et al. Lifestyle behavior pattern is associated with different levels of risk for incident dementia and Alzheimer's disease: the Cache County study. *Journal of the American Geriatrics Society*. 2012 Mar;60(3):405-12. PMID 22316091. *Not cognitive decline prevention intervention*

Nouchi R, Taki Y, Takeuchi H, et al. Brain training game improves executive functions and processing speed in the elderly: a randomized controlled trial. *PLoS ONE [Electronic Resource]*. 2012;7(1):e29676. PMID 22253758. *Inadequate follow up time*

Nouchi R, Taki Y, Takeuchi H, et al. Four weeks of combination exercise training improved executive functions, episodic memory, and processing speed in healthy elderly people: evidence from a randomized controlled trial. *Age*. 2014 Apr;36(2):787-99. PMID 24065294. *Inadequate follow up time*

Novak V, Milberg W, Hao Y, et al. Enhancement of vasoreactivity and cognition by intranasal insulin in type 2 diabetes. *Diabetes Care*. 2014;37(3):751-9. PMID 24101698. *Inadequate follow up time*

Nozawa M, Ichimiya Y, Nozawa E, et al. Clinical effects of high oral dose of donepezil for patients with Alzheimer's disease in Japan. *Psychogeriatrics: The Official Journal of the Japanese Psychogeriatric Society*. 2009 Jun;9(2):50-5. PMID 19604325. *Ineligible population*

Nunes MA, Viel TA, Buck HS. Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer's disease. *Current Alzheimer Research*. 2013;10(1):104-7. PMID 2013746091. *Ineligible population*

O'Callaghan N, Parletta N, Milte CM, et al. Telomere shortening in elderly individuals with mild cognitive impairment may be attenuated with omega-3 fatty acid supplementation: a randomized controlled pilot study. *Nutrition*. 2014 Apr;30(4):489-91. PMID 24342530. *No relevant outcomes reported*

Oehrich D, Berthelot DJ, Gijzen HJ. gamma-Secretase modulators as potential disease modifying anti-Alzheimer's drugs. *Journal of Medicinal Chemistry*. 2011 Feb 10;54(3):669-98. PMID 21141968. *Ineligible study design*

Oei NY, Tollenaar MS, Elzinga BM, et al. Propranolol reduces emotional distraction in working memory: a partial mediating role of propranolol-induced cortisol increases?

Neurobiology of Learning & Memory. 2010 Mar;93(3):388-95. PMID 20018249.  
*Inadequate follow up time*

Ogunniyi A, Gao S, Unverzagt FW, et al. Weight loss and incident dementia in elderly Yoruba Nigerians: a 10-year follow-up study. International Psychogeriatrics. 2011 Apr;23(3):387-94. PMID 20735893. *Ineligible population*

Ohara T, Ninomiya T, Kubo M, et al. Apolipoprotein genotype for prediction of Alzheimer's disease in older Japanese: the Hisayama Study. Journal of the American Geriatrics Society. 2011 Jun;59(6):1074-9. PMID 21649613. *Not cognitive decline prevention intervention*

O'Hare AM, Walker R, Haneuse S, et al. Relationship between longitudinal measures of renal function and onset of dementia in a community cohort of older adults. Journal of the American Geriatrics Society. 2012 December;60(12):2215-22. PMID 2012730823. *Not cognitive decline prevention intervention*

Ohnishi T, Sakiyama Y, Okuri Y, et al. The prediction of response to galantamine treatment in patients with mild to moderate Alzheimer's disease. Current Alzheimer Research. 2014 Feb;11(2):110-8. PMID 24156269. *Ineligible population*

Okereke OI, Kurth T, Pollak MN, et al. Fasting plasma insulin, C-peptide and cognitive change in older men without diabetes: results from the Physicians' Health Study II. Neuroepidemiology. 2010;34(4):200-7. PMID 20197703. *Not cognitive decline prevention intervention*

Okereke OI, Rosner BA, Kim DH, et al. Dietary fat types and 4-year cognitive change in community-dwelling older women.[Erratum appears in Ann Neurol. 2012 Oct;72(4):627]. Annals of Neurology. 2012 Jul;72(1):124-34. PMID 22605573. *Ineligible study design*

Okonkwo OC, Schultz SA, Oh JM, et al. Physical activity attenuates age-related biomarker alterations in preclinical AD. Neurology. 2014 04 Nov;83(19):1753-60. PMID 25298312. *Cohort study with inadequate sample size*

Okonkwo OC, Xu G, Dowling NM, et al. Family history of Alzheimer disease predicts hippocampal atrophy in healthy middle-aged adults. Neurology. 2012 May 29;78(22):1769-76. PMID 22592366. *Not cognitive decline prevention intervention*

Olchik MR, Farina J, Steibel N, et al. Memory training (MT) in mild cognitive impairment (MCI) generates change in cognitive performance. Archives of Gerontology & Geriatrics. 2013 May-Jun;56(3):442-7. PMID 23260332. *Inadequate follow up time*

Olde Rikkert MG, Verhey FR, Blesa R, et al. Tolerability and safety of Souvenaid in patients with mild Alzheimer's disease: results of multi-center, 24-week, open-label

extension study. *Journal of Alzheimer's Disease*. 2015;44(2):471-80. PMID 25322923.  
*Ineligible population*

Olde Rikkert MG, Verhey FR, Sijben JW, et al. Differences in nutritional status between very mild Alzheimer's disease patients and healthy controls. *Journal of Alzheimer's Disease*. 2014;41(1):261-71. PMID 24614903. *Not cognitive decline prevention intervention*

Olin JT, Bhatnagar V, Reyes P, et al. Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32). *International Journal of Geriatric Psychiatry*. 2010 Apr;25(4):419-26. PMID 19670390. *Ineligible population*

Onur OA, Schlaepfer TE, Kukolja J, et al. The N-Methyl-D-Aspartate Receptor Co-agonist D-Cycloserine Facilitates Declarative Learning and Hippocampal Activity in Humans. *Biological Psychiatry*. 2010 15 Jun;67(12):1205-11. PMID 2010302403.  
*Inadequate follow up time*

Optale G, Urgesi C, Busato V, et al. Controlling memory impairment in elderly adults using virtual reality memory training: a randomized controlled pilot study. *Neurorehabilitation & Neural Repair*. 2010 May;24(4):348-57. PMID 19934445.  
*Ineligible population*

Orgeta V, Leung P, Yates L, et al. Individual cognitive stimulation therapy for dementia: A clinical effectiveness and cost-effectiveness pragmatic, multicentre, randomised controlled trial. *Health Technology Assessment*. 2015 01 Aug;19(64):7-73. PMID 2015323100. *Ineligible population*

Ormstad H, Rosness TA, Bergem ALM, et al. Alcohol consumption in the elderly and risk of dementia related death - A Norwegian prospective study with a 17-year follow-up. *International Journal of Neuroscience*. 2016 01 Feb;126(2):135-44. PMID 2015246336.  
*No relevant outcomes reported*

Orrell M, Aguirre E, Spector A, et al. Maintenance cognitive stimulation therapy for dementia: single-blind, multicentre, pragmatic randomised controlled trial. *British Journal of Psychiatry*. 2014 Jun;204(6):454-61. PMID 24676963. *Ineligible population*

Ostrowitzki S, Deptula D, Thurfjell L, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. *Archives of Neurology*. 2012 Feb;69(2):198-207. PMID 21987394. *Ineligible population*

Otilingam PG, Gatz M, Tello E, et al. Buenos habitos alimenticios para una buena salud : evaluation of a nutrition education program to improve heart health and brain health in Latinas. *Journal of Aging & Health*. 2015 Feb;27(1):177-92. PMID 25231884.  
*Inadequate follow up time*

- Owen AM, Hampshire A, Grahn JA, et al. Putting brain training to the test. *Nature*. 2010 Jun 10;465(7299):775-8. PMID 20407435. *Inadequate follow up time*
- Owen L, Scholey A, Finnegan Y, et al. Response variability to glucose facilitation of cognitive enhancement. *British Journal of Nutrition*. 2013 Nov;110(10):1873-84. PMID 23789911. *Inadequate follow up time*
- Ozawa M, Ninomiya T, Ohara T, et al. Dietary patterns and risk of dementia in an elderly Japanese population: the Hisayama Study. *American Journal of Clinical Nutrition*. 2013 May;97(5):1076-82. PMID 23553168. *Not cognitive decline prevention intervention*
- Ozawa M, Ninomiya T, Ohara T, et al. Self-reported dietary intake of potassium, calcium, and magnesium and risk of dementia in the Japanese: the Hisayama Study. *Journal of the American Geriatrics Society*. 2012 Aug;60(8):1515-20. PMID 22860881. *Not cognitive decline prevention intervention*
- Ozawa M, Ohara T, Ninomiya T, et al. Milk and dairy consumption and risk of dementia in an elderly Japanese population: the Hisayama Study. *Journal of the American Geriatrics Society*. 2014 Jul;62(7):1224-30. PMID 24916840. *Not cognitive decline prevention intervention*
- Packard CJ, Westendorp RG, Stott DJ, et al. Association between apolipoprotein E4 and cognitive decline in elderly adults. *Journal of the American Geriatrics Society*. 2007 Nov;55(11):1777-85. PMID 17979899. *Not cognitive decline prevention intervention*
- Paganini-Hill A. Hypertension and dementia in the elderly: The leisure world cohort study. *International Journal of Hypertension*. 2012;2012 (no pagination)(205350)PMID 2012644430. *Not cognitive decline prevention intervention*
- Paganini-Hill A, White SC, Atchison KA. Dentition, dental health habits, and dementia: the Leisure World Cohort Study. *Journal of the American Geriatrics Society*. 2012 Aug;60(8):1556-63. PMID 22860988. *Not cognitive decline prevention intervention*
- Page KA, Williamson A, Yu N, et al. Medium-chain fatty acids improve cognitive function in intensively treated type 1 diabetic patients and support in vitro synaptic transmission during acute hypoglycemia. *Diabetes*. 2009 May;58(5):1237-44. PMID 19223595. *Inadequate follow up time*
- Pai MC, Aref H, Bassil N, et al. Real-world evaluation of compliance and preference in Alzheimer's disease treatment. *Clinical Interventions in Aging*. 2015 03 Nov;10:1779-88. PMID 2015508490. *No relevant outcomes reported*

Paillard-Borg S, Fratiglioni L, Xu W, et al. An active lifestyle postpones dementia onset by more than one year in very old adults. *Journal of Alzheimer's Disease*. 2012;31(4):835-42. PMID 22751170. *Not cognitive decline prevention intervention*

Pakdaman H, Harandi AA, Hatamian H, et al. Effectiveness and safety of MLC601 in the treatment of mild to moderate Alzheimer's disease: A multicenter, randomized controlled trial. *Dementia and Geriatric Cognitive Disorders Extra*. 2015;5(1):96-106. PMID 2015140253. *Ineligible population*

Palinkas LA, Reedy KR, Shepanek M, et al. A randomized placebo-controlled clinical trial of the effectiveness of thyroxine and triiodothyronine and short-term exposure to bright light in prevention of decrements in cognitive performance and mood during prolonged Antarctic residence. *Clinical Endocrinology*. 2010 Apr;72(4):543-50. PMID 19650782. *Inadequate follow up time*

Panza F, Frisardi V, Seripa D, et al. Alcohol consumption in mild cognitive impairment and dementia: harmful or neuroprotective? *International Journal of Geriatric Psychiatry*. 2012 Dec;27(12):1218-38. PMID 22396249. *Ineligible study design*

Panza F, Solfrizzi V, Barulli MR, et al. Coffee, tea, and caffeine consumption and prevention of late-life cognitive decline and dementia: a systematic review. *Journal of Nutrition, Health & Aging*. 2015 Mar;19(3):313-28. PMID 25732217. *Ineligible study design*

Parikh NM, Morgan RO, Kunik ME, et al. Risk factors for dementia in patients over 65 with diabetes. *International Journal of Geriatric Psychiatry*. 2011 July;26(7):749-57. PMID 2011213017. *Not cognitive decline prevention intervention*

Park SH, Seo JH, Kim YH, et al. Long-term effects of transcranial direct current stimulation combined with computer-assisted cognitive training in healthy older adults. *Neuroreport*. 2014 Jan 22;25(2):122-6. PMID 24176927. *Inadequate follow up time*

Park SK, Jung IC, Lee WK, et al. A combination of green tea extract and l-theanine improves memory and attention in subjects with mild cognitive impairment: a double-blind placebo-controlled study. *Journal of Medicinal Food*. 2011 Apr;14(4):334-43. PMID 21303262. *Inadequate follow up time*

Parnetti L, Chiasserini D, Andreasson U, et al. Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease. *Acta Neurologica Scandinavica*. 2011 Aug;124(2):122-9. PMID 20880294. *Ineligible population*

Pasqualetti P, Bonomini C, Dal Forno G, et al. A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer's disease. *Aging-Clinical & Experimental Research*. 2009 Apr;21(2):102-10. PMID 19448381. *Ineligible population*

Patat A, Parks V, Raje S, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple doses of lecozotan in healthy young and elderly subjects. *British Journal of Clinical Pharmacology*. 2009 Mar;67(3):299-308. PMID 19523013. *Inadequate follow up time*

Pathan SS, Gottesman RF, Mosley TH, et al. Association of lung function with cognitive decline and dementia: the Atherosclerosis Risk in Communities (ARIC) Study. *European Journal of Neurology*. 2011 Jun;18(6):888-98. PMID 21244584. *Not cognitive decline prevention intervention*

Peneau S, Galan P, Jeandel C, et al. Fruit and vegetable intake and cognitive function in the SU.VI.MAX 2 prospective study. *American Journal of Clinical Nutrition*. 2011 Nov;94(5):1295-303. PMID 21955649. *No relevant outcomes reported*

Peng J, Lu F, Wang Z, et al. Excessive lowering of blood pressure is not beneficial for progression of brain white matter hyperintensive and cognitive impairment in elderly hypertensive patients: 4-year follow-up study. *Journal of the American Medical Directors Association*. 2014 Dec;15(12):904-10. PMID 25239015. *Cohort study with inadequate sample size*

Peng YH, Wu BR, Su CH, et al. Adult asthma increases dementia risk: a nationwide cohort study. *Journal of Epidemiology & Community Health*. 2015 Feb;69(2):123-8. PMID 25271249. *Not cognitive decline prevention intervention*

Pengelly A, Snow J, Mills SY, et al. Short-term study on the effects of rosemary on cognitive function in an elderly population. *Journal of Medicinal Food*. 2012 Jan;15(1):10-7. PMID 21877951. *Inadequate follow up time*

Peretz C, Korczyn AD, Shatil E, et al. Computer-based, personalized cognitive training versus classical computer games: a randomized double-blind prospective trial of cognitive stimulation. *Neuroepidemiology*. 2011;36(2):91-9. PMID 21311196. *Inadequate follow up time*

Perez L, Heim L, Sherzai A, et al. Nutrition and vascular dementia. *Journal of Nutrition, Health & Aging*. 2012 Apr;16(4):319-24. PMID 22499449. *Ineligible study design*

Perkins KA, Karelitz JL, Jao NC, et al. Effects of bupropion on cognitive performance during initial tobacco abstinence. *Drug & Alcohol Dependence*. 2013 Nov 1;133(1):283-6. PMID 23726977. *Inadequate follow up time*

Persson CM, Wallin AK, Levander S, et al. Changes in cognitive domains during three years in patients with Alzheimer's disease treated with donepezil. *BMC Neurology*. 2009;9:7. PMID 19208247. *Ineligible population*

Persson N, Viitanen M, Almkvist O, et al. A principal component model of medical health: implications for cognitive deficits and decline among adults in a population-based sample. *Journal of Health Psychology*. 2013 Oct;18(10):1268-87. PMID 23180878. *Ineligible study design*

Peters O. [Alzheimer's disease: are non-steroidal anti-inflammatory drugs effective?]. *Deutsche Medizinische Wochenschrift*. 2012 Dec;137(50):2627. PMID 23225182. *Not available in English*

Peters R, Beckett N, Fagard R, et al. Increased pulse pressure linked to dementia: further results from the Hypertension in the Very Elderly Trial - HYVET. *Journal of Hypertension*. 2013 Sep;31(9):1868-75. PMID 23743809. *Ineligible study design*

Phung KTT, Waldorff FB, Buss DV, et al. A three-year follow-up on the efficacy of psychosocial interventions for patients with mild dementia and their caregivers: The multicentre, rater-blinded, randomised Danish Alzheimer Intervention Study (DAISY). *BMJ Open*. 2013;3(11)PMID 2013772352. *Ineligible population*

Pietrzak RH, Lim YY, Ames D, et al. Trajectories of memory decline in preclinical Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of ageing. *Neurobiology of Aging*. 2015 Mar;36(3):1231-8. PMID 25585532. *Not cognitive decline prevention intervention*

Piette F, Belmin J, Vincent H, et al. Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: A randomised, placebo-controlled phase 2 trial. *Alzheimer's Research and Therapy*. 2011;3(2)PMID 2011300018. *Ineligible population*

Pilatus U, Lais C, Rochmont Adu M, et al. Conversion to dementia in mild cognitive impairment is associated with decline of N-acetylaspartate and creatine as revealed by magnetic resonance spectroscopy. *Psychiatry Research*. 2009 Jul 15;173(1):1-7. PMID 19427767. *Cohort study with inadequate sample size*

Pitkala KH, Poysti MM, Laakkonen ML, et al. Effects of the Finnish Alzheimer disease exercise trial (FINALEX): a randomized controlled trial. *JAMA Internal Medicine*. 2013 May 27;173(10):894-901. PMID 23589097. *Ineligible population*

Pitkala KH, Raivio MM, Laakkonen ML, et al. Exercise rehabilitation on home-dwelling patients with Alzheimer disease: A randomized, controlled trial. Baseline findings and feasibility. *European Geriatric Medicine*. 2011 December;2(6):338-43. PMID 2011616075. *Ineligible population*

Pitkala KH, Routasalo P, Kautiainen H, et al. Effects of socially stimulating group intervention on lonely, older people's cognition: a randomized, controlled trial. *American Journal of Geriatric Psychiatry*. 2011 Jul;19(7):654-63. PMID 21709611. *Ineligible population*



Plassman BL, Williams JW, Jr., Burke JR, et al. Systematic review: factors associated with risk for and possible prevention of cognitive decline in later life. *Annals of Internal Medicine*. 2010 Aug 3;153(3):182-93. PMID 20547887. *Ineligible study design*

Plastino M, Fava A, Pirritano D, et al. Effects of insulinic therapy on cognitive impairment in patients with Alzheimer disease and diabetes mellitus type-2. *Journal of the Neurological Sciences*. 2010 Jan 15;288(1-2):112-6. PMID 19836029. *Ineligible population*

Polito L, Abbondanza S, Vaccaro R, et al. Cognitive stimulation in cognitively impaired individuals and cognitively healthy individuals with a family history of dementia: Short-term results from the "allena-Mente" randomized controlled trial. *International Journal of Geriatric Psychiatry*. 2015 01 Jun;30(6):631-8. PMID 2015029633. *Inadequate follow up time*

Poly C, Massaro JM, Seshadri S, et al. The relation of dietary choline to cognitive performance and white-matter hyperintensity in the Framingham Offspring Cohort. *American Journal of Clinical Nutrition*. 2011 Dec;94(6):1584-91. PMID 22071706. *No relevant outcomes reported*

Popa MA, Reynolds SL, Small BJ. Is the effect of reported physical activity on disability mediated by cognitive performance in white and african american older adults? *Journals of Gerontology Series B-Psychological Sciences & Social Sciences*. 2009 Jan;64(1):4-13. PMID 19196688. *No relevant outcomes reported*

Postuma RB, Gagnon JF, Vendette M, et al. Idiopathic REM sleep behavior disorder in the transition to degenerative disease. *Movement Disorders*. 2009 Nov 15;24(15):2225-32. PMID 19768814. *Cohort study with inadequate sample size*

Potter AS, Ryan KK, Newhouse PA. Effects of acute ultra-low dose mecamylamine on cognition in adult attention-deficit/hyperactivity disorder (ADHD). *Human Psychopharmacology*. 2009 Jun;24(4):309-17. PMID 19475630. *Inadequate follow up time*

Power BD, Alfonso H, Flicker L, et al. Body adiposity in later life and the incidence of dementia: The health in men study. *PLoS ONE*. 2011;6 (3) (no pagination)(e17902)PMID 2011168273. *Not cognitive decline prevention intervention*

Pratt SI, Mueser KT, Bartels SJ, et al. The impact of skills training on cognitive functioning in older people with serious mental illness. *American Journal of Geriatric Psychiatry*. 2013 Mar;21(3):242-50. PMID 23395191. *Ineligible population*

Pregelj P. Safety and tolerability of rivastigmine transdermal patch formulation in newly diagnosed patients with Alzheimer's dementia in naturalistic conditions.

- Psychogeriatrics: The Official Journal of the Japanese Psychogeriatric Society. 2012 Sep;12(3):165-71. PMID 22994614. *Ineligible population*
- Pressman P, Gottfried JA. Journal Club: A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. *Neurology*. 2012 24 Jul;79(4):e33-e6. PMID 2012534317. *Ineligible population*
- Pribis P, Bailey RN, Russell AA, et al. Effects of walnut consumption on cognitive performance in young adults. *British Journal of Nutrition*. 2012 May;107(9):1393-401. PMID 21923981. *Inadequate follow up time*
- Puustinen J, Nurminen J, Lopponen M, et al. Use of CNS medications and cognitive decline in the aged: a longitudinal population-based study. *BMC Geriatrics*. 2011;11:70. PMID 22044595. *No relevant outcomes reported*
- Qin B, Adair LS, Plassman BL, et al. Dietary Patterns and Cognitive Decline among Chinese Older Adults. *Epidemiology*. 2015 25 Sep;26(5):758-68. PMID 2015328540. *Ineligible study design*
- Qin B, Plassman BL, Edwards LJ, et al. Fish intake is associated with slower cognitive decline in Chinese older adults. *Journal of Nutrition*. 2014 Oct;144(10):1579-85. PMID 25080536. *Ineligible study design*
- Qiu C, Winblad B, Fratiglioni L. Low diastolic pressure and risk of dementia in very old people: a longitudinal study. *Dementia & Geriatric Cognitive Disorders*. 2009;28(3):213-9. PMID 19752556. *Cohort study with inadequate sample size*
- Quinn JF, Raman R, Thomas RG, et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. *JAMA*. 2010 Nov 3;304(17):1903-11. PMID 21045096. *Ineligible population*
- Raabe RD, Burr RB, Short R. One-year cognitive outcomes associated with carotid artery stent placement. *Journal of Vascular & Interventional Radiology*. 2010 Jul;21(7):983-8; quiz 9. PMID 20537561. *Ineligible study design*
- Radaideh GA, Choueiry P, Ismail A, et al. Eprosartan-based hypertension therapy, systolic arterial blood pressure and cognitive function: analysis of Middle East data from the OSCAR study. *Vascular Health & Risk Management*. 2011;7:491-5. PMID 21915165. *Cohort study with inadequate sample size*
- Rahe J, Liesk J, Rosen JB, et al. Sex differences in cognitive training effects of patients with amnesic mild cognitive impairment. *Aging, Neuropsychology, and Cognition*. 2015 Sep;22(5):620-38. PMID 2015-26603-007. *Ineligible study design*

Rahe J, Petrelli A, Kaesberg S, et al. Effects of cognitive training with additional physical activity compared to pure cognitive training in healthy older adults. *Clinical Interventions In Aging*. 2015;10:297-310. PMID 25632227. *Cohort study with inadequate sample size*

Rainer M, Wuschitz A, Jagsch C, et al. Memantine in moderate to severe Alzheimer's disease: an observational post-marketing study. *Journal of Neural Transmission*. 2011 Aug;118(8):1255-9. PMID 21461744. *Cohort study with inadequate sample size*

Ramirez A, Wolfsgruber S, Lange C, et al. Elevated HbA1c is associated with increased risk of incident dementia in primary care patients. *Journal of Alzheimer's Disease*. 2015;44(4):1203-12. PMID 25524954. *Ineligible study design*

Rantanen KK, Strandberg AY, Pitkala K, et al. Cholesterol in midlife increases the risk of Alzheimer's disease during an up to 43-year follow-up. *European Geriatric Medicine*. 2014 01 Dec;5(6):390-3. PMID 2015641416. *Ineligible study design*

Ravona-Springer R, Beeri MS, Goldbourt U. Repetitive thinking as a psychological cognitive style in midlife is associated with lower risk for dementia three decades later. *Dementia & Geriatric Cognitive Disorders*. 2009;28(6):513-20. PMID 19996596. *Ineligible study design*

Ravona-Springer R, Beeri MS, Goldbourt U. Exposure to the Holocaust and World War II concentration camps during late adolescence and adulthood is not associated with increased risk for dementia at old age. *Journal of Alzheimer's Disease*. 2011;23(4):709-16. PMID 21157030. *Ineligible study design*

Ravona-Springer R, Beeri MS, Goldbourt U. Satisfaction with current status at work and lack of motivation to improve it during midlife is associated with increased risk for dementia in subjects who survived thirty-seven years later. *Journal of Alzheimer's Disease*. 2013;36(4):769-80. PMID 23703153. *Ineligible study design*

Razay G, Williams J, King E, et al. Blood pressure, dementia and Alzheimer's disease: the OPTIMA longitudinal study. *Dementia & Geriatric Cognitive Disorders*. 2009;28(1):70-4. PMID 19648748. *Cohort study with inadequate sample size*

Redick TS, Shipstead Z, Harrison TL, et al. No evidence of intelligence improvement after working memory training: a randomized, placebo-controlled study. *Journal of Experimental Psychology: General*. 2013 May;142(2):359-79. PMID 22708717. *Inadequate follow up time*

Reiner M, Niermann C, Jekauc D, et al. Long-term health benefits of physical activity--a systematic review of longitudinal studies. *BMC Public Health*. 2013;13:813. PMID 24010994. *Ineligible study design*

Reitz C, Tang MX, Miller J, et al. Plasma homocysteine and risk of mild cognitive impairment. *Dementia and Geriatric Cognitive Disorders*. 2009 February;27(1):11-7. PMID 2009076033. *Ineligible study design*

Reitz C, Tang MX, Schupf N, et al. Association of higher levels of high-density lipoprotein cholesterol in elderly individuals and lower risk of late-onset Alzheimer disease. *Archives of Neurology*. 2010 Dec;67(12):1491-7. PMID 21149810. *Ineligible population*

Relkin NR, Szabo P, Adamiak B, et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. *Neurobiology of Aging*. 2009 November;30(11):1728-36. PMID 2009480127. *Ineligible population*

Remington R, Bechtel C, Larsen D, et al. A Phase II Randomized Clinical Trial of a Nutritional Formulation for Cognition and Mood in Alzheimer's Disease. *Journal of Alzheimer's Disease*. 2015;45(2):395-405. PMID 2015856032. *Ineligible population*

Remington R, Chan A, Paskavitz J, et al. Efficacy of a vitamin/nutriceutical formulation for moderate-stage to later-stage Alzheimer's disease: a placebo-controlled pilot study. *American Journal of Alzheimer's Disease & Other Dementias*. 2009 Feb-Mar;24(1):27-33. PMID 19056706. *Ineligible population*

Reppermund S, Brodaty H, Crawford JD, et al. Impairment in instrumental activities of daily living with high cognitive demand is an early marker of mild cognitive impairment: the Sydney memory and ageing study. *Psychological Medicine*. 2013 Nov;43(11):2437-45. PMID 23308393. *Ineligible study design*

Ribeiro Salomon AL, Carvalho Garbi Novaes MR. Outcomes of enteral nutrition for patients with advanced dementia - A systematic review. *Journal of Nutrition, Health and Aging*. 2015;19(2):169-77. PMID 2014834627. *Ineligible population*

Ribeiro Salomon AL, Carvalho Garbi Novaes MR. Outcomes of enteral nutrition for patients with advanced dementia: a systematic review. *Journal of Nutrition, Health & Aging*. 2015 Feb;19(2):169-77. PMID 25651442. *Ineligible population*

Richard E, Gouw AA, Scheltens P, et al. Vascular care in patients with Alzheimer disease with cerebrovascular lesions slows progression of white matter lesions on MRI: The evaluation of vascular care in Alzheimer's disease (EVA) study. *Stroke*. 2010 March;41(3):554-6. PMID 2010142301. *Ineligible population*

Richard E, Jongstra S, Soininen H, et al. Healthy Ageing Through Internet Counselling in the Elderly: The HATICE randomised controlled trial for the prevention of cardiovascular disease and cognitive impairment. *BMJ Open*. 2016 01 Jun;6 (6) (no pagination)(987) PMID 610788580. *Ineligible study design*

Richard E, Kuiper R, Dijkgraaf MG, et al. Vascular care in patients with Alzheimer's disease with cerebrovascular lesions-a randomized clinical trial. *Journal of the American Geriatrics Society*. 2009 May;57(5):797-805. PMID 19484836. *Ineligible population*

Richard E, Van den Heuvel E, Moll van Charante EP, et al. Prevention of dementia by intensive vascular care (PreDIVA): a cluster-randomized trial in progress. *Alzheimer Disease & Associated Disorders*. 2009 Jul-Sep;23(3):198-204. PMID 19812459. *Inadequate follow up time*

Richardson K, Schoen M, French B, et al. Statins and cognitive function: a systematic review. *Annals of Internal Medicine*. 2013 Nov 19;159(10):688-97. PMID 24247674. *Ineligible study design*

Richarz U, Gaudig M, Rettig K, et al. Galantamine treatment in outpatients with mild Alzheimer's disease. *Acta Neurologica Scandinavica*. 2014 Jun;129(6):382-92. PMID 24461047. *Ineligible population*

Richmond LL, Morrison AB, Chein JM, et al. Working memory training and transfer in older adults. *Psychology & Aging*. 2011 Dec;26(4):813-22. PMID 21707176. *Inadequate follow up time*

Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *New England Journal of Medicine*. 2008 Nov 20;359(21):2195-207. PMID 18997196. *No relevant outcomes reported*

Riepe M, Weinman J, Osae-Larbi J, et al. Factors Associated with Greater Adherence to and Satisfaction with Transdermal Rivastigmine in Patients with Alzheimer's Disease and Their Caregivers. *Dementia and Geriatric Cognitive Disorders*. 2015 22 Jul;40(1-2):107-19. PMID 2015125853. *Ineligible population*

Rijpma A, Meulenbroek O, Van Hees AMJ, et al. Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease. *Alzheimer's Research and Therapy*. 2015 24 Jul;7(1) PMID 2015224044. *Ineligible population*

Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. *Lancet Neurology*. 2010 Apr;9(4):363-72. PMID 20189881. *Ineligible population*

Rist PM, Capistrant BD, Wu Q, et al. Dementia and dependence: do modifiable risk factors delay disability? *Neurology*. 2014 Apr 29;82(17):1543-50. PMID 24682970. *Ineligible study design*

- Ritchie K, Ancelin ML, Amieva H, et al. The association between caffeine and cognitive decline: examining alternative causal hypotheses. *International Psychogeriatrics*. 2014 Apr;26(4):581-90. PMID 24423697. *Ineligible study design*
- Ritchie K, Carriere I, Ritchie CW, et al. Designing prevention programmes to reduce incidence of dementia: prospective cohort study of modifiable risk factors. *BMJ*. 2010;341:c3885. PMID 20688841. *Ineligible study design*
- Ritchie LJ. Identifying mild cognitive impairment in older adults. *Dissertation Abstracts International: Section B: The Sciences and Engineering*. 2010;71(6-B):3945. PMID Dissertation Abstract: 2010-99240-330. *Ineligible study design*
- Roberts RO, Geda YE, Cerhan JR, et al. Vegetables, unsaturated fats, moderate alcohol intake, and mild cognitive impairment. *Dementia & Geriatric Cognitive Disorders*. 2010;29(5):413-23. PMID 20502015. *Ineligible study design*
- Roberts RO, Geda YE, Knopman DS, et al. Cardiac disease associated with increased risk of nonamnesic cognitive impairment. *JAMA Neurology*. 2013 March;70(3):374-82. PMID 2013161568. *Ineligible study design*
- Roberts RO, Roberts LA, Geda YE, et al. Relative intake of macronutrients impacts risk of mild cognitive impairment or dementia. *Journal of Alzheimer's Disease*. 2012;32(2):329-39. PMID 22810099. *Ineligible study design*
- Rockwood K, Fay S, Gorman M. The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease. *International Journal of Geriatric Psychiatry*. 2010 Feb;25(2):191-201. PMID 19548273. *Ineligible population*
- Rockwood K, Kirkland S, Hogan DB, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. *Archives of Neurology*. 2002 Feb;59(2):223-7. PMID 11843693. *Ineligible study design*
- Rodriguez-Sanchez E, Criado-Gutierrez JM, Mora-Simon S, et al. Physical activity program for patients with dementia and their relative caregivers: randomized clinical trial in Primary Health Care (AFISDEMyF study). *BMC Neurology*. 2014;14:63. PMID 24684948. *Ineligible population*
- Rojas G, Bartoloni L, Serrano C, et al. Naturalist observational study on effectiveness of drug treatment of a cohort of patients with Alzheimer type dementia. [Spanish] Estudio observacional naturalistico sobre la efectividad del tratamiento farmacologico en una cohorte de pacientes con demencia tipo Alzheimer. *Neurologia Argentina*. 2010;2(1):21-8. PMID 2010675945. *Ineligible population*
- Rondeau V, Jacqmin-Gadda H, Commenges D, et al. Aluminum and silica in drinking water and the risk of Alzheimer's disease or cognitive decline: findings from 15-year

follow-up of the PAQUID cohort. *American Journal of Epidemiology*. 2009 Feb 15;169(4):489-96. PMID 19064650. *Ineligible study design*

Ronnemaa E, Zethelius B, Sundelof J, et al. Glucose metabolism and the risk of Alzheimer's disease and dementia: a population-based 12 year follow-up study in 71-year-old men. *Diabetologia*. 2009 Aug;52(8):1504-10. PMID 19455303. *Ineligible study design*

Ronnemaa E, Zethelius B, Vessby B, et al. Serum fatty-acid composition and the risk of Alzheimer's disease: a longitudinal population-based study. *European Journal of Clinical Nutrition*. 2012 Aug;66(8):885-90. PMID 22713770. *Ineligible study design*

Rosano C, Longstreth WT, Jr., Boudreau R, et al. High blood pressure accelerates gait slowing in well-functioning older adults over 18-years of follow-up. *Journal of the American Geriatrics Society*. 2011 Mar;59(3):390-7. PMID 21391929. *No relevant outcomes reported*

Rosen AC, Sugiura L, Kramer JH, et al. Cognitive training changes hippocampal function in mild cognitive impairment: a pilot study. *Journal of Alzheimer's Disease*. 2011;26 Suppl 3:349-57. PMID 21971474. *Inadequate follow up time*

Rosenberg PB, Mielke MM, Han D, et al. The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer's disease. *International Journal of Geriatric Psychiatry*. 2012 Dec;27(12):1248-57. PMID 22374884. *Cohort study with inadequate sample size*

Rosenbloom MH, Barclay TR, Pyle M, et al. A single-dose pilot trial of intranasal rapid-acting insulin in apolipoprotein E4 carriers with mild-moderate Alzheimer's disease. *CNS Drugs*. 2014 Dec;28(12):1185-9. PMID 25373630. *Ineligible population*

Roth T, Richardson GR, Sullivan JP, et al. Comparative effects of pravastatin and lovastatin on nighttime sleep and daytime performance. *Clinical Cardiology*. 1992 Jun;15(6):426-32. PMID 1617822. *Inadequate follow up time*

Rovner BW, Casten RJ, Leiby BE, et al. Activity loss is associated with cognitive decline in age-related macular degeneration. *Alzheimer's & Dementia*. 2009 Jan;5(1):12-7. PMID 19118805. *Cohort study with inadequate sample size*

Ruiz JR, Gil-Bea F, Bustamante-Ara N, et al. Resistance training does not have an effect on cognition or related serum biomarkers in nonagenarians: a randomized controlled trial. *International Journal of Sports Medicine*. 2015 Jan;36(1):54-60. PMID 25329433. *Inadequate follow up time*

Ryan J, Carriere I, Carcaillon L, et al. Estrogen receptor polymorphisms and incident dementia: the prospective 3C study. *Alzheimer's & Dementia*. 2014 Jan;10(1):27-35. PMID 23491264. *Ineligible study design*

Ryan J, Carriere I, Scali J, et al. Characteristics of hormone therapy, cognitive function, and dementia: the prospective 3C Study. *Neurology*. 2009 Nov 24;73(21):1729-37. PMID 19933973. *Ineligible population*

Ryberg C, Rostrup E, Paulson OB, et al. Corpus callosum atrophy as a predictor of age-related cognitive and motor impairment: a 3-year follow-up of the LADIS study cohort. *Journal of the Neurological Sciences*. 2011 Aug 15;307(1-2):100-5. PMID 21621224. *Ineligible study design*

Sabbagh M, Cummings J, Christensen D, et al. Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response. *BMC Geriatrics*. 2013;13:56. PMID 23742728. *Ineligible population*

Sachs-Ericsson NJ, Sawyer KA, Corsentino EA, et al. APOE epsilon4 allele carriers: Biological, psychological, and social variables associated with cognitive impairment. *Aging & Mental Health*. 2010 Aug;14(6):679-91. PMID 20686979. *Ineligible study design*

Sadhu A, Upadhyay P, Agrawal A, et al. Management of cognitive determinants in senile dementia of Alzheimer's type: therapeutic potential of a novel polyherbal drug product. *Clinical Drug Investigation*. 2014 Dec;34(12):857-69. PMID 25316430. *Ineligible population*

Sadowsky CH, Dengiz A, Meng X, et al. Switching from oral donepezil to rivastigmine transdermal patch in Alzheimer's disease: 20-week extension phase results. *Primary Care Companion to the Journal of Clinical Psychiatry*. 2010;12(5):e1-e8. PMID 2010710976. *Ineligible population*

Safouris A, Tsivgoulis G, Sergentanis TN, et al. Mediterranean diet and risk of dementia. *Current Alzheimer Research*. 2015 01 Sep;12(8):736-44. PMID 2015398944. *Ineligible study design*

Sakurai H, Hanyu H, Sato T, et al. Effects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer's disease and cerebrovascular disease: a pilot study. *Geriatrics & gerontology international*. 2013 Jan;13(1):90-7. PMID 22672107. *Ineligible population*

Salloway S, Mintzer J, Cummings JL, et al. Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe



Alzheimer's disease. American Journal of Alzheimer's Disease & Other Dementias. 2012 Sep;27(6):421-32. PMID 22930699. *Ineligible population*

Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. New England Journal of Medicine. 2014 Jan 23;370(4):322-33. PMID 24450891. *Ineligible population*

Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009 Dec 15;73(24):2061-70. PMID 19923550. *Ineligible population*

Salloway S, Sperling R, Keren R, et al. A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology. 2011 Sep 27;77(13):1253-62. PMID 21917766. *Ineligible population*

Salvatore C, Cerasa A, Battista P, et al. Magnetic resonance imaging biomarkers for the early diagnosis of Alzheimer's disease: A machine learning approach. Frontiers in Neuroscience. 2015;9 (SEP) (no pagination)(307)PMID 2015508042. *Ineligible study design*

Samieri C, Grodstein F, Rosner BA, et al. Mediterranean diet and cognitive function in older age. Epidemiology. 2013 Jul;24(4):490-9. PMID 23676264. *Ineligible study design*

Sano M, Bell KL, Galasko D, et al. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology. 2011 Aug 9;77(6):556-63. PMID 21795660. *Ineligible population*

Sano M, Egelko S, Donohue M, et al. Developing dementia prevention trials: baseline report of the Home-Based Assessment study. Alzheimer Disease & Associated Disorders. 2013 Oct-Dec;27(4):356-62. PMID 23151596. *Ineligible study design*

Sano M, Egelko S, Donohue MC, et al. Assessing clinical progression for dementia prevention trial: Results from the HBA trial [Journal: Conference Abstract]. 2014. <http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/788/CN-01056788/frame.html>10. *Ineligible study design*

Santoro A, Siviero P, Minicuci N, et al. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study. CNS Drugs. 2010 Feb;24(2):163-76. PMID 20088621. *Ineligible population*

Santos C, Costa J, Santos J, et al. Caffeine intake and dementia: systematic review and meta-analysis. Journal of Alzheimer's Disease. 2010;20 Suppl 1:S187-204. PMID 20182026. *Ineligible study design*

Santos-Galduroz RF, Galduroz JC, Facco RL, et al. Effects of isoflavone on the learning and memory of women in menopause: a double-blind placebo-controlled study. *Brazilian Journal of Medical & Biological Research*. 2010 Nov;43(11):1123-6. PMID 20945036. *Inadequate follow up time*

Sato N, Saijo Y, Sasagawa Y, et al. Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial: results after 1 year. *Journal of Hypertension*. 2013 Jun;31(6):1245-55. PMID 23492647. *No relevant outcomes reported*

Sato T, Hanyu H, Hirao K, et al. Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. *Neurobiology of Aging*. 2011 Sep;32(9):1626-33. PMID 19923038. *Ineligible population*

Sattler C, Erickson KI, Toro P, et al. Physical fitness as a protective factor for cognitive impairment in a prospective population-based study in Germany. *Journal of Alzheimer's Disease*. 2011;26(4):709-18. PMID 21694450. *Cohort study with inadequate sample size*

Sattler C, Toro P, Schonknecht P, et al. Cognitive activity, education and socioeconomic status as preventive factors for mild cognitive impairment and Alzheimer's disease. *Psychiatry Research*. 2012 Mar 30;196(1):90-5. PMID 22390831. *Cohort study with inadequate sample size*

Saumier D, Duong A, Haine D, et al. Domain-specific cognitive effects of tramiprosate in patients with mild to moderate Alzheimer's disease: ADAS-cog subscale results from the alphase study. *Journal of Nutrition, Health and Aging*. 2009;13(9):808-12. PMID 2009650262. *Ineligible population*

Scalf PE, Colcombe SJ, McCarley JS, et al. The neural correlates of an expanded functional field of view. *Journals of Gerontology Series B-Psychological Sciences & Social Sciences*. 2007 Jun;62 Spec No 1:32-44. PMID 17565163. *Inadequate follow up time*

Scapagnini G, Sonya V, Nader AG, et al. Modulation of Nrf2/ARE pathway by food polyphenols: A nutritional neuroprotective strategy for cognitive and neurodegenerative disorders. *Molecular Neurobiology*. 2011 October;44(2):192-201. PMID 2011592755. *Ineligible study design*

Scarmeas N, Luchsinger JA, Brickman AM, et al. Physical activity and Alzheimer disease course. *American Journal of Geriatric Psychiatry*. 2011 May;19(5):471-81. PMID 20808142. *Ineligible study design*

Scarmeas N, Luchsinger JA, Schupf N, et al. Physical activity, diet, and risk of Alzheimer disease. *JAMA*. 2009 Aug 12;302(6):627-37. PMID 19671904. *Cohort study with inadequate sample size*

Scarmeas N, Stern Y, Mayeux R, et al. Mediterranean diet and mild cognitive impairment. *Archives of Neurology*. 2009 Feb;66(2):216-25. PMID 19204158. *Ineligible study design*

Scarpini E, Bruno G, Zappala G, et al. Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial. *Journal of Alzheimer's Disease*. 2011;26(2):211-20. PMID 21606568. *Ineligible population*

Schega L, Peter B, Torpel A, et al. Effects of intermittent hypoxia on cognitive performance and quality of life in elderly adults: a pilot study. *Gerontology*. 2013;59(4):316-23. PMID 23652274. *Inadequate follow up time*

Scheltens P, Twisk JW, Blesa R, et al. Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial. *Journal of Alzheimer's Disease*. 2012;31(1):225-36. PMID 22766770. *Ineligible population*

Schenck CH, Boeve BF, Mahowald MW. Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series. *Sleep Medicine*. 2013 Aug;14(8):744-8. PMID 23347909. *Ineligible study design*

Schiepers OJ, van Boxtel MP, de Groot RH, et al. Serum iron parameters, HFE C282Y genotype, and cognitive performance in older adults: results from the FACIT study. *Journals of Gerontology Series A-Biological Sciences & Medical Sciences*. 2010 Dec;65(12):1312-21. PMID 20813792. *Ineligible study design*

Schiepers OJ, van Boxtel MP, de Groot RH, et al. DNA methylation and cognitive functioning in healthy older adults. *British Journal of Nutrition*. 2012 Mar;107(5):744-8. PMID 21791146. *Cohort study with inadequate sample size*

Schifitto G, Yiannoutsos CT, Ernst T, et al. Selegiline and oxidative stress in HIV-associated cognitive impairment. *Neurology*. 2009 December;73(23):1975-81. PMID 2010015684. *Ineligible population*

Schlesinger D, Grinberg LT, Alba JG, et al. African ancestry protects against Alzheimer's disease-related neuropathology. *Molecular Psychiatry*. 2013 Jan;18(1):79-85. PMID 22064377. *Ineligible study design*

Schmidt A, Hammann F, Wolnerhanssen B, et al. Green tea extract enhances parieto-frontal connectivity during working memory processing. *Psychopharmacology*. 2014 Oct;231(19):3879-88. PMID 24643507. *Ineligible study design*

Schmitter-Edgecombe M, Dyck DG. Cognitive rehabilitation multi-family group intervention for individuals with mild cognitive impairment and their care-partners.

Journal of the International Neuropsychological Society. 2014 Oct;20(9):897-908. PMID 25222630. *Inadequate follow up time*

Schneider AL, Lutsey PL, Alonso A, et al. Vitamin D and cognitive function and dementia risk in a biracial cohort: the ARIC Brain MRI Study. *European Journal of Neurology*. 2014 Sep;21(9):1211-8, e69-70. PMID 24846449. *Ineligible study design*

Schneider LS, Insel PS, Weiner MW, et al. Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative. *Archives of Neurology*. 2011 Jan;68(1):58-66. PMID 21220675. *Inadequate follow up time*

Schneider P, Buerger K, Teipel S, et al. Antihypertensive therapy is associated with reduced rate of conversion to Alzheimer's disease in midregional proatrial natriuretic peptide stratified subjects with mild cognitive impairment. *Biological Psychiatry*. 2011 Jul 15;70(2):145-51. PMID 21457948. *Cohort study with inadequate sample size*

Schoene D, Valenzuela T, Toson B, et al. Interactive Cognitive-Motor Step Training Improves Cognitive Risk Factors of Falling in Older Adults - A Randomized Controlled Trial. *PLoS ONE [Electronic Resource]*. 2015;10(12):e0145161. PMID 26673919. *Inadequate follow up time*

Scholey A, Ossoukhova A, Owen L, et al. Effects of American ginseng (*Panax quinquefolius*) on neurocognitive function: an acute, randomised, double-blind, placebo-controlled, crossover study. *Psychopharmacology*. 2010 Oct;212(3):345-56. PMID 20676609. *Inadequate follow up time*

Schott JM, Reiniger L, Thom M, et al. Brain biopsy in dementia: clinical indications and diagnostic approach. *Acta Neuropathologica*. 2010 Sep;120(3):327-41. PMID 20640903. *Cohort study with inadequate sample size*

Schrijvers EM, Wittteman JC, Sijbrands EJ, et al. Insulin metabolism and the risk of Alzheimer disease: the Rotterdam Study. *Neurology*. 2010 Nov 30;75(22):1982-7. PMID 21115952. *Ineligible population*

Schulz V. Ginkgo biloba extract for the prevention of dementia? Placebo-controlled 6-year prevention study without proof of efficacy. 2009. <http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/812/CN-00756812/frame.html>. Accessed on 1 30. *Not available in English*

Schwam E, Xu Y. Cognition and function in Alzheimer's disease: identifying the transitions from moderate to severe disease. *Dementia & Geriatric Cognitive Disorders*. 2010;29(4):309-16. PMID 20395684. *Ineligible study design*

Scogin F, Fairchild JK, Yon A, et al. Cognitive bibliotherapy and memory training for older adults with depressive symptoms. *Aging & Mental Health*. 2014 Jul;18(5):554-60. PMID 24073847. *Inadequate follow up time*

Segal SK, Cotman CW, Cahill LF. Exercise-induced noradrenergic activation enhances memory consolidation in both normal aging and patients with amnesic mild cognitive impairment. *Journal of Alzheimer's Disease*. 2012;32(4):1011-8. PMID 22914593. *Inadequate follow up time*

Selnes OA, Grega MA, Bailey MM, et al. Do management strategies for coronary artery disease influence 6-year cognitive outcomes? *Annals of Thoracic Surgery*. 2009 Aug;88(2):445-54. PMID 19632391. *Ineligible population*

Shah RC, Kamphuis PJ, Leurgans S, et al. The S-Connect study: Results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer's disease. *Alzheimer's Research and Therapy*. 2013 26 Nov;5(6)PMID 2014019819. *Ineligible population*

Shao H, Breitner JC, Whitmer RA, et al. Hormone therapy and Alzheimer disease dementia: new findings from the Cache County Study. *Neurology*. 2012 Oct 30;79(18):1846-52. PMID 23100399. *Ineligible study design*

Shatil E. Does combined cognitive training and physical activity training enhance cognitive abilities more than either alone? A four-condition randomized controlled trial among healthy older adults. *Frontiers in Aging Neuroscience*. 2013;5(MAR)PMID 2013561527. *Inadequate follow up time*

Shatil E, Mikulecka J, Bellotti F, et al. Novel television-based cognitive training improves working memory and executive function. *PLoS ONE [Electronic Resource]*. 2014;9(7):e101472. PMID 24992187. *Inadequate follow up time*

Sherwin BB, Chertkow H, Schipper H, et al. A randomized controlled trial of estrogen treatment in men with mild cognitive impairment. *Neurobiology of Aging*. 2011 Oct;32(10):1808-17. PMID 20004499. *Inadequate follow up time*

Sherwin BB, Grigorova M. Differential effects of estrogen and micronized progesterone or medroxyprogesterone acetate on cognition in postmenopausal women. *Fertility & Sterility*. 2011 Aug;96(2):399-403. PMID 21703613. *Inadequate follow up time*

Shimizu S, Kanetaka H, Hirose D, et al. Differential effects of acetylcholinesterase inhibitors on clinical responses and cerebral blood flow changes in patients with Alzheimer's disease: A 12-month, randomized, and open-label trial. *Dementia and Geriatric Cognitive Disorders Extra*. 2015;5(1):135-46. PMID 2015140257. *Ineligible population*

Shin KY, Lee JY, Won BY, et al. BT-11 is effective for enhancing cognitive functions in the elderly humans. *Neuroscience Letters*. 2009 Nov 13;465(2):157-9. PMID 19699261. *Inadequate follow up time*

Shinto L, Quinn J, Montine T, et al. A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer's disease. *Journal of Alzheimer's Disease*. 2014;38(1):111-20. PMID 24077434. *Ineligible population*

Silverman DH, Geist CL, Kenna HA, et al. Differences in regional brain metabolism associated with specific formulations of hormone therapy in postmenopausal women at risk for AD. *Psychoneuroendocrinology*. 2011 May;36(4):502-13. PMID 20810219. *Inadequate follow up time*

Sittironnarit G, Ames D, Bush AI, et al. Effects of anticholinergic drugs on cognitive function in older Australians: results from the AIBL study. *Dementia & Geriatric Cognitive Disorders*. 2011;31(3):173-8. PMID 21389718. *Ineligible population*

Siuda J, Gorzkowska A, Patalong-Ogiewa M, et al. From mild cognitive impairment to Alzheimer's disease - influence of homocysteine, vitamin B12 and folate on cognition over time: results from one-year follow-up. *Neurologia i Neurochirurgia Polska*. 2009 Jul-Aug;43(4):321-9. PMID 19742390. *Ineligible study design*

Small BJ, Dixon RA, McArdle JJ, et al. Do changes in lifestyle engagement moderate cognitive decline in normal aging? Evidence from the Victoria Longitudinal Study. *Neuropsychology*. 2012 Mar;26(2):144-55. PMID 22149165. *Ineligible study design*

Smirni D, Turriziani P, Mangano GR, et al. Modulating memory performance in healthy subjects with transcranial direct current stimulation over the right dorsolateral prefrontal cortex. *PLoS ONE*. 2015 Dec;10(12) PMID 2016-00642-001. *Inadequate follow up time*

Smith GE, Housen P, Yaffe K, et al. A cognitive training program based on principles of brain plasticity: results from the Improvement in Memory with Plasticity-based Adaptive Cognitive Training (IMPACT) study. *Journal of the American Geriatrics Society*. 2009 Apr;57(4):594-603. PMID 19220558. *Inadequate follow up time*

Smith PJ, Blumenthal JA, Babyak MA, et al. Effects of the dietary approaches to stop hypertension diet, exercise, and caloric restriction on neurocognition in overweight adults with high blood pressure. *Hypertension*. 2010 Jun;55(6):1331-8. PMID 20305128. *Inadequate follow up time*

Smith PJ, Blumenthal JA, Hoffman BM, et al. Aerobic exercise and neurocognitive performance: a meta-analytic review of randomized controlled trials. *Psychosomatic Medicine*. 2010 Apr;72(3):239-52. PMID 20223924. *Ineligible study design*

- Smyth A, Dehghan M, O'Donnell M, et al. Healthy eating and reduced risk of cognitive decline: A cohort from 40 countries. *Neurology*. 2015 Jun 2;84(22):2258-65. PMID 25948720. *Ineligible study design*
- Sofi F, Abbate R, Gensini GF, et al. Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. *American Journal of Clinical Nutrition*. 2010 Nov;92(5):1189-96. PMID 20810976. *Ineligible study design*
- Solfrizzi V, Scafato E, Frisardi V, et al. Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. The Italian Longitudinal Study on Aging. *Age*. 2013 Apr;35(2):441-53. PMID 22203459. *Ineligible study design*
- Solomon A, Kareholt I, Ngandu T, et al. Serum total cholesterol, statins and cognition in non-demented elderly. *Neurobiology of Aging*. 2009 Jun;30(6):1006-9. PMID 18022292. *Ineligible study design*
- Solomon A, Kivipelto M, Wolozin B, et al. Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later. *Dementia & Geriatric Cognitive Disorders*. 2009;28(1):75-80. PMID 19648749. *Ineligible study design*
- Solomon A, Sippola R, Soininen H, et al. Lipid-lowering treatment is related to decreased risk of dementia: a population-based study (FINRISK). *Neurodegenerative Diseases*. 2010;7(1-3):180-2. PMID 20224281. *Ineligible study design*
- Song Y, Nie H, Xu Y, et al. Association of statin use with risk of dementia: a meta-analysis of prospective cohort studies. *Geriatrics & gerontology international*. 2013 Oct;13(4):817-24. PMID 23461525. *Ineligible study design*
- Sonnen JA, Larson EB, Walker RL, et al. Nonsteroidal anti-inflammatory drugs are associated with increased neuritic plaques. *Neurology*. 2010 Sep 28;75(13):1203-10. PMID 20811000. *Ineligible population*
- Sorman DE, Sundstrom A, Ronnlund M, et al. Leisure activity in old age and risk of dementia: a 15-year prospective study. *Journals of Gerontology Series B-Psychological Sciences & Social Sciences*. 2014 Jul;69(4):493-501. PMID 23766435. *Ineligible study design*
- Soto ME, Secher M, Gillette-Guyonnet S, et al. Weight loss and rapid cognitive decline in community-dwelling patients with Alzheimer's disease. *Journal of Alzheimer's Disease*. 2012;28(3):647-54. PMID 22045479. *Ineligible study design*
- Soto ME, van Kan GA, Nourhashemi F, et al. Angiotensin-converting enzyme inhibitors and Alzheimer's disease progression in older adults: results from the Reseau sur la

Maladie d'Alzheimer Francais cohort. Journal of the American Geriatrics Society. 2013 Sep;61(9):1482-8. PMID 24000874. *Ineligible population*

Spalletta G, Caltagirone C, Girardi P, et al. The role of persistent and incident major depression on rate of cognitive deterioration in newly diagnosed Alzheimer's disease patients. Psychiatry Research. 2012 30 Jul;198(2):263-8. PMID 2012633360. *Ineligible study design*

Spalletta G, Caltagirone C, Padovani A, et al. Cognitive and affective changes in mild to moderate Alzheimer's disease patients undergoing switch of cholinesterase inhibitors: a 6-month observational study. PLoS ONE [Electronic Resource]. 2014;9(2):e89216. PMID 24586603. *Cohort study with inadequate sample size*

Sparks DL, Kryscio RJ, Connor DJ, et al. Cholesterol and cognitive performance in normal controls and the influence of elective statin use after conversion to mild cognitive impairment: results in a clinical trial cohort. Neurodegenerative Diseases. 2010;7(1-3):183-6. PMID 20224282. *Ineligible study design*

Sperling R, Johnson K. To sleep, perchance to delay dementia. Archives of Neurology. 2012 Jan;69(1):118-20. PMID 22232352. *Ineligible study design*

Sperling RA, Rentz DM, Johnson KA, et al. The A4 study: Stopping AD before symptoms begin? Science Translational Medicine. 2014 19 Mar;6(228):PMID 2014282892. *Ineligible study design*

St John JA, Henderson VW, Hodis HN, et al. Associations between urine excretion of isoflavonoids and cognition in postmenopausal women in the Women's Isoflavone Soy Health clinical trial. Journal of the American Geriatrics Society. 2014 Apr;62(4):629-35. PMID 24617349. *Ineligible study design*

Steenland K, Zhao L, Goldstein FC, et al. Statins and cognitive decline in older adults with normal cognition or mild cognitive impairment. Journal of the American Geriatrics Society. 2013 September;61(9):1449-55. PMID 2013584156. *Ineligible study design*

Stein EM, Loos S, Schneider A, et al. The effectiveness of regular physical activity and exercise in the prevention and treatment of cognitive impairment and early Alzheimer's disease. [German]

Regelmäßige körperliche Aktivität als nichtpharmakologischer Präventions- und Behandlungsansatz im Frühstadium der Alzheimer-Demenz. Neurologie und Rehabilitation. 2010;16(5):247-50. PMID 2011007309. *Ineligible study design*

Stein MS, Scherer SC, Ladd KS, et al. A randomized controlled trial of high-dose vitamin D2 followed by intranasal insulin in Alzheimer's disease. Journal of Alzheimer's Disease. 2011;26(3):477-84. PMID 21694461. *Ineligible population*



Stephan BCM, Tzourio C, Auriacombe S, et al. Usefulness of data from magnetic resonance imaging to improve prediction of dementia: Population based cohort study. *BMJ (Online)*. 2015 22 Jun;350 (no pagination)(h2863)PMID 2015303074. *Ineligible study design*

Stewart R, Xue QL, Masaki K, et al. Change in blood pressure and incident dementia: a 32-year prospective study. *Hypertension*. 2009 Aug;54(2):233-40. PMID 19564551. *Ineligible study design*

Stough C, Downey L, Silber B, et al. The effects of 90-day supplementation with the omega-3 essential fatty acid docosahexaenoic acid (DHA) on cognitive function and visual acuity in a healthy aging population. *Neurobiology of Aging*. 2012 Apr;33(4):824.e1-3. PMID 21531481. *Inadequate follow up time*

Strand BH, Langballe EM, Hjellvik V, et al. Midlife vascular risk factors and their association with dementia deaths: results from a Norwegian prospective study followed up for 35 years. *Journal of the Neurological Sciences*. 2013 Jan 15;324(1-2):124-30. PMID 23146611. *Cohort study with inadequate sample size*

Strassnig MT, Signorile JF, Potiaumpai M, et al. High velocity circuit resistance training improves cognition, psychiatric symptoms and neuromuscular performance in overweight outpatients with severe mental illness. *Psychiatry Research*. 2015 Sep;229(1-2):295-301. PMID 2015-32473-001. *Ineligible population*

Strobel G. Alzheimer's prevention initiative. *Journal of Alzheimer's Disease*. 2010;21(3):1025-35. PMID 20844340. *Ineligible study design*

Stuart K, Summers MJ, Valenzuela MJ, et al. BDNF and COMT polymorphisms have a limited association with episodic memory performance or engagement in complex cognitive activity in healthy older adults. *Neurobiology of learning and memory*. 2014 01 Apr;110:1-7. PMID 24468545. *Ineligible study design*

Styliadis C, Kartsidis P, Paraskevopoulos E, et al. Neuroplastic effects of combined computerized physical and cognitive training in elderly individuals at risk for dementia: an eLORETA controlled study on resting states. *Neural Plasticity*. 2015;2015:172192. PMID 25945260. *Inadequate follow up time*

Sun L, Zhang XQ, Tang Z, et al. Cognitive function changes in patients with vascular dementia before and after symptom onset and analysis of its cognitive predictor. [Chinese]. *Chinese Journal of Cerebrovascular Diseases*. 2012 March;9(3):132-5. PMID 2012220434. *Ineligible study design*

Sun LM, Chen HJ, Liang JA, et al. Long-term use of tamoxifen reduces the risk of dementia: A nationwide population-based cohort study. *Qjm*. 2016 01 Feb;109(2):103-9. PMID 608857112. *Ineligible population*

Sundelof J, Kilander L, Helmersson J, et al. Systemic tocopherols and F2-isoprostanes and the risk of Alzheimer's disease and dementia: a prospective population-based study. *Journal of Alzheimer's Disease*. 2009;18(1):71-8. PMID 19542632. *Ineligible study design*

Suzuki H, Kuraoka M, Yasunaga M, et al. Cognitive intervention through a training program for picture book reading in community-dwelling older adults: a randomized controlled trial. *BMC Geriatrics*. 2014;14:122. PMID 25416537. *Inadequate follow up time*

Sweetlove M. Phase III CONCERT trial of latrepirdine: Negative results. *Pharmaceutical Medicine*. 2012;26(2):113-5. PMID 2012165417. *Ineligible population*

Tadini L, El-Nazer R, Brunoni AR, et al. Cognitive, mood, and electroencephalographic effects of noninvasive cortical stimulation with weak electrical currents. *Journal of ECT*. 2011 Jun;27(2):134-40. PMID 20938352. *Inadequate follow up time*

Tam CW, Lam LC. Clinical remission of late-onset depression in elderly Chinese: a short-term outcome study. *East Asian Archives of Psychiatry*. 2013 Sep;23(3):126-32. PMID 24088406. *Ineligible study design*

Tanasugarn L, Natearpha P, Kongsakon R, et al. Physical effects and cognitive function after exercising "Rue-si-dad-ton" (exercise using the posture of the hermit doing body contortion): a randomized controlled pilot trial. *Journal of the Medical Association of Thailand*. 2015 Mar;98(3):306-13. PMID 25920302. *Inadequate follow up time*

Tangwongchai S, Thavichachart N, Senanarong V, et al. Galantamine for the treatment of BPSD in Thai patients with possible Alzheimer's disease with or without cerebrovascular disease. *American Journal of Alzheimer's Disease and other Dementias*. 2009 December-January;23(6):593-601. PMID 2009009394. *Ineligible population*

Tao J, Liu J, Egorova N, et al. Increased hippocampus-medial prefrontal cortex resting-state functional connectivity and memory function after Tai Chi Chuan practice in elder adults. *Frontiers in Aging Neuroscience*. 2016;8 (FEB) (no pagination)(25) PMID 608884975. *Inadequate follow up time*

Tariot P, Salloway S, Yardley J, et al. Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer's disease. *BMC Research Notes*. 2012;5:283. PMID 22681723. *Ineligible population*

Tariot PN, Schneider LS, Cummings J, et al. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. *Archives of General Psychiatry*. 2011 Aug;68(8):853-61. PMID 21810649. *Ineligible population*

Tasci I, Naharci MI, Bozoglu E, et al. Cognitive and functional influences of vildagliptin, a DPP-4 inhibitor, added to ongoing metformin therapy in elderly with type 2 diabetes. *Endocrine, Metabolic & Immune Disorders Drug Targets*. 2013 Sep;13(3):256-63. PMID 23848558. *Ineligible study design*

Teixeira CV, Gobbi LT, Corazza DI, et al. Non-pharmacological interventions on cognitive functions in older people with mild cognitive impairment (MCI). *Archives of Gerontology & Geriatrics*. 2012 Jan-Feb;54(1):175-80. PMID 21397960. *Ineligible study design*

Thiel C, Vogt L, Tesky VA, et al. Cognitive intervention response is related to habitual physical activity in older adults. *Aging-Clinical & Experimental Research*. 2012 Feb;24(1):47-55. PMID 21406956. *Inadequate follow up time*

Thivierge S, Jean L, Simard M. A randomized cross-over controlled study on cognitive rehabilitation of instrumental activities of daily living in Alzheimer disease. *American Journal of Geriatric Psychiatry*. 2014 Nov;22(11):1188-99. PMID 23871120. *Ineligible population*

Tierney MC, Ryan J, Ancelin ML, et al. Lifelong estrogen exposure and memory in older postmenopausal women. *Journal of Alzheimer's Disease*. 2013;34(3):601-8. PMID 23246919. *Ineligible study design*

Tolppanen AM, Solomon A, Kulmala J, et al. Leisure-time physical activity from mid- to late life, body mass index, and risk of dementia. *Alzheimer's & Dementia*. 2015 Apr;11(4):434-43.e6. PMID 24721528. *Ineligible study design*

Tranah GJ, Blackwell T, Stone KL, et al. Circadian activity rhythms and risk of incident dementia and mild cognitive impairment in older women. *Annals of Neurology*. 2011 Nov;70(5):722-32. PMID 22162057. *Ineligible study design*

Tsai PF, Chang JY, Beck C, et al. A pilot cluster-randomized trial of a 20-week tai chi program in elders with cognitive impairment and osteoarthritic knee: Effects on pain and other health outcomes. *Journal of Pain and Symptom Management*. 2013 April;45(4):660-9. PMID 2013213752. *Inadequate follow up time*

Tsantali E, Economidis D. Implications of a longitudinal cognitive intervention program in mild Alzheimer's disease. *Archives of Psychiatric Nursing*. 2014 Apr;28(2):128-34. PMID 24673788. *Ineligible population*

Tseng CH, Huang WS, Muo CH, et al. Increased risk of dementia among chronic osteomyelitis patients. *European Journal of Clinical Microbiology & Infectious Diseases*. 2015 Jan;34(1):153-9. PMID 25098680. *Not cognitive decline prevention intervention*

Tsivgoulis G, Judd S, Letter AJ, et al. Adherence to a Mediterranean diet and risk of incident cognitive impairment. *Neurology*. 2013 Apr 30;80(18):1684-92. PMID 23628929. *Not cognitive decline prevention intervention*

Tzimopoulou S, Cunningham VJ, Nichols TE, et al. A multi-center randomized proof-of-concept clinical trial applying [<sup>18</sup>F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease. *Journal of Alzheimer's Disease*. 2010;22(4):1241-56. PMID 2011081259. *Ineligible study design*

Tzourio C, Anderson C, Chapman N, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. *Archives of Internal Medicine*. 2003 May 12;163(9):1069-75. PMID 12742805. *Ineligible population*

Ukawa S, Yuasa M, Ikeno T, et al. Randomised controlled pilot study in Japan comparing a home visit program using a Functioning Improvement Tool with a home visit with conversation alone. *Australasian Journal on Ageing*. 2012 September;31(3):187-9. PMID 22950591. *Inadequate follow up time*

Vaillant GE, Okereke OI, Mukamal K, et al. Antecedents of intact cognition and dementia at age 90 years: a prospective study. *International Journal of Geriatric Psychiatry*. 2014 Dec;29(12):1278-85. PMID 24733646. *Cohort study with inadequate sample size*

Valen-Sendstad A, Engedal K, Stray-Pedersen B, et al. Effects of hormone therapy on depressive symptoms and cognitive functions in women with Alzheimer disease: a 12 month randomized, double-blind, placebo-controlled study of low-dose estradiol and norethisterone. *American Journal of Geriatric Psychiatry*. 2010 Jan;18(1):11-20. PMID 20094015. *Ineligible population*

van de Rest O, Berendsen AA, Haveman-Nies A, et al. Dietary patterns, cognitive decline, and dementia: a systematic review. *Advances in Nutrition*. 2015 Mar;6(2):154-68. PMID 25770254. *Ineligible study design*

van de Rest O, van der Zwaluw NL, de Groot LC. Literature review on the role of dietary protein and amino acids in cognitive functioning and cognitive decline. *Amino Acids*. 2013 Nov;45(5):1035-45. PMID 23990160. *Ineligible study design*

van der Schaft J, Koek HL, Dijkstra E, et al. The association between vitamin D and cognition: a systematic review. *Ageing Research Reviews*. 2013 Sep;12(4):1013-23. PMID 23727408. *Ineligible study design*

van Himbergen TM, Beiser AS, Ai M, et al. Biomarkers for insulin resistance and inflammation and the risk for all-cause dementia and Alzheimer disease: results from the

Framingham Heart Study. Archives of Neurology. 2012 May;69(5):594-600. PMID 22213409. *No relevant outcomes reported*

van Paasschen J, Clare L, Yuen KS, et al. Cognitive rehabilitation changes memory-related brain activity in people with Alzheimer disease. Neurorehabilitation & Neural Repair. 2013 Jun;27(5):448-59. PMID 23369983. *Ineligible population*

van Uffelen JG, Chinapaw MJ, Hopman-Rock M, et al. Feasibility and effectiveness of a walking program for community-dwelling older adults with mild cognitive impairment. Journal of Aging & Physical Activity. 2009 Oct;17(4):398-415. PMID 19940321. *Not cognitive decline prevention intervention*

Van Vleet TM, DeGutis JM, Merzenich MM, et al. Targeting Alertness to Improve Cognition in Older Adults: A Preliminary Report of Benefits in Executive Function and Skill Acquisition. Cortex. 2016. *Ineligible study design*

Vandewoude MFJ. Management of patients with mild cognitive impairment and mild to moderate dementia. Acta Clinica Belgica. 2009 March/April;64(2):92-9. PMID 2009191218. *Ineligible population*

Vaughan C, Goldstein FC, Tenover JL. Exogenous testosterone alone or with finasteride does not improve measurements of cognition in healthy older men with low serum testosterone. Journal of Andrology. 2007 Nov-Dec;28(6):875-82. PMID 17609296. *Not cognitive decline prevention intervention*

Vaughan L, Espeland MA, Snively B, et al. The rationale, design, and baseline characteristics of the Women's Health Initiative Memory Study of Younger Women (WHIMS-Y). Brain Research. 2013 Jun 13;1514:3-11. PMID 23578696. *Ineligible study design*

Vedin I, Cederholm T, Freund-Levi Y, et al. Effects of DHA-rich n-3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PLoS ONE [Electronic Resource]. 2012;7(4):e35425. PMID 22545106. *Ineligible population*

Vedin I, Cederholm T, Freund-Levi Y, et al. Reduced prostaglandin F2 alpha release from blood mononuclear leukocytes after oral supplementation of omega3 fatty acids: the OmegAD study. Journal of Lipid Research. 2010 May;51(5):1179-85. PMID 19965584. *Ineligible population*

Vellas B, Black R, Thal LJ, et al. Long-term follow-up of patients immunized with AN1792: Reduced functional decline in antibody responders. Current Alzheimer Research. 2009 April;6(2):144-51. PMID 2009182642. *Ineligible population*

Vellas B, Carrie I, Gillette-Guyonnet S, et al. MAPT study: a multidomain approach for preventing Alzheimer's disease: design and baseline data. *The journal of prevention of Alzheimer's disease*. 2014;1(1):13. *Ineligible study design*

Venturelli M, Scarsini R, Schena F. Six-month walking program changes cognitive and ADL performance in patients with Alzheimer. *American Journal of Alzheimer's Disease & Other Dementias*. 2011 Aug;26(5):381-8. PMID 21852281. *Ineligible population*

Vercambre MN, Berr C, Ritchie K, et al. Caffeine and cognitive decline in elderly women at high vascular risk. *Journal of Alzheimer's Disease*. 2013;35(2):413-21. PMID 23422357. *Not cognitive decline prevention intervention*

Vercambre MN, Grodstein F, Kang JH. Dietary fat intake in relation to cognitive change in high-risk women with cardiovascular disease or vascular factors. *European Journal of Clinical Nutrition*. 2010 Oct;64(10):1134-40. PMID 20648044. *Not cognitive decline prevention intervention*

Verdelho A, Madureira S, Ferro JM, et al. Physical activity prevents progression for cognitive impairment and vascular dementia: results from the LADIS (Leukoaraiosis and Disability) study. *Stroke*. 2012 Dec;43(12):3331-5. PMID 23117721. *Not cognitive decline prevention intervention*

Vigen CL, Mack WJ, Keefe RS, et al. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. *American Journal of Psychiatry*. 2011 Aug;168(8):831-9. PMID 21572163. *Ineligible population*

Viola S, Viola P, Buongarzone MP, et al. New brain reperfusion rehabilitation therapy improves cognitive impairment in mild alzheimer's disease: A prospective, controlled, open-label 12-month study with nirs correlates. *Aging Clinical and Experimental Research*. 2014;26(4):417-25. PMID 2015687983. *Ineligible population*

Virta JJ, Heikkila K, Perola M, et al. Midlife cardiovascular risk factors and late cognitive impairment. *European Journal of Epidemiology*. 2013 May;28(5):405-16. PMID 23532744. *No relevant outcomes reported*

Viswanathan A. High-dose B vitamin supplementation as a disease-modifying therapy in alzheimer disease. *Archives of Neurology*. 2009 April;66(4):520-2. PMID 2009196917. *Ineligible population*

Viswanathan A, Raj S, Greenberg SM, et al. Plasma Abeta, homocysteine, and cognition: the Vitamin Intervention for Stroke Prevention (VISP) trial. *Neurology*. 2009 Jan 20;72(3):268-72. PMID 19153374. *Ineligible population*

Voigt-Radloff S, Hull M. [Daily functioning in dementia: pharmacological and non-pharmacological interventions demonstrate small effects on heterogeneous scales]. *Psychiatrische Praxis*. 2011 Jul;38(5):221-31. PMID 21425035. *Ineligible population*

Voss MW, Erickson KI, Prakash RS, et al. Neurobiological markers of exercise-related brain plasticity in older adults. *Brain, Behavior, & Immunity*. 2013 Feb;28:90-9. PMID 23123199. *No relevant outcomes reported*

Vranic A, Spanic AM, Carretti B, et al. The efficacy of a multifactorial memory training in older adults living in residential care settings. *International Psychogeriatrics*. 2013 Nov;25(11):1885-97. PMID 23899952. *Ineligible population*

Wade AG, Farmer M, Harari G, et al. Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trial. *Clinical Interventions In Aging*. 2014;9:947-61. PMID 24971004. *Ineligible population*

Wagner G, Icks A, Abholz HH, et al. Antihypertensive treatment and risk of dementia: a retrospective database study.[Erratum appears in *Int J Clin Pharmacol Ther*. 2012 Nov;50(11):850]. *International Journal of Clinical Pharmacology & Therapeutics*. 2012 Mar;50(3):195-201. PMID 22373832. *Ineligible study design*

Wagner S, Paulsen S, Bleichner F, et al. Cognitive training in rehabilitation: a program to treat mild cognitive impairment. [German]  
Gedachtnismanagementtraining in der Rehabilitation (KTR): Programm zur Behandlung leichter kognitiver Beeinträchtigungen. *Zeitschrift für Gerontologie und Geriatrie : Organ der Deutschen Gesellschaft für Gerontologie und Geriatrie*. 2009 Dec;42(6):479-87. PMID 19543680. *Not available in English*

Wagner S, Paulsen S, Bleichner F, et al. [Cognitive training in rehabilitation: a program to treat mild cognitive impairment]. *Zeitschrift für Gerontologie und Geriatrie*. 2009 Dec;42(6):479-87. PMID 19543680. *Ineligible population*

Waldorff FB, Buss DV, Eckermann A, et al. Efficacy of psychosocial intervention in patients with mild Alzheimer's disease: The multicentre, rater blinded, randomised Danish Alzheimer Intervention Study (DAISY). *BMJ (Online)*. 2012 18 Aug;345(7870)PMID 2012491882. *Ineligible population*

Wallin AK, Wattmo C, Minthon L. Galantamine treatment in Alzheimer's disease: Response and long-term outcome in a routine clinical setting. *Neuropsychiatric Disease and Treatment*. 2011;7(1):565-76. PMID 2011624724. *Ineligible population*

Wallin K, Solomon A, Kareholt I, et al. Midlife rheumatoid arthritis increases the risk of cognitive impairment two decades later: a population-based study. *Journal of Alzheimer's*

Disease. 2012;31(3):669-76. PMID 22647255. *Not cognitive decline prevention intervention*

Wang HK, Lin SH, Sung PS, et al. Population based study on patients with traumatic brain injury suggests increased risk of dementia. *Journal of Neurology, Neurosurgery & Psychiatry*. 2012 Nov;83(11):1080-5. PMID 22842203. *Ineligible population*

Wang HX, Karp A, Herlitz A, et al. Personality and lifestyle in relation to dementia incidence. *Neurology*. 2009 Jan 20;72(3):253-9. PMID 19153372. *No relevant outcomes reported*

Wang HX, Wahlberg M, Karp A, et al. Psychosocial stress at work is associated with increased dementia risk in late life. *Alzheimer's & Dementia*. 2012;8(2):114-20. PMID 22404853. *No relevant outcomes reported*

Wang JR, Hsieh S. Neurofeedback training improves attention and working memory performance. *Clinical Neurophysiology*. 2013 Dec;124(12):2406-20. PMID 23827814. *Inadequate follow up time*

Wang LP, Zhang XY, Liu N, et al. Comparison of integrated traditional Chinese and western medicine therapy on vascular cognitive impairment with no dementia. *Genetics and Molecular Research*. 2015 11 May;14(2):4896-902. PMID 2015041645. *Ineligible population*

Wang LQ, Chien WT. Randomised controlled trial of a family-led mutual support programme for people with dementia. *Journal of Clinical Nursing*. 2011 August;20(15-16):2362-6. PMID 21752121. *Ineligible population*

Wang LY, Larson EB, Sonnen JA, et al. Blood pressure and brain injury in older adults: Findings from a community-based autopsy study. *Journal of the American Geriatrics Society*. 2009 November;57(11):1975-81. PMID 2009560327. *Cohort study with inadequate sample size*

Wang S, Jacobs D, Andrews H, et al. Cardiovascular risk and memory in non-demented elderly women. *Neurobiology of Aging*. 2010 Jul;31(7):1250-3. PMID 18805604. *Not cognitive decline prevention intervention*

Wang S, Luo X, Barnes D, et al. Physical activity and risk of cognitive impairment among oldest-old women. *American Journal of Geriatric Psychiatry*. 2014 Nov;22(11):1149-57. PMID 23831179. *Not cognitive decline prevention intervention*

Wang T, Huang Q, Reiman EM, et al. Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24-week,



randomized, clinical trial. *Journal of Clinical Psychopharmacology*. 2013 Oct;33(5):636-42. PMID 23948786. *Ineligible population*

Wang X, Hjorth E, Vedin I, et al. Effects of n-3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: The omegAD study. *Journal of Lipid Research*. 2015 01 Mar;56(3):674-81. PMID 2015856468. *Ineligible population*

Wardle J, Armitage J, Collins R, et al. Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration. Oxford Cholesterol Study Group. *BMJ*. 1996 Jul 13;313(7049):75-8. PMID 8688757. *No relevant outcomes reported*

Wardle J, Rogers P, Judd P, et al. Randomized trial of the effects of cholesterol-lowering dietary treatment on psychological function. *American Journal of Medicine*. 2000 May;108(7):547-53. PMID 10806283. *Inadequate follow up time*

Watfa G, Rossignol P, Kearney-Schwartz A, et al. Use of calcium channel blockers is associated with better cognitive performance in older hypertensive patients with subjective memory complaints. *Journal of Hypertension*. 2010 December;28(12):2485-93. PMID 2012369475. *Ineligible study design*

Watson GS, Baker LD, Cholerton BA, et al. Effects of insulin and octreotide on memory and growth hormone in Alzheimer's disease. *Journal of Alzheimer's Disease*. 2009;18(3):595-602. PMID 19625744. *Ineligible population*

Wattmo C, Londos E, Minthon L. Solitary living in Alzheimer's disease over 3 years: association between cognitive and functional impairment and community-based services. *Clinical Interventions In Aging*. 2014;9:1951-62. PMID 25484578. *Ineligible population*

Wattmo C, Wallin AK, Londos E, et al. Long-term outcome and prediction models of activities of daily living in Alzheimer disease with cholinesterase inhibitor treatment. *Alzheimer Disease & Associated Disorders*. 2011 Jan-Mar;25(1):63-72. PMID 20847636. *Ineligible population*

Wattmo C, Wallin AK, Minthon L. Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer's disease cohort. *BMC Neurology*. 2012;12:134. PMID 23126532. *Ineligible population*

Wei XH, Ji LL. Effect of handball training on cognitive ability in elderly with mild cognitive impairment. *Neuroscience Letters*. 2014 Apr 30;566:98-101. PMID 24582900. *Ineligible population*

Weiner MW, Sadowsky C, Saxton J, et al. Magnetic resonance imaging and neuropsychological results from a trial of memantine in Alzheimer's disease. *Alzheimer's & Dementia*. 2011 Jul;7(4):425-35. PMID 21646051. *Ineligible population*

Weinstein G, Beiser AS, Choi SH, et al. Serum brain-derived neurotrophic factor and the risk for dementia: the Framingham Heart Study. *JAMA Neurology*. 2014 Jan;71(1):55-61. PMID 24276217. *Not cognitive decline prevention intervention*

Weintraub D, Rosenberg PB, Drye LT, et al. Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes. *American Journal of Geriatric Psychiatry*. 2010 Apr;18(4):332-40. PMID 20220589. *Ineligible population*

Weintraub D, Somogyi M, Meng X. Rivastigmine in alzheimer's disease and Parkinson's disease dementia: An ADAS-Cog factor analysis. *American Journal of Alzheimer's Disease and other Dementias*. 2011 September;26(6):443-9. PMID 2012001003. *Ineligible population*

Welmer AK, Rizzuto D, Qiu C, et al. Walking speed, processing speed, and dementia: a population-based longitudinal study. *Journals of Gerontology Series A-Biological Sciences & Medical Sciences*. 2014 Dec;69(12):1503-10. PMID 24706441. *Not cognitive decline prevention intervention*

Wenger NS, Roth CP, Shekelle PG, et al. A practice-based intervention to improve primary care for falls, urinary incontinence, and dementia. *Journal of the American Geriatrics Society*. 2009 Mar;57(3):547-55. PMID 19175441. *No relevant outcomes reported*

Werner NS, Duschek S, Schandry R. D-camphor-crataegus berry extract combination increases blood pressure and cognitive functioning in the elderly - a randomized, placebo controlled double blind study. *Phytomedicine*. 2009 Dec;16(12):1077-82. PMID 19560327. *Inadequate follow up time*

Westwoo W, Beiser A, DeCarli C, et al. Insulin-like growth factor-1 and risk of Alzheimer dementia and brain atrophy. *Neurology*. 2014 06 May;82(18):1613-9. PMID 2014392068. *Not cognitive decline prevention intervention*

Weyerer S, Schaufele M, Wiese B, et al. Current alcohol consumption and its relationship to incident dementia: results from a 3-year follow-up study among primary care attenders aged 75 years and older. *Age & Ageing*. 2011 Jul;40(4):456-63. PMID 21367764. *Not cognitive decline prevention intervention*

Whalley LJ, Duthie SJ, Collins AR, et al. Homocysteine, antioxidant micronutrients and late onset dementia. *European Journal of Nutrition*. 2014 Feb;53(1):277-85. PMID 23625136. *Not cognitive decline prevention intervention*

Whalley LJ, Sharma S, Fox HC, et al. Anticholinergic drugs in late life: adverse effects on cognition but not on progress to dementia. *Journal of Alzheimer's Disease*. 2012;30(2):253-61. PMID 22426015. *Cohort study with inadequate sample size*

Wharton W, Baker LD, Gleason CE, et al. Short-term hormone therapy with transdermal estradiol improves cognition for postmenopausal women with Alzheimer's disease: results of a randomized controlled trial. *Journal of Alzheimer's Disease*. 2011;26(3):495-505. PMID 21694454. *Ineligible population*

Wharton W, Gleason CE, Dowling NM, et al. The KEEPS-Cognitive and Affective Study: baseline associations between vascular risk factors and cognition. *Journal of Alzheimer's Disease*. 2014;40(2):331-41. PMID 24430001. *Not cognitive decline prevention intervention*

White RS, Lipton RB, Hall CB, et al. Nonmelanoma skin cancer is associated with reduced Alzheimer disease risk. *Neurology*. 2013 May 21;80(21):1966-72. PMID 23677746. *Not cognitive decline prevention intervention*

White WB, Marfatia R, Schmidt J, et al. INtensive versus standard ambulatory blood pressure lowering to prevent functional DeclINe in the ElderLY (INFINITY). *American Heart Journal*. 2013 Mar;165(3):258-65.e1. PMID 23453090. *Ineligible population*

Whitehair DC, Sherzai A, Emond J, et al. Influence of apolipoprotein E varepsilon4 on rates of cognitive and functional decline in mild cognitive impairment. *Alzheimer's & Dementia*. 2010 Sep;6(5):412-9. PMID 20813342. *Ineligible study design*

Whitlock JA, Jr. Brain injury, cognitive impairment, and donepezil. *Journal of Head Trauma Rehabilitation*. 1999 Aug;14(4):424-7. PMID 10407214. *Ineligible study design*

Whitmer RA, Quesenberry CP, Zhou J, et al. Timing of hormone therapy and dementia: the critical window theory revisited. *Annals of Neurology*. 2011 Jan;69(1):163-9. PMID 21280086. *No relevant outcomes reported*

Wightman EL, Reay JL, Haskell CF, et al. Effects of resveratrol alone or in combination with piperine on cerebral blood flow parameters and cognitive performance in human subjects: a randomised, double-blind, placebo-controlled, cross-over investigation. *British Journal of Nutrition*. 2014 Jul;112(2):203-13. PMID 24804871. *Inadequate follow up time*

Wilkinson D, Fox NC, Barkhof F, et al. Memantine and brain atrophy in Alzheimer's disease: a 1-year randomized controlled trial. *Journal of Alzheimer's Disease*. 2012;29(2):459-69. PMID 22269160. *Ineligible population*

Wilkinson D, Roman G, Salloway S, et al. The long-term efficacy and tolerability of donepezil in patients with vascular dementia. *International Journal of Geriatric Psychiatry*. 2010 Mar;25(3):305-13. PMID 19623601. *Ineligible population*

Wilkinson D, Schindler R, Schwam E, et al. Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate alzheimer's disease. *Dementia &*

Geriatric Cognitive Disorders. 2009;28(3):244-51. PMID 19786776. *Ineligible population*

Wilkinson D, Windfeld K, Colding-Jorgensen E. Safety and efficacy of idalopirdine, a 5-HT<sub>6</sub> receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial. *Lancet Neurology*. 2014 Nov;13(11):1092-9. PMID 25297016. *Ineligible population*

Williams PT. Lower risk of Alzheimer's disease mortality with exercise, statin, and fruit intake. *Journal of Alzheimer's Disease*. 2015;44(4):1121-9. PMID 25408208. *Ineligible population*

Wilson RS, Barnes LL, Aggarwal NT, et al. Cognitive activity and the cognitive morbidity of Alzheimer disease. *Neurology*. 2010 Sep 14;75(11):990-6. PMID 20811001. *Ineligible population*

Winblad B, Black SE, Homma A, et al. Donepezil treatment in severe Alzheimer's disease: a pooled analysis of three clinical trials. *Current Medical Research & Opinion*. 2009 Nov;25(11):2577-87. PMID 19735164. *Ineligible population*

Winblad B, Gauthier S, Astrom D, et al. Memantine benefits functional abilities in moderate to severe Alzheimer's disease. *Journal of Nutrition, Health & Aging*. 2010 Nov;14(9):770-4. PMID 21085908. *Ineligible population*

Winblad B, Giacobini E, Frolich L, et al. Phenserine efficacy in Alzheimer's disease. *Journal of Alzheimer's Disease*. 2010;22(4):1201-8. PMID 20930279. *Ineligible population*

Winchester J, Dick MB, Gillen D, et al. Walking stabilizes cognitive functioning in Alzheimer's disease (AD) across one year. *Archives of Gerontology & Geriatrics*. 2013 Jan-Feb;56(1):96-103. PMID 22959822. *Ineligible population*

Wingenfeld K, Kuffel A, Uhlmann C, et al. Effects of noradrenergic stimulation on memory in patients with major depressive disorder. *Stress*. 2013 Mar;16(2):191-201. PMID 22746337. *Inadequate follow up time*

Winslow BT, Onysko MK, Stob CM, et al. Treatment of Alzheimer disease. *American Family Physician*. 2011 June;83(12):1403-12. PMID 2011343700. *Ineligible population*

Wolkenstein L, Plewnia C. Amelioration of cognitive control in depression by transcranial direct current stimulation. *Biological Psychiatry*. 2013 Apr 1;73(7):646-51. PMID 23219367. *No relevant outcomes reported*

Wolozin B, Wang SW, Li NC, et al. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. *BMC Medicine*. 2007;5:20. PMID 17640385.

*Ineligible study design*

Wong RH, Howe PR, Bryan J, et al. Chronic effects of a wild green oat extract supplementation on cognitive performance in older adults: a randomised, double-blind, placebo-controlled, crossover trial. *Nutrients*. 2012 May;4(5):331-42. PMID 22690320.

*Inadequate follow up time*

Wright RM, Roumani YF, Boudreau R, et al. Effect of central nervous system medication use on decline in cognition in community-dwelling older adults: findings from the Health, Aging And Body Composition Study. *Journal of the American Geriatrics Society*. 2009 Feb;57(2):243-50. PMID 19207141. *Ineligible study design*

Wroolie TE, Kenna HA, Williams KE, et al. Differences in verbal memory performance in postmenopausal women receiving hormone therapy: 17beta-estradiol versus conjugated equine estrogens. *American Journal of Geriatric Psychiatry*. 2011 Sep;19(9):792-802. PMID 21873835. *Ineligible study design*

Wroolie TE, Kenna HA, Williams KE, et al. Cognitive effects of memantine in postmenopausal women at risk of dementia: a pilot study. *Acta Neurologica Scandinavica*. 2009 Mar;119(3):172-9. PMID 18705678. *Ineligible study design*

Wu MS, Lan TH, Chen CM, et al. Socio-demographic and health-related factors associated with cognitive impairment in the elderly in Taiwan. *BMC Public Health*. 2011;11:22. PMID 21223555. *Ineligible study design*

Wucherer D, Eichler T, Kilimann I, et al. Antidementia drug treatment in people screened positive for dementia in primary care. *Journal of Alzheimer's Disease*. 2015;44(3):1015-21. PMID 25391382. *Ineligible population*

Xiu LL, Wahlqvist ML, Lee MS, et al. Cognitive impairment and limited dietary diversity or physical inactivity are conjoint precursors of incident diabetes more so in elderly women than men. *Asia Pacific Journal of Clinical Nutrition*. 2013;22(4):635-45. PMID 24231025. *Ineligible study design*

Xu WL, von Strauss E, Qiu CX, et al. Uncontrolled diabetes increases the risk of Alzheimer's disease: a population-based cohort study. *Diabetologia*. 2009 Jun;52(6):1031-9. PMID 19280172. *Ineligible study design*

Xu ZQ, Liang XM, Juan W, et al. Treatment with Huperzine A improves cognition in vascular dementia patients. *Cell Biochemistry & Biophysics*. 2012 Jan;62(1):55-8. PMID 21833673. *Ineligible population*

Yaffe K, Falvey CM, Hamilton N, et al. Association between hypoglycemia and dementia in a biracial cohort of older adults with diabetes mellitus. *JAMA Internal Medicine*. 2013 22 Jul;173(14):1300-6. PMID 2013468296. *Ineligible study design*

Yakoot M, Salem A, Helmy S. Effect of Memo, a natural formula combination, on Mini-Mental State Examination scores in patients with mild cognitive impairment. *Clinical Interventions In Aging*. 2013;8:975-81. PMID 23950642. *Inadequate follow up time*

Yamada S, Akishita M, Fukai S, et al. Effects of dehydroepiandrosterone supplementation on cognitive function and activities of daily living in older women with mild to moderate cognitive impairment. *Geriatrics & gerontology international*. 2010 Oct;10(4):280-7. PMID 20497239. *Ineligible population*

Yamamoto T, Kondo K, Hirai H, et al. Association between self-reported dental health status and onset of dementia: A 4-year prospective cohort study of older Japanese adults from the Aichi Gerontological Evaluation Study (AGES) Project. *Psychosomatic Medicine*. 2012 April;74(3):241-8. PMID 2012211620. *Ineligible study design*

Yamashita T, Ogasawara K, Kuroda H, et al. Combination of preoperative cerebral blood flow and 123I-iomazenil SPECT imaging predicts postoperative cognitive improvement in patients undergoing uncomplicated endarterectomy for unilateral carotid stenosis. *Clinical Nuclear Medicine*. 2012 Feb;37(2):128-33. PMID 22228333. *Ineligible population*

Yancheva S, Ihl R, Nikolova G, et al. Ginkgo biloba extract EGb 761, donepezil or both combined in the treatment of Alzheimer's disease with neuropsychiatric features: A randomised, double-blind, exploratory trial. *Aging and Mental Health*. 2009 March;13(2):183-90. PMID 2009516891. *Ineligible population*

Yancheva S, Ihl R, Nikolova G, et al. Ginkgo biloba extract EGb 761(R), donepezil or both combined in the treatment of Alzheimer's disease with neuropsychiatric features: a randomised, double-blind, exploratory trial. *Aging & Mental Health*. 2009 Mar;13(2):183-90. PMID 19347685. *Ineligible population*

Yang BF, Zeng XH, Liu Y, et al. Effect of acupuncture treatment on vascular cognitive impairment without dementia: study protocol for a randomized controlled trial. *Trials [Electronic Resource]*. 2014;15:442. PMID 25391431. *Ineligible study design*

Yang CM, Shen YC, Weng SF, et al. Increased Risk of Dementia in Patients With Erectile Dysfunction: A Population-Based, Propensity Score-Matched, Longitudinal Follow-Up Study. *Medicine*. 2015 Jun;94(24):e990. PMID 26091478. *Ineligible study design*

Yang YH, Chen CH, Chou MC, et al. Concentration of donepezil to the cognitive response in Alzheimer disease. *Journal of Clinical Psychopharmacology*. 2013 Jun;33(3):351-5. PMID 23609381. *Ineligible population*

Yang YH, Teng HW, Lai YT, et al. Statins reduces the risk of dementia in patients with late-onset depression: A retrospective cohort study. *PLoS ONE*. 2015 18 Sep;10 (9) (no pagination)(e0137914)PMID 2015503958. *Ineligible study design*

Yang Z, Zhou X, Zhang Q. Effectiveness and safety of memantine treatment for Alzheimer's disease. *Journal of Alzheimer's Disease*. 2013;36(3):445-58. PMID 2013505142. *Ineligible population*

Yannakoulia M, Kontogianni M, Scarmeas N. Cognitive health and Mediterranean diet: just diet or lifestyle pattern? *Ageing Research Reviews*. 2015 Mar;20:74-8. PMID 25461244. *Ineligible study design*

Yasar S, Lin FM, Fried LP, et al. Diuretic use is associated with better learning and memory in older adults in the Ginkgo Evaluation of Memory Study. *Alzheimer's & Dementia*. 2012 May;8(3):188-95. PMID 22465175. *Not cognitive decline prevention intervention*

Yasar S, Xia J, Yao W, et al. Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study. *Neurology*. 2013 Sep 3;81(10):896-903. PMID 23911756. *Not cognitive decline prevention intervention*

Ye R, Hu Y, Yao A, et al. Impact of renin - angiotensin system-targeting antihypertensive drugs on treatment of Alzheimer's disease: A meta-analysis. *International Journal of Clinical Practice*. 2015 01 Jun;69(6):674-81. PMID 2015077237. *Ineligible study design*

Yeh YC, Liu CL, Peng LN, et al. Potential benefits of reducing medication-related anticholinergic burden for demented older adults: a prospective cohort study. *Geriatrics & gerontology international*. 2013 Jul;13(3):694-700. PMID 23216534. *Ineligible population*

Yesavage JA, Mumenthaler MS, Taylor JL, et al. Donepezil and flight simulator performance: effects on retention of complex skills. *Neurology*. 2002 Jul 9;59(1):123-5. PMID 12105320. *Inadequate follow up time*

Yeung CM, St John PD, Menec V, et al. Is bilingualism associated with a lower risk of dementia in community-living older adults? Cross-sectional and prospective analyses. *Alzheimer Disease & Associated Disorders*. 2014 Oct-Dec;28(4):326-32. PMID 24614266. *Not cognitive decline prevention intervention*

Young H, Benton D, Carter N. The effect of chicken extract on mood, cognition and heart rate variability. *Nutrients*. 2015;7(2):887-904. PMID 25642970. *Inadequate follow up time*

Yu F, Bronas UG, Konety S, et al. Effects of aerobic exercise on cognition and hippocampal volume in Alzheimer's disease: study protocol of a randomized controlled trial (The FIT-AD trial). *Trials [Electronic Resource]*. 2014;15:394. PMID 25304364. *Ineligible population*

Yu F, Nelson NW, Savik K, et al. Affecting Cognition and Quality of Life via Aerobic Exercise in Alzheimer's Disease. *Western Journal of Nursing Research*. 2013 January;35(1):24-38. PMID 21911546. *Ineligible population*

Yu F, Ryan LH, Schaie KW, et al. Factors associated with cognition in adults: the Seattle Longitudinal Study. *Research in Nursing & Health*. 2009 Oct;32(5):540-50. PMID 19606423. *No relevant outcomes reported*

Yu F, Savik K, Wyman JF, et al. Maintaining physical fitness and function in Alzheimer's disease: a pilot study. *American Journal of Alzheimer's Disease & Other Dementias*. 2011 Aug;26(5):406-12. PMID 21750046. *Ineligible population*

Yu F, Thomas W, Nelson NW, et al. Impact of 6-month aerobic exercise on Alzheimer's symptoms. *Journal of Applied Gerontology*. 2015 04 Jun;34(4):484-500. PMID 2015097557. *Ineligible population*

Yu L, Lin SM, Zhou RQ, et al. Chinese herbal medicine for patients with mild to moderate Alzheimer disease based on syndrome differentiation: A randomized controlled trial. *Journal of Chinese Integrative Medicine*. 2012 July;10(7):766-76. PMID 2012439210. *Ineligible population*

Yu L, Shulman JM, Chibnik L, et al. The CETP I405V polymorphism is associated with an increased risk of Alzheimer's disease. *Aging Cell*. 2012 Apr;11(2):228-33. PMID 22122979. *Ineligible study design*

Yu W, Chen Y, Wang S, et al. Cataract surgery is associated with a reduced risk of dementia: A nationwide population-based cohort study. *European Journal of Neurology*. 2015 Oct;22(10):1370-9. PMID 2014-37655-001. *Ineligible study design*

Yu WK, Chen YT, Wang SJ, et al. Cataract surgery is associated with a reduced risk of dementia: A nationwide population-based cohort study. *European Journal of Neurology*. 2015 01 Oct;22(10):1370-e80. PMID 2014941288. *Ineligible study design*

Zanchetti A, Liu L, Mancia G, et al. Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient: Design of the European Society of Hypertension-Chinese Hypertension League Stroke in



Hypertension Optimal Treatment randomized trial. *Journal of Hypertension*. 2014 September;32(9):1888-97. PMID 2014544821. *Ineligible population*

Zaninotto AL, Bueno OF, Pradella-Hallinan M, et al. Acute cognitive effects of donepezil in young, healthy volunteers. *Human Psychopharmacology*. 2009 Aug;24(6):453-64. PMID 19637397. *Inadequate follow up time*

Zeidan F, Johnson SK, Diamond BJ, et al. Mindfulness meditation improves cognition: evidence of brief mental training. *Consciousness & Cognition*. 2010 Jun;19(2):597-605. PMID 20363650. *Inadequate follow up time*

Zelinski EM, Peters KD, Hindin S, et al. Evaluating the relationship between change in performance on training tasks and on untrained outcomes. *Frontiers in human neuroscience*. 2014;8:617. *Inadequate follow up time*

Zelinski EM, Spina LM, Yaffe K, et al. Improvement in memory with plasticity-based adaptive cognitive training: results of the 3-month follow-up. *Journal of the American Geriatrics Society*. 2011 Feb;59(2):258-65. PMID 21314646. *Inadequate follow up time*

Zhang N, Wei C, Du H, et al. The Effect of Memantine on Cognitive Function and Behavioral and Psychological Symptoms in Mild-to-Moderate Alzheimer's Disease Patients. *Dementia and Geriatric Cognitive Disorders*. 2015 22 Jul;40(1-2):85-93. PMID 2015126070. *Ineligible population*

Zhang X, Ni X, Chen P. Study about the effects of different fitness sports on cognitive function and emotion of the aged. *Cell Biochemistry & Biophysics*. 2014 Dec;70(3):1591-6. PMID 24997050. *Cohort study with inadequate sample size*

Zhao MX, Dong ZH, Yu ZH, et al. Effects of Ginkgo biloba extract in improving episodic memory of patients with mild cognitive impairment: A randomized controlled trial. *Journal of Chinese Integrative Medicine*. 2012 June;10(6):628-34. PMID 2012376956. *Not available in English*

Zhao Q, Lee JH, Pang D, et al. Estrogen receptor-Beta variants are associated with increased risk of Alzheimer's disease in women with down syndrome. *Dementia & Geriatric Cognitive Disorders*. 2011;32(4):241-9. PMID 22156442. *Cohort study with inadequate sample size*

Zhao X, Zhou R, Fu L. Working memory updating function training influenced brain activity. *PLoS ONE [Electronic Resource]*. 2013;8(8):e71063. PMID 24015182. *No relevant outcomes reported*

Zhao Y, Navia BA, Marra CM, et al. Memantine for AIDS dementia complex: open-label report of ACTG 301. *HIV Clinical Trials*. 2010 Jan-Feb;11(1):59-67. PMID 20400412. *Inadequate follow up time*

Zheng Z, Zhu X, Yin S, et al. Combined cognitive-psychological-physical intervention induces reorganization of intrinsic functional brain architecture in older adults. *Neural Plasticity*. 2015;2015:713104. PMID 25810927. *Inadequate follow up time*

Zhitkova JV. Comparison of different doses of escitalopram in the prevention of dementia in patients with depression and moderate cognitive dysfunction associated with chronic brain ischemia. [Russian]. *Zhurnal Nevrologii i Psihatrii imeni S.S. 2015;Korsakova*. 2015(8):53-60. PMID 609429789. *Not available in English*

Zhong Y, Miao Y, Jia WP, et al. Hyperinsulinemia, insulin resistance and cognitive decline in older cohort. *Biomedical & Environmental Sciences*. 2012 Feb;25(1):8-14. PMID 22424621. *Cohort study with inadequate sample size*

Zhong Y, Zheng X, Miao Y, et al. Effect of CYP2D6 10 and APOE polymorphisms on the efficacy of donepezil in patients with Alzheimer's disease. *American Journal of the Medical Sciences*. 2013 Mar;345(3):222-6. PMID 22986607. *Ineligible population*

Zhuang JP, Fang R, Feng X, et al. The impact of human-computer interaction-based comprehensive training on the cognitive functions of cognitive impairment elderly individuals in a nursing home. *Journal of Alzheimer's Disease*. 2013;36(2):245-51. PMID 23587747. *Ineligible population*

Ziemann U, Siebner HR. Inter-subject and inter-session variability of plasticity induction by non-invasive brain stimulation: Boon or bane? *Brain Stimulation*. 2015 May;8(3):662-3. PMID 2015-26434-013. *Ineligible study design*

Zieschang T, Schwenk M, Oster P, et al. Sustainability of motor training effects in older people with dementia. *Journal of Alzheimer's Disease*. 2013;34(1):191-202. PMID 23202438. *Ineligible population*

Zimmermann N, Netto TM, Amodeo MT, et al. Working memory training and poetry-based stimulation programs: are there differences in cognitive outcome in healthy older adults? *Neurorehabilitation*. 2014;35(1):159-70. PMID 24990015. *Inadequate follow up time*

Zlatic CO, Mao Y, Ryan TM, et al. FluphenazineHCl and Epigallocatechin Gallate Modulate the Rate of Formation and Structural Properties of Apolipoprotein C-II Amyloid Fibrils. *Biochemistry*. 2015 Jun 23;54(24):3831-8. PMID 26021642. *Ineligible study design*

## Appendix E. Prospective Cohort Studies

The Health and Medicine Division (HMD) committee of the National Academies of Sciences, Engineering, and Medicine (NASEM) provided a list of longitudinal studies that may provide evidence on interventions to prevent age-related cognitive decline, MCI, and clinical Alzheimer's-type dementia. We used Google search engine to locate, where available, the longitudinal study's website, and where not available, academic sites or curated databases that provided a description of the study. (Some longitudinal studies are hosted or conducted primarily in countries where English is not the first language; descriptions for those studies were drawn from the associated publications in the table.) Study descriptions were used to confirm the prospective cohort study design, usually interested in determining incidence or risk factors, and that treatment was not assigned.

For each study, we iteratively searched PubMed using the study name and a key word (such as "cognitive impairment" and "dementia") derived from the search algorithms in Appendix A to identify related publications. These example articles were compared to the general search results to try to identify gaps in the literature. No gaps were found. Articles that were examples of the type of publication derived from the prospective cohort study but excluded from this review are provided in the table below. The studies were excluded because treatment was not assigned and appropriate techniques to address selection bias were not employed in order to provide information on causal relationships.

Next, for each study we again iteratively searched PubMed using the study name and key words that identify an analytic method that may be applied to a prospective cohort study to simulate an experimental design by "assigning" exposure to the intervention, for example, "instrumental variable" (IV) or "Mendelian randomization." No publications were identified using this method.

As can be seen in the cohort study descriptions, many of these prospective cohort studies have been generating data for decades. The derivative publications can number in the hundreds, possibly greater than 1000 articles per cohort study. Given the potentially large number of publications, which, based on our searches, did not rise to inclusion criteria due to study design (treatment was not assigned or appropriate techniques to address selection bias were not employed in order to provide information on causal relationships), we did not provide full bibliographies for each cohort study.

**Appendix Table E1. Prospective cohort studies searched for relevant literature**

Committee-suggested Cohort Studies Country	Cohort Study Description	Example of excluded publication derived from cohort study
3C (Three Cities Study) France	The Three-City Study (3C Study) is a population-based longitudinal study aiming to examine the relation between vascular diseases and dementia in adults 65 years and older. <a href="http://www.three-city-study.com/the-three-city-study.php">http://www.three-city-study.com/the-three-city-study.php</a>	Ancelin ML, et al. Steroid and nonsteroidal anti-inflammatory drugs, cognitive decline, and dementia. <i>Neurobiology of Aging</i> , 2011, doi:10.1016/j.neurobiolaging.2011.09.038.
Adult Changes in Thought Study (ACT) US	ACT is made up of 3 cohorts. Current total enrollment is 4,960. Between 1994 and 1996, the study enrolled 2,581 participants. The purpose of this cohort study is to prospectively examine the incidence of AD and dementia, as well as risk factors for those conditions. <a href="https://www.maelstrom-research.org/mica/study/act">https://www.maelstrom-research.org/mica/study/act</a>	Gray SL, et al. Antioxidant vitamin supplement use and risk of dementia or Alzheimer's disease in older adults. <i>J Am Geriatr Soc</i> . 2008 Feb;56(2):291-5.
Age, Gene/Environment Susceptibility – Reykjavik Study (AGES-RS) Iceland	The AGES will phenotype the surviving 12,000 members of the Reykjavik Study cohort (now 67 years and older) for quantitative traits related to diseases and conditions of old age, and collect genetic and other biologic specimens. <a href="http://www.hjartarannsokn.is/index.aspx?GroupId=346">http://www.hjartarannsokn.is/index.aspx?GroupId=346</a>	Sigurdur Sigurdsson, et.al. Brain tissue volumes in the general population of the elderly: The AGES-Reykjavik Study, <i>NeuroImage</i> , Volume 59, Issue 4, 15 February 2012, Pages 3862-3870, ISSN 1053-8119, <a href="http://dx.doi.org/10.1016/j.neuroimage.2011.11.024">http://dx.doi.org/10.1016/j.neuroimage.2011.11.024</a> .
Atherosclerosis Risk in Communities (ARIC) US	The Atherosclerosis Risk in Communities Study (ARIC), sponsored by the National Heart, Lung, and Blood Institute (NHLBI) is a prospective epidemiologic study conducted in four U.S. The Cohort Component of the ARIC study began in 1987, and each of the four ARIC field centers randomly selected and recruited a cohort sample of approximately 4,000 individuals aged 45-64 from a defined population in their community. A total of 15,792 participants received an extensive examination, including medical, social, and demographic data. <a href="https://www2.csc.unc.edu/aric/desc">https://www2.csc.unc.edu/aric/desc</a>	Lutsey PL, et. al. 2016. Obstructive Sleep Apnea and 15-Year Cognitive Decline: The Atherosclerosis Risk in Communities (ARIC) Study. <i>Sleep</i> . 39(2):309-16.PubMed
Austrian Study of Stroke Prevention (ASPS) Austria	Community-based cohort study on vascular risk factors and brain structure and function in older adults. 2000 participants, 1000 with imaging, healthy population, aged 45 – 85 years old (non-English website)	Enzinger C, et al. Risk factors for progression of brain atrophy: 6-year follow up of the ASPS. <i>Neurology</i> , 2005
Baltimore Longitudinal Study of Aging (BLSA) US	The BLSA is a longitudinal study, with over 1300 participants currently and over 3100 since study inception. The aim of the study is to understand what is aging. Researchers measure physical and cognitive changes associated with aging in real time among a dedicated group of BLSA participants who come in for testing at regular intervals over the course of their lives. <a href="https://www.blsa.nih.gov/">https://www.blsa.nih.gov/</a>	Beydoun MA, et al. Statins and serum cholesterol's associations with incident dementia and mild cognitive impairment. <i>Journal of epidemiology and community health</i> . 2011;65(11):949-957. doi:10.1136/jech.2009.100826.
Cache County	The study is designed to examine genetic and environmental factors associated with risk	Peters M, et al. Neuropsychiatric symptoms as

Committee-suggested Cohort Studies Country	Cohort Study Description	Example of excluded publication derived from cohort study
Study on Memory Health and Aging  US	for Alzheimer's disease and other forms of dementia. Started in 1995, the study enrolled 5,092 permanent residents of the county (90%), including approximately 800 individuals aged 85 years and older. The CCMS is a longitudinal investigation of aging and Alzheimer's disease (AD) based in an exceptionally long-lived population residing in northern Utah. The elderly of Cache County have a longer life expectancy, higher educational attainment, and lower incidence of chronic disease (which can complicate the diagnosis of dementias) than other similar populations. <a href="http://www.usu.edu/epicenter/htm/studies/memorystudy">http://www.usu.edu/epicenter/htm/studies/memorystudy</a>	risk factors for progression from CIND to dementia: The Cache County Study. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. 2013;21(11):10.1016/j.jagp.2013.01.049. doi:10.1016/j.jagp.2013.01.049.
Cardiovascular Health Study (CHS)  US	The Cardiovascular Health Study (CHS) is an NHLBI-funded observational study of risk factors for cardiovascular disease in adults 65 years or older. Starting in 1989, and continuing through 1999, participants underwent annual extensive clinical examinations. Measurements included traditional risk factors such as blood pressure and lipids as well as measures of subclinical disease, including echocardiography of the heart, carotid ultrasound, and cranial magnetic-resonance imaging (MRI). At six month intervals between clinic visits, and once clinic visits ended, participants were contacted by phone to ascertain hospitalizations and health status. The main outcomes are coronary heart disease (CHD), angina, heart failure (HF), stroke, transient ischemic attack (TIA), claudication, and mortality. Participants continue to be followed for these events. <a href="https://chs-nhlbi.org/">https://chs-nhlbi.org/</a>	Incidence of mild cognitive impairment in the Pittsburgh Cardiovascular Health Study– Cognition Study Oscar L. et. al. October 9, 2012, 79:15 1599-1606; published ahead of print September 26, 2012, doi:10.1212/WNL.0b013e31826e25f0:1526-632X
Chicago Health and Aging Project (CHAP)  US	CHAP is a longitudinal population study of common chronic health problems of older persons, especially of risk factors for incident Alzheimer's disease, in a biracial neighborhood of the south side of Chicago. <a href="http://www.alzrisk.org/cohort.aspx?cohortID=15&amp;rfid=2">http://www.alzrisk.org/cohort.aspx?cohortID=15&amp;rfid=2</a>	Morris MC, et al. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA. 2002 Jun 26;287(24):3230-7.
Coronary Artery Risk Development in Young Adults Study (CARDIA)  US	The Coronary Artery Risk Development in Young Adults (CARDIA) Study is a study examining the development and determinants of clinical and subclinical cardiovascular disease and their risk factors. It began in 1985-6 with a group of 5115 black and white men and women aged 18-30 years. The participants were selected so that there would be approximately the same number of people in subgroups of race, gender, education (high school or less and more than high school) and age (18-24 and 25-30) in each of 4 centers: Birmingham, AL; Chicago, IL; Minneapolis, MN; and Oakland, CA. <a href="http://www.cardia.dopm.uab.edu/">http://www.cardia.dopm.uab.edu/</a>	No relevant studies immediately found
Framingham Heart Study (note: Framingham cohorts include the Original, Offspring and	The objective of the Framingham Heart Study was to identify the common factors or characteristics that contribute to CVD by following its development over a long period of time in a large group of participants who had not yet developed overt symptoms of CVD or suffered a heart attack or stroke. The researchers recruited 5,209 men and women between the ages of 30 and 62 from the town of Framingham, Massachusetts. Since 1948, the subjects have continued to return to the study every two years for a detailed medical history, physical examination, and laboratory tests. In 1971, the Study enrolled a	Karakis I, et al. Association of Serum Vitamin D with the Risk of Incident Dementia and Subclinical Indices of Brain Aging: The Framingham Heart Study. J Alzheimers Dis. 2016. Epub 2016/02/19. doi: 10.3233/jad-150991. (PubMed ID Number: 26890771).

Committee-suggested Cohort Studies Country	Cohort Study Description	Example of excluded publication derived from cohort study
Gen 3 cohorts) US	second generation - 5,124 of the original participants' adult children and their spouses - to participate in similar examinations. In 1994, the need to establish a new study reflecting a more diverse community of Framingham was recognized, and the first Omni cohort of the Framingham Heart Study was enrolled. In April 2002 the Study entered a new phase, the enrollment of a third generation of participants, the grandchildren of the Original Cohort. In 2003, a second group of Omni participants was enrolled. <a href="https://www.framinghamheartstudy.org/">https://www.framinghamheartstudy.org/</a>	
Health and Retirement Study (HRS) US	The University of Michigan Health and Retirement Study (HRS) is a longitudinal panel study that surveys a representative sample of approximately 20,000 people in America over the age of 50 every two years. <a href="http://hrsonline.isr.umich.edu/">http://hrsonline.isr.umich.edu/</a>	Saczynski JS, et al. Antidepressant Use and Cognitive Decline: The Health and Retirement Study. The American journal of medicine. 2015;128(7):739-746. doi:10.1016/j.amjmed.2015.01.007.
Health, Aging and Body Composition Study (Health ABC) US	The HEALTH ABC Study will characterize the extent of change in body composition in older men and women, identify clinical conditions accelerating these changes, and examine the health impact of these changes on strength, endurance, disability, and weight-related diseases of old age. The study population consists of 3,075 persons age 70-79 at baseline with about equal numbers of men and women. Thirty-three percent of the men are African-Americans as are 46% of the women. All persons in the study were selected to be free of disability in activities of daily living and free of functional limitation (defined as any difficulty walking a quarter of a mile or any difficulty walking up 10 steps without resting) at baseline. <a href="https://www.nia.nih.gov/research/intramural-research-program/dynamics-health-aging-and-body-composition-health-abc">https://www.nia.nih.gov/research/intramural-research-program/dynamics-health-aging-and-body-composition-health-abc</a>	No relevant studies immediately found
Honolulu-Asia Aging Study (HAAS) US	The Honolulu-Asia Aging Study (HAAS) is a longitudinal epidemiologic investigation of rates, risk factors, and neuropathologic abnormalities associated with cognitive decline and dementia in aged Japanese-American men. <a href="http://www.alzrisk.org/cohort.aspx?cohortID=3&amp;rfid=5">http://www.alzrisk.org/cohort.aspx?cohortID=3&amp;rfid=5</a>	Taaffe, Dennis R., et al. "Physical activity, physical function, and incident dementia in elderly men: the Honolulu-Asia Aging Study." The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 63.5 (2008): 529-535.
Kame Project (a cohort study of Japanese Americans in King County, Washington) US	A large population-based prospective study of Japanese Americans in King County, Washington, who were followed from 1992 to 2001, as part of the Ni-Hon-Sea Project, a cross-cultural study of prevalence and incidence rates of Alzheimer's disease and vascular dementia among Japanese populations living in Hiroshima, Japan; Oahu, Hawaii; and the metropolitan area of Seattle, Washington. <a href="http://www.alzrisk.org/cohort.aspx?cohortID=55&amp;rfid=6">http://www.alzrisk.org/cohort.aspx?cohortID=55&amp;rfid=6</a>	Dai Q, et al. Fruit and Vegetable Juices and Alzheimer's Disease: The Kame Project. The American journal of medicine. 2006;119(9):751-759. doi:10.1016/j.amjmed.2006.03.045.
Kungsholmen Project	The Kungsholmen Project is a longitudinal population-based study on ageing and dementia, carried out by the Stockholm Gerontology Research Center in collaboration with Aging Research Center (ARC), Karolinska Institutet. The project, which started in	Qiu C, et. al. Decline in blood pressure over time and risk of dementia: a longitudinal study from the Kungsholmen project. Stroke 2004;35:1810-5.

Committee-suggested Cohort Studies Country	Cohort Study Description	Example of excluded publication derived from cohort study
Sweden	1987, has gathered a 12-year long database and offers information on aging from a multidisciplinary perspective. <a href="http://www.kungsholmenproject.se/">http://www.kungsholmenproject.se/</a>	
Leisure World Cohort Study (note: the Leisure World is now extended as the 90+ Study)  US	The Leisure World Cohort Study was established to study the effect of modifiable lifestyle practices on longevity and successful aging when all residents of a California retirement community (Leisure World Laguna Hills) were mailed a postal health survey in 1981. New residents who moved into the community after this date were mailed the survey in 1982, 1983, and 1985. Of the 22,910 residents, 13,978 (61%) completed the questionnaire. The population and cohort are mostly Caucasian, well educated, upper-middle class, and elderly. <a href="https://www.mind.uci.edu/research/90plus-study/">https://www.mind.uci.edu/research/90plus-study/</a>	Paganini-Hill, Annlia. "Hypertension and Dementia in the Elderly: The Leisure World Cohort Study." International journal of hypertension 2012 (2011).
Lothian Birth Cohorts  UK	The Lothian Birth Cohorts of 1921 and 1936 are follow-up studies of the Scottish Mental Surveys of 1932 and 1947. The surveys had, respectively, tested the intelligence of almost every child born in 1921 or 1936 and attending school in Scotland in the month of June in those years. Therefore, tracing, recruiting and re-testing people who had taken part in the Surveys offered a rare opportunity to examine the distribution and causes of cognitive ageing across most of the human life course. The studies described here were initially set up to study determinants of non-pathological cognitive ageing; i.e. the ageing of cognitive functions largely in the normal range, and not principally dementia or other pathological cognitive disorders <a href="http://www.lothianbirthcohort.ed.ac.uk/">http://www.lothianbirthcohort.ed.ac.uk/</a>	No relevant studies immediately found
Mayo Clinic Study of Aging (MCSA)  US	The MCSA is a population-based study that was designed to study incident mild cognitive impairment and dementia. The sampling frame included all persons aged 70–89 years who were residents of Olmsted County, Minnesota, as of October 1, 2004 (age- and sex-stratified random sample). The medical records of potential participants were formally reviewed prior to contact to exclude those with diagnoses of dementia, those in hospice care, or those considered to have conditions deemed imminently fatal. (Mayo Clinic does not appear to have a searchable site for this study.)	Vassilaki, Maria, et al. "Multimorbidity and risk of mild cognitive impairment." Journal of the American Geriatrics Society 63.9 (2015): 1783-1790.
MEMENTO  France	This cohort aims at studying the evolution of a variety of potentially early signs (cognitive complaints, deficit in some domain of cognition, psycho-behavioural disturbances, changes in imaging or biological markers) of Alzheimer's disease and related dementia and to estimate the prognostic value of different markers (neuro-psychological, vascular, psychopathological, socio-educational, genetic, biological, neuro-imaging) on the progression to clinical dementia or severe cognitive deterioration stages, and then to death. <a href="http://www.memento-cohort.org/memento_web/Portals/0/Chercheurs/MEMENTO_Formulaire_AccesDonnees.pdf">http://www.memento-cohort.org/memento_web/Portals/0/Chercheurs/MEMENTO_Formulaire_AccesDonnees.pdf</a>	No relevant studies immediately found
Minority Aging Research Study (MARS)	The Minority Aging Research Study (MARS) began in 2004 and is a study of risk factors for cognitive decline in older Blacks. Participants are recruited from community-based organizations, churches, and senior-subsidized housing facilities; the catchment area is within that of MAP. Study participation requires agreeing to detailed annual clinical	No relevant studies immediately found

Committee-suggested Cohort Studies Country	Cohort Study Description	Example of excluded publication derived from cohort study
US	evaluations and cognitive testing. Between 2004 and 2007, >350 older persons enrolled in the study. <a href="https://www.rush.edu/services-treatments/alzheimers-disease-center/minority-aging-research-study">https://www.rush.edu/services-treatments/alzheimers-disease-center/minority-aging-research-study</a>	
Monongahela Valley Independent Elders Survey (MoVIES)  US	The MoVIES project investigated various aspects of normal and abnormal aging. It also studied the incidence, risk factors, and outcome in late-life dementia, including Alzheimer's disease, in a prospective community-based epidemiologic study for 15 years. The study cohort was drawn from a rural, largely blue-collar community in the mid-Monongahela Valley of Southwestern Pennsylvania. The original cohort of 1681 individuals aged 65+ years was assembled between 1987 and 1989 and was followed until 2002 with multi-stage clinical "Waves" of cognitive and risk factor screening. Screening waves were interspersed with multi-stage clinical evaluations to detect the presence of Alzheimer's and other dementias. <a href="http://www.wpic.pitt.edu/research/dementia_epidemiology/Movies/MoviesHomePage.htm">http://www.wpic.pitt.edu/research/dementia_epidemiology/Movies/MoviesHomePage.htm</a>	No relevant studies immediately found
Monongahela-Youghiogheny Healthy Aging Team (MYHAT)  US	The MYHAT project seeks to describe the distribution of Cognitive Impairment, No Dementia (CIND) and Mild Cognitive Impairment (MCI) and related entities, their associated features, their outcomes over time, and the predictors of these outcomes. An age-stratified random community sample of approximately 2,100 was recruited and screened using cognitive, functional, and other health-related measures to identify the non-demented who are cognitively impaired. Among them, we identified subgroups meeting operational criteria for MCI of amnesic and other varieties. <a href="http://www.wpic.pitt.edu/research/dementia_epidemiology/MYHAT/MYHATHomePage.htm">http://www.wpic.pitt.edu/research/dementia_epidemiology/MYHAT/MYHATHomePage.htm</a>	Hughes TF, et al. Independent and combined effects of cognitive and physical activity on incident MCI. <i>Alzheimers and Dement.</i> 2015 Nov; 11(11): 1377-84. doi: 10.1016/j.jalz.2014.11.007. (PMC4536189)  Ganguli M, et al. Rates and risk factors for progression to incident dementia vary by age in population cohort. <i>Neurology</i> , 84(1):72-80. (PMC4336092)
Multi-Ethnic Study of Atherosclerosis (MESA)  US	The MESA study examines the characteristics of subclinical cardiovascular disease (disease detected non-invasively before it has produced clinical signs and symptoms) and the risk factors that predict progression to clinically overt cardiovascular disease or progression of the subclinical disease. From July 2000 to January 2012, MESA is a prospective population-based sample of 6,814 asymptomatic men and women aged 45-84. Approximately 38 percent of the recruited participants are white, 28 percent African-American, 22 percent Hispanic, and 12 percent Asian, predominantly of Chinese descent. <a href="https://www.mesa-nhlbi.org/">https://www.mesa-nhlbi.org/</a>	No relevant studies immediately found
Northern Manhattan Study (NOMAS)  US	NOMAS is a study of the population of Washington Heights in Northern Manhattan. The ongoing study, which began in 1990, is based in the Neurological Institute of Columbia Presbyterian Hospital, located in Washington Heights. NOMAS has enrolled over 4,400 people from the surrounding community. NOMAS is the first study of its kind to focus on stroke risk factors in whites, blacks, and Hispanics living in the same community. It is helping to fill gaps in our knowledge of stroke epidemiology in minority populations.	No relevant studies immediately found



Committee-suggested Cohort Studies Country	Cohort Study Description	Example of excluded publication derived from cohort study
Nurses' Health Study US	<p><a href="http://columbianomas.org/">http://columbianomas.org/</a></p> <p>The Nurses' Health Studies are among the largest prospective investigations into the risk factors for major chronic diseases in women. Starting with the original Nurses' Health Study in 1976, the studies are now in their third generation with Nurses' Health Study 3 (which is still enrolling male and female nurses) and count more than 275,000 participants. <a href="http://www.nurseshealthstudy.org/">http://www.nurseshealthstudy.org/</a></p>	<p>Devore, Elizabeth E., et al. "Dietary intakes of berries and flavonoids in relation to cognitive decline." <i>Annals of neurology</i> 72.1 (2012): 135-143.</p> <p>Okereke, Olivia I., et al. "Plasma C-peptide levels and rates of cognitive decline in older, community-dwelling women without diabetes." <i>Psychoneuroendocrinology</i> 33.4 (2008): 455-461.</p>
Reasons for Geographic and Racial Differences in Stroke (REGARDS) US	<p>REGARDS is an observational study of risk factors for stroke in adults 45 years or older. 30,239 participants were recruited between January 2003 and October 2007. They completed a telephone interview followed by an in-home physical exam. Measurements included traditional risk factors such as blood pressure and cholesterol levels, and an echocardiogram of the heart. At six month intervals, participants are contacted by phone to ask about stroke symptoms, hospitalizations and general health status. The study is ongoing and will follow participants for many years. <a href="http://www.regardsstudy.org/">http://www.regardsstudy.org/</a></p>	<p>Zhu, Wenfei, et al. "Association Between Objectively Measured Physical Activity and Cognitive Function in Older Adults—The Reasons for Geographic and Racial Differences in Stroke Study." <i>Journal of the American Geriatrics Society</i> 63.12 (2015): 2447-2454.</p>
Religious Orders Study US	<p>The Religious Orders Study is a collaborative study with Rush and other U.S. medical centers. It involves more than 1,100 older religious clergy (nuns, priests and brothers) who have agreed to medical and psychological evaluation each year and brain donation after death. Researchers are using information from the study to discover what changes in the brain are responsible for memory and movement problems. <a href="https://www.rush.edu/services-treatments/alzheimers-disease-center/religious-orders-study">https://www.rush.edu/services-treatments/alzheimers-disease-center/religious-orders-study</a></p>	<p>Yu, Lei, et al. "The CETP I405V polymorphism is associated with an increased risk of Alzheimer's disease." <i>Aging cell</i> 11.2 (2012): 228-233.</p>
Rochester Epidemiology Project (Olmsted County Study) US	<p>The REP includes the medical records of all persons who have ever lived in Olmsted County, Minnesota between January 1, 1966 and the present, and who have given permission for their medical information to be used for research.[6] Those persons comprise more than 500,000 unique individuals and more than 6 million person years of follow-up through 2010. <a href="http://www.mayo.edu/research/centers-programs/rochester-epidemiology-project/overview">http://www.mayo.edu/research/centers-programs/rochester-epidemiology-project/overview</a></p>	<p>Savica, Rodolfo, et al. "Incidence of dementia with Lewy bodies and Parkinson disease dementia." <i>JAMA neurology</i> 70.11 (2013): 1396-1402.</p>
Rotterdam Study Netherlands	<p>The Rotterdam Elderly Study is a prospective cohort study in the Ommoord district in the city of Rotterdam, the Netherlands. Recruitment started in January 1990. The main objectives of the Rotterdam Study were to investigate the risk factors of cardiovascular, neurological, ophthalmological and endocrine diseases in the elderly. Up to 2008, approximately 15,000 subjects aged 45 years or over have been recruited. <a href="http://www.epib.nl/research/ergo.htm">http://www.epib.nl/research/ergo.htm</a></p>	<p>Ruitenberg A, et al. "Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study." <i>Annals of neurology</i> 57.6 (2005): 789-794.</p> <p>Engelhart, Marianne J., et al. "Inflammatory proteins in plasma and the risk of dementia: the Rotterdam study." <i>Archives of neurology</i> 61.5 (2004): 668-672.</p>
Rush Memory and Aging Project	<p>The Rush MAP is a companion study that is more diverse in life experience make-up than ROS. Participants are older community-dwelling persons who are recruited and</p>	<p>Buchman, A. S., et al. "Total daily physical activity and the risk of AD and cognitive decline in older</p>

Committee-suggested Cohort Studies Country	Cohort Study Description	Example of excluded publication derived from cohort study
(MAP) US	followed with nearly identical annual evaluations to ROS and all agree to donate brain, spinal cord, nerve and muscle to Rush investigator's at the time of death. More than 1,350 participants have enrolled and are seen annually and have had up to 13 clinical evaluations. <a href="https://www.rush.edu/services-treatments/alzheimers-disease-center/radc-research/memory-and-aging-project-rush">https://www.rush.edu/services-treatments/alzheimers-disease-center/radc-research/memory-and-aging-project-rush</a>	adults." Neurology 78.17 (2012): 1323-1329.
The Sacramento Area Latino Study on Aging (SALSA) US	The Sacramento Area Latino Study on Aging (SALSA Study) project tracked the incidence of physical and cognitive impairment as well as dementia and cardiovascular diseases in elderly Latinos in the Sacramento, California, region. <a href="http://www.icpsr.umich.edu/icpsrweb/NACDA/studies/29323">http://www.icpsr.umich.edu/icpsrweb/NACDA/studies/29323</a>	Haan, Mary N., et al. "Homocysteine, B vitamins, and the incidence of dementia and cognitive impairment: results from the Sacramento Area Latino Study on Aging." The American journal of clinical nutrition 85.2 (2007): 511-517.
Singapore Longitudinal Ageing Study (SLAS) Singapore	Between September 2003 and December 2005, a whole population of older adults aged 55 years and above who were Singaporean residents in contiguous precincts in the South East region of Singapore were identified from a door-to-door census and invited to participate in the Singapore Longitudinal Ageing Study (SLAS). (No identifiable website)	Ng, Tze Pin, et al. "Metabolic Syndrome and the Risk of Mild Cognitive Impairment and Progression to Dementia: Follow-up of the Singapore Longitudinal Ageing Study Cohort." JAMA neurology 73.4 (2016): 456-463.
Study of Osteoporotic Fractures (SOF) US	The multi-center Study of Osteoporotic Fractures (SOF) has 20 years of prospective data about osteoporosis that has served as the basis for many findings about osteoporosis and aging in women $\geq$ age 65. In addition to adjudication of fractures, SOF has tracked cases of incident breast cancer, and total and cause-specific mortality <a href="http://sof.ucsf.edu/interface/">http://sof.ucsf.edu/interface/</a>	Slinin, Yelena, et al. "Cystatin C and cognitive impairment 10 years later in older women." The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 70.6 (2015): 771-778.
The Sydney Memory and Ageing Study (Sydney MAS) Australia	The Sydney Memory and Ageing Study (Sydney MAS) began in 2005 to examine the clinical characteristics and prevalence of mild cognitive impairment (MCI) and related syndromes, and to determine the rate of change in cognitive function over time. It is one of the largest longitudinal studies of this kind in Australia. At the baseline assessment from 2005 to 2007, 1037 non-demented individuals aged 70-90 were recruited from two areas of Sydney, following a random approach to 8914 individuals on the electoral roll. They underwent detailed neuropsychological and medical assessments and donated a blood sample for clinical chemistry, proteomics and genomics. <a href="https://cheba.unsw.edu.au/project/sydney-memory-and-ageing-study">https://cheba.unsw.edu.au/project/sydney-memory-and-ageing-study</a>	Heffernan, Megan, et al. "Alcohol Consumption and Incident Dementia: Evidence from the Sydney Memory and Ageing Study." Journal of Alzheimer's Disease Preprint (2016): 1-10.  Sachdev, Perminder S., et al. "Risk profiles for mild cognitive impairment vary by age and sex: the Sydney Memory and Ageing Study." The American Journal of Geriatric Psychiatry 20.10 (2012): 854-865.
UK Health and Lifestyle Study UK	The Health Survey for England (HSE) is an important annual survey looking at changes in the health and lifestyles of people all over the country. Around 8,000 adults and 2,000 children take part in the survey each year. Information is collected through an interview, and if participants agree, a visit from a specially trained nurse. The surveys, which have been carried out since 1991, provide regular information that cannot be obtained from other sources. <a href="https://www.ucl.ac.uk/hssrg/studies/hse">https://www.ucl.ac.uk/hssrg/studies/hse</a>	No relevant studies immediately found
Washington-	The Washington Heights-Hamilton Heights-Inwood Community Aging Project (WHICAP)	Helzner, Elizabeth P., et al. "Contribution of

<b>Committee-suggested Cohort Studies Country</b>	<b>Cohort Study Description</b>	<b>Example of excluded publication derived from cohort study</b>
Heights Inwood Columbia Aging Project (WHICAP)  US	is a community-based longitudinal study of aging and dementia among elderly, urban-dwelling residents. The project began enrolling patients in 1989 and has followed more than 5,900 residents over 65 years of age. The WHICAP study has enabled researchers to capture detailed information about the onset of dementia and how symptoms develop over time. <a href="http://www.alzrisk.org/cohort.aspx?cohortID=16&amp;rfid=3">http://www.alzrisk.org/cohort.aspx?cohortID=16&amp;rfid=3</a>	vascular risk factors to the progression in Alzheimer disease." Archives of neurology 66.3 (2009): 343-348.
Whitehall II Prospective Cohort Study  UK	Whitehall II is a longitudinal, prospective cohort study of 10,308 women and men, all of whom were employed in the London offices of the British Civil Service at the time they were recruited to the study in 1985. The initial data collection included a clinical examination and self-report questionnaire. Research continues to explore the pathways and mechanisms through which social position influences health. The research group aims to build a causal model leading from social position through psychosocial and behavioural pathways to pathophysiological changes, sub-clinical markers of disease, functional change, and clinical disease. <a href="https://www.ucl.ac.uk/whitehallII">https://www.ucl.ac.uk/whitehallII</a>	Singh-Manoux, Archana, et al. "Interleukin-6 and C-reactive protein as predictors of cognitive decline in late midlife." Neurology 83.6 (2014): 486-493.  Akbaraly, Tasnime N., et al. "Metabolic Syndrome Over 10 Years and Cognitive Functioning in Late Midlife The Whitehall II study." Diabetes care 33.1 (2010): 84-89.

## Appendix F. Cognitive Training Interventions

**Appendix Table F1. Characteristics of eligible studies: ACTIVE trial publications**

Study Design Country RoB	N=	Population Inclusion Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome timing	Outcome Domain [Instrument]
Rebok 2014 <sup>1</sup> RCT US High	2832	Older adults aged 65 to 94 years with good functional and cognitive status and a MMSE score greater than 22 Age, Mean (SD) 74 (6) 76% Female 73% White 88.6% High School Graduate MMSE, Mean (SD) 27.2 (2.0)	Verbal episodic memory training or reasoning training or speed of processing training -10 small group sessions, 60-75 minutes each over 5 to 6 weeks	No contact control group (study duration)	10 years	<u>Executive/Attention/Processing Speed</u> [Reasoning Composite] [Speed of Processing Composite] <u>Memory</u> [Memory Composite]
Rebok 2013 <sup>2</sup> RCT US High	629	Older adults aged 65 to 94 years with good functional and cognitive status and a MMSE score greater than 22 Age, Mean (SD) 73.5 (6.0) 77% Female 76% White Years Education, Mean (SD) 13.7 (2.7) MMSE, Mean (SD)	Verbal episodic memory training -10 small group sessions, 60-75 minutes each over 5 to 6 weeks	No contact control group (study duration)	1 year 2 years 3 years 5 years	<u>Memory</u> [Memory Composite]

Study Design Country RoB	N=	Population Inclusion Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome timing	Outcome Domain [Instrument]
		27.3 (2)				
Jones, 2013 <sup>3</sup> RCT US High	1659	Older adults aged 65 to 94 years with good functional and cognitive status and a MMSE score greater than 22 Age, Mean (SD) 74 (6) 77% Female 73% White Education, Mean (SD) 13.5 (3) MMSE, Mean (SD) 27 (2)	Verbal episodic memory training or reasoning training or speed of processing training -10 small group sessions, 60-75 minutes each over 5 to 6 weeks	No contact control group (study duration)	5 years	<u>Executive/Attention/Processing Speed</u> [Reasoning Composite] [Speed of Processing Composite] <u>Memory</u> [Memory Composite]
Sisco 2013 <sup>4</sup> RCT US High	1912	Older adults aged 65 to 94 years with good functional and cognitive status and a MMSE score greater than 22 Age, Mean (SD) 72.9 (5.4) 76% Female 72% White Years Education, Mean (SD) 13.2 (2.6) MMSE, Mean (SD) 27.3 (2)	Verbal episodic memory training or reasoning training or speed of processing training -10 small group sessions, 60-75 minutes each over 5 to 6 weeks	No contact control group (study duration)	1 year 2 years 3 years 5 years	<u>Memory</u> [Rivermead Paragraph Recall Test, Verbatim Recall] [Rivermead Paragraph Recall Test, Paraphrase Recall] [HVL, Total Recall] [AVLT, Total Recall]

<b>Study Design Country RoB</b>	<b>N=</b>	<b>Population Inclusion Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition</b>	<b>Intervention Mode Components Frequency Duration</b>	<b>Comparison Mode Components Frequency Duration</b>	<b>Outcome timing</b>	<b>Outcome Domain [Instrument]</b>
Valdes 2012 <sup>5</sup> RCT US High	195	Older adults from ACTIVE trial with psychometrically-defined MCI Age, Mean (SD) 78 (6) 67% Female 60% White Education Level, Mean (SD) 12 (2.5) Baseline Cognition NR	Speed of processing training -10 small group sessions, 60-75 minutes each over 5 to 6 weeks	No contact control group (study duration)	10 years	<u>Executive/Attention/Processing Speed</u> [UFOV Performance]
Unverzagt 2012 <sup>6</sup> RCT US High		Older adults aged 65 to 94 years with good functional and cognitive status and a MMSE score greater than 22 Age, Mean (SD) 74 (6) 76% Female 73% White 88.6% High School Graduate MMSE, Mean (SD) 27.2 (2.0)	Verbal episodic memory training or reasoning training or speed of processing training -10 small group sessions, 60-75 minutes each over 5 to 6 weeks	No contact control group (study duration)	5 years	<u>Diagnosis</u> [Dementia]
Wolinsky, 2010 <sup>7</sup> RCT US High	1534	Older adults aged 65 to 94 years with good functional and cognitive status and a MMSE score greater than 22	Verbal episodic memory training or reasoning training or speed of processing training -10 small group sessions, 60-75 minutes each over	No contact control group (study duration)	5 years	<u>Executive/Attention/Processing Speed</u> [Internal Locus of Control] [Chance Locus of Control] [Powerful Others Locus of Control]

Study Design Country RoB	N=	Population Inclusion Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome timing	Outcome Domain [Instrument]
		Age, Mean 73 78% Female 73% White Education Level, Mean 13 Baseline Cognition NR	5 to 6 weeks			
Wolinsky, 2010b <sup>8</sup> RCT US High	1804	Older adults aged 65 to 94 years with good functional and cognitive status and a MMSE score greater than 22 Age, Mean (SD) 74 (6) 76% Female 73% White 88.6% High School Graduate MMSE, Mean (SD) 27.2 (2.0)	Verbal episodic memory training or reasoning training or speed of processing training -10 small group sessions, 60-75 minutes each over 5 to 6 weeks	No contact control group (study duration)	2 years 3 years 5 years	<u>Executive/Attention/Processing Speed</u> [Reasoning Composite] [Speed of Processing Composite] <u>Memory</u> [Memory Composite]
Unverzagt 2007 <sup>9</sup> RCT US High	2832	Older adults aged 65 to 94 years with good functional and cognitive status and a MMSE score greater than 22 Age, Mean (SD) 74 (6) 76% Female 73% White	Verbal episodic memory training or reasoning training or speed of processing training -10 small group sessions, 60-75 minutes each over 5 to 6 weeks	No contact control group (study duration)	2 years	<u>Executive/Attention/Processing Speed</u> [Reasoning Composite] [Speed of Processing Composite] <u>Memory</u> [Memory Composite]

Study Design Country RoB	N=	Population Inclusion Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome timing	Outcome Domain [Instrument]
		88.6% High School Graduate MMSE, Mean (SD) 27.2 (2.0)				
Willis 2006 <sup>10</sup> US RCT High	2832	Older adults aged 65 to 94 years with good functional and cognitive status and a MMSE score greater than 22 Age, Mean (SD) 74 (6) 76% Female 73% White 88.6% High School Graduate MMSE, Mean (SD) 27.2 (2.0)	Verbal episodic memory training or reasoning training or speed of processing training -10 small group sessions, 60-75 minutes each over 5 to 6 weeks	No contact control group (study duration)	5 years	<u>Executive/Attention/Processing Speed</u> [Reasoning Composite] [Speed of Processing Composite] <u>Memory</u> [Memory Composite]
Ball 2002 <sup>11</sup> RCT US Medium	2832	Older adults aged 65 to 94 years with good functional and cognitive status and a MMSE score greater than 22 Age, Mean (SD) 74 (6) 76% Female 73% White 88.6% High School Graduate MMSE, Mean (SD) 27.2 (2.0)	Verbal episodic memory training or reasoning training or speed of processing training -10 small group sessions, 60-75 minutes each over 5 to 6 weeks	No contact control group (study duration)	2 years	<u>Executive/Attention/Processing Speed</u> [Reasoning Composite] [Speed of Processing Composite] <u>Memory</u> [Memory Composite]



ACTIVE=Advanced Cognitive Training for Independent and Vital Elderly; AVLT=Auditory Verbal Learning Test; HVLT=Hopkins Verbal Learning Test; N=sample size; NR=not reported; RCT=Randomized Controlled Trial; RoB=Risk of Bias; SD=standard deviation; US=United States

**Appendix Table F2. ACTIVE Sample Loss (Based on Initial Enrollment)**

	<b>Memory</b>	<b>Reasoning</b>	<b>Speed</b>	<b>Control</b>
Enrolled	711	705	712	704
Completed Training	620	627	637	
<b>2 Years</b>	<b>563</b>	<b>555</b>	<b>574</b>	<b>584</b>
2 Years Loss	148	150	138	120
2 Years % Loss	21%	21%	19%	17%
2 Years Deaths	6	3	9	9
2 years % Loss/Death	4%	2%	7%	8%
<b>5 Years</b>	<b>472</b>	<b>469</b>	<b>490</b>	<b>448</b>
5 Years Loss	239	236	222	256
5 Years % Loss	34%	33%	31%	36%
5 Years Deaths	32	41	46	46
5 Years % Loss/Death	13%	17%	21%	18%
<b>10 Years</b>	<b>300</b>	<b>316</b>	<b>319</b>	<b>285</b>
10 Years Loss	411	389	393	419
10 Years % Loss	58%	55%	55%	60%
10 Years Deaths	103	85	103	98
10 Years % Loss/Death	25%	22%	26%	23%

ACTIVE=Advanced Cognitive Training for Independent and Vital Elderly

**Appendix Table F3. Summary risk of bias assessments: ACTIVE trial**

<b>Study</b>	<b>Overall Risk of Bias Assessment</b>	<b>Rationale</b>
Rebok 2014 <sup>1</sup>	High	Potential attrition bias with attrition rate of 57%.
Rebok 2013 <sup>2</sup>	High	Potential attrition and reporting bias.
Jones 2013 <sup>3</sup>	High	Attrition rate is greater than 21% with insufficient analysis to address potential for bias.
Sisco 2013 <sup>4</sup>	High	Attrition rate is 33% with insufficient analysis to address potential for bias.
Valdes 2012 <sup>5</sup>	High	Potential attrition and reporting bias.
Unverzagt 2012 <sup>6</sup>	High	Attrition rate is 33% with insufficient analysis to address potential for bias.
Wolinsky 2010 <sup>7</sup>	High	Potential attrition bias with attrition rate of 55%.
Wolinsky 2010b <sup>8</sup>	High	Attrition rate is 36% with insufficient analysis to address potential for bias.
Unverzagt 2007 <sup>9</sup>	High	Attrition rate is greater than 21% with insufficient analysis to address potential for bias.
Willis 2006 <sup>10</sup>	High	Attrition rate is 33% with insufficient analysis to address potential for bias.
Ball 2002 <sup>11</sup>	Medium	Potential attrition and detection bias.

ACTIVE=Advanced Cognitive Training for Independent and Vital Elderly

**Appendix Table F4. Strength of evidence assessments: ACTIVE Trial**

Outcome Timing	Outcome	# Trials (n)	Summary statistics [95% CI]	Study Limitations	Directness	Precision	Consistency	Reporting Bias	Optional Components	SOE
2-Year Outcomes	Memory	1 (2,832)	Improvement with memory training intervention (ES=0.17). No significant differences with reasoning speed of processing training.	Medium	Indirect	Precise	Unknown	Undetected	NA	Moderate
	Reasoning	1 (2,832)	Improvement with reasoning training (ES=0.257). No significant differences with memory or speed of processing training.	Medium	Indirect	Precise	Unknown	Undetected	NA	Moderate
	Speed of Processing	1 (2,832)	Improvement with speed of processing training (ES=0.87). No significant differences with reasoning or memory training.	Medium	Indirect	Precise	Unknown	Undetected	NA	Moderate
5- and 10-Year Outcomes	Diagnosis	1 (2,832)	No statistically significant differences between intervention arms (aggregate) and control (5-Years).	High	Direct	Precise	Unknown	Undetected	NA	Insufficient
	Memory	1 (2,832)	<u>5-Years</u> Improvement with memory training (ES=0.23). No significant differences with reasoning speed of processing training.	High	Indirect	Precise	Unknown	Undetected	NA	Low

Outcome Timing	Outcome	# Trials (n)	Summary statistics [95% CI]	Study Limitations	Directness	Precision	Consistency	Reporting Bias	Optional Components	SOE
			<u>10 Years</u> No statistically significant differences between intervention arms and control.							
	Reasoning	1 (2,832)	Improvement with reasoning training (5-Years: ES=0.26; 10-Years: ES=0.23). No significant differences with memory or speed of processing training.	High	Indirect	Precise	Unknown	Undetected	NA	Low
	Speed of Processing	1 (2,832)	5-Years Improvement with reasoning training (ES=0.15) and speed of processing training (ES=0.076). No significant differences with memory training.  <u>10 Years</u> Improvement with speed of processing training (ES=0.66). No significant differences with reasoning or memory training.	High	Indirect	Precise	Unknown	Undetected	NA	Low

ACTIVE=Advanced Cognitive Training for Independent and Vital Elderly; CI=confidence interval; ES=effect size; n=sample size; NA=not applicable; SOE=strength of evidence



**Appendix Table F5. Characteristics of eligible studies: other cognitive training trials in adults with normal cognition**

<b>Study Design Country RoB</b>	<b>N=</b>	<b>Population Inclusion Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition</b>	<b>Intervention Mode Components Frequency Duration</b>	<b>Comparison Mode Components Frequency Duration</b>	<b>Outcome Timing</b>	<b>Outcome Domain [Instrument]</b>
Corbett 2015 RCT UK High	6742	Adults over 50 with access to a computer and internet Age, Mean (SD) 58.9 (6.5) 67% Female 97% White 50% University Graduate Baseline Cognition NR	Evidence-based reasoning and problem solving cognitive training or general cognitive training - 10 minutes daily for 6 months	Internet-based tasks and games --10 minutes daily for 6 months	6 month	<u>Executive/Attention/Processing Speed</u> [Digit Vigilance, DSTask] <u>Memory</u> [PALS] [HVLTL] [Spatial Working Memory]
Anderson 2014 RCT US High	62	Adults age 55 to 70 years old Age, Mean (SD) 63 (4) 55% Female Race NR Education NR Baseline Cognition NR	Brain Fitness Program, a in-home auditory-based program of six modules to increase speed and accuracy of auditory processing -1 hour/day, 5 days/week for 8 weeks	In-home educational DVDs -1 hour/day, 5 days/week for 8 weeks	6 months	<u>Executive/Attention/Processing Speed</u> [Visual Matching Sub-test, Woodcock-Johnson III Tests of Cognitive Abilities] <u>Memory</u> [Memory for Words Sub-test, Woodcock-Johnson III Tests of Cognitive Abilities]
Lampit 2014 RCT Australia High	80	Older adults without dementia who were able to use a computer and had an MMSE score greater than 23 Age, Mean (SD) 71 (6.2) 66% Female Race NR Education NR MMSE, Mean (SD) 28 (1.6)	Computerized cognitive training with 24 exercises providing training in the domains of memory, attention, response speed, executive functions and language -30-45 minute sessions, 3 times/week, over 12 weeks	National geographic videos and multiple choice questions after videos -30-45 minute sessions, 3 times/week, over 12 weeks	52 weeks	<u>Multidomain Neuropsychological Performance</u> [Global Cognition Composite] <u>Executive/Attention/Processing Speed</u> [Information Processing Speed Composite] [Executive Function Composite] <u>Memory</u> [Memory Composite] <u>Language</u> [Language Composite]
Stine-Morrow 2014 <sup>12</sup> RCT	461	Adults without dementia or neurological impairment	Odyssey of the Mind engagement program –16 weekly meetings for 1.5	Waitlist control	8 months	<u>Executive/Attention/Processing Speed</u> [Processing Speed Composite] <u>Memory</u> [Episodic Memory Composite]

Study Design Country RoB	N=	Population Inclusion Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome Timing	Outcome Domain [Instrument]
US Medium		Age, Mean (SD) 23 (7.6) 75% Female Race NR Education Level, Mean (SD) 15.4 (2.6) MoCA, Mean (SD) 26 (3)	hours  Home-based reasoning training -10 weekly lessons supplemented with 6 packs of crossword and Sudoku puzzles			<u>Visuospatial</u> [Visuospatial Composite]
Anguera 2013	80	Treatment naïve older adults Age, Mean (SD)	Neuroracer, a three dimensional video game either in single-task or multi-tasking mode -1 hour/day, 3 times/week for 4 weeks	No contact control	6 months	<u>Executive/Attention/Processing Speed</u> [Test of Variables of Attention, RT] [Test of Variables of Attention, RT Variability] [UFOV] <u>Memory</u> [Delayed-recognition Working Memory Task Ignoring Distraction RT] [Delayed-Recognition Working Memory Task Attend to Distraction RT] [Delayed-recognition Working Memory Task No Distraction RT]
Borness 2013 RCT Australia High	135	Full and part time staff from an Australian national public service organization Age, Mean (SD) 41.6 (13) 63.7% Female Race NR Education, Mean (SD) 13.7 (2.4) Baseline Cognition NR	Thirty-six online exercises across the domains of memory, attention, language, executive function and visuospatial abilities -20 minutes/sessions, 3 sessions/week, for 16 weeks	Videos about about the natural environment and answering multiple choice questions in a survey -20 minutes/sessions, 3 sessions/week, for 16 weeks	6 months	<u>Executive/Attention/Processing Speed</u> [Matrix Reasoning] [COWAT] SCWT 1] [SCWT 2] [SCWT 3] [Staged Information Processing Speed Level 1] [Staged Information Processing Speed Level 2] [Staged Information Processing Speed Level 3] [Divided Attention Indicator Alone Median Response Time] <u>Memory</u> [Verbal Memory, Total Accuracy] [Delayed Verbal Memory, Total Accuracy] [Non Verbal Memory, Total Accuracy] [Delayed Non Verbal Memory, Total Accuracy] <u>Language</u> [COWAT] <u>Visuospatial</u> [Visual Spatial Orientation] [Visual Sequence Comparison Thruput]



Study Design Country RoB	N=	Population Inclusion Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome Timing	Outcome Domain [Instrument]
						I [Visual Sequence Comparison Median Response Time]
Carretti 2013 <sup>13</sup> RCT Italy Medium	40	Healthy older adults active in cultural and social activities in their neighborhood Age, Mean (SD) 70 (3.6) Sex NR Race NR Education, Mean (SD) 8.56 (4.3) Baseline Cognition NR	Six individual training sessions over 2 weeks (sessions 2-4 were training, sessions 1, 5, and 6 were for baseline, posttest, and 6 month follow-up, respectively)	Paper-and-pencil questionnaires	6 months	Memory [CWMS] [Working Memory Updating Word Span Test, Updating]
Miller 2013 <sup>14</sup> RCT US Medium	84	Adults with no signs of dementia and a MMSE score of 24 or more Age, Mean (SD) 81.8 (6) 67% Female 96% White Years Education, Mean (SD) 16 (2.2) MMSE, Mean (SD) 28 (1.6)	Computer brain fitness program -5 days a week for 20-25 minutes/day for 8 weeks followed by 4 months of doing as many sessions as they preferred	Wait-list control -2 months wait period prior to access to intervention for 4 months	6 months	Memory [Delayed Memory Composite] [Immediate Memory Composite] Language [Language Composite]
Wolinsky 2013 <sup>15</sup> RCT US Low	681	Adults without a diagnosis of cognitive impairment Age, Mean 57.2 68.6% Female 94.2% White 71.9% College Graduate	On-site visual speed of processing training with and without 2 hour boosters after 11 months - Five weekly, 2 hour training sessions  At home visual speed of processing training -10	On-site computerized crossword game – Five weekly, 2 hour training session	1 year	Executive/Attention/Processing Speed [UFOV] [TMT A] [TMT B] [SDMT] [SCWT (Word)] [SCWT (Color)] [SCWT (Color-Word)] [COWAT] [DVT, Time] [DVT, Errors]

Study Design Country RoB	N=	Population Inclusion Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome Timing	Outcome Domain [Instrument]
		Baseline Cognition NR	hours			
Cheng 2012 <sup>16</sup> RCT China High	270	Older adults with no evidence of significant cognitive impairment Age, Mean (SD) 70 (3.5) 48% Female Race NR Education, Mean (SD) 9.6 (3.9) Baseline Cognition NR	Multidomain training or reasoning training group cognitive training sessions –Twice a week for 12 weeks	Wait list control	6 months 12 months	<u>Brief Cognitive Test Performance</u> [MMSE] <u>Multidomain Neuropsychological Performance</u> [RBANS Total Score] [RBANS Attention] [SCWT (Interference)] [SCWT (Number of Naming Errors)] [TMT A] [TMT B] <u>Memory</u> [RBANS Immediate Memory] [RBANS Delayed Memory] [Visual Reasoning Test] <u>Language</u> [RBANS Language] <u>Visuospatial</u> [RBANS Visuospatial/Constructional]
Mortimer 2012 <sup>17</sup> RCT China High	75	Adults age 60-79 with an education-adjusted Chinese MMSE score greater than 26 Age, Mean (SD) 67.8 (5.8) 67% Female Race NR Years of Education, Mean (SD) 11.7 (3.4) Mattis Dementia Scale Score, Mean (SD) 137.6 (7.6)	Social interaction – Meeting at community center for 1 hour, 3 times/week	Inactive control with 4 check-in calls over 40 weeks	40 weeks	<u>Biomarker</u> [Whole Brain Volume, % of Total Intracranial Volume] <u>Multidomain Neuropsychological Performance</u> [Mattis Dementing Rating Scale, Total Score] <u>Executive/Attention/Processing Speed</u> [DS Forward] [DS Backward] [SCWT (Word)] [SCWT (Color)] [SCWT (Color-Word)] [WAIS Similarities] [TMT A] [TMT B] [Mattis Attention Score] [Mattis Initiation Score] [Mattis Conceptualization Score] <u>Memory</u> [AVLT, Immediate Recall] [AVLT, Delayed Recall] [AVLT, Delayed Recognition] [RCFT, Recall] [Mattis Memory Score] <u>Language</u> [CVFT, Animals] [BNT] <u>Visuospatial</u> [Bell Cancellation Test] [RCFT, Copying] [RCFT, Recall] [CLOX-1] [Mattis Construction Score]
Szelag 2012 <sup>18</sup> RCT Poland	30	Healthy adults between 65 and 75 years old Age, Mean (SD)	Temporal information processing training -32 hour-long sessions for 8	Non-temporal training using computer games or no	18 months	<u>Executive/Attention/Processing Speed</u> [Attention Measure] <u>Memory</u> [Spatial Span] [Delayed Matching to

Study Design Country RoB	N=	Population Inclusion Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome Timing	Outcome Domain [Instrument]
High		69 (2) 57% Female Race NR Years Education, Mean (SD) 13 (3) MMSE, Range 27-30	weeks	intervention over 8 weeks		Sample] [Pattern Recognition Memory Test]
Evers 2011 <sup>19</sup> RCT Germany High	161	Women age 70 and over with no more than 4 errors on the MMSE Age, Mean (SD) 73.6 (4.2) 100% Female Race NR Years of Education, Mean (SD) 12 (2.6) MMSE, Mean (SD) 28.78 (0.96)	Computer course (writing, playing, calculating, surfing the Internet, emailing, drawing, image editing, and video taping)	Inactive control (live their habitual life)	6 months	<u>Executive/Attention/Processing Speed</u> [SCWT] [TMT B/A] <u>Memory</u> [RBMT, Immediate] [RBMT, Delayed Recall] [FCSRT, Short Delay] [FCSRT, Long Delay] <u>Language</u> [Semantic Verbal Fluency]
Borella 2010 <sup>20</sup> RCT Italy High	40	Healthy adults with not pathologies causing possible cognitive impairments Age, Mean (SD) 69 (3) Sex NR Race NR Education, Mean (SD) 9.3 (3.7) Baseline Cognition NR	Working memory training - 3 60- minute sessions over 2 weeks	Memory questionnaires -3 60-minute sessions over 2 weeks	8 months	<u>Executive/Attention/Processing Speed</u> [DS Forward] [DS Backward] [SCWT (Color Incongruent, RTs)] [SCWT (Color Control II, RTs)] [SCWT (Color Index, RTs)] [SCWT (Color Incongruent, Errors)] [SCWT (Color Control II, Errors)] [SCWT (Color Index, Errors)] [Pattern Comparison] <u>Memory</u> [CWMS] <u>Visuospatial</u> [Dot Matrix]
Klusmann, 2010 <sup>21</sup> RCT Germany	168	Women older than 70 without cognitive impairment	Computer courses focusing on creative tasks and coordinative and	Living habitual life over 6 months	6 months	<u>Executive/Attention/Processing Speed</u> [TMT A/B] [SCWT] <u>Memory</u> [RBMT, Immediate] [RBMT, Delayed

Study Design Country RoB	N=	Population Inclusion Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome Timing	Outcome Domain [Instrument]
Medium		Age, Mean (SD) 74 (4) 100% Female Race NR Years Education, Mean (SD) 12 (2.6) MMSE, Mean (SD) 28.8 (0.97)	memory tasks -75 intervention units of 90 minutes over 6 months			Recall] [FCSRT, Short Delay] [FCSRT, Long Delay]
McDougall 2010 <sup>22</sup> RCT US High	265	Non-demented older adults Age, Mean 75 79% Female 71% White Education, Mean (SD) 13.6 (3.8) Baseline Cognition MMSE, Mean 26	Small group memory training -2 times/week for a month, 12 hours total with 4, 2-hour booster sessions over 3 months following training	Health promotion training focusing on 18 topics -2 times/week for a month, 12 hours total with 4, 2-hour booster sessions over 3 months following training	6 months 14 months 26 months	<u>Brief Cognitive Test Performance</u> [MMSE] <u>Memory</u> [RBMT] [BVMT, Delayed Recall] [HVLTL, Delayed Recall]
Park 2009 <sup>23</sup> RCT South Korea High	129	Adults age 65 and over without clinically significant diseases Age, Mean (SD) 78.3 (6,22) 93% Female Race NR Years Education, Mean (SD) 4.62 (4.33) MMSE, Mean (SD) 22.14 (4.61)	Cognitive training program -12, 60-minute sessions followed by an observational period	Delayed cognitive training program -8 weeks of observation followed by cognitive training program	24 weeks	<u>Brief Cognitive Test Performance</u> [MMSE]
Slegers 2009 <sup>24</sup> RCT Netherlands High	191	Healthy older adults with no prior computer experience Age NR	Small group practice with personal computer following by at home practice with a personal	No training/no intervention	12 months	<u>Brief Cognitive Test Performance</u> [Cognitive Failures Questionnaire] <u>Executive/Attention/Processing Speed</u> [Letter-Digit Substitution Test] [SCWT]

Study Design Country RoB	N=	Population Inclusion Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome Timing	Outcome Domain [Instrument]
		Sex NR Race NR Education NR MMSE, Mean (SD) 28 (1.4)	computer with at home assignments -4 hour training sessions over 2 weeks followed by home practice over 12 months			<u>Memory</u> [Visual Verbal Learning Test] <u>Motor</u> [Motor Choice RT]
Buiza 2008 <sup>25</sup> RCT Spain High	238	Adults age 65 and over without cognitive impairment Age, Mean (SD) 74 (8) 73% Female Race NR Education NR Baseline Cognition NR	Structured and unstructured cognitive training with and without information on well-being -Weekly sessions with 180 sessions over 2 years	No training (regular daily activities)	1 year 2 years	<u>Executive/Attention/Processing Speed</u> [Abstraction] [TMT A] [Pho-Phonetic Fluency Execution] [Ideomotor Praxia] <u>Memory</u> [Immediate Memory, WMS] [Recent Logical Execution Memory, AVLTL] [Short Term Memory] [Working Memory] <u>Language</u> [Ideomotor Praxia]
Buschkuehl 2008 RCT Switzerland High	39	High-functioning without any severe psychiatric problems Age, Mean (SD) 80 (3.3) 59% Female Race NR Education NR Baseline Cognition NR	Working memory training - 45 minute sessions, 2 sessions/week for 12 weeks	Physical training with an eccentric bicycle ergometer -45 minute sessions, 2 sessions/week for 12 weeks	1 year	<u>Executive/Attention/Processing Speed</u> [DSST] <u>Memory</u> [Verbal Free Recall] [Visual Free Recall] <u>Visuospatial</u> [Block-Span Task]
Yesavage 2008 <sup>26</sup> RCT US High	168	Community-dwelling adults aged 55-90 with a MMSE score between 24 and 30 Age, Mean (SD) 65 (8) 52% Female Race NR Education, Mean (SD) 16.3 (2.3) MMSE, Mean (SD)	Daily dose of 5 mg of Donepezil for 6 weeks, then increased to 10mg daily for 46 weeks; 2 weeks of cognitive training at weeks 13-14	Placebo and 2 weeks of cognitive training at weeks 13-14	1 year	<u>Executive/Attention/Processing Speed</u> [DSST] <u>Memory</u> [Word List Recall] [Name-Face Recall] [Logical Memory I Score] [Logical Memory II Score]

<b>Study Design Country RoB</b>	<b>N=</b>	<b>Population Inclusion Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition</b>	<b>Intervention Mode Components Frequency Duration</b>	<b>Comparison Mode Components Frequency Duration</b>	<b>Outcome Timing</b>	<b>Outcome Domain [Instrument]</b>
		28.6 (1.2)				

AVLT=Auditory Verbal Learning Test; BNT=Boston Naming Test; BVMT=Brief Visuospatial Memory Test; BVRT=Benton Visual Retention Test; CLOX-1=Clock Drawing Test; COWAT=Controlled Oral Word Association Test; DS=Digit Span (Forward and/or Backward); DVT=Digit Vigilance Test; FCSRT=Free and Cued Selective Reminding Test; HVLT=Hopkins Verbal Learning Test; MCI=mild cognitive impairment; MMSE=Mini-Mental Status Examination; N=sample size; PALS=Paired Association Learning Test; RBANS=Repeatable Battery for Neuropsychological Status; RBMT= Rivermead Behavioral Memory Test; RCFT=Rey-Osterrieth Complex Figure Test; RCT=randomized controlled trial; RoB=risk of bias; RT=Reaction Time; SCWT=Stroop Color Word Test; SD=standard deviation; SDMT=Symbol Digit Modalities Test; SOE=strength of evidence; TMT=Trail Making Test (Part A and/or B); UFOV=Useful Field of View; US=United States;

**Appendix Table F6. Summary risk of bias assessments: other cognitive training trials in adults with normal cognition**

<b>Study</b>	<b>Overall Risk of Bias Assessment</b>	<b>Rationale</b>
Corbett 2015	High	Suspected selection bias due to process for participant recruitment and attrition bias due to attrition rate of over 40%.
Anderson 2014	High	Process for randomization is unclear and attrition rate is 22% with no analysis to address potential bias.
Lampit 2014		Attrition rate is 31% with no analysis to address potential bias.
Stine-Morrow 2014 <sup>12</sup>	Medium	Process for randomization is unclear with potential attrition bias.
Anguera 2013	High	Suspected selection, attrition, and detection bias.
Borness 2013	High	Process for randomization is unclear and attrition rate is 35% with no analysis to address potential bias.
Carretti 2013 <sup>13</sup>	Medium	Process for randomization is unclear with potential performance bias.
Miller 2013 <sup>14</sup>	Medium	Process for randomization is unclear with potential attrition bias.
Wolinsky 2013 <sup>15</sup>	Low	No suspected biases
Cheng 2012 <sup>16</sup>	High	Potential attrition bias with attrition rate of 40%.
Mortimer 2012 <sup>17</sup>	High	Potential selection bias due to process for randomization
Szelag 2012 <sup>18</sup>	High	Potential selection and attrition bias.
Evers 2011 <sup>19</sup>	High	Potential selection, attrition, and performance bias.
Borella 2010 <sup>20</sup>	High	Process for randomization is unclear and potential detection bias.
Klusmann 2010 <sup>21</sup>	Medium	Process for randomization is unclear with potential attrition bias.
McDougall 2010 <sup>22</sup>	High	Potential attrition and reporting bias.
Park 2009 <sup>23</sup>	High	Process for randomization is unclear with potential attrition and reporting bias.

<b>Study</b>	<b>Overall Risk of Bias Assessment</b>	<b>Rationale</b>
Slegers 2009 <sup>24</sup>	High	Potential reporting bias and selection bias due to process for selecting participants.
Buiza 2008 <sup>25</sup>	High	Potential attrition, detection, and reporting bias.
Buschkuehl 2008	High	Attrition bias with an attrition rate is 44%.
Yesavage 2008 <sup>26</sup>	High	Potential attrition bias with attrition rate of 29%.
Oswald 2006	High	Suspected selection bias due to process for randomization.




**Appendix Table F7. Cognitive Training vs. Inactive Comparison, Normal Cognition: Effect Sizes for Miller 2013 (n=84), Klusmann 2010 (n=259), and Carretti 2012 (n=40)**

<b>Study</b>	<b>Test</b>	<b>Cohen's D</b>	<b>95% CI Lower</b>	<b>95% CI Upper</b>
Miller 2013	Memory: Delayed Buschke-Fuld	0.12	-0.34	0.57
Miller 2013	Memory: Delayed Rey-Osterrieth	-0.02	-0.48	0.43
Miller 2013	Memory: Delayed Verbal Pairs, Weschler	0.12	-0.34	0.58
Miller 2013	Memory: Buschke-Fuld Total	0.14	-0.32	0.59
Miller 2013	Memory: Rey-Osterrieth Copy	0.38	-0.08	0.84
Miller 2013	Memory: Verbal Pairs Total, Weschler	0.10	-0.36	0.55
Klusmann 2010	Memory: RBMT, Immediate Recall	0.34	0.15	0.66
Klusmann 2010	Memory: RBMT, Delayed Recall	0.33	0.01	0.65
Klusmann 2010	Memory: FCSRT, Short Delay	0.04	-0.29	0.36
Klusmann 2010	Memory: FCSRT, Long Delay	0.31	-0.01	0.63
Carretti 2012	Memory: Categorization Working Memory Span Test	1.44	0.73	2.13
Carretti 2012	Memory: Working Memory Updating Word Span Test	1.92	1.16	2.67
Klusmann 2010	Executive/Attention/Processing Speed: Stroop Test	-0.13	-0.45	0.20
Klusmann 2010	Executive/Attention/Processing Speed: TMT B/A	-0.32	-0.65	0.00

CI=Confidence Interval; FCSRT= Free and Cued Selective Reminding Test; RBMT= Rivermead Behavioral Memory Test; TMT=Trail Making Test

**Appendix Figure F1. Cognitive Training vs. Inactive Comparison, Normal Cognition: Plots of Effect Sizes for Miller 2013 (n=84), Klusmann 2010 (n=259), and Carretti 2012 (n=40)**




CI=Confidence Interval; RBMT= Rivermead Behavioral Memory Test; FCSRT= Free and Cued Selective Reminding Test; TMT=Trail Making Test

**Appendix Table F8. Cognitive Training vs. Active Comparison, Normal Cognition: Effect Sizes for Wolinsky 2013 (n=681)**

<b>Study Arm</b>	<b>Test</b>	<b>Cohen's D</b>	<b>95% CI Lower</b>	<b>95% CI Upper</b>
<b>At Home Training</b>	UFOV	-0.37	-0.55	-0.15
	TMT A	-0.27	-0.49	-0.04
	TMT B	-0.26	-0.49	-0.04
	SDMT	0.31	0.07	0.55
	Stroop Word	0.24	0.00	0.48
	Stroop Color	0.18	-0.06	0.42
	Stroop Color-Word	0.19	-0.05	0.44
	COWAT	0.23	-0.01	0.47
	DVT, Time	-0.21	-0.44	0.04
	DVT, Errors	-0.05	-0.27	0.17
<b>Onsite Training</b>	UFOV	-0.32	-0.56	-0.09
	TMT A	-0.26	-0.50	-0.23
	TMT B	-0.23	-0.46	0.01
	SDMT	0.26	0.01	0.51
	Stroop Word	0.27	0.02	0.52
	Stroop Color	0.03	-0.22	0.28
	Stroop Color-Word	0.11	-0.14	0.37
	COWAT	0.11	-0.14	0.36
	DVT, Time	-0.06	-0.31	0.19
	DVT, Errors	-0.11	-0.35	0.12
<b>Onsite Training with Boosters</b>	UFOV	-0.58	-0.82	-0.34
	TMT A	-0.20	-0.45	0.04
	TMT B	-0.32	-0.57	-0.07
	SDMT	0.35	0.09	0.61
	Stroop Word	0.27	0.01	0.53
	Stroop Color	0.25	-0.01	0.51
	Stroop Color-Word	0.19	-0.08	0.45
	COWAT	0.15	-0.11	0.41
	DVT, Time	-0.25	-0.51	0.01
	DVT, Errors	-0.10	-0.35	0.14

CI=Confidence Interval; COWAT=Controlled Oral Word Association Test; DVT=Digit Vigilance Test; SDMT= Symbol Digit Modalities Test; TMT=Trail Making Test (Parts A and B); UFOV= Useful Field of View

Appendix Figure F2. Cognitive Training vs. Active Comparison, Normal Cognition: Plots of Effect Sizes for Wolinsky 2013 (n=681)



CI=Confidence Interval; COWAT=Controlled Oral Word Association Test; DVT=Digit Vigilance Test; SDMT= Symbol Digit Modalities Test; TMT=Trail Making Test (Parts A and B); UFOV= Useful Field of View

**Appendix Table F9. Characteristics of eligible studies: other cognitive training trials in adults with MCI**

Study Design Country RoB	N=	Population Inclusion Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome timing	Outcome Domain [Instrument]
Jeong 2016 RCT South Korea High	195	Adults age 50-85 diagnosed with aMCI using Peteresen criteria Age, Mean (SD) 70.3 (11) 63% Female Race NR Education, Mean (SD) 9.8 (4.4) MMSE, Mean (SD) 25.7 (2.5)	Group-based cognitive intervention -90 minute sessions, 2 times/week for 12 weeks	Wait list control	6 months	<u>Diagnosis</u> [CDR, Sums of Boxes] <u>Brief Cognitive Test Performance</u> [MMSE] <u>Multidomain Neuropsychological Test Performance</u> [ADAS-Cog] <u>Executive/Attention/Processing Speed</u> [Executive Function Composite] <u>Memory</u> [Logical Memory Composite] [Working Memory Composite] [Prospective Memory Test]
Jeong 2016 RCT South Korea High	197	Adults age 50-85 diagnosed with aMCI using Peteresen criteria Age, Mean (SD) 70.3 (11) 63% Female Race NR Education, Mean (SD) 9.8 (4.4) MMSE, Mean (SD) 25.7 (2.5)	Home-based cognitive intervention that involved homework materials (memory tasks) to be completed 5 days/week for 12 weeks	Wait list control	6 months	<u>Diagnosis</u> [CDR, Sums of Boxes] <u>Brief Cognitive Test Performance</u> [MMSE] <u>Multidomain Neuropsychological Test Performance</u> [ADAS-Cog] <u>Executive/Attention/Processing Speed</u> [Executive Function Composite] <u>Memory</u> [Logical Memory Composite] [Working Memory Composite] [Prospective Memory Test]
Lam 2015 <sup>27</sup> RCT China High	277	Chinese older adults with MCI (presence of subjective cognitive complaints and objective impairments in cognitive function) Age, Mean (SD) 75.4 (6.5) 78.2% Female Race NR	Cognitive and mind-body exercises -1 hour sessions 3 times/week	Cognitively demanding activities (e.g., reading and discussing news, board games) –At least 3 sessions/weeks	8 months 12 months	<u>Diagnosis</u> [CDR, Sums of Boxes] <u>Brief Cognitive Test Performance</u> [MMSE] <u>Multidomain Neuropsychological Test Performance</u> [ADAS-Cog, Chinese Version] <u>Memory</u> [Delayed Recall] <u>Language</u> [CVFT]

Study Design Country RoB	N=	Population Inclusion Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome timing	Outcome Domain [Instrument]
		Education Level, Mean (SD) 3.9 (3.6) ADAS-cog, Mean (SD) 11.5 (3.3)				
Moro 2015 Crossover RCT Italy High	30	Adults with MCI diagnosed with Mayo criteria Age, Mean (SD) 74.8 (6.7) Sex NR Race NR Education, Mean (SD) 9.6 (4) MOCA, Mean (SD) 24.4 (3.7)	Individualized cognitive training program for 6 months followed by 6 months of no intervention - 2 sessions/week for 2 months followed by 1 session/week for 4 months	No intervention for 6 months followed by 6 months of an individualized cognitive training program - 2 sessions/week for 2 months followed by 1 session/week for 4 months	6 months 12 months	<u>Brief Cognitive Test Performance</u> [MOCA] <u>Executive/Attention/Processing Speed</u> [TMT B/A] [Tower of London] [Dual Task] [Attention Elevator Test] <u>Memory</u> [RBMT] [Listening Span Test] <u>Language</u> [Comprehension, Aachener Aphasia Test] [Denomination, Aachener Aphasia Test] [Repetition, Aachener Aphasia Test]
Vidovich 2015 <sup>28</sup> RCT US Low (52 weeks) High (104 Weeks)	150	Adults age 65 years and older with MCI Age, Mean (SD) 75 (6) 54% Female 80% With High School Education Baseline Cognition NR	Cognitive activity training strategy program (attention, memory, and executive processes) -10, 90-minute sessions/week over 5 weeks; Booster telephone call at 6 months	Education about healthy aging -10, 90-minute sessions/week over 5 weeks; Booster telephone call at 6 months	52 weeks 104 weeks	<u>Brief Cognitive Test Performance</u> [CAMCOG-R Score] <u>Executive/Attention/Processing Speed</u> [DS Forward] [DS Backward] [DS Total Score] [TMT A] [TMT B] [Symbol Search, Items Completed]] [COWAT] <u>Memory</u> [CVLT-II Total Recall] [CVLT-II Short Delay Free Recall] [CVLT-II Long Delay Free Recall] <u>Language</u> [COWAT]
Fiatarone Singh 2014 <sup>29</sup> RCT Australia High	51	Adults age 55 and older with a MCI diagnosis consistent with Petersen criteria Age NR Sex NR Education NR	Cognitive training (computer-based exercises targeting memory, executive function, attention, and processing speed) -100 minutes 2 days/week for 6 months	Sham cognitive training and sham exercise	6 months 18 months	<u>Multidomain Neuropsychological Test Performance</u> [ADAS-Cog] [Global Cognition Domain Composite] <u>Executive/Attention/Processing Speed</u> [WAIS Similarities] [WAIS Matrices] [COWAT] [Executive Function Domain Composite] [SDMT]

Study Design Country RoB	N=	Population Inclusion Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome timing	Outcome Domain [Instrument]
		MMSE, Mean (SD) 27 (1)				Memory [List learning Memory Sum from ADAS-Cog] Memory [BVRT] [Logical Memory, Immediate] [Logical Memory, Delayed] [Memory Domain Composite] Language [Category Fluency, Animal Naming] [COWAT]
Kwok 2013 <sup>30</sup> RCT China Medium	223	Chinese adults aged 65 and over with subjective memory complaints Age, Mean (SD) 75 (6) 85% Female Race NR 70% Below or at primary level education MMSE. Mean (SD) 25.6 (2.6)	Cognitive therapy delivered by an occupation therapist 1 time/week, 1.5 hours each session for 12 weeks	Health-related educational lectures for 12 weeks, delivered by occupational therapist	12 months	Executive/Attention/Processing Speed [Attention Composite] [Initiation/Perseveration] [Conceptualization] Memory [Memory Composite]
Rojas 2013 <sup>31</sup> RCT Argentina High	46	Adults with MCI based on Petersen's criteria Age, Mean (SD) 74 (10.7) 43% Female Race NR Education Level, Mean (SD) 10.54 (3.8) MMSE. Mean (SD) 27.3 (2)	Group cognitive stimulation training sessions and cognitive training –120 minutes/week over 6 months	Routine treatment with monthly consultations with doctor over 6 months	1 year	Diagnosis [CDR] Brief Cognitive Test Performance [MMSE] Executive/Attention/Processing Speed [Similarities and Matrix Reasoning] [TMT A] [TMT B] [DS Forward] [DS Backward] Memory [Signoret's Memory Battery] Language [BNT] [Verbal Fluency] [Vocabulary, WAIS] Visuospatial [Block Design]
Buschert 2012 <sup>32</sup> Forster 2011 <sup>33</sup> RCT Germany	24	Participants with aMCI based on Petersen's criteria Age, Mean (SD)	Group-based formal mnemonic memory training and informal cognitive and social engagement	Exercises of isolated, sustained attention – Monthly sessions for 8 months followed by	15 months 28 months	Diagnosis [Conversion to Alzheimer's Disease] Biomarker [FDG-PET Reuptake] Brief Cognitive Test Performance [MMSE]

Study Design Country RoB	N=	Population Inclusion Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome timing	Outcome Domain [Instrument]
Medium		73 (6.6) 55% Male Race NR Years Education, Mean (SD) 12.8 (5) MMSE, Mean (SD) 26.3 (2)	activities -120 minutes/week for 6 months	cross-over to intervention		<u>Multidomain Neuropsychological Performance</u> [ADAS-Cog] <u>Executive/Attention/Processing Speed</u> [TMT A/B] <u>Memory</u> [RBANS Memory] [RBANS, Story Recall]
Herrera 2012 <sup>34</sup> RCT France Medium	22	Adults with a MCI based on Petersen's criteria Age, Mean (SD) 77 (1.71) 50% Female Race NR 14% With More than Secondary School MMSE. Mean (SD) 27.4 (0.5)	Computer-based memory and attention training -24, 1-hour sessions over 12 weeks	Cognitive activities (e.g., organizing lists, reading comprehension -24, 1-hour sessions over 12 weeks	6 months	<u>Executive/Attention/Processing Speed</u> [DS Forward] [DS Backward] <u>Memory</u> [Doors Recognition Subtest, Set A] [Doors Recognition Subtest, Set B] [DMS48 Test] [BEM-144 Word List Recall] [16-Item Free and Cued Reminding Test] [MMSE, Recall of 3 Words] [RCFT, Recall]
Moro 2012 <sup>35</sup> RCT Italy High		Adults with a MCI Age, Mean (SD) 71 (8) Sex NR Race NR Education, Mean (SD) 10 (3.5) Baseline Cognition NR	Individual cognitive training sessions- 3 sessions/week for one month. 1 session/week (at home with support of caregiver) for the subsequent 5 months.	No intervention for 6 months (crossover design)	6 months 12 months	<u>Executive/Attention/Processing Speed</u> [Attentional Matrices] [TMT A] [Bourdon Test] [Verbal Span] [Tower of London] [Analogies] [SCWT] [TMT B/A] <u>Memory</u> [AVLT, Immediate Recall] [AVLT, Delayed Recall] [Omissions] [False Recognitions] [Listening Span Test] [Story Recall] <u>Language</u> [CVFT]
Rapp 2002 <sup>36</sup> RCT US Medium	19	Older adults meeting criteria for MCI based on Petersen's criteria Age, Mean (SD) 74 (6.8) 58% Female	Memory training and education –Six weekly, 2 hour group meetings with homework assignments	No memory education or training (no intervention)	6 months	<u>Memory</u> [Word List, Immediate] [Word List Delayed] [Shopping List Immediate] [Shopping List Delayed] [Names and Faces Immediate] [Names and Faces Delayed] [Paragraph, Immediate] [Paragraph, Delayed]



<b>Study Design Country RoB</b>	<b>N=</b>	<b>Population Inclusion Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition</b>	<b>Intervention Mode Components Frequency Duration</b>	<b>Comparison Mode Components Frequency Duration</b>	<b>Outcome timing</b>	<b>Outcome Domain [Instrument]</b>
		95% White 37% With Some College MMSE. Mean (SD) 27.6 (1.7)				

ADAS=Cog-Alzheimer's Disease Assessment Scale-Cognitive; AVLT=Auditory Verbal Learning Test; BNT=Boston Naming Test; BVRT=Benton Visual Retention Test; CAMCOG=Cambridge Cognition Examination; CDR=Clinical Dementia Rating; COWAT=Controlled Oral Word Association Test; CVFT=Category Verbal Fluency Test; CVLT=California Verbal Learning Test; DS=Digit Span (Forward and/or Backward); MCI=mild cognitive impairment; MMSE=Mini-Mental Status Examination; MRI=magnetic resonance imaging; N=sample size; NR=not reported; RBMT= Rivermead Behavioral Memory Test; RCFT=Rey-Osterrieth Complex Figure Test; RCT=randomized controlled trial; RoB=risk of bias; RT=Reaction Time; SCWT=Stroop Color Word Test; SD=standard deviation; SOE=strength of evidence; TMT=Trail Making Test (Part A and/or B); UFOV=Useful Field of View; US=United States; VP=Verbal Proficiency; VR=Visual Reproduction; VRM=Verbal Recognition Memory; WAIS=Wechsler Adult Intelligence Scale; WMS=Wechsler Memory Scale

**Appendix Table F10. Summary risk of bias assessments: other cognitive training trials in adults with MCI**

<b>Study</b>	<b>Overall Risk of Bias Assessment</b>	<b>Rationale</b>
Jeong 2016	High	Attrition rate is 33% with no analysis to address potential bias.
Lam 2015 <sup>27</sup>	High	Potential selection bias with attrition greater than 21%
Moro 2015	High	Suspected selection bias, unclear attrition, and suspected detection bias.
Vidovich 2015 <sup>28</sup>	Low (52 Weeks) High (104 weeks)	Attrition rate greater than 21% at 104 weeks with no analysis to address potential bias.
Fiatarone Singh 2014 <sup>29</sup>	High	Potential reporting bias.
Kwok 2013 <sup>30</sup>	Medium	Potential selection, attrition, and performance bias.
Rojas 2013 <sup>31</sup>	High	Potential selection bias with an attrition rate of 35%.
Buschert 2012 <sup>32</sup> Forster 2011 <sup>33</sup>	Medium	Process for randomization is unclear.
Herrera 2012 <sup>34</sup>	Medium	Process for randomization is unclear with potential detection bias.
Moro 2012 <sup>35</sup>	High	Potential selection, detection, and performance bias.
Rapp 2002 <sup>36</sup>	Medium	Process for randomization unclear.


MCI=mild cognitive impairment

**Appendix Table F11. Cognitive Training vs. Inactive Comparison, MCI: Effect Sizes for Rapp 2002 (n=19)**

<b>Test</b>	<b>Cohen's D</b>	<b>95% CI Lower</b>	<b>95% CI Upper</b>
Word List, Immediate	0.14	-0.85	1.13
Word List, Delayed	0.23	-0.77	1.22
Shopping List, Immediate	0.52	-0.50	1.52
Shopping List, Delayed	-0.01	-1.00	0.98
Names and Faces, Immediate	0.44	-0.57	1.43
Names and Faces, Delayed	0.21	-0.78	1.20
Paragraph, Immediate	-0.59	-1.59	0.43
Paragraph, Delayed	-0.10	-1.09	0.89

CI=confidence interval; MCI=mild cognitive impairment; n=sample size

Appendix Figure F3. Cognitive Training vs. Inactive Comparison, MCI: Plot of Effect Sizes for Rapp 2002 (n=19)




CI=confidence interval; MCI=mild cognitive impairment; n=sample size

**Appendix Table F12. Cognitive Training vs. Active Comparison, MCI: Effect Sizes for Herrera 2012 (n=22)**

<b>Test</b>	<b>Cohen's D</b>	<b>95% CI Lower</b>	<b>95% CI Upper</b>
Memory: Doors recognition subtest, Set A/12	3.06	1.78	4.30
Memory: Doors recognition subtest, Set B/12	2.62	1.44	3.76
Memory: DMS48 test (recognition score)	2.56	1.39	3.69
Memory: BEM-144 12-Word-List Recall Test	3.15	1.85	4.41
Memory: 16-Item Free and Cued Reminding Test	2.44	1.30	3.54
Memory: MMSE, Recall of 3 Words	1.87	0.84	2.87
Memory: Recall of Rey's Complex Figure	0.37	-0.48	1.21
Executive/Attention/Processing Speed: Digit Span Forward	4.59	2.93	6.21
Executive/Attention/Processing Speed: Digit Span Backward	2.17	1.09	3.23

CI=confidence interval; BEM-144=Batterie d'Efficiency Mnesique 144; DSM48=Delayed Matching-to-Sample Task; MMSE=Mini-Mental Status Examination; n=sample size

Appendix Figure F4. Cognitive Training vs. Active Comparison, MCI: Plot of Effect Sizes for Herrera 2012 (n=22)



CI=confidence interval; BEM-144=Batterie d'Efficiency Mnesique 144; DSM48=Delayed Matching-to-Sample Task; MMSE=Mini-Mental Status Examination; n=sample size

## References for Appendix F

1. Rebok GW, Ball K, Guey LT, et al. Ten-year effects of the advanced cognitive training for independent and vital elderly cognitive training trial on cognition and everyday functioning in older adults. *Journal of the American Geriatrics Society*. 2014 Jan;62(1):16-24. doi: <http://dx.doi.org/10.1111/jgs.12607>. PMID: 24417410.
2. Rebok GW, Langbaum JB, Jones RN, et al. Memory training in the ACTIVE study: how much is needed and who benefits? *Journal of Aging & Health*. 2013 Dec;25(8 Suppl):21S-42S. doi: <http://dx.doi.org/10.1177/0898264312461937>. PMID: 23103452.
3. Jones RN, Marsiske M, Ball K, et al. The ACTIVE cognitive training interventions and trajectories of performance among older adults. *Journal of Aging & Health*. 2013 Dec;25(8 Suppl):186S-208S. doi: <http://dx.doi.org/10.1177/0898264312461938>. PMID: 23103453.
4. Sisco SM, Marsiske M, Gross AL, et al. The influence of cognitive training on older adults' recall for short stories. *Journal of Aging & Health*. 2013 Dec;25(8 Suppl):230S-48S. doi: <http://dx.doi.org/10.1177/0898264313501386>. PMID: 24385636.
5. Valdes EG, O'Connor ML, Edwards JD. The effects of cognitive speed of processing training among older adults with psychometrically- defined mild cognitive impairment. *Current Alzheimer Research*. 2012 Nov;9(9):999-1009. PMID: 22594383.
6. Unverzagt FW, Guey LT, Jones RN, et al. ACTIVE cognitive training and rates of incident dementia. *J Int Neuropsychol Soc*. 2012 Jul;18(4):669-77. doi: 10.1017/s1355617711001470. PMID: 22400989.
7. Wolinsky FD, Mahncke H, Vander Weg MW, et al. Speed of processing training protects self-rated health in older adults: enduring effects observed in the multi-site ACTIVE randomized controlled trial. *International Psychogeriatrics*. 2010 May;22(3):470-8. doi: <http://dx.doi.org/10.1017/S1041610209991281>. PMID: 20003628.
8. Wolinsky FD, Vander Weg MW, Martin R, et al. Does cognitive training improve internal locus of control among older adults? *Journals of Gerontology Series B-Psychological Sciences & Social Sciences*. 2010 Sep;65(5):591-8. doi: <http://dx.doi.org/10.1093/geronb/gbp117>. PMID: 20008028.
9. Unverzagt FW, Kasten L, Johnson KE, et al. Effect of memory impairment on training outcomes in ACTIVE. *Journal of the International Neuropsychological Society*. 2007 Nov;13(6):953-60. PMID: 17942013.
10. Willis SL, Tennstedt SL, Marsiske M, et al. Long-term effects of cognitive training on everyday functional outcomes in older adults. *JAMA*. 2006 Dec 20;296(23):2805-14. PMID: 17179457.
11. Ball K, Berch DB, Helmers KF, et al. Effects of cognitive training interventions with older adults: a randomized controlled trial. *JAMA*. 2002 Nov 13;288(18):2271-81. PMID: 12425704.
12. Stine-Morrow EA, Payne BR, Roberts BW, et al. Training versus engagement as paths to cognitive enrichment with aging. *Psychology & Aging*. 2014 Dec;29(4):891-906. doi: <http://dx.doi.org/10.1037/a0038244>. PMID: 25402337.
13. Carretti B, Borella E, Zavagnin M, et al. Gains in language comprehension relating to working memory training in healthy older adults. *Int J Geriatr Psychiatry*. 2013 May;28(5):539-46. doi: 10.1002/gps.3859. PMID: 22821686.
14. Miller KJ, Dye RV, Kim J, et al. Effect of a computerized brain exercise program on cognitive performance in older adults. *American Journal of Geriatric Psychiatry*. 2013 Jul;21(7):655-63. doi: <http://dx.doi.org/10.1016/j.jagp.2013.01.077>. PMID: 23602310.
15. Wolinsky FD, Vander Weg MW, Howren MB, et al. A randomized controlled trial of cognitive training using a visual speed of processing intervention in middle aged and older adults. *PLoS ONE [Electronic Resource]*. 2013;8(5):e61624. doi: <http://dx.doi.org/10.1371/journal.pone.0061624>. PMID: 23650501.

16. Cheng Y, Wu W, Feng W, et al. The effects of multi-domain versus single-domain cognitive training in non-demented older people: a randomized controlled trial. *BMC Med.* 2012;10:30. doi: 10.1186/1741-7015-10-30. PMID: 22453114.
17. Mortimer JA, Ding D, Borenstein AR, et al. Changes in brain volume and cognition in a randomized trial of exercise and social interaction in a community-based sample of non-demented Chinese elders. *J Alzheimers Dis.* 2012;30(4):757-66. doi: 10.3233/JAD-2012-120079. PMID: 22451320.
18. Szelag E, Skolimowska J. Cognitive function in elderly can be ameliorated by training in temporal information processing. *Restorative Neurology & Neuroscience.* 2012;30(5):419-34. doi: <http://dx.doi.org/10.3233/RNN-2012-120240>. PMID: 22751354.
19. Evers A, Klusmann V, Schwarzer R, et al. Improving cognition by adherence to physical or mental exercise: a moderated mediation analysis. *Aging Ment Health.* 2011 May;15(4):446-55. doi: 10.1080/13607863.2010.543657. PMID: 21500011.
20. Borella E, Carretti B, Riboldi F, et al. Working memory training in older adults: evidence of transfer and maintenance effects. *Psychol Aging.* 2010 Dec;25(4):767-78. doi: 10.1037/a0020683. PMID: 20973604.
21. Klusmann V, Evers A, Schwarzer R, et al. Complex mental and physical activity in older women and cognitive performance: a 6-month randomized controlled trial. *J Gerontol A Biol Sci Med Sci.* 2010 Jun;65(6):680-8. doi: 10.1093/gerona/gkq053. PMID: 20418350.
22. McDougall GJ, Jr., Becker H, Pituch K, et al. Differential benefits of memory training for minority older adults in the SeniorWISE study. *Gerontologist.* 2010 Oct;50(5):632-45. doi: <http://dx.doi.org/10.1093/geront/gnq017>. PMID: 20203096.
23. Park MH, Kwon DY, Seo WK, et al. The effects of cognitive training on community-dwelling elderly Koreans. *Journal of Psychiatric & Mental Health Nursing.* 2009 Dec;16(10):904-9. doi: <http://dx.doi.org/10.1111/j.1365-2850.2009.01467.x>. PMID: 19930364.
24. Slegers K, van Boxtel M, Jolles J. Effects of computer training and internet usage on cognitive abilities in older adults: a randomized controlled study. *Aging-Clinical & Experimental Research.* 2009 Feb;21(1):43-54. PMID: 19225269.
25. Buiza C, Etxeberria I, Galdona N, et al. A randomized, two-year study of the efficacy of cognitive intervention on elderly people: the Donostia Longitudinal Study. *Int J Geriatr Psychiatry.* 2008 Jan;23(1):85-94. doi: 10.1002/gps.1846. PMID: 17530622.
26. Yesavage JA, Friedman L, Ashford JW, et al. Acetylcholinesterase inhibitor in combination with cognitive training in older adults. *J Gerontol B Psychol Sci Soc Sci.* 2008 Sep;63(5):P288-94. PMID: 18818443.
27. Lam LC, Chan WC, Leung T, et al. Would older adults with mild cognitive impairment adhere to and benefit from a structured lifestyle activity intervention to enhance cognition?: a cluster randomized controlled trial. *PLoS One.* 2015 31 Mar;10(3):e0118173. doi: 10.1371/journal.pone.0118173. PMID: 25826620.
28. Vidovich MR, Lautenschlager NT, Flicker L, et al. The PACE study: A randomized clinical trial of cognitive activity strategy training for older people with mild cognitive impairment. *American Journal of Geriatric Psychiatry.* 2015 01 Apr;23(4):360-72. doi: <http://dx.doi.org/10.1016/j.jagp.2014.04.002>. PMID: 2014736543.
29. Fiatarone Singh MA, Gates N, Saigal N, et al. The Study of Mental and Resistance Training (SMART) study-resistance training and/or cognitive training in mild cognitive impairment: a randomized, double-blind, double-sham controlled trial. *J Am Med Dir Assoc.* 2014 Dec;15(12):873-80. doi: 10.1016/j.jamda.2014.09.010. PMID: 25444575.
30. Kwok TC, Bai X, Li JC, et al. Effectiveness of cognitive training in Chinese older people with subjective cognitive complaints: a randomized placebo-controlled trial. *International Journal of Geriatric Psychiatry.* 2013 Feb;28(2):208-15. doi: <http://dx.doi.org/10.1002/gps.3812>. PMID: 22528470.



31. Rojas GJ, Villar V, Iturry M, et al. Efficacy of a cognitive intervention program in patients with mild cognitive impairment. *International Psychogeriatrics*. 2013 May;25(5):825-31. doi: <http://dx.doi.org/10.1017/S1041610213000045>. PMID: 23414646.
32. Buschert VC, Giegling I, Teipel SJ, et al. Long-term observation of a multicomponent cognitive intervention in mild cognitive impairment. *Journal of Clinical Psychiatry*. 2012 Dec;73(12):e1492-8. doi: <http://dx.doi.org/10.4088/JCP.11m07270>. PMID: 23290333.
33. Forster S, Buschert VC, Teipel SJ, et al. Effects of a 6-month cognitive intervention on brain metabolism in patients with amnesic MCI and mild Alzheimer's disease. *Journal of Alzheimer's Disease*. 2011;26 Suppl 3:337-48. doi: <http://dx.doi.org/10.3233/JAD-2011-0025>. PMID: 21971473.
34. Herrera C, Chambon C, Michel BF, et al. Positive effects of computer-based cognitive training in adults with mild cognitive impairment. *Neuropsychologia*. 2012 Jul;50(8):1871-81. doi: <http://dx.doi.org/10.1016/j.neuropsychologia.2012.04.012>. PMID: 22525705.
35. Moro V, Condoleo MT, Sala F, et al. Cognitive stimulation in a-MCI: an experimental study. *American Journal of Alzheimer's Disease & Other Dementias*. 2012 Mar;27(2):121-30. doi: <http://dx.doi.org/10.1177/1533317512441386>. PMID: 22495340.
36. Rapp S, Brenes G, Marsh AP. Memory enhancement training for older adults with mild cognitive impairment: a preliminary study. *Aging & Mental Health*. 2002 Feb;6(1):5-11. PMID: 11827617

## Appendix G. Physical Activity Interventions

**Appendix Table G1. Characteristics of eligible studies: physical activity interventions vs. inactive controls in adults with normal cognition**

Physical Exercise Intervention Type	Study Design Country RoB	N=	Population Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome timing	Outcome Domain [Instrument]
<b>Multicomponent Physical Activity</b>	Bun 2015 <sup>1</sup> Observational Japan High	1268	Cognitively normal, community-dwelling volunteers aged 65 Age, Mean (SD) 72.8 (5.1) 42% Female Race NR Years Education, Mean (SD) 10.55 (2.6) Baseline Cognition NR	Stretching, massaging, ball exercise, and easy dancing -60 minute sessions 6 times/month for 2 years	No Intervention or Nutritional supplementation (n-3 polyunsaturated fatty acid, Ginkgo biloba, leaf dry extracts, and 84 mg of lycopene) for 3 years	3 years 7 years	<u>Diagnosis</u> [Incident Dementia and Alzheimer's Disease, DSM-III-R and and NINCDS-ADRDA Criteria]
	Sink 2015 <sup>2</sup> RCT USA Medium	1635	Sedentary adults without a diagnosis of dementia or significant cognitive impairment aged 70 to 89 57% aged 70 to 79 43% aged 80 to 89 67% Female 76% White	Individual physical activity training intervention focused on walking, strength, flexibility, and balance -2 center-based visits/week and 3-4 home-based activities/week for 2 years	Group health education workshops - 1 workshop/week for 26 weeks, at least once a month after for 2 years	NP battery: 2 years Computer battery: 18 or 30 months depending on enrollment	<u>Diagnosis</u> [Incident Dementia, Panel of Clinical Experts] [Incident MCI, Panel of Clinical Experts] [Incident MCI or Dementia, Panel of Clinical Experts] <u>Multidomain Neuropsychological Test Performance</u> [Composite] <u>Executive/Attention/Processing Speed</u> [DSST] [N-back Task, 1-back] [N-back Task, 2-back] [Eriksen Flanker Task, Congruent] [Eriksen Flanker Task, Incongruent] [Eriksen Flanker Task, Composite] [Task Switching Exercise, No] [Task Switching Exercise, Yes] <u>Memory</u> [HVL, Immediate Word Recall]

		67% With a College Education 3MS, Mean (SD): 91.7 (5.4)				[HVL, Delayed Word Recall] [HVL, Composite]
Napoli 2014 <sup>3</sup> RCT US Medium	53	Obese, sedentary adults age 65 and older with a stable weight and a minimum MMSE score of 24 Age, Mean (SD) 70 (4) 63% Female 85% White Years of Education, Mean (SD) 16.3 (3.7) 3MSE, Mean (SD) 95.7 (0.8)	Aerobic exercise, resistance training, and balance exercises -90 minutes sessions 3 times/week at an exercise facility for 1 year	Information about healthy diet (not allowed to participate in any exercise program)	1 year	<u>Brief Cognitive Test Performance [3MSE]</u> <u>Executive/Attention/Processing Speed [TMT A] [TMT B]</u> <u>Memory [Word List Fluency]</u>
Klusmann 2010 <sup>4</sup> Evers 2011 <sup>5</sup> RCT Germany High	167	Women age 70 and over with no more than 4 errors on the MMSE Age, Mean (SD) 73.6 (4.2) 100% Female Race NR Years of Education, Mean (SD) 12 (2.6) MMSE, Mean (SD) 28.78 (0.96)	Aerobic, endurance, strength and flexibility training, and balance and coordination training -90 minute sessions for 6 months	Inactive control (live their habitual life)	6 months	<u>Executive/Attention/Processing Speed [SCWT] [TMT B/A]</u> <u>Memory [RBMT, Immediate] [RBMT, Delayed Recall] [FCSRT, Short Delay] [FCSRT, Long Delay]</u> <u>Language [Semantic Verbal Fluency]</u>
Rosano 2010 <sup>6</sup> RCT US High	30	Sedentary older adults Age, Mean (SD) 81.1 (3.36) 40% Female Race NR	Aerobic, strength, balance, and flexibility exercises -150 minutes per week for 1 year	Successful aging sessions –Weekly sessions for 26 weeks followed by monthly sessions for duration of study	2 years	<u>Biomarker [MRI]</u> <u>Brief Cognitive Test Performance [MMSE]</u> <u>Executive/Attention/Processing Speed [DSST]</u>

			43% Completed High School or Equivalent MMSE, Mean (SD) 27.7 (2)				
Taylor-Pillae 2010 <sup>7</sup> RCT US Medium-6 mo High-12 mo	95	Sedentary adults aged 60 years or older without severe cognitive impairment Age, Mean (SD) 69.0 (5.8) 70% Female 85% White Years of Education, Mean (SD) 16.1 (2.1)	Western Exercise: Endurance, resistance/strength, and flexibility exercises- 60 minutes classes 2.times/week and home based exercise 3 times/week for 6 months, 1 class-based session/week and 3 home-based exercise sessions for the remaining 6 months	Healthy aging classes on topics including health eating, elder law, and foot and eye care - 90 minute classes 1 time/week for 6 months	6 months 12 months	<u>Executive/Attention/Processing Speed</u> [DS Forward] [DS Backward] <u>Language</u> [Animal Naming]	
Williamson 2009 <sup>8</sup> (early results Sink 2015) <sup>2</sup> RCT US Medium	102	Sedentary adults aged 70-89 years with a MMSE score of 21 or more. Age, Mean (SD) 77.4 (4.3) 70.6% Female 81% White 77% with more than a high school education 3MS, Mean (SD) 90.3 (6.4)	Aerobic (walking), strength, balance, and flexibility exercises - 60 minute center-based sessions 3 times/week for 2 months -60 minute center-based sessions 2 times/per week and home-based exercise (endurance, strengthening, flexibility) at least 3 times/week for 4 months	Successful aging health education – Weekly small group sessions for 26 weeks -Monthly small group sessions for 26 weeks	12 months	<u>Brief Cognitive Test Performance</u> [3MS] <u>Executive/Attention/Processing Speed</u> [SCWT] <u>Memory</u> [DSST] [RAVLT]	
Liu-Ambrose 2008 <sup>9</sup> RCT Australia 2008	74	Community-dwelling men and women age 70 years and older who attended a falls clinic Age, Mean (SD) 82.3 (6.3) 69% Female Race NR	Home-based balanced and strength training program 3 times/week for 30 minutes and walking 2 times/week for 6 months	Guideline based-care for fall prevention	6 months	<u>Executive/Attention/Processing Speed</u> [TMT B] [SCWT (Color-Word)] [DS Backward]	

			Education NR MMSE, Mean (SD) 28 (1.8)				
	Oswald 2006 <sup>10</sup> RCT Germany High	135	Adults age 75 and older without functional cognitive or physical decline Age, Mean (SD) 79.5 (3.5) 64.8% Female 58.9% With Secondary School Education or Higher	Physical training for balance, perceptual, and motor coordination and flexibility = 30, 45 minute sessions	No intervention for duration of study	5 years	<u>Multidomain Neuropsychological Test Performance</u> [Composite]
	Williams 1997 <sup>11</sup> RCT Australia High	374	Community- dwelling women at least 60 years old Age, Mean (SD) 71.7 (5.4) 100% Female Race NR Formal Education, Mean (SD) 9.5 (2.0) Baseline Cognition NR	Low intensity aerobic, stretching, and balance and strengthening exercises -1 hour sessions, 2 times/week for 10-12 months	Inactive control group (no organized activity)	1 year	<u>Executive/Attention/Processing Speed</u> [DS, WAIS] [Picture Arrangement, WAIS] [Cattell's Matrices]
<b>Resistance Training</b>	van de Rest 2014 <sup>12</sup> RCT Netherlands Medium	62	Frail and pre-frail adults age 65 and over Age, Mean (SD) 79 (8) 61% Female Race NR 44% With Higher Education MMSE, Mean (Range)	Resistance-type exercise program and placebo -2 sessions/week with personal supervision for 24 weeks	Usual Care and placebo for 24 weeks	24 weeks	<u>Executive/Attention/Processing Speed</u> [Executive Functioning Composite] [DS Forward] [DS Backward] [TMT A] [TMT B/A] [SCWT (Test 1)] [SCWT (Test 2)] [SCWT (Interference)] [Finger Precuing, Reaction Time Uncued] [Finger Precuing, Reaction Time Cued] [Information Processing Speed Composite] <u>Memory</u> [Word Learning Test, Immediate Recall-75 Words] [Word Learning Test,

			28 (26-30)				Delayed Recall-15 Words] [Word Learning Test, Decay] [Word Learning Test, Recognition, 30 Words] [Attention and Working Memory Composite] <u>Language</u> [Word Fluency, Animals] [Word Fluency, Letter P]
Hotting 2012 <sup>13</sup> RCT Germany High	66	Healthy, sedentary men and women aged 40-56 years Age, Mean (SD) 47.8 (4.35) 82% Female Race NR Education NR Baseline Cognition NR	Stretching and coordination training exercises -60 minute sessions 2 times/week for 6 months	Sedentary control (no exercise intervention for 6 months)	6 months		<u>Executive/Attention/Processing Speed</u> [D2 Test] [Zahlenverbindungstest, German] [SCWT] <u>Memory</u> [AVLT, German] <u>Visuospatial</u> [Leistungsprufsystem, Subtests 8 and 9]
Komulainen 2010 <sup>14</sup> RCT Finland High	472	Men and women age 55 to 74 Age, Mean (SD) 66.3 (5.3) Sex NR Race NR Education, Mean (SD) 11.3 (3.9) MMSE, Mean (SD) 27.6 (2.1)	Individualized, independent, strength training program either 2 times/week or 3 times per week	General health advice on diet and physical activity	2 years		<u>Brief Cognitive Test Performance</u> [MMSE] <u>Memory</u> [Immediate Memory Composite] [Delayed Memory Composite] <u>Language</u> [Verbal Performance Composite] <u>Visuospatial</u> [Visual Performance Composite]
Cassilhas 2007 <sup>15</sup> RCT Brazil Medium	43	Sedentary males age 65-75 with a minimum MMSE score of 24 Age, Mean (SD) 68.2 (0.77) 100% Male Race NR Education NR Baseline Cognition NR	High intensity resistance training -60 minute sessions, 3 times/week for 24 weeks	Warm-up and stretching at center once a week for 24 weeks	24 weeks		<u>Executive/Attention/Processing Speed</u> [DS Forward] [DS Backward] [Corsi Block-Tapping, Forward] [Corsi Block-Tapping, Backward] [Corsi Block-Tapping, Similarities] [Toulouse-Pieron, Cancellations Numbers] [Toulouse-Pieron, Errors] <u>Memory</u> [RCFT, Copy] [RCFT, Immediate Recall]

	Cassilhas 2007 <sup>15</sup> RCT Brazil Medium	42	Sedentary males age 65-75 with a minimum MMSE score of 24 Age, Mean (SD) 68.2 (0.77) 100% Male Race NR Education NR Baseline Cognition NR	Moderate intensity resistance training -60 minute sessions, 3 times/week for 24 weeks	Warm-up and stretching at center once a week for 24 weeks	24 weeks	<u>Executive/Attention/Processing Speed</u> [DS Forward] [DS Backward] [Corsi Block-Tapping, Forward] [Corsi Block-Tapping, Backward] [Corsi Block-Tapping, Similarities] [Toulouse-Pieron, Cancellations Numbers] [Toulouse-Pieron, Errors] <u>Memory</u> [RCFT, Copy] [RCFT, Immediate Recall]
	Lachman 2006 <sup>16</sup> RCT US Medium	210	Sedentary, community-residing older adults with at least one disability Age, Mean (SD) 75.3 (7.4) 77.6% Female 93% White Education, Mean (SD) 14.3 (2.7) Baseline Cognition NR	Video tape of 35 minutes of resistance training -3 times/week for 6 months	No intervention for duration of study	6 months	<u>Executive/Attention/Processing Speed</u> [DS Backward]
<b>Aerobic Training</b>	Antunes 2015 <sup>17</sup> RCT Brazil Medium	46	Healthy, sedentary men with minimum MMSE score of 24 Age, Mean(SD): 66.94 (4.65) Race NR Education NR Baseline Cognition NR	Aerobic physical fitness regime with supplementary stretching and joint flexibility exercises -60 minute sessions 3 times/week for 6 months	Maintain regular everyday activities. Instructed to not start a physical exercise program for study duration	6 months	<u>Executive/Attention/Processing Speed</u> [Picture Arrangement, WAIS] [Corsi Block-Tapping, Forward] [Corsi Block-Tapping, Backward] <u>Memory</u> [Verbal Paired Associates, Trial 1, Easy Pair] [Verbal Paired Associates, Trial 1, Hard Pair] [Verbal Paired Associates, Trial 2, Easy Pair] [Verbal Paired Associates, Trial 2, Hard Pair] [Verbal Paired Associates, Trial 3, Easy Pair] [Verbal Paired Associates, Trial 3, Hard Pair] [Verbal Paired Associates, Recall Test, Easy Pair] [Verbal Paired Associates, Recall Test, Hard Pair] [Free Word Recall, Total Words Recalled Non-Semantic] [Free Word Recall, Total Words Recalled Semantic] [Free Word

							Recall, Intrusions] [Free Word Recall, Repetitions] [Free Word Recall, Preservations]
Satoh 2014 <sup>18</sup> RCT Japan High	79	Physically and psychologically healthy residents age 65 and older Age, Mean (SD) 72.9 (4.6) 64% Female Race NR Years Education, Mean (SD) 10.4 (1.8) MMSE, Mean (SD) 27.6 (2.2)	Physical exercise -40, 60-minute exercise sessions over 1 year	Inactive control group (no intervention)	1 year		<u>Brief Cognitive Test Performance</u> [MMSE] <u>Executive/Attention/Processing Speed</u> [Raven's Coloured Progressive Matrices] [TMT A] [TMT B] [Word Fluency] <u>Memory</u> [Logical Memory-I] [Logical Memory-II]
Mortimer 2012 <sup>19</sup> RCT China High	75	Adults age 60-79 with an education-adjusted Chinese MMSE score greater than 26 Age, Mean (SD) 67.8 (5.8) 67% Female Race NR Years of Education, Mean	Walking-50 minute group sessions 3 times/week for 40 weeks	Inactive control with 4 check-in calls over 40 weeks	40 weeks		<u>Biomarker</u> [Whole Brain Volume, % of Total Intracranial Volume] <u>Multidomain Neuropsychological Test Performance</u> [Mattis Dementing Rating Scale, Total Score] <u>Executive/Attention/Processing Speed</u> [DS Forward] [DS Backward] [SCWT (Word)] [SCWT (Color)] [SCWT (Color-Word)] [WAIS Similarities] [TMT A] [TMT B] [Mattis Attention Score] [Mattis Initiation Score] [Mattis Conceptualization Score]



		(SD) 11.7 (3.4) Mattis Dementia Scale Score, Mean (SD) 137.6 (7.6)				<u>Memory</u> [AVLT, Immediate Recall] [AVLT, Delayed Recall] [AVLT, Delayed Recognition] [RCFT, Copying] [RCFT, Recall] [Mattis Memory Score] <u>Language</u> [CVFT, Animals] [BNT] <u>Visuospatial</u> [Bell Cancellation Test] [RCFT, Copying] [RCFT, Recall] [CLOX- 1] [Mattis Construction Score]
Hotting 2012 <sup>3</sup> RCT Germany High	67	Healthy, sedentary men and women aged 40-56 years Age, Mean (SD) 47.8 (4.35) 82% Female Race NR Education NR Baseline Cognition NR	Indoor cycling on stationary bikes -60 minute sessions 2 times/week for 6 months	Sedentary control (no exercise intervention for 6 months)	6 months	<u>Executive/Attention/Processing Speed</u> [D2 Test] [Zahlenverbindungstest, German] [SCWT] <u>Memory</u> [AVLT, German] <u>Visuospatial</u> [Leistungsprufsystem, Subtests 8 and 9]
	41	Sedentary adults aged 50-72 with MMSE scores above 26 Age, Mean (SD) 59.1 (6.5) 69% Female Race NR Education, Mean (SD) 10.7 (3.5) MMSE, Mean (SD) 29.2 (2.8)	Nordic walking (intensity levels corresponding to 50–60% of maximal exertion) for 6 months	No exercise for duration of study	6 months	<u>Memory</u> [AVLT, German]
Ruscheweyh 2011 <sup>20</sup> RCT Germany Medium	42	Sedentary adults aged 50-72 with MMSE scores above 26 Age, Mean (SD) 60.3 (6.5) 65% Female Race NR Education, Mean (SD)	Gymnastics ( stretching, limbering, and toning of upper and lower extremities; intensity levels corresponding to 30–40% of maximal exertion) for 6 months	No exercise for duration of study	6 months	<u>Memory</u> [AVLT, German]

			11.0 (3.4) MMSE, Mean (SD) 29.2 (2.8)				
Komulainen 2010 <sup>14</sup> RCT Finland High	470	Men and women age 55 to 74 Age, Mean (SD) 66.5 (5.3) Sex NR Race NR Education, Mean (SD) 11.4 (4.0) MMSE, Mean (SD) 27.6 (2.1)	Individualized, independent, aerobic exercise program either 5 times/week for 60 min or 5 times/week for 90 min for 2 years	General health advice on diet and physical activity	2 years	<u>Brief Cognitive Test Performance</u> [MMSE] <u>Memory</u> [Immediate Memory Composite] [Delayed Memory Composite] <u>Language</u> [Verbal Performance Composite] <u>Visuospatial</u> [Visual Performance Composite]	
Muscari 2010 <sup>21</sup> RCT Italy Medium	120	Healthy adults age 64-75 with a minimum MMSE of 24 Age, Mean (SD) 69.2 (2.7) 52% Male Race NR Years of Education, Mean (Range) 6.5 (5-13) MMSE, Mean (Range) 27.0 [25.9-28.0]	Group endurance exercise training (cycle ergometer, treadmill and free-body activity) -60 minute sessions 3 times/week for 1 year	Educational materials that provided suggestions to improve lifestyle. Suggestions included individualized self-administered programs to increase physical activity	12 months	<u>Brief Cognitive Test Performance</u> [MMSE]	
Lautenschlager 2008 <sup>22</sup> RCT Australia Low	170	Adults reporting difficulty with memory and a MMSE score of at least 24 Age, Mean (SD): 68.7 (8.6) 51% Female Race NR Years of Education, Mean (SD)	Home-based physical activity program with behavioral intervention – At minimum 50 minutes sessions 3 times/week of moderately intense exercise for 24 weeks and a social cognitive theory-based behavioral package (workshop, manual, newsletters, and telephone calls)	Educational material about memory loss, stress management, healthful diet, alcohol consumption, and smoking. No materials on physical activity.	18 months	<u>Diagnosis</u> [CDR, Sum of Boxes] <u>Multidomain Neuropsychological Test Performance</u> [ADAS-Cog] <u>Executive/Attention/Processing Speed</u> [Dsy, WAIS] [Executive Function Battery] <u>Memory</u> [Word List, Immediate Recall (CERAD)] [Word List, Delayed Recall (CERAD)] <u>Language</u> [Verbal Fluency, Delis-Kaplin	

			12.4 (3.3) ADAS-Cog, Mean (SD) 7.0 (1.8)				
	Oken 2006 <sup>23</sup> RCT US Medium	91	Generally healthy men and women age 65-85 years Age, Mean (SD) 72.3 (5.0) 74% Female 86% White Education, Mean (SD) 15.1 (2.5) Baseline Cognition NR	Walking on a track for 60 minutes once/week	Wait list control, no intervention for duration of study	6 months	<u>Executive/Attention/Processing Speed</u> [SCWT (Interference)] [Covert Orienting (Invalid-Valid)] [Divided Attention Threshold] [% Errors Above Threshold] [Set Shifting, Highest Shift] [Simple RT] [Choice RT] [Word List Delayed Recall] [Letter-Number Sequencing, WAIS] <u>Memory</u> [Word List Delayed Recall] [Letter-Number Sequencing, WAIS]
	Okumiya 1996 <sup>24</sup> RCT Japan Medium	42	Healthy adults aged 75-87 years Age, Mean (SD) 78.8 (4.6) 57% Female Race NR Education NR MMSE, Mean (SD) 27.9 (2.6)	Aerobic exercise program -60 minutes, 2 times/week for 6 months	No exercise program for the duration of the invention	6 months	<u>Brief Cognitive Test Performance</u> [MMSE] [[Hasegawa Dementia Scale] <u>Visuospatial</u> [Visuospatial Cognitive Performance Test]
<b>Tai Chi</b>	Mortimer 2012 <sup>19</sup> RCT China High	74	Adults age 60-79 with an education-adjusted Chinese MMSE score greater than 26 Age, Mean (SD) 67.8 (5.8) 67% Female Race NR Years of Education, Mean (SD) 11.7 (3.4) Mattis Dementia Scale Score, Mean (SD)	Tai Chi -50 minute group sessions 3 times/week for 40 weeks	Inactive control with 4 check-in calls over 40 weeks	40 weeks	<u>Biomarker</u> [Whole Brain Volume, % of Total Intracranial Volume] <u>Multidomain Neuropsychological Test Performance</u> [Mattis Dementing Rating Scale, Total Score] <u>Executive/Attention/Processing Speed</u> [DS Forward] [DS Backward] [WAIS Similarities] [TMT A] [TMT B] [SCWT (Word)] [SCWT (Color)] [SCWT (Color-Word)] [Mattis Attention Score] [Mattis Initiation Score] [Mattis Conceptualization Score] <u>Memory</u> [AVLT, Immediate Recall] [AVLT, Delayed Recall] [AVLT, Delayed Recognition] Memory [Mattis Memory Score] <u>Language</u> [CVFT, Animals] [BNT, Correct

			137.6 (7.6)				Names] [RCFT, Copying] [RCFT, Recall] <u>Visuospatial</u> [CLOX-1] [Bell Cancellation Test] [RCFT, Copying] [RCFT, Recall] [Mattis Construction Score]
	Nguyen 2012 <sup>25</sup> RCT Germany High	96	Adults age 60-75 with a minimum MMSE score of 25 Age, Mean (SD) 68.98 (5.1) 50% Female Race NR 28.1% With more than 12 years of education Baseline Cognition NR	Tai Chi Exercise -60 minute sessions 2 times/week for 6 months	Routine daily activities (instructed not to start exercise program) for study duration	6 months	<u>Executive/Attention/Processing Speed</u> [TMT A] [TMT B]
	Taylor-Pillae 2010 <sup>7</sup> RCT US Medium-6 mo High-12 mo	93	Sedentary adults aged 60 years or older without severe cognitive impairment Age, Mean (SD) 69.0 (5.8) 70% Female 85% White Years of Education, Mean (SD) 16.1 (2.1)	Tai Chi -45 minutes classes 2.times/week and home based exercise 3 times/week for 6 months, 1 class-based session/week and 3 home-based exercise sessions for the remaining 6 months	Healthy aging classes on topics including health eating, elder law, and foot and eye care -90 minute classes 1 time/week for 6 months	6 months 12 months	<u>Executive/Attention/Processing Speed</u> [DS Forward] [DS Backward] <u>Language</u> [Animal Naming]

3MS=Modified Mini Mental Status Examination; AD=Alzheimer's disease; AVLT=Auditory Verbal Learning Test; BNT=Boston Naming Test; CDR=Clinical Dementia Rating; CERAD=Consortium to Establish a Registry for Alzheimer's Disease; DS=Digit Span (Forward and/or Backward); DSM=Diagnostic Statistical Manual of Mental Disorders; DSST=Digit Symbol Substitution Test; FCSRT=Free and Cued Selective Reminding Test; HVLT=Hopkins Verbal Learning Test; MCI=mild cognitive impairment; MMSE=Mini-Mental Status Examination; N=sample size; NINCDS-ADRDA=National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease; NR=not reported; RAVLT=Rey's Auditory Verbal Learning Test; RBMT= Rivermead Behavioral Memory Test; RCFT=Rey-Osterrieth Complex Figure Test; RCT=randomized controlled trial; RoB=risk of bias; RT=Reaction Time; SCWT=Stroop Color Word Test; SD=standard deviation; TMT=Trail Making Test (Part A and/or B); US=United States; WAIS=Wechsler Adult Intelligence Scale

**Appendix Table G2. Characteristics of eligible studies: physical activity interventions vs. active controls in adults with normal cognition**

<b>Physical Exercise Intervention Type</b>	<b>Study Design Country RoB</b>	<b>N=</b>	<b>Population Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition</b>	<b>Intervention Mode Components Frequency Duration</b>	<b>Comparison Mode Components Frequency Duration</b>	<b>Outcome timing</b>	<b>Outcome Domain [Instrument]</b>
<b>Resistance Training</b>	Best 2015 <sup>26</sup> Liu-Ambrose 2010 <sup>27</sup> RCT Canada High	103	Women aged 65-75 years, with a MMSE score of 24 or more and a visual acuity of at least 20/40 Age, Mean (SD) 69.6 (2.7) 100% Female Race NR 39% With a University Degree MMSE, Mean (SD) 28.6 (1.3)	Once-weekly progressive and high intensity resistance training (biceps curls, triceps extension, seated row, latissimus dorsi pull downs, leg press, hamstring curls, and calf raises; two sets of 6-8 reps)	Twice-weekly balance and tone training (stretching exercises, range of motion exercises, basic core-strength exercises including kegals, balance exercises, and relaxation techniques)	1 year 2 years	<u>Biomarker</u> [MRI, Cortical Gray Matter] [MRI, Cortical White Matter] [MRI, Left Hippocampus] [MRI, Right Hippocampus] <u>Executive/Attention/Processing Speed</u> [Latent Executive Function Composite] <u>Memory</u> [Memory Composite]
	Best 2015 <sup>26</sup> Liu-Ambrose 2010 <sup>27</sup> RCT Canada High	101	Women aged 65-75 years, with a MMSE score of 24 or more and a visual acuity of at least 20/40 Age, Mean (SD) 69.6 (2.7) 100% Female Race NR 39% With a University Degree MMSE, Mean (SD) 28.6 (1.3)	Twice-weekly resistance training (biceps curls, triceps extension, seated row, latissimus dorsi pull downs, leg press, hamstring curls, and calf raises; two sets of 6-8 reps)	Twice-weekly balance and tone training (stretching exercises, range of motion exercises, basic core-strength exercises including kegals, balance exercises, and relaxation techniques)	1 year 2 years	<u>Biomarker</u> [MRI, Cortical Gray Matter] [MRI, Cortical White Matter] [MRI, Left Hippocampus] [MRI, Right Hippocampus] <u>Executive/Attention/Processing Speed</u> [Latent Executive Function Composite] <u>Memory</u> [Memory Composite]
	Hotting 2011 <sup>13</sup> RCT Germany High	97	Healthy, sedentary men and women aged 40-56 years Age, Mean (SD) 47.8 (4.35)	Stretching and coordination training exercises -60 minute sessions 2 times/week for 6 months	Indoor cycling on stationary bikes -60 minute sessions 2 times/week for 6 months	6 months	<u>Executive/Attention/Processing Speed</u> [D2 Test] [Zahlenverbindungstest, German] [SCWT] <u>Memory</u> [AVLT, German] <u>Visuospatial</u> [Leistungsprufsystem,

Physical Exercise Intervention Type	Study Design Country RoB	N=	Population Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome timing	Outcome Domain [Instrument]
			82% Female Race NR Education NR Baseline Cognition NR				Subtests 8 and 9]
	Cassilhas 2007 <sup>15</sup> RCT Brazil Medium	39	Sedentary males age 65-75 with a minimum MMSE score of 24 Age, Mean (SD) 68.2 (0.77) 100% Male Race NR Education NR Baseline Cognition NR	High intensity resistance training -60 minute sessions, 3 times/week for 24 weeks	Moderate intensity resistance training - 60 minute sessions, 3 times/week for 24 weeks	24 weeks	<u>Executive/Attention/Processing Speed</u> [DS Forward] [DS Backward] [Corsi Block-Tapping, Forward] [Corsi Block-Tapping, Backward] [Corsi Block-Tapping, Similarities] [Toulouse-Pieron, Cancellations Numbers] [Toulouse-Pieron, Errors] <u>Memory</u> [RCFT, Copy] [RCFT, Immediate Recall]
<b>Aerobic Training</b>	Eggenberger 2015 <sup>28</sup> RCT Switzerland Medium	46	Seniors older than 70 years with an MMSE score greater than 22 Age, Mean (SD) 78.9 (5.4) 52% Female Race NR Years of Education, Mean (SD) 13.2 (1.9) MMSE, Mean (SD) 28.2 (1.4)	Virtual reality video game dancing with cognitive training -60 minute group sessions 2 times/week for 6 months	Treadmill walking with verbal memory exercise -60 minute group sessions 2 times/week for 6 months	6 months	<u>Executive/Attention/Processing Speed</u> [TMT A] [TMT B] [Executive Control Task] [DSST] [DS Forward] [Age Concentration Test A] [Age Concentration Test B] <u>Memory</u> [PALS] [Story Recall, WMS]

Physical Exercise Intervention Type	Study Design Country RoB	N=	Population Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome timing	Outcome Domain [Instrument]
	Ferreira 2015 <sup>29</sup> RCT Brazil High	102	Adults age 60 to 79 years with no MCI or diagnosis of dementia Age, Mean (SD) 67.1 (5.2) 87% Female Race NR MMSE, Mean (SD) 28.5 (1.5)	Supervised walking -40-50 minute sessions 3 times/ week for 6 months	Social interaction group without physical exercise or respiratory training (breathing exercises) -40-50 minute sessions 3 times/ week for 6 months	6 months	<u>Brief Cognitive Test Performance</u> [MMSE] <u>Executive/Attention/Processing Speed</u> [DS, Vocabulary, Information, and Symbol Search, WAIS] [Corsi Block-Tapping Test] [Wisconsin Card Sorting Test] <u>Memory</u> [Logic Memory I and II]
	Napoli 2014 <sup>3</sup> RCT US Medium	53	Obese, sedentary adults age 65 and older with a stable weight and a minimum MMSE score of 24 Age, Mean (SD) 70 (4) 63% Female 85% White Years of Education, Mean (SD) 16.3 (3.7) 3MSE, Mean (SD) 95.7 (0.8)	Aerobic exercise, resistance training, and balance exercises -90 minutes sessions 3 times/week at an exercise facility for 1 year	Diet and aerobic exercise, resistance training, and balance exercises - 90 minutes sessions 3 times/week at an exercise facility for 1 year and energy deficit of 500-750 kcal/day to achieve 10% weight loss over 6 months followed by 6 months of weight maintenance	1 year	<u>Brief Cognitive Test Performance</u> [3MS] <u>Executive/Attention/Processing Speed</u> [TMT A] [TMT B] <u>Memory</u> [Word List Fluency]

Physical Exercise Intervention Type	Study Design Country RoB	N=	Population Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome timing	Outcome Domain [Instrument]
	Mortimer 2012 <sup>19</sup> RCT China High	74	Adults age 60-79 with an education-adjusted Chinese MMSE score greater than 26 Age, Mean (SD) 67.8 (5.8) 67% Female Race NR Years of Education, Mean (SD) 11.7 (3.4) Mattis Dementia Scale Score, Mean (SD) 137.6 (7.6)	Walking-50 minute group sessions 3 times/week for 40 weeks	Social interaction – Meeting at community center for 1 hr 3 times/week	40 weeks	<u>Biomarker</u> [Whole Brain Volume, % of Total Intracranial Volume] <u>Multidomain Neuropsychological Test Performance</u> [Mattis Dementing Rating Scale, Total Score] <u>Executive/Attention/Processing Speed</u> [DS Forward] [DS Backward] [SCWT (Word)] [SCWT (Color)] [SCWT (Color-Word)] [WAIS Similarities] [TMT A] [TMT B] [Mattis Attention Score] [Mattis Initiation Score] [Mattis Conceptualization Score] <u>Memory</u> [AVLT, Immediate Recall] [AVLT, Delayed Recall] [AVLT, Delayed Recognition] [Mattis Memory Score] [RCFT, Copying] [RCFT, Recall] <u>Language</u> [CVFT, Animals] [BNT, Correct Names] <u>Visuospatial</u> [Bell Cancellation Test] [CLOX-1] [RCFT, Copying] [RCFT, Recall] [Mattis Construction Score]
	Colcombe 2011 <sup>30</sup> RCT US High	59	Older, healthy, sedentary adults Mean Age 66.5 55% Female Race NR	Aerobic exercise (intensity based on desired peak heart rate) – 1 hour training sessions 3 times/week for 6 months	Whole body stretching and toning – 1 hour training sessions 3 times/week for 6 months	6 months	<u>Biomarker</u> [MRI, Gray Matter] [MRI, Regional Brain Volume]



Physical Exercise Intervention Type	Study Design Country RoB	N=	Population Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome timing	Outcome Domain [Instrument]
			Mean Education 13.8 years MMSE, Mean (SD) 29.2 (1.3)				
	Erickson 2011 <sup>31</sup> RCT US High	120	Older adults without dementia and a score of 51 or more on the MMSE Age, Mean (SD) 66.6 (5.63) 67% Female Education NR Baseline Cognition NR	Moderate intensity walking exercise -3 days/week for 1 year	Stretching and toning exercises (muscle-toning exercises using dumbbells or resistance bands, exercises designed to improve balance, and yoga sequences) -3 days/week for 1 year	6 months 1 year	<u>Biomarker</u> [MRI, Hippocampal Volume] <u>Memory</u> [Spatial Memory Task]
	Ruscheweyh 2011 <sup>20</sup> RCT Germany Medium	42	Sedentary adults aged 50-72 with MMSE scores above 26 Age, Mean (SD) 60.3 (6.5) 65% Female Race NR Education, Mean (SD) 11.0 (3.4) MMSE, Mean (SD) 29.2 (2.8)	Gymnastics ( stretching, limbering, and toning of upper and lower extremities; intensity levels corresponding to 30–40% of maximal exertion) for 6 months	Nordic walking (intensity levels corresponding to 50–60% of maximal exertion) for 6 months	6 months	<u>Memory</u> [AVLT, German]
	Baker 2010 <sup>32,33</sup> RCT US Medium	28	Individuals with abnormal glucose tolerance and normal cognitive status	Aerobic exercise (using a treadmill, stationary bicycle, or elliptical machine) -45-60 minutes sessions 4 times/week for	Stretching -45-60 minutes sessions 4 times/week for 6 months	6 months	<u>Executive/Attention/Processing Speed</u> [TMT B] [Task Switching] [SCWT (Interference)] [Self-Ordered Pointing Test] [Verbal Fluency]

Physical Exercise Intervention Type	Study Design Country RoB	N=	Population Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome timing	Outcome Domain [Instrument]
			Age, Mean (SD) 68.5 (6.8) 64% Female Race NR	6 months			<u>Memory</u> [Story Recall] [List Learning]
	Komulainen 2010 <sup>14</sup> RCT Finland High	470	Men and women age 55 to 74 Age, Mean (SD) 66.5 (5.4) Sex NR Race NR Education, Mean (SD) 11.4 (3.9) MMSE, Mean (SD) 27.6 (2.1)	Individualized, independent, aerobic exercise program either 5 times/week for 60 min or 5 times/week for 90 min for 2 years	Counseling by nutritionists to modify diet to specific recommendations	2 years	<u>Brief Cognitive Test Performance</u> [MMSE] <u>Memory</u> [Immediate Memory Composite] [Delayed Memory Composite] <u>Language</u> [Verbal Performance Composite] <u>Visuospatial</u> [Visual Performance Composite]
	Komulainen 2010 <sup>14</sup> RCT Finland High	472	Men and women age 55 to 74 Age, Mean (SD) 66.3 (5.3) Sex NR Race NR Education, Mean (SD) 11.3 (3.9) MMSE, Mean (SD) 27.6 (2.1)	Individualized, independent, strength training program either 2 times/week or 3 times per week	Counseling by nutritionists to modify diet to specific recommendations	2 years	<u>Brief Cognitive Test Performance</u> [MMSE] <u>Memory</u> [Immediate Memory Composite] [Delayed Memory Composite] <u>Language</u> [Verbal Performance Composite] <u>Visuospatial</u> [Visual Performance Composite]
	Smiley-Owen 2008 <sup>34</sup> RCT US High	109	Adults age 64 or older who were npt physically active or physically fit Age, Mean (SD) 70.2 (4.7) 72% Female	Cardiovascular training 25–30 min on the aerobic exercise equipment of their choice; individualized prescriptions started at 45–60% of heart rate reserve, progressed to	Exercise training (strength, flexibility, and balance exercises) for 25–30 min -3 times week/10 months	10 months	<u>Executive/Attention/Processing Speed</u> [8-Choice RT Test] [SCWT] [Wisconsin Card Sort Test] [Go/No-Go Reaction Time] [Simple RT Test] [8-Choice Incompatible RT Test]

Physical Exercise Intervention Type	Study Design Country RoB	N=	Population Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome timing	Outcome Domain [Instrument]
			Race NR Education, Mean (SD) 15.9 (2.6) Baseline Cognition NR	60–70%, and were then maintained at 65–80% -3 times/week for 10 months			
	Oken 2006 <sup>23</sup> RCT US Medium	91	Generally healthy men and women age 65-85 years Age, Mean (SD) 72.3 (5.0) 74% Female 86% White Education, Mean (SD) 15.1 (2.5) Baseline Cognition NR	Walking on a track for 60 minutes once/week	Beginner Iyengar yoga once/week for 90 minutes	6 months	<u>Executive/Attention/Processing Speed</u> [SCWT (Interference)] [Covert Orienting, Invalid-Valid] [Divided Attention Threshold] [% Errors Above Threshold] [Set Shifting, Highest Shift] [Simple RT] [Choice RT] [Word List Delayed Recall] [Letter-Number Sequencing, WAIS] <u>Memory</u> [Word list Delayed Recall] [Letter-Number Sequencing, WAIS]
	Kramer 1999 <sup>35</sup> RCT US High	124	Sedentary adults age 60 to 75 years Age NR Sex NR Race NR Education NR Baseline Cognition NR	Walking for 6 months	Stretching and toning for 6 months	6 months	<u>Executive/Attention/Processing Speed</u> [Task Switching] [Response Compatability] [Stopping]
	Blumenthal 1991 <sup>36</sup> Madden 1989 <sup>37</sup> Crossover RCT US High	101	Sedentary adults over 60 free from coronary disease Age, Mean (SD) 67.05 (4.9) 50% Female Race NR Education, Mean	Aerobic exercise (based on a 6-bpm (beats per minute) training range equivalent to 70% maximum heart rate reserve) for 8 months. Optional aerobic intervention available for	Wait-list control for 4 months followed by aerobic exercise for 4 months. Optional aerobic intervention available for an additional 6	8 months 14 months	<u>Executive/Attention/Processing Speed</u> [RT Tasks] [Word-Comparison Task] [DS Forward] [DS Backward] [DSST] [TMT B] [SCWT] <u>Memory</u> [Short Story Module] [Randt Memory Test] [BVRT] [Selective Reminding Test] <u>Language</u> [Verbal Fluency]

Physical Exercise Intervention Type	Study Design Country RoB	N=	Population Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome timing	Outcome Domain [Instrument]
			(SD) 15.2 (2.4) Baseline Cognition NR	an additional 6 months.	months.		<u>Motor</u> [Finger Tapping Test]
<b>Tai Chi or Yoga</b>	Mortimer 2012 <sup>19</sup> RCT China High	73	Adults age 60-79 with an education-adjusted Chinese MMSE score greater than 26 Age, Mean (SD) 67.8 (5.8) 67% Female Race NR Years of Education, Mean (SD) 11.7 (3.4) Mattis Dementia Scale Score, Mean (SD) 137.6 (7.6)	Tai Chi -50 minute group sessions 3 times/week for 40 weeks	Social interaction – Meeting at community center for 1 hr 3 times/week	40 weeks	<u>Biomarker</u> [Whole Brain Volume, % of Total Intracranial Volume]) <u>Multidomain Neuropsychological Test Performance</u> [Mattis Dementing Rating Scale, Total Score] <u>Executive/Attention/Processing Speed</u> [DS Forward ] [DS Backward ] [SCWT (Word)] [SCWT (Color)] [SCWT (Color-Word)] [WAIS Similarities] [TMT A] [TMT B] [Mattis Conceptualization Score] [Mattis Attention Score] [Mattis Initiation Score] <u>Memory</u> [RCFT, Copying] [RCFT, Recall] [AVLT, Immediate Recall] [AVLT, Delayed Recall] [AVLT, Delayed Recognition] [BNT, Correct Names] [Mattis Memory Score] <u>Language</u> [CVFT, Animals] <u>Visuospatial</u> [Bell Cancellation Test] [RCFT, Copying] [RCFT, Recall] [CLOX-1] [Mattis Construction Score]
	Mortimer 2012 <sup>19</sup> RCT China High	74	Adults age 60-79 with an education-adjusted Chinese MMSE score greater than 26 Age, Mean (SD) 67.8 (5.8) 67% Female Race NR	Tai Chi -50 minute group sessions 3 times/week for 40 weeks	Walking-50 minute group sessions 3 times/week for 40 weeks	40 weeks	<u>Biomarker</u> [Whole Brain Volume, % of Total Intracranial Volume]) <u>Multidomain Neuropsychological Test Performance</u> [Mattis Dementing Rating Scale, Total Score] <u>Executive/Attention/Processing Speed</u> [DS Forward ] [DS Backward ] [SCWT (Word)] [SCWT (Color)] [SCWT (Color-Word)] [WAIS Similarities] [TMT A] [TMT

Physical Exercise Intervention Type	Study Design Country RoB	N=	Population Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome timing	Outcome Domain [Instrument]
			Years of Education, Mean (SD) 11.7 (3.4) Mattis Dementia Scale Score, Mean (SD) 137.6 (7.6)				B) [Mattis Conceptualization Score] [Mattis Attention Score] [Mattis Initiation Score] <u>Memory</u> [RCFT, Copying] [RCFT, Recall] [AVLT, Immediate Recall] [AVLT, Delayed Recall] [AVLT, Delayed Recognition] [BNT, Correct Names] [Mattis Memory Score] <u>Language</u> [CVFT, Animals] <u>Visuospatial</u> [Bell Cancellation Test] [RCFT, Copying] [RCFT, Recall] [CLOX-1] [Mattis Construction Score]
	Taylor-Pillae 2010 <sup>7</sup> RCT US Medium-6 mo High-12 mo	76	Sedentary adults aged 60 years or older without severe cognitive impairment Age, Mean (SD) 69.0 (5.8) 70% Female 85% White Years of Education, Mean (SD) 16.1 (2.1)	Western Exercise: Endurance, resistance/strength, and flexibility exercises- 60 minutes classes 2.times/week and home based exercise 3 times/week for 6 months, 1 class-based session/week and 3 home-based exercise sessions for the remaining 6 months	Tai Chi -45 minutes classes 2.times/week and home based exercise 3 times/week for 6 months, 1 class-based session/week and 3 home-based exercise sessions for the remaining 6 months	6 months 12 months	<u>Executive/Attention/Processing Speed</u> [DS Forward] [DS Backward] <u>Language</u> [Animal Naming]
	Blumenthal 1991 <sup>36</sup> Madden 1989 <sup>37</sup> Crossover RCT US High	101	Sedentary adults over 60 free from coronary disease Age, Mean (SD) 67.05 (4.9) 50% Female Race NR Education, Mean (SD)	Yoga (60 minutes, twice a week for 4 months) followed by aerobic exercise for 4 months. Optional aerobic intervention available for an additional 6 months	Wait-list control for 4 months followed by aerobic exercise for 4 months. Optional aerobic intervention available for an additional 6 months.	8 months 14 months	<u>Executive/Attention/Processing Speed</u> [RT Tasks] [Word-Comparison Task] [DS Forward] [DS Backward] [Digit Symbol Subtest] [TMT B] [SCWT (Color-Word)] <u>Memory</u> [Short Story Module] [Randt Memory Test] [BVRT] [Selective Reminding Test] [Letter Search Task]

Physical Exercise Intervention Type	Study Design Country RoB	N=	Population Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome timing	Outcome Domain [Instrument]
			15.2 (2.4) Baseline Cognition NR				<u>Language</u> [Verbal Fluency] <u>Motor</u> [Finger Tapping Test]

3MS=Modified Mini Mental Status Examination; AVLT=Auditory Verbal Learning Test; BNT=Boston Naming Test; BVMT=Brief Visuospatial Memory Test; CLOX-1=Clock Drawing Test; CVFT=Category Verbal Fluency Test; DS=Digit Span (Forward and/or Backward); DSST=Digit Symbol Substitution Test; MMSE=Mini-Mental Status Examination; MRI=magnetic resonance imaging; N=sample size; NR=not reported; PALS=Paired Association Learning Test; RCFT=Rey-Osterrieth Complex Figure Test; RCFT=Rey-Osterrieth Complex Figure Test; RCT=randomized controlled trial; RoB=risk of bias; RT=reaction time; SCWT=Stroop Color Word Test; SD=standard deviation; WAIS=Wechsler Adult Intelligence Scale; WMS=Wechsler Memory Scale

**Appendix Table G3. Summary risk of bias assessments: physical activity interventions in adults with normal cognition**

<b>Study</b>	<b>Overall Risk of Bias Assessment</b>	<b>Rationale</b>
Antunes 2015 <sup>17</sup>	Medium	Process for randomization is unclear/poorly described.
Best 2015 <sup>26</sup> Liu-Ambrose 2010 <sup>27</sup>	High	Attrition rate is over 13-22% with suspected detection and reporting bias.
Bun 2015 <sup>1</sup>	High	No randomization (participants self-selected into study arms) and attrition greater than 21%.
Eggenberger 2015 <sup>28</sup>	Medium	Attrition rate is 20% with potential performance bias.
Ferreira 2015 <sup>29</sup>	High	High attrition rate with suspected reporting bias.
Sink 2015 <sup>2</sup>	Medium	Attrition 10%; potential differences in timing of certain outcomes measurements.
Napoli 2014 <sup>3</sup>	Medium	Process for randomization is unclear and 13% attrition rate.
Satoh 2014 <sup>18</sup>	High	Semi-randomly assigned groups and 33% attrition rate.
van de Rest 2014 <sup>12</sup>	Medium	Attrition is 15% with potential reporting bias.
Mortimer 2012 <sup>19</sup>	High	Suspected selection bias due to modifications post-randomization.
Nguyen 2012 <sup>25</sup>	High	Randomization not well described with 24% attrition rate.
Colcombe 2011 <sup>30</sup>	High	Unclear reporting of attrition with suspected detection and reporting bias.
Erickson 2011 <sup>31</sup>	High	Unclear randomization, high attrition rate and suspected detection and reporting biases.
Hotting 2011 <sup>13</sup>	High	Suspected selection bias due to selection procedure for control group.
Ruscheweyh 2011 <sup>20</sup>	Medium	Attrition is 17% with potential detection bias.
Baker 2010 <sup>32, 33</sup>	Medium	Attrition is 18% with potential reporting bias
Klusmann 2010 <sup>4</sup> Evers 2011 <sup>5</sup>	High	Attrition is over 25% with no analysis to address potential bias.
Komulainen 2010 <sup>14</sup>	High	Flaw in study design related to the analysis of the data and suspected reporting bias
Muscari 2010 <sup>21</sup>	Medium	Randomization not well described with 11% attrition rate.

<b>Study</b>	<b>Overall Risk of Bias Assessment</b>	<b>Rationale</b>
Rosano 2010 <sup>6</sup>	High	Participants self-selected for inclusion for additional follow-up based on willingness to participate. High attrition rate from original study population.
Taylor-Pillae 2010 <sup>7</sup>	High-12 mo outcomes Medium-6 mo outcomes	Randomization not well described with 21% attrition at 12 months.
Williamson 2009 <sup>8</sup>	Medium	Potential performance and reporting bias.
Lautenschlager 2008 <sup>22</sup>	Low	No suspected biases.
Liu-Ambrose 2008 <sup>9</sup>	High	Attrition rate is over 21% with no analysis to address potential bias.
Smiley-Owen 2008 <sup>34</sup>	High	Attrition rate is 27% with no analysis to address potential bias.
Cassilhas 2007 <sup>15</sup>	Medium	Randomization not well described with potential reporting bias.
Lachman 2006 <sup>16</sup>	Medium	Attrition information is not reported and suspected detection bias.
Oswald 2006 <sup>10</sup>	High	Suspected selection bias due to process for randomization.
Oken 2006 <sup>23</sup>	Medium	Attrition rate is 13% with suspected detection bias.
Kramer 1999 <sup>35</sup>	High	Medium risk of selection bias, no attrition data reported, and high risk of reporting bias.
Williams 1997 <sup>11</sup>	High	Selection and attrition bias due to flaws in randomization process and high attrition rate.
Okumiya 1996 <sup>24</sup>	Medium	Randomization not well described with potential detection bias.
Blumenthal 1991 <sup>36</sup> Madden 1989 <sup>37</sup>	High	Selection bias due to flaws in crossover design and reporting bias.



**Appendix Table G4. Strength of evidence assessments: physical activity interventions versus inactive control in adults with normal cognition**

Physical Exercise Type	Outcome	# Trials (n)	Summary statistics [95% CI]	Study Limitations	Directness	Precision	Consistency	Reporting Bias	Optional Components	SOE
Multicomponent Physical Activity	Dementia	1 (1,635)	OR: 0.96 [0.57 to 1.63]	Medium	Direct	Imprecise	Unknown	Undetected	NA	Insufficient
	MCI	1 (1,635)	OR: 1.14 [0.79 to 1.62]	Medium	Direct	Imprecise	Unknown	Undetected	NA	Insufficient
	Brief cognitive test performance	2 (155)	1 of 2 tests shows statistically significant improvement with intervention, but effect size not clinically meaningful:  <u>Napoli 2014</u> Difference in change from baseline (3MS): 3.0 [1.5 to 4.5] <u>Williamson 2009</u> Difference in adjusted mean change from baseline (3MS): -0.86 [-3.16 to 1.44]	Medium	Indirect	Imprecise	Inconsistent	Undetected	NA	Insufficient
	Multidomain neuropsychological performance	1 (1,635)	One test shows no statistically significant improvement	Medium	Indirect	Precise	Unknown consistency	Undetected	NA	Low

Physical Exercise Type	Outcome	# Trials (n)	Summary statistics [95% CI]	Study Limitations	Directness	Precision	Consistency	Reporting Bias	Optional Components	SOE
			with intervention.  Sink 2015 Difference in mean global composite z score: 0.029 [-0.038 to 0.095]							
	Executive/Attention/Processing Speed	4 (1,885)	1 of 13 tests show statistically significant improvement with Intervention	Medium	Indirect	Imprecise	Consistent	Undetected	NA	Low
	Memory	3 (1,836)	1 of 6 tests show statistically significant improvement with Intervention	Medium	Indirect	Imprecise	Consistent	Undetected	NA	Low
	Biomarkers	NR								Insufficient
	Adverse Effects	NR								Insufficient
<b>Resistance Training</b>	Dementia	NR								Insufficient
	MCI	NR								Insufficient
	Brief cognitive test performance	NR								Insufficient
	Multidomain neuropsychological performance	NR								Insufficient
	Executive/Attention/	2 (120)	8 of 25 tests show	Medium	Indirect	Imprecise	Inconsistent	Undetected	NA	Insufficient

Physical Exercise Type	Outcome	# Trials (n)	Summary statistics [95% CI]	Study Limitations	Directness	Precision	Consistency	Reporting Bias	Optional Components	SOE
	Processing Speed		statistically significant improvement with Intervention							
	Memory	3 (172)	3 of 11 tests show statistically significant improvement with Intervention	Medium	Indirect	Imprecise	Inconsistent	Undetected	NA	Insufficient
	Biomarkers	NR								
	Adverse Effects	NR								
Aerobic Training	Dementia	Limited data	1 of 1 test shows statistically significant improvement with intervention							Insufficient
	MCI	NR								Insufficient
	Brief cognitive test performance	2 (162)	1 of 3 tests show statistically significant improvement with intervention data  <u>Muscari 2010</u> MMSE, Mean Difference [95% CI] I: -0.21 [0.79, 0.37] C: -1.21 [1.83, 0.60]	Medium	Indirect	Imprecise	Inconsistent	Undetected	NA	Insufficient

Physical Exercise Type	Outcome	# Trials (n)	Summary statistics [95% CI]	Study Limitations	Directness	Precision	Consistency	Reporting Bias	Optional Components	SOE
			<p><u>Okumiya 1996</u> MMSE (6 months), Mean (SD) I: 28.2 ± 2.3 C: 26.5 ± 3.6</p> <p>Hasegawa Dementia Scale (6 months), Mean (SD) I: 28.2 ± 1.7 C: 26.5 ± 3.5</p>							
	Multidomain neuropsychological performance	1 (170)	<p>1 of 1 tests show statistically significant improvement with intervention data</p> <p><u>Lautenschlager 2008</u> ADAS-Cog (18 months), Mean Difference [95% CI] I: -0.73 [-1.27, 0.03] C: -0.04 [-0.46, 0.88]</p>	Medium	Indirect	Precise	Unknown	Undetected	NA	Insufficient
	Executive Function	3 (307)	3 of 14 tests show statistically significant	Medium	Indirect	Imprecise	Inconsistent	Undetected	NA	Insufficient

Physical Exercise Type	Outcome	# Trials (n)	Summary statistics [95% CI]	Study Limitations	Directness	Precision	Consistency	Reporting Bias	Optional Components	SOE
			improvement with Intervention Data							
	Memory	4 (369)	6 of 18 tests show statistically significant improvement with Intervention	Medium	Indirect	Imprecise	Inconsistent	Undetected	NA	Insufficient
	Biomarkers	NR								Insufficient
	Adverse Effects	NR								Insufficient
<b>Tai Chi</b>	Dementia	NR								Insufficient
	MCI	NR								Insufficient
	Brief cognitive test performance	NR								Insufficient
	Multidomain neuropsychological performance	NR								Insufficient
	Executive Function	Limited data								Insufficient
	Memory	NR								Insufficient
	Biomarkers	NR								
	Adverse Effects	NR								Insufficient

3MS=Modified Mini Mental Status Examination; C=control; CI=confidence interval; ES=effect size; I=Intervention; ITT=intention to treat; MCI=mild cognitive impairment; mg=milligrams; n=sample size; NA=not applicable; NR=not reported; RCT=randomized controlled trial; RR=risk ratio; SD=standard deviation; SOE=strength of evidence

**Appendix G Table 5. Characteristics of eligible studies: physical activity interventions vs. inactive controls in adults with MCI**

<b>Physical Exercise Type</b>	<b>Study Design Country RoB</b>	<b>N=</b>	<b>Population Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition</b>	<b>Intervention Mode Components Frequency Duration</b>	<b>Comparison Mode Components Frequency Duration</b>	<b>Outcome timing</b>	<b>Outcome Domain [Instrument]</b>
<b>Multicomponent Physical Activity</b>	Suzuki 2013 <sup>38</sup> Suzuki 2012 <sup>39</sup> RCT Japan Medium	100	Older adults with MCI and aMCI determined by Peterson's criteria Age, Mean 75,7 (7.0) 22% Female Race NR Education Level, Mean (SD) 10.95 (2.55) MMSE, Mean (SD) 26.6 (2.1)	Aerobic exercises, muscle strength training, and postural balance retraining -90 minutes, 2 times/week for 6 months	Health education/health promotion classes -2 classes over 6 months	6 months	<u>Biomarker [Medial Temporal Areas Including the Entorhinal Cortex]</u> <u>[Whole Brain Cortices]</u> <u>Brief Cognitive Test Performance [MMSE]</u> <u>Multidomain Neuropsychological Test Performance [ADAS-Cog]</u> <u>Memory [Logical Memory I, WMS]</u> <u>[Logical Memory, WMS II]</u>
	<b>Suzuki 2012<sup>39</sup> (subset of Suzuki 2013<sup>38</sup>)</b> RCT Japan Medium	50	Older adults with aMCI determined by education-adjusted WMS-LM II score Age, Mean 75 46% Female Race NR Education Level, Mean (SD) 10.95 (2.55) MMSE, Mean (SD)	Aerobic exercises, muscle strength training, and postural balance retraining -90 minutes, 2 times/week for 1 years	Health education/health promotion classes -3 classes over 1 year	6 months 12 months	<u>Brief Cognitive Test Performance [MMSE]</u> <u>Executive/Attention/Processing Speed [DSST] [SCWT I] [SCWT II] [LVFT]</u> <u>Memory [Logical Memory I, WMS]</u> <u>[Logical Memory, WMS II]</u> <u>Language [CVFT]</u>

			26.7 (1.7)				
<b>Resistance Training</b>	Fiatarone Singh 2014 <sup>40</sup> RCT Australia High	49	Adults age 55 and older with a MCI diagnosis consistent with Petersen criteria Age NR Sex NR Education NR MMSE, Mean (SD) 27 (1)	Resistance Training -100 minutes 2 days/week for 6 months	Sham cognitive training and sham exercise	6 months 18 months	<u>Multidomain Neuropsychological Performance</u> [ADAS-Cog] [Global Cognition Domain Composite] <u>Executive/Attention/Processing Speed</u> [Executive Function Domain Composite] [WAIS Similarities] [WAIS Matrices] [COWAT] [SDMT] <u>Memory</u> [List Learning Memory Sum from ADAS-Cog] [BVRT] [Logical Memory, Immediate] [Logical Memory, Delayed] [Memory Domain Composite] <u>Language</u> [Category Fluency, Animal Naming] [COWAT]
<b>Aerobic Training</b>	Hildreth 2015 <sup>41</sup> RCT US Medium	53	Sedentary, obese adults age 55 and over with MCI Age, Mean (SD) 65 (7) 45% Female 74% White Years of Education, Mean (SD) 16 (2) MMSE, Mean (SD) 28.6 (1.2)	Endurance exercise training –Treadmill walking for 60 minutes 3 times/week for 6 months	Maintaining current level of physical activity and placebo for study duration	6 months	<u>Multidomain Neuropsychological Performance</u> [ADAS-Cog] <u>Executive/Attention/Processing Speed</u> [Composite] [VR II, WMS] [TMT B] [DSST] [SCWT (Interference)] [DS Backward] [Picture Completion, WAIS] <u>Memory</u> [Composite] [Logical Memory II, WMS] [RAVLT] <u>Language</u> [Composite] [BNT] [Category Fluency] <u>Visuospatial</u> [Composite] [Block Design, WAIS] [Picture Completion, WAIS] [CLOX-1]
	Lautenschlager 2008 <sup>22</sup> RCT Australia Low	100	Adults reporting difficulty with memory and a MMSE score of at least 24 Age, Mean (SD): 68.7 (8.6) 51% Female	Home-based physical activity program with behavioral intervention –At minimum 50 minutes sessions 3	Educational material about memory loss, stress management, healthful diet, alcohol consumption, and	18 months	<u>Diagnosis</u> [CDR, Sum of Boxes] <u>Multidomain Neuropsychological Performance</u> [ADAS-Cog] <u>Executive/Attention/Processing Speed</u> [Executive Function Battery],[DSST] <u>Memory</u> [Word List, Immediate Recall (CERAD)] [Word List, Delayed Recall (CERAD)]

			Race NR Years of Education, Mean (SD) 12.4 (3.3) ADAS-Cog, Mean (SD) 7.0 (1.8)	times/week of moderately intense exercise for 24 weeks and a social cognitive theory-based behavioral package (workshop, manual, newsletters, and telephone calls)	smoking. No materials on physical activity.		<u>Language</u> [Verbal Fluency, Delis-Kaplin]
	Van Uffelen 2008 <sup>12</sup> RCT Netherlands High	179	Adults aged 70-80 years with MCI Age, Mean (SD) 75 (2.9) 47% Male Race NR Education NR MMSE, Median 29	Walking program (group-based, moderate intensity) twice weekly for 1 year	Low-intensity placebo activity group	1 year	<u>Executive/Attention/Processing Speed</u> [Verbal Fluency Test] [DSST] [SCWT] <u>Memory</u> [AVLT]

3MS=Modified Mini Mental Status Examination; ADAS=Cog-Alzheimer's Disease Assessment Scale-Cognitive; AVLT=Auditory Verbal Learning Test; BNT=Boston Naming Test; BVMT=Brief Visuospatial Memory Test; BVRT=Benton Visual Retention Test; CDR=Clinical Dementia Rating; CLOX-1=Clock Drawing Test; COWAT=Controlled Oral Word Association Test; CVFT=Category Verbal Fluency Test; CVLT=California Verbal Learning Test; DS=Digit Span (Forward and/or Backward); DSST=Digit Symbol Substitution Test; DVT=Digit Vigilance Test; EBMT=East Boston Memory Test; FCSRT=Free and Cued Selective Reminding Test; HVLT=Hopkins Verbal Learning Test; MCI=Mild Cognitive Impairment; MMSE=Mini-Mental Status Examination; MRI=Magnetic Resonance Imaging; N=sample size; NR=not reported; RAVLT=Rey's Auditory Verbal Learning Test; RCFT=Rey-Osterrieth Complex Figure Test; RCPM=Raven's Colored Progressive Matrices; RCT=Randomized controlled trial; RoB=risk of bias; SCWT=Stroop Color Word Test; SD=standard deviation; SDMT=Symbol Digit Modalities Test; SOE=Strength of Evidence; SWM=Spatial Working Memory; TICS=Telephone Interview for Cognitive Status (TICS-M=Modified); TMT=Trail Making Test (Part A and/or B); WAIS=Wechsler Adult Intelligence Scale; WMS=Wechsler Memory Scale



**Appendix Table G6. Characteristics of eligible studies: physical activity interventions vs. active controls in adults with MCI**

Physical Exercise Type	Study Design Country RoB	N=	Population Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome Timing	Outcome Domain [Instrument]
<b>Multicomponent Physical Activity vs. Active Control</b>	Lam 2015 <sup>43</sup> RCT China High	278	Older adults with MCI (determined by subjective and objective impairments in cognitive function) and without dementia Age, Mean (SD) 75.4 (6.5) 78.2% Female Race NR Education Level (Years), Mean (SD) 3.9 (3.6) Catonese MMSE. Mean (SD) 25.6 (2.3)	One stretching and toning, one mind body exercise, and one aerobic session -60 minutes per session for 1 year	Social activities - At least 3, 1-hr sessions/week	12 months	<u>Diagnosis</u> [CDR, Sum of Boxes] <u>Brief Cognitive Test Performance</u> [MMSE] <u>Multidomain Neuropsychological Test Performance</u> [ADAS-Cog, Chinese Version] <u>Memory</u> [Delayed recall] <u>Language</u> [CVFT]
	Lam 2015 <sup>43</sup> RCT China High	292	Older adults with MCI (determined by subjective and objective impairments in cognitive function) and without dementia Age, Mean (SD) 75.4 (6.5) 78.2% Female Race NR Education Level (Years), Mean (SD) 3.9 (3.6) Catonese MMSE. Mean (SD) 25.6 (2.3)	One stretching and toning, one mind body exercise, and one aerobic session -60 minutes per session for 1 year	Cognitively demanding activities -At least 3, 1-hr sessions/week	12 months	<u>Diagnosis</u> [CDR, Sum of Boxes] <u>Brief Cognitive Test Performance</u> [MMSE] <u>Multidomain Neuropsychological Test Performance</u> [ADAS-Cog, Chinese Version] <u>Memory</u> [Delayed recall] <u>Language</u> [CVFT]

	Lam 2015 <sup>43</sup> RCT China High	239	Older adults with MCI (determined by subjective and objective impairments in cognitive function) and without dementia Age, Mean (SD) 75.4 (6.5) 78.2% Female Race NR Education Level (Years), Mean (SD) 3.9 (3.6) Catonese MMSE. Mean (SD) 25.6 (2.3)	One stretching and toning, one mind body exercise, and one aerobic session -60 minutes per session for 1 year	Combination of cognitive and mind body exercises –At least 3, 1-hr sessions/week	12 months	<u>Diagnosis</u> [CDR, Sum of Boxes] <u>Brief Cognitive Test Performance</u> [MMSE] <u>Multidomain Neuropsychological Test Performance</u> [ADAS-Cog, Chinese Version] <u>Memory</u> [Delayed recall] <u>Language</u> [CVFT]
	Law 2014 <sup>44</sup> RCT Australia Medium	83	Adults age 60 and older with MCI Age, Mean (SD) 73.8 (7.1) 60.2% Females Race NR 33% with Secondary or Tertiary Education MMSE, Mean (SD) 24.17 (3.29)	Functional task exercise group (FcTSim programme: 5-10 min warm-up of light stretching, 30-min core FcTSim and 5-10 min cooldown) -13 sessions in 10 weeks	Active control - cognitive training group (30 min of computer-based cognitive training and 30 min of cognitive strategy training) -6 sessions over 10 weeks	6 months	<u>Multidomain Neuropsychological Test Performance</u> [Neurobehavioral Cognitive Status Exam, Chinese Version] <u>Executive/Attention/Processing Speed</u> [TMT A, Chinese Version] [TMT B, Chinese Version] <u>Memory</u> [CVVLT, Immediate] [CVVLT, Delayed] <u>Language</u> [CVFT, Chinese Version]
<b>Resistance Training vs. Active Control</b>	ten Brinke 2015 <sup>45</sup> High	56	Women with probable MCI (minimum MMSE score of 24 and reported difficulty with memory) Age, Mean (SD) 75.1 (3.7) 100% Female Race NR 28% with a University Degree MMSE, Mean (SD) 26.46 (2)	Resistance Training-2 times/week for 60 minutes for 6 months  Walking -2 times/week for 60 minutes for 6 months	Balance and Tone: Stretching exercises, range of motion exercises, balance exercises, functional and relaxation techniques -2 times/week for 60 minutes for 6 months	26 weeks	<u>Biomarker</u> [MRI] <u>Memory</u> [RAVLT, Total Acquisition] [RAVLT, Recall After Interference] [RAVLT, Loss After Interference] [RAVLT, Long Delay Free Recall]

ten Brinke 2015 <sup>45</sup> High	58	Women with probable MCI (minimum MMSE score of 24 and reported difficulty with memory) Age, Mean (SD) 75.1 (3.7) 100% Female Race NR 28% with a University Degree MMSE, Mean (SD) 26.46 (2)	Resistance Training-2 times/week for 60 minutes for 6 months	Walking -2 times/week for 60 minutes for 6 months	26 weeks	<u>Biomarker [MRI]</u> <u>Memory</u> [RAVLT, Total Acquisition] [RAVLT, Recall After Interference] [RAVLT, Loss After Interference] [RAVLT, Long Delay Free Recall]
Fiatarone Singh 2014 <sup>40</sup> RCT Australia High	46	Adults age 55 and older with a MCI diagnosis consistent with Petersen criteria Age NR Sex NR Education NR MMSE, Mean (SD) 27 (1)	Resistance Training -100 minutes 2 days/week for 6 months	Cognitive training (computer-based exercises targeting memory, executive function, attention, and processing speed) -100 minutes 2 days/week for 6 months	6 months 18 months	<u>Multidomain Neuropsychological Test Performance</u> [ADAS-Cog] [Global Cognition Domain Composite] <u>Executive/Attention/Processing Speed</u> [Executive Function Domain Composite] [WAIS Similarities] [WAIS Matrices] [COWAT] [SDMT] <u>Memory</u> [List learning Memory Sum from ADAS-Cog] <u>Language</u> [Category Fluency, Animal Naming] [COWAT] <u>Memory</u> [BVRT] [Logical Memory, Immediate] [Logical Memory, Delayed] [Memory Domain Composite]
Fiatarone Singh 2014 <sup>40</sup> RCT Australia High	49	Adults age 55 and older with a MCI diagnosis consistent with Petersen criteria Age NR Sex NR Education NR MMSE, Mean (SD) 27 (1)	Resistance Training -100 minutes 2 days/week for 6 months	Cognitive training (computer-based exercises targeting memory, executive function, attention, and processing speed) and Resistance Training -100 minutes 2 days/week for 6 months	6 months 18 months	<u>Multidomain Neuropsychological Test Performance</u> [ADAS-Cog] [Global Cognition Domain Composite] <u>Executive/Attention/Processing Speed</u> [Executive Function Domain Composite] [WAIS Similarities] [WAIS Matrices] [COWAT] [SDMT] <u>Memory</u> [List learning Memory Sum from ADAS-Cog] <u>Language</u> [Category Fluency, Animal Naming] [COWAT] <u>Memory</u> [BVRT] [Logical Memory, Immediate] [Logical Memory,

					months		Delayed] [Memory Domain Composite]
	Nagamatsu 2013 <sup>46, 47</sup> RCT Canada Medium High (Spatial Memory Outcome)	56	Women with probable MCI (minimum MMSE score of 24 and reported difficulty with memory) Age, Mean (SD) 74.9 (3.5) 100% Female Race NR 22% with a University Degree MMSE, Mean (SD) 27.2 (1.6)	Resistance Training-2 times/week for 60 minutes for 6 months	Balance and Tone: Stretching exercises, range of motion exercises, balance exercises, functional and relaxation techniques -2 times/week for 60 minutes for 6 months	26 weeks	Memory [RAVLT, Total Acquisition] [RAVLT, Recall After Interference] [RAVLT, Loss After Interference] [RAVLT, Long Delay Free Recall]
<b>Aerobic Training vs. Active Control</b>	ten Brinke 2015 <sup>45</sup> High	58	Women with probable MCI (minimum MMSE score of 24 and reported difficulty with memory) Age, Mean (SD) 75.1 (3.7) 100% Female Race NR 28% with a University Degree MMSE, Mean (SD) 26.46 (2)	Walking -2 times/week for 60 minutes for 6 months	Balance and Tone: Stretching exercises, range of motion exercises, balance exercises, functional and relaxation techniques -2 times/week for 60 minutes for 6 months	26 weeks	Biomarker [MRI] Memory [RAVLT, Total Acquisition] [RAVLT, Recall After Interference] [RAVLT, Loss After Interference] [RAVLT, Long Delay Free Recall]
	Nagamatsu 2013 <sup>46, 47</sup> RCT Canada Medium High (Spatial Memory Outcome)	58	Women with probable MCI (minimum MMSE score of 24 and reported difficulty with memory) Age, Mean (SD) 74.9 (3.5) 100% Female Race NR 22% with a University Degree	Walking -2 times/week for 60 minutes for 6 months	Balance and Tone: Stretching exercises, range of motion exercises, balance exercises, functional and relaxation techniques -2 times/week for 60	26 weeks	Memory [RAVLT, Total Acquisition] [RAVLT, Recall After Interference] [RAVLT, Loss After Interference] [RAVLT, Long Delay Free Recall]

			MMSE, Mean (SD) 27.2 (1.6))		minutes for 6 months		
	Baker 2010 <sup>32, 33</sup> RCT US High	33	Sedentary adults with amnesic MCI (single or multiple domain) based on Petersen criteria Age, Mean (Range) 70 (55-85) 52% Female Race NR Education NR MMSE, Mean (SD) 27.5 (1.9)	High-intensity aerobic exercise -4 times/week for 45-60 minutes over 6 months	Supervised stretching -4 times/week for 45-60 minutes over 6 months	6 months	<u>Executive/Attention/Processing Speed</u> [TMT] [SCWT] [Task Switching] <u>Memory</u> [Symbol Digit Modalities] [Story Recall] [List Learning] Delayed-Match-To-Sample] <u>Language</u> [Verbal Fluency]
<b>Tai Chi vs. Active Control</b>	Lam 2012 <sup>48</sup> RCT China High	389	Adults age 65 and older with a CDR of 0.5 or aMCI with subjective cognitive complaints Age, Mean (SD) 78 (6.4) 74% Female Race NR Education Level, Mean (SD) 3.4 (3.8) MMSE, Mean (SD) 24.5 (3.0)	Training on 24- forms of simplified Tai Chi (in person for 4-6 weeks, then via home video) -30 minutes 3 times/week for 1 year	Muscle stretching and toning exercise developed by physiotherapists (in person for 4-6 weeks, then via home video) -30 minutes 3 times/week for 1 year	1 year	<u>Diagnosis</u> [Incident Dementia, DSM- IV criteria] <u>Multidomain Neuropsychological Test Performance</u> [ADAS-cog]

3MS=Modified Mini Mental Status Examination; ADAS=Cog-Alzheimer's Disease Assessment Scale-Cognitive; AVLT=Auditory Verbal Learning Test; BNT=Boston Naming Test; BVMT=Brief Visuospatial Memory Test; BVRT=Benton Visual Retention Test; CDR=Clinical Dementia Rating; CLOX-1=Clock Drawing Test; COWAT=Controlled Oral Word Association Test; CVFT=Category Verbal Fluency Test; CVLT=California Verbal Learning Test; DS=Digit Span (Forward and/or Backward); DSST=Digit Symbol Substitution Test; DVT=Digit Vigilance Test; EBMT=East Boston Memory Test; FCSRT=Free and Cued Selective Reminding Test; HVLT=Hopkins Verbal Learning Test; MCI=Mild Cognitive Impairment; MMSE=Mini-Mental Status Examination; MRI=Magnetic Resonance Imaging; N=sample size; NR=not reported; RAVLT=Rey's Auditory Verbal Learning Test; RCFT=Rey-Osterrieth Complex Figure Test; RCPM=Raven's Colored Progressive Matrices; RCT=Randomized controlled trial; RoB=risk of bias; SCWT=Stroop Color Word Test; SD=standard deviation; SDMT=Symbol Digit Modalities Test; SOE=Strength of Evidence; SWM=Spatial Working Memory; TICS=Telephone Interview for Cognitive Status (TICS-M=Modified); TMT=Trail Making Test (Part A and/or B); WAIS=Wechsler Adult Intelligence Scale; WMS=Wechsler Memory Scale

**Appendix Table G7. Summary risk of bias assessments: physical activity interventions in adults with MCI**

Study	Overall Risk of Bias Assessment	Rationale
Hildreth 2015 <sup>41</sup>	Medium	Attrition rate is 15% with differential attrition rates in study arms. No analysis to address potential attrition bias.

Fiatarone Singh 2014 <sup>40</sup>	High	Suspected reporting bias. Results for intervention arms are combined in the analysis,
ten Brinke 2015 <sup>45</sup>	High	Attrition rates is over 21% with no analysis to address potential attrition bias.
Law 2014 <sup>44</sup>	Medium	Randomization not fully described and potential detection bias.
Nagamatsu 2013 <sup>46</sup>	Medium Spatial Memory: High	Unaccounted differences in sample size for outcome measures. Spatial memory outcome is rated high due to high rate of attrition for outcome measure.
Suzuki 2013 <sup>38</sup>	Medium	Attrition and suspected performance bias.
Lam 2012 <sup>48</sup>	High	Attrition rate is over 30% with no analysis to address potential attrition bias.
Suzuki 2012 <sup>39</sup>	Medium	Randomization not adequately described.
Baker 2010 <sup>33</sup>	High	Suspected attrition bias and reporting bias based on reporting of study results (all results divided into subgroups, results for complete sample not reported).
Lautenschlager 2008 <sup>22</sup>	Low	No suspected biases.
van Uffelen 2008 <sup>42</sup>	High	Attrition rate is 16-22% with potential reporting bias

MCI=mild cognitive impairment

**Appendix Table G8. Strength of evidence assessments: physical activity interventions versus inactive control in adults with MCI**

Physical Exercise Type	Outcome	# Trials (n)	Summary statistics [95% CI]	Study Limitations	Directness	Precision	Consistency	Reporting Bias	Optional Components	SOE
Multicomponent Physical Activity	Dementia	NR								
	MCI	NR								
	Brief cognitive test performance	2 (150)	1 of 3 tests show a statistically significant difference with the intervention	Medium	Indirect	Imprecise	Consistent	Undetected	NA	Insufficient
	Multidomain neuropsychological performance	NR								
	Executive/Attention/Processing Speed	NR								
	Memory	2 (150)	1 of 5 tests show a statistically significant difference with the intervention	Medium	Indirect	Imprecise	Consistent	Undetected	NA	Insufficient
	Biomarkers	NR								
	Adverse Effects	NR								
Aerobic Training	Dementia	NR								
	MCI	NR								
	Brief cognitive test performance	NR								
	Multidomain neuropsychological performance	2 (153)	1 of 2 tests shows a statistically significant difference with the intervention  <u>Hildreth 2015<sup>41</sup></u>	Medium	Indirect	Imprecise	Inconsistent	Undetected	NA	Insufficient

Physical Exercise Type	Outcome	# Trials (n)	Summary statistics [95% CI]	Study Limitations	Directness	Precision	Consistency	Reporting Bias	Optional Components	SOE
			ADAS-Cog, Mean Difference from Baseline [95% CI] I: -1.6 [-4.9, 1.6] C: -0.3, [-3.5, 3.0]  <u>Lautenschlager 2008<sup>22</sup></u> ADAS-Cog, Mean Difference from Baseline [95% CI] I: -0.38 [-1.39 to 0.63] C: 0.45 [-0.46 to 1.36]							
	Executive/Attention/ Processing Speed	2 (153)	8 of 8 tests do not show a statistically significant difference with the intervention	Medium	Indirect	Imprecise	Consistent	Undetected	NA	Insufficient
	Memory	2 (153)	5 of 5 tests do not show a statistically significant difference with the intervention	Medium	Indirect	Imprecise	Consistent	Undetected	NA	Insufficient
	Biomarkers	NR	NA	NA	NA	NA	NA	NA	NA	NA



Physical Exercise Type	Outcome	# Trials (n)	Summary statistics [95% CI]	Study Limitations	Directness	Precision	Consistency	Reporting Bias	Optional Components	SOE
	Adverse Effects	2 (153)	3 of 4 reports of adverse effects do not show a statistically significant difference with the intervention.	Medium	Indirect	Imprecise	Consistent	Undetected	NA	Insufficient

C=control; CI=confidence interval; ES=effect size; HR=hazard ratio; I=Intervention; MCI=mild cognitive impairment; mg=milligrams; n=sample size; NA=not applicable; NR=not reported; RCT=randomized controlled trial; RR=risk ratio; SD=standard deviation; SOE=strength of evidence

## References for Appendix G

1. Bun S, Ikejima C, Kida J, et al. A combination of supplements may reduce the risk of Alzheimer's disease in elderly Japanese with normal cognition. *J Alzheimers Dis.* 2015;45(1):15-25. doi: 10.3233/JAD-142232. PMID: 25524956.
2. Sink KM, Espeland MA, Castro CM, et al. Effect of a 24-Month Physical Activity Intervention vs Health Education on Cognitive Outcomes in Sedentary Older Adults: The LIFE Randomized Trial. *JAMA.* 2015 Aug 25;314(8):781-90. doi: 10.1001/jama.2015.9617. PMID: 26305648.
3. Napoli N, Shah K, Waters DL, et al. Effect of weight loss, exercise, or both on cognition and quality of life in obese older adults. *Am J Clin Nutr.* 2014 Jul;100(1):189-98. doi: 10.3945/ajcn.113.082883. PMID: 24787497.
4. Klusmann V, Evers A, Schwarzer R, et al. Complex mental and physical activity in older women and cognitive performance: a 6-month randomized controlled trial. *J Gerontol A Biol Sci Med Sci.* 2010 Jun;65(6):680-8. doi: 10.1093/gerona/glq053. PMID: 20418350.
5. Evers A, Klusmann V, Schwarzer R, et al. Improving cognition by adherence to physical or mental exercise: a moderated mediation analysis. *Aging Ment Health.* 2011 May;15(4):446-55. doi: 10.1080/13607863.2010.543657. PMID: 21500011.
6. Rosano C, Venkatraman VK, Guralnik J, et al. Psychomotor speed and functional brain MRI 2 years after completing a physical activity treatment. *J Gerontol A Biol Sci Med Sci.* 2010 Jun;65(6):639-47. doi: 10.1093/gerona/glq038. PMID: 20348185.
7. Taylor-Piliae RE, Newell KA, Cherin R, et al. Effects of Tai Chi and Western exercise on physical and cognitive functioning in healthy community-dwelling older adults. *J Aging Phys Act.* 2010 Jul;18(3):261-79. PMID: 20651414.
8. Williamson JD, Espeland M, Kritchevsky SB, et al. Changes in cognitive function in a randomized trial of physical activity: results of the lifestyle interventions and independence for elders pilot study. *J Gerontol A Biol Sci Med Sci.* 2009 Jun;64(6):688-94. doi: 10.1093/gerona/glp014. PMID: 19244157.
9. Liu-Ambrose T, Donaldson MG, Ahamed Y, et al. Otago home-based strength and balance retraining improves executive functioning in older fallers: a randomized controlled trial. *Journal of the American Geriatrics Society.* 2008 Oct;56(10):1821-30. doi: <http://dx.doi.org/10.1111/j.1532-5415.2008.01931.x>. PMID: 18795987.
10. Oswald WD, Gunzelmann T, Rupprecht R, et al. Differential effects of single versus combined cognitive and physical training with older adults: the SimA study in a 5-year perspective. *European Journal of Ageing.* 2006;3(4):179-92.
11. Williams P, Lord SR. Effects of group exercise on cognitive functioning and mood in older women. *Australian & New Zealand Journal of Public Health.* 1997 Feb;21(1):45-52. PMID: 9141729.
12. van de Rest O, van der Zwaluw NL, Tieland M, et al. Effect of resistance-type exercise training with or without protein supplementation on cognitive functioning in frail and pre-frail elderly: secondary analysis of a randomized, double-blind, placebo-controlled trial. *Mech Ageing Dev.* 2014 Mar-Apr;136-137:85-93. doi: 10.1016/j.mad.2013.12.005. PMID: 24374288.
13. Hotting K, Reich B, Holzschneider K, et al. Differential cognitive effects of cycling versus stretching/coordination training in middle-aged adults. *Health Psychol.* 2012 Mar;31(2):145-55. doi: 10.1037/a0025371. PMID: 21895371.
14. Komulainen P, Kivipelto M, Lakka T, et al. Exercise, fitness and cognition—A randomised controlled trial in older individuals: The DR's EXTRA study. *European Geriatric Medicine.* 2010;1(5):266-72.

15. Cassilhas RC, Viana VA, Grassmann V, et al. The impact of resistance exercise on the cognitive function of the elderly. *Med Sci Sports Exerc.* 2007 Aug;39(8):1401-7. doi: 10.1249/mss.0b013e318060111f. PMID: 17762374.
16. Lachman ME, Neupert SD, Bertrand R, et al. The effects of strength training on memory in older adults. *Journal of Aging & Physical Activity.* 2006 Jan;14(1):59-73. PMID: 16648652.
17. Antunes HK, De Mello MT, Santos-Galduroz RF, et al. Effects of a physical fitness program on memory and blood viscosity in sedentary elderly men. *Braz J Med Biol Res.* 2015 Sep;48(9):805-12. doi: 10.1590/1414-431X20154529. PMID: 26222648.
18. Satoh M, Ogawa J, Tokita T, et al. The effects of physical exercise with music on cognitive function of elderly people: Mihama-Kiho project. *PLoS One.* 2014;9(4):e95230. doi: 10.1371/journal.pone.0095230. PMID: 24769624.
19. Mortimer JA, Ding D, Borenstein AR, et al. Changes in brain volume and cognition in a randomized trial of exercise and social interaction in a community-based sample of non-demented Chinese elders. *J Alzheimers Dis.* 2012;30(4):757-66. doi: 10.3233/JAD-2012-120079. PMID: 22451320.
20. Ruscheweyh R, Willemer C, Kruger K, et al. Physical activity and memory functions: an interventional study. *Neurobiology of Aging.* 2011 Jul;32(7):1304-19. doi: <http://dx.doi.org/10.1016/j.neurobiolaging.2009.08.001>. PMID: 19716631.
21. Muscari A, Giannoni C, Pierpaoli L, et al. Chronic endurance exercise training prevents aging-related cognitive decline in healthy older adults: a randomized controlled trial. *Int J Geriatr Psychiatry.* 2010 Oct;25(10):1055-64. doi: 10.1002/gps.2462. PMID: 20033904.
22. Lautenschlager NT, Cox KL, Flicker L, et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. *JAMA.* 2008 Sep 3;300(9):1027-37. doi: 10.1001/jama.300.9.1027. PMID: 18768414.
23. Oken BS, Zajdel D, Kishiyama S, et al. Randomized, controlled, six-month trial of yoga in healthy seniors: effects on cognition and quality of life. *Alternative Therapies in Health & Medicine.* 2006 Jan-Feb;12(1):40-7. PMID: 16454146.
24. Okumiya K, Matsubayashi K, Wada T, et al. Effects of exercise on neurobehavioral function in community-dwelling older people more than 75 years of age. *Journal of the American Geriatrics Society.* 1996 May;44(5):569-72. PMID: 8617907.
25. Nguyen MH, Kruse A. A randomized controlled trial of Tai chi for balance, sleep quality and cognitive performance in elderly Vietnamese. *Clin Interv Aging.* 2012;7:185-90. doi: 10.2147/CIA.S32600. PMID: 22807627.
26. Best JR, Chiu BK, Liang Hsu C, et al. Long-term effects of resistance exercise training on cognition and brain volume in older women: Results from a randomized controlled trial. *Journal of the International Neuropsychological Society.* 2015 Nov;21(10):745-56. doi: <http://dx.doi.org/10.1017/S1355617715000673>. PMID: 2015-53115-004.
27. Liu-Ambrose T, Nagamatsu LS, Graf P, et al. Resistance training and executive functions: a 12-month randomized controlled trial. *Archives of Internal Medicine.* 2010 Jan 25;170(2):170-8. doi: <http://dx.doi.org/10.1001/archinternmed.2009.494>. PMID: 20101012.
28. Eggenberger P, Schumacher V, Angst M, et al. Does multicomponent physical exercise with simultaneous cognitive training boost cognitive performance in older adults? A 6-month randomized controlled trial with a 1-year follow-up. *Clin Interv Aging.* 2015 17 Aug;10:1335-49. doi: 10.2147/CIA.S87732. PMID: 26316729.
29. Ferreira L, Tanaka K, Santos-Galduroz RF, et al. Respiratory training as strategy to prevent cognitive decline in aging: a randomized controlled trial. *Clin Interv Aging.* 2015 20 Mar;10:593-603. doi: 10.2147/CIA.S79560. PMID: 25848235.

30. Colcombe SJ, Erickson KI, Scalf PE, et al. Aerobic exercise training increases brain volume in aging humans. *Journals of Gerontology Series A-Biological Sciences & Medical Sciences*. 2006 Nov;61(11):1166-70. PMID: 17167157.
31. Erickson KI, Voss MW, Prakash RS, et al. Exercise training increases size of hippocampus and improves memory. *Proceedings of the National Academy of Sciences of the United States of America*. 2011 Feb 15;108(7):3017-22. doi: <http://dx.doi.org/10.1073/pnas.1015950108>. PMID: 21282661.
32. Baker LD, Frank LL, Foster-Schubert K, et al. Aerobic exercise improves cognition for older adults with glucose intolerance, a risk factor for Alzheimer's disease. *J Alzheimers Dis*. 2010;22(2):569-79. doi: 10.3233/JAD-2010-100768. PMID: 20847403.
33. Baker LD, Frank LL, Foster-Schubert K, et al. Effects of aerobic exercise on mild cognitive impairment: a controlled trial. *Arch Neurol*. 2010 Jan;67(1):71-9. doi: 10.1001/archneurol.2009.307. PMID: 20065132.
34. Smiley-Oyen AL, Lowry KA, Francois SJ, et al. Exercise, fitness, and neurocognitive function in older adults: the "selective improvement" and "cardiovascular fitness" hypotheses. *Annals of Behavioral Medicine*. 2008 Dec;36(3):280-91. doi: <http://dx.doi.org/10.1007/s12160-008-9064-5>. PMID: 18825471.
35. Kramer AF, Hahn S, Cohen NJ, et al. Ageing, fitness and neurocognitive function. *Nature*. 1999 Jul 29;400(6743):418-9. PMID: 10440369.
36. Blumenthal JA, Emery CF, Madden DJ, et al. Long-term effects of exercise on psychological functioning in older men and women. *Journal of Gerontology*. 1991 Nov;46(6):P352-61. PMID: 1940092.
37. Madden DJ, Blumenthal JA, Allen PA, et al. Improving aerobic capacity in healthy older adults does not necessarily lead to improved cognitive performance. *Psychology & Aging*. 1989 Sep;4(3):307-20. PMID: 2803624.
38. Suzuki T, Shimada H, Makizako H, et al. A randomized controlled trial of multicomponent exercise in older adults with mild cognitive impairment. *PLoS One*. 2013;8(4):e61483. doi: 10.1371/journal.pone.0061483. PMID: 23585901.
39. Suzuki T, Shimada H, Makizako H, et al. Effects of multicomponent exercise on cognitive function in older adults with amnesic mild cognitive impairment: a randomized controlled trial. *BMC Neurol*. 2012;12:128. doi: 10.1186/1471-2377-12-128. PMID: 23113898.
40. Fiatarone Singh MA, Gates N, Saigal N, et al. The Study of Mental and Resistance Training (SMART) study-resistance training and/or cognitive training in mild cognitive impairment: a randomized, double-blind, double-sham controlled trial. *J Am Med Dir Assoc*. 2014 Dec;15(12):873-80. doi: 10.1016/j.jamda.2014.09.010. PMID: 25444575.
41. Hildreth KL, Van Pelt RE, Moreau KL, et al. Effects of pioglitazone or exercise in older adults with mild cognitive impairment and insulin resistance: a pilot study. *Dement Geriatr Cogn Dis Extra*. 2015 Jan-Apr;5(1):51-63. doi: 10.1159/000371509. PMID: 25852732.
42. van Uffelen JG, Chinapaw MJ, van Mechelen W, et al. Walking or vitamin B for cognition in older adults with mild cognitive impairment? A randomised controlled trial. *British Journal of Sports Medicine*. 2008 May;42(5):344-51. doi: <http://dx.doi.org/10.1136/bjism.2007.044735>. PMID: 18308888.
43. Lam LC, Chan WC, Leung T, et al. Would older adults with mild cognitive impairment adhere to and benefit from a structured lifestyle activity intervention to enhance cognition?: a cluster randomized controlled trial. *PLoS One*. 2015 31 Mar;10(3):e0118173. doi: 10.1371/journal.pone.0118173. PMID: 25826620.
44. Law LL, Barnett F, Yau MK, et al. Effects of functional tasks exercise on older adults with cognitive impairment at risk of Alzheimer's disease: a randomised controlled trial. *Age Ageing*. 2014 Nov;43(6):813-20. doi: 10.1093/ageing/afu055. PMID: 24850540.
45. ten Brinke LF, Bolandzadeh N, Nagamatsu LS, et al. Aerobic exercise increases hippocampal volume in older women with probable mild cognitive impairment: a 6-month randomised controlled trial. *Br J Sports Med*. 2015 Feb;49(4):248-54. doi: 10.1136/bjsports-2013-093184. PMID: 24711660.

46. Nagamatsu LS, Chan A, Davis JC, et al. Physical activity improves verbal and spatial memory in older adults with probable mild cognitive impairment: a 6-month randomized controlled trial. *J Aging Res.* 2013;2013(861893):861893. doi: 10.1155/2013/861893. PMID: 23509628.
47. Nagamatsu LS, Handy TC, Hsu CL, et al. Resistance training promotes cognitive and functional brain plasticity in seniors with probable mild cognitive impairment. *Arch Intern Med.* 2012 Apr 23;172(8):666-8. doi: 10.1001/archinternmed.2012.379. PMID: 22529236.
48. Lam LC, Chau RC, Wong BM, et al. A 1-year randomized controlled trial comparing mind body exercise (Tai Chi) with stretching and toning exercise on cognitive function in older Chinese adults at risk of cognitive decline. *J Am Med Dir Assoc.* 2012 Jul;13(6):568 e15-20. doi: 10.1016/j.jamda.2012.03.008. PMID: 22579072.

## Appendix H. Nutraceutical Interventions

**Appendix Table H1. Characteristics of eligible studies: nutraceutical interventions in adults with normal cognition**

Nutraceutical Intervention Type	Study Design Country RoB	N=	Population Inclusion Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome Timing	Outcome Domain [Instrument]
<b>Omega 3 fatty acids efficacy</b>	Boespflug 2016 <sup>1</sup> United States RCT High	21	Individuals without dementia, diabetes, kidney disease, liver disease, serious psychiatric condition, substance abuse, or taking supplements that might affect outcome measures or interact with fish oil. Mean age (SD): 68.3 (4.94) 62.3% Female Race: NR Education: NR Mean Clinical Dementia Rating Score (SD): 0.2 (0.37)	Fish oil 2.4g daily [1.6g EPA and 0.8g DHA] and either whole fruit or freeze-dried blueberry powered for 6 months	Matching placebo for 6 months	6 months	<u>Biomarker</u> [fMRI] <u>Memory</u> [Sequential Letter N-back Working Memory]
	Cukierman-Yaffe, 2014 <sup>2</sup> (Substudy of ORIGIN trial) RCT Multinational Medium (High for outcomes at t5 for MMSE and t6	11, 685	Adults older than 50 with dysglycaemia, with additional risk factors for cardiovascular events, not taking insulin, and taking no more than 1 oral glucose drug. Mean age (SD): 63 (7.75) 35% female 59% white	Omega 3 (EPA 465 mg+ DHA 375 mg) daily for 6 years	Placebo daily for 6 years	Median 6.2 years	<u>Diagnosis</u> [Incident Probable Cognitive Impairment = Reported Dementia or an MMSE score of <24] <u>Brief Cognitive Test Performance</u> [MMSE] <u>Executive/Attention/Processing Speed</u> [DSST]

	for DSS)		Education: 35% <8 years 27% 9-12 years 38% >12 years Mean MMSE (SD): 28 (2.75)				
	Mahmoudi 2014 <sup>3</sup> Iran RCT High	199	Individuals ≥65 with normal or mild to moderate cognitive impairment. Mean age (SD): 74.63 (5.4) 54.75% Female Race: NR 68.35% Illiterate 16.6% Primary education 10.55% Secondary education 4.5% Higher education Mean MMSE (SD): 18.70 (5.25) 28.6% with normal MMSE 41.7% with mild MMSE 29.6% with moderate MMSE	Fish oil 1g daily [180mg DHA plus 120mg EPA	Matching- placebo	180 days	<u>Brief Cognitive Test Performance</u> [MMSE] <u>Memory</u> [Abbreviated Mental Test]
	Witte, 2014 <sup>4</sup> RCT Germany Medium	80	Healthy adults aged 50-75 years Mean age (SD): 64 (± 6.5) years 46 % female Race not reported Mean education (SD) (range 0=no educ - 5=college): 4.2 (1.2) Mean MMSE (SD): 29.3 (1)	Omega 3 (fish oil, 2.2 g) daily for 6 months	Placebo capsules (sunflower oil) daily for 6 months (26 weeks)	6 months	<u>Biomarker</u> [MRI: Gray Matter Changes And White Matter Integrity] <u>Executive/Attention/Processing</u> <u>Speed</u> [Executive Function Composite] [Attention Composite] [Sensorimotor Speed Composite] <u>Memory</u> [Memory Composite]
	Stonehouse, 2013 <sup>5</sup> RCT New Zealand High	176	Healthy adults with normal cognition aged 18-45 years & low DHA intake Mean age (SD): 33.3 (7.8) years 64% female 80% European	Omega 3 (DHA 1.16 g) daily for 6 months	Placebo daily for 6 months	6 months	<u>Executive/Attention/Processing</u> <u>Speed</u> [Composite Attention] [Reaction Time Attention] [Finding As Task] [Reaction Time Episodic Memory] [Reaction Time Working Memory] <u>Memory</u> [Composite Episodic

			28% secondary education 72% tertiary education Baseline global cog not reported				Memory] [Composite Working Memory]
	Geleijnse, 2012 <sup>6</sup> RCT subset Netherlands Medium	291 1	Coronary patients aged 60-80 years Mean age (SD): 69 (5.5) years 22% female Race not reported 22% elementary ed 66% secondary or higher vocational education 12% college Mean MMSE (SD): 28.2 (1.7)	Omega 3 (EPA-DHA 400 mg or ALA 200 mg) daily for 40 months  (There is also an EPA-DHA + ALA arm; however, 2X2 factorial design was collapsed into combined group analysis of all EPA-DHA vs placebo and all ALA versus placebo)	Placebo daily for 40 months	40 months	Brief Cognitive Test Performance [MMSE] [Risk of Cognitive Decline based on MMSE Score]
	Andreeva, 2011 <sup>7</sup> RCT followup France Medium	174 8	Adults with normal cognition aged 45-80 with a history of ischemic heart disease Mean age (SD): 61 (8.8) years 20% female Race not reported 10% foreign-born 58% < high school Mean Isaacs Set Test (SD): 35.8 (7.5)	Omega 3 (EPA + DHA 600 mg in a 2:1 ratio) daily for 4 years or Omega 3 + Vitamin B for 4 years	Placebo for 4 years	4 years	Brief Cognitive Test Performance [F-TICS] Memory [F-TICS Memory Subscore] [F-TICS Recall Subscore]
	Dangour, 2010 <sup>8</sup> RCT UK Medium	867	Cognitively healthy adults aged 70-79 years, MMSE ≥24 Mean age (SD): 75 (2.6) years 58% aged 70-74 42% aged 75-79 45% female Race not reported	Omega 3 (EPA 200 mg + DHA 500 mg) daily for 2 years	Olive oil capsules for 2 years	2 years	Multidomain Neuropsychological Test Performance [Composite] Executive/Attention/Processing Speed [Executive Composite] [Processing Composite] [Letter Search/Cancellation - # Correct, % of Total Attempts] [Symbol Letter Modality - # Correct] [RT, Simple] [RT, Choice] [DS Forward]



			Education: 33% no qualifications 26% O level, clerical 18% A level, college 23% other Median MMSE (IQR): 29 (28, 30)				[DS Backward] <u>Memory</u> [Memory Composite] [Global Delay Composite] [CVLT] [Story Recall, Immediate] [Story Recall, Delayed] [Spatial Memory, Correct Images - Immediate] [Spatial Memory, Correct Images - Delayed] <u>Language</u> [Verbal Fluency, Animals Named]
	Yurko-Mauro, 2010 <sup>9</sup> RCT US Low/Medium	485	Healthy adults aged 55+ with MMSE scores >26 and a Logical Memory (WMS III) baseline score of at least 1 SD below younger adults Mean age (SD): 70 (9) years 58% female 84% white Logical memory – immediate recall (SD): 25 (6.8) Logical memory – delayed recall (SD): 11.3 (4.1)	Omega 3 (DHA 900 mg) daily for 6 months	Placebo daily for 6 months	6 months	<u>Brief Cognitive Test Performance</u> [MMSE] <u>Executive/Attention/Processing Speed</u> [CANTAB Stockings of Cambridge] <u>Memory</u> [CANTAB PAL] [CANTAB VRM – Free Recall] [CANTAB VRM - Immediate Recall] [CANTAB VRM - Delayed Recall] [CANTAB SWM] [CANTAB PRM - Delayed]
	Van de Rest, 2008 <sup>10</sup> RCT Netherlands Low	302	Cognitively healthy (MMSE ≥21) adults aged 65+ Mean age (SD): 70 (3.5) years 45% female Race not reported Education: 9% low 54% medium 37% high Median MMSE (IQR): 28 (27-29)	Omega 3 (EPA- DHA 400 mg or 1800 mg) daily for 6 months	Placebo capsules for 6 months	6 months	<u>Executive/Attention/Processing Speed</u> [Executive Function Composite] [Attention Composite] [Sensorimotor Speed Composite] [TMT A] [TMT B] [Stroop Part 1] [Stroop Part 2] [Stroop Part 3 – (Part 1 + Part 2/2)] <u>Memory</u> [Memory Composite] <u>Language</u> [Word Fluency-Animals] [Word Fluency-Letter]
<b>Ginkgo biloba efficacy</b>	Lewis, 2014 <sup>11</sup> RCT USA High	97	English-speaking, nonsmoking, healthy older adults aged 60+ with an MMSE score ≥ 23 Mean age (SD): 69 (7) years	Ginkgo Synergy for 6 months (2 capsules/day providing 120 mg/d Ginkgo biloba leaf, 80	Placebo (cellulose, lactose, and beet powder) for 6 months	6 months	<u>Brief Cognitive Test Performance</u> [MMSE] <u>Executive/Attention/Processing Speed</u> [SCWT] [TMT A] [TMT B] [DSST] <u>Memory</u> [HVLIT]

			72% female 83% white Education: 12% ≤ high school 35% some post-high school training 25% college grad 28% ≥ master's degree No baseline cognition reported other than inclusion criteria	mg/d Ginkgo biloba whole extract, plus various other extracts)			<u>Language</u> [COWAT]
	Vellas, 2012 <sup>12</sup> France RCT Medium	285 4	Adults aged 70+ who spontaneously reported memory complaints to their primary care physician; screened and excluded diagnosed dementia, major memory impairment Mean age (SD): 76 (4.4) years 67% female Race not reported Education: 14% no formal educ 37% primary school 24% some secondary educ 24% high school diploma Mean MMSE (SD): 27.6 (1.9)	Ginkgo biloba extract (EGb761) 120 mg twice daily for at least 4 years	Matched placebo for at least 4 years	5 years	<u>Diagnosis</u> [Incidence Of Probable AD According to DSM-IV and NINCDS-ADRDA Criteria at 5 years]
	Snitz, 2009 <sup>13</sup> DeKosky, 2008 <sup>14</sup> RCT USA Low	306 9 (normal cog & MCI) 258 7 nor	Community-dwelling participants aged 72 to 96 years; 15% baseline MCI Mean age (SD): 79.1 (3.3) years 46% female 95% white Education mean (SD): 14.4 (3) years Mean 3MSE (SD): 93.4 (4.7)	Ginkgo biloba extract 120 mg twice daily for a median of 6.1 years	Identical appearing placebo for a median of 6.1 years	Global cognition: average annual change reported  Other cognitive outcomes at year 4	<u>Diagnosis</u> [Incident Dementia & AD (5 categories)] <u>Multidomain Neuropsychological Test Performance</u> [Global Composite] <u>Executive/Attention/Processing Speed</u> [Executive Composite [Attention and Psychomotor Speed Composite] [TMT B] [SCWT] [TMT A] [Digit Span] <u>Memory</u> [Memory Composite] [CVLT] [RCFT]

		mal cog					<u>Visuospatial</u> [Visuospatial Composite] [Copy Condition Of The Rey Osterrieth Figure Test] [WAIS-R Block Design]  <u>Language</u> [Language Composite] [BNT] [Semantic Verbal Fluency]
	Dodge, 2008 <sup>15</sup> RCT USA Medium	118	Cognitively intact subjects aged 85+ Mean age (SD): 87.5 (2) years 60% female Race not reported Mean education (SD): 14 (2.5) years Mean MMSE (SD): 28.25 (1.4)	Ginkgo biloba extract 80 mg three times daily (240 mg/d) for 3 years 6 months	Placebo	3 years 6 months	<u>Diagnosis</u> (estimate): [Mild Cognitive Decline Defined As Progress from CDR = 0 to 0.5] <u>Memory</u> [CERAD Word List Delayed Recall]
<b>Multi-nutritional supplement</b>	Strike 2016 <sup>16</sup> United Kingdom RCT Low	27	Non-ill community dwelling females ≥60 who could walk ≥50 m and negotiate stairs Mean age (SD): 66.8 (9.3) 100% Female Race: NR Education: NR Mean Number errors National Adult Reading Score (SD): 8.1 (4.8)	Efalex Active 50+ per day [1g DHA, 160mg EPA, 240mg Ginkgo biloba, 60mg phosphatidylserine, 20mg α-tocopherol, 1mg folic acid, and 20ug B12] for 6 months	Matching-placebo for 6 months	6 months	<u>Executive/Attention/Processing Speed</u> [Stockings of Cambridge, Motor Screening Task] <u>Memory</u> [PALS]
	Lewis, 2014 <sup>11</sup> RCT USA High	97	Healthy older adults aged 60+ with an MMSE score ≥23 Mean age (SD): 69 (7) years 72% female 83% white Education: 12% ≤ high school 35% some post-high school training 25% college grad 28% ≥ master's No baseline cognition	OPC Synergy for 6 months (2 capsules/d providing 100 mg/d grape seed extract, 50 mg/d green tea extract, 50 mg/d bilberry fruit, dried buckwheat leaf and juice, green tea leaf powder, and dried carrot root plus Catalyn	Placebo (cellulose, lactose, and beet powder) for 6 months	6 months	<u>Brief Cognitive Test Performance</u> [MMSE] <u>Executive/Attention/Processing Speed</u> [SCWT] [TMT A] [TMT B] [DSST] <u>Memory</u> [HVLt-R] <u>Language</u> [COWAT]

			reported other than inclusion criteria	(4 tablets/d providing 312 IU/d vitamin D, 1600 IU/d vitamin A, 5.3 mg/d vitamin C, 0.3 mg/d thiamine, 0.3 mg/d riboflavin, 1.3 mg/d vitamin B6, defatted wheat germ, carrot (root), and various other ingredients) for 6 months			
<b>Resveratrol efficacy</b>	Witte, 2014 <sup>17</sup> RCT Germany Medium	46	Healthy overweight older adults aged 50-80 years Mean age (SD): 64 (6) years 64% female Race not reported Mean education (SD): 17 (3) years Mean MMSE (SD): 29 (1)	Resveratrol (200 mg/d) for 6 months	Placebo for 6 months	6 months	<u>Biomarker</u> [MRI: Volume, Microstructure, and Functional Connectivity of the Hippocampus] <u>Memory</u> [AVLT Retention] [AVLT Delayed Recall] [AVLT Recognition] [AVLT Learning Ability] [AVLT 5th Learning Trial]
<b>Plant sterols/ plant stanols efficacy</b>	Schiepers, 2009 <sup>18</sup> RCT Netherlands Medium	57	People aged 43-69 years taking statins Mean age (SD): 60 (7) years 42% female Race not reported 39% low education Baseline cognition not reported	Margarines enriched with plant sterol esters (2.5 g/d) or plant stanol esters (2.5 g/d) for 7 years (85 weeks)	Control margarine for 7 years (85 weeks)	7 years (85 weeks)	<u>Executive/Attention/Processing Speed</u> [Simple Information Processing Speed Composite] [Complex Speed Composite] <u>Memory</u> [Memory Composite]
<b>Omega 3 comparative effectiveness</b>	Andreeva, 2011 <sup>7</sup> RCT France Medium	1748	People with normal cognition aged 45-80 with a history of ischemic heart disease Mean age (SD): 61 (8.8) years 20% female 10% foreign-born 58% < high school	Omega 3 (EPA + DHA 600 mg in a 2:1 ratio) daily for 4 years or Omega 3 + Vitamin B for 4 years	Omega 3 + Vitamin B for 4 years or Vitamin B for 4 years	4 years	<u>Brief Cognitive Test Performance</u> [F-TICS] <u>Memory</u> [F-TICS-m Subscore] [F-TICS-m Recall Subscore]

			diploma Mean F-TICS-m (SD): 28.5 (4.8)				
	Chew, 2015 <sup>19</sup> RCT USA High	350 1	Adults at risk for developing macular degeneration Mean age (SD): 72.7 (± 7.7) years 57.5% female 97% white 29% ≤ high school 49% ≥ some college 22% postgraduate Mean TICS (SD): 33 (3.4)	Long-chain polyunsaturated fatty acids (1 g, specifically DHA 350 mg and EPA 650 mg) for 5 years	No long-chain polyunsaturated fatty acids (other groups) for 5 years	Yearly for 5 years	<u>Brief Cognitive Test Performance</u> [TICS Total Score] <u>Multidomain Neuropsychological Test Performance</u> [Composite] <u>Executive/Attention/Processing Speed</u> [Backwards Counting] [Verbal Fluency – Animal, Letter & Alternating] <u>Memory</u> [Wechsler Logical Memory I & II] [TICS Word List Recall] <u>Language</u> [Verbal Fluency – Animal] [Verbal Fluency – Letter] [Verbal Fluency – Category]
<b>Lutein/ Zeaxanthin</b>	Chew, 2015 <sup>19</sup> RCT USA High	350 1	Adults at risk for developing age-related macular degeneration Mean age (SD): 72.7 (± 7.7) years 57.5% female 97% white 29% ≤ high school 49% ≥ some college 22% postgraduate Mean TICS (SD): 33 (3.4)	Lutein (10mg)/zeaxanthin (2mg) daily 5 years	No Lutein/zeaxanthin (other groups) for 5 years	Yearly for 5 years	<u>Brief Cognitive Test Performance</u> [TICS Total Score] <u>Multidomain Neuropsychological Test Performance</u> [Composite] <u>Executive/Attention/Processing Speed</u> [Backwards Counting] [Verbal Fluency – Animal, Letter & Alternating] <u>Memory</u> [Wechsler Logical Memory I & II] [TICS Word List Recall] <u>Language</u> [Verbal Fluency – Animal] [Verbal Fluency – Letter] [Verbal Fluency – Category]
<b>Multi-nutritional supplement</b>	Bun, 2015 <sup>20</sup> Open label intervention study (observational) Japan High	825	People aged 65+ Mean age (SD): 72 (5) years 42% female Race not reported Mean education (SD): 10 (2.5) years Baseline cog exclusion score < 1.5 SD on ≥ 1 domain of the 5-cog test after adjustment	Nutritional supplementation (n-3 polyunsaturated fatty acid, Ginkgo biloba, leaf dry extracts, and lycopene) for 3 years	No nutritional supplementation (exercise and inactive control groups)	3 years	<u>Diagnosis</u> [Diagnosis of AD]

3MS=Modified Mini Mental Status Examination; AD=Alzheimer's disease; ADAS=Cog-Alzheimer's Disease Assessment Scale-Cognitive; ALA=alpha-linolenic acid; AVLT=Auditory Verbal Learning Test; BNT=Boston Naming Test; BVMT=Breif Visuospatial Memory Test; BVRT=Benton Visual Retention Test; CAMCOG=Cambridge Cognition Examination; CDR=Clinical Dementia Rating; CERAD=Consortium to Establish a Registry for Alzheimer's Disease; CLOX-1=Clock Drawing Test;

COWAT=Controlled Oral Word Association Test; CVFT=Category Verbal Fluency Test; CVLT=California Verbal Learning Test; DHA=docosahexaenoic acid; DS=Digit Span (Forward and/or Backward); DSM=Diagnostic Statistical Manual of Mental Disorders; DSST=Digit Symbol Substitution Test; DVT=Digit Vigilance Test; EBMT=East Boston Memory Test; EPA=eicosapentaenoic acid; FCSRT=Free and Cued Selective Reminding Test; F-TICS=French Version, Telephone Interview Cognitive Status; HVLT=Hopkins Verbal Learning Test; MCI=mild cognitive impairment; MMSE=Mini-Mental Status Examination; MRI=magnetic resonance imaging; n=sample size; NINCDS-ADRDA=National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease; NR=PALS=Paired Association Learning Test; PRM=Pattern Recognition Memory; RAVLT=Rey's Auditory Verbal Learning Test; RBANS=Repeatable Battery for Neuropsychological Status; RBMT= Rivermead Behavioral Memory Test; RCFT=Rey-Osterrieth Complex Figure Test; RCPM=Raven's Colored Progressive Matrices; RCT=Randomized Controlled Trial; RoB=Risk of Bias; SCWT=Stroop Color Word Test; SD=Standard Deviation; SDMT=Symbol Digit Modalities Test; SOE=Strength of Evidence; SWM=Spatial Working Memory; TICS=Telephone Interview for Cognitive Status (TICS-M=Modified); TMT=Trail Making Test (Part A and/or B); VP=Verbal Proficiency; VR=Visual Reproduction; VRM=Verbal Recognition Memory; WAIS=Wechsler Adult Intelligence Scale; WMS=Wechsler Memory Scale

**Table H2. Summary risk of bias assessments: nutraceuticals interventions in adults with normal cognition**

<b>Nutraceutical Intervention Type</b>	<b>Study</b>	<b>Overall Risk of Bias Assessment</b>	<b>Rationale</b>
<b>Omega 3 fatty acids efficacy</b>	Boespflug, 2016 <sup>1</sup>	High	Attrition > 20% without appropriate analysis to correct for potential bias
	Cukierman-Yaffe, 2014 <sup>2</sup>	Medium	Attrition >20% at some time points; sensitivity analysis conducted
	Mahmoudi, 2014 <sup>3</sup>	High	Includes people with dementia, MCI and normal cognition
	Witte, 2014 <sup>4</sup>	Medium	Unclear randomization procedures; attrition >10% without analysis to account for possible bias
	Stonehouse, 2013 <sup>5</sup>	High	Attrition >20% without analysis to conduct for possible bias
	Geleijnse, 2012 <sup>6</sup>	Medium	Unclear randomization procedures; attrition
	Andreeva, 2011 <sup>7</sup>	Medium	Subset of RCT followup using participants with a history of cardiovascular disease. Original RCT baseline measures on subset – no differences between groups.
	Dangour, 2010 <sup>8</sup>	Medium	Attrition >10% without analysis to correct for potential bias
	Yurko-Mauro, 2010 <sup>9</sup>	Medium	Attrition >10% without appropriate analysis; unclear whether assessor was independent)
van de Rest, 2008 <sup>10</sup>	Low		
<b>Ginkgo biloba efficacy</b>	Lewis, 2014 <sup>11</sup>	High	Attrition >25% without analysis
	Vellas, 2012 <sup>12</sup>	Medium	Attrition >30% (analysis conducted)
	Snitz, 2009 <sup>13</sup> DeKosky, 2008 <sup>14</sup>	Medium	High attrition, but analysis conducted to correct for potential bias
	Dodge, 2008 <sup>15</sup>	Medium	Attrition >10% without analysis; possible detection bias (unclear outcome assessment blinding/independence)
<b>Multi-nutraceutical efficacy</b>	Strike, 2016 <sup>16</sup>	Low	
	Lewis, 2014 <sup>11</sup>	High	Attrition >25% without appropriate analysis
<b>Resveratrol efficacy</b>	Witte, 2014 <sup>17</sup>	Medium	Unclear randomization procedures; unclear whether outcome assessor was blinded and independent
<b>Plant sterols or plant stanols</b>	Schiepers 2009 <sup>18</sup>	Medium	Unclear randomization procedures; unclear whether outcome assessor was blind to treatment
<b>Comparative effectiveness</b>	Andreeva, 2011 (Omega 3) <sup>7</sup>	Medium	Subset of RCT followup using participants with a history of cardiovascular disease. Original RCT baseline measures on subset – no differences between groups.
	Chew, 2015 <sup>19</sup> (Omega 3 & Lutein/Zeaxanthin)	High	Unclear randomization procedures; high attrition; reporting bias due to discrepancies in number randomized in 2 study papers
	Bun, 2015 <sup>20</sup> (Multi-nutraceutical supplement)	High	Participants not randomized; high attrition

MCI=mild cognitive impairment; RCT=randomized controlled trial

**Appendix Table H3. Strength of evidence assessments: nutraceutical interventions in adults with normal cognition**

Nutraceutical Intervention Type	Outcome	# Trials (n)	Evidence Summary Summary statistics [95% CI]	Study Limitations	Directness	Precision	Consistency	Reporting Bias	Optional Components	SOE
Omega 3 fatty acids versus inactive control	Dementia	1 (12,536)	0 of 1 tests show statistically significant improvement with intervention  <u>Cukierman-Yaffe 2014<sup>2</sup></u> Hazard ratio for incident cognitive impairment (composite of either incident dementia diagnosis or follow-up MMSE <24): 0.93 [0.86 to 1.0]	High	Direct	Precise	Unknown	Undetected	N/A	Low (due to study limitation of composite outcome with component of unequal importance, one of which is not clinical diagnosis and may be achieved due to chance)
	MCI		NR							Insufficient
	Brief cognitive test performance (6 months to 6 years)	4 (16,431)	0 of 9 tests show statistically significant improvement with intervention (no differences between	Medium	Indirect	Imprecise	Consistent	Undetected	NA	Low



			<p>groups)</p> <p><u>Cukierman-Yaffe, 2014<sup>2</sup></u> Rate of change from baseline MMSE: 0.0013 [-0.0165, 0.0191]</p> <p><u>Geleijnse, 2012<sup>6</sup></u> <i>EPA-DHA</i> Difference in change from baseline MMSE: 0.05 [-0.07, 0.17]</p> <p>Risk of moderate/severe cognitive decline (decrease of <math>\geq 3</math> MMSE pts or incidence of cognitive decline or dementia): OR 1.03 [0.84, 1.26]</p> <p>Risk of</p>							
--	--	--	--	--	--	--	--	--	--	--

			<p>severe cognitive decline (decrease of <math>\geq 5</math> MMSE pts or incidence of cognitive decline or dementia): OR 0.99 [0.73, 1.34]</p> <p>ALA Difference in change from baseline MMSE: 0.14 [-0.04, 0.32]</p> <p>Risk of moderate /severe cognitive decline: OR 0.90 [0.74, 1.10]</p> <p>Risk of severe cognitive decline: OR 0.88 [0.65, 1.19]</p> <p><u>Andreeva,</u></p>							
--	--	--	---	--	--	--	--	--	--	--

			<p><u>2011</u><sup>7</sup> No statistically significant effects of group assignment on cognitive function. Difference in mean F-TICS-m scores are not reported.</p> <p><u>Yurko-Mauro, 2010</u><sup>9</sup> Difference in change from baseline MMSE treatment vs. placebo: 0 [-0.30, 0.30]</p>							
Multidomain neuropsychological performance  (2 years)	1 (744)	0 of 1 test shows statistically significant improvement with intervention (no differences between groups)	Medium	Indirect	Imprecise	Unknown	Undetected	NA	Low	
		<p><u>Dangour, 2010</u><sup>8</sup> Difference</p>								

			in change from baseline (measure of global cognitive function) treatment vs placebo: -0.01 [-0.05, 0.04]							
	Executive/ Attention/ Processing Speed (6 months to 2 years)	5 (5079)	2 of 31 favor I	Medium	Indirect	Imprecise	Consistent (2 I>C from n=548 over 6 months; 29 NS from 5079 over 6 years)	Undetected	NA	Low
	Memory (6 months to 4 years)	5 (3428)	3 of 25 favor I	Medium	Indirect	Imprecise	Consistent (3 I>C from 1 study of n=483; 22 from all)	Undetected	NA	Low
<b>Ginkgo biloba versus inactive control</b>	Dementia (5-6 years)	2 (5407)	0 of 5 tests show statistically significant differences between intervention and control groups.  <u>Vellas, 2012</u> <sup>12</sup> Incidence of probable AD by year of study (hazard not proportional by time) 1 year: HR	Medium	Direct	Imprecise	Consistent	Undetected	NA	Low

			0.72 [0.32-1.61] 2 years: HR 1.66 [0.81-3.40] 3 years: HR 1.11 [0.51-2.43] 4 years: HR 0.57 [0.19-1.69] ≥5 years: HR 0.49 [0.25-0.96]  <u>DeKosky, 2008<sup>14</sup></u> Incidence of dementia: All dementia: HR 1.05 [0.84-1.30] AD without vascular dementia: HR 1.13 [0.86-1.48] AD with vascular dementia: HR 1.12 [0.72-1.74] Total AD: HR 0.13 [0.90-1.42] Vascular dementia without AD: HR 0.36 [0.13-1.00]							
MCI	Single trial <500	Limited Data								Insufficient (limited)

		participants								data)
	Brief cognitive test performance	NR								Insufficient (no data)
	Multidomain neuropsychological performance (6 years)	1 (3069) (includes 482 MCI; 15.7% total)	0 of 1 (no statistically significant differences between groups)  <u>Snitz, 2009</u> <sup>13</sup> Results of linear mixed models:  Treatment effect (overall difference in z scores ginkgo vs. placebo): mean (95% CI): 0.015 [-0.018, 0.047]  Treatment x time interaction: annual difference in rates of change between ginkgo and placebo: mean (95% CI): -0.002 [-	Medium	Indirect	Imprecise	Unknown	Undetected	NA	Low

			0.009, 0.005]							
	Executive/ Attention/ Processing Speed (6 years)	1 (3069) (includes 482 MCI; 15.7% total)	0 of 5 (no differences)	Medium	Indirect	Imprecise	Consistent	Undetected	NA	Low
	Memory (3.5 to 6 years)	2 (3187)	0 of 4 (no differences)	Medium	Indirect	Imprecise	Consistent	Undetected	NA	Low
<b>Multi-nutraceutical supplement efficacy</b>	Dementia	NR								
	MCI	NR								
	Biomarkers	NR								
	Brief Cognitive Test Performance	NR								
	Multidomain Composites	NR								
	Executive/ Attention/ Processing Speed	Single study with sample size < 500								
	Memory	Single study with sample size < 500								
<b>Omega 3 versus B Vitamins</b>	Dementia	NR								Insufficient (no data)
	MCI	NR								Insufficient (no data)
	Biomarkers	NR								Insufficient (no data)
	Brief Cognitive Test Performance	1 (885)	0 of 1 test show statistically significant differences	Medium	Indirect	Imprecise	Unknown	Undetected	NA	Low
	Multidomain Composites	NR								Insufficient (no data)
	Executive/ Attention/ Processing Speed	NR								Insufficient (no data)

	Memory	1 (885)	0 of 2 tests show statistically significant differences	Medium	Indirect	Imprecise	Unknown	Undetected	NA	Low
<b>Omega 3 versus Omega 3 + B Vit</b>	Dementia	NR								Insufficient (no data)
	MCI	NR								Insufficient (no data)
	Biomarkers	NR								Insufficient (no data)
	Brief Cognitive Test Performance	1 (877)	0 of 1 test show statistically significant differences	Medium	Indirect	Imprecise	Unknown	Undetected		Low
	Multidomain Composites	NR								Insufficient (no data)
	Executive/ Attention/ Processing Speed	NR								Insufficient (no data)
	Memory (4 years)	1 (877)	0 of 2 tests show statistically significant differences	Medium	Indirect	Imprecise	Unknown	Undetected	NA	Low

AD=Alzheimer's disease; ALA=alpha-linolenic acid; C=control; CI=confidence interval; DHA=docosahexaenoic acid; EPA=eicosapentaenoic acid; F-TICS=French version, Telephone Interview Cognitive Status; HR=hazard ratio; I=intervention; MCI=mild cognitive impairment; MMSE=Mini Mental Status Examination; NA=not applicable; NR=not reported; OR=odds ratio; SOE=strength of evidence



**Appendix Table H4. Characteristics of eligible studies: Intervention type in adults with MCI**

<b>Nutraceutical Intervention Type</b>	<b>Study Design Country RoB</b>	<b>N=</b>	<b>Population Inclusion Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition</b>	<b>Intervention Mode Components Frequency Duration</b>	<b>Comparison Mode Components Frequency Duration</b>	<b>Outcome Timing</b>	<b>Outcome Domain [Instrument]</b>
<b>Omega 3 fatty acids efficacy</b>	Lee, 2013 <sup>21</sup> RCT Malaysia Medium	36	Low SES people aged 60+ with MCI Mean age (SD): 65 (4) years 77% female Race not reported Mean education (SD): 5.9 (3) years Mean MMSE (95% CI): 26.7 (25.7-27.5)	Omega 3 fatty acids (DHA 430 mg and EPA 150 mg) daily for 1 year	Placebo capsules daily for 1 year	1 year	<u>Brief Cognitive Test Performance [MMSE]</u> <u>Executive/Attention/Processing Speed</u> [Executive Function Attention Composite] [DSST] [DS Forward] [DS Backward] <u>Memory [Memory Composite] [VR I] [VR II] [RAVLT, Immediate Recall] [RAVLT, Delayed Recall]</u> <u>Visuospatial [Visuospatial Skills Composite] [Clock Drawing Test] [Matrix Reasoning] [Block Design]</u>
<b>Ginkgo biloba efficacy</b>	Gavrilova, 2014 <sup>22</sup> RCT Russia Low	160	People with MCI who scored at least 6 on the 12-item Neuropsychiatric Inventory (NPI) Mean age (SD): 64 (7) 62% female Race not reported Mean education (SD): 9.7 (0.9) years Mean MMSE (SD): 25.7 (1.4)	Ginkgo biloba (EGb 761) 240 mg daily for 6 months	Placebo tablet for 6 months	6 months	<u>Executive/Attention/Processing Speed</u> [TMT A] [TMT B]
	DeKosky, 2008 <sup>14</sup> RCT USA Medium	3069 (total) 482 MCI	For full sample: Community-dwelling participants aged 72 to 96 years; 15% baseline MCI Mean age (SD): 79.1 (3.3) years 46% female 95% white Education mean (SD): 14.4	Ginkgo biloba extract 120 mg twice daily for a median of 6.1 years	Identical appearing placebo for a median of 6.1 years	Global cognition: average annual change reported	Diagnosis: Incident Dementia & AD (5 categories)

			(3) years Mean 3MSE (SD): 93.4 (4.7)				
<b>Omega 3 fatty acids comparative effectiveness</b>	Sinn, 2011 <sup>23</sup> RCT Australia High	50	People aged 65+ with MCI Mean age (SD): 74 (5) years 33% female Race not reported Average education: slightly under year 12 Mean MMSE (SD): 27 (2.5)	Omega 3 supplementation Diet rich in EPA (1.67 g EPA + 0.16 g DHA daily) or DHA (1.55 DHA + 0.40 g EPA daily) or n-6 PUFA linoleic acid (PUFA linoleic acid 2.2 g) daily for 6 months	Other groups (a diet rich in EPA, or DHA, or 6-6 PUFA linoleic acid)	6 months	<u>Executive/Attention/Processing Speed</u> [DS Forward] [DS Backward] [Letter-Number Sequencing] [TMT A] [TMT B] [SCWT] <u>Memory</u> [RAVLT] <u>Language</u> [Verbal Fluency]

AD=Alzheimer's disease; DHA= docosahexaenoic acid; DS=Digit Span (Forward and/or Backward); EPA=eicosapentaenoic acid; g=grams; MCI=mild cognitive impairment; MMSE=Mini-Mental Status Examination; N=sample size; NR=not reported; PUFA=polyunsaturated fatty acids; RAVLT=Rey's Auditory Verbal Learning Test; RCT=randomized controlled trial; RoB=risk of bias; SCWT=Stroop Color Word Test; SD=standard deviation; VR=Verbal Recognition

**Appendix Table H5. Summary risk of bias assessments: nutraceuticals in adults with MCI**

<b>Nutraceutical Type</b>	<b>Study</b>	<b>Overall Risk of Bias Assessment</b>	<b>Rationale</b>
<b>Omega 3 fatty acids efficacy</b>	Lee 2013 <sup>21</sup>	Low/Medium	Possible detection bias (unclear outcomes assessment)
<b>Ginkgo biloba</b>	Gavrilova, 2014 <sup>22</sup>	Low	
	DeKosky, 2008 <sup>14</sup>	Low	
<b>Omega 3 fatty acids comparative effectiveness</b>	Sinn, 2012 <sup>23</sup>	High	Randomization not well described; attrition > 25% without appropriate analysis to account for possible bias

MCI=mild cognitive impairment

## References for Appendix H

1. Boespflug EL, McNamara RK, Eliassen JC, et al. Fish Oil Supplementation Increases Event-Related Posterior Cingulate Activation in Older Adults with Subjective Memory Impairment. *J Nutr Health Aging*. 2016 Feb;20(2):161-9. doi: 10.1007/s12603-015-0609-6. PMID: 26812512.
2. Cukierman-Yaffe T, Bosch J, Diaz R, et al. Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial. *The Lancet Diabetes & Endocrinology*. 2014 Jul;2(7):562-72. doi: [http://dx.doi.org/10.1016/S2213-8587\(14\)70062-2](http://dx.doi.org/10.1016/S2213-8587(14)70062-2). PMID: 24898834.
3. Mahmoudi MJ, Hedayat M, Sharifi F, et al. Effect of low dose omega-3 poly unsaturated fatty acids on cognitive status among older people: a double-blind randomized placebo-controlled study. *J Diabetes Metab Disord*. 2014 Feb 07;13(1):34. doi: 10.1186/2251-6581-13-34. PMID: 24507770.
4. Witte AV, Kerti L, Hermannstadter HM, et al. Long-chain omega-3 fatty acids improve brain function and structure in older adults. *Cerebral Cortex*. 2014 Nov;24(11):3059-68. doi: <http://dx.doi.org/10.1093/cercor/bht163>. PMID: 23796946.
5. Stonehouse W, Conlon CA, Podd J, et al. DHA supplementation improved both memory and reaction time in healthy young adults: a randomized controlled trial. *American Journal of Clinical Nutrition*. 2013 May;97(5):1134-43. doi: <http://dx.doi.org/10.3945/ajcn.112.053371>. PMID: 23515006.
6. Geleijnse JM, Giltay EJ, Kromhout D. Effects of n-3 fatty acids on cognitive decline: a randomized, double-blind, placebo-controlled trial in stable myocardial infarction patients. *Alzheimer's & Dementia*. 2012 Jul;8(4):278-87. doi: <http://dx.doi.org/10.1016/j.jalz.2011.06.002>. PMID: 21967845.
7. Andreeva VA, Kesse-Guyot E, Barberger-Gateau P, et al. Cognitive function after supplementation with B vitamins and long-chain omega-3 fatty acids: ancillary findings from the SU.FOL.OM3 randomized trial. *Am J Clin Nutr*. 2011 Jul;94(1):278-86. doi: 10.3945/ajcn.110.006320. PMID: 21593490.
8. Dangour AD, Allen E, Elbourne D, et al. Effect of 2-y n-3 long-chain polyunsaturated fatty acid supplementation on cognitive function in older people: a randomized, double-blind, controlled trial. *American Journal of Clinical Nutrition*. 2010 Jun;91(6):1725-32. doi: <http://dx.doi.org/10.3945/ajcn.2009.29121>. PMID: 20410089.
9. Yurko-Mauro K, McCarthy D, Rom D, et al. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. *Alzheimer's & Dementia*. 2010 Nov;6(6):456-64. doi: <http://dx.doi.org/10.1016/j.jalz.2010.01.013>. PMID: 20434961.
10. van de Rest O, Geleijnse JM, Kok FJ, et al. Effect of fish oil on cognitive performance in older subjects: a randomized, controlled trial. *Neurology*. 2008 Aug 5;71(6):430-8. doi: <http://dx.doi.org/10.1212/01.wnl.0000324268.45138.86>. PMID: 18678826.
11. Lewis JE, Melillo AB, Tiozzo E, et al. A double-blind, randomized clinical trial of dietary supplementation on cognitive and immune functioning in healthy older adults.[Erratum appears in *BMC Complement Altern Med*. 2014;14:332]. *BMC Complementary & Alternative Medicine*. 2014;14:43. doi: <http://dx.doi.org/10.1186/1472-6882-14-43>. PMID: 24495355.
12. Vellas B, Coley N, Ousset PJ, et al. Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. *Lancet Neurology*. 2012 Oct;11(10):851-9. doi: [http://dx.doi.org/10.1016/S1474-4422\(12\)70206-5](http://dx.doi.org/10.1016/S1474-4422(12)70206-5). PMID: 22959217.
13. Snitz BE, O'Meara ES, Carlson MC, et al. Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. *JAMA*. 2009 Dec 23;302(24):2663-70. doi: <http://dx.doi.org/10.1001/jama.2009.1913>. PMID: 20040554.
14. DeKosky ST, Williamson JD, Fitzpatrick AL, et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial.[Erratum appears in *JAMA*. 2008 Dec 17;300(23):2730]. *JAMA*. 2008 Nov 19;300(19):2253-62. doi: <http://dx.doi.org/10.1001/jama.2008.683>. PMID: 19017911.
15. Dodge HH, Zitzelberger T, Oken BS, et al. A randomized placebo-controlled trial of Ginkgo biloba for the prevention of cognitive decline. *Neurology*. 2008 May 6;70(19 Pt 2):1809-17. doi: <http://dx.doi.org/10.1212/01.wnl.0000303814.13509.db>. PMID: 18305231.
16. Strike SC, Carlisle A, Gibson EL, et al. A High Omega-3 Fatty Acid Multinutrient Supplement Benefits Cognition and Mobility in Older Women: A Randomized, Double-blind, Placebo-controlled Pilot Study. *J Gerontol A Biol Sci Med Sci*. 2016 Feb;71(2):236-42. doi: 10.1093/gerona/glv109. PMID: 26265727.

17. Witte AV, Kerti L, Margulies DS, et al. Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults. *Journal of Neuroscience*. 2014 Jun 4;34(23):7862-70. doi: <http://dx.doi.org/10.1523/JNEUROSCI.0385-14.2014>. PMID: 24899709.
18. Schiepers OJ, de Groot RH, van Boxtel MP, et al. Consuming functional foods enriched with plant sterol or stanol esters for 85 weeks does not affect neurocognitive functioning or mood in statin-treated hypercholesterolemic individuals. *Journal of Nutrition*. 2009 Jul;139(7):1368-73. doi: <http://dx.doi.org/10.3945/jn.108.103721>. PMID: 19458031.
19. Chew EY, Clemons TE, Agron E, et al. Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial. *JAMA*. 2015 Aug 25;314(8):791-801. doi: 10.1001/jama.2015.9677. PMID: 26305649.
20. Bun S, Ikejima C, Kida J, et al. A combination of supplements may reduce the risk of Alzheimer's disease in elderly Japanese with normal cognition. *J Alzheimers Dis*. 2015;45(1):15-25. doi: 10.3233/JAD-142232. PMID: 25524956.
21. Lee LK, Shahar S, Chin AV, et al. Docosahexaenoic acid-concentrated fish oil supplementation in subjects with mild cognitive impairment (MCI): a 12-month randomised, double-blind, placebo-controlled trial. *Psychopharmacology*. 2013 Feb;225(3):605-12. doi: <http://dx.doi.org/10.1007/s00213-012-2848-0>. PMID: 22932777.
22. Gavrilova SI, Preuss UW, Wong JW, et al. Efficacy and safety of Ginkgo biloba extract EGb 761 in mild cognitive impairment with neuropsychiatric symptoms: a randomized, placebo-controlled, double-blind, multi-center trial. *International Journal of Geriatric Psychiatry*. 2014 Oct;29(10):1087-95. doi: <http://dx.doi.org/10.1002/gps.4103>. PMID: 24633934.
23. Sinn N, Milte CM, Street SJ, et al. Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial. *British Journal of Nutrition*. 2012 Jun;107(11):1682-93. doi: <http://dx.doi.org/10.1017/S0007114511004788>. PMID: 21929835.

## Appendix I. Diet Interventions

**Appendix Table I1. Characteristics of eligible studies: nutrition/lifestyle interventions in adults with normal cognition**

<b>Diet Intervention Type</b>	<b>Study Design Country RoB</b>	<b>N=</b>	<b>Population Inclusion Age (mean) Sex Race Education Baseline Cog</b>	<b>Intervention Mode Components Frequency Duration</b>	<b>Comparison Mode Components Frequency Duration</b>	<b>Outcome timing</b>	<b>Outcome Domain [Instrument]</b>
<b>Caloric restriction diet interventions</b>	Martin 2007 <sup>1</sup> RCT USA High	48	Overweight adults aged 25 to 50 with a BMI $\leq$ 25 and <30 Mean age: 38 56% Female 63% White Education: NR Baseline cognition: NR	1) calorie restriction (25% calorie restriction based on baseline energy requirements); food provided at a center weeks 1-12, and 22-24, diets self-selected in weeks 13-22 2) calorie restriction + structured exercise (12.5% calorie restriction + 12.5% increase in energy expenditure via structured exercise) 3) very low-calorie diet (890 kcal/d liquid formula diet until 15% of body weight is lost, followed by weight maintenance)	Weight maintenance diet	6 months	<u>Executive/Attention/Processing Speed</u> [Conners' CPT-II] <u>Memory</u> [RAVLT] [ACT] [BVRT]
<b>Energy restriction diet interventions</b>	Napoli 2014 <sup>2</sup> RCT Italy Medium	107	Obese (BMI $\geq$ 30), sedentary adults with stable body weight aged $\geq$ 65 Mean age: 70 Sex: 63% Female Race: 85% White Mean education: 16 years Baseline cognition: NR	1) Diet: calorie restriction; counseling; goal setting; 10% weight loss with maintenance 2) Exercise: counseled on weight maintenance; multicomponent exercise 3 times/week 3) Diet + Exercise: both interventions	Information control: general nutrition information; instructed not to make changes to daily routine	1 year	<u>Multidomain Neuropsychological Test Performance</u> [3MS] <u>Executive/Attention/Processing Speed</u> [TMT A] [TMT B] <u>Language</u> [Word List Fluency]

	Brinkworth 2009 <sup>3</sup> RCT Australia High	118	Adults aged 24 to 64 years with abdominal obesity and at least 1 additional metabolic syndrome risk factor Mean age: 50 Sex: NR Race: NR Education: NR Mean 3MS (SE): 96.3 (0.8) control 96 (0.6) diet only 95.6 (0.8) diet-exercise	Energy-restricted, planned, isocaloric, very low carbohydrate, high fat (LC) diet	High-carbohydrate, low-fat diet with individual counseling for first 8 weeks.	1 year	<u>Executive/Attention/Processing Speed</u> [DS Backward] [Inspection Time]
<b>Mediterranean Diet interventions</b>	Valls-Pedret 2015 <sup>4</sup> PREDIMED RCT Spain High	447	Adults aged 55 to 80 with no cardiovascular disease, but high vascular risk Mean age: 67 51% Women Mean education: 7 years Baseline global cog: NR	1) Mediterranean Diet high consumption plant-based foods, fish and seafood; low consumption of dairy, meat, processed grains; regular moderate alcohol (red wine with meals preferred) plus extra-virgin olive oil 2) Mediterranean Diet + mixed nuts	Information control (leaflet about low-fat diets)	5 years	<u>Brief Cognitive Test Performance</u> [MMSE] <u>Executive/Attention/Processing Speed</u> [DS Forward] [DS Backward] [Color Trail Test Part 1] [Color Trail Test Part 2] <u>Memory</u> [RAVLT, Total Learning And Delayed Recall] [Verbal Paired Associates] <u>Language</u> [Verbal Fluency]
	Martinez-Lapiscina 2013(a) <sup>5</sup> PREDIMED RCT Spain High	1055	Adults aged 55 to 80 with no cardiovascular disease, but high vascular risk Mean age: 67 55% Female Race: NR Education: >8 years: 29% Baseline global cog: NR	1) Mediterranean Diet high consumption plant-based foods, fish and seafood; low consumption of dairy, meat, processed grains; regular moderate alcohol (red wine with meals preferred) plus extra-virgin olive oil 2) Mediterranean Diet + mixed nuts	Information control (leaflet about low-fat diets)	6.5 years	<u>Diagnosis</u> [Incidence of MCI] <u>Brief Cognitive Test Performance</u> [MMSE] <u>Visuospatial</u> [Clock Drawing Test]
	Martinez-Lapiscina	285	Adults aged 55 to 80 with no	1) Mediterranean Diet high consumption plant-	Information control (leaflet about low-	6.5 years	<u>Diagnosis</u> [Incidence of MCI] <u>Brief Cognitive Test Performance</u> [MMSE]

	2013(b) <sup>6</sup> PREDIMED (subgroup) RCT Spain High		cardiovascular disease, but high vascular risk Mean age: 67 55% Female Race: NR Mean education: 9 years Baseline global cog: NR	based foods, fish and seafood; low consumption of dairy, meat, processed grains; regular moderate alcohol (red wine with meals preferred) plus extra-virgin olive oil 2) Mediterranean Diet + mixed nuts	fat diets)		<u>Executive/Attention/Processing Speed</u> [TMT A] [TMT B] [DS Forward] [DS Backward] <u>Memory</u> [RAVLT, Immediate And Delay] [Verbal Paired Associates] [RCFT] <u>Language</u> [Similarities] [Semantic Verbal Fluency Test-Animals] [Phonemic Verbal Fluency Test] [BNT] <u>Visuospatial</u> [Clock Drawing Test] [RCFT]
	Komulainen 2010 <sup>7</sup> RCT Finland High	450	Men and women age 55 to 74 Age, Mean (SD) 66.3 (5.3) Sex NR Race NR Education, Mean (SD) 11.3 (3.9) MMSE, Mean (SD) 27.6 (2.1)	Counseling by nutritionists to modify diet to specific recommendations	General health advice on diet and physical activity	2 years	<u>Brief Cognitive Test Performance</u> [MMSE] <u>Memory</u> [Immediate Memory Composite] [Delayed Memory Composite] <u>Language</u> [Verbal Performance Composite] <u>Visuospatial</u> [Visual Performance Composite]
<b>Protein supplement interventions</b>	van der Zwaluw 2014 <sup>8</sup> RCT Netherlands Medium	65	Elderly adults aged ≥65 and an elevated plasma Hcy level (12-50 μmol/L) Mean age: 80 55% Female Education: Low: 9% (protein) and 0% (placebo) Middle: 59% (protein) and 55% (placebo) High: 32% (protein) and 45% (placebo) Mean MMSE (IQR): 29 (26-30) protein 28 (26-30) placebo	Protein drink (15mg of protein) twice daily	Placebo drink	24 weeks	<u>Brief Cognitive Test Performance</u> [MMSE] <u>Executive/Attention/Processing Speed</u> [DS Forward] [Digit Span Backward] [TMT A] [TMT B] [SCWT] [DSST] [Reaction Time Test] <u>Memory</u> [Word Learning Test] <u>Language</u> [Letter Fluency]

	Wouters-Wesseling 2005 <sup>9</sup> RCT USA High	101	White adults aged ≥65 and a BMI ≤25 kg/m <sup>2</sup> Mean age: 83 58% Female 100% White Education: ≤6 years: 50% (intervention) 38% (placebo) 7-9 years: 35% (intervention) 47% (placebo) >9 years 15% (intervention) 15% (placebo) Baseline global cog: NR	125-ml enriched drink containing 30%–150% of the U.S. Recommended Daily Allowance of vitamins and minerals, with enhanced amounts of antioxidants, and containing 250 kcal energy in a daily dose	Placebo drink	6 months	Memory [Recognition Memory Test for Words] Language [Category Fluency] [Word Learning Test]
--	---	-----	--	---	---------------	----------	--

3MS=Modified Mini Mental Status Examination; BVRT=Benton Visual Retention Test; cog=cognitive; N=sample size; DS=Digit Span (Forward and/or Backward); NR=not reported; RAVLT=Rey's Auditory Verbal Learning Test; RCT=randomized controlled trial; RoB=risk of bias; SD=standard deviation; SE=standard error; TMT=Trail Making Test (Part A and/or B); US=United States

**Appendix Table I2. Summary risk of bias assessments: diet interventions in adults with normal cognition**

Diet Intervention Type	Study	Overall Risk of Bias Assessment	Rationale
Caloric restriction diet	Martin 2007 <sup>1</sup>	High	Method of randomization unclear. High reporting bias due to unclear results
Energy restriction diet	Napoli 2014 <sup>2</sup>	Medium	Method of randomization unclear. 13% attrition with no sensitivity analysis.
	Brinkworth 2009 <sup>3</sup>	High	Method of randomization unclear. Attrition 44%
Mediterranean Diet	Valls-Pedret 2015 <sup>4</sup>	High	Attrition 25% with no sensitivity analysis



	Martinez-Lapiscina 2013(a) <sup>5</sup>	High	Attrition 51%
	Martinez-Lapiscina 2013(b) <sup>6</sup>	High	Poor randomization
	Komulainen 2010 <sup>7</sup>	High	Flaw in study design related to the analysis of the data and suspected reporting bias
<b>Protein supplement</b>	van der Zwaluw <sup>8</sup>	Low	Did not report if outcome assessor was blinded or independent
<b>Nutrient supplement</b>	Wouters-Wesseling <sup>9</sup>	High	Attrition 34%

## References for Appendix I

1. Martin CK, Anton SD, Han H, et al. Examination of cognitive function during six months of calorie restriction: results of a randomized controlled trial. *Rejuvenation Res.* 2007 Jun;10(2):179-90. doi: 10.1089/rej.2006.0502. PMID: 17518698.
2. Napoli N, Shah K, Waters DL, et al. Effect of weight loss, exercise, or both on cognition and quality of life in obese older adults. *Am J Clin Nutr.* 2014 Jul;100(1):189-98. doi: 10.3945/ajcn.113.082883. PMID: 24787497.
3. Brinkworth GD, Buckley JD, Noakes M, et al. Long-term effects of a very low-carbohydrate diet and a low-fat diet on mood and cognitive function. *Arch Intern Med.* 2009 Nov 9;169(20):1873-80. doi: 10.1001/archinternmed.2009.329. PMID: 19901139.
4. Valls-Pedret C, Sala-Vila A, Serra-Mir M, et al. Mediterranean Diet and Age-Related Cognitive Decline: A Randomized Clinical Trial. *JAMA Intern Med.* 2015 Jul;175(7):1094-103. doi: 10.1001/jamainternmed.2015.1668. PMID: 25961184.
5. Martinez-Lapiscina EH, Clavero P, Toledo E, et al. Mediterranean diet improves cognition: the PREDIMED-NAVARRA randomised trial. *J Neurol Neurosurg Psychiatry.* 2013 Dec;84(12):1318-25. doi: 10.1136/jnnp-2012-304792. PMID: 23670794.
6. Martinez-Lapiscina EH, Clavero P, Toledo E, et al. Virgin olive oil supplementation and long-term cognition: the PREDIMED-NAVARRA randomized, trial. *J Nutr Health Aging.* 2013;17(6):544-52. doi: 10.1007/s12603-013-0027-6. PMID: 23732551.
7. Komulainen P, Kivipelto M, Lakka T, et al. Exercise, fitness and cognition—A randomised controlled trial in older individuals: The DR's EXTRA study. *European Geriatric Medicine.* 2010;1(5):266-72.
8. van der Zwaluw NL, van de Rest O, Tieland M, et al. The impact of protein supplementation on cognitive performance in frail elderly. *Eur J Nutr.* 2014 Apr;53(3):803-12. doi: 10.1007/s00394-013-0584-9. PMID: 24045855.
9. Wouters-Wesseling W, Wagenaar LW, Rozendaal M, et al. Effect of an enriched drink on cognitive function in frail elderly persons. *Journals of Gerontology Series A-Biological Sciences & Medical Sciences.* 2005 Feb;60(2):265-70. PMID: 15814873.

## Appendix J. Multimodal Interventions

**Appendix Table J1. Characteristics of eligible studies: multimodal interventions vs. inactive controls in adults with normal cognition**

Intervention Type	Study Design Country RoB	N=	Population Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome timing	Outcome Domain [Instrument]
Physical Activity and Diet	Lehtisalo 2016 <sup>1</sup> RCT Finland High	364	Overweight or obese adults with impaired glucose intolerance Age, Mean (SD) 55.1 (6.8) 60% Female Race NR 34% With Higher Education Baseline Cognition NR	Seven initial counseling sessions followed by sessions every 3 months with nutritionist on Individualized dietary, physical activity, and weight and voluntary supervised exercise sessions for 4 years.	General health advice at baseline.	4 years	<u>Executive/Attention/Processing Speed</u> [TMT A] <u>Memory</u> [CERAD Total Score]
	Napoli 2014 <sup>2</sup> RCT US Medium	55	Obese, sedentary adults age 65 and older with a stable weight and a minimum MMSE score of 24 Age, Mean (SD) 70 (4) 63% Female 85% White Years of Education, Mean (SD) 16.3 (3.7) 3MS, Mean (SD) 95.7 (0.8)	Diet and aerobic exercise, resistance training, and balance exercises -90 minutes sessions 3 times/week at an exercise facility for 1 year and energy deficit of 500-750 kcal/day to achieve 10% weight loss over 6 months followed by 6 months of weight maintenance	Information about healthy diet (not allowed to participate in any exercise program)	1 year	Brief Cognitive Test Performance [3MS] <u>Executive/Attention/Processing Speed</u> [TMT A] <u>Executive/Attention/Processing Speed</u> [TMT B] Language [Word List Fluency]
	Komulainen 2010 <sup>3</sup> RCT Finland High	470	Men and women age 55 to 74 Age, Mean (SD) 66.3 (5.3) Sex NR Race NR	Individualized, independent, aerobic exercise program either 5 times/week for 60 min or 5 times/week for 90	General health advice on diet and physical activity	2 years	<u>Brief Cognitive Test Performance</u> [MMSE] <u>Memory</u> [Immediate Memory Composite] [Delayed Memory Composite] Language [Verbal Performance]

Intervention Type	Study Design Country RoB	N=	Population Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome timing	Outcome Domain [Instrument]
			Education, Mean (SD) 11.3 (3.9) MMSE, Mean (SD) 27.6 (2.1)	min for 2 years and counseling by nutritionists to modify diet to specific recommendations			Composite] <u>Visuospatial</u> [Visual Performance Composite]
	Komulainen 2010 <sup>3</sup> RCT Finland High	470	Men and women age 55 to 74 Age, Mean (SD) 66.3 (5.3) Sex NR Race NR Education, Mean (SD) 11.3 (3.9) MMSE, Mean (SD) 27.6 (2.1)	Individualized, independent, strength training program either 2 times/week or 3 times per week and counseling by nutritionists to modify diet to specific recommendations	General health advice on diet and physical activity	2 years	<u>Brief Cognitive Test Performance</u> [MMSE] <u>Memory</u> [Immediate Memory Composite] [Delayed Memory Composite] <u>Language</u> [Verbal Performance Composite] <u>Visuospatial</u> [Visual Performance Composite]
	Martin 2007 <sup>4</sup> RCT US Medium	24	Overweight adults aged 25 to 50 years Age, Mean (SD) 37.5 (1.9) 56% Female 62.5% White Education NR Baseline Cognition NR	Individual-based calorie restriction (12.5% reduction) and structured exercise (12.5% increase in energy expenditure) for 6 months	Weight maintenance for 6 months	6 months	<u>Executive/Attention/Processing Speed</u> [CPT-II, Beta (Response Style)] [CPT-II, Omissions] [CPT-II, Detectability] [CPT-II, RT] [CPT-II, RT SE] [CPT-II, Commissions] [CPT-II, Perseverations] [CPT-II, RT Block Changes] <u>Memory</u> [RAVLT, Trial I-V] [RAVLT, Trial B] [RAVLT, Trial VI] [RAVLT, Delayed Recall] [RAVLT, Recognition] [Auditory Consonant Trigram, 9 sec] [Auditory Consonant Trigram, 18 sec] [Auditory Consonant Trigram, 36 sec] [BVRT, Correct Deviation] [BVRT, Error Deviation]
<b>Physical Activity and Cognitive Training</b>	Hars 2014 <sup>5</sup> RCT Switzerland Medium	134	Community dwelling adults age 65 and older with an increased risk of falling, balance	Structured music-based multitask exercise classes (walking while following changes to	Maintain usual lifestyle habits for 6 months (delayed intervention)	6 months	<u>Brief Cognitive Test Performance</u> [MMSE] <u>Executive/Attention/Processing Speed</u> [FAB] [Sensitivity to Inference Subtest, FAB]

Intervention Type	Study Design Country RoB	N=	Population Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome timing	Outcome Domain [Instrument]
			impairment, or frailty. Age, Mean (SD) 75.5 (7) 96% Female Race NR 18% With High School Education MMSE, Mean (SD) 26.1 (2.9)	rhythmic patterns in piano music and handling objects) -60 minute sessions, 1 session/per week for 25 weeks			<u>Visuospatial</u> [CLOX-1]
	Tesky 2011 <sup>6</sup> RCT Germany High	307	Adults age 65 + with no previous dementia or MCI diagnosis Age, Mean (SD) 71 (6) 73% Female Race NR Years Education, Mean (SD) 10.4 (1.8) ADAS-cog, Mean (SD) 7.15 (2.7)	Group cognitive stimulating leisure activities (8 weekly sessions and 2 booster sessions after 16 weeks post-intervention) with nutritional education and physical activity (courses on gymnastics, walking, yoga)	Usual care for Booklet on training topics (received at the end of the study)	32 weeks	<u>Diagnosis</u> [CDR] <u>Brief Cognitive Test Performance</u> [MMSE] <u>Multidomain Neuropsychological Test Performance</u> [ADAS-Cog] <u>Executive/Attention/Processing Speed</u> [TMT A] [TMT B]
	Oswald 2006 <sup>7</sup> RCT Germany High	375	Adults age ≥75 years without functional, cognitive or physical decline Age, Mean (SD) 79.5 (3.5) 64.8% Female 58.9% Secondary school education or higher	Memory training (90 minutes sessions) and gymnastic exercises (45 minute sessions), 30 sessions total	No intervention for duration of study	5 years	<u>Multidomain Neuropsychological Test Performance</u> [Composite]
	Carlson 2008 <sup>8</sup> RCT US High	149	Cognitively intact older adults with a MMSE of ≥24 Age, Mean (SD)	Experience Corps Program-Cognitive activity (reading to children and library	Wait-list control	8 months	<u>Executive/Attention/Processing Speed</u> [TMT A] [TMT B] <u>Memory</u> [Word List Memory, Immediate

Intervention Type	Study Design Country RoB	N=	Population Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome timing	Outcome Domain [Instrument]
			69 (6) 90% Female 95% African American Education, Mean (SD): 11.5 (3) years MMSE, Mean (SD) 25.1 (3)	service), physical activity, and social engagement for 15 hrs/week over a school year			Recall] [Word List Memory, Delayed Recall] [RCFT, Copy Score] [RCFT, Delayed Recall] <u>Visuospatial</u> [RCFT, Copy Score] [RCFT, Delayed Recall]
<b>Physical Activity, Diet, and Cognitive Training</b>	Ngandu 2015 <sup>9</sup> RCT Finland Low	1260	Individuals age 60–77 years with a CAIDE (Cardiovascular Risk Factors, Aging and Dementia) Dementia Risk Score of at least 6 points and cognition at mean level or slightly lower than expected for age. Age, Mean (SD) 69.5 (4.6) Race NR Years Education, Mean (SD) 10.0 (3.4) MMSE, Mean (SD) 26.7 (2)	Individual and group nutritional intervention, individualized aerobic (1-3 times/week) and strength training (2-5 times/week) programs, group and individual cognitive training, and management of metabolic and vascular risk factors (via lifestyle changes) for 2 years.	General health advice	2 years	<u>Multidomain Neuropsychological Test Performance</u> [NTB, Total Score] <u>Executive/Attention/Processing Speed</u> [NTB, Executive Functioning] [NTB, Processing Speed] <u>Memory</u> [NTB, Memory] [NTB, Abbreviated Memory]
<b>Physical Activity and Protein Supplementation</b>	van de Rest 2014 <sup>10</sup> RCT Netherlands Medium	58	Frail and pre-frail adults age 65 and over Age, Mean (SD) 77.8 (8.5) 62% Female 34% with Higher Education Race NR MMSE, Mean (Range) 28.5 (21-30))	Resistance-type exercise program and protein supplementation -2 sessions/week with personal supervision for 24 weeks	Usual Care (no exercise) and protein supplementation for 24 weeks	24 weeks	<u>Executive/Attention/Processing Speed</u> [Executive Functioning Composite] [DS Forward] [DS Backward] [TMT A] [TMT B/A] [SCWT (Test 1)] [SCWT (Test 2)] [SCWT (Interference)] [Finger Precuing, Reaction Time Uncued] [Finger Precuing, Reaction Time Cued] [Information Processing Speed Composite]

Intervention Type	Study Design Country RoB	N=	Population Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome timing	Outcome Domain [Instrument]
							<u>Memory</u> [Word Learning Test, Immediate Recall-75 Words] [Word Learning Test, Delayed Recall-15 Words] [Word Learning Test, Decay] [Word Learning Test, Recognition, 30 Words] [Attention and Working Memory Composite] <u>Language</u> [Word Fluency, Animals] [Word Fluency, Letter P]
<b>Goal Setting</b>	Clare 2015 <sup>11</sup> RCT UK Medium	46	Individuals aged 50 and over, living and functioning independently in the community Age, Mean (SD) 68.21 (7.92) 86.7% Female Race NR Year of Education, Mean (SD) 13.33 (2.93) Baseline Cognition NR	Goal Setting: Structured goal-setting process using Bangor Goal Setting Interview during 90 minute session. Participant set 5 goals for the coming year relating to physical activity, cognitive activity, physical health, diet, or social engagement.  OR  Goal Setting and Mentoring: Goal setting with five, bimonthly follow-up mentoring calls from researchers to review progress, discuss obstacles, and reinforce	Information: 90-minute session with interview where information was provided about activities and health.	1 year	<u>Brief Cognitive Test Performance</u> [Montreal Cognitive Assessment] <u>Executive/Attention/Processing Speed</u> [TMT] <u>Memory</u> [CVLT, Immediate Recall] [CVLT, Delayed Recall] <u>Language</u> [Verbal Fluency, Delis-Kaplan Executive Function System]

Intervention Type	Study Design Country RoB	N=	Population Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome timing	Outcome Domain [Instrument]
				success.			
<b>Occupational Therapy</b>	Clark 2012 <sup>12</sup> RCT US High	460	Individuals aged 60 years or older with no overt signs of dementia or psychosis. 52% Age 75 or older 37.4% White 16.7% with 4 or more years of college Baseline Cognition NR	Lifestyle-based occupational therapy intervention –Weekly 2 hour small group sessions for 6 months and 10 individual 1 hour sessions	No treatment	6 months	<u>Executive/Attention/Processing Speed</u> [Reaction Time, Visual Search Task] [DSST] <u>Memory</u> [CERAD, Immediate Recall] [CERAD, Delayed Recall] [CERAD, Recognition]



<b>Intervention Type</b>	<b>Study Design Country RoB</b>	<b>N=</b>	<b>Population Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition</b>	<b>Intervention Mode Components Frequency Duration</b>	<b>Comparison Mode Components Frequency Duration</b>	<b>Outcome timing</b>	<b>Outcome Domain [Instrument]</b>
<b>Care Management</b>	Lee 2014 <sup>13</sup> RCT South Korea High	1,115	Community-dwelling adults aged 60 and over Age. Mean (SD) 77.1 (2.5) 78.6% Female Race NR 21.9 % Middle school or higher MMSE, Mean (SD) 24.1 (1.7)	Telephonic or in-person care management including providing educational materials, counseling regarding health behavior, and recommendations for physical activity - Monthly or bi-monthly for 18 months	Standard care (no care management)	18 months	<u>Brief Cognitive Test Performance</u> [MMSE]
<b>Cognitive Training and acetylcholinesterase inhibitor</b>	Yesavage 2008 <sup>14</sup> RCT US High	168	Community-dwelling adults aged 55-90 with a MMSE score between 24 and 30 Age, Mean (SD) 65 (8) 52% Female Race NR Education, Mean (SD) 16.3 (2.3) MMSE, Mean (SD) 28.6 (1.2)	Daily dose of 5 mg of Donepezil for 6 weeks, then increased to 10mg daily for 46 weeks; 2 weeks of cognitive training at weeks 13-14	Placebo and 2 weeks of cognitive training at weeks 13-14	1 year	<u>Executive/Attention/Processing Speed</u> [DSST] <u>Memory</u> [Word List Recall] [Name-Face Recall] [Logical Memory I Score] [Logical Memory II Score]

Intervention Type	Study Design Country RoB	N=	Population Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome timing	Outcome Domain [Instrument]
<b>Lifestyle Advice and Drug Treatment</b>	Moll van Charante 2016 <sup>15</sup> RCT Netherlands Medium	3526	Community-dwelling adults without dementia Age, Mean (SD): 74.5 (2.5) 55% Female 96% White 62% 7-12 Years of Education Baseline cog NR	Visits to a practice nurse to assess cardiovascular risk and receive lifestyle advice, every 4 months for 6 years. Medication prescribed as needed.	Usual care (defined by standards for cardiovascular risk management) for 6 years.	6 years	<u>Diagnosis</u> [All-Cause Dementia] [AD] <u>Brief Cognitive Test Performance</u> [MMSE] <u>Memory</u> [Visual Association Test A]

3MS=Modified Mini Mental Status Examination; AD=Alzheimer's disease; CDR=Clinical Dementia Rating; CLOX-1=Clock Drawing Test; cog=cognition; CPT=Conners' Continuous Performance Test-II; MMSE=Mini-Mental Status Examination; N=sample size; NR=not reported; RAVLT=Rey's Auditory Verbal Learning Test; RCFT=Rey-Osterrieth Complex Figure Test; RCT=randomized controlled trial; RoB=risk of bias; sec=seconds; SCWT=Stroop Color Word Test; SD=standard deviation; TMT=Trail Making Test (Part A and/or B); US=United States

**Appendix Table J2. Characteristics of eligible studies: multimodal interventions vs. active controls in adults with normal cognition**

Intervention Type	Study Design Country RoB	N=	Population Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome timing	Outcome Domain [Instrument]
<b>Physical Activity and Diet vs. Diet</b>	Napoli 2014 <sup>2</sup> RCT US Medium	647	Obese, sedentary adults age 65 and older with a stable weight and a minimum MMSE score of 24 Age, Mean (SD) 70 (4) 63% Female 85% White	Diet and aerobic exercise, resistance training, and balance exercises -90 minutes sessions 3 times/week at an exercise facility for 1 year and energy deficit of 500-750 kcal/day to achieve 10% weight loss over 6 months followed	Diet - Energy deficit of 500-750 kcal/day to achieve 10% weight loss over 6 months followed by 6 months of weight maintenance	1 year	<u>Brief Cognitive Test Performance</u> [3MS] <u>Executive/Attention/Processing Speed</u> [TMT A] [TMT B] <u>Language</u> [Word List Fluency]

Intervention Type	Study Design Country RoB	N=	Population Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome timing	Outcome Domain [Instrument]
			Years of Education, Mean (SD) 16.3 (3.7) 3MS, Mean (SD) 95.7 (0.8)	by 6 months of weight maintenance			
	Komulainen 2010 <sup>3</sup> RCT Finland High	470	Men and women age 55 to 74 Age, Mean (SD) 66.5 (5.4) Sex NR Race NR Education, Mean (SD) 11.4 (3.9) MMSE, Mean (SD) 27.6 (2.1)	Individualized, independent, aerobic exercise program either 5 times/week for 60 min or 5 times/week for 90 min for 2 years and counseling by nutritionists to modify diet to specific recommendations	Counseling by nutritionists to modify diet to specific recommendations	2 years	<u>Brief Cognitive Test Performance</u> [MMSE] <u>Memory</u> [Immediate Memory Composite] [Delayed Memory Composite] <u>Language</u> [Verbal Performance Composite] <u>Visuospatial</u> [Visual Performance Composite]
	Komulainen 2010 <sup>3</sup> RCT Finland High	470	Men and women age 55 to 74 Age, Mean (SD) 66.3 (5.3) Sex NR Race NR Education, Mean (SD) 11.3 (3.9) MMSE, Mean (SD) 27.6 (2.1)	Individualized, independent, strength training program either 2 times/week or 3 times per week and counseling by nutritionists to modify diet to specific recommendations	Counseling by nutritionists to modify diet to specific recommendations	2 years	<u>Brief Cognitive Test Performance</u> [MMSE] <u>Memory</u> [Immediate Memory Composite] [Delayed Memory Composite] <u>Language</u> [Verbal Performance Composite] <u>Visuospatial</u> [Visual Performance Composite]
	Martin 2007 <sup>4</sup> RCT US Medium	24	Overweight adults aged 25 to 50 years Age, Mean (SD) 37.5 (1.9) 56% Female	Individual-based calorie restriction (12.5% reduction) and structured exercise (12.5% increase in energy expenditure) for 6 months	Calorie restriction (25% restriction) for 6 months	6 months	<u>Executive/Attention/Processing Speed</u> [CPT-II, Beta (Response Style)] [CPT-II, Omissions] [CPT-II, Detectability] [CPT-II, RT] [CPT-II, RT Standard Error] [CPT-II, Commissions]

Intervention Type	Study Design Country RoB	N=	Population Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome timing	Outcome Domain [Instrument]
			62.5% White Education NR Baseline Cognition NR				[CPT-II, Perseverations] [CPT-II, RT Block Changes] <u>Memory</u> [RAVLT, Trial I-V] [RAVLT, Trial B] [RAVLT, Trial VI] [RAVLT, Delayed Recall] [RAVLT, Recognition] [Auditory Consonant Trigram, 9 sec] [Auditory Consonant Trigram, 18 sec] [Auditory Consonant Trigram, 36 sec] [BVRT, Correct Deviation] [BVRT, Error Deviation]
	Martin 2007 <sup>4</sup> RCT US Medium	24	Overweight adults aged 25 to 50 years Age, Mean (SD) 37.5 (1.9) 56% Female 62.5% White Education NR Baseline Cognition NR	Individual-based calorie restriction (12.5% reduction) and structured exercise (12.5% increase in energy expenditure) for 6 months	Low-calorie diet (890 kcal/d liquid formula diet until 15% of body weight is lost, followed by weight maintenance) for 6 months	6 months	<u>Executive/Attention/Processing Speed</u> [CPT-II, Beta (Response Style)] [CPT-II, Omissions] [CPT-II, Detectability] [CPT-II, RT] [CPT-II, RT Standard Error] [CPT-II, Commissions] [CPT-II, Perseverations] [CPT-II, RT Block Changes] <u>Memory</u> [RAVLT, Trial I-V] [RAVLT, Trial B] [RAVLT, Trial VI] [RAVLT, Delayed Recall] [RAVLT, Recognition] [Auditory Consonant Trigram, 9 sec] [Auditory Consonant Trigram, 18 sec] [Auditory Consonant Trigram, 36 sec] [BVRT, Correct Deviation] [BVRT, Error Deviation]
<b>Physical Activity and Diet vs. Physical Activity</b>	Napoli 2014 <sup>2</sup> RCT US Medium	54	Obese, sedentary adults age 65 and older with a stable weight and a minimum MMSE score of 24 Age, Mean (SD) 70 (4) 63% Female 85% White	Diet and aerobic exercise, resistance training, and balance exercises -90 minutes sessions 3 times/week at an exercise facility for 1 year and energy deficit of 500-750 kcal/day to achieve 10% weight loss over 6 months followed	Aerobic exercise, resistance training, and balance exercises -90 minutes sessions 3 times/week at an exercise facility for 1 year	1 year	<u>Brief Cognitive Test Performance</u> [3MS] <u>Executive/Attention/Processing Speed</u> [TMT A] [TMT B] <u>Language</u> [Word List Fluency]

Intervention Type	Study Design Country RoB	N=	Population Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome timing	Outcome Domain [Instrument]
			Years of Education, Mean (SD) 16.3 (3.7) 3MS, Mean (SD) 95.7 (0.8)	by 6 months of weight maintenance			
	Komulainen 2010 <sup>3</sup> RCT Finland High	468	Men and women age 55 to 74 Age, Mean (SD) 66.5 (5.4) Sex NR Race NR Education, Mean (SD) 11.4 (3.9) MMSE, Mean (SD) 27.6 (2.1)	Individualized, independent, aerobic exercise program either 5 times/week for 60 min or 5 times/week for 90 min for 2 years and counseling by nutritionists to modify diet to specific recommendations	Individualized, independent, aerobic exercise program either 5 times/week for 60 min or 5 times/week for 90 min for 2 years	2 years	<u>Brief Cognitive Test Performance</u> [MMSE] <u>Memory</u> [Immediate Memory Composite] [Delayed Memory Composite] <u>Language</u> [Verbal Performance Composite] <u>Visuospatial</u> [Visual Performance Composite]
	Komulainen 2010 <sup>3</sup> RCT Finland High	470	Men and women age 55 to 74 Age, Mean (SD) 66.3 (5.3) Sex NR Race NR Education, Mean (SD) 11.3 (3.9) MMSE, Mean (SD) 27.6 (2.1)	Individualized, independent, strength training program either 2 times/week or 3 times per week and counseling by nutritionists to modify diet to specific recommendations	Individualized, independent, strength training program either 2 times/week or 3 times per week	2 years	<u>Brief Cognitive Test Performance</u> [MMSE] <u>Memory</u> [Immediate Memory Composite] [Delayed Memory Composite] <u>Language</u> [Verbal Performance Composite] <u>Visuospatial</u> [Visual Performance Composite]

Intervention Type	Study Design Country RoB	N=	Population Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome timing	Outcome Domain [Instrument]
<b>Physical Activity and Cognitive Training vs. Physical Activity and Cognitive Training</b>	Eggenberger 2015 <sup>16</sup> RCT Switzerland Medium	89	Seniors older than 70 years with an MMSE score greater than 22 Age, Mean (SD) 78.9 (5.4) 52% Female Race NR Years of Education, Mean (SD) 13.2 (1.9) MMSE, Mean (SD) 28.2 (1.4)	Virtual reality video game dancing with cognitive training -60 minute group sessions 2 times/week for 6 months	Treadmill walking with verbal memory exercise -60 minute group sessions 2 times/week for 6 months	6 months	<u>Executive/Attention/Processing Speed</u> [TMT A] [TMT B] [Executive Control Task] [DS Forward] [DSST] [Age Concentration Test A] [Age Concentration Test B] <u>Memory</u> [Paired-Associates Learning] [Story Recall, WMS]

<b>Intervention Type</b>	<b>Study Design Country RoB</b>	<b>N=</b>	<b>Population Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition</b>	<b>Intervention Mode Components Frequency Duration</b>	<b>Comparison Mode Components Frequency Duration</b>	<b>Outcome timing</b>	<b>Outcome Domain [Instrument]</b>
<b>Physical Activity and Cognitive Training vs. Physical Activity</b>	McDaniel 2014 <sup>17</sup> RCT US High	96	Adults age 55 to 75 without dementia or MCI Age, Mean (SD) 65 (8) 67% Female 88% White Years Education, Mean (SD) 16 (2) MMSE, Mean (SD) 29 (1)	Treadmill walking or exercise bicycle program (45-50 minute sessions 3 times/week) for 6 months and cognitive training 3 days/week for 8 weeks	Low-intensity home exercise program focusing on flexibility for 6 months and in-person health education for 8 weeks	6 months	<u>Executive/Attention/Processing Speed</u> [SCWT Part 1] [SCWT Part 2] [DSST] [TMT A] [TMT B] <u>Memory</u> [Logical Memory Immediate] [Logical Memory Delayed, Wechsler] [Virtual Week (5-min Break)] [Memory for Health Information Part 1] [Memory for Health Information Part 2]
	McDaniel 2014 <sup>17</sup> RCT US High	96	Adults age 55 to 75 without dementia or MCI Age, Mean (SD) 65 (8) 67% Female 88% White Years Education, Mean (SD) 16 (2) MMSE, Mean (SD) 29 (1)	Treadmill walking or exercise bicycle program (45-50 minute sessions 3 times/week) for 6 months and cognitive training 3 days/week for 8 weeks	Treadmill walking or exercise bicycle program -45-50 minute sessions 3 times/week for 6 months	6 months	<u>Executive/Attention/Processing Speed</u> [SCWT Part 1] [SCWT Part 2] [DSST] [TMT A] [TMT B] <u>Memory</u> [Logical Memory Immediate] [Logical Memory Delayed, Wechsler] [Virtual Week (5-min Break)] [Memory for Health Information Part 1] [Memory for Health Information Part 2]

Intervention Type	Study Design Country RoB	N=	Population Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome timing	Outcome Domain [Instrument]
	McDaniel 2014 <sup>17</sup> RCT US High	96	Adults age 55 to 75 without dementia or MCI Age, Mean (SD) 65 (8) 67% Female 88% White Years Education, Mean (SD) 16 (2) MMSE, Mean (SD) 29 (1)	Treadmill walking or exercise bicycle program (45-50 minute sessions 3 times/week) for 6 months and cognitive training 3 days/week for 8 weeks	Low-intensity home exercise program focusing on flexibility for 6 months and cognitive training 3 days/week for 8 weeks	6 months	<u>Executive/Attention/Processing Speed</u> [SCWT Part 1] [SCWT Part 2] [DSST] [TMT A] [TMT B] <u>Memory</u> [Logical Memory Immediate] [Logical Memory Delayed, Wechsler] [Virtual Week (5-min Break)] [Memory for Health Information Part 1] [Memory for Health Information Part 2]

3MS=Modified Mini Mental Status Examination; AD=Alzheimer's disease; CDR=Clinical Dementia Rating; CLOX-1=Clock Drawing Test; cog=cognition; CPT=Conners' Continuous Performance Test-II; MMSE=Mini-Mental Status Examination; N=sample size; NR=not reported; RAVLT=Rey's Auditory Verbal Learning Test; RCFT=Rey-Osterrieth Complex Figure Test; RCT=randomized controlled trial; RoB=risk of bias; sec=seconds; SCWT=Stroop Color Word Test; SD=standard deviation; TMT=Trail Making Test (Part A and/or B); US=United States; WMS=Wechsler Memory Scale



**Appendix Table J3. Summary risk of bias assessments: multimodal interventions in adults with normal cognition**

<b>Study</b>	<b>Overall Risk of Bias Assessment</b>	<b>Rationale</b>
Lehtisalo 2016 <sup>1</sup>	High	High rate of attrition with no analysis to address risk of bias.
Moll van Charante 2016 <sup>15</sup>	Medium	Potential for bias due to high dropout rate across all study arms.
Clare 2015 <sup>11</sup>	Medium	Potential performance and detection bias.
Eggenberger 2015 <sup>16</sup>	Medium	Attrition rate is 20% with potential performance bias.
Ngandu 2015 <sup>9</sup>	Low	No significant risk of bias detected.
Hars 2014 <sup>5</sup>	Medium	Process for randomization is unclear and attrition rate is 16%.
Lee 2014 <sup>13</sup>	High	High potential for bias due to over 50% attrition.
McDaniel 2014 <sup>17</sup>	High	Process for randomization is unclear with suspected reporting bias.
Napoli 2014 <sup>2</sup>	Medium	Process for randomization is unclear and 13% attrition rate.
van de Rest 2014 <sup>10</sup>	Medium	Attrition is 15% with potential reporting bias.
Clark 2012 <sup>12</sup>	High	Attrition rate is greater than 21% with no analysis to address potential bias.
Tesky 2011 <sup>6</sup>	High	Attrition rate is greater than 21% with no analysis to address potential bias.
Komulainen 2010 <sup>3</sup>	High	Flaw in study design related to the analysis of the data and suspected reporting bias
Carlson 2008 <sup>8</sup>	High	Attrition rate is greater than 21% with no analysis to address potential bias.
Yesavage 2008 <sup>14</sup>	High	Attrition rate is greater than 21% with no analysis to address potential bias.
Martin 2007 <sup>4</sup>	Medium	Process for attrition is unclear with potential detection bias.
Oswald 2006 <sup>7</sup>	High	Suspected selection bias due to process for randomization.

**Appendix Table J4. Strength of evidence assessments: multimodal interventions versus inactive control in adults with normal cognition**

Comparison	Outcome	# Trials (n)	Summary statistics [95% CI]	Study Limitations	Directness	Precision	Consistency	Reporting Bias	Optional Components	Evidence Rating
Physical activity and diet vs. inactive control	Dementia	NR								
	MCI	NR								
	Brief Cognitive Test Performance									
	Multidomain Neuropsychological Performance	NR								
	Executive Function	2 (79)	1 of 10 tests shows a statistically significant difference with intervention.	Medium	Indirect	Imprecise	Inconsistent	Undetected	NA	Insufficient
	Memory	NR								
	Biomarkers Adverse Effects	NR NR								
Physical activity, diet, and cognitive training vs. inactive control	Dementia	NR								
	MCI	NR								
	Brief Cognitive Test Performance	NR								
	Multidomain Neuropsychological Performance	1 (1260)	1 of 1 test show a statistically significant difference with intervention.  <u>Ngandu 2015<sup>9</sup></u> NTB, Difference between groups per year [95% CI]	Low	Indirect	Precise	Unknown	Undetected	NA	Low

Comparison	Outcome	# Trials (n)	Summary statistics [95% CI]	Study Limitations	Directness	Precision	Consistency	Reporting Bias	Optional Components	Evidence Rating
			0.022 [0.002, 0.042]							
	Executive Function	1 (1260)	2 of 2 tests show a statistically significant difference with intervention.  <u>Ngandu 2015<sup>9</sup></u> NTB Executive Functioning, Difference between groups per year [95% CI] 0.027 [0.001, 0.052]  NTB Processing Speed, Difference groups per year [95% CI] 0.030 [0.003, 0.057]	Low	Indirect	Precise	Unknown	Undetected	NA	Low
	Memory	1 (1260)	1 of 2 tests shows a statistically significant difference	Low	Indirect	Imprecise	Inconsistent	Undetected	NA	Insufficient

Comparison	Outcome	# Trials (n)	Summary statistics [95% CI]	Study Limitations	Directness	Precision	Consistency	Reporting Bias	Optional Components	Evidence Rating
			with intervention.  <u>Ngandu 2015</u> <sup>9</sup> NTB Memory, Difference between groups per year [95% CI] 0.015 [-0.017, 0.048]  NTB Abbreviated Memory, Difference between groups per year [95% CI] 0.038 [0.002, 0.073]							
	Biomarkers	NR								
	Adverse Effects	NR								
Lifestyle advice with drug treatment vs. inactive control	Dementia	1 (3526)	No difference with intervention in dementia incidence.  <u>Moll van Charante 2016</u> <sup>15</sup>	Medium	Direct	Precise	Unknown	Undetected	NA	Low

Comparison	Outcome	# Trials (n)	Summary statistics [95% CI]	Study Limitations	Directness	Precision	Consistency	Reporting Bias	Optional Components	Evidence Rating
			All-cause Dementia Hazard Ratio, [95% CI] 0.92 [0.71, 1.19]  Alzheimer's Disease, Hazard Ratio [95% CI] 1.05 [0.78, 1.41]							
	MCI	NR								
	Brief Cognitive Test Performance	1 (3526)	1 of 1 tests shows no difference with intervention  <u>Moll van Charante 2016<sup>15</sup></u> MMSE, Adjusted mean difference [95% CI] -0.02 [-0.14 0.10]	Medium	Indirect	Precise	Unknown	Undetected	NA	Low
	Multidomain Neuropsychological Performance	NR								
	Executive Function	NR								
	Memory	1 (3526)	1 of 1 tests shows no	Medium	Indirect	Precise	Unknown	Undetected	NA	Low

Comparison	Outcome	# Trials (n)	Summary statistics [95% CI]	Study Limitations	Directness	Precision	Consistency	Reporting Bias	Optional Components	Evidence Rating
			<p>diference with intervention</p> <p><u>Moll van Charante 2016</u><sup>15</sup> Visual Association Test A, Adjusted mean difference [95% CI] -0.02 [-0.09, 0.04]</p>							
	Biomarkers	NR								
	Adverse Effects	1 (3526)	<p>No difference in serious adverse effects between intervention and control group.</p> <p><u>Moll van Charante 2016</u><sup>15</sup> Serious adverse events (hospital admissions), Hazard Ratio (p-value) 0.96 (p=0.56)</p>	Medium	Indirect	Precise	Unknown	Undetected	NA	Low

C=control; CI=confidence interval; I=intervention; MCI=mild cognitive impairment; MMSE=MMSE=Mini-Mental Status Examination; n=sample size; NA=not applicable; NR=not reported; NTB=Neuropsychological Test Battery; RCT=randomized controlled trial; SD=standard deviation

**Appendix Table J5. Strength of evidence assessments: multimodal interventions versus active comparison in adults with normal cognition**

Comparison	Outcome	# Trials (n)	Summary statistics [95% CI]	Study Limitations	Directness	Precision	Consistency	Reporting Bias	Optional Components	Evidence Rating
Physical activity and diet vs. diet	Dementia	NR								
	MCI	NR								
	Brief Cognitive Test Performance									
	Multidomain Neuropsychological Performance	NR								
	Executive Function	2 (90)	18 of 18 tests show no statistically significant difference with intervention.	Medium	Indirect	Imprecise	Consistent	Undetected	NA	Insufficient
	Memory	NR								
	Biomarkers	NR								
Adverse Effects	NR									

C=control; CI=confidence interval; I=intervention; MCI=mild cognitive impairment; NA=not applicable; NR=not reported; vs.=versus



**Appendix Table J6. Characteristics of eligible studies: multimodal interventions vs. inactive controls in adults with MCI**

Study Design Country RoB	N=	Population Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome timing	Outcome Domain [Instrument]
Fiatarone Singh 2014 <sup>18</sup> RCT Australia High	51	Adults age 55 and older with a MCI diagnosis consistent with Petersen criteria Age NR Sex NR Education NR MMSE, Mean (SD) 27 (1)	Cognitive training (computer-based exercises targeting memory, executive function, attention, and processing speed) and Resistance Training -100 minutes 2 days/week for 6 months	Sham cognitive training and sham exercise	6 months 18 months	<u>Multidomain Neuropsychological Test Performance</u> [ADAS-Cog] [Global Cognition Domain Composite] <u>Executive/Attention/Processing Speed</u> [Executive Function Domain Composite] [WAIS Similarities] [WAIS Matrices] [COWAT] [SDMT] <u>Memory</u> [Memory Domain Composite] [List Learning Memory Sum from ADAS-Cog] [BVRT] [Logical Memory, Immediate] [Logical Memory, Delayed] <u>Language</u> [Category Fluency, Animal Naming] [COWAT]
Johari 2014 <sup>19</sup> RCT Malaysia High	35	Individuals with MCI based on Petersen criteria Age, Mean (SD) 65.7 (3.8) 54.3% Female 83% Malay 94% with Formal Education MMSE, Mean (SD) 27 (3)	Nutrition and lifestyle education (7 guidelines) – Monthly sessions for 12 months	No education, supplementation with placebo capsule containing 1000 mg corn oil (taken 3 times a day for 12 months)	12 months	<u>Brief Cognitive Test Performance</u> [MMSE] <u>Executive/Attention/Processing Speed</u> [DS Forward] [DS Backward] [DSST] [Matrix Reasoning] <u>Memory</u> [VR I] [VR II, Delayed] [RAVLT] <u>Visuospatial</u> [Block Design] [CLOX-1]

ADAS=Cog-Alzheimer's Disease Assessment Scale-Cognitive; BVRT=Benton Visual Retention Test; COWAT=Controlled Oral Word Association Test; MCI=mild cognitive impairment; mg=milligrams; MMSE=Mini-Mental Status Examination; N=sample size; NR=not reported; RCT=randomized controlled trial; RoB=risk of bias; SD=standard deviation; SDMT=Symbol Digit Modalities Test; VR=Visual Reproduction; WAIS=Wechsler Adult Intelligence Scale;

**Appendix Table J7. Characteristics of eligible studies: multimodal interventions vs. active controls in adults with MCI**

<b>Study Design Country RoB</b>	<b>N=</b>	<b>Population Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition</b>	<b>Intervention Mode Components Frequency Duration</b>	<b>Comparison Mode Components Frequency Duration</b>	<b>Outcome timing</b>	<b>Outcome Domain [Instrument]</b>
Kobe, 2016 <sup>20</sup> RCT Germany High	35	MCI patients diagnosed according to Mayo criteria Age, Mean (SD) 70 (6.2) 64% Male Years of Education, Mean (SD) 16.3 (3.5) MMSE, Mean (SD) 28.2 (1.4)	Aerobic exercise (45 minutes twice a week), cognitive stimulation (cognitive stimulating leisure activities and memory strategies; 12, 90 minute sessions), and omega-3 FA supplementation (2200 mg) for 6 months	Non-aerobic exercise (45 minutes twice a week) and omega-3 FA supplementation (2200 mg) for 6 months.	6 months	<u>Brief Cognitive Test Performance [MMSE]</u> <u>Executive/Attention/Processing Speed [Composite]</u> [Attention Composite] <u>Memory [Composite]</u>
Lam 2015 <sup>21</sup> RCT China High	263	Chinese older adults with MCI (presence of subjective cognitive complaints, and objective impairments in cognitive function) Age, Mean (SD) 75.4 (6.5) 78.2% Female Race NR Education Level, Mean (SD) 3.9 (3.6) ADAS-cog, Mean (SD) 11.5 (3.3)	Cognitive and mind-body exercises -1 hour sessions 3 times/week	Social activities (e.g., tea gathering, film watching) –At least 1 hour sessions 3 times/week	8 months 12 months	<u>Diagnosis [CDR, Sums of Boxes]</u> <u>Brief Cognitive Test Performance [MMSE]</u> <u>Multidomain Neuropsychological Test Performance [ADAS-Cog, Chinese Version]</u> <u>Memory [Delayed Recall]</u> <u>Language [CVFT]</u>

Study Design Country RoB	N=	Population Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome timing	Outcome Domain [Instrument]
Lam 2015 <sup>21</sup> RCT China High	277	Chinese older adults with MCI (presence of subjective cognitive complaints, and objective impairments in cognitive function) Age, Mean (SD) 75.4 (6.5) 78.2% Female Race NR Education Level, Mean (SD) 3.9 (3.6) ADAS-cog, Mean (SD) 11.5 (3.3)	Cognitive and mind-body exercises -1 hour sessions 3 times/week	Cognitively demanding activities (e.g., reading and discussing news, board games) –At least 3 sessions/weeks	8 months 12 months	<u>Diagnosis</u> [CDR, Sums of Boxes] <u>Brief Cognitive Test Performance</u> [MMSE] <u>Multidomain Neuropsychological Test Performance</u> [ADAS-Cog, Chinese Version] <u>Memory</u> [Delayed Recall] <u>Language</u> [CVFT]
Lam 2015 <sup>21</sup> RCT China High	279	Chinese older adults with MCI (presence of subjective cognitive complaints, and objective impairments in cognitive function) Age, Mean (SD) 75.4 (6.5) 78.2% Female Race NR Education Level, Mean (SD) 3.9 (3.6) ADAS-cog, Mean (SD) 11.5 (3.3)	Cognitive and mind-body exercises -1 hour sessions 3 times/week	Stretching and toning, mind body exercise (e.g., Tai Chi), and aerobic exercise -1 session/week of each type, 60 minutes/session	8 months 12 months	<u>Diagnosis</u> [CDR, Sums of Boxes] <u>Brief Cognitive Test Performance</u> [MMSE] <u>Multidomain Neuropsychological Test Performance</u> [ADAS-Cog, Chinese Version] <u>Memory</u> [Delayed Recall] <u>Language</u> [CVFT]

Study Design Country RoB	N=	Population Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome timing	Outcome Domain [Instrument]
Fiatarone Singh 2014 <sup>18</sup> RCT Australia High	51	Adults age 55 and older with aMCI diagnosis consistent with Petersen criteria Age NR Sex NR Education NR MMSE, Mean (SD) 27 (1)	Cognitive training (computer-based exercises targeting memory, executive function, attention, and processing speed) and Resistance Training -100 minutes 2 days/week for 6 months	Cognitive training (computer-based exercises targeting memory, executive function, attention, and processing speed) -100 minutes 2 days/week for 6 months	6 months 18 months	<u>Multidomain Neuropsychological Test Performance</u> [Global Cognition Domain Composite] [ADAS-Cog] <u>Executive/Attention/Processing Speed</u> [Executive Function Domain Composite] [WAIS Similarities] [WAIS Matrices] [COWAT] [SDMT] <u>Language</u> [Category Fluency, Animal Naming] [COWAT] <u>Memory</u> [List Learning Memory Sum from ADAS-Cog] [BVRT] [Logical Memory, Immediate] [Logical Memory, Delayed] [Memory Domain Composite]
Fiatarone Singh 2014 <sup>18</sup> RCT Australia High	49	Adults age 55 and older with a MCI diagnosis consistent with Petersen criteria Age NR Sex NR Education NR MMSE, Mean (SD) 27 (1)	Cognitive training (computer-based exercises targeting memory, executive function, attention, and processing speed) and Resistance Training -100 minutes 2 days/week for 6 months	Resistance Training - 100 minutes 2 days/week for 6 months	6 months 18 months	<u>Multidomain Neuropsychological Test Performance</u> [Global Cognition Domain Composite] [ADAS-Cog] <u>Executive/Attention/Processing Speed</u> [Executive Function Domain Composite] [WAIS Similarities] [WAIS Matrices] [COWAT] [SDMT] <u>Memory</u> [List Learning Memory Sum from ADAS-Cog] [BVRT] [Logical Memory, Immediate] [Logical Memory, Delayed] [Memory Domain Composite] <u>Language</u> [Category Fluency, Animal Naming] [COWAT]

ADAS=Cog-Alzheimer's Disease Assessment Scale-Cognitive; CDR=Clinical Dementia Rating; CVFT=Category Verbal Fluency Test; MCI=mild cognitive impairment; MMSE=Mini-Mental Status Examination; N=sample size; NR=not reported; RCT=randomized controlled trial; RoB=risk of bias; SD=standard deviation; SDMT=Symbol Digit Modalities Test; WAIS=Wechsler Adult Intelligence Scale

**Appendix Table J8. Summary Risk of Bias Assessments: Multimodal interventions in adults with MCI**

Study	Overall Risk of Bias Assessment	Rationale
Kobe 2016 <sup>20</sup>	High	Suspected selection, attrition, and detection bias.
Lam 2015 <sup>21</sup>	High	Attrition rate is higher than 21% with no analysis to address potential bias.
Fiatarone Singh 2014 <sup>18</sup>	High	Suspected reporting bias. Results for intervention arms are combined in the analysis,
Johari 2014 <sup>19</sup>	High	Process for randomization not described, potential detection bias, and potential performance bias due to concurrent intervention.

MCI=mild cognitive impairment

## References for Appendix J

1. Lehtisalo J, Lindstrom J, Ngandu T, et al. Association of Long-Term Dietary Fat Intake, Exercise, and Weight with Later Cognitive Function in the Finnish Diabetes Prevention Study. *Journal of Nutrition, Health & Aging*. 2016 Feb;20(2):146-54. doi: <http://dx.doi.org/10.1007/s12603-015-0565-1>. PMID: 26812510.
2. Napoli N, Shah K, Waters DL, et al. Effect of weight loss, exercise, or both on cognition and quality of life in obese older adults. *Am J Clin Nutr*. 2014 Jul;100(1):189-98. doi: 10.3945/ajcn.113.082883. PMID: 24787497.
3. Komulainen P, Kivipelto M, Lakka T, et al. Exercise, fitness and cognition—A randomised controlled trial in older individuals: The DR's EXTRA study. *European Geriatric Medicine*. 2010;1(5):266-72.
4. Martin CK, Anton SD, Han H, et al. Examination of cognitive function during six months of calorie restriction: results of a randomized controlled trial. *Rejuvenation Res*. 2007 Jun;10(2):179-90. doi: 10.1089/rej.2006.0502. PMID: 17518698.
5. Hars M, Herrmann FR, Gold G, et al. Effect of music-based multitask training on cognition and mood in older adults. *Age Ageing*. 2014 Mar;43(2):196-200. doi: 10.1093/ageing/aft163. PMID: 24212920.
6. Tesky VA, Thiel C, Banzer W, et al. Effects of a Group Program to Increase Cognitive Performance Through Cognitively Stimulating Leisure Activities in Healthy Older Subjects. *GeroPsych*. 2011 01 Jun;24(2):83-92. doi: 10.1024/1662-9647/a000035. PMID: 2011313185.
7. Oswald WD, Gunzelmann T, Rupprecht R, et al. Differential effects of single versus combined cognitive and physical training with older adults: the SimA study in a 5-year perspective. *European Journal of Ageing*. 2006;3(4):179-92.
8. Carlson MC, Saczynski JS, Rebok GW, et al. Exploring the effects of an "everyday" activity program on executive function and memory in older adults: Experience Corps. *Gerontologist*. 2008 Dec;48(6):793-801. PMID: 19139252.
9. Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. *Lancet*. 2015 Jun 6;385(9984):2255-63. doi: 10.1016/S0140-6736(15)60461-5. PMID: 25771249.
10. van de Rest O, van der Zwaluw NL, Tieland M, et al. Effect of resistance-type exercise training with or without protein supplementation on cognitive functioning in frail and pre-frail elderly: secondary analysis of a randomized, double-blind, placebo-controlled trial. *Mech Ageing Dev*. 2014 Mar-Apr;136-137:85-93. doi: 10.1016/j.mad.2013.12.005. PMID: 24374288.
11. Clare L, Nelis SM, Jones IR, et al. The Agewell trial: a pilot randomised controlled trial of a behaviour change intervention to promote healthy ageing and reduce risk of dementia in later life. *BMC Psychiatry*. 2015;15:25. doi: 10.1186/s12888-015-0402-4. PMID: 25880911.
12. Clark F, Jackson J, Carlson M, et al. Effectiveness of a lifestyle intervention in promoting the well-being of independently living older people: results of the Well Elderly 2 Randomised Controlled Trial. *J Epidemiol Community Health*. 2012 Sep;66(9):782-90. doi: 10.1136/jech.2009.099754. PMID: 21636614.
13. Lee KS, Lee Y, Back JH, et al. Effects of a multidomain lifestyle modification on cognitive function in older adults: an eighteen-month community-based cluster randomized controlled trial. *Psychother Psychosom*. 2014;83(5):270-8. doi: 10.1159/000360820. PMID: 25116574.
14. Yesavage JA, Friedman L, Ashford JW, et al. Acetylcholinesterase inhibitor in combination with cognitive training in older adults. *J Gerontol B Psychol Sci Soc Sci*. 2008 Sep;63(5):P288-94. PMID: 18818443.

15. Moll van Charante EP, Richard E, Eurelings LS, et al. Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA): A cluster-randomised controlled trial. *The Lancet*. 2016 Aug;388(10046):797-805. doi: <http://dx.doi.org/10.1016/S0140-6736%2816%2930950-3>. PMID: 2016-41615-029.
16. Eggenberger P, Schumacher V, Angst M, et al. Does multicomponent physical exercise with simultaneous cognitive training boost cognitive performance in older adults? A 6-month randomized controlled trial with a 1-year follow-up. *Clin Interv Aging*. 2015 17 Aug;10:1335-49. doi: 10.2147/CIA.S87732. PMID: 26316729.
17. McDaniel MA, Binder EF, Bugg JM, et al. Effects of cognitive training with and without aerobic exercise on cognitively demanding everyday activities. *Psychol Aging*. 2014 Sep;29(3):717-30. doi: 10.1037/a0037363. PMID: 25244489.
18. Fiatarone Singh MA, Gates N, Saigal N, et al. The Study of Mental and Resistance Training (SMART) study-resistance training and/or cognitive training in mild cognitive impairment: a randomized, double-blind, double-sham controlled trial. *J Am Med Dir Assoc*. 2014 Dec;15(12):873-80. doi: 10.1016/j.jamda.2014.09.010. PMID: 25444575.
19. Johari SM, Shahar S, Ng TP, et al. A Preliminary Randomized Controlled Trial of Multifaceted Educational Intervention for Mild Cognitive Impairment Among Elderly Malays in Kuala Lumpur. *International Journal of Gerontology*. 2014 Jun;8(2):74-80. doi: 10.1016/j.ijge.2013.07.002. PMID: WOS:000339088200006.
20. Kobe T, Witte A, Schnelle A, et al. Combined omega-3 fatty acids, aerobic exercise and cognitive stimulation prevents decline in gray matter volume of the frontal, Parietal and cingulate cortex in patients with mild cognitive impairment. *NeuroImage*. 2016 01 May;131:226-38. doi: <http://dx.doi.org/10.1016/j.neuroimage.2015.09.050>. PMID: 607245692.
21. Lam LC, Chan WC, Leung T, et al. Would older adults with mild cognitive impairment adhere to and benefit from a structured lifestyle activity intervention to enhance cognition?: a cluster randomized controlled trial. *PLoS One*. 2015 31 Mar;10(3):e0118173. doi: 10.1371/journal.pone.0118173. PMID: 25826620.

## Appendix K. Hormone Interventions

**Appendix Table K1. Characteristics of eligible studies: hormone interventions vs. inactive controls in adults with normal cognition**

<b>Homone Intervention Type</b>	<b>Study Design Country RoB</b>	<b>N=</b>	<b>Population Inclusion Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition</b>	<b>Intervention Mode Components Frequency Duration</b>	<b>Comparison Mode Components Frequency Duration</b>	<b>Outcome timing</b>	<b>Outcome Domain [Instrument]</b>
<b>HRT-Estrogen</b>	Henderson 2016 <sup>1</sup> RCT USA Medium (2.5 years) High (5 years)	567	Healthy postmenopausal women Mean age (SD) (early menopause): 55.5 (4.1) years Mean age (SD) (late menopause): 64.4 (6) years 100% female 71% White 79% college graduate Baseline cognition: NR	Oral estrogen therapy (17 beta-estradiol, 1 mg/day) for a mean duration of 57 months	Identically appearing placebo for a mean duration of 57 months	2.5 & 5 years	<u>Multidomain Neuropsychological Test Performance</u> [Global Cognition Composite] <u>Executive/Attention/Processing Speed</u> [Executive Functions Composite] <u>Memory</u> [Verbal Episodic Memory]
	Wroolie 2015 <sup>2</sup> Rasgon 2014 <sup>3</sup> RCT USA Medium (cognitive outcomes) High (MRI)	64	Postmenopausal women aged 49-69 years at risk of developing dementia Mean age (SD): 58 (5) years Race: NR Mean education (SD): 16 (2) years Baseline cog: NR	Continued estrogen-based hormone therapy (17 beta-estradiol or conjugated equine estrogen) for 2 years after an average of 10 years of use	Discontinuation of estrogen therapy for 2 years after an average of 10 years of use	2 years	<u>Biomarker</u> [PET scan to assess changes on regional cerebral metabolism] <u>Executive/Attention/Processing Speed</u> [Attention/Working Memory/Processing Speed Composite] [Executive Function Composite] <u>Memory</u> [Verbal Memory Composite] [Visual Memory Composite] [Subjective Memory Composite]
	Espeland 2013 <sup>4</sup> Espeland 2010 <sup>5</sup> Coker 2009 <sup>6</sup> Resnick 2009 <sup>7</sup>	2947	Community dwelling postmenopausal women aged 65-80 years, free of probable dementia at enrollment 45% aged 65-69 37% aged 70-74	Estrogen (conjugated equine estrogen 0.625 mg) daily	Placebo daily	Varied 5.7 – 8+ years	<u>Diagnosis</u> [Incidence of Probable Dementia] [Incidence of MCI] <u>Biomarker</u> [MRI: Total Brain Volume] [MRI: Ventricle Volume] [MRI: Hippocampal Volume] [MRI: Frontal Lobe Volume] [MRI: White and Gray Matter (outside of basal ganglia)] [MRI:



Resnick 2009 <sup>8</sup> Resnick, 2006 <sup>9, 10</sup> Shumaker 2004 <sup>11</sup> Rapp 2003 <sup>12</sup> (Women's Health Initiative sub-studies) Medium		18% aged 75+ 100% female 85% White Education 31% ≤ high school 42% > some college 27% ≥ college Mean 3MSE (SD): 94.6 (4.8)				Basal Ganglia] [MRI: Total Brain Lesion Volume] <u>Brief Cognitive Test Performance</u> [3MS] [TICS] <u>Executive/Attention/Processing Speed</u> [DS Forward] [DS Backward] [TMT A] [TMT B] <u>Memory</u> [BVRT] [CVLT] [EBMT] <u>Language</u> [Primary Mental Abilities-Verbal] [Verbal Fluency] <u>Visuospatial</u> [Card Rotations Test] <u>Motor</u> [Finger Tapping, Dominant Hand] [Finger Tapping, Non-Dominant Hand]
Gorenstein 2011 <sup>13</sup> RCT Brazil Medium	65	Healthy, postmenopausal women aged 40-59 years Mean age: 26.5 100% female Race not reported Mean education (SD): 9.1 (4) years Baseline cog: NR	Estrogen (conjugated equine estrogens 0.625 mg/day) for 6 months	Placebo for 6 months	6 months	<u>Executive/Attention/Processing Speed</u> [DS Forward] [DS Backward] [DSST] [3-min Reasoning Test, Correct] [3-min Reasoning Test, Time] <u>Memory</u> [PALS, Easy] [PALS, Difficult] [Immediate Verbal Recall] [Delayed Verbal Recall] [Free Recall of Words]
Pefanco 2007 <sup>14</sup> RCT USA Medium	57	Healthy postmenopausal women aged 65 and older Mean age (SD): 75(5) years 100% female Race: NR 77% college graduate Baseline cognition: NR	Micronized 17-beta estradiol 0.25 mg/day for 3 years	Placebo for 3 years	3 years	<u>Executive/Attention/Processing Speed</u> [COWAT] [Animal Naming] [TMT A] [TMT B] [Wisconsin Test] [Total Perservative Error] [Digital Written Score] <u>Memory</u> [Immediate Recall] [Delayed Recall] [Fuld Object Memory Evaluation] [Total Recall Trial 5] [Total Recall, 5-Minute Delay] [Total Recognized 5-Delay] [Wechsler Logical Memory 1] [Verbal Paired Association 1] [Visual Representation 1] [Logical Memory 2] [Verbal Paired Association 2] [Visual Representation] [Recognition Total Score 1] [Recognition Total Score 2] [Recognition Total Score 3] <u>Language</u> [BNT] <u>Visuospatial</u> [RCFT]
Yaffe 2006 <sup>15</sup> RCT USA	417	Postmenopausal women aged 60 to 80 years Mean age (SD): 66.8 (5)	Weekly transdermal patch that	Placebo patch for 2 years	2 years	<u>Brief Cognitive Test Performance</u> [3MS] <u>Executive/Attention/Processing Speed</u>

	Low		years 100% female 93% White 73% ≥ high school Baseline cognition (3MS):Mean (SD): 96.8 (3.4)	delivers 0.014 mg estradiol/day for 2 years			[TMT B] <u>Memory</u> [Logical Memory, Immediate] [Logical Memory, Delayed] [Brief Visuospatial Memory Test, Immediate] [Brief Visuospatial Memory Test, Delayed] [Word List, Memory] [Word List, Recall] <u>Language</u> [BNT] [Verbal Fluency]
<b>HRT- estrogen + progestin</b>	Kantarci 2016 <sup>16</sup> Gleason 2015 <sup>17</sup> RCT USA Medium (cognitive tests) High (MRI)	505	Healthy postmenopausal women aged 52 to 65 years Mean age (SD): 52.5 (2.6) years 100% female 77% White 73% college graduate Baseline cognition (3MS):Mean (SD): 96.6 (4.3)	Low dose oral conjugated equine estrogen 0.45 mg daily plus cyclical micronized progesterone 200 mg capsule or transdermal estradiol (200 mg daily) plus cyclical micronized progesterone	Placebo	4 years	<u>Biomarker</u> [MRI] <u>Brief Cognitive Test Performance</u> [3MS] <u>Executive/Attention/Processing Speed</u> [Visual Attention & Executive Function Composite] <u>Memory</u> [Verbal Learning & Memory Composite] [Auditory Attention & Working Memory Composite] <u>Language</u> [Speeded Language & Mental Flexibility]
	Espeland 2013 <sup>4</sup> Espeland 2010 <sup>5</sup> Coker 2009 <sup>6</sup> Resnick 2009 <sup>8</sup> Resnick 2006 <sup>9</sup> Espeland 2004 <sup>10</sup> Shumaker 2004 <sup>11</sup> Shumaker 2003 <sup>18</sup> Rapp 2003 <sup>12</sup> RCT (Women's Health Initiative substudies)	4532	Community dwelling postmenopausal women aged 65-80 years, free of probable dementia at enrollment 45% aged 65-69 37% aged 70-74 18% aged 75+ 100% female 85% White Education 31% ≤ high school 42% > some college 27% ≥ college Mean 3MSE (SD): 94.7 (4.5)	Estrogen (conjugated equine estrogen 0.625 mg) daily with progestin (medroxyprogest erone acetate 2.5 mg) daily	Placebo daily	Average 7 years	<u>Diagnosis</u> [Incidence of Probable Dementia] [Incidence of MCI] <u>Biomarker</u> [MRI: Total Brain Volume] [MRI: Ventricle Volume] [MRI: Hippocampal Volume] [MRI: Frontal Lobe Volume] [MRI: White and Gray Matter (outside of basal ganglia)] [MRI: Basal Ganglia] [MRI: Total Brain Lesion Volume] <u>Brief Cognitive Test Performance</u> [3MS] [TICS] <u>Executive/Attention/Processing Speed</u> [DS Forward] [DS Backward] [TMT A] [TMT B] <u>Memory</u> [BVRT] [CVLT] [EBMT] <u>Language</u> [Primary Mental Abilities- Verbal] [Verbal Fluency] <u>Visuospatial</u> [Card Rotations Test] <u>Motor</u> [Finger Tapping, Dominant Hand] [Finger Tapping, Non-Dominant Hand]

	USA Medium						
	Davison 2013 <sup>19</sup> RCT Australia Medium	23 13 (MRI)	Healthy postmenopausal women aged 49-55 years Mean age: 53 100% women Race: NR Education: NR Baseline cognition: NR	Estrogen (oral estradiol + progestin (drospirenone) for 6 months	Placebo for 6 months	6 months	<u>Executive/Attention/Processing Speed</u> [Groton Maze Learning Task] [CogState Identification] [CogState Detection Speed] [Mental Rotation] <u>Memory</u> [Groton Maze Recall] [CogState International Shopping List, Learn] [CogState International Shopping List, Recall] [CogState Continued Paired Associate Learning] <u>Visuospatial</u> [Mental Rotation]
	Alhola 2010 <sup>20</sup> RCT Finland High	32	Premenopausal (aged 45- 51 years) and postmenopausal (aged 58- 70 years) women Mean age pre-menop (SD): 48 (1.5) Mean age post-menop (SD): 63 (2.5) 100% female Race: NR Mean education (years): 15 years Mean MMSE (SD): 27 (1.5)	Estrogen + progestin daily for 6 months	Placebo daily for 6 months	6 months	<u>Executive/Attention/Processing Speed</u> [Verbal Functions, Similarities] [Digit Span] [Counting] [Digit Symbol] [CogniSpeed, SRT] [CogniSpeed, 2- CRT] [CogniSpeed, 10-CRT] [CogniSpeed, Subtraction] [CogniSpeed, Verification] [CogniSpeed, Vigilance] [Stroop Congruence] [Stroop Incongruence] [PASAT, Easy, Correct] [PASAT, Easy, Correct Consecutive] [PASAT, Difficult, Correct] [PASAT, Difficult, Correct Consecutive] [Shared Attention Dual Task Efficiency, Cancellation] [Shared Attention Dual Efficiency, Counting] [Shared Attention Dual Task Smaller Percentage, Efficiency] <u>Memory</u> [RAVLT, Trial 1] [RAVLT, Trial 2] [RAVLT, Trial 3] [RAVLT, Immediate Recall] [RAVLT, Delayed Recall] [Benton Visual Retention, Immediate Recall] [Benton Visual Retention, Delayed Recall] <u>Visuospatial</u> [Block Design] [Cancellation]
	Maki 2009 <sup>21</sup> RCT USA High	66	Midlife women aged 61-87 years with ≥ 35 weekly hot flashes Mean age (SD): 53 (4.5) years	Estrogen + progestin (0.625 mg conjugated equine estrogen + 2.5 mg	Placebo for 1 year	1 year	<u>Executive/Attention/Processing Speed</u> [DS Forward] [DS Backward] [Brief Test of Attention] [Finding As Test] <u>Memory</u> [CVLT, Total Learning] [CVLT, Short-Delay Free Recall] [CVLT, Long-

			100% female 45% White Education: NR Baseline cog: NR	medroxyprogesterone acetate) for 1 year			Delay Free Recall] [Logical Memory Subtest-WMS – Immediate Total Score] [Logical Memory Subtest-WMS – Delayed Total Score] [BVRT] <u>Language</u> [Letter Fluency Test] <u>Visuospatial</u> [Modified Card Rotations Test]
	Tierney 2009 <sup>22</sup> RCT Canada Medium	142	Older postmenopausal women with normal to mildly impaired memory functioning ( <b>28% had MCI at baseline</b> ) Mean age (SD): 75 (6) years 100% female 90% White Education mean (SD): 13 (3) years Mean MMSE (SD): 28 (1.5)	Estrogen + progestin (1 mg 17-B estradiol daily and 0.35 mg norethindrone 3 days/week) for 2 years	Placebo daily for 2 years	2 years	<u>Memory</u> [CVLT, Short Delay Recall]
	Grady 2002 <sup>23</sup> USA RCT Medium	1063	Postmenopausal women with coronary disease Mean age (SD): 66.8 (6.3) years 100% female 91% White Mean education (SD): 12.7 (2.7) years Baseline cognition: NR	Conjugated estrogen (0.625 mg) plus medroxyprogesterone acetate (2.5 mg) daily for a mean of 4.2 (± 0.4) years	Identical placebo daily for a mean of 4.2 (± 0.4) years	Mean 4.2 (± 0.4 years)	<u>Brief Cognitive Test Performance</u> [MMSE] <u>Executive/Attention/Processing Speed</u> [TMT B] <u>Memory</u> [Word List Memory] [Word List Recall] <u>Language</u> [Verbal Fluency] [BNT]
	Binder <sup>24</sup> USA RCT High	67	Postmenopausal women aged 75 to 91 years Mean age (SD): 81 (4) years 100% female 86% White 30% college graduate Baseline cognition: NR	Conjugated estrogen (0.625 mg/day) plus trimonthly medroxyprogesterone acetate (5 mg/day) for 9 months	Placebo for 9 months	9 months	<u>Executive/Attention/Processing Speed</u> [TMT A] [TMT B] <u>Memory</u> [Wechsler Associate Learning and 20 Min Delayed Recall] <u>Language</u> [Word Fluency, Animal] <u>Visuospatial</u> [Cancellation Random Letter and Random Figure Tests]
<b>HRT-DHEA</b>	Kritz-Silverstein 2008 <sup>25</sup> USA RCT Medium	225	Healthy men & women aged 55 to 85 years Mean age (SD): 68 (8) years 53% female Race: NR	Oral DHEA supplementation 50 mg/day for 1 year	Placebo daily for 1 year	1 year	<u>Brief Cognitive Test Performance</u> [MMSE] <u>Executive/Attention/Processing Speed</u> [TMT B] <u>Memory</u> [Word List] [Word List Recall] <u>Language</u> [Verbal Fluency] [BNT]

			Mean education (SD): 16 (2.4) years Median 3MS (IQR): 96 (5)				
<b>HRT-Testosterone</b>	Vaughn 2007 <sup>26</sup> RCT USA High	69	Men aged 65 to 83 years without evidence of cognitive impairment and baseline testosterone levels below 350 ng/dL Mean age: NR 0% female Race: NR Education: NR Baseline cognition: mean NR but participants had baseline MMSE scores $\geq$ 28	Testosterone enanthate 200 mg intramuscularly every 2 weeks or testosterone enanthate 200 mg intramuscularly every 2 weeks plus finasteride 5 mg/day orally	Placebo (sesame oil injections) plus placebo pill daily	3 years	<u>Executive/Attention/Processing Speed</u> [DS Forward] [DS Backward][TMT A] [TMT B] <u>Memory</u> [BBVRT # Correct] [BVRT # Errors] [Selective Reminding Test, Total Recall] [Selective Reminding Test, Long-Term Storage] [Selective Reminding Test, Consistent Long-Term Retrieval] [Selective Reminding Test, Delayed Recall] [Selective Reminding Test, # of Intrusions] <u>Visuospatial</u> [Judgment of Line Orientation]
	Kenny 2002 <sup>27</sup> RCT USA High	67	Men aged 65-87 years with low biotestosterone levels Mean age (SD): 75.5 (4.5) years 0% female Race: NR 65% $\geq$ college Baseline cognition: NR	Testosterone (transdermal testosterone patch 2-2.5 mg daily)	Placebo patch	1 year	<u>Executive/Attention/Processing Speed</u> [Digit Span] [DSST] [TMT A] [TMT B]
<b>Selective estrogen receptor modulator (SERM)</b>	Yaffe 2005 <sup>28</sup> Yaffe 2001 <sup>29</sup> RCT USA Medium	7478	Postmenopausal women with osteoporosis Mean age (SD): 68 (7) years 100% female 95% white Mean education (SD): 12 (4) years Baseline cognition: NR	Raloxifene 60 mg or 120 mg daily for 3 years	Oral placebo daily	3 years	<u>Diagnosis</u> [MCI] [Alzheimer's Disease] [Any Type of Dementia] [Dementia or MCI] <u>Executive/Attention/Processing Speed</u> [Short Blessed] [TMT A] [TMT B] <u>Memory</u> [Word List Memory] [Word List Recall] Language [Word List Fluency]
	Nickelsen 1998 <sup>30</sup> RCT USA Medium	143	Postmenopausal women aged 45-75 years with osteoporosis Mean age: 68 years 100% female Race: NR Education: NR Baseline cognition: NR	Raloxifene 60 mg or 120 mg daily for 1 year	Placebo for 1 year	1 year	<u>Executive/Attention/Processing Speed</u> [Walter Reed Performance Assessment Battery (PAB) 2-Letter Search] [Walter Reed PAB: 6-Letter Search] [Walter Reed PAB: 4-Choice Serial Reaction Time] <u>Memory</u> [MAC Battery: Name-Face Association, Total Acquisition] [MAC Battery: Name-Face Association,

							Delayed Recall] [MAC Battery: First-Last Name Association, Delayed Recall] [MAC Battery: First-Last Name Association, Total Acquisition] [MAC Battery: Facial Recognition, Number Before 1 <sup>st</sup> Error] [Telephone Number Recall, Before Interference] [Telephone Number Recall, After Interference]
<b>Soy</b>	Henderson 2012 <sup>31</sup> RCT USA Low	350	Healthy postmenopausal women aged 45-92 years Mean age (SD): 61 (7) years 100% female 63% White 60% college graduate Baseline cognition: NR	Soy (isoflavone rich soy protein 25 g) daily for 2.5 years	Milk protein-matched placebo for 2.5 years	2.5 years	<u>Multidomain Neuropsychological Test Performance</u> [Cognitive Composite] <u>Executive/Attention/Processing Speed</u> [Executive/Expressive/Visuospatial Factor Composite] [SDMT] [TMT B] [Shipley Abstraction] [Letter-Number Sequencing] <u>Memory</u> [Verbal Episodic Memory Composite] [CVLT, Immediate Recall] [CVLT, Delayed Recall] [Visual Episodic Memory Composite] [EBMT, Immediate Recall] [EBMT, Delayed Recall] [Visual Episodic Memory Composite] <u>Language</u> [Category Fluency] [BNT] <u>Visuospatial</u> [Block Design] [Judgment of Line Orientation]
	Gleason 2009 <sup>32</sup> RCT USA Medium	30	Older women aged 62-89 years without dementia Mean age (SD): 74 (7) years 100% female Race: NR Mean education (SD): 16.5 (3) years Mean MMSE (SD): 29 (1)	Soy isoflavonea 100 mg/d for 6 months	Matching placebo tablets for 6 months	6 months	<u>Executive/Attention/Processing Speed</u> [Stroop Color Word Test] [TMT B] [Mazes] [Language Fluency, Letter] <u>Memory</u> [Buschke Selective Reminding Test] [Buschke Selective Reminding Test, Total of Learning Trials – Words] [Buschke Selective Reminding Test, Learning Slope, Trial 5 vs. Trial 1] [Delayed Recall, Words] [Paragraph Recall Test, Total Immediate Recall] [Paragraph Recall Test, Total Delayed Recall] [Rey Complex Figure Test, Immediate Recall] [Rey Complex Figure Test, Delayed Recall] [Visual Spatial Learning Test, Total Correction Positions + Designs] [Visual Spatial Learning Test, Learning Slope Position + Design, Trial 5 Vs. Trial 1] [Visual

							Spatial Learning Test, Learning Slope Incorrect Designs] <u>Language</u> [Bnt] [Language Fluency, Letter & Category] <u>Visuospatial</u> [RCFT] [Grooved Pegboard
	Ho 2007 <sup>33</sup> RCT China Medium	191	Generally healthy women aged 55-76 years Mean age (SD): 65 (6) years 100% female Race: NR 30% secondary education 17% postsecondary education Mean MMSE (SD): 28 (1.9)	Soy (soy-derived isoflavones 80 mg) daily for 6 months	Identical appearing placebo daily for 6 months	6 months	<u>Brief Cognitive Test Performance</u> [MMSE] <u>Multidomain Neuropsychological Test</u> <u>Performance</u> [Composite Cognitive Score, including all cognitive test scores] <u>Executive/Attention/Processing Speed</u> [Color Trail I] [Color Trail II] [DSST] <u>Memory</u> [Hong Kong List Learning Test (HKLLT), Trials 1-5] [HKLLT, Short Delay Recall] [HKLLT, Long Delay Recall] [VR I] [VR II] [VR, Copy] <u>Language</u> [BNT] [Verbal Fluency, Categories] <u>Motor</u> [Finger Tapping, Right] [Finger Tapping, Left]
	Casini 2006 <sup>34</sup> RCT crossover Italy High	78	Postmenopausal women Mean age (SD): 50 (4.1) years 100% female Race: NR Education: NR Baseline cog: NR	Soy (soy-derived isoflavones 60 mg) daily for 6 months	Identical appearing placebo daily for 6 months	6 months	<u>Executive/Attention/Processing Speed</u> [Digit Symbol Text, Pairs Recalled Correctly] [Digit Symbol Text, Time (sec)] [Digit Symbol Text, Raw Scores] [DS Backward] [DS Forward] [Visual Scanning Test, Time] [Visual Scanning Test, Total Correct] [Visual Scanning Test, Errors]
	Kreijkamp- Kaspers 2004 <sup>35</sup> RCT Netherlands Medium	202	Healthy postmenopausal women aged 60 to 75 years Mean age (SD): 66.5 (4.7) years 100% female Race: NR Baseline MMSE (SD): 27.6 (1.6)	Soy (soy-derived isoflavones 99 mg) daily for 12 months	Total milk protein for 12 months	1 year	<u>Brief Cognitive Test Performance</u> [MMSE] <u>Executive/Attention/Processing Speed</u> [DS Forward] [DS Backward] [TMT A] [TMT B] [DSST] [Verbal Fluency, Letter N] [Verbal Fluency, Letter A] <u>Memory</u> [RAVLT, Immediate Recall] [RAVLT, Delayed Recall] [RAVLT,Recog] [Doors Test] <u>Language</u> [Verbal Fluency, Letter N] [Verbal Fluency, Letter A] [Verbal Fluency, Animals] [Verbal Fluency,

							Occupations] [BNT]
	Kritz-Silverstein 2003 <sup>36</sup> RCT USA Low	56	Postmenopausal women aged 55 to 74 years, not using estrogen therapy Mean age (SD): 60 (5) years 100% female 86% White Mean education (SD): 15 (2.5) years Mean MMSE (SD): 29 (1.2)	Soy (soy-extracted isoflavones (110 mg) daily for 6 months	Identical appearing placebo daily for 6 months	6 months	<u>Executive/Attention/Processing Speed</u> [TMT A] [TMT B] <u>Memory</u> [Logical Memory I, Immediate] [Logical Memory II, Delayed] <u>Language</u> [Category Fluency]
<b>Red clover</b>	Maki 2009 <sup>21</sup> RCT USA High	66	Midlife women aged 61-87 years with ≥ 35 weekly hot flashes Mean age (SD): 53 (4.5) years 100% female 45% White Education: NR Baseline cog: NR	Red clover (an ethanolic extract of the aerial parts of red clover, 398 mg/day standardized to 120 mg isoflavone aglycones) or an ethanolic extract of black cohosh below ground parts (128 mg day)	Placebo for 1 year	1 year	<u>Executive/Attention/Processing Speed</u> [DS Forward] [DS Backward] [Brief Test of Attention] [Finding A's Test] <u>Memory</u> [CVLT, Total Learning] [CVLT, Short-Delay Free Recall] [CVLT, Long-Delay Free Recall] [Logical Memory Subtest-WMS – Immediate Total Score] [Logical Memory Subtest-WMS – Delayed Total Score] [BVRT] <u>Language</u> [Letter Fluency Test] <u>Visuospatial</u> [Modified Card Rotations Test]
	Howes 2004 <sup>37</sup> RCT crossover USA Medium	30	Postmenopausal women aged 60 + with memory complaints Mean age: NR 100% female Race: NR Baseline cognition: NR, but MMSE score of 27+ was required	An extract of aglycone isoflavones from red clover	Placebo	6 months	<u>Executive/Attention/Processing Speed</u> [Arithmetic Test] [TMT A] Block Design Test] [DSST] <u>Memory</u> [Digit Recall Test] [Memory 1 Test] [Memory 2 Test] [Verbal Memory 1 Test] [Verbal Memory 2 Test] [Visual Memory 1 Test] [Visual Memory 2 Test] <u>Language</u> [BNT] [FAS Test] [Animals Naming Test] [Similarities Test]

3MS=Modified Mini Mental Status Examination; AD=Alzheimer's disease; ADAS=Cog-Alzheimer's Disease Assessment Scale-Cognitive; AVLT=Auditory Verbal Learning Test; BNT=Boston Naming Test; BVMT=Brief Visuospatial Memory Test; BVRT=Benton Visual Retention Test; CDR=Clinical Dementia Rating; CLOX-1=Clock Drawing Test; cog=cognition; COWAT=Controlled Oral Word Association Test; CVLT=California Verbal Learning Test; DS=Digit Span (Forward and/or Backward); DSST=Digit Symbol Substitution Test; DVT=Digit Vigilance Test; EBMT=East Boston Memory Test; FCSRT=Free and Cued Selective Reminding Test; F-TICS=French Version, Telephone Interview Cognitive Status; HVLT=Hopkins Verbal Learning Test; MCI=mild cognitive impairment; MMSE=Mini-Mental Status Examination; MRI=magnetic resonance imaging; N=sample size; NR=not reported; PALS=Paired Association Learning Test; PRM=Pattern Recognition Memory; RAVLT=Rey's Auditory Verbal Learning Test;



RBMT= Rivermead Behavioral Memory Test; RCFT=Rey-Osterrieth Complex Figure Test; RCPM=Raven's Colored Progressive Matrices; RCT=Randomized Controlled Trial; RoB=Risk of Bias; SCWT=Stroop Color Word Test; SD=Standard Deviation; SDMT=Symbol Digit Modalities Test; SOE=Strength of Evidence; SWM=Spatial Working Memory; TICS=Telephone Interview for Cognitive Status (TICS-M=Modified); TMT=Trail Making Test (Part A and/or B); VP=Verbal Proficiency; VR=Visual Reproduction; VRM=Verbal Recognition Memory; WAIS=Wechsler Adult Intelligence Scale; WMS=Wechsler Memory Scale

**Appendix Table K2. Summary risk of bias assessments: hormone interventions vs. inactive controls in adults with normal cognition**

Intervention Type	Study	Overall Risk of Bias Assessment	Rationale
HRT-estrogen efficacy	Henderson 2016 <sup>1</sup>	Medium/High	Medium attrition (10%) at 2.5 years; high attrition (30%) at 5 years without correction for possible bias; unclear whether outcome assessor was independent
	Wroolie 2015 <sup>2</sup> Rasgon 2014 <sup>3</sup>	Medium	Medium (16%) attrition for cognitive outcomes; high (30%) attrition for MRI without correction to account for possible bias; participants not blinded to treatment
	Espeland 2013 <sup>4</sup> Espeland 2010 <sup>5</sup> Coker 2009 <sup>6</sup> Resnick 2009 <sup>7</sup> Resnick 2009 <sup>8</sup> Resnick, 2006 <sup>9, 10</sup> Shumaker 2004 <sup>11</sup> Rapp 2003 <sup>12</sup> (Women's Health Initiative sub-studies) Medium	Medium	Medium attrition (rate varies by specific outcome); possible detection bias for some outcomes
	Gorenstein 2011 <sup>13</sup>	Medium	Medium attrition (19%) without correction to account for possible bias; unclear whether outcome assessor was independent
	Pefanco 2007 <sup>14</sup>	Medium	Medium (21%) attrition with some analysis to account for possible bias; unclear whether outcome assessor was independent
	Yaffe 2006 <sup>15</sup>	Low	
	HRT-estrogen + progestin efficacy	Kantarci 2016 <sup>16</sup> Gleason 2015 <sup>17</sup>	Medium (cognitive outcomes) High (MRI)
Espeland 2013 <sup>4</sup> Espeland 2010 <sup>5</sup> Coker 2009 <sup>6</sup> Resnick 2009 <sup>8</sup> Resnick 2006 <sup>9</sup> Espeland 2004 <sup>10</sup> Shumaker 2004 <sup>11</sup> Shumaker 2003 <sup>18</sup> Rapp 2003 <sup>12</sup> RCT (Women's Health Initiative substudies) USA Medium		Medium	Medium attrition (rate varies by specific outcome); possible detection bias for some outcomes

	Davison 2013 <sup>19</sup>	Medium	Attrition (17%) without analysis to account for possible bias; unclear whether outcome assessor independent
	Alhola 2010 <sup>20</sup>	High	Attrition (>25%) from original randomization without analysis to account for possible bias
	Maki 2009 <sup>21</sup>	High	High attrition (>25%) without appropriate analysis
	Tierney 2009 <sup>22</sup>	Low/Medium	Unclear whether outcome assessor independent
	Grady 2002 <sup>23</sup>	Medium	Medium attrition (20%) without appropriate analysis; unclear whether outcome assessor independent
	Binder 2001 <sup>24</sup>	High	High attrition (22%) without appropriate analysis; unclear whether outcome assessor independent
<b>DHEA efficacy</b>	Kritz-Silverstein 2008 <sup>25</sup>	Medium	Randomization not well described; medium attrition (15%) without appropriate analysis; unclear whether outcome assessor independent
<b>HRT-testosterone efficacy</b>	Vaughn 2007 <sup>26</sup>	High	High attrition (33%) without appropriate analysis; unclear whether outcome assessor independent
	Kenny 2002 <sup>27</sup>	High	Randomization not well described; high attrition (34%) without appropriate analysis; unclear whether outcome assessor independent
<b>SERM efficacy</b>	Yaffe, 2005 <sup>28</sup> Yaffe, 2001 <sup>29</sup>	Medium	Medium attrition without appropriate analysis; unclear whether outcome assessor independent
	Nickelsen 1998 <sup>27</sup>	Medium	Randomization not well described; unclear whether outcome assessor blinded and independent
<b>Soy efficacy</b>	Henderson 2012 <sup>31</sup>	Low	
	Gleason 2009 <sup>32</sup>	Medium	Randomization not well described; medium (12%) attrition without appropriate analysis; unclear whether outcome assessor blinded
	Ho 2007 <sup>33</sup>	Medium	Medium attrition (12%) without appropriate analysis; unclear whether outcome assessor independent
	Casini 2006 <sup>34</sup>	High	Unclear whether baseline cognitive tests were performed (no baseline data presented); unclear whether outcome assessor independent
	Kreijkamp-Kaspers 2004 <sup>35</sup>	Medium	Medium attrition (24%) with some analysis; unclear whether outcome assessor independent
	Kritz-Silverstein 2003 <sup>36</sup>	Low	
<b>Red clover efficacy</b>	Maki 2009 <sup>21</sup>	High	High attrition (>25%) without appropriate analysis
	Howes, 2004 <sup>37</sup>	Medium	Unclear whether outcome assessor blinded and independent; participants may have been unblinded to treatment during crossover

DHEA=dehydroepiandrosterone; RCT=randomized controlled trial;

**Appendix Table K3. Characteristics of eligible studies: hormone interventions vs. active controls in adults with normal cognition**

<b>Hormone Intervention Type</b>	<b>Study Design Country RoB</b>	<b>N=</b>	<b>Population Inclusion Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition</b>	<b>Intervention Mode Components Frequency Duration</b>	<b>Comparison Mode Components Frequency Duration</b>	<b>Outcome timing</b>	<b>Outcome Domain [Instrument]</b>
<b>HRT-estrogen + progestin vs. tibolone</b>	Pan 2003 <sup>38</sup> RCT Taiwan Medium	50	Healthy postmenopausal women Mean age (SD): 52 (4) years 100% female Race: NR Mean MMSE (SD): 26.6 (2.3)	Estrogen + progestin (conjugated equine estrogen 0.625 mg/day + methyleprogesterone acetate 5 mg/day) for 6 months	Tibolone 2.5 mg/day for 6 months	6 months	<u>Brief Cognitive Test Performance</u> [MMSE] [Cognitive Abilities Screening Instrument]
<b>HRT-estrogen + testosterone vs. estrogen</b>	Moller 2013 <sup>39</sup> Moller 2010 <sup>40</sup> RCT crossover Sweden Medium	50	Women aged 45-60 years with surgically-induced menopause Mean age (SD): 54 (2.9) years 100% female Race: NR Baseline global cognition: NR	Estrogen + testosterone (estradiol valerate 2 mg/day + testosterone undecanoate 40 mg/day) for 6 months	Estrogen (estradiol valerate 2 mg/day) plus placebo	6 months	<u>Executive/Attention/Processing Speed</u> [DSST, used To assess “cognitive fatigue,” = difference between the # of digits produced during the first 30 seconds and last 30 seconds of a 90 second session] [Digit Symbol, Free Recall of Words] [Digit Symbol, Paired Recall of Symbols] [Digit Symbol, % Spatial Errors] <u>Memory</u> [Logical Story, Immediate Recall] [Logical Story, Delayed Recall]
<b>SERM Tamoxifen vs. Raloxifene</b>	Legault 2009 <sup>41</sup> RCT US High	1498	Healthy postmenopausal women aged 65+ with increased risk of breast cancer, without dementia Mean age (SD):	Tamoxifen 20 mg/d daily for up to 5 years	Raloxifene 60 mg daily for up to 5 years	Up to 5 years	<u>Brief Cognitive Test Performance</u> [3MS] <u>Executive/Attention/Processing Speed</u> [DS Forward] [DS Backward] <u>Memory</u> [BVRT] [CVLT] <u>Language</u> [Primary Mental Abilities-Verbal] [Verbal Fluency, Letter] [Verbal Fluency, Semantic] <u>Visuospatial</u> [Card Rotations]

			70 (4.2) years 100% female 94% White 34% some college 34% college graduate 67% 3MSE ≤ 95 23% 3MSE 90-94 10% 3MSE < 90				<u>Motor</u> [Finger Tapping]
<b>SERM/HRT - Tamoxifen or Raloxifene vs. CEE</b>	Espeland 2010 <sup>42</sup> RCT USA High	6461 (WHI & Co-STAR trial participants)	Women aged 65-80 years who participated in the WHI or CoSTAR trials Age, years (approx.) 65-59: 51% 70-74: 34% 75+: 15% 100% female % white: 90% Education: 7% < high school 25% high school graduate 38% some college 30% college grad Baseline 3MS (SD): 95 (4.25)	Congugated equine estrogen 0.625 with or without medroxyprogesterone for at least 3 years	Tamoxifen (20 mg/d) or raloxifene (60 mg/d) for at least 3 years  (There were also Placebo arms in both trials included in the analysis)	Mean follow-up: 4.6 years (range 1-8) years	<u>Brief Cognitive Test Performance</u> [3MS]

3MS=Modified Mini Mental Status Examination; AD=Alzheimer's disease; DHEA=dehydroepiandrosterone; BVRT=Benton Visual Retention Test; Co-STAR=The Study of Tamoxifen and Raloxifene Cognitive Substudy; DS=Digit Span (Forward and/or Backward); CVLT=California Verbal Learning Test; DSST=Digit Symbol Substitution Test; HRT=hormone replacement therapy; mg/d=milligrams per day; N=sample size; NR=not reported; RCT=randomized controlled trial; RoB=risk of bias; SD=standard deviation; SERM=selective estrogen receptor modulator; vs.=versus; WHI=Women's Health Initiative

**Appendix Table K4. Summary risk of bias assessments: hormone interventions vs. active controls in adults with normal cognition**

Intervention Type	Study	Overall Risk of Bias Assessment	Rationale
<b>HRT-estrogen vs. estrogen + progestin</b>	Pan 2003 <sup>38</sup>	Medium	Medium attrition (20%) without appropriate analysis to correct for potential bias
<b>HRT-estrogen vs. estrogen + testosterone</b>	Moller 2010 <sup>39</sup> Moller 2013 <sup>40</sup>	Medium	Medium attrition (12%) without appropriate analysis to correct for possible bias
<b>SERM Tamoxifen vs. Raloxifene</b>	Legault 2009 <sup>41</sup>	High	High attrition
<b>Raloxifene vs. CEE</b>	Espeland 2010 <sup>42</sup>	High	Considerable variation in study populations included in analysis; original studies already included in review

CEE=conjugated equine estrogen; HRT=hormone replacement therapy; SERM=selective estrogen receptor modulator; vs.=versus

**Appendix Table K5. Strength of evidence assessments: hormone therapies in adults with normal cognition**

Hormone Intervention type	Outcome	# Trials (n)	Evidence Summary Summary statistics [95% CI]	Study Limitations	Directness	Precision	Consistency	Reporting Bias	Optional Components	SOE
HRT-estrogen	Dementia	1 (2947)	1 of 2 tests show statistically significant differences between groups (favoring placebo) (p=0.04) <u>Shumaker 2004<sup>11</sup></u> (WHI) Probable Dementia: Not significant HR: 1.49 [0.83, 2.66] Probable Dementia or Mild Cognitive Impairment: C>I HR: 1.38 [1.01, 1.89]	Medium	Direct	Precise	Unknown	Undetected	NA	Low
	MCI	1 (2947)	<u>Shumaker 2004<sup>11</sup></u> MCI: Not significant HR: 1.34 [0.95, 1.89]	Medium	Direct	Precise	Unknown	Undetected	NA	Low
	Brief Cognitive Test	2 (3364)	1 of 3 tests favors C <u>Espelund 2004<sup>10</sup></u> (WHI) Mean difference in change from baseline 3MSE scores, estrogen group minus placebo (p=0.04): Mean [95% CI]: -0.26 [-0.52, 0] <u>Yaffe 2006<sup>15</sup></u> Mean difference in change from baseline 3MS scores, estrogen group minus placebo, baseline 3MS ≤ 90 (p=0.53): Mean [95% CI]: -1.21 [-5.05, 2.64]	Medium	Indirect	Precise	Consistent	Undetected	NA	Low

			Mean difference in change from baseline 3MS scores, estrogen group minus placebo, baseline 3MS > 90 (p=0.18): Mean [95% CI]: -0.30 [-0.74, 0.14]							
	Multidomain Composite	1 (567)	0 of 1 (no differences)	Medium	Indirect	Imprecise	Unknown	Undetected	NA	Insufficient
	Executive/Attention/Processing Speed	6 (2056)	2 of 19 favor I	Medium	Indirect	Imprecise	Consistent	Undetected	NA	Low
	Memory	6 (2056)	2 of 35 favor I	Medium	Indirect	Imprecise	Consistent	Undetected	NA	Low
<b>HRT-estrogen + progestin</b>	Dementia	1 (4532)	1 of 2 tests show statistically significant differences between groups <u>Shumaker 2003<sup>18</sup></u> (WHI) Probable Dementia: C>I HR: 2.05 [1.21, 3.48] Probable Dementia or MCI: NS HR: 1.37 [0.99, 1.89]	Medium	Direct	Precise	Unknown	Undetected	NA	Low
	MCI	1 (4532)	No statistically significant differences between groups <u>Shumaker 2003<sup>18</sup></u> (WHI) MCI: NS HR: 1.07 [0.74, 1.55]	Medium	Direct	Precise	Unknown	Undetected	NA	Low
	Brief Cognitive Test	3 (6288)	One of four tests favors placebo: <u>Gleason 2015<sup>17</sup></u> Beta estimates for estrogen versus placebo groups not statistically significant: p=0.18 (conjugated	Medium	Indirect	Precise	Consistent	Undetected	NA	Low



			<p>equine estrogen + progesterone versus placebo)  p=0.84 (transdermal estradiol + progesterone versus placebo)  <u>Rapp 2003<sup>12</sup> (WHI)</u>  Statistically significant in favor of placebo.  Mean difference between treatment groups (estrogen + progestin – placebo) in 3MS [95% CI]: -0.063 [-0.120, -0.006]; p=0.03  <u>Grady 2002<sup>23</sup></u>  Difference between groups in post-intervention 3MS scores [95% CI]: -0.4 [-1.1, 0.4]; p=0.36 [<b>NOTE: no baseline/pre-test was conducted,</b> making it impossible to determine the actual difference between groups]</p>							
	Multidomain Composite	NR								
	Executive/Attention/Processing Speed	5 (3404)	1 of 11 tests was statistically significant in favor of placebo	Medium	Indirect	Imprecise	Consistent	Undetected	NA	Low
	Memory	5 (3404)	4 of 17 tests favor C	Medium	Indirect	Imprecise	Consistent	Undetected	NA	Low
<b>DHEA</b>	Dementia	NR								
	MCI	NR								
	Brief Cognitive Test	Single trial <500 participants								

	Multidomain Composite	NR								
	Executive function/attention/processing speed	Single trial <500 participants								
	Memory	Single trial <500 participants								
<b>SERM</b>	Dementia	1 (5386)	<u>Yaffe 2005<sup>28</sup></u> Relative risk of cognitive impairment, SERM (60 & 120 mg doses) vs. placebo: no significant differences Alzheimer's disease: NS (either group) RR (60 mg): 0.82 [0.39, 1.71] RR (120 mg): 0.52 [0.22, 1.21] Any type of dementia NS (either group) RR (60 mg): 0.90 [0.47, 1.74] RR (120 mg): 0.91 [0.47, 1.76] Dementia or MCI NS (either group) RR (60 mg): 1.12 [0.84, 1.49] RR (120 mg): 0.73 [0.53, 1.01]	Medium	Direct	Precise	Unknown	Undetected	NA	Low
	MCI	1 (5386)	<u>Yaffe 2005<sup>28</sup></u> Relative risk of cognitive impairment, SERM (60 & 120 mg doses) vs. placebo MCI: Significant (p=0.04) at 120 mg dose; not significant at 60 mg I>C (lower risk in	Medium	Direct	Precise	Unknown	Undetected	NA	Low

			SERM group) RR (60 mg): 1.18 [0.85, 1.64] RR (120 mg): 0.67 [0.46, 0.98]							
	Brief Cognitive Test	NR								
	Multidomain Composite	NR								
	Executive function/attention/processing speed	2 (5877)	0 of 6 (no differences)	Medium	Indirect	Precise	Consistent	Undetected	NA	Low
	Memory	2 (5739)	0 of 9 (no differences)	Medium	Indirect	Precise	Consistent	Undetected	NA	Low
<b>Soy</b>	Dementia	NR								
	MCI	NR								
	Brief Cognitive Test	2 (393)	0 of 2 (no differences)	Medium	Indirect	Imprecise	Consistent	Undetected	NA	Insufficient
	Multidomain Composite	2 (541)	0 of 3 (no differences)	Medium	Indirect	Imprecise	Consistent	Undetected	NA	Insufficient
	Executive/Attention/Processing Speed	5 (829)	2 of 14 tests favor C	Medium	Indirect	Imprecise	Consistent	Undetected	NA	Low
	Memory	5 (829)	5 of 31 tests favor I 1 of 31 tests favors C	Medium	Indirect	Imprecise	Consistent	Undetected	NA	Low
<b>Red clover</b>	Dementia	NR								
	MCI	NR								
	Brief Cognitive Test	NR								
	Multidomain Composite	NR								

	Executive/ Attention/ Processing Speed	Single trial <500 participants								
	Memory	Single trial <500 participants								

C=control; CI=confidence interval; I=intervention; HR=hazard ratio; MCI=mild cognitive impairment; mg=milligrams; n=sample size; NA=not applicable; NR=not reported; NS=not significant; RR=relative risk; RoB=risk of bias; SD=standard deviation; SERM=selective estrogen receptor modulator; vs.=versus; WHI=Women's Health Initiative

**Appendix Table K6. Characteristics of eligible studies: hormone interventions vs. inactive controls in adults with MCI**

<b>Hormone Intervention Type</b>	<b>Study Design Country RoB</b>	<b>N=</b>	<b>Population Inclusion Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition</b>	<b>Intervention Mode Components Frequency Duration</b>	<b>Comparison Mode Components Frequency Duration</b>	<b>Outcome timing</b>	<b>Outcome Domain [Instrument]</b>
<b>HRT-testosterone</b>	Cherrier 2010 <sup>43</sup> RCT US Medium	22	Men aged 60-90 years with both MCI and low serum testosterone levels Mean age (SD): 70.5 (8) years 0% female Race NR Education NR Mean 3MS (SD) 92.5 (6.7)	Testosterone gel 50-100 mg/d with a target total T level of 500 to 900 ng/dL	Placebo gel daily for 6 months	6 months	<u>Executive/Attention/Processing Speed</u> [Letter-Number Sequencing, Total Score] [Letter-Number Sequencing, Span] [Computerized Simple RT, 2-Second Interval] [Computerized Simple RT, 5-Second Interval] [Computerized Choice RT, 2-Second Interval] [Computerized Choice RT, 5-Second] [Mental Rotation] <u>Memory</u> [RAVLT, Immediate] [RAVLT, Short Delay] [RAVLT, Long Delay] [Story Recall, Immediate] [Story Recall, Delay] [Visual Spatial Learning Test, Immediate & Delayed] <u>Language</u> [Verbal Fluency] <u>Visuospatial</u> [Route Test, Immediate] [Route Test, Delay] [Complex Design Construction]
<b>Soy</b>	Kato-Kataoka 2010 <sup>44</sup> RCT Japan Medium	78	People aged 50-69 years with MCI Mean age (SD): 60 (1) years 48% female Japanese Mean education (SD): 14 (0.4) years Mean MMSE (SD) 27.8 (0.4)	Soybean derived phosphatidylserine (Soy-PS) 100 mg or 300 mg daily for 6 months	Placebo for 6 months	6 months	<u>Brief Cognitive Test Performance</u> [MMSE] [Hasegawa Dementia Scale] <u>Memory</u> [RBMT]

3MS=Modified Mini Mental Status Examination; MCI=mild cognitive impairment; mg=milligrams; mg/d=milligrams per day; MMSE=Mini-Mental Status Examination; N=sample size; NR=not reported; RAVLT=Rey's Auditory Verbal Learning Test; RBMT= Rivermead Behavioral Memory Test; RCT=randomized controlled trial; RoB=risk of bias; RT=reaction time; SD=standard deviation; vs.=versus

**Appendix Table K7. Summary risk of bias assessments: hormone interventions vs. inactive controls in adults with MCI**

Intervention Type	Study	Overall Risk of Bias Assessment	Rationale
<b>HRT-testosterone</b>	Cherrier 2015 <sup>43</sup>	Medium	Medium attrition (14%) without appropriate analysis; unclear whether outcome assessor independent
<b>Soy</b>	Kato-Kataoka 2010 <sup>44</sup>	Medium	Unclear whether outcome assessor blinded and independent; possible concurrent intervention

MCI=mild cognitive impairment

## References for Appendix K

1. Henderson VW, St John JA, Hodis HN, et al. Cognitive effects of estradiol after menopause: A randomized trial of the timing hypothesis. *Neurology*. 2016 Aug 16;87(7):699-708. doi: 10.1212/wnl.0000000000002980. PMID: 27421538.
2. Woolie TE, Kenna HA, Williams KE, et al. Cognitive Effects of Hormone Therapy Continuation or Discontinuation in a Sample of Women at Risk for Alzheimer Disease. *American Journal of Geriatric Psychiatry*. 2015 01 Nov;23(11):1117-26. doi: <http://dx.doi.org/10.1016/j.jagp.2015.05.009>. PMID: 609354671.
3. Rasgon NL, Geist CL, Kenna HA, et al. Prospective randomized trial to assess effects of continuing hormone therapy on cerebral function in postmenopausal women at risk for dementia. *PLoS One*. 2014;9(3):e89095. doi: 10.1371/journal.pone.0089095. PMID: 24622517.
4. Espeland MA, Shumaker SA, Leng I, et al. Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years. *JAMA Intern Med*. 2013 Aug 12;173(15):1429-36. doi: 10.1001/jamainternmed.2013.7727. PMID: 23797469.
5. Espeland MA, Brunner RL, Hogan PE, et al. Long-term effects of conjugated equine estrogen therapies on domain-specific cognitive function: results from the Women's Health Initiative study of cognitive aging extension. *J Am Geriatr Soc*. 2010 Jul;58(7):1263-71. doi: 10.1111/j.1532-5415.2010.02953.x. PMID: 20649689.
6. Coker LH, Hogan PE, Bryan NR, et al. Postmenopausal hormone therapy and subclinical cerebrovascular disease: the WHIMS-MRI Study. *Neurology*. 2009 Jan 13;72(2):125-34. doi: 10.1212/01.wnl.0000339036.88842.9e. PMID: 19139363.
7. Resnick SM, Espeland MA, An Y, et al. Effects of conjugated equine estrogens on cognition and affect in postmenopausal women with prior hysterectomy. *J Clin Endocrinol Metab*. 2009 Nov;94(11):4152-61. doi: 10.1210/jc.2009-1340. PMID: 19850684.
8. Resnick SM, Espeland MA, Jaramillo SA, et al. Postmenopausal hormone therapy and regional brain volumes: the WHIMS-MRI Study. *Neurology*. 2009 Jan 13;72(2):135-42. doi: 10.1212/01.wnl.0000339037.76336.cf. PMID: 19139364.
9. Resnick SM, Maki PM, Rapp SR, et al. Effects of combination estrogen plus progestin hormone treatment on cognition and affect. *J Clin Endocrinol Metab*. 2006 May;91(5):1802-10. doi: 10.1210/jc.2005-2097. PMID: 16522699.
10. Espeland MA, Rapp SR, Shumaker SA, et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. *JAMA*. 2004 Jun 23;291(24):2959-68. doi: 10.1001/jama.291.24.2959. PMID: 15213207.
11. Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. *JAMA*. 2004 Jun 23;291(24):2947-58. doi: 10.1001/jama.291.24.2947. PMID: 15213206.
12. Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. *Jama*. 2003 May 28;289(20):2663-72. doi: 10.1001/jama.289.20.2663. PMID: 12771113.
13. Gorenstein C, Renno J, Jr., Vieira Filho AH, et al. Estrogen replacement therapy and cognitive functions in healthy postmenopausal women: a randomized trial. *Arch Womens Ment Health*. 2011 Oct;14(5):367-73. doi: 10.1007/s00737-011-0230-6. PMID: 21732218.
14. Pefanco MA, Kenny AM, Kaplan RF, et al. The effect of 3-year treatment with 0.25 mg/day of micronized 17beta-estradiol on cognitive function in older postmenopausal women. *J Am Geriatr Soc*. 2007 Mar;55(3):426-31. doi: 10.1111/j.1532-5415.2007.01085.x. PMID: 17341247.
15. Yaffe K, Vittinghoff E, Ensrud KE, et al. Effects of ultra-low-dose transdermal estradiol on cognition and health-related quality of life. *Arch Neurol*. 2006 Jul;63(7):945-50. doi: 10.1001/archneur.63.7.945. PMID: 16831962.
16. Kantarci K, Lowe VJ, Lesnick TG, et al. Early postmenopausal transdermal 17beta-estradiol therapy and amyloid-beta deposition. *Journal of Alzheimer's Disease*. 2016;53(2):547-56. doi: <http://dx.doi.org/10.3233/JAD-160258>. PMID: 2016-36847-015.

17. Gleason CE, Dowling NM, Wharton W, et al. Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS-Cognitive and Affective Study. *PLoS Med.* 2015 Jun;12(6):e1001833; discussion e. doi: 10.1371/journal.pmed.1001833. PMID: 26035291.
18. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. *JAMA.* 2003 May 28;289(20):2651-62. doi: 10.1001/jama.289.20.2651. PMID: 12771112.
19. Davison SL, Bell RJ, Robinson PJ, et al. Continuous-combined oral estradiol/drospirenone has no detrimental effect on cognitive performance and improves estrogen deficiency symptoms in early postmenopausal women: a randomized placebo-controlled trial. *Menopause.* 2013 Oct;20(10):1020-6. doi: 10.1097/GME.0b013e318287474f. PMID: 23591255.
20. Alhola P, Tuomisto H, Saarinen R, et al. Estrogen + progestin therapy and cognition: a randomized placebo-controlled double-blind study. *J Obstet Gynaecol Res.* 2010 Aug;36(4):796-802. doi: 10.1111/j.1447-0756.2010.01214.x. PMID: 20666948.
21. Maki PM, Rubin LH, Fornelli D, et al. Effects of botanicals and combined hormone therapy on cognition in postmenopausal women. *Menopause.* 2009 Nov-Dec;16(6):1167-77. doi: 10.1097/gme.0b013e3181ace484. PMID: 19590458.
22. Tierney MC, Oh P, Moineddin R, et al. A randomized double-blind trial of the effects of hormone therapy on delayed verbal recall in older women. *Psychoneuroendocrinology.* 2009 Aug;34(7):1065-74. doi: 10.1016/j.psyneuen.2009.02.009. PMID: 19297102.
23. Grady D, Yaffe K, Kristof M, et al. Effect of postmenopausal hormone therapy on cognitive function: the Heart and Estrogen/progestin Replacement Study. *Am J Med.* 2002 Nov;113(7):543-8. PMID: 12459399.
24. Binder EF, Schechtman KB, Birge SJ, et al. Effects of hormone replacement therapy on cognitive performance in elderly women. *Maturitas.* 2001 Apr 20;38(2):137-46. PMID: 11306202.
25. Kritz-Silverstein D, von Muhlen D, Laughlin GA, et al. Effects of dehydroepiandrosterone supplementation on cognitive function and quality of life: the DHEA and Well-Ness (DAWN) Trial. *J Am Geriatr Soc.* 2008 Jul;56(7):1292-8. doi: 10.1111/j.1532-5415.2008.01768.x. PMID: 18482290.
26. Vaughan C, Goldstein FC, Tenover JL. Exogenous testosterone alone or with finasteride does not improve measurements of cognition in healthy older men with low serum testosterone. *J Androl.* 2007 Nov-Dec;28(6):875-82. doi: 10.2164/jandrol.107.002931. PMID: 17609296.
27. Kenny AM, Bellantonio S, Gruman CA, et al. Effects of transdermal testosterone on cognitive function and health perception in older men with low bioavailable testosterone levels. *J Gerontol A Biol Sci Med Sci.* 2002 May;57(5):M321-5. PMID: 11983727.
28. Yaffe K, Krueger K, Cummings SR, et al. Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. *Am J Psychiatry.* 2005 Apr;162(4):683-90. doi: 10.1176/appi.ajp.162.4.683. PMID: 15800139.
29. Yaffe K, Krueger K, Sarkar S, et al. Cognitive function in postmenopausal women treated with raloxifene. *N Engl J Med.* 2001 Apr 19;344(16):1207-13. doi: 10.1056/nejm200104193441604. PMID: 11309635.
30. Nickelsen T, Lufkin EG, Riggs BL, et al. Raloxifene hydrochloride, a selective estrogen receptor modulator: safety assessment of effects on cognitive function and mood in postmenopausal women. *Psychoneuroendocrinology.* 1999 Jan;24(1):115-28. PMID: 10098223.
31. Henderson VW, St John JA, Hodis HN, et al. Long-term soy isoflavone supplementation and cognition in women: a randomized, controlled trial. *Neurology.* 2012 Jun 5;78(23):1841-8. doi: 10.1212/WNL.0b013e318258f822. PMID: 22665144.
32. Gleason CE, Carlsson CM, Barnett JH, et al. A preliminary study of the safety, feasibility and cognitive efficacy of soy isoflavone supplements in older men and women. *Age Ageing.* 2009 Jan;38(1):86-93. doi: 10.1093/ageing/afn227. PMID: 19054783.
33. Ho SC, Chan AS, Ho YP, et al. Effects of soy isoflavone supplementation on cognitive function in Chinese postmenopausal women: a double-blind, randomized, controlled trial. *Menopause.* 2007 May-Jun;14(3 Pt 1):489-99. doi: 10.1097/GME.0b013e31802c4f4f. PMID: 17308499.
34. Casini ML, Marelli G, Papaleo E, et al. Psychological assessment of the effects of treatment with phytoestrogens on postmenopausal women: a randomized, double-blind, crossover, placebo-controlled study. *Fertil Steril.* 2006 Apr;85(4):972-8. doi: 10.1016/j.fertnstert.2005.09.048. PMID: 16580383.



35. Kreijkamp-Kaspers S, Kok L, Grobbee DE, et al. Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women: a randomized controlled trial. *Jama*. 2004 Jul 7;292(1):65-74. doi: 10.1001/jama.292.1.65. PMID: 15238592.
36. Kritz-Silverstein D, Von Muhlen D, Barrett-Connor E, et al. Isoflavones and cognitive function in older women: the SOy and Postmenopausal Health In Aging (SOPHIA) Study. *Menopause*. 2003 May-Jun;10(3):196-202. PMID: 12792289.
37. Howes JB, Bray K, Lorenz L, et al. The effects of dietary supplementation with isoflavones from red clover on cognitive function in postmenopausal women. *Climacteric*. 2004 Mar;7(1):70-7. PMID: 15259285.
38. Pan HA, Wang ST, Pai MC, et al. Cognitive function variations in postmenopausal women treated with continuous, combined HRT or tibolone. A comparison. *J Reprod Med*. 2003 May;48(5):375-80. PMID: 12815913.
39. Moller MC, Radestad AF, von Schoultz B, et al. Effect of estrogen and testosterone replacement therapy on cognitive fatigue. *Gynecol Endocrinol*. 2013 Feb;29(2):173-6. doi: 10.3109/09513590.2012.730568. PMID: 23095007.
40. Moller MC, Bartfai AB, Radestad AF. Effects of testosterone and estrogen replacement on memory function. *Menopause*. 2010 Sep-Oct;17(5):983-9. doi: 10.1097/gme.0b013e3181dc2e40. PMID: 20555288.
41. Legault C, Maki PM, Resnick SM, et al. Effects of tamoxifen and raloxifene on memory and other cognitive abilities: cognition in the study of tamoxifen and raloxifene. *J Clin Oncol*. 2009 Nov 1;27(31):5144-52. doi: 10.1200/JCO.2008.21.0716. PMID: 19770382.
42. Espeland MA, Shumaker SA, Limacher M, et al. Relative effects of tamoxifen, raloxifene, and conjugated equine estrogens on cognition. *J Womens Health (Larchmt)*. 2010 Mar;19(3):371-9. doi: 10.1089/jwh.2009.1605. PMID: 20136553.
43. Cherrier MM, Anderson K, Shofer J, et al. Testosterone treatment of men with mild cognitive impairment and low testosterone levels. *Am J Alzheimers Dis Other Demen*. 2015 Jun;30(4):421-30. doi: 10.1177/1533317514556874. PMID: 25392187.
44. Kato-Kataoka A, Sakai M, Ebina R, et al. Soybean-derived phosphatidylserine improves memory function of the elderly Japanese subjects with memory complaints. *J Clin Biochem Nutr*. 2010 Nov;47(3):246-55. doi: 10.3164/jcbn.10-62. PMID: 21103034.

## Appendix L. Vitamin Interventions

**Appendix Table L1. Characteristics of eligible studies: vitamins in adults with normal cognition**

<b>Vitamin Intervention Type</b>	<b>Study Design Country RoB</b>	<b>N=</b>	<b>Population Inclusion Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition</b>	<b>Intervention Duration</b>	<b>Comparison</b>	<b>Outcome timing</b>	<b>Outcome Domain [Instrument]</b>
<b>Multivitamins</b>	Chew 2015 <sup>1</sup> Age-related Eye Disease Study 2 RCT USA High	3501	Adults at risk for developing late age-related macular degeneration Age 73 Female 58% White 97% Black 1% Asian <1% American Indian <1% Native Hawaiian or Pacific Islander <1% Other <1% Education ≤ High school 29% ≥ Some college 49% Postgrad 22% Baseline cognition: TICS 33	Vitamin C (500 mg) Vitamin E (400 IU) Beta carotene (15 mg) Zinc (80 or 25 mg) daily for 5 years	No beta carotene or no zinc	5 years	Brief Cognitive Test Performance [TICS] Multidomain Neuropsychological Test Performance [Composite] Executive/Attention/Processing [Animal Category] [Letter Fluency] [Alternating Fluency] [DS Backward] Memory [WMS-III Logical Memory Part I and II] [Recall Paragraph] Language [Animal Category] [Letter Fluency] [Alternating Fluency]
	Grodstein 2013 <sup>2</sup> Physicians' Health Study II RCT USA Medium: followup 1 and 3 High: followup 3 and 4 (time in years NR)	5947	Substudy of Physicians' Health Initiative recruited men physicians without serious disease aged 65+ 65-74 72% 75-84 26% 85+ 2% Female 0% Race NR Education 100% medical school Baseline cognition	Multivitamin (Centrum Silver) daily for approximately 13 years	Placebo	8.5 years (mean)	<u>Brief Cognitive Test Performance [TICS]</u> <u>Multidomain Neuropsychological Test Performance [Composite]</u> <u>Memory [Memory Composite]</u> <u>Language [Category Fluency]</u>

Vitamin Intervention Type	Study Design Country RoB	N=	Population Inclusion Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Duration	Comparison	Outcome timing	Outcome Domain [Instrument]
			TICS 34				
	Kesse-Guyot 2011 <sup>3</sup> Supplementation in Vitamins and Mineral Antioxidants 2011 RCT France High	4447	Healthy adults aged 45-60 Age 52 Female 48% Race NR Education: Primary 21% Secondary 40% University 39% Baseline cognition NR	Vitamin C (120 mg) Vitamin E (30 mg) Beta carotene (6 mg) Selenium (100 µg) Zinc (20 mg) daily for 6 years	Placebo	6 years	<u>Executive/Attention/Processing Speed</u> [TMT] [DS Forward] [DS Backward] <u>Memory</u> [RI-48] <u>Language</u> [Verbal Fluency] [Semantic Fluency] [Phonetic Fluency]
	McNeill 2007 <sup>4</sup> Mineral and Vitamin Intervention Study RCT Scotland Low	910	Aged 65+ and not taken vitamins, minerals or fish oil in prior 3 months Age 72 Female 48% Race NR Education: 7 years Baseline cognition NR	Supplement containing 11 vitamins & 5 minerals: Vitamin A (800 µg) B vitamins (1 µg B <sub>12</sub> ; 200 µg folic acid; 1.4 mg thiamin; 1.6 mg riboflavin; 18 mg niacin; 6 mg pantothenic acid) Vitamin C (60 mg) Vitamin D (5 µg) Vitamin E (10 mg) Pyridoxine (2 mg) Iron (14 mg) Iodine (150 µg)	Placebo	1 year	<u>Executive/Attention/Processing Speed</u> [DS Forward] <u>Language</u> [Verbal Fluency Test]

Vitamin Intervention Type	Study Design Country RoB	N=	Population Inclusion Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Duration	Comparison	Outcome timing	Outcome Domain [Instrument]
				Copper (0.75 mg) Zinc (15 mg) Manganese (1 mg) daily for 1 year			
	Wolters 2005 <sup>5</sup> RCT Germany Low	220	Healthy women aged 60+ not taking vitamins in prior 2 months Age 63 Female 100% Race NR Education: No secondary school 35% Grammar school 43% High school grad 22% Baseline cognition NR	B vitamins (0.4 mg folic acid; 9 µg cobalamin; 0.2 mg biotin; 35 mg niacin; 16 mg pantothenic acid; 3.2 mg riboflavin; 2.4 mg thiamine) Vitamin C (150 mg) Vitamin E (36 mg) Beta carotene (9 mg) Magnesium (50 mg) Selenium (60 µg) Daily for 6 months	Placebo	6 months	<u>Executive/Attention/Processing Speed</u> [WAIS-III Symbol Search Subtest] Kurztest fuer Allgemeine Intelligenz] <u>Memory</u> [Berliner Amnesie Test]
	Yaffe 2004 <sup>6</sup> Age-Related Eye Disease Study RCT USA High	2,166	Elderly adults Age 75 Female NR Race NR Education NR Baseline cognition NR	Vitamin C (500 mg) Vitamin E (400 IU) Beta carotene (15 mg) Zinc (80 mg) Copper (2 mg) Daily for 7 years	Placebo	7 years	<u>Diagnosis</u> [MCI] <u>Brief Cognitive Test Performance</u> [MMSE] <u>Executive/Attention/Processing Speed</u> [Buschke Selective Reminding Test] [DS Backward] <u>Memory</u> [Logical Memory Parts I and II, Wechsler Memory Scale-Revised, Immediate Recall] <u>Language</u> [Category Fluency] [Letter

Vitamin Intervention Type	Study Design Country RoB	N=	Population Inclusion Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Duration	Comparison	Outcome timing	Outcome Domain [Instrument]
							Fluency]
	Heart Protection Study 2002 <sup>7</sup> RCT UK Medium	20,536	Aged 40-80 with substantial risk of death from coronary heart disease in next 5 years. Some were concurrently taking simvastatin, which was the primary study drug. Age 70+: 28% Female 25% Race NR Education NR Baseline cognition NR	Vitamin E (600 mg) Vitamin C (250 mg) Beta carotene (20 mg) daily for 5 years	Placebo	5 Years	<u>Diagnosis</u> [Dementia, MCI] <u>Brief Cognitive Test Performance</u> [TICS]
	Cockle 2000 <sup>8</sup> RCT UK High	139	Healthy, elderly, free-living adults Age 70 Female 63% Race NR Education NR Baseline cognition: MMSE 29	Vitamin A (palmitate 3334 IU) B vitamins (4 mg folic acid; 2 mg d-biotin; 180 mg nicotinamide; 14 mg thiamine mononitrate; 16 mg riboflavin; 22 mg pyridoxine; 0.03 mg B <sub>12</sub> ) Vitamin C (600 mg) Vitamin E (100 mg dl-alpha-tocopherol acetate) Daily for 6 months	Placebo	6 months	<u>Brief Cognitive Test Performance</u> [MMSE] <u>Multidomain Neuropsychological Test Performance</u> [Syndrom Kurztest, Alice Heim's 4 and 5 Tests of General Intelligence] <u>Executive/Attention/Processing Speed</u> [Choice Reaction Time] <u>Memory</u> [Sternberg Memory Scanning Task, Word Scan Task] <u>Language</u> [National Adult Reading Test]

Vitamin Intervention Type	Study Design Country RoB	N=	Population Inclusion Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Duration	Comparison	Outcome timing	Outcome Domain [Instrument]
	Smith 1999 <sup>9</sup> RCT UK High	110	Healthy adults aged 60-80 and with MMSE 18+ Age 67 Female 54% Race NR Education NR Baseline cognition NR	Vitamin C (500 mg) Vitamin E (400 mg) Beta carotene (2 mg) daily for 1 year	Placebo	1 year	<u>Executive/Attention/Processing Speed</u> [Logical Reasoning Task, Simple Reaction Time Task, Repeated-digits Vigilance Task, Focused Attention Task, Categorical Search Task] <u>Memory</u> [Free Recall Task, Delayed Recognition Memory Task]
Folic acid	Durga 2007 <sup>10</sup> Folic Acid and Carotid Intimamedia Thickness Trial RCT Netherlands Low	818	Age 50-70, high homocysteine levels likely due to suboptimal folate concentrations. Age 60 Female 29% Race NR Education NR Baseline cognition: MMSE 29	Folic acid (0.8 mg) Daily for 3 years	Placebo	3 years	<u>Multidomain Neuropsychological Test Performance</u> [Composite] <u>Executive/Attention/Processing Speed</u> [SCWT] [LDST] [Concept Shifting Test (modified TMT)] <u>Memory</u> [RAVLT] <u>Language</u> [Verbal Fluency Test]
Folic acid + B <sub>12</sub>	van der Zwaluw 2014 <sup>11</sup> B-vitamins for the Prevention of Osteoporotic Fractures RCT Netherlands Low	2919	Aged 65+ with elevated homocysteine levels, able to make own decisions and compliant Age 74 Female 50% Race NR Education: Low 51% Medium 21% High 26% Baseline cognition: MMSE 28	Folic acid (400 mg) Vitamin B <sub>12</sub> (500 mg) Daily for 2 years	Placebo	2 years	<u>Brief Cognitive Test Performance</u> [MMSE] <u>Executive/Attention/Processing Speed</u> [Composite] [Composite: Information Processing Speed] <u>Memory</u> [Composite: Episodic Memory [RAVLT]] <u>Language</u> [Verbal Fluency Test]
	Walker 2012 <sup>12</sup> RCT Australia Low	900	Age 60-74 with elevated psychological distress, did not exercise or take vitamins	Folic acid (0.4 mg) Vitamin B <sub>12</sub> (0.1 mg)	Placebo	2 years	<u>Brief Cognitive Test Performance</u> [TICS] <u>Executive/Attention/Processing Speed</u> [TICS Orientation/Calculation & Attention] <u>Memory</u> [TICS Immediate & Delayed

Vitamin Intervention Type	Study Design Country RoB	N=	Population Inclusion Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Duration	Comparison	Outcome timing	Outcome Domain [Instrument]
			Age 66 Female 60% Race NR Education 14 years Baseline cognition: TICS-m 27	Daily for 2 years			Recall And Semantic Memory]
Folate/folic acid + B <sub>6</sub> + B <sub>12</sub>	Andreeva 2011 <sup>13</sup> Supplementation with Folate, vitamins B <sub>6</sub> and B <sub>12</sub> and/or Omega-3 fatty acids RCT France Low	1248	Age 45-70 with heart disease Age 61 Female 58% Race NR Education: Less than high school diploma 37% Baseline cognition: Isaac set test: 35.8	Folate (0.56 mg) Vitamin B <sub>6</sub> (3 mg) Vitamin B <sub>12</sub> (0.02 mg) Daily for 4 years	Placebo	4 years	Brief Cognitive Test Performance [TICS French version] Memory [TICS Memory & Recall]
	Brady 2009 <sup>14</sup> VA HOST RCT USA High	659	Veterans aged 21+ with advanced chronic kidney disease Age 64 Female 2% White 49% Black 37% Hispanic 11% Other 3% Education NR Baseline cognition: TICS 32	Folic acid (40 mg) Vitamin B <sub>6</sub> (100 mg) Vitamin B <sub>12</sub> (2 mg) Daily for 6 years	Placebo	1 year	Brief Cognitive Test Performance [TICS]
	Kang 2008 <sup>15</sup> Women's Antioxidant and Folic Acid Cardiovascular Study	5,442	Female health professionals aged 40+ with heart disease or 3+ risk factors Age 71 Female 100%	Folic acid (2.5 mg) Vitamin B <sub>6</sub> (50 mg) Vitamin B <sub>12</sub> (1 mg)	Placebo	5.4 years	Brief Cognitive Test Performance [TICS] Multidomain Neuropsychological Test Performance [Composite] Memory [Composite] Language [Category Fluency]

Vitamin Intervention Type	Study Design Country RoB	N=	Population Inclusion Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Duration	Comparison	Outcome timing	Outcome Domain [Instrument]
	RCT USA High		Race NR Education: Nursing degree: 70% Bachelor's degree or higher: 30% Baseline cognition: TICS 34	Daily for 5.4 years			
	McMahon 2006 <sup>16</sup> RCT New Zealand Low	276	Age 65+ with healthy cognition and homocysteine at least 13 micromoles/liter Age 74 Female 44% Race NR Education: <3 years secondary 35% ≥3 years secondary 11% Tertiary 54% Baseline cognition: MMSE 29	Folate (1 mg) Vitamin B <sub>12</sub> (0.5 mg) Vitamin B <sub>6</sub> (10 mg) Daily for 2 years	Placebo	2 years	<u>Brief Cognitive Test Performance</u> [MMSE] <u>Executive/Attention/Processing Speed</u> [Raven's Progressive Matrices] [TMT B] [COWAT] <u>Memory</u> [RAVLT] [Paragraph Recall, WMS] <u>Language</u> [Category Word Fluency] [National Adult Reading Test] [COWAT]
<b>Vitamin E</b>	Kang 2009 <sup>17</sup> The Women's Antioxidant and Cardiovascular Study RCT USA Low: followup 1-3 High: followup 4 (exact time in years NR)	2824	Women aged 40+ with CVD or 3+ coronary risk factors who are part of the larger RCT; this sub-study included women aged 65+ Age 69 Female 100% Race NR Education: Technical nursing degree 70% Bachelor's or higher 30% Baseline cognition NR	Vitamin E (402 mg) Every other day for 9 years	Placebo	5.4 years (4 follow up calls)	<u>Brief Cognitive Test Performance</u> [TICS] <u>Multidomain Neuropsychological Test Performance</u> [Composite] <u>Memory</u> [Composite] <u>Language</u> [Category Fluency Test]
	Kang 2006 <sup>18</sup> Women's Health	6377	Women age 65+ Age 72	Vitamin E (600 IU)	Placebo	4 years	<u>Brief Cognitive Test Performance</u> [TICS] <u>Multidomain Neuropsychological</u>



<b>Vitamin Intervention Type</b>	<b>Study Design Country RoB</b>	<b>N=</b>	<b>Population Inclusion Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition</b>	<b>Intervention Duration</b>	<b>Comparison</b>	<b>Outcome timing</b>	<b>Outcome Domain [Instrument]</b>
	Study RCT USA Low		Female 100% Race NR Technical nursing degree 68% Bachelor's or higher 32% Baseline cognition: TICS 34	Every other day for 10 years			<u>Performance</u> [Composite] <u>Memory</u> [Composite] <u>Language</u> [Category Fluency Test]
<b>Vitamin C</b>	Kang 2009 <sup>17</sup> The Women's Antioxidant and Cardiovascular Study RCT USA Low: followup 1-3 High: followup 4 (exact time in years NR)	2824	Women aged 40+ with CVD or 3+ coronary risk factors who are part of the larger RCT; this sub-study included women aged 65+ Age 69 Female 100% Race NR Education: Technical nursing degree 70% Bachelor's or higher 30% Baseline cognition NR	Vitamin C (500 mg) Daily for 9 years	Placebo	5.4 years (4 follow up calls)	<u>Brief Cognitive Test Performance</u> [TICS] <u>Multidomain Neuropsychological Test Performance</u> [Composite] <u>Memory</u> [Composite] <u>Language</u> [Category Fluency Test]
<b>Vitamin D + Calcium</b>	Rossum 2012 <sup>19</sup> Women's Health Initiative Calcium and Vitamin D Trial RCT USA Low: 7 years High: 8 years	4143	Participants in the Women's Health Initiative Memory Study Age 71 Female 100% Race: White 88% Black 6% Hispanic 3% Asian 2% Native American 1% Education: <High school 7%	Calcium carbonate (1000 mg) Vitamin D <sub>3</sub> (400 IU) Daily for 8 years  Optional use of calcium (1000 mg) Vitamin D (600 mg)	Placebo	7.8 years (mean)	<u>Diagnosis</u> [Probable Dementia or MCI] <u>Brief Cognitive Test Performance</u> [MMSE] <u>Executive/Attention/Processing Speed</u> [DS Forward] [DS Backward] <u>Memory</u> [CVLT] [BVRT] <u>Language</u> [Letter & Category Fluency, Primary Abilities Vocabulary] <u>Motor</u> [Finger Tapping] <u>Visuospatial</u> [Card Rotations]

Vitamin Intervention Type	Study Design Country RoB	N=	Population Inclusion Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Duration	Comparison	Outcome timing	Outcome Domain [Instrument]
			High school grad 22% >High school 40% College grad 31% Baseline cognition: MMSE-m 95				
<b>Beta carotene</b>	Kang 2009 <sup>17</sup> The Women's Antioxidant and Cardiovascular Study RCT USA Low: followup 1-3 High: followup 4 (exact time in years NR)	2824	Women aged 40+ with CVD or 3+ coronary risk factors who are part of the larger RCT; this sub-study included women aged 65+ Age 69 Female 100% Race NR Education: Technical nursing degree 70% Bachelor's or higher 30% Baseline cognition NR	Beta carotene (50 mg) Every other day for 9 years	Placebo	5.4 years (4 follow up calls)	<u>Brief Cognitive Test Performance [TICS]</u> <u>Multidomain Neuropsychological Test Performance [Composite]</u> <u>Memory [Composite]</u> <u>Language [Category Fluency Test]</u>

µg=microgram (1000 µg=1 mg) (1000 µg=1 g); BVRT=Benton Visual Retention Test; COWAT=Controlled Oral Word Association Test; CVLT=California Verbal Learning Test; DS=Digit Span (Forward and/or Backward); IU=internal units; mg=milligrams; MCI=mild cognitive impairment; MMSE=Mini Mental Status Exam; N=sample size; NR=not reported; RAVLT=Rey's Auditory Verbal Learning; RCT=randomized controlled trial; SCWT=Stroop Color Word Test; TICS=Telephone Interview Cognitive Status; TMT=Trail Making Test (Part A and/or B); vs=versus; WAIS=Wechsler Adult Intelligence Scale; WMS=Wechsler Memory Scale

**Appendix Table L2. Characteristics eligible studies: B vitamin combinations vs. active control in adults with normal cognition**

Study Design Country RoB	N=	Population Inclusion Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Duration	Comparison	Outcome timing	Outcome Domain [Instrument]
Stott 2005 <sup>20</sup> RCT UK Medium	185	Age 65+ and history of ischemic vascular disease. Age 74 Female 56% Race NR Education NR Baseline cognition: TICS-m: 26	1) folic acid (2.5 mg)/B <sub>12</sub> (0.4 mg) 2) B <sub>2</sub> (25 mg) 3) B <sub>6</sub> (25 mg) 4) folic acid/B <sub>12</sub> + B <sub>2</sub> 5) folic acid/B <sub>12</sub> + B <sub>6</sub> 6) B <sub>2</sub> + B <sub>6</sub> 7) folic acid/B <sub>12</sub> + B <sub>2</sub> + B <sub>6</sub> Daily for 3 months	Placebo	6 months and 1 year	Brief Cognitive Test Performance [TICS] Executive/Attention/Processing Speed [SDMT]

µg=microgram (1000 µg=1 mg) (1000 µg=1 g); IU=internal units; mg=milligrams; NR=not reported; SDMT=Symbol Digit Modalities Test; RCT=randomized controlled trial; TICS=Telephone Interview for Cognitive Status; UK=United Kingdom

**Appendix Table L3. Summary risk of bias assessments: vitamins in adults with normal cognition**

<b>Vitamin Intervention Type</b>	<b>Study</b>	<b>Overall Risk of Bias Assessment</b>	<b>Rationale</b>
<b>Multivitamins</b>	Chew 2015 <sup>1</sup>	High	Randomization methods unclear, reported attrition (19%) conflicting with related publication, concurrent intervention not controlled for.
	Grodstein 2013 <sup>2</sup>	Medium at followup 2 High at followup 3+	Randomization and blinding methods adequate, attrition 11% at second followup (medium), 31% at third followup (high) and 60% and final followup (high) with no missing data imputation, independent outcome assessor unclear.
	Kesse-Guyot 2006 <sup>3</sup>	High	Randomization unclear, attrition 35% with no missing data imputation.
	McNeill 2007 <sup>4</sup>	Low	Randomization and blinding methods adequate, attrition unclear but likely 15%, ITT, all outcomes reported.
	Wolters 2005 <sup>5</sup>	Low	Randomization and blinding methods unclear, comparable outcome assessment timing between groups, blinding likely adequate, concurrent interventions unclear.
	Yaffe 2004 <sup>6</sup>	High	Randomization and allocation methods likely adequate, attrition 40%.
	Heart Protection Study 2002 <sup>7</sup>	Medium	Randomization methods adequate, attrition unclear but used survival analyses, outcome assessor blinding and independence unclear, ITT.
	Cockle 2000 <sup>8</sup>	High	Randomization methods unclear, attrition 35%, missing data imputation methods inappropriate.
	Smith 1999 <sup>9</sup>	High	Randomization methods unclear, attrition not reported, blinding methods adequate, ITT not reported.
<b>B Vitamins</b>	van der Zwaluw 2014 <sup>11</sup>	Low	Randomization methods adequate, attrition 24% with no missing data imputation, outcome assessor not independent, all outcomes reported.
	Walker 2012 <sup>12</sup>	Low	Randomization methods adequate, blinding unclear, attrition 16% at two year followup and no missing data imputation, outcome assessor independence unclear.
	Andreeva 2011 <sup>13</sup>	Low	Adequate randomization and blinding, low attrition in this followup study, ITT.

<b>Vitamin Intervention Type</b>	<b>Study</b>	<b>Overall Risk of Bias Assessment</b>	<b>Rationale</b>
	Brady 2009 <sup>14</sup>	High	Attrition 25-27% and no missing data imputation.
	Kang 2008 <sup>15</sup>	High	Subset of randomized trial studied, attrition at timepoint 4 48%, confounder controlling likely inadequate, lining methods unclear.
	Durga 2007 <sup>10</sup>	Low	Randomization and allocation methods adequate, attrition 3% at 3-year followup, all outcomes reported clearly.
	McMahon 2006 <sup>16</sup>	Low	Randomization and blinding methods adequate, outcome assessor independence unclear, ITT not reported.
	Stott 2005 <sup>20</sup>	Medium	Randomization and blinding methods adequate, attrition 10%, outcome assessor independence unclear.
<b>Vitamin E</b>	Kang 2009 <sup>17</sup>	Low at followup 3 High at final followup	Attrition 12% at third followup (medium) and 20% by final followup (high), outcome assessment timing not comparable between groups, ITT unclear.
	Kang 2006 <sup>18</sup>	Low	Randomization unclear, attrition 20% and no missing data imputation, outcome assessment timing unclear.
<b>Vitamin C</b>	Kang 2009 <sup>17</sup>	Low at followup 3 High at final followup	Attrition 12% at third followup (medium) and 20% by final followup (high), outcome assessment timing not comparable between groups, ITT unclear.
<b>Vitamin D + Calcium</b>	Rossom 2012 <sup>19</sup>	Low at followup 7 High at followup 8	Randomization and blinding methods adequate, outcome assessor independent, ITT, all outcomes reported.
<b>Beta carotene</b>	Kang 2009 <sup>17</sup>	Low at followup 3 High at final followup	Attrition 12% at third followup (medium) and 20% by final followup (high), outcome assessment timing not comparable between groups, ITT unclear.

ITT=intention to treat

**Appendix Table L4. Strength of evidence assessments: vitamins in adults with normal cognition**

Vitamin Intervention Type	Outcome	# Trials (n)	Evidence Summary Summary statistics [95% CI]	Study Limitations	Directness	Precision	Consistency	Reporting Bias	Optional Components	SOE
Multivitamin vs. placebo	Dementia	1 (20,469)	1 test showed no statistically significant improvement <u>Heart Protection Study 2002<sup>7</sup></u> Dementia diagnosis 0.3% vs 0.3%	Medium	Direct	Unclear	Unknown	Suspected	NA	Low
	MCI	1 (20,469)	1 test showed no statistically significant improvement <u>Heart Protection Study 2002<sup>7</sup></u> MCI diagnosis 23.7% vs 24.2%	Medium	Direct	Unclear	Unknown	Suspected	NA	Low
	Brief Cognitive Test Performance  Grodstein 2013 <sup>2</sup> : Followup 2 (time NR) Heart Protection Study 2002 <sup>7</sup> : 5 years	2 (25,765)	2 tests showed no statistically significant improvement <u>Grodstein 2013<sup>2</sup></u> TICS, between groups difference from longitudinal models of mean cognitive performance 0.10 (-0.05 to 0.24)  <u>Heart Protection Study 2002<sup>7</sup></u> TICS-m, between groups mean difference at followup (time NR) 0.02 (SE 0.07)	Medium	Indirect	Imprecise	Consistent	Suspected	NA	Insufficient

Vitamin Intervention Type	Outcome	# Trials (n)	Evidence Summary Summary statistics [95% CI]	Study Limitations	Directness	Precision	Consistency	Reporting Bias	Optional Components	SOE
	Multidomain Neuropsychological Performance  Grodstein 2013 <sup>2</sup> : Followup 2 (time NR)	1 (5296)	1 test showed no statistically significant improvement <u>Grodstein 2013<sup>2</sup></u> Composite z-score, between groups difference from longitudinal models of mean cognitive performance -0.01 (-0.05 to 0.03)	Medium	Indirect	Precise	Unknown	Undetected	NA	Low
	Executive/Attention/Processing Speed  McNeill 2007 <sup>4</sup> : 1 year Wolters 2005 <sup>5</sup> 6 months	2 (992)	3 tests showed no statistically significant improvement <u>McNeill 2007<sup>4</sup></u> Digit span forwards, mean difference -0.1 (-0.3 to 0.2)  <u>Wolters 2005<sup>5</sup></u> Kurtztest fuer Allgemeine Intelligenz, between groups change from baseline* -1 [NR] WAIS-III symbol search, between groups change from baseline* 0 [NR]	Low	Indirect	Unclear	Consistent	Undetected	NA	Low
	Memory Grodstein 2013 <sup>2</sup> :	2 (5516)	2 tests showed no statistically significant	Medium	Indirect	Unclear	Consistent	Undetected	NA	Low

Vitamin Intervention Type	Outcome	# Trials (n)	Evidence Summary Summary statistics [95% CI]	Study Limitations	Directness	Precision	Consistency	Reporting Bias	Optional Components	SOE
	Followup 2 (time NR) Wolters 2005 <sup>5</sup> : 6 months		improvement <u>Grodstein 2013<sup>2</sup></u> Composite z-score, between groups difference from longitudinal models of mean cognitive performance 0.00 (-0.05 to 0.04)  <u>Wolters 2005<sup>5</sup></u> Berliner Amnesit Test, between groups change from baseline* -0.8 [NR]							
	Adverse Effects		NR							
<b>B vitamins: folic acid vs. placebo</b>	Dementia		NR							
	MCI		NR							
	Brief Cognitive Test Performance		NR							
	Durga 2007 <sup>10</sup> : 3 years									
	Multidomain Neuropsychological Performance	1 (818)	1 test showed statistically significant improvement with intervention Composite, between groups change from baseline 0.05 [0.004 to 0.096] p=0.03	Low	Indirect	Precise	Unknown	Suspected	NA	Insufficient
Executive/Attention/	1 (818)	1 of 3 tests showed statistically	Low	Indirect	Imprecise	Inconsistent	Suspected	NA	Insufficient	



Vitamin Intervention Type	Outcome	# Trials (n)	Evidence Summary Summary statistics [95% CI]	Study Limitations	Directness	Precision	Consistency	Reporting Bias	Optional Components	SOE
	Processing Speed		significant improvement with control Composite: sensorimotor speed, between groups change from baseline 0.06 [-0.001 to 0.13] p=0.055 Composite: complex speed, between groups change from baseline 0.04 [-0.05 to 0.12] p=0.4 LDST, between groups change from baseline 0.09 [0.016 to 0.16] p=0.02							
	Memory	1 (818)	1 test showed statistically significant improvement with intervention RAVLT, between groups change from baseline 0.13 [0.03 to 0.23] p=0.01	Low	Indirect	Precise	Unknown	Suspected	NA	Insufficient
	Adverse Effects		NR							
<b>B vitamins: folic acid + B<sub>12</sub> vs. placebo</b>	Dementia		NR							
	MCI		NR							
	Brief Cognitive Test Performance	2 (3456)	1 of 2 tests showed statistically	Low	Indirect	Precise	Inconsistent	Suspected	NA	Insufficient

Vitamin Intervention Type	Outcome	# Trials (n)	Evidence Summary Summary statistics [95% CI]	Study Limitations	Directness	Precision	Consistency	Reporting Bias	Optional Components	SOE
	van der Zwaluw 2014 <sup>11</sup> : 2 years Walker 2012 <sup>12</sup> : 2 years		significant improvement with intervention <u>van der Zwaluw 2014<sup>11</sup></u> MMSE, between groups change from baseline* 2.0 [NR] p=0.05  <u>Walker 2012<sup>12</sup></u> TICS-m total, time by intervention effect size 0.17 [NR] p=0.03							
	Multidomain Neuropsychological Performance		NR							
	Executive/Attention/Processing Speed	2 (3456)	11 tests showed no statistically significant improvement <u>van der Zwaluw 2014<sup>11</sup></u> Executive functioning composite, between groups change from baseline* 0.07 [NR] Attention/working memory composite, between groups change from baseline* -0.03 [NR] Information processing speed	Low	Indirect	Unclear	Consistent	Suspected	NA	Medium

Vitamin Intervention Type	Outcome	# Trials (n)	Evidence Summary Summary statistics [95% CI]	Study Limitations	Directness	Precision	Consistency	Reporting Bias	Optional Components	SOE
			composite, between groups change from baseline* -0.01 [NR] DS Forward, between groups change from baseline* -0.1 [NR] DS Backward, between groups change from baseline* 0.0 [NR] Trails B/A, between groups change from baseline* 0.0 [NR] Stroop I&II, between groups change from baseline* 0.4 [NR] Stroop Interference, between groups change from baseline* -1.6 [NR] Symbol digit modalities, between groups change from baseline* -0.1 [NR]  <u>Walker 2012<sup>12</sup></u> TICS-m orientation/calculati							

Vitamin Intervention Type	Outcome	# Trials (n)	Evidence Summary Summary statistics [95% CI]	Study Limitations	Directness	Precision	Consistency	Reporting Bias	Optional Components	SOE
			on NR; NS TICS-m attention NR; NS							
	Memory Walker 2012 <sup>12</sup> : 2 years	2 (3456)	2 of 7 tests showed statistically significant improvement with intervention <u>van der Zwaluw 2014<sup>11</sup></u> Memory composite, between groups change from baseline* 0.03 [NR] RAVLT-immediate recall, between groups change from baseline* 0.2 [NR] RAVLT-delayed recall, between groups change from baseline* 0.1 [NR] RAVLT recognition, between groups change from baseline* 0.0 [NR]  <u>Walker 2012<sup>12</sup></u> TICS-m immediate recall, time by intervention effect size 0.15 (p<0.05) TICS-m delayed	Low	Indirect	Unclear	Inconsistent	Suspected	NA	Low

Vitamin Intervention Type	Outcome	# Trials (n)	Evidence Summary Summary statistics [95% CI]	Study Limitations	Directness	Precision	Consistency	Reporting Bias	Optional Components	SOE
			recall, time by intervention effect size 0.18 (p=0.01) TICS-m semantic memory NR							
	Adverse Effects		NR							
<b>B vitamins: folate + B<sub>6</sub> + B<sub>12</sub> vs. placebo</b>	Dementia		NR							
	MCI		NR							
	Brief Cognitive Test Performance	2 (1124)	2 tests showed no statistically significant improvement <u>Andreeva 2011<sup>13</sup></u> TICS-m total (French), between groups difference at followup* -0.4 [NR]  <u>McMahon 2006<sup>16</sup></u> MMSE, adjusted between groups change from baseline -0.09 [-0.30 to 1.13] p=0.42	Low	Indirect	Precise	Consistent	Suspected	NA	Low
	Multidomain Neuropsychological Performance		NR							
	Executive/Attention/Processing Speed	1 (253)	1 of 2 tests showed statistically significant improvement <b>with control</b> <u>McMahon 2006<sup>16</sup></u> Trails B, adjusted	Low	Indirect	Imprecise	Inconsistent	Suspected	NA	Insufficient

Vitamin Intervention Type	Outcome	# Trials (n)	Evidence Summary Summary statistics [95% CI]	Study Limitations	Directness	Precision	Consistency	Reporting Bias	Optional Components	SOE
			between groups change from baseline 1.08 [1.02 to 1.14] p<0.01 Raven's Progressive Matrices, adjusted between groups change from baseline -0.31 [-0.81 to 0.19] p=0.22							
	Memory	2 (1124)	4 tests showed no statistically significant improvement <u>Andreeva 2011</u> <sup>13</sup> TICS-m memory (French), between groups difference at followup* 0.0 [NR] TICS-m recall (French), between groups difference at followup* -0.1 [NR]  <u>McMahon 2006</u> <sup>16</sup> RAVLT, adjusted between groups change from baseline -0.35 [-0.85 to 0.14] p=0.16 WMS paragraph recall, adjusted	Low	Indirect	Imprecise	Consistent	Suspected	NA	Low

Vitamin Intervention Type	Outcome	# Trials (n)	Evidence Summary Summary statistics [95% CI]	Study Limitations	Directness	Precision	Consistency	Reporting Bias	Optional Components	SOE
			between groups change from baseline -0.88 [-1.98 to 0.21] p=0.12							
	Adverse Effects		NR							
Vitamin E vs. placebo	Dementia		NR							
	MCI		NR							
	Brief Cognitive Test Performance	2 (7497)	2 tests showed no statistically significant improvement <u>Kang 2009<sup>17</sup></u> TICS, between groups change from baseline -0.08 [-0.37 to 0.21] p=0.61  <u>Kang 2006<sup>18</sup></u> TICS, between groups change from baseline 0.04 [-0.12 to 0.21]	Low	Indirect	Precise	Consistent	Suspected	NA	Moderate
	Multidomain Neuropsychological Performance	2 (7497)	2 tests showed no statistically significant improvement <u>Kang 2009<sup>17</sup></u> Composite, between groups change from baseline z-score -0.02 [-0.09 to 0.05] p=0.55  <u>Kang 2006<sup>18</sup></u>	Low	Indirect	Precise	Consistent	Suspected	NA	Moderate

Vitamin Intervention Type	Outcome	# Trials (n)	Evidence Summary Summary statistics [95% CI]	Study Limitations	Directness	Precision	Consistency	Reporting Bias	Optional Components	SOE
			Composite, between groups change from baseline z-score 0.00 [-0.04 to 0.04]							
	Executive/ Attention/ Processing Speed		NR							
	Memory	2 (7497)	2 tests showed no statistically significant improvement <u>Kang 2009<sup>17</sup></u> Composite, between groups change from baseline z-score -0.01 [-0.08 to 0.06] p=0.61  <u>Kang 2009<sup>17</sup></u> Composite, between groups change from baseline z-score 0.01 [-0.03 to 0.05]	Low	Indirect	Precise	Consistent	Suspected	NA	Moderate
	Adverse Effects	1 (2271)	<u>Kang 2009<sup>17</sup></u> None	Low	Direct	Unclear	Unknown	Suspected	NA	Insufficient
<b>Vitamin C vs. placebo</b>	Dementia		NR							
	MCI		NR							
	Brief Cognitive Test Performance ~4 years <u>Kang 2009<sup>17</sup></u> : Followup 3 (~4 years)	1 (2271)	1 test showed no statistically significant improvement TICS, between groups change from baseline	Low	Indirect	Imprecise	Unknown	Suspected	NA	Low



Vitamin Intervention Type	Outcome	# Trials (n)	Evidence Summary Summary statistics [95% CI]	Study Limitations	Directness	Precision	Consistency	Reporting Bias	Optional Components	SOE
			0.15 [-0.14 to 0.44] p=0.31							
	Multidomain Neuropsychological Performance	1 (2271)	1 test showed no statistically significant improvement Composite, between groups change from baseline z-score 0.05 [-0.01 to 0.12] p=0.1	Low	Indirect	Imprecise	Unknown	Suspected	NA	Low
	Executive/ Attention/ Processing Speed		NR							
	Memory	1 (2271)	1 test showed statistically significant improvement with vitamin C, but effect size was not clinically meaningful. Composite, between groups change from baseline z-score 0.07 [0.00 to 0.13] p=0.05	Low	Indirect	Imprecise	Unknown	Suspected	NA	Low
	Adverse Effects	1 (2271)	No adverse effects were reported, but no statistics were presented	Low	Direct	Unclear	Unknown	Suspected	NA	Insufficient
<b>Vitamin D + calcium vs. placebo</b>	Dementia Rossom 2012 <sup>19</sup> : 7.8 years	1 (4122)	1 test showed no statistically significant	Low	Direct	Precise	Unknown	Suspected	NA	Low

Vitamin Intervention Type	Outcome	# Trials (n)	Evidence Summary Summary statistics [95% CI]	Study Limitations	Directness	Precision	Consistency	Reporting Bias	Optional Components	SOE
			difference Incidence of probable dementia or MCI (pooled), hazard ratio 0.94 (0.72 to 1.24) p=0.68							
	MCI	1 (4122)	See above							
	Brief Cognitive Test Performance 7 years	1 (41)	1 test showed no statistically significant improvement MMSE-m, unadjusted between group change from baseline -0.05 (SE 0.17) p=0.77	Low	Indirect	Imprecise	Unknown	Suspected	NA	Insufficient
	Multidomain Neuropsychological Performance		NR							
	Executive/ Attention/ Processing Speed	1 (4122)	1 test showed no statistically significant improvement Digit span forwards and backwards (pooled), adjusted standardized between groups change from baseline 0.02 (SE 0.04) p=0.46	Low	Indirect	Precise	Unknown	Suspected	NA	Low
	Memory	1 (4122)	2 tests showed no statistically	Low	Indirect	Imprecise	Consistent	Suspected	NA	Low

Vitamin Intervention Type	Outcome	# Trials (n)	Evidence Summary Summary statistics [95% CI]	Study Limitations	Directness	Precision	Consistency	Reporting Bias	Optional Components	SOE
			significant improvement California Verbal Learning Test, adjusted standardized between groups change from baseline -0.05 (SE 0.04) p=0.15 Benton Visual Retention Test, adjusted standardized between groups change from baseline -0.02 (SE 0.04) p=0.66							
	Adverse Effects		NR							
<b>Beta carotene vs. placebo</b>	Dementia		NR							
	MCI		NR							
	Brief Cognitive Test Performance Kang 2009 <sup>17</sup> : Followup 3 (~4 years)	1 (2271)	1 test showed no statistically significant improvement TICS, between groups change from baseline 0.14 [-0.15 to 0.43] p=0.35	Low	Indirect	Imprecise	Unknown	Suspected	NA	Low
	Multidomain Neuropsychological Performance	1 (2271)	1 test showed no statistically significant improvement Composite,	Low	Indirect	Precise	Unknown	Suspected	NA	Low

Vitamin Intervention Type	Outcome	# Trials (n)	Evidence Summary Summary statistics [95% CI]	Study Limitations	Directness	Precision	Consistency	Reporting Bias	Optional Components	SOE
			between groups change from baseline z-score 0.01 [-0.06 to 0.07] p=0.82							
	Executive/ Attention/ Processing Speed		NR							
	Memory	1 (2271)	1 test showed no statistically significant improvement Composite, between groups change from baseline z-score 0.02 [-0.04 to 0.09] p=0.50	Low	Indirect	Precise	Unknown	Suspected	NA	Low
	Adverse Effects	1 (2271)	No adverse effects were reported, but no statistics were presented	Low	Direct	Unclear	Unknown	Suspected	NA	Insufficient

\*calculated by EPC

BCT=brief cognitive screening test; BVRT=Benton Visual Retention Test; C=control; CI=confidence interval; CVLT=California Verbal Learning Test; DS=Digit Span (Forward and/or Backward); DSST=Digit Symbol Substitution Test; DSy=Digit Symbol Coding; EMBT=East Boston Memory Test; HVLt-R=Hopkins Verbal Learning Test-Revised; I=intervention; k=number of studies; LDST=Letter Digit Substitution Test; MCI=mild cognitive impairment; MMSE=Mini-Mental State Examination; MNP=multidomain neuropsychological test performance; n=sample size; NA=not applicable; NS=no statistically significant difference; RAVLT=Rey Auditory Verbal Learning Test; SDMT=Symbol Digit Modalities Test; Stroop=Modified Stroop; TICS=Telephone Interview for Cognitive Status (TICS-m=modified); TMT=Trail Making Test (parts A and or B); WAIS=Wechsler Adult Intelligence Scale

**Appendix Table L5. Characteristics of eligible studies: vitamins vs. inactive control in adults with MCI**

<b>Vitamin Intervention Type</b>	<b>Study Design Country RoB</b>	<b>N=</b>	<b>Population Inclusion Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition</b>	<b>Intervention Duration</b>	<b>Comparison</b>	<b>Outcome timing</b>	<b>Outcome Domain [Instrument]</b>
<b>Multivitamins</b>	Naeini 2014 <sup>22</sup> RCT Iran Low	256	Adults aged 60-75 with MCI (MMSE 21-26) Age 67 Female 53% Race NR Education: Primary 16% Secondary 11% Diploma 40% University degree 33% Baseline cognition: MMSE 24	Vitamin E (300 mg) Vitamin C (400 mg) Daily for 1 year	Placebo	1 year	<u>Brief Cognitive Test Performance [MMSE]</u>
<b>B vitamins</b>	Remington 2015 <sup>23</sup> RCT US High	34	Community-dwelling adults with MCI Age 66 Female NR Race NR Education: 15 years Baseline cognition NR	Folic acid (0.4 mg) Vitamin B <sub>12</sub> (6 µg) Vitamin E (30 IU) SAM (S-adenosyl methionine 400 mg) ALCAR (acetyl-Lcarnitine 500 mg) NAC (N-acetyl cysteine 600 mg) Two doses daily for 6 months	Placebo	6 months	<u>Brief Cognitive Test Performance [Mattis Dementia Rating Scale]</u> <u>Visuospatial [CLOX-1]</u>
	Smith 2010 <sup>24</sup> deJager 2012 <sup>25</sup> Duouad 2013 <sup>26</sup> Oulhaj 2016 <sup>27</sup> RCT UK Low	266	Adults aged 70+ diagnosed with MCI (Peterson's criteria) Age 77 Female 47% Race NR Mean years of education: 15 Baseline cognition: MMSE 28 TICS 25	Folic Acid (0.8 mg) Vitamin B <sub>6</sub> (20 mg) Vitamin B <sub>12</sub> (0.5 mg) Daily for 2 years	Placebo	2 years	<u>Biomarker [Posterior Brain Atrophy, Rate of Atrophy]</u> <u>Brief Cognitive Test Performance [MMSE]</u> <u>Memory [HVLIT]</u> <u>Language [Category Fluency Test]</u> <u>Visuospatial [CLOX-1]</u>

Vitamin Intervention Type	Study Design Country RoB	N=	Population Inclusion Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention Duration	Comparison	Outcome timing	Outcome Domain [Instrument]
	van Uffelen 2008 <sup>28</sup> RCT Netherlands High	152	Community-dwelling adults with MCI aged 70-80 Age 75 Female 44% Race NR Education: Low 58% Medium 25% High 17% Baseline education: MMSE 29	Folic acid (5 mg) Vitamin B <sub>6</sub> (50 mg) Vitamin B <sub>12</sub> (0.4 mg) Daily for 1 year	Placebo	1 year	<u>Brief Cognitive Test Performance</u> [MMSE] <u>Executive/Attention/Processing Speed</u> [Verbal Fluency Test] [DSST] [SCWT] <u>Memory</u> [RAVLT] <u>Language</u> [Verbal Fluency Test]
<b>Vitamin E</b>	Petersen 2005 <sup>29</sup> Jack 2008 <sup>30</sup> RCT USA Low (Petersen) High (Jack)	516	Adults aged 55-90 with degenerative amnesic MCI Age 73 Female 47% Race NR Education NR Baseline cognition: MMSE 27	Vitamin E (2000 IU) Daily for 3 years (study included a donepezil arm)	Placebo	3 years	<u>Diagnosis</u> [Possible or Probable AD] [CDR Sum of Boxes, AD] <u>Brief Cognitive Test Performance</u> [MMSE] <u>Multidomain Neuropsychological Test Performance</u> [ADAS-Cog] <u>Executive/Attention/Processing Speed</u> [from Composite Battery, presumed to be DS Backward, SDMT, Number Cancellation, Maze Tracing] <u>Memory</u> [from Composite Battery, presumed to be New York University Paragraph Recall Test] <u>Language</u> [from Composite Battery, presumed to be BNT, Category Fluency] <u>Visuospatial</u> [from Composite Battery, presumed to be CLOX-1]

µg=micrograms (1000 µg=1 mg) (1000 µg=1 g); AD=Alzheimer's disease; ADAS-Cog=Alzheimer's Disease Assessment Scale-Cognitive Subscale; CDR=Clinical Dementia Rating; CLOX-1= Clock Drawing Test; DSST=Digit Symbol Substitution Test; HVL=Hopkins Verbal Learning Test; IU=internal units; MCI=mild cognitive impairment; mg=milligrams; MMSE=Mini Mental Status Exam; NR=not reported; RAVLT=Rey Auditory Verbal Learning Test; RCT=randomized controlled trial; SCWT=Stroop Color Word Test; SDMT=Symbol Digit Modalities Test; US=United States

**Appendix Table L6. Summary risk of bias assessments: vitamins in adults with MCI**

<b>Intervention</b>	<b>Study</b>	<b>Overall Risk of Bias Assessment</b>	<b>Rationale</b>
<b>Multivitamins</b>	Naeini 2014 <sup>22</sup>	Low	Randomization methods unclear, blinding methods adequate, attrition low, ITT not reported.
<b>B vitamins</b>	Oulhaj 2015 <sup>27</sup>	Low	Randomization methods adequate, attrition 16%, blinding and outcome assessment methods unclear but likely reported in previous publications.
	Remington 2015 <sup>23</sup>	High	Randomization methods unclear, attrition 45% at 6 month followup with no missing data imputation.
	Douaud 2013 <sup>26</sup>	Low	Randomization and blinding methods adequate, attrition low, all outcomes reported.
	de Jager 2012 <sup>25</sup>	Low	Randomization methods adequate, attrition 16% for cognitive outcomes and no missing data imputation, blinding methods likely adequate, all outcomes reported.
	Smith 2010 <sup>24</sup>	Low	Randomization and blinding methods adequate, attrition low for primary outcome and medium for secondary outcomes, ITT, comparable outcome assessment timing between groups.
	van Uffelen 2008 <sup>28</sup>	High	Randomization and allocation methods adequate, attrition 16%, outcome assessor blinding unclear, outcomes inexplicably reported stratified by gender (not reported overall).
<b>Vitamin E</b>	Jack 2008 <sup>30</sup>	High	Randomization and allocation methods unclear, volunteer cohort of original randomized trial, attrition 33%.
	Petersen 2005 <sup>29</sup>	Low	Randomization and blinding methods adequate, attrition 30% but performed appropriate sensitivity analyses, ITT.

ITT=intention to treat; MCI=mild cognitive impairment

**Appendix Table L7. Strength of evidence assessments: vitamins vs. inactive control in adults with MCI**

Vitamin Intervention Type	Outcome	# Trials (n)	Evidence Summary Summary statistics [95% CI]	Study Limitations	Directness	Precision	Consistency	Reporting Bias	Optional Components	SOE
Vitamin E vs. placebo	Dementia Peterson 2005 <sup>29</sup> : 3 years	1 (516)	2 tests showed no statistically significant decrease in diagnosis of Alzheimer's disease with vitamin E, Diagnosis, between groups probability of progression to Alzheimer's disease HR=1.02 [0.74 to 1.41] p=0.91 CDR Sum of Boxes, between groups change from baseline (z-score)* 0.03 [NR]	Medium	Direct	Imprecise	Consistent	Undetected	NA	Low
	Brief Cognitive Test Performance	1 (516)	1 test showed no statistically significant improvement with vitamin E MMSE, between	Medium	Indirect	Imprecise	Unknown	Undetected	NA	Insufficient



Vitamin Intervention Type	Outcome	# Trials (n)	Evidence Summary Summary statistics [95% CI]	Study Limitations	Directness	Precision	Consistency	Reporting Bias	Optional Components	SOE
			groups change from baseline (z-score)* 0.55 [NR]							
	Multidomain Neuropsychological Performance	1 (516)	1 test showed no statistically significant improvement with vitamin E ADAS-Cog, between groups change from baseline (z-score)* 0.85 [NR]	Medium	Indirect	Imprecise	Unknown	Undetected	NA	Insufficient
	Executive/ Attention/ Processing Speed	1 (516)	1 composite test showed no statistically significant improvement with vitamin E Composite, between groups change from baseline (z-score)* 0.0 [NR]	Medium	Indirect	Imprecise	Unknown	Undetected	NA	Insufficient
	Memory	1 (516)	1 composite test showed no statistically	Medium	Indirect	Imprecise	Unknown	Undetected	NA	Insufficient

Vitamin Intervention Type	Outcome	# Trials (n)	Evidence Summary Summary statistics [95% CI]	Study Limitations	Directness	Precision	Consistency	Reporting Bias	Optional Components	SOE
			significant improvement with vitamin E Composite, between groups change from baseline (z-score)* -0.03 [NR]							
	Adverse Effects	1 (516)	No significant difference between groups for withdrawals 28% vs. 25%* RR*=1.10 [0.83 to 1.46] p=0.52	Medium	Direct	Imprecise	Unknown	Undetected	NA	Low

\*calculated by EPC

ADAS-Cog=Alzheimer's Disease Assessment Scale-Cognitive Subscale; CDR=Clinical Dementia Rating; HR=hazard ratio; k=number of studies; MMSE= Mini-Mental Status Exam; n=sample size; NA=not applicable; NR=not reported; RR=relative risk

## References for Appendix L

1. Chew EY, Clemons TE, Agron E, et al. Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial. *JAMA*. 2015 Aug 25;314(8):791-801. doi: 10.1001/jama.2015.9677. PMID: 26305649.
2. Grodstein F, O'Brien J, Kang JH, et al. Long-term multivitamin supplementation and cognitive function in men: a randomized trial. *Ann Intern Med*. 2013 Dec 17;159(12):806-14. doi: 10.7326/0003-4819-159-12-201312170-00006. PMID: 24490265.
3. Kesse-Guyot E, Fezeu L, Jeandel C, et al. French adults' cognitive performance after daily supplementation with antioxidant vitamins and minerals at nutritional doses: a post hoc analysis of the Supplementation in Vitamins and Mineral Antioxidants (SU.VI.MAX) trial. *Am J Clin Nutr*. 2011 Sep;94(3):892-9. doi: 10.3945/ajcn.110.007815. PMID: 21775560.
4. McNeill G, Avenell A, Campbell MK, et al. Effect of multivitamin and multimineral supplementation on cognitive function in men and women aged 65 years and over: a randomised controlled trial. *Nutr J*. 2007;6:10. doi: 10.1186/1475-2891-6-10. PMID: 17474991.
5. Wolters M, Hickstein M, Flintermann A, et al. Cognitive performance in relation to vitamin status in healthy elderly German women-the effect of 6-month multivitamin supplementation. *Prev Med*. 2005 Jul;41(1):253-9. doi: 10.1016/j.ypmed.2004.11.007. PMID: 15917019.
6. Yaffe K, Clemons TE, McBee WL, et al. Impact of antioxidants, zinc, and copper on cognition in the elderly: a randomized, controlled trial. *Neurology*. 2004 Nov 9;63(9):1705-7. PMID: 15534261.
7. Heart Protection Study Collaborative G. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet*. 2002 Jul 6;360(9326):23-33. doi: 10.1016/S0140-6736(02)09328-5. PMID: 12114037.
8. Cockle S, Haller J, Kimber S, et al. The influence of multivitamins on cognitive function and mood in the elderly. *Aging & Mental Health*. 2000;4(4):339-53.
9. Smith A, Clark R, Nutt D, et al. Anti-oxidant vitamins and mental performance of the elderly. *Human Psychopharmacology-Clinical and Experimental*. 1999 Oct;14(7):459-71. doi: Doi 10.1002/(Sici)1099-1077(199910)14:7<459::Aid-Hup128>3.0.Co;2-0. PMID: WOS:000083485200003.
10. Durga J, van Boxtel MP, Schouten EG, et al. Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial. *Lancet*. 2007 Jan 20;369(9557):208-16. PMID: 17240287.
11. van der Zwaluw NL, Dhonukshe-Rutten RA, van Wijngaarden JP, et al. Results of 2-year vitamin B treatment on cognitive performance: secondary data from an RCT. *Neurology*. 2014 Dec 2;83(23):2158-66. doi: 10.1212/WNL.0000000000001050. PMID: 25391305.
12. Walker JG, Batterham PJ, Mackinnon AJ, et al. Oral folic acid and vitamin B-12 supplementation to prevent cognitive decline in community-dwelling older adults with depressive symptoms--the Beyond Ageing Project: a randomized controlled trial. *Am J Clin Nutr*. 2012 Jan;95(1):194-203. doi: 10.3945/ajcn.110.007799. PMID: 22170358.
13. Andreeva VA, Kesse-Guyot E, Barberger-Gateau P, et al. Cognitive function after supplementation with B vitamins and long-chain omega-3 fatty acids: ancillary findings from the

- SU.FOL.OM3 randomized trial. *Am J Clin Nutr*. 2011 Jul;94(1):278-86. doi: 10.3945/ajcn.110.006320. PMID: 21593490.
14. Brady CB, Gaziano JM, Cxypoliski RA, et al. Homocysteine lowering and cognition in CKD: the Veterans Affairs homocysteine study. *Am J Kidney Dis*. 2009 Sep;54(3):440-9. doi: 10.1053/j.ajkd.2009.05.013. PMID: 19628319.
  15. Kang JH, Cook N, Manson J, et al. A trial of B vitamins and cognitive function among women at high risk of cardiovascular disease. *American Journal of Clinical Nutrition*. 2008 Dec;88(6):1602-10. doi: <http://dx.doi.org/10.3945/ajcn.2008.26404>. PMID: 19064521.
  16. McMahon JA, Green TJ, Skeaff CM, et al. A controlled trial of homocysteine lowering and cognitive performance. *N Engl J Med*. 2006 Jun 29;354(26):2764-72. doi: 10.1056/NEJMoa054025. PMID: 16807413.
  17. Kang JH, Cook NR, Manson JE, et al. Vitamin E, vitamin C, beta carotene, and cognitive function among women with or at risk of cardiovascular disease: The Women's Antioxidant and Cardiovascular Study. *Circulation*. 2009 Jun 2;119(21):2772-80. doi: 10.1161/CIRCULATIONAHA.108.816900. PMID: 19451353.
  18. Kang JH, Cook N, Manson J, et al. A randomized trial of vitamin E supplementation and cognitive function in women. *Arch Intern Med*. 2006 Dec 11-25;166(22):2462-8. doi: 10.1001/archinte.166.22.2462. PMID: 17159011.
  19. Rossom RC, Espeland MA, Manson JE, et al. Calcium and vitamin D supplementation and cognitive impairment in the women's health initiative. *J Am Geriatr Soc*. 2012 Dec;60(12):2197-205. doi: 10.1111/jgs.12032. PMID: 23176129.
  20. Stott DJ, MacIntosh G, Lowe GD, et al. Randomized controlled trial of homocysteine-lowering vitamin treatment in elderly patients with vascular disease. *American Journal of Clinical Nutrition*. 2005 Dec;82(6):1320-6. PMID: 16332666.
  21. Carlsson CM, Papcke-Benson K, Carnes M, et al. Health-related quality of life and long-term therapy with pravastatin and tocopherol (vitamin E) in older adults. *Drugs Aging*. 2002;19(10):793-805. PMID: 12390056.
  22. Naeini AM, Elmadfa I, Djazayeri A, et al. The effect of antioxidant vitamins E and C on cognitive performance of the elderly with mild cognitive impairment in Isfahan, Iran: a double-blind, randomized, placebo-controlled trial. *Eur J Nutr*. 2014 Aug;53(5):1255-62. doi: 10.1007/s00394-013-0628-1. PMID: 24326981.
  23. Remington R, Lortie JJ, Hoffmann H, et al. A Nutritional Formulation for Cognitive Performance in Mild Cognitive Impairment: A Placebo-Controlled Trial with an Open-Label Extension. *J Alzheimers Dis*. 2015 01 Oct;48(3):591-5. doi: 10.3233/JAD-150057. PMID: 26402075.
  24. Smith AD, Smith SM, de Jager CA, et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. *PLoS One*. 2010;5(9):e12244. doi: 10.1371/journal.pone.0012244. PMID: 20838622.
  25. de Jager CA, Oulhaj A, Jacoby R, et al. Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial. *Int J Geriatr Psychiatry*. 2012 Jun;27(6):592-600. doi: 10.1002/gps.2758. PMID: 21780182.
  26. Douaud G, Refsum H, de Jager CA, et al. Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment. *Proc Natl Acad Sci U S A*. 2013 Jun 4;110(23):9523-8. doi: 10.1073/pnas.1301816110. PMID: 23690582.

27. Oulhaj A, Jerneren F, Refsum H, et al. Omega-3 fatty acid status enhances the prevention of cognitive decline by B Vitamins in mild cognitive impairment. *Journal of Alzheimer's Disease*. 2015 10 Dec;50(2):547-57. doi: <http://dx.doi.org/10.3233/JAD-150777>. PMID: 608047606.
28. van Uffelen JG, Chinapaw MJ, van Mechelen W, et al. Walking or vitamin B for cognition in older adults with mild cognitive impairment? A randomised controlled trial. *British Journal of Sports Medicine*. 2008 May;42(5):344-51. doi: <http://dx.doi.org/10.1136/bjsm.2007.044735>. PMID: 18308888.
29. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. *N Engl J Med*. 2005 Jun 9;352(23):2379-88. doi: 10.1056/NEJMoa050151. PMID: 15829527.
30. Jack CR, Jr., Petersen RC, Grundman M, et al. Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. *Neurobiology of Aging*. 2008 Sep;29(9):1285-95. PMID: 17452062.

## Appendix M. Antihypertension Treatment

**Appendix Table M1. Characteristics of eligible studies: antihypertension interventions in adults with normal cognition**

Intervention Type	Study Design Country RoB	N=	Population Inclusion Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cog	Intervention (INT) Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome measurement timing	Outcome (Instrument)
<i>ACE and Thiazide Efficacy</i>	Peters 2008 <sup>1</sup> (HYVET-COG) RCT Multinational Medium	3,845	Adults aged ≥80 years with an average sitting systolic blood pressure between 160 mmHg and 200 mmHg and an average standing systolic blood pressure ≥140 mmHg, and a sitting diastolic blood pressure of ≤110 mmHg. Normal cognition. Mean age (SD): 83.5 (3.1) 61% Female Race: NR 27% no education 28% primary education 29% secondary education 12% higher education 3% more than higher education Median MMSE (range): 26 (15 – 30)	Indapamide 1.5 mg with optional perindopril (2mg up to 4 mg)	Matching-placebo	2.2 years mean follow up	<u>Diagnosis</u> [Committee-reported diagnosis of dementia] <u>Brief Cognitive Test Performance</u> [MMSE, cognitive decline defined as MMSE <24 or a decline of >3 MMSE points in a year]

	Patel 2007 <sup>2</sup> ADVANCE Collaborative Group 2007 <sup>2</sup> RCT Multinational Low	11,140	Adults diagnosed with type 2 diabetes at the age ≥30 years, and were aged ≥55 years at study entry. Patients also need to have a history of cardiovascular disease or at risk for cardiovascular disease. Normal cognition. Mean age (SD): 66 (7) 43% Female Race: NR Education: NR Median MMSE (range): NR	Combined perindopril (2 mg up to 4 mg) and indapamide (0.625 mg up to 1.25 mg) and open label perindopril up to 4 mg	Matching-placebo and open label perindopril up to 4 mg.	4.3 yeas mean follow up	<u>Diagnosis</u> <u>Brief Cognitive Test Performance [MMSE]</u>
ARB Efficacy	Anderson 2011 <sup>3</sup> (TRANSCEND trial) RCT Multinational Medium	5926	Adults aged ≥55 years with evidence of coronary artery, peripheral vascular, or cerebrovascular disease or diabetes with end-organ damage, intolerance to ACE inhibitors, and normal cognition. Mean age (SD): 66.9 43% Female 61% European ethnic origin 62% ≥9 years of education Median MMSE (IRQ): 29 (27 – 30)	Telmisartan 80 mg daily	Placebo daily	56 months median follow up	<u>Brief Cognitive Test Performance [Cognitive decline - drop of 3 or more MMSE points]</u>

	Saxby 2008 <sup>4</sup> (single center in SCOPE trial) RCT United Kingdom Medium	257	Hypertensive adults aged 70 to 89 years with systolic blood pressure of 160 to 179 mmHg and diastolic blood pressure of 90 to 99 mmHg and normal cognition. Mean age (SD): 76 (4) 54% Female Race: NR Mean years education (SD): 10 (2) Mean MMSE (SD): 29 (1)	Candesartan (8 mg – 16 mg) daily with hydrochlorothiazide 12.5 mg added as needed. When target blood pressure not achieved (<160/90 mmHg) other drugs added as needed.	Placebo daily and hydrochlorothiazide 12.5 mg added as needed. When target blood pressure not achieved (<160/90 mmHg) other drugs added as needed.	44 months mean follow up	<u>Brief Cognitive Test Performance</u> [MMSE] <u>Executive/Attention/Processing Speed</u> [Composite] <u>Memory</u> [Composite]
	Lithell 2003 <sup>5</sup> Skog 2005 <sup>6</sup> (SCOPE trial) RCT Multinational Medium	4937	Hypertensive adults aged 70 to 89 years with systolic blood pressure of 160 to 179 mmHg and diastolic blood pressure of 90 to 99 mmHg and normal cognition with results stratified by low (MMSE 24 – 28) and high (29 – 30) cognitive function. Mean age (SD): 76 (NR) 64% female Race: NR 10% less than primary school education 44% primary school education 40% more than primary school education 6% University	Candesartan (8mg – 16 mg) daily with hydrochlorothiazide 12.5 mg added as needed. When target blood pressure not achieved (<160/90 mmHg) other drugs added as needed.	Placebo daily and hydrochlorothiazide 12.5mg added as needed. When target blood pressure not achieved (<160/90 mmHg) other drugs added as needed.	44 months mean follow up	<u>Diagnosis</u> <u>Brief Cognitive Test Performance</u> [MMSE]



			education Mean MMSE (SD): 28.5 (NR)				
<i>Beta Blocker Efficacy</i>	Perez-Stable 2000 <sup>7</sup> RCT United States High	312	Adults aged 18 to 59 with diastolic blood pressure between 90 and 104 mmHg and normal cognition.	Propranolol (40 mg first three days then 80 mg daily as tolerated then increased up to 400 mg daily)	Placebo daily	12 months	<u>Executive/Attention/Processing Speed</u> [Stimulus Evaluation/Response Selection, CPT, DSST] <u>Memory</u> [CVLT]
	Bird 1990 <sup>8,9</sup> RCT United Kingdom Medium	2401	Adults aged 65 to 74 with systolic blood pressure of 160 to 209 mmHg and diastolic blood pressure of <114 mmHg, and normal cognition. Mean age (SD): 70.3 (2.7) 58% Female Race: NR Education: NR Cognition: NR	Atenolol 50 mg daily	Placebo daily	9 months	<u>Executive/Attention/Processing Speed</u> [TMT] <u>Memory</u> [PALS]
<i>Combination therapy Efficacy</i>	Forette 2002 <sup>10</sup> (Syst-Eur trial 1 & 2) RCT and open-label follow up Multinational Medium	3228	Adults aged >60 years with systolic blood pressure of 160 to 219 mmHg and diastolic blood pressure <95 mmHg and normal cognition. Median age (range): 68 (60-92) Sex: NR Race: NR Mean age (SD) on leaving school: 16.7 (4.5) Cognition: NR	Antihypertensive stepwise therapy with titration with goal of lowering systolic blood pressure by 20 mmHg or below 150 mmHg (step 1: nitrendipine 10 -40 mg daily; step 2: enalapril 5 – 20 mg daily; step 3: hydrochlorothiazide 12.5 – 25 mg daily)	Placebo daily (in open-label phase offered active treatment)	3.9 years median follow up	<u>Diagnosis</u> <u>Brief Cognitive Test</u> <u>Performance</u> [MMSE]
	Forette 1998 <sup>11</sup> (Syst-Eur trial	3162	Adults >60 years with systolic blood	Antihypertensive stepwise therapy	Placebo daily	2 years median follow up	<u>Diagnosis</u> <u>Brief Cognitive Test</u>

	1) RCT Multinational Medium		pressure of 160 to 219 mmHg and diastolic blood pressure <95 mmHg and normal cognition. Mean age (SD): 69.9 (6.4) Sex: NR Race: NR Mean age (SD) on leaving school: 16.2 (4.4) Median MMSE (range): 29 (15-30)	with titration with goal of lowering systolic blood pressure by 20 mmHg or below 150 mmHg (step 1: nitrendipine 10 -40 mg daily; step 2: enalapril 5 – 20 mg daily; step 3: hydrochlorothiazide 12.5 – 25 mg daily)			<u>Performance</u> [MMSE]
	Applegate 1994 <sup>12, 13</sup> (SHEP trial) RCT United States High	4736	Adults >60 years with systolic blood pressure of 160 to 220 mmHg and diastolic blood pressure <90 mmHg and normal cognition. Mean age (range): 72 (60 – 94) 57% Female 86% White Mean years of education (SD): 11.7 (NR) 0.4% Evidence of cognitive impairment	Step therapy: step 1: chlorthalidone (12.5 – 25 mg); step 2: atenolol (25 – 50 mg) or reserpine (0.05 – 0.1 mg).	Placebo daily	5 year average follow up	<u>Diagnosis</u> <u>Brief Cognitive Test</u> <u>Performance</u> [SHORT-CARE Dementia] <u>Executive/Attention/Processing Speed</u> [DSST] <u>Memory</u> [Addition Test] [Finding A's Test] [Delayed Recognition Span Test] <u>Language</u> [BNT] <u>Visuospatial</u> [Letter Sets Test]
	Gurland 1988 <sup>14</sup> (SHEP feasibility trial) RCT United States Medium	551	Adults >60 years with systolic blood pressure >160 mmHg and diastolic blood pressure <90 mmHg and normal cognition. Mean Age: NR Sex: NR 83% White Education: NR Cognition: NR	Step therapy: step 1: chlorthalidone; step 2: reserpine, metoprolol, or hydralazine)	Placebo	1 year	<u>Diagnosis</u> <u>Executive/Attention/Processing Speed</u> [TMT] [DSST] [Composite Battery <sup>b</sup> ]

Comparative Effectiveness ARB versus ACE	Hajjar 2013 <sup>15</sup> RCT United States Medium	53	Adults aged ≥60 years with systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg or receiving antihypertensive medications and normal cognition. Mean age (SD): 72 (7) 57% Female 70% White 19% ≤High school Mean MMSE (SD): 26 (2)	I <sub>1</sub> :Lisinopril 10 mg with titration to 40 mg I <sub>2</sub> : Candesartan 8 mg with titration to 32 mg I <sub>3</sub> : Hydrochlorothiazide 12.5 mg with titration to 25 mg  If systolic blood pressure of less than 140 mmHG and diastolic blood pressure of less than 90 mmHG not get then long-acting nifedipine (30 mg increased to 90 mg) was added followed by long-acting metoprolol (12.5 mg to 50 mg).		6 months	<u>Executive/Attention/Processing Speed [TMT] [DS Test] Memory [HVL T]</u>
	Anderson 2011 <sup>3</sup> (ONTARGET trial) RCT Multinational Medium	17118	Adults aged ≥55 with evidence of coronary artery, peripheral vascular, or cerebrovascular disease or diabetes with end-organ damage, and normal cognition. Mean age (SD): 66 (7.2) 27% Female 73% European ethnic origin 67% ≥ 9 years of education Median MMSE (IQR): 29 (27 – 30)	Ramipril 5mg (increased to 10 mg after 2 weeks) daily	Telmisartan 80 mg daily	56 months median follow up	<u>Brief Cognitive Test Performance [Cognitive decline - drop of 3 or more MMSE points]</u>
	Forgari 2006 <sup>16</sup> RCT open-	160	Adults aged 61 to 75 with systolic	Telmisartan 80 mg and	Lisinopril 20 mg and	6 months	<u>Executive/Attention/Processing Speed [TMT B]</u>

	label Italy Low		blood pressure >140 mmHg diastolic blood pressure ≥95 and <110 mmHg, and normal cognition. Mean age (SD): 68 (5.5) 54% Female Race: NR Education: NR Cognition: NR	hydrochlorothiazide 12.5 mg daily	hydrochlorothiazide 12.5mg daily		<u>Memory</u> [Word-List Memory Test] [Word-List Recall Test] [Word-List Recognition Test] <u>Language</u> [BNT] [Name Animals]
<i>Comparative Effectiveness ARB versus Thiazide</i>	Hajjar 2013 <sup>15</sup> RCT United States Medium	53	Adults aged ≥60 years with systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg or receiving antihypertensive medications and normal cognition. Mean age (SD): 72 (7) 57% Female 70% White 19% ≤High school Mean MMSE (SD): 26 (2)	I <sub>1</sub> :Lisinopril 10 mg with titration to 40 mg I <sub>2</sub> : Candesartan 8 mg with titration to 32 mg I <sub>3</sub> : Hydrochlorothiazide 12.5 mg with titration to 25 mg  If systolic blood pressure of less than 140 mmHG and diastolic blood pressure of less than 90 mmHG not get then long-acting nifedipine (30 mg increased to 90 mg) was added followed by long-acting metoprolol (12.5 mg to 50 mg).		6 months	<u>Executive/Attention/Processing Speed</u> [TMT, DSST] <u>Memory</u> [HVLt-R]
	Tedesco 1999 <sup>17</sup> RCT Italy Low	69	Adults aged 30 to 73 with mild-to-moderate essential hypertension: diastolic blood pressure of 90 to 114 mmHg and normal cognition.	Losartan 50 mg daily	Hydrochlorothiazide 25 mg daily	26 months	<u>Brief Cognitive Test Performance</u> [MMSE]

			Mean age (SD): 55 (11) 48% Female Race: NR Mean years education (SD): 9.1 (4) Mean MMSE (SD): 23 (3)				
<i>Comparative Effectiveness – Unique comparisons</i>	Williamson 2014 <sup>18</sup> (ACCORD BP trial) RCT United States Medium	1439	Middle-aged and older adults with diabetes at high risk of cardiovascular events and systolic blood pressure of 130 to 180 mmHg and normal cognition. Mean age (SD): 62 (5.8) 55% Female 66% White 13% <High school 26% High school graduate 36% Some college 25% college graduate or more Median MMSE (25 <sup>th</sup> and 75 <sup>th</sup> percentile): 28 (26-29)	Intensive intervention (systolic blood pressure <120 mm Hg)	Standard therapy (systolic blood pressure <140 mm Hg)	40 months	<u>Brief Cognitive Test Performance [MMSE]</u> <u>Executive/Attention/Processing Speed [SCWT] [DSST]</u> <u>Memory [RAVLT]</u>
	Hajjar 2013 <sup>15</sup> RCT United States Medium	53	Adults aged ≥60 years with systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg or receiving antihypertensive medications and normal cognition. Mean age (SD): 72 (7) 57% Female 70% White	I <sub>1</sub> : Lisinopril 10mg with titration to 40 mg I <sub>2</sub> : Candesartan 8 mg with titration to 32 mg I <sub>3</sub> : Hydrochlorothiazide 12.5mg with titration to 25 mg  If systolic blood pressure of less		6 months	<u>Executive/Attention/Processing Speed [TMT] [DSST]</u> <u>Memory [HVL-R]</u>

			19% ≤High school Mean MMSE (SD): 26 (2)	than 140 mmHG and diastolic blood pressure of less than 90mmHG not get then long-acting nifedipine (30 mg increased to 90 mg) was added followed by long-acting metoprolol (12.5 mg to 50 mg).			
Sato 2013 <sup>19</sup> (CAMUI trial) RCT open- label Japan Low	142	Hypertensive adults aged ≥65 years that had not attained the blood pressure goal (systolic blood pressure <140 mmHg and or diastolic blood pressure >90 mmHg) with monotherapy with typical dosage of ARB and normal cognition. Mean age (SD): 74 (6.2) Sex: NR Race: NR Education: NR Mean MMSE (SD): 26.7 (3)	Combined losartan 50mg and hydrochlorothiazide 12.5 mg daily in quarterly visits if blood pressure goals not obtained titration was undertaken	Combined amlodipine 5mg and typical dosage of a angiotensin receptor blocker daily during quarterly visits if blood pressure goals not obtained titration was undertaken	12 months	<u>Brief Cognitive Test Performance</u> [MMSE]	
Anderson 2011 <sup>3</sup> (ONTARGET trial) RCT Multinational Medium	17078	Adults aged ≥55 years with evidence of coronary artery, peripheral vascular, or cerebrovascular disease or diabetes with end-organ damage, and normal cognition. Mean age (SD): 66 (7.2) 27% Female 73% European	Ramipril 5mg (increased to 10mg after 2wks) daily	Combined ramipril 5 mg (increased to 10mg after 2wks) daily and telmisartan 80 mg daily	56 months median follow up	<u>Brief Cognitive Test Performance</u> [Cognitive decline - drop of 3 or more MMSE points]	

			ethnic origin 67% ≥ 9 years of education Median MMSE (IRQ): 29 (27 – 30)				
	Forgari 2003 <sup>20</sup> RCT Italy Low	120	Adults aged 75 to 89 with mild to moderate essential hypertension: systolic blood pressure <200 mmHg and diastolic blood pressure of 90 to 105 mmHg. Normal cognition. Mean age (SD): 83 (4.3) 56% Female Race: NR Mean years education (SD): 8.6 (4.1) Cognition: NR	Atenolo 50 mg with titration to 100 mg	Losartan 50 mg with titration to 100 mg	6 months	<u>Memory</u> [Word-List Test] [Memory Word Recall Test] <u>Language</u> [Word-List Frequency]
	Yodfat 1996 <sup>21</sup> RCT Israel Low	368	Males aged 40 to 65 with essential hypertension: diastolic blood pressure of 95 to 105 mmHg. Normal cognition. Mean age (SD): 52 (7.6) 100% Male Race: NR Education: NR Cognition: NR	I <sub>1</sub> : Isradipine 1.25 mg twice a day (dose doubled if normotension not achieved at 4 weeks and if normotension not achieved at 6 weeks captopril 25mg daily) I <sub>2</sub> : Methyldopa 250 mg twice a day (dose doubled if normotension not achieved at 4 weeks and if normotension not achieved at 6 weeks captopril 25 mg daily)	placebo twice a day	12 months	<u>Language</u> [Semantic Memory]
	Bird 1990 <sup>8</sup>	2446	Adults aged 65 to	I <sub>1</sub> : Atenolol 50mg	Placebo	9 months	<u>Executive/Attention/Processing</u>

	RCT United Kingdom Medium		74 with systolic blood pressure of 160 to 209 mmHg and diastolic blood pressure of <114 mmHg, and normal cognition. Mean age (SD): 70.3 (2.7) 58% Female Race: NR Education: NR Cognition: NR	daily  I <sub>2</sub> : Moduretic (hydrochlorothiazide 25mg and amiloride 2.5mg) daily			<u>Speed</u> [TMT] <u>Memory</u> [PALS]
	Goldstein 1990 <sup>22</sup> RCT United States High	690	Men aged >60 with mild-to-moderate hypertension and normal cognition.  Mean Age: NR 100% Male Race: NR Mean years of education (SD): 10.6 (NR) Cognition: NR	Hydrochlorothiazide 25mg once or twice a day if target blood pressure not achieved (<90 mmHg and ≤5 mmHg decline from baseline) randomly assigned to additional therapy (hydralazine 50-200 mg daily, methyldopa 550-2,000 mg daily, metoprolol 100-400 mg daily, and reserpine 0.05-0.25mg daily).	Hydrochlorothiazide 50mg once or twice a day if target blood pressure not achieved (<90 mmHg and ≤5 mmHg decline from baseline) randomly assigned to additional therapy (hydralazine 50-200mg daily, methyldopa 550-2,000 mg daily, metoprolol 100-400 mg daily, and reserpine 0.05-0.25mg daily).	1 year	<u>Executive/Attention/Processing Speed</u> [TMT] [Symbol Digit (no. correct)] [Time Estimation] [Digit Span] <u>Memory</u> [BVRT [Immediate and Delayed Logical Memory] PALS] [Complex Cognition Composite] [Memory composite] <u>Language</u> [Token Test, Controlled word production] <u>Motor</u> [Halstead Finger Tapping [Motor Speed Composite] <u>Visuospatial</u> [Hooper Visual Organization]

<sup>a</sup> Saxby 2008<sup>4</sup> evaluated a composite measures of episodic memory (composed of immediate word recall, immediate word recognition, delayed word recall, delayed word recognition, picture recognition), attention (composited simple reaction time, number vigilance, choice reaction time), working memory (composed of spatial memory, numeric working memory), speed of cognition (composed of reaction time scores from episodic memory recognition tasks, attention, and working memory tasks), and executive function (composed of trail making A & B, verbal fluency for letters F, A, and S, verbal fluency for category animals).

<sup>b</sup> Gurland 1988<sup>14</sup> evaluated a composite executive/attention/processing speed measure composed of SHORT-CARE dementia, Trail Making, and Digit Symbol test. ACE=angiotensin converting enzyme inhibitors; BNT=Boston Naming Test; DSST=Digit Symbol Substitution Test; HVLT=Hopkins Verbal Learning Test; IQR=interquartile range; mg=milligrams; mmHg=millimeter of mercury; MMSE=Mini-Mental Status Examination; N=sample size; NR=not reported; PALS=Paired Association Learning Test; RAVLT=Rey's Auditory Verbal Learning Test; RCT=randomized controlled trial; RoB=risk of bias; SCWT=Stroop Color Word Test; SD=standard deviation; TMT=Trail Making Test (Part A and/or B)

**Appendix Table M2. Summary risk of bias assessments: antihypertensives in adults with normal cognition**

Intervention	Study	Overall Risk of	Rationale
--------------	-------	-----------------	-----------



Type		Bias Assessment	
<i>ACE and Thiazide versus Placebo</i>	Peters 2008 <sup>1</sup>	Medium	Attrition 19%
	ADVANCE Collaborative Group 2007 <sup>2</sup>	Low	
<i>ARB versus Placebo</i>	Anderson 2011 <sup>3</sup>	Medium (TRANSCEND)	Attrition 12%
	Saxby 2008 <sup>4</sup>	Medium	Attrition 13%
	Lithell 2003 <sup>5</sup> , Skoog 2005 <sup>6</sup>	Medium	Attrition 32%
<i>Beta Blocker versus Placebo</i>	Perez-Stable 2000 <sup>7</sup>	High	Attrition 34%
	Bird 1990 <sup>8</sup>	Medium	Attrition 11%
<i>Combination Therapy versus Placebo</i>	Forette 2002 <sup>10</sup>	Medium	Attrition unclear and outcome assessor not independent
	Forette 1998 <sup>11</sup>	Medium	Attrition 14%
	Applegate 1994 <sup>9, 12</sup>	High	Attrition 25%
	Gurland 1988 <sup>14</sup>	Medium	Attrition 12%
<i>ARB versus ACE</i>	Anderson 2011 <sup>3</sup>	Medium (ONTARGET)	Attrition 12%
	Hajjar 2013 <sup>15</sup>	Medium (6 month outcomes) High (12 month outcomes)	Medium: Attrition 11% High: Attrition 42%
	Fogari 2006 <sup>16</sup>	Low	
<i>ARB versus Thiazide</i>	Hajjar 2013 <sup>15</sup>	Medium (6 month outcomes) High (12 month outcomes)	Medium: Attrition 11% High: Attrition 42%
	Tedesco 1999 <sup>17</sup>	Low	
<i>Comparative Effectiveness – Unique Comparisons</i>	Williamson 2014 <sup>18</sup>	Medium High (MIND substudy)	Medium (ACCORD BP trial): Attrition 13% High (ACCORD BP MIND trial): Attrition 24% among those in the intensive intervention
	Hajjar 2013 <sup>15</sup>	Medium (6 month outcomes) High (12 month outcomes)	Medium: Attrition 11% High: Attrition 42%
	Sato 2013 <sup>19</sup>	Low	
	Anderson 2011 <sup>3</sup>	Medium (ONTARGET)	Attrition 12%

	Fogari 2003 <sup>20</sup>	Low	
	Yodfat 1996 <sup>21</sup>	Medium	Attrition 19%
	Bird 1990 <sup>8</sup>	Medium	Attrition 11%
	Goldstein 1990 <sup>22</sup>	High	Attrition 52%

ACE=angiotensin converting enzyme inhibitors; ARB=angiotensin receptor blocker

**Appendix Table M3. Strength of evidence assessments: antihypertensives in adults with normal cognition**

Intervention Type	Outcome	# Trials (n)	Evidence Summary Summary statistics [95% CI]	Study Limitations	Directness	Precision	Consistency	Reporting Bias	Optional Components	SOE
Antihypertension (ACE and Thiazide)	Dementia	2 (14,985)	0 of 2 tests show statistically significant improvement  <u>Peters 2008 (HYVET-COG)<sup>1</sup></u>  Diagnosis HR: 0.86 [0.67 to 1.09]  <u>ADVANCE Collaborative Group 2007<sup>2</sup></u>  Relative risk reduction diagnosis: -4% [-64% to 33%]	Medium	Direct	Imprecise	Consistent	Suspected	NA	Low
	MCI	NR								Insufficient
	Brief Cognitive Test	2 (14,985)	0 of 3 tests show statistically significant improvement  <u>Peters 2008 (HYVET-COG)<sup>1</sup></u>  Cognitive decline (MMSE <24 or a decline of >3 MMSE points in a year HR: 0.93 [0.82 to 1.05])	Medium	Indirect	Precise	Consistent	Suspected	NA	Moderate

			<p>Mean MMSE change score in indapamide and perindopril 0.07 (SD 4.0) versus placebo -1.1 (SD 3.9) p = 0.08</p> <p><u>ADVANCE Collaborative Group 2007<sup>2</sup></u></p> <p>Relative risk reduction cognitive function: 2% [-9% to 12%]</p>							
	Multidomain Composites	NR								Insufficient
	Executive/Attention/Processing Speed	NR								Insufficient
	Memory	NR								Insufficient
	Serious Adverse Events	2 (14,985)	<p>1 of 2 tests show statistically fewer adverse events</p> <p><u>Peters 2008 (HYVET-COG)<sup>1</sup></u> Number of adverse events in indapamide and perindopril (358) vs placebo (448) p &lt;0.001</p> <p><u>ADVANCE Collaborative Group 2007<sup>2</sup></u> Number of adverse drug reactions in</p>	Medium	Direct	Precise	Unknown	Suspect	NA	Low

			perindopril and indapamide (47) and placebo (31).							
<b>Antihypertension (ARBs)</b>	Dementia	1 (4937)	0 of 1 tests show statistically significant improvement  <u>Lithell 2003<sup>5</sup> and Skoog 2005<sup>6</sup> (SCOPE)</u>  Dement events per 1000 patient years candesartan (6.8) vs control (6.3) p > 0.20	Medium	Direct	Precise	Unknown	Suspect	NA	Low
	MCI	NR								Insufficient
	Brief Cognitive Test	2 (10,863)	0 of 3 tests show statistically significant improvement:  <u>Anderson 2011<sup>3</sup> (TRANSCEND)</u> OR cognitive decline (drop of 3 or more MMSE points) Telmisartan vs placebo 1.10 [0.95 to 1.27]  <u>Saxby 2008<sup>4</sup> (single center in SCOPE)</u> Difference in mean change from baseline to closeout visit (MMSE) candesartan (baseline 28.7 to closeout visit 28.3) vs placebo (baseline 28.9 to closeout visit 28.5) p-value = 0.94	Medium	Indirect	Precise	Consistent	Suspect	NA	Moderate

			for change in MMSE between groups.  <u>Lithell 2003<sup>5</sup> and Skoog 2005<sup>6</sup> (SCOPE)</u>  Difference in mean change (MMSE) candesartan vs placebo 0.15 [-0.08 to 0.38]							
	Multidomain Composites	NR								Insufficient
	Executive/ Attention/ Processing Speed	1 (257)	1 of 3 tests show statistically significant improvement with Intervention	Medium	Indirect	Unknown	Inconsistent	Suspect	NA	Insufficient
	Memory	1 (257)	1 of 2 tests show statistically significant improvement with Intervention  <u>Saxby 2008<sup>4</sup> (single center in SCOPE)</u> Coefficient (SD) for decline in episodic memory for candesartan 0.14 (1.38) and placebo - 0.22 (1.21). p = 0.04.  Coefficient (SD) for decline in working memory for candesartan 0.0014 (0.012) and placebo 0.0010 (0.012). p = 0.90.	Medium	Indirect	Unknown	Inconsistent	Suspect	NA	Insufficient
	Serious Adverse	1 (5,926)	<u>Lithell 2003<sup>5</sup> and Skoog 2005<sup>6</sup></u>	Medium	Direct	Unknown	Unknown	Suspect	NA	Insufficient

	Events		(SCOPE) No difference adverse events reported between groups							
<b>Antihypertension (Beta blocker)</b>	Dementia	NR								Insufficient
	MCI	NR								Insufficient
	Brief Cognitive Test	NR								Insufficient
	Neuropsychological Performance	NR								Insufficient
	Executive/Attention/Processing Speed	1 (1859)	0 of 1 tests show statistically significant improvement with Intervention	Medium	Indirect	Unknown	Unknown	Suspect	NA	Insufficient
	Memory	1 (1859)	0 of 2 tests show statistically significant improvement with Intervention	Medium	Indirect	Unknown	Inconsistent	Suspect	NA	Insufficient
	Serious Adverse Events	NR								Insufficient
<b>Antihypertension (Combination therapy)</b>	Dementia	2 (3779)	Forette 1998 <sup>11</sup> (Syst-Eur 1) Forette 2002 <sup>10</sup> (Syst-Eur 1 & 2) 2011 RR 0.50 (95%CI, 0.24-1.00) reduction in the rate of dementia for treatment vs. placebo	Medium	Direct	Imprecise	Unknown	Suspect	Low	Insufficient
	MCI	NR								Insufficient
	Brief Cognitive Test	1 (3228)	0 of 2 tests show statistically significant improvement:	Medium	Indirect	Precise	Consistent	Suspect	NA	Low

			<p><u>Forette 2002<sup>10</sup> (Syst-Eur 1 &amp; 2) 2011</u>  Change in MMSE score at year 1 [treatment 0.10 (SD 1.44) control 0.16 (SD 1.52); p = 0.28], year 2 [treatment 0.17 (SD 1.64) control 0.15 (SD 1.69); p = 0.75], year 3 [treatment 0.17 (SD 1.82) control 0.14 (SD 1.85); p = 0.73]</p> <p><u>Forette 1998<sup>11</sup> (Syst-Eur 1)</u>  MD MMSE 0.07 [-0.09 to 0.23]</p>							
	Executive Function	1 (551)	1 of 3 tests show statistically significant improvement	Medium	Indirect	Imprecise	Inconsistent	Suspect	NA	Insufficient
	Memory	NR								Insufficient
	Serious Adverse Events	NR								Insufficient
<b>Antihypertension (ARB versus ACE)</b>	Dementia	NR								Insufficient
	MCI	NR								Insufficient
	Brief Cognitive Test	1 (17,118)	<p>0 of 1 test show statistical significant improvement</p> <p><u>Anderson 2011<sup>3</sup> (ONTARGET)</u>  cognitive decline (drop of 3 or more MMSE points) telmisartan vs</p>	Medium	Indirect	Precise	Unknown	Suspect	NA	Low



			ramipril RR 0.97 [0.89 to 1.06]							
	Neuropsychological Performance	NR								
	Executive Function	1 (160)	0 of 1 test show statistically significant improvement	Medium	Indirect	Unknown	Unknown	Suspect	NA	Insufficient
	Memory	1 (160)	1 of 2 tests show statistically significant improvement	Low	Indirect	Unknown	Unknown	Suspect	NA	Insufficient
	Serious adverse events	1 (160)	0 of 1 test show statistically significant difference  <u>Forgari 2006<sup>16</sup></u> No difference in adverse events	Low	Direct	Unknown	Unknown	Suspect	NA	Insufficient
<b>ARB versus Thiazide</b>	Dementia	NR								Insufficient
	MCI	NR								Insufficient
	Biomarkers	NR								Insufficient
	Global Cognition	NR								Insufficient
	Executive Function	NR								Insufficient
	Memory	NR								Insufficient
	Serious adverse events	2 (122)	0 of 2 test show statistically significant difference  <u>Hajjar 2013<sup>15</sup></u> No difference in adverse events  <u>Tedesco 1999<sup>17</sup></u> No difference in adverse events	Medium	Direct	Unknown	Unknown	Suspect	NA	Insufficient
Intensive blood	Dementia	NR	NR							Insufficient

pressure control (systolic blood pressure <120 mm Hg) versus standard blood pressure control (standard therapy (systolic blood pressure <140 mm Hg))	MCI	NR	NR							Insufficient
	Brief Cognitive Test	1 (1439)	0 if 1 test show statistically significant difference  <u>Williamson 2014<sup>18</sup> (ACCORD BP trial)</u> MD MMSE 0.05 [-0.20 to 0.29]	Medium	Indirect	Precise	Unknown	Suspect	NA	Low
	Multidomain Neuropsychological Performance	NR								
	Executive Function	1 (1439)	0 of 2 tests show statistically significant difference	Medium	Indirect	Imprecise	Consistent	Suspect	NA	Low
	Memory	1 (1439)	0 of 1 test show statistically significant difference	Medium	Indirect	Precise	Unknown	Suspect	NA	Low
	Serious adverse events	NR								
(I <sub>1</sub> ) Ramipril up to 10 mg daily vs. (I <sub>2</sub> ) combined ramipril up to 10 mg daily and telmisartan 80 mg daily	Dementia	NR								Insufficient
	MCI	NR								Insufficient
	Screening Tools	1 (17,078)	0 if 1 test shows statistically significant difference  <u>Anderson 2011<sup>3</sup> (ONTARGET)</u>  OR cognitive decline (drop of 3 or more MMSE points) combined ramipril and telmisartan vs. ramipril 0.95 [0.88 to 1.04]	Medium	Indirect	Precise	Unknown	Suspect	NA	Low
	Multidomain Composites	NR								Insufficient
	Executive	NR								Insufficient

	Function									
	Memory	NR								Insufficient
	Serious adverse events	NR								Insufficient

ACE=angiotensin converting enzyme inhibitors; ARB=angiotensin receptor blocker; C=control; CI=confidence interval; MCI=mild cognitive impairment; mg=milligrams; MMSE=Mini Mental Status Exam; NA=not applicable; NR=not reported; OR=odds ratio; SD=standard deviation; vs=versus

**Appendix Table M4. Characteristics of eligible studies: antihypertension interventions in adults with MCI**

Study Design Country RoB	N=	Population Inclusion Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cog	Intervention (INT) Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome measurement timing	Outcome (Instrument)
Starr 1996 <sup>23</sup> , 2005 <sup>24</sup> (HOPE trial) RCT United Kingdom Medium	81	Adults aged 70 to 85 with median systolic blood pressure of 160 to 220 mmHg and diastolic blood pressure of 100 to 120 mmHg, or median systolic blood pressure of 180 to 220 mmHg and diastolic blood pressure of ≥85 mmHg. Mild cognitive impairment.  Mean age (range): 76.1 (70-84) 65% Female Race: NR Education: NR Mean MMSE (range): 26.1 (20-28)	Captopril 12.5mg twice a day	Bendrofluazide 2.5 mg once a day	26 weeks	<u>Executive/Attention/Processing Speed</u> [TMT A, RCPM] <u>Memory</u> [Logical Memory Immediate] [Delayed Memory Immediate] [Anomalous Sentences Repetition Test] [PALS]

NR=not reported; MCI=mild cognitive impairment mg=milligrams; PALS=Paired Association Learning Test; RCPM = Raven's Colored Progressive Matrices; RCT=randomized controlled trial; TMT A = Trail Making Test Part A

**Appendix Table M5. Summary risk of bias assessments: antihypertension in adults with mild cognitive impairment**

Study	Overall Risk of Bias Assessment	Rationale
Starr 1996 <sup>23</sup> , 2005 <sup>24</sup>	Medium	Attrition 12%

## References for Appendix M

1. Peters R, Beckett N, Forette F, et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. *Lancet Neurology*. 2008 Aug;7(8):683-9. doi: [http://dx.doi.org/10.1016/S1474-4422\(08\)70143-1](http://dx.doi.org/10.1016/S1474-4422(08)70143-1). PMID: 18614402.
2. Patel A, Group AC, MacMahon S, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. *Lancet*. 2007 Sep 8;370(9590):829-40. PMID: 17765963.
3. Anderson C, Teo K, Gao P, et al. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. *Lancet Neurology*. 2011 Jan;10(1):43-53. doi: [http://dx.doi.org/10.1016/S1474-4422\(10\)70250-7](http://dx.doi.org/10.1016/S1474-4422(10)70250-7). PMID: 20980201.
4. Saxby BK, Harrington F, Wesnes KA, et al. Candesartan and cognitive decline in older patients with hypertension: a substudy of the SCOPE trial. *Neurology*. 2008 May 6;70(19 Pt 2):1858-66. doi: <http://dx.doi.org/10.1212/01.wnl.0000311447.85948.78>. PMID: 18458219.
5. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. *Journal of Hypertension*. 2003 May;21(5):875-86. PMID: 12714861.
6. Skoog I, Lithell H, Hansson L, et al. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). *American Journal of Hypertension*. 2005 Aug;18(8):1052-9. PMID: 16109319.
7. Perez-Stable EJ, Halliday R, Gardiner PS, et al. The effects of propranolol on cognitive function and quality of life: a randomized trial among patients with diastolic hypertension. *American Journal of Medicine*. 2000 Apr 1;108(5):359-65. PMID: 10759091.
8. Bird AS, Blizard RA, Mann AH. Treating hypertension in the older person: an evaluation of the association of blood pressure level and its reduction with cognitive performance. *Journal of Hypertension*. 1990 Feb;8(2):147-52. PMID: 2162877.
9. Prince MJ, Bird AS, Blizard RA, et al. Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. *BMJ*. 1996 Mar 30;312(7034):801-5. PMID: 8608285.
10. Forette F, Seux ML, Staessen JA, et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study.[Erratum appears in *Arch Intern Med*. 2003 Jan 27;163(2):241.]. *Archives of Internal Medicine*. 2002 Oct 14;162(18):2046-52. PMID: 12374512.
11. Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. *Lancet*. 1998 Oct 24;352(9137):1347-51. PMID: 9802273.
12. Applegate WB, Pressel S, Wittes J, et al. Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program. *Archives of Internal Medicine*. 1994 Oct 10;154(19):2154-60. PMID: 7944835.
13. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. *JAMA*. 1991 Jun 26;265(24):3255-64. PMID: 2046107.
14. Gurland BJ, Teresi J, Smith WM, et al. Effects of treatment for isolated systolic hypertension on cognitive status and depression in the elderly. *Journal of the American Geriatrics Society*. 1988 Nov;36(11):1015-22. PMID: 3171039.
15. Hajjar I, Hart M, Chen YL, et al. Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial. *Journal of the American Geriatrics Society*. 2013 Feb;61(2):194-201. doi: <http://dx.doi.org/10.1111/jgs.12100>. PMID: 23350899.
16. Fogari R, Mugellini A, Zoppi A, et al. Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. *Journal of Human Hypertension*. 2006 Mar;20(3):177-85. PMID: 16306998.
17. Tedesco MA, Ratti G, Mennella S, et al. Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. *American Journal of Hypertension*. 1999 Nov;12(11 Pt 1):1130-4. PMID: 10604491.

18. Williamson JD, Launer LJ, Bryan RN, et al. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. *JAMA Intern Med.* 2014 Mar;174(3):324-33. doi: 10.1001/jamainternmed.2013.13656. PMID: 24493100.
19. Sato N, Saijo Y, Sasagawa Y, et al. Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial: results after 1 year. *J Hypertens.* 2013 Jun;31(6):1245-55. doi: 10.1097/HJH.0b013e32835fdf60. PMID: 23492647.
20. Fogari R, Mugellini A, Zoppi A, et al. Influence of losartan and atenolol on memory function in very elderly hypertensive patients. *Journal of Human Hypertension.* 2003 Nov;17(11):781-5. PMID: 14578918.
21. Yodfat Y, Bar-On D, Amir M, et al. Quality of life in normotensives compared to hypertensive men treated with isradipine or methyldopa as monotherapy or in combination with captopril: the LOMIR-MCT-IL study. *Journal of Human Hypertension.* 1996 Feb;10(2):117-22. PMID: 8867566.
22. Goldstein G, Materson BJ, Cushman WC, et al. Treatment of hypertension in the elderly: II. Cognitive and behavioral function. Results of a Department of Veterans Affairs Cooperative Study. *Hypertension.* 1990 Apr;15(4):361-9. PMID: 2318518.
23. Starr JM, Whalley LJ, Deary IJ. The effects of antihypertensive treatment on cognitive function: results from the HOPE study. *Journal of the American Geriatrics Society.* 1996 Apr;44(4):411-5. PMID: 8636587.
24. Starr JM, Whalley LJ. Differential cognitive outcomes in the Hypertensive Old People in Edinburgh study. *Journal of the Neurological Sciences.* 2005 Mar 15;229-230:103-7. PMID: 15760627.

## Appendix N. Lipid Lowering Treatment

**Appendix Table N1. Characteristics of eligible studies: lipid lowering interventions in adults with normal cognition**

Intervention Type	Study Design Country RoB	N=	Population Inclusion Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cog	Intervention (INT) Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome measurement Timing	Outcome (Instrument)
<i>Statins Versus Placebo</i>	Trompet 2010 <sup>1,2</sup> RCT Multinational High	5804	Adults aged 70 to 82 years with preexisting vascular disease or at increased risk of vascular disease and normal cognition. Mean age (SD): 75 (3) 52% Female Race: NR Mean years of education (SD): 15.1 (2) Mean MMSE (SD): 28 (1.5)	Pravastatin	Placebo	42 months mean follow up	<u>Brief Cognitive Test Performance</u> [MMSE] <u>Executive/Attention/Processing Speed</u> [SCWT] [Letter-Digit Coding Test] <u>Memory</u> [15-Picture Learning Test Immediate And Delayed]
	Parale 2006 <sup>3</sup> Observational India High	97	Adults age ≥40 years with cardiovascular indications for statin use and normal cognition. Mean age (SD): 56.5 (8) 67% Female Race: NR Mean years education (SD): 11 (2.9) Mean MMSE (SD): 28.4 (1.8)	Atorvastatin 10 mg daily	Placebo	6 months	<u>Brief Cognitive Test Performance</u> [MMSE] <u>Executive/Attention/Processing Speed</u> [DSST] [DVT] [TMT B] <u>Memory</u> [Picture-Word Learning] [COWAT] [Auditory Vigilance] <u>Adverse Events</u>
	Muldoon 2004 <sup>4</sup> RCT	308	Adults aged 35 to 70 years with low-density lipoprotein cholesterol level between	Simvastatin 10 mg daily or Simvastatin 40 mg	Placebo	6 months	<u>Executive/Attention/Processing Speed</u> <sup>a</sup> [Composite] <u>Memory</u> [Memory Composite 1]

United States Medium		160 and 220 mg/dL and normal cognition. Mean age (SD): 53.7 (9.1) 52% Female 86% White Mean years education (SD): 14.8 (3.4) Mean Digit Vigilance (errors), and Recurring Words (errors): 6.6, 81.84.	daily			[Memory Composite 2] <u>Adverse Events</u>
Heart Protection Study 2002 <sup>5</sup> RCT United Kingdom Medium	20,536	Adults aged 40-80 years with total cholesterol concentrations $\geq$ 135 mg/dL and with substantial 5-risk of death from coronary heart disease and normal cognition. 28% > 70 years 28% Female Race: NR Education: NR Mean TICS-M (SD): 24.07 (NR)	Simvastatin 40 mg daily	Matching-placebo	5 years mean follow up	<u>Diagnosis</u> <u>Brief Cognitive Test Performance [TICS]</u> <u>Adverse Events [Hospitalizations]</u>
Muldoon 2000 <sup>6</sup> RCT United States Medium	209	Adults aged 24 to 60 with hypercholesterolemia (serum low-density-lipoprotein cholesterol level $\geq$ 160 md/dL) and normal cognition. Mean age (SD): 46.4 (8.9) 46% Female 88% White Mean years education (SD): 15 (3) Mean Digit Span (SD), Digit Symbol (SD), Trailing Making B (SD): 7 (1.3), 11.8 (2.5), 65 (21).	Lovastatin 20 mg daily	Matching placebo	6 months	<u>Executive/Attention/Processing Speed<sup>b</sup></u> [Composite Measure of Attention] [Composite of Mental Flexibility] [Composite Measure of Psychomotor Speed] <u>Executive/Attention/Processing Speed<sup>b</sup></u> <u>Memory [Working Memory Composite]</u> <u>[Memory Retrieval Composite]</u>
Santanello 1997 <sup>7</sup> RCT United States Medium	431	Adults aged $\geq$ 65 years with low-density lipoprotein-cholesterol >159 md/dL and < 221 mg/dL and normal cognition and MMSE $\geq$ 24.	(I <sub>1</sub> ) lovastatin 20 mg daily (I <sub>2</sub> ) lovastatin 40 mg daily	Placebo	6 months	<u>Executive/Attention/Processing Speed [DSST]</u> <u>Adverse Events [Number of Events]</u>



			Mean age (SD): 71.2 (NR) 71% Female 24% White Education: NR Mean Digit Symbol Substation Score (SD): 41.86 (13.88)				
<i>Statin Plus Ezetimibe Versus Placebo</i>	Tendolkar 2010 <sup>8</sup> RCT Netherlands Low	34	Elderly stroke-free patients with chronic or paroxysmal atrial fibrillation and normal cognition. Mean age (SD): 74 (4) 24% Female Race: NR Education: NR Mean MMSE (SD): 27.4 (2)	Atorvastatin 20mg for 2 weeks then increased to 40mg, after 4 weeks ezetimibe 10mg was added. Standard anticoagulant therapy	Matching-placebo and standard anticoagulant therapy	1 year	<u>Biomarker [Brain Volume Change]</u> <u>Brief Cognitive Test Performance [MMSE]</u> <u>Executive/Attention/Processing Speed [DSST]</u> <u>Memory [Dutch Modified Version RAVLT]</u> Immediate and Delayed Word Recall]
	<i>Statin Plus Fenofibrate Versus Statin Plus Placebo</i>						
	Williamson 2014 <sup>9</sup> (ACCORD Lipid trial) RCT United States Medium	1538	Middle-aged and older adults with diabetes at high risk of cardiovascular events with low-density lipoprotein cholesterol levels of less than 100 mg/dL and normal cognition. Mean age (SD): 62.5 (5.7) 38.9% Female 73% White 13% <High school 25% High school graduate 33% Some college 28% college graduate or more Median MMSE (25th and 75th percentile): 28 (26-29)	Fenofibrate plus statin	Placebo plus statin	40 months	<u>Brief Cognitive Test Performance [MMSE]</u> <u>Executive/Attention/Processing Speed [SCWT] [DSST]</u> <u>Memory [RAVLT]</u>
<i>Comparative Effectiveness</i>	Muldoon 2004 <sup>4</sup> RCT United States Medium	189	Adults aged 35 to 70 years with low-density lipoprotein cholesterol level between 160 and 220 mg/dL and normal cognition. Mean age (SD): 53.7 (9.1)	Simvastatin 10 mg daily	Simvastatin 40 mg daily	6 months	<u>Executive/Attention/Processing Speed<sup>a</sup> [Composite 1] [Composite 2]</u> <u>Memory [Memory Composite]</u> <u>Adverse Events</u>

			52% Female 86% White Mean years education (SD): 14.8 (3.4) Mean Digit Vigilance (errors), and Recurring Words (errors): 6.6, 81.84.				
	Carlsson 2002 <sup>10</sup> RCT- Crossover United States Medium	41	Adults ≥70 years with low- density lipoprotein- cholesterol ≥140 mg/dl and tri-glyceride levels ≤140 mg/dl and normal cognition. Mean age (SD): 76.3 (4.3) 68% Female Race: NR Education: NR Mean Digit Symbol Substitution (SD): 42.45 (9.69)	Pravastatin 20 mg daily	Tocopherol 440 IU daily	6 months	<u>Executive/Attention/Processing Speed</u> [DSST] <u>Adverse Events</u> [Physical Adverse Events] [Hospitalizations]

<sup>a</sup>Muldoon 2004<sup>3</sup> grouped tests into composite measures and if there was a significant difference in the composite measure individual items were evaluated. The composite measures were: 1) composite Executive/Attention/Processing Speed 1: Elithorn mazes, digit vigilance, recurring words, grooved pegboard; 2) memory composite 1: mirror tracing, 4-word short term memory, 3) memory composite 1: digit symbol, stroop interference, trail making B, digit span, complex figure, letter rotation;

<sup>b</sup>Muldoon 2005<sup>5</sup> grouped tests into composite measures and if there was a significant difference in the composite measure individual items were evaluated. The composite measures were: 1) composite measure of attention: digit vigilance, letter rotation, digit span, recurring words; 2) composite measure of psychomotor speed: grooved pegboard, Elithorn Maze, Digit Symbol; 3) composite of mental flexibility: Stroop Interference, Trail Making Digit Vigilance, Letter Rotation; 4) working memory composite: Associative Learning, Digit Span, 5) memory retrieval composite: Controlled Oral Word Association, Digit Symbol Recall, Verbal Recall, Complex Figure.

DVT=Digit Vigilance Test; COWAT=Controlled Oral Word Association Test; DSST=Digit Symbol Substitution Test; IU=international units; mg=milligrams; MMSE=Mini-Mental State Examination; NR=not reported; RCT=randomized controlled trial; RAVLT=Rey's Auditory Verbal Learning Test; SCWT = Stroop Color Word Test; SD=standard deviation; TICS=Telephone Interview for Cognitive Status

**Appendix Table N2. Summary risk of bias assessments: lipid lowering treatment in adults with normal cognition**

Study	Overall Risk of Bias Assessment	Rationale
Williamson 2014 <sup>9</sup> (ACCORD Lipid trial)	Low (ACCORD Lipid-MIND trial) High (ACCORD Lipid-MIND MRI sub-trial)	Low (ACCORD Lipid-MIND trial) High (ACCORD Lipid MIND MRI sub-trial): Attrition 21%
Tendolkar 2012 <sup>7</sup>	Low	

Trompet 2010 <sup>1,2</sup>	High	Attrition 25%
Parale 2006 <sup>3</sup>	High	Method of randomization and performance bias
Muldoon 2004 <sup>4</sup>	Medium	Reporting bias
Heart Protection Study 2002 <sup>5</sup>	Medium	Attrition unclear, detection bias
Muldoon 2000 <sup>6</sup>	Medium	Reporting bias
Santanello 1997 <sup>6</sup>	Medium	Attrition 15%
Carlsson 2002 <sup>10</sup>	Medium	Attrition 12%

**Appendix Table N3. Strength of evidence assessments: lipid lowering interventions in adults with normal cognition**

Intervention Type	Outcome	# Trials (n)	Evidence Summary Summary statistics [95% CI]	Study Limitations	Directness	Precision	Consistency	Reporting Bias	Optional Components	SOE
<b>Statins Versus Placebo</b>	Dementia	1 (20,536)	0 of 1 tests shows statistically significant improvement: Heart Protection Study 20025 Number in statins versus placebo who developed dementia during follow up: 31 [0.3%] vs. 31 [0.3%]	Medium	Direct	Unknown	Unknown	Suspect	NA	Insufficient
	MCI	NR								Insufficient
	Biomarkers	NR								Insufficient
	Brief Cognitive test	1 (20,53)	0 of 1 tests shows statistically significant	Medium	Indirect	Unknown	Unknown	Suspect	NA	Insufficient

		6)	improvement: Heart Protection Study 2002 <sup>5</sup> Mean difference TICS-M [SE]: 0.02 [0.07] Percent of participant classified as cognitively impaired statins versus placebo: 23.7% vs. 24.2%							
	Multidomain Composites	NR								
	Executive/ Attention/ Processing Speed	3 (948)	0 of 4 tests shows statistically significant improvement for statins. 3 of 4 tests shows statically significant improvement for placebo. Muldoon 20044 Mean difference composite Executive/Attention/Proce ssing Speed [CI]: 0.18 [0.07 to 0.29] Muldoon 20006 Mean difference in change composite Executive/Attention/Proce ssing Speed [95% CI]: 0.18 [0.06 to 0.31] Mean difference in change composite psychomotor speed [95% CI]: 0.17 [0.05 to 0.28] Santanello 19977 Mean change DSST [SD] placebo 0.33 [13.06], lovastatin 20 mg -0.80 [13.28], and lovastatin 40 mg 1.66 [8.98]. P-value for difference between groups 0.66	Medium	Indirect	Imprecise	Inconsistent	Suspect	NA	Low
	Memory	2 (517)	0 of 4 tests shows statistically significant	Medium	Indirect	Imprecise	Inconsistent	Suspect	NA	Insufficient

			improvement for statins. 1 of 4 tests shows statically significant improvement for placebo.							
	Serious Adverse Events	2 (20,967)	1 of 17 test shows a statistically significant difference: Heart Protection Study 2002 <sup>5</sup> Number of hospitalization in statins versus placebo. NS Santanello 1997 <sup>7</sup> Abdominal pain %: placebo 4.4, lovastatin 20 mg 5.8, lovastatin 40 mg 9.6. P-value for difference between groups <0.01 For 15 other common symptoms no difference reported.	Medium	Direct	Unknown	Consistent	Suspect	NA	Insufficient
Fenofibrate plus statin versus placebo plus statin	Dementia	NR								Insufficient
	MCI	NR								Insufficient
	Biomarkersa	NR								Insufficient
	Screening	1 (1,538)	0 of 1 tests shows statistically significant improvement: Williamson 2014 <sup>9</sup> (ACCORD Lipid trial) Mean difference MMSE 0.07 [95% CI]: [-0.17 to 0.31]	Low	Indirect	Precise	Unknown	Suspect	NA	Low
	Multidomain Composites									
	Executive/Attention/Processing Speed	1 (1,538)	0 of 2 tests shows statistically significant improvement	Low	Indirect	Imprecise	Consistent	Suspect	NA	Low
	Memory	1 (1,538)	0 of 1 tests shows statistically significant	Low	Indirect	Precise	Unknown	Suspect	NA	Low

		)	improvement							
	Serious Adverse Events	NR								Insufficient

<sup>a</sup> Williamson 2014<sup>8</sup> (ACCORD Lipid trial) reported total brain volume but data was excluded from analysis due to high risk of bias (attrition 21%).

C=control; CI=confidence interval; DSST=Digit Symbol Substitution Test; MCI=mild cognitive impairment; mg=milligrams; MMSE=Mini-Mental Status Examination; I=intervention; NA=not applicable; NR=not reported; TICS=Telephone Interview for Cognitive Status (TICS-m=modified);

## References for Appendix N

1. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. *Lancet*. 2002 Nov 23;360(9346):1623-30. PMID: 12457784.
2. Trompet S, van Vliet P, de Craen AJ, et al. Pravastatin and cognitive function in the elderly. Results of the PROSPER study. *J Neurol*. 2010 Jan;257(1):85-90. doi: 10.1007/s00415-009-5271-7. PMID: 19653027.
3. Parale GP, Baheti NN, Kulkarni PM, et al. Effects of atorvastatin on higher functions. *Eur J Clin Pharmacol*. 2006 Apr;62(4):259-65. doi: 10.1007/s00228-005-0073-z. PMID: 16489473.
4. Muldoon MF, Ryan CM, Sereika SM, et al. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. *Am J Med*. 2004 Dec 1;117(11):823-9. doi: 10.1016/j.amjmed.2004.07.041. PMID: 15589485.
5. Heart Protection Study Collaborative G. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet*. 2002 Jul 6;360(9326):7-22. doi: 10.1016/S0140-6736(02)09327-3. PMID: 12114036.
6. Muldoon MF, Barger SD, Ryan CM, et al. Effects of lovastatin on cognitive function and psychological well-being. *Am J Med*. 2000 May;108(7):538-46. PMID: 10806282.
7. Santanello NC, Barber BL, Applegate WB, et al. Effect of pharmacologic lipid lowering on health-related quality of life in older persons: results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study. *J Am Geriatr Soc*. 1997 Jan;45(1):8-14. PMID: 8994481.
8. Tendolkar I, Enajat M, Zwiars MP, et al. One-year cholesterol lowering treatment reduces medial temporal lobe atrophy and memory decline in stroke-free elderly with atrial fibrillation: evidence from a parallel group randomized trial. *Int J Geriatr Psychiatry*. 2012 Jan;27(1):49-58. doi: 10.1002/gps.2688. PMID: 21308791.
9. Williamson JD, Launer LJ, Bryan RN, et al. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. *JAMA Intern Med*. 2014 Mar;174(3):324-33. doi: 10.1001/jamainternmed.2013.13656. PMID: 24493100.
10. Carlsson CM, Papcke-Benson K, Carnes M, et al. Health-related quality of life and long-term therapy with pravastatin and tocopherol (vitamin E) in older adults. *Drugs Aging*. 2002;19(10):793-805. PMID: 12390056.

## Appendix O. Nonsteroidal Anti-Inflammatory Drugs

**Appendix Table O1. Characteristics of eligible studies: NSAIDs in adults with normal cognition**

Study Design Country RoB	N=	Population Inclusion Age (mean) Sex (% female) Race (% White) Education (mean years) Baseline Cognition	Intervention	Comparison	Outcome Timing	Outcome Domain [Instrument]
ADAPT Group <sup>1-</sup> <sup>5</sup> RCT USA  <u>10 years</u> <sup>4</sup> High  <u>8 years</u> Medium  <u>5 years</u> Medium  <u>4 years</u> 2008: Medium 2007: Medium	<u>10 years</u> 1689  <u>8 years</u> 2117  <u>5 years</u> 2071  <u>4 years</u> 2528	Adults aged 70+ with normal cognition and at least 1 first-degree relative with AD-like dementia <b>Age</b> (median) 70-74: 55% 75-79: 32% 80-84: 11% 85+: 2% <b>Sex</b> 46% <b>Race</b> White: 97% Black: 2% Hispanic: 1% <b>Education</b> Less than high school: 4% High school degree: 20% College, no degree: 27% College degree: 19% Postgrad: 30% <b>Baseline cognition</b> (median) Adjusted 3MS: 95.0	Celecoxib (200 mg BID) or naproxen (220 mg BID)	Placebo	<u>10 years</u>  <u>8 years</u> <sup>1</sup>  <u>5 years</u> <sup>2</sup>  <u>4 years</u> <sup>3,4</sup>	<b>10 years</b> <u>Brief Cognitive Test Performance</u> [3MS] <u>Multidomain Neuropsychological Test Performance</u> [Composite: HVLT-R, Informant-Rated Dementia Severity Rating Scale, Digit Span, Naming Supermarkets, RBMT] <u>Executive/Attention/Processing Speed</u> [Digit Span] <u>Memory</u> [HVLT] [RBMT] <u>Language</u> [Generative Verbal Fluency]  <b>8 years</b> <u>Diagnosis</u> [Alzheimer's Disease]  <b>5 years</b> <u>Diagnosis</u> [Alzheimer's Disease] <u>Biomarker</u> [CSF tau : Ab1-42]  <b>4 years</b> <u>Diagnosis</u> [Alzheimer's Disease] <u>Brief Cognitive Test Performance</u> [3MS] <u>Multidomain Neuropsychological Test Performance</u> [Composite: HVLT-R, Informant-Rated Dementia Severity Rating Scale,



						Digit Span, Naming Supermarkets, RBMT] <u>Executive/Attention/Processing Speed</u> [Digit Span] <u>Memory</u> [HVLT] [RBMT]
Small, 2008 <sup>6</sup> RCT USA High	88	Middle-aged and older volunteers with normal cognition and self-reported age-related memory complaints <b>Age</b> 58 <b>Sex</b> 38% <b>Race</b> NR <b>Education</b> (mean years) 15 <b>Baseline cognition</b> (median) MMSE: 29.2	Celecoxib 200 mg or 400 mg QD	Placebo	1.5 years	<u>Executive/Attention/Processing Speed</u> [TMT A] [TMT B] [DSST] [Stroop Interference Kaplan Version] [F.A.S. Letter Fluency Test] <u>Memory</u> [Buschke Selective Reminding Test Total And Delayed Recall] [WMS Verbal Paired Associations] [BVRT] <u>Language</u> [BNT] [Animal Naming Test] <u>Visuospatial</u> [WAIS-III Block Design Test] [RCFT]]
Kang, 2007 <sup>7</sup> RCT USA Medium	6377	Normal cognition, women aged 65+ participating in healthy study <b>Age</b> 72 <b>Sex</b> 100% <b>Race</b> NR <b>Education</b> Licensed vocational or registered nurse/associates degree: 67% Bachelors/masters/doctorate degree: 33% <b>Baseline cognition</b> TICS: 34	Aspirin (100 mg QAD)	Placebo	10 years	<u>Brief Cognitive Test Performance</u> [TICS] <u>Multidomain Neuropsychological Test Performance</u> [Composite: TICS, Category Fluency, 10 Words List Immediate And Delayed Recall, EBMT] <u>Memory</u> [Composite: 10 Words List Immediate And Delayed Recall, EBMT]

3MS=Modified Mini-Mental State Examination; BID=twice daily; EBMT=East Boston Memory Test; mg=milligrams; n=sample size; NP=Neuropsychological; NR=not reported; QAD=every other day; QD=every day; SD=standard deviation; RCT=randomized controlled trial; RBMT= Rivermead Behavioral Memory Test; RCFT=Rey-Osterrieth Complex Figure Test; USA=United States; WAIS=Wechsler Adult Intelligence Scale; WMS=Wechsler Memory Scale

**Appendix Table O2. Summary risk of bias assessments: NSAIDs in adults with normal cognition**

Study	Overall Risk of Bias Assessment	Rationale
ADAPT Group <sup>1-5</sup> 10 year	High	Attrition > 40%
8 year	Medium	Attrition 39% but use survival and sensitivity analyses; unclear if concurrent interventions
5 year	Medium	Attrition 18% but use survival analysis; participant and outcome assessor blinding methods unclear
4 year (2008 publication)	Medium	Attrition 20%; unclear if concurrent interventions
4 year (2007 publication)	Low	Attrition 15% but use survival analysis; unclear if concurrent interventions
Small, 2008 <sup>6</sup>	High	Attrition 44%
Kang, 2007 <sup>7</sup>	Medium	Attrition 29%; outcome assessor independence unclear; unclear if concurrent interventions

NSAIDs=Nonsteroidal Antiinflammatory Drugs

**Appendix Table O3. Strength of evidence assessments: NSAIDs in adults with normal cognition**

Intervention Type	Outcome	# Trials (n)	Evidence Summary Summary statistics [95% CI]	Study Limitations	Direct-ness	Precision	Consistency	Reporting Bias	Optional Components	SOE
Aspirin vs. Placebo	Dementia	NR								
	MCI	NR								
	Brief Cognitive Test Performance 10 years	1 (6377)	0 of 1 tests showed no statistically significant difference.  <u>TICS. mean difference from baseline</u> -0.02 [-0.19 to 0.14]	Medium	Indirect	Precise	Unknown	Undetected	NA	Low
	Multidomain Neuropsychological Performance 10 years	1 (6377)	0 of 1 tests showed no statistically significant difference.  <u>Composite. mean difference from baseline</u> 0.0 [-0.04 to 0.04]	Medium	Indirect	Precise	Unknown	Undetected	NA	Low
	Executive/ Attention/ Processing Speed	NR								
Memory 10 years	1 (6377)	0 of 1 test showed no statistically significant difference.  <u>Composite.</u>	Medium	Indirect	Precise	Unknown	Undetected	NA	Low	

			<u>mean difference from baseline</u> -0.02 [-0.06 to 0.02]							
	Adverse Effects	NR								
<b>Non-aspirin</b> (Celecoxib 200 mg BID; Naproxen 220 mg BID) vs. <b>Placebo</b>	Dementia 8 years	1 (2117)	0 of 2 tests at longest follow-up showed no significant difference.  <u>Adjusted HR for Alzheimer's disease</u> Celecoxib: 1.03 [0.72 to 1.50] p=0.86 Naproxen: 0.92 [0.62 to 1.35] p=0.66	Medium	Direct	Precise	Unknown	Undetected	NA	Low
	MCI	NR								
	Brief Cognitive Test Performance 4 years	1 (2528)	0 of 2 tests showed no statistically significant difference.  <u>Adjusted 3MS, generalized estimating equation regression vs placebo (B coefficient)</u> Celecoxib: -0.20 [-0.47 to 0.07] p=0.14 Naproxen: -0.19 [-0.47 to	Medium	Indirect	Imprecise	Unknown	Undetected	NA	Insufficient

			0.09] p=0.19							
Multidomain Neuropsychological Performance4 years	1 (2528)	0 of 2 tests showed no statistically significant difference.  <u>Composite, generalized estimating equation regression vs placebo (B coefficient)</u> Celecoxib: -0.004 [-0.04 to 0.03] p=0.84 Naproxen: -0.03 [-0.07 to 0.01] p=0.09	Medium	Indirect	Precise	Unknown	Undetected	NA	Low	
Executive/ Attention/ Processing Speed 4 years	1 (2528)	0 of 4 tests show no statistically significant improvement with intervention  <u>Digit Span Forward, generalized estimating equation regression vs</u>	Medium	Indirect	Imprecise	Consistent	Undetected	NA	Low	

			<u>placebo (B coefficient)</u> Celecoxib: - 0.05 [-0.19 to 0.09] p=0.48 Naproxen: - 0.03 [-0.17 to 0.11] p=0.69  <u>Digit Span Backward, generalized estimating equation regression vs placebo (B coefficient)</u> Celecoxib: 0.03 [-0.11 to 0.18] p=0.64 Naproxen: - 0.09 [-0.23 to 0.05] p=0.22							
Memory 4 years	1 (2528)	0 of 6 tests show no statistically significant improvement with intervention  <u>Hopkins Verbal Learning Test, generalized estimating equation regression vs placebo (B</u>	Medium	Indirect	Imprecise	Consistent	Undetected	NA	Low	

			<p>coefficient)  Celecoxib:  0.12  [-0.06 to 0.30]  p=0.20  Naproxen: -  0.04  [-0.23 to 0.16]  p=0.70</p> <p><u>Rivermead Behavioral Memory Test, generalized estimating equation regression vs placebo (B coefficient)</u>  Celecoxib: -  0.06  [-0.29 to 0.18]  p=0.64  Naproxen: -  0.13  [-0.37 to 0.11]  p=0.28</p> <p><u>Brief Visuospatial Memory Test- Revised, generalized estimating equation regression vs placebo (B coefficient)</u>  Celecoxib:  0.05  [-0.14 to 0.23]  p=0.62  Naproxen: -</p>						
--	--	--	--	--	--	--	--	--	--

			0.07 [-0.26 to 0.12] p=0.45							
	Adverse Effects	NR								

3ME=Modified Mini-Mental State Examination; k=number of studies; MCI=mild cognitive impairment; n=sample size; NP=neuropsychological; NA=not applicable; NR=not reported; RCT=randomized controlled trial; SD=standard deviation;

**Appendix Table O4. Characteristics of eligible studies: NSAIDs in adults with MCI**

<b>Study Design Country RoB</b>	<b>N=</b>	<b>Population Inclusion Age (mean) Sex Race Education Baseline Cog</b>	<b>Intervention</b>	<b>Comparison</b>	<b>Outcome Timing</b>	<b>Outcome Domain [Instrument]</b>
Thal, 2005 <sup>s</sup> RCT USA High	1457	People aged 65+ with 8+ years of education and met criteria for MCI <b>Age</b> 75 <b>Sex</b> 32% <b>Race</b> NR <b>Education</b> (years) <11: 10% 12-17: 77% 18+: 13% <b>Baseline cognition</b> MMSE: 27.4 ADAS-Cog: 9.3	Rofecoxib 25 mg QD	Placebo	4 years	Brief Cognitive Test Performance [MMSE] [ADAS-Cog] Memory [Buschke Selective Reminding Test (Summed And Delayed)]

3ME=Modified Mini-Mental State Examination; ADAS=Cog-Alzheimer's Disease Assessment Scale-Cognitive; BID=twice daily; Cog=cognition; MCI=mild cognitive impairment; N=sample size; NP=neuropsychological; NR=not reported; QD=daily; NSAIDS=Nonsteroidal Antiinflammatory Drugs; RCT=Randomized Controlled Trial; RoB=risk of bias; SD=Standard Deviation; USA=United States



**Appendix Table O5. Summary risk of bias assessments: NSAIDs in adults with MCI**

<b>Study</b>	<b>Overall Risk of Bias Assessment</b>	<b>Rationale</b>
Thal, 2005 <sup>8</sup>	High	Attrition 45%

MCI=mild cognitive impairment; NSAIDS=Nonsteroidal Antiinflammatory Drugs

## References for Appendix O

1. Adapt Research Group. Results of a follow-up study to the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). *Alzheimer's & Dementia*. 2013 Nov;9(6):714-23. doi: <http://dx.doi.org/10.1016/j.jalz.2012.11.012>. PMID: 23562431.
2. Adapt Research Group, Lyketsos CG, Breitner JC, et al. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. *Neurology*. 2007 May 22;68(21):1800-8. PMID: 17460158.
3. Adapt Research Group, Martin BK, Szekely C, et al. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. *Archives of Neurology*. 2008 Jul;65(7):896-905. doi: <http://dx.doi.org/10.1001/archneur.2008.65.7.nct70006>. PMID: 18474729.
4. Breitner J, Baker L, Drye L, et al. Follow-up evaluation of cognitive function in the randomized Alzheimer's disease anti-inflammatory prevention trial and its follow-up study. *Alzheimer's and Dementia*. 2015;11(2):216-25.e1. doi: <http://dx.doi.org/10.1016/j.jalz.2014.03.009>. PMID: 53231681.
5. Breitner JC, Baker LD, Montine TJ, et al. Extended results of the Alzheimer's disease anti-inflammatory prevention trial. *Alzheimer's & Dementia*. 2011 Jul;7(4):402-11. doi: <http://dx.doi.org/10.1016/j.jalz.2010.12.014>. PMID: 21784351.
6. Small GW, Siddarth P, Silverman DH, et al. Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with age-related memory loss: randomized controlled study. *American Journal of Geriatric Psychiatry*. 2008 Dec;16(12):999-1009. doi: <http://dx.doi.org/10.1097/JGP.0b013e31818cd3a4>. PMID: 19038899.
7. Kang JH, Cook N, Manson J, et al. Low dose aspirin and cognitive function in the women's health study cognitive cohort. *BMJ*. 2007 May 12;334(7601):987. PMID: 17468120.
8. Thal LJ, Ferris SH, Kirby L, et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. *Neuropsychopharmacology*. 2005 Jun;30(6):1204-15. PMID: 15742005.

## Appendix P. Antidementia Drugs

**Appendix Table P1. Characteristics of eligible studies: antidementia interventions in adults with normal cognition**

Study Design Country RoB	N=	Population Inclusion Age (mean) Sex Race Education Baseline Cog	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome timing	Outcome Domain [Instrument]
Gavrilova 2011 <sup>1</sup> Observational Russia High	110	Adults aged 55 to 85 with MMSE scores above 26, signs of cognitive deficit corresponding to stage 3 on the Global Deterioration Scale (GDS), and assessments of 0.5 on the Clinical Dementia Rating (CDR) scale Mean age: 67 years 74% Female Race: NR Education: NR Mean MMSE (SD): 28.4 (0.1)	Cerebrolysin (two courses per year for 3 years [lasting 4 weeks each] of 30ml cerebrolysin infusions in 100ml of physiological saline), or Cavinton (two courses per year for three years [lasting 4 weeks each] of 5 mg three times daily	Groups compared to one-another	3 years	<u>Brief Cognitive Test Performance</u> [MMSE] <u>Executive/Attention/Processing Speed</u> [Forward Number Naming] [Reverse Number Naming] [Frontal Dysfunction Battery] [Wechsler Scale, Sound and Categorical Associations] <u>Memory</u> [Delayed 10-Word Reproduction] <u>Language</u> [Boston Naming Test] <u>Visuospatial</u> [CLOX-1]
Devi 2007 <sup>2</sup> RCT USA Medium	28	Postmenopausal women aged 46 to 60 without depression Mean age: 54 100% female 75% White Education: 100% ≥16 years Baseline global cognition: NR	Donepezil 5mg daily for 6 weeks, then 10mg daily (if tolerated) for the remaining 20 weeks	Placebo daily for 6 months	6 months	<u>Executive/Attention/Processing Speed</u> [WMS-III, Working Memory] <u>Memory</u> [WMS-III, Logical Memory] [Buschke Selective Reminding Test, List Learning] <u>Language</u> [Boston Diagnostic Aphasia Examination, naming] [WAIS-III, Vocabulary] <u>Language</u> [COWAT]

ADAS=Cog-Alzheimer's Disease Assessment Scale-Cognitive; AVLT=Auditory Verbal Learning Test; BEM= Batterie d'Efficiency Mnesique; BVRT=Benton Visual Retention Test; CDR=Change in Dementia Rating; CLOX-1=Clock Drawing Test; COWAT=Controlled Oral Word Association Test; CVFT=Category Verbal Fluency Test; CVLT=California Verbal Learning Test; DS=Digit Span; DSM=Diagnostic Statistical Manual of Mental Disorders; FDG-PET=; MCI=Mild Cognitive Impairment; MMSE=Mini

Mental Status Exam; n=sample size; NR=not reported; RBANS=Repeat Battery for the Assessment of Neuropsychological Status; RCT=randomized controlled trial; RoB=risk of bias; SCWT=Stroop Test; SD=Standard Deviation; TMT=Trail Making Trial (Parts A and/or B); USA=United States; WAIS=Wechsler Adult Intelligence Scale; WMS=Wechsler Memory Scale

**Appendix Table P2. Summary risk of bias assessments: antedementia drug interventions in adults with normal cognition**

Study	Overall Risk of Bias Assessment	Rationale
<b>Antedementia</b>		
Gavrilova 2011 <sup>1</sup>	High	Systematic assignment instead of randomization. Attrition 20% without appropriate analysis to account for potential bias.
Devi 2007 <sup>2</sup>	Medium	Attrition 14% in treatment group. Outcome assessor not independent.

**Appendix Table P3. Characteristics of eligible studies: antedementia interventions in adults with MCI**

Intervention Type	Study Design Country RoB	N=	Population Inclusion Age (mean) Sex Race Education Baseline Cog	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome timing	Outcome Domain [Instrument]
<b>Donepezil efficacy</b>	Doody 2009 <sup>3</sup> Schuff 2011 <sup>4</sup> (subset of Doody 2009) RCT USA High	821	Healthy adults with MCI aged 45 to 90 who expressed a memory complaint Mean age: 70 45% female 87% White Education: 0-7 years: <1% 8-15 years: 53% >15 years: 47% MMSE ≤ 28: 84%	Donepezil 5mg daily for 6 weeks, then 10mg daily for the remaining 42 weeks	Placebo daily for 48 weeks, with a 3-week single-blind run-in period	48 weeks	<u>Biomarker</u> [MRI: APC in Hippocampal Volume; Changes in Whole Brain Atrophy, Ventricular Atrophy, and Cortical Atrophy] <u>Brief Cognitive Test Performance</u> [MMSE] <u>Multidomain Neuropsychological Test Performance</u> [ADAS-Cog] <u>Executive/Attention/Processing Speed</u> [SDMT] [DS Backward]
	Petrella 2009 <sup>5</sup> RCT USA High	13	Healthy adults with MCI aged 55 to 90 with MMSE scores of at least 24 and without depressive	Donepezil 5mg daily for 6 weeks, followed by 10 mg daily for the remaining 4	Placebo daily for 6 months	6 months	<u>Biomarker</u> [fMRI: Changes in Dorsolateral Prefrontal Activation and Ventrolateral Prefrontal Cortex Activation] <u>Brief Cognitive Test Performance</u> [MMSE]

		<p>symptoms  Mean age: 68  Sex: NR  Race: NR  Mean education: 16  Mean MMSE (SD):  28.3 (1.7)</p>	months and 2 weeks			<p><u>Multidomain Neuropsychological Test Performance [ADAS-Cog]</u>  <u>Executive/Attention/Processing Speed [DSST] [DS Backward]</u>  <u>Memory [NYU Delayed Recall]</u></p>
Petersen2005 <sup>6</sup> Jack, 2008 <sup>7</sup> RCT USA Medium High (MRI outcomes)	769	<p>Adults with amnesic MCI aged 55 to 90 with impaired memory, a Logical Memory Delayed-recall score approximately 1.5 to 2 SD below an education-adjusted norm, a Clinical Dementia Rating (CDR) of 0.5, and a score of 24 to 30 on the MMSE  Mean age: 73  46% Female  Race: NR  Education: NR  Mean MMSE (SD):  27.27 (1.8)  Mean ADAS-cog (SD):  11.26 (4.4) original  17.72 (6.1) modified</p>	Donepezil 5mg daily for 6 weeks, followed by 10 mg daily for the remainder of the study	Placebo	3 years	<p><u>Diagnosis [Clinical Criteria of the NINCDS-ADRDA]</u>  <u>Biomarker [MRI: APC in Hippocampus, Entorhinal Cortex, Whole Brain, and Ventricle;</u>  <u>Rate of Hippocampal Atrophy] [MRI and Cognitive Performance Correlation]</u>  <u>Brief Cognitive Test Performance [MMSE]</u>  <u>Multidomain Neuropsychological Test Performance [ADAS-Cog, Original]</u>  <u>[ADAS-Cog, Modified]</u>  <u>Executive/Attention/Processing Speed [Composite Measure]</u>  <u>Language [Composite Measure]</u>  <u>Memory [Composite Measure]</u>  <u>Visuospatial [Composite Measure]</u></p>
Salloway 2004 <sup>8</sup> RCT USA High	270	<p>Healthy adults aged 55 to 90 with MCI, a documented memory complaint, and MMSE scores <math>\geq 24</math>, global Clinical Dementia Rating (CDR) score of 0.5 with memory box scores of 0.5 or 1, no more than two box scores other than memory rated as high as 1, and no box score rated greater than 1  Mean age: 72  42% female  94% White  Mean education: 15  Mean MMSE (SD):  27.5 (2)</p>	Donepezil 5mg daily for 42 days, then 10mg daily for the remainder of the study	Placebo daily for 2 years	2 years	<p><u>Multidomain Neuropsychological Test Performance [ADAS-Cog, Modified]</u>  <u>Executive/Attention/Processing Speed [DS Backward] [SDMT] [Maze Test]</u>  <u>Memory [NYU Paragraph Test]</u>  <u>Language [BNT] [Verbal Fluency]</u></p>

<b>Donepezil &amp; antidepressant efficacy</b>	Reynolds 2011 <sup>9</sup> RCT USA High	130	Adults at least 65 years of age with normal cognition or MCI, and with remitted depression (a score of 15 or higher on the 17-item Hamilton Rating Scale for Depression)	Donepezil (mean of) 7.8mg daily for 2 years plus antidepressant pharmacotherapy with supportive depression care management (12 to 16 weeks)	Placebo for 2 years	2 years	<u>Multidomain Neuropsychological Test Performance</u> [Composite of all Tests] <u>Executive/Attention/Processing Speed</u> [Composite] <u>Memory</u> [Composite] <u>Language</u> [Composite] <u>Visuospatial</u> [Composite]
<b>Rivastigmine efficacy</b>	Feldman 2007 <sup>10</sup> RCT USA High	508	Adults aged 55 to 85 with MCI (having a global CDR score = 0.5, NYU Delayed Paragraph Recall <9, 17-item HAM-D score <13, and HAM-D Item 1 [depressed mood] score =1) Mean age: 70 52% female Race: NR Mean education: 11 Mean MMSE (SD): 27 (2.7)	Rivastigmine 1mg daily for 2 weeks, then 3-12mg daily (increases of 3mg at minimum of 4-week intervals) until end of study or progression to AD; latter group could continue with starting dose of 3mg daily irrespective of treatment assignment	Placebo daily for 4 years	Until diagnosis of AD, up to 4 years	<u>Diagnosis</u> [Time to AD] <u>Brief Cognitive Test Performance</u> [MMSE]
<b>Galantamine efficacy</b>	Peters 2012 <sup>11</sup> RCT Germany High	232	Adults with amnesic MCI Mean age: 68 Sex: NR Race: NR Education: NR Mean MMSE (SD): 27 (2.4)	Galantamine 8mg twice daily, galantamine (8mg) and memantine (10mg) twice daily	Placebo	2 years	<u>Multidomain Neuropsychological Test Performance</u> [ADAS-Cog]
		990	Adults ≥ 50 years with MCI, a CDR score of 0.5 and CDR memory score ≥0.5 Mean age: 70 55% female 95% White Education: NR Median ADAS-cog/MCI (range): 16	Galantamine 4 mg twice daily for 1 month, then 8 mg twice daily. If well tolerated, dose could be titrated to 12 mg twice daily, but could be lowered back to 8 mg twice daily after 1 month, if necessary. The dose selected at month 3	Placebo daily for 2 years	2 years	<u>Biomarker</u> [MRI: Hippocampal Atrophy] <u>Diagnosis</u> [CDR] <u>Multidomain Neuropsychological Test Performance</u> [CDR-Sum of Boxes] [ADAS-Cog/MCI] <u>Executive/Attention/Processing Speed</u> [DSST]

				(8 or 12 mg twice daily) was fixed for the remainder of the study (23 months)			
Winblad 2008 <sup>12</sup> Prins 2014 <sup>13</sup> RCT (2) USA High	1058	Adults ≥ 50 years with a CDR score of 0.5 and CDR memory score ≥0.5 Mean age: 70 44% female 95% White Education: NR Median ADAS-cog/MCI (range): 17.5 (1-63)	Galantamine 4 mg twice daily for 1 month, then 8 mg twice daily for 1 month. If well tolerated, dose could be titrated to 12 mg twice daily, but could be lowered back to 8 mg twice daily after 1 month, if necessary. The dose selected at month 3 (8 or 12 mg twice daily) was fixed for the remainder of the study (23 months)	Placebo daily for 2 years	2 years	<u>Multidomain Neuropsychological Test Performance [ADAS-Cog/MCI]</u> <u>Executive/Attention/Processing Speed [DSST]</u>	

3MS=Modified Mini Mental Status Examination; AD=Alzheimer's disease; ADAS=Cog-Alzheimer's Disease Assessment Scale-Cognitive; BNT=Boston Naming Test; CDR=Clinical Dementia Rating; COWAT=Controlled Oral Word Association Test; DS=Digit Span (Forward and/or Backward); DSST=Digit Symbol Substitution Test; N=sample size; NR=not reported; NYU=New York University; RCT=randomized controlled trial; RoB=risk of bias; SD=standard deviation; SDMT=Symbol Digit Modalities Test; USA=United States

**Appendix Table P4. Summary risk of bias assessments: antideementia drug interventions in adults with MCI**

Study	Overall Risk of Bias Assessment	Rationale
Doody 2009 <sup>3</sup> Schuff 2011 <sup>4</sup>	High	High attrition (39%)
Petrella 2009 <sup>5</sup>	High	Poor randomization. Attrition 13%.
Petersen 2005 <sup>6</sup> Jack 2008 <sup>7</sup>	Medium/High	Medium attrition (30%) for cognitive outcomes with sensitivity analysis; high attrition (33%) for MRI
Salloway 2004 <sup>8</sup>	High	High attrition (24%) without appropriate analysis
Reynolds 2011 <sup>9</sup>	High	High attrition (30%)O with sensitivity analysis; groups not described so not clear whether randomization held
Feldman 2007 <sup>10</sup>	High	High attrition (35%)
Peters 2012 <sup>11</sup>	High	Method of randomization unclear. Attrition not clearly reported; likely greater than 50%.
Winblad 2008 <sup>12</sup> Prins 2014 <sup>13</sup>	High	High attrition (35%)

MCI=mild cognitive impairment



**Appendix Table P5. Strength of evidence assessments: antedementia medication versus placebo control in adults with MCI**

Outcome	# Trials (n)	Evidence Summary Summary statistics [95% CI]	Study Limitations	Directness	Precision	Consistency	Reporting Bias	Optional Components	SOE
Dementia	1 (769)	No reduction in dementia diagnoses with donepezil  <u>Petersen 2005<sup>o</sup> (Donepezil)</u> Hazard Ratio for risk of progression to AD (3 years): 0.8 [0.57 to 1.13]	Medium	Direct	Precise	Unknown	Undetected	NA	Low
MCI	NR								
Biomarkers	NR								
Brief cognitive test performance	1 (769)	0 of 1 tests show statistically significant improvement at 3 years  <u>Petersen 2005<sup>o</sup> (Donepezil)</u> Mean change from baseline in MMSE (SD) scores: Difference in mean [CI] change: -0.44 [-1.11 to 0.23]	Medium	Indirect	Precise	Unknown	Undetected	NA	Low

Multidomain neuropsychological performance	1 (769)	0 of 2 tests show statistically significant improvement at 3 years  <u>Petersen 2005<sup>6</sup></u> <u>(Donepezil)</u> Mean change from baseline in ADAS-cog original (SD) scores: Difference in mean [CI] change: 0.06 [-1.07 to 1.19] Mean change from baseline in ADAS-cog (SD) modified scores: Difference in mean [CI] change: 0.6 [-0.79 to 1.99]	Medium	Indirect	Precise	Unknown	Undetected	NA	Low
Executive/Attention/Processing Speed	1 (769)	0 of 1 tests show statistically significant improvement with Intervention	Medium	Indirect	Imprecise	Unknown	Undetected	NA	Insufficient
Memory	1 (769)	0 of 1 tests show statistically significant improvement with Intervention	Medium	Indirect	Imprecise	Unknown	Undetected	NA	Insufficient

C=control; CI=confidence interval; ES=effect size; HR=hazard ratio; I=Intervention; ITT=intention to treat; MCI=mild cognitive impairment; mg=milligrams; n=sample size; NA=not applicable; NR=not reported; RCT=randomized controlled trial; RR=risk ratio; SD=standard deviation; SOE=strength of evidence

## References for Appendix P

1. Gavrilova SI, Kolykhalov IV, Fedorova YB, et al. Potential of Preventive Treatment of Alzheimer's Disease: Results of a Three-Year Prospective Open Comparative Trial of the Efficacy and Safety of Courses of Treatment with Cerebrolysin and Cavinton in Elderly Patients with Mild Cognitive Impairment Syndrome. *Neuroscience and Behavioral Physiology*. 2011 May;41(4):391-8. doi: 10.1007/s11055-011-9427-4. PMID: 2011362050.
2. Devi G, Massimi S, Schultz S, et al. A double-blind, placebo-controlled trial of donepezil for the treatment of menopause-related cognitive loss. *Gend Med*. 2007 Dec;4(4):352-8. PMID: 18215726.
3. Doody RS, Ferris SH, Salloway S, et al. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. *Neurology*. 2009 May 5;72(18):1555-61. doi: 10.1212/01.wnl.0000344650.95823.03. PMID: 19176895.
4. Schuff N, Suhy J, Goldman R, et al. An MRI substudy of a donepezil clinical trial in mild cognitive impairment. *Neurobiol Aging*. 2011 Dec;32(12):2318 e31-41. doi: 10.1016/j.neurobiolaging.2010.04.005. PMID: 20541841.
5. Petrella JR, Prince SE, Krishnan S, et al. Effects of donepezil on cortical activation in mild cognitive impairment: a pilot double-blind placebo-controlled trial using functional MR imaging. *AJNR Am J Neuroradiol*. 2009 Feb;30(2):411-6. doi: 10.3174/ajnr.A1359. PMID: 19001543.
6. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. *N Engl J Med*. 2005 Jun 9;352(23):2379-88. doi: 10.1056/NEJMoa050151. PMID: 15829527.
7. Jack CR, Jr., Petersen RC, Grundman M, et al. Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. *Neurobiology of Aging*. 2008 Sep;29(9):1285-95. PMID: 17452062.
8. Salloway S, Ferris S, Kluger A, et al. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. *Neurology*. 2004 Aug 24;63(4):651-7. PMID: 15326237.
9. Reynolds CF, 3rd, Butters MA, Lopez O, et al. Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy. *Arch Gen Psychiatry*. 2011 Jan;68(1):51-60. doi: 10.1001/archgenpsychiatry.2010.184. PMID: 21199965.
10. Feldman HH, Ferris S, Winblad B, et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEX study. *Lancet Neurol*. 2007 Jun;6(6):501-12. doi: 10.1016/S1474-4422(07)70109-6. PMID: 17509485.
11. Peters O, Lorenz D, Fesche A, et al. A combination of galantamine and memantine modifies cognitive function in subjects with amnesic MCI. *J Nutr Health Aging*. 2012;16(6):544-8. PMID: 22659994.
12. Winblad B, Gauthier S, Scinto L, et al. Safety and efficacy of galantamine in subjects with mild cognitive impairment. *Neurology*. 2008 May 27;70(22):2024-35. doi: 10.1212/01.wnl.0000303815.69777.26. PMID: 18322263.
13. Prins ND, van der Flier WA, Knol DL, et al. The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial. *Alzheimers Res Ther*. 2014 21 Jul;6(4):47. doi: 10.1186/alzrt275. PMID: 25478019.

## Appendix Q. Diabetic Medication Treatment

**Appendix Table Q1. Characteristics of eligible studies: diabetic medication treatments in adults with normal cognition**

Intervention type	Study Design Country RoB	N=	Population Inclusion Age (mean) Sex Race Education Baseline Cog	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome timing	Outcome Domain [Instrument]
<b>Glycemic control efficacy</b>	Cukierman-Yaffe 2014 <sup>1</sup> (Substudy of ORIGIN trial) RCT Multinational Medium (High for outcomes at t5 for MMSE and t6 for DSS)	15077	Adults older than 50 with dysglycaemia, with additional risk factors for cardiovascular events, not taking insulin, and taking no more than 1 oral glucose drug Mean age: 63 65% Male 59% White Mean MMSE (SD): 27.93 (2.74) MMSE group 27.50 (2.79) DSST group	Titrated basal insulin glargine targeting a fasting plasma glucose concentration of 5.3 mmol/L or lower – injected in evenings until target values achieved, then injected at least twice per week	Standard approaches to glycemic control (continuation of pre-randomization therapy)	Median 6.2 years	<u>Diagnosis [MMSE&lt;24, Report Forms]</u> <u>Brief Cognitive Test Performance [MMSE]</u> <u>Executive/Attention/Processing Speed [DSST]</u>
	Seaquist 2013 <sup>2</sup> RCT (Substudy of ACCORD trial) USA Medium	2977	Adults aged 55 to 80 with type 2 diabetes, high HbA1c concentrations (>7.5%, >58 mmol/mol), and high risk for cardiovascular disease events Mean age: 63 47% Women	Intensive glycemic control targeting HbA1c to less than 6.0% for 40 months	Standard glycemic control targeting HbA1c to 7-7.9% for 40 months	40 months	<u>Executive/Attention/Processing Speed [DSST]</u>

		70% White Mean MMSE (IQR): 28 (26-29)				
Launer 2011 <sup>3</sup> RCT (Substudy of ACCORD trial) USA Medium	2977	Adults aged 55 to 80 with type 2 diabetes, high HbA1c concentrations (>7.5%, >58 mmol/mol), and high risk for cardiovascular disease events Mean age: 63 47% Women 70% White Mean MMSE (IQR): 28 (26-29)	Intensive glycemic control targeting HbA1c to less than 6.0% for 40 months	Standard glycemic control targeting HbA1c to 7-7.9% for 40 months	40 months	<u>Biomarker</u> [MRI: Total Brain Volume] <u>Executive/Attention/Processing Speed</u> [SCWT] [DSST] <u>Memory</u> [RAVLT]
Cheatham 2009 <sup>4</sup> RCT USA High	42	Healthy overweight (BMI 25-29.9 kg/m <sup>2</sup> ) adults aged 20 to 42 without depression or diabetes Mean age: 35 Sex: NR Race: NR Education: NR Baseline global cog: NR	High glycemic load energy-restricted diet (116g/1000 kcal), or a low glycemic load energy-restricted diet (45g/1000 kcal) for 6 months	Groups compared to one-another	6 months	<u>Executive/Attention/Processing Speed</u> [Visual Reaction Time Test] [Repeated Acquisition Test] [Scanning Visual Vigilance Test] <u>Language</u> [Grammatical Reasoning Test]
Luchsinger 2011 <sup>5</sup> RCT USA High	2169	Adults at least 55 years of age with type 2 diabetes Mean age: 71 61% Female 52% White Education: 53% Elementary 29% High School 16% College	Diabetes case management (target HgbA1c was ≤7%, or ≤8% for participants with reduced life expectancy and/or severe hypoglycemic unawareness; BP goal was <130/85 mmHg, or <125/75 mmHg in the	Usual care - care from primary care physicians without guidance from study personnel; primary care physicians were mailed diabetes care guidelines for 5 years	Up to 5 years (mean 3.5)	<u>Multidomain Neuropsychological Test Performance</u> [Comprehensive Assessment and Referral Evaluation (CARE), Diagnostic Scale]

			Baseline global cog: NR	presence of proteinuria (>1g/24h) or renal insufficiency; in 2003 BP goal changed to <130/80 mmHg, except for proteinuria or renal insufficiency; LDL goals were < 130 mg/dl for primary prevention, and <100 mg/dl for those with cardiovascular disease) implemented by a diabetes nurse via telemedicine unit in participant's home in coordination with primary care physician for 5 years			
<b>Lifestyle advice &amp; glycemic control efficacy</b>	Koekkoek 2012 <sup>6</sup> RCT Netherlands High	252	Adults aged 50 to 70 years with type II diabetes Mean age: 60 61% Female Race: NR Education: 10 years Baseline global cog: NR	Lifestyle advice (regarding diet, physical activity, and smoking); HbA1c level had to be kept <53 mmol/mol (a biguanide, prandial glucose regulator or sulphonylurea) and had to be altered when HbA1c was >48 mmol/mol., Antihypertensive treatment with an ACE inhibitor if needed, and blood pressure treatment with calcium channel blockers, thiazides or beta-blockers if needed (6 years)	Routine care (GPs were informed about diagnostic test results and patients received treatment according to the current guidelines of the Dutch College of GPs) for 6 years. Also reference group of spouses and acquaintances of the patients, without diabetes, was recruited and matched for age, sex, and education level	6 years	<u>Executive/Attention/Processing Speed</u> [DS Forward] [DS Backward] [DSST] [Corsi Block-Tapping Test Forward] [Corsi Block-Tapping Test Backward] [SCWT I] [SCWT II] [SCWT IIK] [TMT A] [TMT B] [Brixton Spatial Anticipation Test] <u>Memory</u> [RAVLT, Trials 1-5 And Delayed Recall And Recognition] [Location Learning Test, Trials 1-5 and Learning Index and Delayed Trial] [Complex Figure Test Delay] <u>Language</u> [Letter Fluency] [Category Fluency]

ADAS=Cog-Alzheimer's Disease Assessment Scale-Cognitive; AVLT=Auditory Verbal Learning Test; BEM= Batterie d'Efficiency Mnesique; BVRT=Benton Visual Retention Test; CDR=Change in Dementia Rating; COWAT=Controlled Oral Word Association Test; CVFT= Category Verbal Fluency Test; CVLT=California Verbal Learning Test; DS=Digit Span; DSM=Diagnostic Statistical Manual of Mental Disorders; FDG-PET=; MCI=Mild Cognitive Impairment; MMSE=Mini Mental Status Exam; NR=not reported ; RBANS=Repeat Battery for the Assessment of Neuropsychological Status; RCT=Randomized Controlled Trial; RoB=Risk of Bias; SCWT=Stroop Test; SD=Standard Deviation; TMT=Trail Making Trial; WAIS=Wechsler Adult Intelligence Scale

**Appendix Table Q2. Summary risk of bias assessments: diabetic medication treatment in adults with normal cognition**

<b>Intervention Type</b>	<b>Study</b>	<b>Overall Risk of Bias Assessment</b>	<b>Rationale</b>
<b>Glycemic control efficacy</b>	Cukierman-Yaffe 2014 <sup>1</sup>	Medium (High for MMSE outcomes at year 5)	Attrition not clearly reported and sensitivity analysis performed only for the Digit Symbol Substitution cohort. Participants and outcome assessors not blinded
	Seaquist 2013 <sup>2</sup>	Medium (Table 4 and 5 analyses) High (other analyses)	Medium: Attrition not clearly reported. High: unclear if evaluations done by treatment assignment
	Launer 2011 <sup>3</sup>	Medium	Attrition 13%. Participants and outcome assessors not blinded
	Luchsinger 2011 <sup>5</sup>	High	Attrition not clearly reported. Participants not blinded
	Cheatham 2009 <sup>4</sup>	High	Method of randomization not clear. High attrition due to technical difficulties with encrypted data.
<b>Lifestyle advice &amp; glycemic control efficacy</b>	Koekkoek 2012 <sup>6</sup>	High	Attrition 26%

MMSE=Mini-Mental Status Examination



**Appendix Table Q3. Strength of evidence assessments: diabetic medication treatments versus standard of care/standard glycemic control in adults with normal cognition**

Outcome	# Trials (n)	Evidence Summary Summary statistics [95% CI]	Study Limitations	Directness	Precision	Consistency	Reporting Bias	Optional Components	SOE
Dementia	1 (12537)	0 of 1 tests show statistically significant improvement with intervention  <u>Cukierman-Yaffe 2014<sup>1</sup></u> Hazard ratio for incident cognitive impairment (composite of either incident dementia diagnosis or follow-up MMSE <24): 0.93 [0.86 to 1.0]	High	Direct	Precise	Unknown	Undetected	N/A	Low (due to study limitation of composite outcome with component of unequal importance, one of which is not clinical diagnosis and may be achieved due to chance)
MCI		NR							
Biomarkers	1 (2977)	1 of 2 tests show statistically significant improvement with intervention  <u>Launer 2011<sup>3</sup></u> Difference in decline in mean total brain volume: -13.0 vs. -17.7 cm <sup>3</sup> (mean difference 4.6 cm <sup>3</sup> [2.0 to 7.3] (favors intervention)  Difference in geometric mean abnormal white matter at follow-up: 1.10 cm <sup>3</sup> [1.02 to 1.19]	Medium	Indirect	Precise	Inconsistent	Undetected	N/A	Insufficient

		(favors control)							
Brief cognitive test performance	2 (15514)	0 of 2 tests show statistically significant improvement:  <u>Cukierman-Yaffe 2014<sup>1</sup></u> Difference in least-squares mean raw MMSE score: 0.0037 [-0.0144 to 0.0217]  <u>Launer 2011<sup>3</sup></u> Difference in mean raw MMSE score: -0.01 [-0.18 to 0.16]	Medium	Indirect	Imprecise	Consistent	Undetected	N/A	Low
Multidomain neuropsychological performance		NR							
Executive Function	2 (15514)	0 of 3 tests show statistically significant improvement with Intervention	Medium	Indirect	Imprecise	Consistent	Undetected	N/A	Low
Memory	1 (2977)	0 of 1 tests show statistically significant improvement with Intervention	Medium	Indirect	Imprecise	Unknown	Undetected	N/A	Low

ADAS=Cog-Alzheimer's Disease Assessment Scale-Cognitive; AVLT=Auditory Verbal Learning Test; BEM= Batterie d'Efficiency Mnesique; BVRT=Benton Visual Retention Test; CDR=Change in Dementia Rating; COWAT=Controlled Oral Word Association Test; CVFT= Category Verbal Fluency Test; CVLT=California Verbal Learning Test; DS=Digit Span; DSM=Diagnostic Statistical Manual of Mental Disorders; FDG-PET=; MCI=Mild Cognitive Impairment; MMSE=Mini Mental Status Exam; NR=not reported ; RBANS=Repeat Battery for the Assessment of Neuropsychological Status; RCT=Randomized Controlled Trial; RoB=Risk of Bias; SCWT=Stroop Test; SD=Standard Deviation; TMT=Trail Making Trial; WAIS=Wechsler Adult Intelligence Scale

**Appendix Table Q4. Characteristics of eligible studies: diabetic medication treatments in adults with MCI**

<b>Intervention Type</b>	<b>Study Design Country RoB</b>	<b>N=</b>	<b>Population Inclusion Age (mean) Sex Race Education Baseline Cog</b>	<b>Intervention Mode Components Frequency Duration</b>	<b>Comparison Mode Components Frequency Duration</b>	<b>Outcome timing</b>	<b>Outcome Domain [Instrument]</b>
<b>Pioglitazone efficacy</b>	Hildreth 2015 <sup>7</sup> RCT USA Low	78	Sedentary community-dwelling obese adults at least 55 years of age with MCI (90% had MCI) and without diabetes Mean age: 66 57% Female 88% White Education: 16 years Mean MMSE (SD): 28.4 (1.3) pioglitazone group 28.8 (1.3) placebo group	Pioglitazone 30mg daily for 1 month, then 45mg daily as tolerated for 5 months	Placebo for 6 months	6 months	<u>Multidomain Neuropsychological Test Performance</u> [ADAS-Cog] <u>Executive/Attention/Processing Speed</u> [Composite] [SCWT] [TMT B] [DS Backward] [DSST] <u>Memory</u> [Composite] [RAVLT] [WMS Logical Memory II] [VR] <u>Language</u> [Composite] [BNT] [Category Fluency] <u>Visuospatial</u> [Composite] [WAIS-R, Block Design] [CLOX-1]
<b>Metformin efficacy</b>	Luchsinger 2016 <sup>8</sup> RCT USA Medium	80	Overweight or obese (BMI at least 25 kg/m <sup>2</sup> ) adults aged 55 to 90 years, untreated diabetes, with aMCI Mean age: 64 53% Female 30% White Education Level (Years), Mean (SD): Metformin: 13.8 (3.4) Placebo: 13.1 (4.5) Mean ADAS-Cog (SD):	Metformin 1000mg twice daily for 12 months	Placebo daily for 12 months	12 months	<u>Biomarker</u> [PET and MRI] <u>Brief Cognitive Test Performance</u> [MMSE] <u>Multidomain Neuropsychological Test Performance</u> [ADAS-Cog] <u>Executive/Attention/Processing Speed</u> [DS Backward] <u>Memory</u> [Bushcke Selective Reminding Test] [WMS Logical Memory II Delayed] [Paragraph Recall]

		Metformin: 12 (4.0) Placebo: 14.6 (6.1)				
--	--	--	--	--	--	--

ADAS=Cog-Alzheimer’s Disease Assessment Scale-Cognitive; AVLT=Auditory Verbal Learning Test; BEM= Batterie d’Efficiencie Mnesique; BVRT=Benton Visual Retention Test; CDR=Change in Dementia Rating; COWAT=Controlled Oral Word Association Test; CVFT= Category Verbal Fluency Test; CVLT=California Verbal Learning Test; DS=Digit Span; DSM=Diagnostic Statistical Manual of Mental Disorders; FDG-PET=; MCI=Mild Cognitive Impairment; MMSE=Mini Mental Status Exam; NR=not reported ; RBANS=Repeat Battery for the Assessment of Neuropsychological Status; RCT=Randomized Controlled Trial; RoB=Risk of Bias; SCWT=Stroop Test; SD=Standard Deviation; TMT=Trail Making Trial; WAIS=Wechsler Adult Intelligence Scale

**Appendix Table Q5. Summary risk of bias assessments: diabetic medication treatment in adults with MCI**

<b>Intervention Type</b>	<b>Study</b>	<b>Overall Risk of Bias Assessment</b>	<b>Rationale</b>
<b>Pioglitazone efficacy</b>	Hildreth 2015 <sup>7</sup>	Low	
<b>Metformin efficacy</b>	Luchsinger 2016 <sup>8</sup>	Medium	Attrition 19%

## References for Appendix Q

1. Cukierman-Yaffe T, Bosch J, Diaz R, et al. Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial. *Lancet Diabetes Endocrinol*. 2014 Jul;2(7):562-72. doi: 10.1016/S2213-8587(14)70062-2. PMID: 24898834.
2. Seaquist ER, Miller ME, Fonseca V, et al. Effect of thiazolidinediones and insulin on cognitive outcomes in ACCORD-MIND. *J Diabetes Complications*. 2013 Sep-Oct;27(5):485-91. doi: 10.1016/j.jdiacomp.2013.03.005. PMID: 23680059.
3. Launer LJ, Miller ME, Williamson JD, et al. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. *Lancet Neurol*. 2011 Nov;10(11):969-77. doi: 10.1016/S1474-4422(11)70188-0. PMID: 21958949.
4. Cheatham RA, Roberts SB, Das SK, et al. Long-term effects of provided low and high glycemic load low energy diets on mood and cognition. *Physiol Behav*. 2009 Sep 7;98(3):374-9. doi: 10.1016/j.physbeh.2009.06.015. PMID: 19576915.
5. Luchsinger JA, Palmas W, Teresi JA, et al. Improved diabetes control in the elderly delays global cognitive decline. *J Nutr Health Aging*. 2011 Jun;15(6):445-9. PMID: 21623465.
6. Koekkoek PS, Ruis C, van den Donk M, et al. Intensive multifactorial treatment and cognitive functioning in screen-detected type 2 diabetes--the ADDITION-Netherlands study: a cluster-randomized trial. *J Neurol Sci*. 2012 Mar 15;314(1-2):71-7. doi: 10.1016/j.jns.2011.10.028. PMID: 22093142.
7. Hildreth KL, Van Pelt RE, Moreau KL, et al. Effects of pioglitazone or exercise in older adults with mild cognitive impairment and insulin resistance: a pilot study. *Dement Geriatr Cogn Dis Extra*. 2015 Jan-Apr;5(1):51-63. doi: 10.1159/000371509. PMID: 25852732.
8. Luchsinger JA, Perez T, Chang H, et al. Metformin in amnesic mild cognitive impairment: Results of a pilot randomized placebo controlled clinical trial. *Journal of Alzheimer's Disease*. 2016 15 Mar;51(2):501-14. doi: <http://dx.doi.org/10.3233/JAD-150493>. PMID: 609260209.

## Appendix R. Other Interventions

**Appendix Table R1. Characteristics of eligible studies: other interventions in adults with normal cognition**

<b>Intervention Type</b>	<b>Study Design Country RoB</b>	<b>N=</b>	<b>Population Inclusion Age (mean) Sex Race Education Baseline Cog</b>	<b>Intervention Mode Components Frequency Duration</b>	<b>Comparison Mode Components Frequency Duration</b>	<b>Outcome timing</b>	<b>Outcome Domain [Instrument]</b>
<b>Other Medications</b>	Newhouse 2012 <sup>1</sup> RCT US Medium	74	Non-smoking adults ≥55 with MCI (determined by subjective and objective impairments in cognitive function) Age, Mean (SD) 76 (7.6) 39% Female Race NR Years of Education, Mean (SD) 15.9 (2.7) MMSE, Mean (SD) 27.4 (2.0)	Transdermal nicotine patch 15 mg/day for 6 months	Placebo	6 months	<u>Diagnosis</u> [CDR] <u>Multidomain Neuropsychological Test Performance</u> [Cognitive Drug Research Battery] <u>Executive/Attention/Processing Speed</u> [Connors Continuous Performance Test] [Immediate and Delayed Paragraph Recall Test, NYU Version] [DSST]
	Forlenza 2011 <sup>2</sup> RCT Brazil Medium	45	Community-dwelling adults ≥60 diagnosed with amnesic MCI per Mayo criteria Age, Mean (SD) 72.5 (5.9) Sex NR Race NR Years of education, Mean (SD) 10.5 (5.3) ADAS-Cog Score, Mean (SD) 10.9 (5.9)	Lithium titrated to serum levels 0.25-0.5 mmol/l (lower than dose for affective disorders); daily doses for 12 months	Placebo	12 months	<u>Diagnosis</u> [CDR, Sum of Boxes] <u>Biomarker</u> [Amyloid-Beta] [Phosphorylated Tau At Threonine] [Total Tau] <u>Multidomain Neuropsychological Test Performance</u> [ADAS-Cog] <u>Executive/Attention/Processing Speed</u> [TMT A] [TMT B] Memory [CERAD Delayed Recall] [CERAD Figure Recall] <u>Memory</u> [Sequence of Letters and Numbers Score] (Cognitive Performance outcomes compared only baseline to endpoint within group, not between group)
<b>Music Interventions</b>	Hars 2014 <sup>3</sup> Secondary analysis of	134	Adults ≥65 at increased risk of falling	Weekly 1 hour supervised group class; multitask	Inactive control	6 months	<u>Brief Cognitive Test Performance</u> [MMSE] <u>Executive/Attention/Processing Speed</u> [TMT A]

Intervention Type	Study Design Country RoB	N=	Population Inclusion Age (mean) Sex Race Education Baseline Cog	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome timing	Outcome Domain [Instrument]
	RCT Switzerland Medium		Age, Mean (SD) 75 (7) 96.5% Female Race NR Education, 15% primary, 67% middle, 18% highschool MMSE, Mean (SD) 26.1 (2.9)	exercises to rhythm			<u>Visuospatial</u> [CLOX-1]
	Bugos 2007 <sup>4</sup> US RCT High	31	Musically naïve older adults Age, Mean (SD) 70.5 (5.6) 81% Females Race NR Years of Education, Mean (SD) 16.4 (NR) No baseline cognitive screen	Individualized piano instruction ½ hour per week and independent practice 3 hours per week for 6 months. (Music theory instruction component)	Inactive control	9 months	<u>Multidomain Neuropsychological Test Performance</u> [WAIS] <u>Executive/Attention/Processing Speed</u> [TMT A] [TMT B]
<b>Sleep interventions</b>	Lucassen 2014 <sup>5</sup> US RCT High	121	Short-sleeping (<6.5 hours/night), obese (BMI 30-55 kg/m2) adults Age, Mean (SD) 41.1 (7) 76% Female 60% Black Years of Education NR No baseline cognitive screen	Sleep extension (up to 7.5 hours/night) with life-style modifications using personalized sleep plans	Continue current sleep habits; habits reviews every 2 months	Median 14 months	<u>Multidomain Neuropsychological Test Performance</u> [WAIS] <u>Executive/Attention/Processing Speed</u> [TMT A] [TMT B] [Wisconsin Card Sort Test] <u>Memory</u> [RCFT] [CVLT] <u>Language</u> [Verbal Fluency] <u>Visuospatial</u> [RCFT] <u>Motor</u> [Grooved Peg Board]
	Sun 2013 <sup>9</sup> RCT China High	80	Adults ≥60 years with reduced sleep quality (Pittsburgh Sleep Quality Index >5) Age, Mean (SD)	Sleep hygiene educational pamphlet; guided progressive muscle relaxation	Sleep hygiene educational pamphlet	12 months	<u>Brief Cognitive Test Performance</u> [MMSE] <u>Memory</u> [Wechsler Memory Scale, Chinese Revised]

Intervention Type	Study Design Country RoB	N=	Population Inclusion Age (mean) Sex Race Education Baseline Cog	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome timing	Outcome Domain [Instrument]
			69 (8) 74.7% Female Race NR 1.3% high school or above MMSE, Mean (SD) 24.2 (3.7)	tape (unclear frequency and duration; presumably daily for 12 months)			
<b>Social Engagement</b>	Lam 2015 <sup>7</sup> RCT China High	276	Older adults with MCI (determined by subjective and objective impairments in cognitive function) and without dementia Age, Mean (SD) 75.4 (6.5) 78.2% Female Race NR Education Level (Years), Mean (SD) 3.9 (3.6) Catonese MMSE. Mean (SD) 25.6 (2.3)	Cognitive group (board games, reading/discussing newspapers) at least 3, 1-hr sessions/week	Social activities - At least 3, 1-hr sessions/week	12 months	<u>Diagnosis</u> [CDR, Sum of Boxes] <u>Brief Cognitive Test Performance</u> [MMSE] <u>Multidomain Neuropsychological Test Performance</u> [ADAS-Cog, Chinese Version] <u>Memory</u> [Delayed Recall] <u>Language</u> [CVFT]
	Mortimer 2012 <sup>8</sup> RCT China High	74	Adults age 60-79 with an education-adjusted Chinese MMSE score greater than 26 Age, Mean (SD) 67.8 (5.8) 67% Female Race NR Years of Education, Mean (SD) 11.7 (3.4) Mattis Dementia Scale Score, Mean	Group social interaction for 1 hour 3 times per week at a neighborhood community center	Inactive control with 4 check-in calls over 40 weeks	40 weeks	<u>Biomarker</u> [Whole Brain Volume, % of Total Intracranial Volume] <u>Multidomain Neuropsychological Test Performance</u> [Mattis Dementing Rating Scale, Total Score] <u>Executive/Attention/Processing Speed</u> [DS Forward] [DS Backward] [SCWT, Word] [SCWT, Color] [SCWT, Color-Word] [WAIS Similarities] [TMT A] [TMT B] [Mattis Attention Score] [Mattis Initiation Score] [Mattis Conceptualization Score] <u>Memory</u> [RCFT, Copying] [RCFT, Recall] [AVLT, Immediate Recall] [AVLT, Delayed Recall] [AVLT, Delayed Recognition] [Mattis



Intervention Type	Study Design Country RoB	N=	Population Inclusion Age (mean) Sex Race Education Baseline Cog	Intervention Mode Components Frequency Duration	Comparison Mode Components Frequency Duration	Outcome timing	Outcome Domain [Instrument]
			(SD) 137.6 (7.6)				Memory Score] <u>Language</u> [Category Verbal Fluency, Animals] [BNT] <u>Visuospatial</u> [Bell Cancellation Test] [RCFT, Copying] [RCFT, Recall] [CLOX-1] [Mattis Construction Score]
<b>Transcranial random noise stimulation</b>	Snowball, 2013(Snowball, 2013 #795) United Kingdom RCT High	29 (4 excluded due to drop-out)	Adults with normal or corrected-to-normal vision, no history of psychiatric illness.  Mean age (SD): 21 (SD~2.7) 59% Female Race: NR Education: NR No baseline cognition	Transcranial random noise stimulation by DC stimulator-Plus device, noise in high-frequency band, for 20 minutes per day for 5 days	Sham procedure: current applied for 30 seconds after upward ramping and then terminated for 5 days	6 months	<u>Executive/Attention/Processing Speed</u> [Arithmetic Calculation And Drill] [Mental Rotation Task] [Attention Network Test]

3MSE=Modified Mini Mental Status Examination; AD=Alzheimer's disease; ADAS-Cog=Alzheimer's Disease Assessment Scale-Cognitive Subscale; CERAD=Consortium to Establish a Registry for Alzheimer's Disease; CVLT=California Verbal Learning Test; CDR=Change in Dementia Rating; COWAT= Controlled Oral Word Association Test; DSM=Diagnostic and Statistical Manual of Mental Disorders; MMSE=Mini-Mental State Examination; NINCDS-ADRDA=National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association; N=sample size; NR=not reported; RCT=randomized controlled trial;RoB=risk of bias; SD=standard deviation; TMT=Trails Making Test (A and/or B); WAIS=Wechsler Adult Intelligence Scale; WMS=Wechsler Memory Scale

**Appendix Table R2. Summary risk of bias assessments: other interventions in adults with normal cognition and MCI**

<b>Intervention Type</b>	<b>Study</b>	<b>Overall Risk of Bias Assessment</b>	<b>Rationale</b>
<b>Other Medications</b>	Newhouse 2012 <sup>1</sup>	Medium	Method of randomization unclear. Likely selective outcome reporting
	Forlenza 2011 <sup>2</sup>	Medium	Method of randomization unclear.
<b>Music</b>	Hars 2014 <sup>3</sup>	Medium	Method of randomization unclear. 16% attrition with no sensitivity analysis.
	Bugos 2007 <sup>4</sup>	High	Method of randomization unclear. Attrition 21%.
<b>Sleep</b>	Lucassen 2014 <sup>5</sup>	High	Method of randomization unclear. Attrition 39%.
	Sun 2013 <sup>6</sup>	High	Attrition 51%
	Lam 2015 <sup>7</sup>	High	Method of randomization unclear. Attrition 22% at 8 months, 24% at 1 year.
	Mortimer 2012 <sup>8</sup>	High	Suspected selection bias due to modifications post-randomization.
<b>Transcranial random noise stimulation</b>	Snowball 2013	High	Method of randomization not reported. 52% (only 12/25 available for recall). Outcome assessor not blinded.

MCI=mild cognitive impairment

## References for Appendix R

1. Newhouse P, Kellar K, Aisen P, et al. Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial. *Neurology*. 2012 Jan 10;78(2):91-101. doi: 10.1212/WNL.0b013e31823efcbb. PMID: 22232050.
2. Forlenza OV, Diniz BS, Radanovic M, et al. Disease-modifying properties of long-term lithium treatment for amnesic mild cognitive impairment: randomised controlled trial. *Br J Psychiatry*. 2011 May;198(5):351-6. doi: 10.1192/bjp.bp.110.080044. PMID: 21525519.
3. Hars M, Herrmann FR, Gold G, et al. Effect of music-based multitask training on cognition and mood in older adults. *Age Ageing*. 2014 Mar;43(2):196-200. doi: 10.1093/ageing/aft163. PMID: 24212920.
4. Bugos JA, Perlstein WM, McCrae CS, et al. Individualized piano instruction enhances executive functioning and working memory in older adults. *Aging Ment Health*. 2007 Jul;11(4):464-71. doi: 10.1080/13607860601086504. PMID: 17612811.
5. Lucassen EA, Piaggi P, Dsurney J, et al. Sleep extension improves neurocognitive functions in chronically sleep-deprived obese individuals. *PLoS One*. 2014;9(1):e84832. doi: 10.1371/journal.pone.0084832. PMID: 24482677.
6. Sun J, Kang J, Wang P, et al. Self-relaxation training can improve sleep quality and cognitive functions in the older: a one-year randomised controlled trial. *J Clin Nurs*. 2013 May;22(9-10):1270-80. doi: 10.1111/jocn.12096. PMID: 23574290.
7. Lam LC, Chan WC, Leung T, et al. Would older adults with mild cognitive impairment adhere to and benefit from a structured lifestyle activity intervention to enhance cognition?: a cluster randomized controlled trial. *PLoS One*. 2015 31 Mar;10(3):e0118173. doi: 10.1371/journal.pone.0118173. PMID: 25826620.
8. Mortimer JA, Ding D, Borenstein AR, et al. Changes in brain volume and cognition in a randomized trial of exercise and social interaction in a community-based sample of non-demented Chinese elders. *J Alzheimers Dis*. 2012;30(4):757-66. doi: 10.3233/JAD-2012-120079. PMID: 22451320.

## Appendix S. Biomarkers

**Appendix Table S1. Relationship between biomarkers and cognitive performance and incidence outcomes in adults with normal cognition**

Author Year Comparison N= Follow-up	Diagnosis	Biomarkers [specific biomarker]	BCT & MNP [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
<b>Cognitive Training</b>		None reported					
<b>Physical Activity</b>		None reported					
<b>Nutraceuticals</b>							
<b><i>Omega 3 versus Placebo</i></b>							
<b>Witte, 2014<sup>1</sup></b> Omega 3 (fish oil LC-n3-FA) 2.2 g daily vs placebo n=65 6 months		I>C [MRI - grey matter volume]		I>C [Executive Composite: Phonemic & Semantic Fluency, TMT A&B, Stroop Parts 1-3]	NS [Memory Composite: AVLT Learning, Delayed Recall, Recognition, Digit Span Backward]	2 of 6 favor I	
		NS [MRI - white matter integrity]		NS [Sensorimotor Speed Composite: TMT Part A, Stroop A & B]			
				NS [DS Forward]			
<b><i>Resveratrol versus Placebo</i></b>							
<b>Witte 2014<sup>2</sup></b> Resveratrol 200 mg daily versus placebo n=46 6 months (Resveratrol belongs to a group of plant compounds called polyphenols with possible antioxidant		NS [MRI-total grey matter volume]			I>C [Memory Composite: AVLT Retention, Delayed Recall, Recognition, Learning Ability, 5th Learning Trial]	5 of 11 favor I	
		NS [MRI-HC microstructure]			I>C [AVLT Retention]		

Author Year Comparison N= Follow-up	Diagnosis	Biomarkers [specific biomarker]	BCT & MNP [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
properties)							
		I>C [MRI- functional capacity, HC frontal]			NS [AVLT Delayed Recall]		
		I>C [MRI- functional capacity, HC parietal]			NS [AVLT Recognition]		
		I>C [MRI- functional capacity, HC occipital]			NS [AVLT Learning Ability]		
					NS [AVLT Fifth Learning Trial]		
<b>Diet Types</b>		<b>None Reported</b>					
<b>Multimodal Interventions</b>		<b>None Reported</b>					
<b>Other Health/ Lifestyle Intervention</b>		<b>None Reported</b>					
<b>Hormone Therapies</b>							
<b><i>HRT- Estrogen versus Placebo</i></b>							
<b>Women's Health Initiative (WHI) substudies</b>	NS [Probable Dementia] n=2947	NS [MRI - total brain volume] n=520	<b>BCT C&gt;I [3MS] N=2947</b>	NS [Letter Fluency] n=886	NS [BVRT Errors] n=886	2 of 16 favors C	Increased risk of probable dementia in women taking

Author Year Comparison N= Follow-up	Diagnosis	Biomarkers [specific biomarker]	BCT & MNP [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
Coker, 2009 <sup>3</sup> Resnick, 2009a <sup>4</sup> Resnick, 2009b <sup>5</sup> Espeland, 2004 <sup>6</sup> Shumaker, 2004 <sup>7</sup> Rapp, 2003 <sup>8</sup> Estrogen daily Mean followup varies by outcome up to 8 years	NS [MCI] n=2947	NS [MRI - ventricle volume] n=520		NS [DS Forward] n=886	NS [CLVT Total List A Trials] n=886		estrogen. Increased risk of global cognitive
	<b>C&gt;I</b> [Probable Dementia or MCI] n=2947	NS [MRI - hippocampal volume] n=520		NS [DS Backward] n=886	NS [CVLT Total List B] n=886		decline in women taking estrogen.
		<b>C&gt;I</b> [MRI- frontal lobe volume] n=520			NS [CVLT Short Delay Free] n=886		
		NS [White & grey matter] n=520			NS [CVLT Long Delay Free] n=886		
		NS [Basal ganglia] n=520					
		NS [Total brain lesion volume] n=520					
<b>HRT – Estrogen + Progesterone versus Placebo</b>							
<b>Women’s Health Initiative (WHI)</b> Coker, 2009 <sup>3</sup> Resnick, 2009a <sup>4</sup> Resnick, 2009b <sup>5</sup> Espeland, 2004 <sup>6</sup> Shumaker, 2004 <sup>7</sup> Rapp, 2003 <sup>8</sup> Estrogen + progestin daily Mean followup varies by outcome	<b>C&gt;I</b> [Probable Dementia] n=4532	NS [MRI - total brain volume] n=883	<b>BCT</b> <b>C&gt;I</b> [3MS] n=4532	NS [Letter Fluency] n=1416	<b>C&gt;I</b> [BVRT Errors] n=1416	5 of 16 favor C	In addition to increased risk of probable dementia and
	NS [MCI] n=4532	NS [MRI - ventricle volume] n=883		NS [DS Forward] n=1416	<b>C&gt;I</b> [CLVT Total List A Trials] n=1416		memory decline, women taking estrogen +
	NS	NS		NS	NS		progestin

Author Year Comparison N= Follow-up	Diagnosis	Biomarkers [specific biomarker]	BCT & MNP [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
up to 8 years	[Probable Dementia or MCI] n=4532	[MRI - hippocampal volume] n=883		[Digits Backward] n=1416	[CVLT Total List B] n=1416		experienced more strokes than women taking placebo
		NS [MRI - frontal lobe volume] n=883			C>I [CVLT Short Delay Free] n=1416		
		NS [White and grey matter] n=883			C>I [CVLT Long Delay Free] n=1416		
		NS [Basal ganglia] n=883					
		NS [Total brain lesion volume] n=883					
<b>Vitamins</b>							
<b><i>Vitamin B versus Placebo</i></b>							
<b>Douaud 2013<sup>9</sup> de Jager 2012<sup>10</sup> Smith 2010<sup>11</sup></b> Vitamin B (folic acid + B12 + B6) n=266 MRI n=166 2 years		I>C [Reduction of posterior atrophy]	NS [MMSE]		NS [HVLT]	1 of 3 favor I	NR
<b>Antihypertensive Treatment</b>							
		<b>None reported</b>					

Author Year Comparison N= Follow-up	Diagnosis	Biomarkers [specific biomarker]	BCT & MNP [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
<b>Lipid Lowering Treatment</b>							
<b>Atorvastatin versus Placebo</b>							
<b>Tendolkar 2010<sup>12</sup></b> Atorvastatin 20mg for 2 weeks then increased to 40mg, after 4 weeks Ezetimibe 10mg was added. Standard anticoagulant therapy vs matching-placebo and standard anticoagulant therapy n = 34 1 year		<b>I&gt;C</b> [Left amygdala volume]	NS <b>BCT</b> [MMSE]	<b>I&gt;C</b> [Digit Symbol Substitution]	NS [Dutch Modified Version of the RAVLT Immediate Word Recall]	3 of 9 favor I	
		NS [Right amygdala volume]			<b>I&gt;C</b> [Dutch Modified version of the RAVLT Delayed Word Recall]		
		NS [Left hippocampal volume]					
		NS [Right hippocampal volume]					
		NS [White Matter Lesion Volume]					
<b>NSAIDs</b>		<b>None Reported</b>					
<b>Antidementia Drugs</b>		<b>None Reported</b>					
<b>Diabetes Treatment</b>							
<b>Glycemic Control vs Placebo</b>							



Author Year Comparison N= Follow-up	Diagnosis	Biomarkers [specific biomarker]	BCT & MNP [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
<b>ACCORD-MIND Trial Seaquist 2013<sup>13</sup> Launer, 2011<sup>14</sup></b> Intensive glycemic control targeting HbA1c to less than 6.0% vs. standard glycemic control targeting HbA1c to 7-7.9% n=2977 40 months		I>C [Total brain volume]	BCT NS [MMSE]	NS [Stroop Test]	NS [RAVLT]	1 of 6 favor I 1 of 6 favor C	NS [Mortality]
		C>I [Abnormal white matter]		NS [DSST]			
<b>Other Drugs</b>							
<b>Forlenza 2011<sup>15</sup></b> Lithium titrated to serum levels 0.25- 0.5 mmol/l vs placebo n=41 12 months	NS [Conversion to Probable AD]	I>C [Amyloid- beta]				2 of 3 favor I	NS [Ischemic stroke, death due to sepsis;
		NS [Total tau]					neither deemed due
		I>C [Phosphorylat ed tau]					to treatment]

3MS=Modified Mini Mental Status Examination; AD=Alzheimer's disease; AVLT=Auditory Verbal Learning Test; BCT=brief cognitive test; BVRT=Benton Visual Retention Test; C=control; CVLT=California Verbal Learning Test; DS=Digit Span (Forward and/or Backward); I=intervention; g=grams; LC-n3-FA=long-chain omega-3 fatty acid; MCI=mild cognitive impairment; mg=milligrams; MMSE=Mini-Mental Status Examination; MNP=multidomain neuropsychological performance; MMSE=Mini-Mental Status Examination; MRI=magnetic resonance imaging; n=sample size; NS=no statistically significant difference; NR=not reported; RCT=randomized controlled trial; RoB=risk of bias; SD=standard deviation; TMT=Trail Making Test (Part A and/or B)

**Appendix Table S2. Relationship between biomarkers and cognitive performance and incidence outcomes in adults with MCI**

Author Year Comparison N= Follow-up	Diagnosis	Biomarkers [specific biomarker]	BCT & MNP [instrument]	Executive/Attention/ Processing Speed [instrument]	Memory [instrument]	Intermediate Outcomes Summary	Adverse Effects [specific adverse effect]
---	-----------	---------------------------------------	---------------------------	--	------------------------	-------------------------------------	---

<b>Cognitive Training</b>							
<b>Buschert, 2012<sup>16</sup></b> <b>Forster, 2011<sup>17</sup></b> Group-based formal mnemonic memory training & informal cognitive & social engagement activities vs. exercises of isolated, sustained attention n=24 (MCI) 15 & 28 months	I>C [Conversion to CATD]	I>C [FDG-PET Reuptake]	NS BCT [MMSE]	NS [TMT A]	I>C [RBANS-Immediate Memory]	3 of 7 favor I	NR
			I>C MNP [ADAS-Cog]	NS [TMT B]	NS [RBANS-Delayed Recall]		
<b>Physical Activity</b>							
<b>Suzuki, 2013<sup>18</sup></b> <b>Suzuki, 2012<sup>19</sup></b> Multicomponent physical activity vs. attention control n=100 (MCI) n=50 (aMCI)* <sup>19</sup> 6 months		NS [MTA-ERC]	BCT NS [MMSE]		NS [WMS-LM I]	0 of 6 (no differences)	NS [Falls & hospitalization for illness]
		NS [WBS]	MNP NS [ADAS-Cog]		NS [WMS-LM II]		
<b>Nutraceuticals</b>		<b>None Reported</b>					
<b>Diet Interventions</b>		<b>None Reported</b>					
<b>Multimodal Interventions</b>		<b>None Reported</b>					
<b>Other Health / Lifestyle Interventions</b>		<b>None Reported</b>					

<b>Hormone Therapies</b>		<b>None Reported</b>					
<b>Vitamins</b>		<b>None Reported</b>					
<b>Antihypertensive Treatment</b>		<b>None Reported</b>					
<b>Lipid Lowering Treatment</b>		<b>None Reported</b>					
<b>NSAIDs</b>		<b>None Reported</b>					
<b>Antidementia Drugs</b>		<b>None Reported</b>					
<b>Diabetes Treatment</b>		<b>None Reported</b>					
<b>Other Drugs</b>		<b>None Reported</b>					

3MS=Modified Mini Mental Status Examination; AD=Alzheimer's disease; AVLT=Auditory Verbal Learning Test; BCT=brief cognitive test; BVRT=Benton Visual Retention Test; C=control; CVLT=California Verbal Learning Test; DS=Digit Span (Forward and/or Backward); I=intervention; g=grams; LC-n3-FA=long-chain omega-3 fatty acid; MCI=mild cognitive impairment; mg=milligrams; MMSE=Mini-Mental Status Examination; MNP=multidomain neuropsychological performance; MMSE=Mini-Mental Status Examination; MRI=magnetic resonance imaging; n=sample size; NS=no statistically significant difference; NR=not reported; RCT=randomized controlled trial; RoB=risk of bias; SD=standard deviation; TMT=Trail Making Test (Part A and/or B)

## References for Appendix S

1. Witte AV, Kerti L, Hermannstadter HM, et al. Long-chain omega-3 fatty acids improve brain function and structure in older adults. *Cerebral Cortex*. 2014 Nov;24(11):3059-68. doi: <http://dx.doi.org/10.1093/cercor/bht163>. PMID: 23796946.
2. Witte AV, Kerti L, Margulies DS, et al. Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults. *Journal of Neuroscience*. 2014 Jun 4;34(23):7862-70. doi: <http://dx.doi.org/10.1523/JNEUROSCI.0385-14.2014>. PMID: 24899709.
3. Coker LH, Hogan PE, Bryan NR, et al. Postmenopausal hormone therapy and subclinical cerebrovascular disease: the WHIMS-MRI Study. *Neurology*. 2009 Jan 13;72(2):125-34. doi: 10.1212/01.wnl.0000339036.88842.9e. PMID: 19139363.
4. Resnick SM, Espeland MA, An Y, et al. Effects of conjugated equine estrogens on cognition and affect in postmenopausal women with prior hysterectomy. *J Clin Endocrinol Metab*. 2009 Nov;94(11):4152-61. doi: 10.1210/jc.2009-1340. PMID: 19850684.
5. Resnick SM, Espeland MA, Jaramillo SA, et al. Postmenopausal hormone therapy and regional brain volumes: the WHIMS-MRI Study. *Neurology*. 2009 Jan 13;72(2):135-42. doi: 10.1212/01.wnl.0000339037.76336.cf. PMID: 19139364.
6. Espeland MA, Rapp SR, Shumaker SA, et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. *JAMA*. 2004 Jun 23;291(24):2959-68. doi: 10.1001/jama.291.24.2959. PMID: 15213207.
7. Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. *JAMA*. 2004 Jun 23;291(24):2947-58. doi: 10.1001/jama.291.24.2947. PMID: 15213206.
8. Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. *Jama*. 2003 May 28;289(20):2663-72. doi: 10.1001/jama.289.20.2663. PMID: 12771113.
9. Douaud G, Refsum H, de Jager CA, et al. Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment. *Proc Natl Acad Sci U S A*. 2013 Jun 4;110(23):9523-8. doi: 10.1073/pnas.1301816110. PMID: 23690582.
10. de Jager CA, Oulhaj A, Jacoby R, et al. Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial. *Int J Geriatr Psychiatry*. 2012 Jun;27(6):592-600. doi: 10.1002/gps.2758. PMID: 21780182.
11. Smith AD, Smith SM, de Jager CA, et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. *PLoS One*. 2010;5(9):e12244. doi: 10.1371/journal.pone.0012244. PMID: 20838622.
12. Tendolkar I, Enajat M, Zwiers MP, et al. One-year cholesterol lowering treatment reduces medial temporal lobe atrophy and memory decline in stroke-free elderly with atrial fibrillation: evidence from a parallel group randomized trial. *Int J Geriatr Psychiatry*. 2012 Jan;27(1):49-58. doi: 10.1002/gps.2688. PMID: 21308791.
13. Seaquist ER, Miller ME, Fonseca V, et al. Effect of thiazolidinediones and insulin on cognitive outcomes in ACCORD-MIND. *J Diabetes Complications*. 2013 Sep-Oct;27(5):485-91. doi: 10.1016/j.jdiacomp.2013.03.005. PMID: 23680059.
14. Launer LJ, Miller ME, Williamson JD, et al. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. *Lancet Neurol*. 2011 Nov;10(11):969-77. doi: 10.1016/S1474-4422(11)70188-0. PMID: 21958949.

15. Forlenza OV, Diniz BS, Radanovic M, et al. Disease-modifying properties of long-term lithium treatment for amnesic mild cognitive impairment: randomised controlled trial. *Br J Psychiatry*. 2011 May;198(5):351-6. doi: 10.1192/bjp.bp.110.080044. PMID: 21525519.
16. Buschert VC, Giegling I, Teipel SJ, et al. Long-term observation of a multicomponent cognitive intervention in mild cognitive impairment. *Journal of Clinical Psychiatry*. 2012 Dec;73(12):e1492-8. doi: <http://dx.doi.org/10.4088/JCP.11m07270>. PMID: 23290333.
17. Forster S, Buschert VC, Teipel SJ, et al. Effects of a 6-month cognitive intervention on brain metabolism in patients with amnesic MCI and mild Alzheimer's disease. *Journal of Alzheimer's Disease*. 2011;26 Suppl 3:337-48. doi: <http://dx.doi.org/10.3233/JAD-2011-0025>. PMID: 21971473.
18. Suzuki T, Shimada H, Makizako H, et al. A randomized controlled trial of multicomponent exercise in older adults with mild cognitive impairment. *PLoS One*. 2013;8(4):e61483. doi: 10.1371/journal.pone.0061483. PMID: 23585901.
19. Suzuki T, Shimada H, Makizako H, et al. Effects of multicomponent exercise on cognitive function in older adults with amnesic mild cognitive impairment: a randomized controlled trial. *BMC Neurol*. 2012;12:128. doi: 10.1186/1471-2377-12-128. PMID: 23113898.